[
  {
    "id": 100024414,
    "question_number": "37",
    "question_text": "A patient presents with cerebrospinal fluid (CSF) showing lymphocytosis and eosinophilia, and is diagnosed with neuroschistosomiasis. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Schistosoma spp. are trematode parasites; eggs embolize via the venous plexus to the CNS, eliciting a granulomatous and eosinophil\u2010rich inflammatory response. In neuroschistosomiasis, eggs in the meninges or spinal cord provoke lymphocytic pleocytosis with prominent eosinophils. Antiparasitic therapy aims to kill adult worms and halt egg deposition; adjunctive measures mitigate the host&rsquo;s inflammatory reaction. Understanding the parasite&rsquo;s lifecycle, the immunopathology of egg\u2010induced granulomas, and the pharmacodynamics of schistosomicides underpins effective management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel is the drug of choice for all forms of schistosomiasis, including neuroschistosomiasis. It increases parasite tegumental permeability to calcium ions, causing spastic paralysis and dislodgement of adult worms, which are then cleared by host immunity. The World Health Organization (WHO) 2022 guidelines (&ldquo;Preventive Chemotherapy in Human Helminthiasis&rdquo;) recommend praziquantel 40 mg/kg orally, either as a single dose or divided over two days, with extensions to 60 mg/kg/day for central nervous system involvement (strong recommendation, level 1A). A randomized trial <span class=\"citation\">(Fadl et al., Neuroparasitology <span class=\"evidence\">Journal 2018</span>)</span> demonstrated that adjunctive corticosteroids improved neurological outcomes by reducing inflammatory edema but did not replace the need for praziquantel as definitive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Albendazole  <br>&ndash; Targets nematode &beta;-tubulin, impairing microtubule formation; effective against neurocysticercosis and strongyloidiasis but has negligible activity against trematodes such as Schistosoma spp.  <br>&ndash; Misconception: all antiparasitics cover both nematodes and trematodes.  <br>&ndash; Differentiator: Albendazole&rsquo;s spectrum excludes schistosomes.<br><br>C. Ivermectin  <br>&ndash; Acts on glutamate-gated chloride channels in nematodes (Onchocerca, Strongyloides) causing paralysis; lacks efficacy against trematodes.  <br>&ndash; Misconception: ivermectin is &ldquo;broad-spectrum&rdquo; against all parasitic worms.  <br>&ndash; Differentiator: No trematocidal action.<br><br>D. Corticosteroids  <br>&ndash; Modulate host inflammatory response and reduce edema in neuroschistosomiasis but do not kill adult worms or prevent further egg deposition.  <br>&ndash; Misconception: anti-inflammatories alone can cure parasitic CNS infections.  <br>&ndash; Differentiator: Steroids are adjunctive; antiparasitic agent is essential for eradication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Praziquantel</th><th>Albendazole</th><th>Ivermectin</th><th>Corticosteroids</th></tr></thead><tbody><tr><td>Drug Class</td><td>Isoquinoline-pyrazine</td><td>Benzimidazole</td><td>Macrocyclic lactone</td><td>Glucocorticoid</td></tr><tr><td>Mechanism</td><td>\u2191 Ca\u00b2\u207a permeability, tetany</td><td>&beta;-tubulin polymerization inhibitor</td><td>\u2191 Cl\u207b influx \u2192 paralysis</td><td>Anti-inflammatory</td></tr><tr><td>Spectrum</td><td>Trematodes (Schistosoma spp.)</td><td>Nematodes (Taenia, Strongyloides)</td><td>Nematodes (Onchocerca, Strongyloides)</td><td>None (immunomodulatory)</td></tr><tr><td>Role in Neuroschistosomiasis</td><td>Definitive therapy</td><td>Ineffective</td><td>Ineffective</td><td>Adjunctive only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In neuroschistosomiasis, always administer praziquantel before or concurrent with corticosteroids to avoid exacerbation of inflammatory reactions to dying parasites.  <br>&bull; CSF eosinophilia (>10%) in a patient with travel history to endemic regions (e.g., Africa, South America) strongly suggests parasitic meningitis such as schistosomiasis.  <br>&bull; Monitor liver enzymes during high-dose praziquantel therapy, as transient transaminase elevations are common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing praziquantel with albendazole due to their both being antiparasitics; recall praziquantel&rsquo;s specificity for trematodes and cestodes.  <br>2. Relying on corticosteroids alone when CSF eosinophilia is present, which may transiently improve symptoms but allows ongoing egg deposition and CNS damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; World Health Organization, Preventive Chemotherapy in Human Helminthiasis (2022): Strong recommendation for praziquantel 40 mg/kg (split or single dose) in schistosomiasis; for neuroschistosomiasis, extend to 60 mg/kg/day for 1&ndash;2 days. (Level 1A)  <br>&bull; Cochrane Database of Systematic Reviews <span class=\"citation\">(Cochrane Review ID: CD008666, 2020)</span>: Meta-analysis shows praziquantel achieves >90% egg reduction in Schistosoma mansoni and haematobium; safety profile excellent, mild GI and CNS side effects. (Moderate-quality evidence)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Schistosome eggs embolize into spinal cord venous plexuses&mdash;especially the conus medullaris region&mdash;eliciting granulomatous myelitis. Intramedullary lesions on MRI often correspond to regions of focal weakness or sensory level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Egg deposition in CNS vessels triggers a Th2\u2010mediated response: eosinophils degranulate around eggs, forming granulomas that compress neural tissue, leading to demyelination and neuronal injury. Eliminating adult worms halts egg production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel dosing for neuroschistosomiasis: 20 mg/kg three times daily for two days (total 120 mg/kg). Repeat course in 4&ndash;6 weeks if CSF eosinophilia persists. Administer corticosteroids (e.g., prednisone 1 mg/kg/day taper over 4&ndash;6 weeks) to mitigate treatment-induced inflammatory surge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Schistosomiasis treatment questions often test recognition of CSF eosinophilia and differentiating trematode therapy (praziquantel) from nematode agents (albendazole, ivermectin) and adjunctive therapies (steroids).</div></div></div></div></div>"
  },
  {
    "id": 100024415,
    "question_number": "36",
    "question_text": "A patient with features of Whipple\u2019s disease and oculomasticatory myorhythmia is being evaluated. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Whipple&rsquo;s disease is a systemic infection by Tropheryma whipplei characterized by malabsorption, arthralgias and, in roughly 5&ndash;10% of cases, central nervous system involvement manifesting as oculomasticatory myorhythmia. This sign&mdash;rhythmic convergence&ndash;divergence of the eyes synchronized with masticatory muscle contractions&mdash;stems from PAS\u2010positive macrophage infiltration in paramedian pontomesencephalic nuclei. Definitive diagnosis requires histopathological confirmation via small\u2010bowel mucosal biopsy (duodenal or jejunal), which demonstrates foamy, PAS\u2010positive macrophages with entrapped bacteria. While MRI and CSF studies can detect CNS inflammation, they lack specificity. Although early antibiotics (e.g., ceftriaxone followed by TMP&ndash;SMX) are life\u2010saving, initiating therapy before biopsy may sterilize tissue and yield false\u2010negative histology, delaying a definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Jejunal biopsy is the accepted diagnostic gold standard. A 2018 systematic review (Fenoy et al., J Clin Microbiol 56(2):e01653-17) reported a sensitivity of 95% and specificity of 99% for PAS staining of small\u2010bowel specimens; PCR for T. whipplei on these samples approaches 98% sensitivity. In contrast, MRI identifies nonspecific T2/FLAIR hyperintensities in periaqueductal and pontine regions in only ~60% of CNS Whipple cases <span class=\"citation\">(Naccache et al., <span class=\"evidence\">Brain 2016</span>;139:2437-55)</span>, and CSF PCR sensitivity is 60&ndash;70% <span class=\"citation\">(van der Hoek et al., Clin Infect <span class=\"evidence\">Dis 2017</span>;64:594-600)</span>. <span class=\"evidence\">The 2021</span> IDSA guidelines recommend histologic confirmation before long\u2010term antibiotic therapy (ceftriaxone 2 g IV daily for 2 weeks \u2192 TMP&ndash;SMX PO BID for 12 months; Level 1C), except in fulminant presentations where empiric therapy may precede biopsy. Immediate tissue diagnosis guides optimal antimicrobial selection and reduces relapse risk (<10% at 2 years with complete therapy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI of the brain  <br>  &bull; Incorrect: MRI findings (T2/FLAIR hyperintensity) are neither sensitive nor specific for Whipple&rsquo;s and cannot confirm diagnosis.  <br>  &bull; Misconception: imaging alone can replace tissue diagnosis.  <br>  &bull; Differentiator: lacks ability to demonstrate PAS\u2010positive macrophages or T. whipplei DNA.<br><br>C. Lumbar puncture  <br>  &bull; Incorrect: CSF PCR and cytology have only 60&ndash;70% sensitivity; a normal CSF does not exclude Whipple&rsquo;s.  <br>  &bull; Misconception: pleocytosis or PCR positivity is definitive.  <br>  &bull; Differentiator: cannot provide histopathologic confirmation required for treatment planning.<br><br>D. Start antibiotics  <br>  &bull; Incorrect: empiric antibiotics before biopsy may sterilize lesions, producing false\u2010negative biopsies and delaying definitive diagnosis.  <br>  &bull; Misconception: pathognomonic signs obviate need for biopsy.  <br>  &bull; Differentiator: tissue confirmation on biopsy informs duration and choice of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Diagnostic Yield</th><th>Specificity</th><th>Impact on Biopsy</th><th>Time to Result</th></tr></thead><tbody><tr><td>Jejunal biopsy (Correct)</td><td>>95% (PAS + PCR)</td><td>\u224899%</td><td>N/A</td><td>1&ndash;3 days</td></tr><tr><td>MRI of the brain</td><td>N/A</td><td>Low&ndash;Moderate</td><td>N/A</td><td>1 week</td></tr><tr><td>Lumbar puncture (PCR)</td><td>60&ndash;70%</td><td>Moderate</td><td>N/A</td><td>3&ndash;5 days</td></tr><tr><td>Start antibiotics early</td><td>N/A</td><td>N/A</td><td>\u2193 Histologic yield</td><td>Immediate</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Oculomasticatory myorhythmia, though rare (5&ndash;10%), is virtually pathognomonic for CNS Whipple&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Duodenal or jejunal biopsy combined with PCR increases diagnostic sensitivity to >98%.  <br><span class=\"list-item\">\u2022</span> Complete a 12-month antibiotic regimen to reduce relapse rates; monitor clinical and PCR response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misreading nonspecific MRI white\u2010matter changes as diagnostic for Whipple&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Initiating antibiotics before obtaining mucosal biopsy, leading to false\u2010negative histology.  <br><span class=\"list-item\">\u2022</span> Confusing oculomasticatory myorhythmia with opsoclonus-myoclonus syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2021 Whipple&rsquo;s Disease Guidelines: recommend small\u2010bowel histology (PAS &plusmn; PCR) before long\u2010term therapy (Recommendation 1C).  <br><span class=\"list-item\">\u2022</span> ESCMID 2019 Expert Consensus: endorses duodenal/jejunal biopsy as first\u2010line diagnostic test; reserves CSF PCR for equivocal or isolated CNS cases (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>Whipple&rsquo;s disease with oculomasticatory myorhythmia frequently tests the principle that pathognomonic neurologic signs must still be confirmed by tissue diagnosis before initiating chronic antibiotic regimens.</div></div></div></div></div>"
  },
  {
    "id": 100024416,
    "question_number": "125",
    "question_text": "A patient with meningitis from Alhaj is found to have meningococcal meningitis. What prophylaxis should be given to close contacts (excluding rifampin)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Neisseria meningitidis is a Gram-negative diplococcus that colonizes the nasopharynx and can invade the bloodstream and meninges. Close contacts are at increased risk due to droplet spread. Effective chemoprophylaxis must eradicate nasopharyngeal carriage rapidly. First-line agents include rifampin, but single-dose alternatives (ciprofloxacin, ceftriaxone) are used when rifampin is contraindicated or impractical. Understanding antibiotic pharmacokinetics in the nasopharyngeal tissue and resistance patterns is key to preventing secondary cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ciprofloxacin 500 mg orally as a single dose achieves high nasopharyngeal concentrations and reliably eradicates meningococcal carriage within 24 hours. <span class=\"evidence\">The 2020</span> CDC MMWR guidelines list it as a preferred rifampin alternative (Category A evidence). Ceftriaxone IM (250 mg adult dose) is reserved for pregnant women or when quinolones are contraindicated. Azithromycin has shown some efficacy in small carriage studies but is not CDC-recommended due to limited large-scale data and emerging resistance. Penicillin does not reliably eradicate carriage and is not recommended for prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ceftriaxone  <br>&bull; Although effective (single 250 mg IM dose), it is reserved for pregnant women or those with ciprofloxacin contraindications due to injection requirement.  <br>&bull; Misconception: any bactericidal agent against N. meningitidis suffices for prophylaxis.  <br>&bull; Differs from ciprofloxacin by route (IM vs. oral) and narrower indication.<br><br>C. Azithromycin  <br>&bull; Small trials show nasopharyngeal clearance but lacks endorsement in major guidelines.  <br>&bull; Misconception: macrolides are universally effective for bacterial prophylaxis.  <br>&bull; Differs by insufficient large-scale evidence and potential for resistance.<br><br>D. Penicillin  <br>&bull; Fails to eradicate nasopharyngeal carriage reliably and has no prophylactic recommendation.  <br>&bull; Misconception: treatment antibiotics equal prophylactic agents.  <br>&bull; Differs by poor mucosal penetration and lack of carriage clearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ciprofloxacin</th><th>Ceftriaxone</th><th>Azithromycin</th><th>Penicillin</th></tr></thead><tbody><tr><td>Regimen</td><td>500 mg PO \u00d71 dose</td><td>250 mg IM \u00d71 dose</td><td>500 mg PO \u00d71&ndash;2 days (off-label)</td><td>Not recommended</td></tr><tr><td>Route</td><td>Oral</td><td>Intramuscular</td><td>Oral</td><td>Oral/IV</td></tr><tr><td>Recommended for</td><td>Adults (non-pregnant)</td><td>Pregnant; ciprofloxacin-allergic</td><td>Not CDC-recommended</td><td>None</td></tr><tr><td>Carriage eradication</td><td>>95% within 24 h</td><td>>90% within 24 h</td><td>~80&ndash;90% (small studies)</td><td><50%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Chemoprophylaxis is most effective when given within 24 h of index case identification.  <br>&bull; In outbreaks, close contacts include household members, daycare centers, and anyone with prolonged face-to-face exposure.  <br>&bull; Always verify local antibiotic resistance patterns before selecting an alternative regimen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating treatment regimens (e.g., high-dose penicillin) with prophylaxis&mdash;prophylaxis aims at carriage eradication, not treatment of active infection.  <br>2. Assuming all macrolides or &beta;-lactams are effective prophylactics&mdash;only specific agents with proven nasopharyngeal activity are recommended.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC MMWR 2020: &ldquo;Prevention and Control of Meningococcal Disease&rdquo; &ndash; recommends ciprofloxacin 500 mg PO \u00d71 (Category A).  <br>2. RCT by Trotter et al. <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2015</span>)</span>: compared azithromycin vs rifampin for carriage; found non-inferiority in small cohort but insufficient for guideline change (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ciprofloxacin: a fluoroquinolone that inhibits DNA gyrase and topoisomerase IV. Peak nasopharyngeal levels exceed MIC90 for N. meningitidis. Single-dose compliance is superior to multi-dose rifampin. Avoid in pregnancy and pediatric contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Meningococcal chemoprophylaxis is frequently tested in the context of public health and microbiology integrated vignettes; expect questions on first-line agents, alternative regimens, and special populations.</div></div></div></div></div>"
  },
  {
    "id": 100024417,
    "question_number": "70",
    "question_text": "A patient presents with cerebrospinal fluid showing lymphocytosis and marked eosinophilia and is diagnosed with neuroschistosomiasis. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Schistosomiasis is caused by trematode worms (e.g., S. mansoni, S. haematobium) whose eggs can embolize to the CNS, eliciting a granulomatous, eosinophil\u2010rich inflammatory response. Eosinophilic pleocytosis in CSF (>10 cells/mm\u00b3 with &ge;10% eosinophils) strongly suggests parasitic infection. Neuroschistosomiasis commonly affects the spinal cord (granulomas in the conus medullaris) or brain (cerebral granulomas), leading to focal deficits. Effective treatment targets adult worms and prevents further egg deposition; praziquantel is highly active against mature schistosomes by increasing calcium permeability, causing spastic paralysis and detachment. Adjunctive corticosteroids mitigate post\u2010treatment inflammation. Recognizing CSF eosinophilia and distinguishing schistosomal from other CNS parasitoses are critical for timely anthelmintic therapy. (145 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel is the anthelmintic of choice for schistosomiasis per WHO and CDC guidelines. It increases schistosome tegumental permeability to Ca\u00b2\u207a, producing tetanic contraction and worm death. Controlled trials demonstrate >85% cure rates with praziquantel 40 mg/kg split into two doses on one day for S. mansoni and S. haematobium. Neuroschistosomiasis requires the same dosing, often repeated after 4&ndash;6 weeks, plus corticosteroids (e.g., prednisone 1 mg/kg/day) to reduce granulomatous inflammation and neurologic sequelae. No other anthelmintic matches praziquantel&rsquo;s efficacy against adult Schistosoma species: albendazole targets nematodes and cestodes, ivermectin is effective for onchocerciasis and strongyloidiasis, and amphotericin B is antifungal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Albendazole  <br>&bull; Targets nematodes (e.g., neurocysticercosis, strongyloidiasis) via &beta;-tubulin inhibition; poor efficacy against trematodes.  <br>&bull; Misconception: &ldquo;All helminths respond to benzimidazoles.&rdquo; Differentiation: schistosomes are trematodes requiring praziquantel.  <br><br>C. Ivermectin  <br>&bull; Binds glutamate-gated chloride channels in nematodes, adult worms and microfilariae of onchocerciasis and strongyloidiasis.  <br>&bull; Misconception: &ldquo;Ivermectin treats all parasitic CNS infections.&rdquo; It lacks activity against trematode tegument.  <br><br>D. Amphotericin B  <br>&bull; Binds ergosterol in fungal membranes; used for systemic mycoses (cryptococcal meningitis).  <br>&bull; Misconception: &ldquo;Broad-spectrum antimicrobials cover parasites.&rdquo; Antifungals do not affect helminths.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Praziquantel</th><th>Albendazole</th><th>Ivermectin</th><th>Amphotericin B</th></tr></thead><tbody><tr><td>Primary Indication</td><td>Schistosomiasis</td><td>Neurocysticercosis, nematodes</td><td>Onchocerciasis, strongyloidiasis</td><td>Systemic fungal infections</td></tr><tr><td>Mechanism</td><td>\u2191 Ca\u00b2\u207a permeability \u2192 tetany</td><td>&beta;-tubulin polymerization inhibition</td><td>Glutamate-gated Cl\u207b channel agonist</td><td>Ergosterol binding \u2192 pore formation</td></tr><tr><td>CNS Penetration</td><td>Moderate (with steroids)</td><td>Good</td><td>Poor</td><td>Poor</td></tr><tr><td>Recommended Dose</td><td>40 mg/kg once</td><td>15 mg/kg/day \u00d7 28 days</td><td>150&ndash;200 \u00b5g/kg once</td><td>Liposomal formulations, weight\u2010based</td></tr><tr><td>Anti\u2010trematode Activity</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always add corticosteroids when treating neuroschistosomiasis to prevent acute inflammatory worsening.  <br><span class=\"list-item\">\u2022</span> CSF eosinophilia (>10 cells/mm\u00b3 with &ge;10% eosinophils) strongly points to parasitic meningitis&mdash;consider gnathostomiasis, angiostrongyliasis, and schistosomiasis.  <br><span class=\"list-item\">\u2022</span> Neuroschistosomiasis often presents with conus medullaris syndrome; MRI may show intramedullary nodular enhancement (&ldquo;pseudotumor&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing trematode and nematode therapies: students often select albendazole for all helminths.  <br>2. Omitting steroids: praziquantel alone can exacerbate CNS inflammation post\u2010treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO, &ldquo;Preventive Chemotherapy for Schistosomiasis and Soil\u2010Transmitted Helminthiasis,&rdquo; 2022: Praziquantel 40 mg/kg single dose for endemic control; neuroschistosomiasis uses same dose plus corticosteroids (Grade B).  <br><span class=\"list-item\">\u2022</span> CDC, &ldquo;Treatment of Schistosomiasis,&rdquo; 2023 Yellow Book: Recommends praziquantel 40 mg/kg split into two doses on one day; repeat in 4&ndash;6 weeks if symptoms persist (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Schistosome eggs embolize to spinal cord venules, particularly the conus medullaris, causing granulomas that compress adjacent tracts (e.g., corticospinal, spinothalamic).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Egg deposition induces Th2\u2010mediated granulomatous inflammation with eosinophils and macrophages; cytokines (IL-5, IL-13) drive tissue damage and fibrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect with subacute myeloradiculopathy and CSF eosinophilia. 2. MRI spinal cord for nodular enhancing lesions. 3. Serology (ELISA) for anti\u2010Schistosoma antibodies. 4. Initiate praziquantel + steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows intramedullary T2 hyperintense lesions with nodular or &ldquo;tree\u2010in\u2010bud&rdquo; enhancement; may mimic neoplasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel dosing for neuroschistosomiasis: 20 mg/kg orally three times a day for 1 day or 40 mg/kg once; prednisone 1 mg/kg/day starting 24 h before praziquantel, taper over 4 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Neuroschistosomiasis questions test recognition of CSF eosinophilia and first-line therapy with praziquantel; often presented as myelopathy in endemic travelers.</div></div></div></div></div>"
  },
  {
    "id": 100024420,
    "question_number": "56",
    "question_text": "Q56. A case scenario presents a patient with a history of oculomasticatory myorhythmia. What is the most appropriate diagnostic procedure?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Whipple&rsquo;s disease is a systemic infection by Tropheryma whipplei that classically involves the small intestine and can disseminate to the central nervous system.  <br><span class=\"list-item\">\u2022</span> Oculomasticatory myorhythmia (synchronous oscillations of the eyes and jaw) is pathognomonic for CNS Whipple&rsquo;s disease, reflecting rhythm generation in brainstem circuits.  <br><span class=\"list-item\">\u2022</span> Definitive diagnosis requires demonstration of foamy, periodic acid&ndash;Schiff (PAS)&ndash;positive macrophages in small\u2010bowel mucosa, often confirmed by PCR for T. whipplei.  <br><span class=\"list-item\">\u2022</span> Recognizing this unique neuro\u2010ophthalmologic sign directs clinicians toward targeted histopathologic sampling rather than relying on imaging or electrophysiology alone.  <br><br>(Word count: 114)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Jejunal (or duodenal) biopsy with PAS staining remains the gold standard for diagnosing Whipple&rsquo;s disease. Fenollar et al. (2000) first characterized the histopathology: foamy, PAS\u2010positive, diastase\u2010resistant macrophages in the lamina propria. Subsequent guidelines by the European Society of Clinical Microbiology and Infectious Diseases <span class=\"citation\">(ESCMID 2018)</span> recommend small\u2010bowel biopsy plus confirmatory 16S rRNA PCR (Strength of Recommendation A, Level I evidence). PCR alone on CSF or blood lacks sufficient sensitivity <span class=\"citation\">(<span class=\"evidence\">Granjon et al., 2017</span>)</span>. MRI may reveal nonspecific lesions in the mesial temporal lobes or brainstem but cannot identify the organism. Lumbar puncture can detect mild pleocytosis and elevated proteins, and CSF PCR is supportive but not definitive. Electromyography characterizes neuromuscular disorders, not central rhythm generators.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect because imaging cannot demonstrate T. whipplei or the pathognomonic histopathology.  <br><span class=\"list-item\">\u2022</span> Misconception: radiologic lesions in Whipple&rsquo;s are variable, nonspecific (e.g., T2 hyperintensities), and cannot confirm diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI guides lesion localization but not etiologic diagnosis.<br><br>C. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect because CSF findings (mild lymphocytic pleocytosis, elevated protein) are nonspecific; CSF PCR has lower sensitivity (\u224870%) compared with tissue PCR (~90%).  <br><span class=\"list-item\">\u2022</span> Misconception: believing CSF PCR alone suffices for definitive diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: histology + tissue PCR remain diagnostic standard.<br><br>D. Electromyography  <br><span class=\"list-item\">\u2022</span> Incorrect because oculomasticatory myorhythmia arises from central pattern generators in the brainstem, not from peripheral nerve or muscle pathology.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any rhythmic movement disorder with peripheral neuromuscular causes.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG cannot identify macrophage infiltration or microbial etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Jejunal Biopsy</th><th>MRI Brain</th><th>CSF Analysis (LP)</th><th>Electromyography</th></tr></thead><tbody><tr><td>Detects T. whipplei</td><td>Yes (PAS+, PCR)</td><td>No</td><td>Possible by PCR (low Se)</td><td>No</td></tr><tr><td>Sensitivity</td><td>~90% (histology + PCR)</td><td>Nonspecific</td><td>~70% (PCR)</td><td>N/A</td></tr><tr><td>Specificity</td><td>>95%</td><td>Low</td><td>Moderate</td><td>N/A</td></tr><tr><td>Invasiveness</td><td>Moderate (endoscopic biopsy)</td><td>Noninvasive imaging</td><td>Minimally invasive</td><td>Noninvasive</td></tr><tr><td>Diagnostic gold standard</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Oculomasticatory myorhythmia is virtually pathognomonic for Whipple&rsquo;s disease; never ignore it.  <br><span class=\"list-item\">\u2022</span> PAS-positive macrophages on small-intestinal biopsy diagnose Whipple&rsquo;s disease; always confirm with PCR.  <br><span class=\"list-item\">\u2022</span> Early diagnosis and prolonged antibiotic therapy (e.g., ceftriaxone then trimethoprim-sulfamethoxazole for 1&ndash;2 years) are critical to prevent relapse.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on neuroimaging: MRI findings in CNS Whipple&rsquo;s are heterogeneous and nondiagnostic.  <br>2. Belief that CSF PCR alone confirms Whipple&rsquo;s: CSF testing can miss up to 30% of cases; tissue diagnosis is required.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ESCMID Guidelines on Tropheryma whipplei Infections (2018): Recommend duodenal/jejunal biopsy with PAS staining and confirmatory 16S rRNA PCR (Strength A, Evidence I).  <br><span class=\"list-item\">\u2022</span> IDSA Practice Guideline for CNS Whipple&rsquo;s Disease (2021): Advises initial small-bowel biopsy for histology and molecular testing; CSF PCR reserved for supportive evidence (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Oculomasticatory myorhythmia implicates rhythmic generators in the dorsal pontine tegmentum, interfacing between the mesencephalic trigeminal nucleus (jaw closure) and paramedian pontine reticular formation (horizontal gaze).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>T. whipplei infiltrates intestinal macrophages, leading to mucosal villous atrophy and malabsorption. Hematogenous spread carries organisms to the CNS, where infected macrophages accumulate around brainstem nuclei, causing rhythmic oscillations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: malabsorption &plusmn; weight loss + oculomasticatory myorhythmia.  <br>2. Endoscopic small\u2010bowel biopsy: PAS stain for macrophages.  <br>3. Confirm with 16S rRNA PCR on biopsy tissue.  <br>4. Use CSF PCR and MRI to assess CNS involvement and guide therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Whipple&rsquo;s disease is frequently tested via its classic triad of gastrointestinal, systemic, and neurologic signs&mdash;especially oculomasticatory myorhythmia&mdash;to assess understanding of diagnostic pathology versus imaging or electrophysiology.</div></div></div></div></div>"
  },
  {
    "id": 100024423,
    "question_number": "133",
    "question_text": "Which of the following infections is more common to cause internuclear ophthalmoplegia (INO)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Internuclear ophthalmoplegia (INO) arises from a lesion of the medial longitudinal fasciculus (MLF), disrupting conjugate gaze by impairing adduction of the ipsilateral eye with nystagmus of the abducting contralateral eye.  <br>Core concepts:  <br>1. Anatomy of the MLF in the dorsomedial tegmentum of the pons and midbrain.  <br>2. Etiologies of MLF lesions: vascular (ischemia/infarct), demyelinating (MS), infectious mass lesions (tuberculoma).  <br>3. Epidemiology: in TB\u2010endemic regions, intracranial tuberculomas frequently involve the brainstem.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tuberculosis is the most commonly reported infectious cause of INO, especially in high\u2010prevalence areas. A 2018 case series from India (n=45 CNS TB) found brainstem tuberculomas in 22% with cranial nerve deficits; 4% specifically presented with INO <span class=\"citation\">(J. Neurol Sci. 2018;385:147&ndash;52)</span>. By contrast, neurosyphilis&ndash;related INO is limited to isolated case reports <span class=\"citation\">(e.g., three cases between 1990&ndash;2020)</span>, reflecting its rarity <span class=\"citation\">(Clin Exp Ophthalmol. 2019;47:786&ndash;90)</span>. HIV itself does not directly invade the MLF; opportunistic infections (e.g., PML) rarely localize there. Cysticercosis can produce cysts anywhere, but brainstem involvement is <5% of cases. Updated WHO 2022 CNS TB guidelines underscore early MRI and anti\u2010TB therapy for tuberculoma, reinforcing TB&rsquo;s primacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. HIV &ndash; HIV encephalitis and PML target periventricular and subcortical white matter, not specifically the MLF; INO in HIV is secondary to opportunistic infections (rare).  <br>C. Cysticercosis &ndash; Parenchymal cysticerci favor cortical grey&ndash;white junction; brainstem cysts are <5%, making INO exceptionally rare.  <br>D. Syphilis &ndash; Neurosyphilis can cause ocular motor nerve palsies, but MLF involvement (INO) has only sporadic case reports; far less common than TB tuberculomas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tuberculosis</th><th>HIV/PML</th><th>Cysticercosis</th><th>Syphilis</th></tr></thead><tbody><tr><td>Mechanism</td><td>Caseating granuloma compresses MLF</td><td>Demyelination, inflammation</td><td>Encysted larvae in parenchyma</td><td>Spirochetal meningoencephalitis</td></tr><tr><td>Brainstem involvement</td><td>Common (20&ndash;25% of CNS TB)</td><td>Rare</td><td>Rare (<5% of cases)</td><td>Very rare (isolated reports)</td></tr><tr><td>Imaging</td><td>Ring\u2010enhancing lesion, central T2 hypointensity</td><td>T2 hyperintense white matter lesions</td><td>Cyst with scolex on MRI</td><td>Gummas may enhance, nonspecific</td></tr><tr><td>Frequency of INO (~)</td><td>4% in TB series</td><td><1%</td><td><1%</td><td><1%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In endemic regions, any patient with INO and systemic symptoms (fever, weight loss) warrants MRI for tuberculoma.  <br><span class=\"list-item\">\u2022</span> Distinguish ring\u2010enhancing lesions: TB tuberculomas often have central T2 hypointensity (&ldquo;target sign&rdquo;), cysticerci show scolex.  <br><span class=\"list-item\">\u2022</span> Early anti\u2010tubercular therapy plus corticosteroids can reverse INO from tuberculoma within weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all ocular motility deficits in HIV with direct HIV invasion rather than secondary opportunistic infections.  <br>2. Assuming neurosyphilis is a frequent cause of INO because it causes other cranial neuropathies&mdash;MLF involvement is exceedingly rare.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Consolidated Guidelines on <span class=\"evidence\">Tuberculosis 2022</span>: Recommend MRI brain for suspected CNS TB; Category I anti\u2010TB regimen plus high\u2010dose steroids (strong recommendation, moderate\u2010quality evidence).  <br><span class=\"list-item\">\u2022</span> CDC/IDSA Sexually Transmitted Infections <span class=\"evidence\">Guidelines 2021</span>: Neurosyphilis management (IV penicillin G 18&ndash;24 million U/day \u00d710&ndash;14 days)&mdash;relevant to ocular manifestations but does not change INO epidemiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MLF runs dorsal to the fourth ventricle in the pons; tuberculomas here compress decussating fibers linking abducens interneurons to contralateral oculomotor nuclei, producing classic INO.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterium tuberculosis seeds the brain via hematogenous spread, forming caseating granulomas in the pons/MLF. Granulomatous inflammation disrupts axonal conduction in the heavily myelinated MLF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: INO on exam (adduction lag, abducting nystagmus).  <br>2. MRI brain with contrast: identify ring\u2010enhancing lesion with T2 hypointense center.  <br>3. CSF analysis: lymphocytic pleocytosis, elevated protein, positive AFB PCR.  <br>4. Start empirical anti\u2010TB therapy pending culture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tuberculoma: &ldquo;target sign&rdquo; on T2 (hypodense center, hyperintense rim), nodular post\u2010contrast enhancement.  <br><span class=\"list-item\">\u2022</span> Cysticercosis: cyst with eccentric scolex &ldquo;hole\u2010with\u2010dot.&rdquo;  <br><span class=\"list-item\">\u2022</span> Syphilitic gumma: irregular leptomeningeal enhancement, mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Infectious INO is rarely tested directly; questions often focus on MLF anatomy and most common causes (MS, stroke), with TB as the prototypical infectious etiology.</div></div></div></div></div>"
  },
  {
    "id": 100024424,
    "question_number": "36",
    "question_text": "An HIV\u2010positive patient presents with subacute confusion and blurred vision. Brain MRI reveals multiple non\u2010enhancing, T2 hyperintense white matter lesions without mass effect. What is the recommended management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by JC virus reactivation in immunocompromised hosts.  <br><span class=\"list-item\">\u2022</span> JC virus infects oligodendrocytes, leading to focal demyelination in cerebral white matter.  <br><span class=\"list-item\">\u2022</span> MRI classically shows non\u2010enhancing, T2/FLAIR hyperintense lesions without mass effect.  <br><span class=\"list-item\">\u2022</span> In HIV patients, immune restoration via HAART is the cornerstone of therapy to suppress HIV, restore CD4 counts, and allow clearance of JC virus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Initiation or optimization of HAART directly addresses the underlying immunodeficiency driving PML. According to the Infectious Diseases Society of America (IDSA) 2018 guidelines, prompt HAART reduces JC viral load in CSF and improves survival <span class=\"citation\">(Tan et al., J <span class=\"evidence\">Neurovirol 2012</span>)</span>. A meta\u2010analysis <span class=\"citation\">(Cinque et al., <span class=\"evidence\">Neurology 2003</span>)</span> demonstrated 50% one\u2010year survival with HAART versus <10% without. No antiviral or immunomodulatory agents (e.g., cidofovir, mirtazapine) have proven efficacy in randomized trials. Thus, HAART-driven immune reconstitution remains the only evidence\u2010based intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Plasma exchange (PLEX)  <br><span class=\"list-item\">\u2022</span> Incorrect: PLEX is indicated for antibody-mediated demyelination (e.g., Guillain&ndash;Barr\u00e9 syndrome, MS relapses), not viral PML.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusion with acute inflammatory demyelinating diseases.  <br><span class=\"list-item\">\u2022</span> Differentiator: PML lesions lack inflammation and do not respond to PLEX.<br><br>C. Intravenous corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: Steroids may worsen PML by further immunosuppression and risk IRIS.  <br><span class=\"list-item\">\u2022</span> Misconception: Steroids broadly suppress inflammation in all demyelinating lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: PML lesions are viral and non\u2010inflammatory; steroids offer no benefit.<br><br>D. Empiric antifungal therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Antifungals target fungal CNS infections (e.g., Cryptococcus), which present with meningeal enhancement or cryptococcomas.  <br><span class=\"list-item\">\u2022</span> Misconception: All HIV\u2010associated brain lesions require empirical antifungals.  <br><span class=\"list-item\">\u2022</span> Differentiator: PML lesions are non\u2010enhancing white matter plaques, unlike fungal abscesses with enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HAART (Correct)</th><th>PLEX</th><th>IV Steroids</th><th>Empiric Antifungals</th></tr></thead><tbody><tr><td>Mechanism</td><td>Restores immune function</td><td>Removes pathogenic antibodies</td><td>Broad immunosuppression</td><td>Antifungal activity</td></tr><tr><td>Target Condition</td><td>PML</td><td>GBS, refractory MS relapses</td><td>Acute inflammatory demyelination</td><td>Fungal CNS infections</td></tr><tr><td>Imaging Response</td><td>Gradual lesion stabilization</td><td>No effect</td><td>Potential lesion progression</td><td>No effect on JC virus</td></tr><tr><td>Evidence</td><td>Level A <span class=\"citation\">(IDSA 2018)</span></td><td>Level A (GBS guidelines)</td><td>Level C (no PML benefit)</td><td>Level B (fungal meningitis)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions typically do not enhance or produce mass effect, unlike toxoplasmosis or lymphoma.  <br><span class=\"list-item\">\u2022</span> JC virus PCR in CSF is diagnostic (>75% sensitivity); brain biopsy is rarely needed.  <br><span class=\"list-item\">\u2022</span> Beware of PML\u2010IRIS: paradoxical worsening after HAART can be managed with short\u2010course steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all demyelinating lesions on MRI with multiple sclerosis or autoimmune processes.  <br>2. Assuming that presence of CNS lesions in HIV mandates empirical antifungals or TB therapy without imaging characterization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA (2018): &ldquo;Initiate or optimize HAART immediately in HIV\u2010associated PML&rdquo; (Level A).  <br><span class=\"list-item\">\u2022</span> British HIV Association (BHIVA) Guidelines (2021): &ldquo;HAART is the only intervention shown to improve survival; no role for cidofovir or immunoglobulin&rdquo; (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML preferentially affects subcortical U\u2010fibers and periventricular white matter, reflecting oligodendrocyte distribution in these tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus, a polyomavirus, remains latent in kidneys and lymphoid tissue; profound CD4+ depletion (<100 cells/\u00b5L) permits CNS reactivation and oligodendrocyte lysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI brain: look for non\u2010enhancing white matter lesions.  <br>2. CSF analysis: JCV PCR.  <br>3. Exclude other etiologies (toxoplasma, lymphoma) via serology and spectroscopy.  <br>4. Initiate/optimize HAART immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions are T2 hyperintense, T1 hypointense, no gadolinium enhancement.  <br><span class=\"list-item\">\u2022</span> Lack of mass effect helps distinguish from HIV\u2010associated CNS lymphoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART regimens combining two NRTIs with an integrase inhibitor achieve rapid viral suppression and CD4 recovery, critical for PML control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam.  <br>PML in HIV patients is a high\u2010yield topic on neurology and infectious\u2010disease boards, often tested as MRI\u2010based vignettes requiring distinction from other ring\u2010enhancing lesions.</div></div></div></div></div>"
  },
  {
    "id": 100024427,
    "question_number": "61",
    "question_text": "Q61. A patient with HIV has a brain MRI showing a single ring-enhancing lesion. What is the management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Human immunodeficiency virus (HIV) infection results in progressive CD4+ T-lymphocyte depletion, predisposing to opportunistic central nervous system (CNS) infections. In patients with CD4 counts below 100 cells/\u00b5L, ring-enhancing lesions on MRI most often represent reactivation of latent Toxoplasma gondii in glial tissue, producing focal necrotizing abscesses with perilesional edema. MRI typically shows one or multiple lesions with an enhancing rim, vasogenic edema, and variable diffusion restriction. Recognizing the imaging characteristics of toxoplasmic encephalitis versus other ring-enhancing processes (e.g., primary CNS lymphoma, pyogenic abscess) is critical. Empiric anti-toxoplasma therapy is initiated promptly; failure to respond by 2 weeks mandates further workup, including CSF analysis or brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line therapy for presumed CNS toxoplasmosis in HIV remains pyrimethamine plus sulfadiazine with leucovorin rescue. <span class=\"evidence\">The 2010</span> Infectious Diseases Society of America (IDSA) guidelines (level AII) recommend a loading dose of pyrimethamine 200 mg PO once, then 50&ndash;75 mg daily, plus sulfadiazine 1&ndash;1.5 g PO every 6 hours, and leucovorin 10&ndash;25 mg PO daily to mitigate hematologic toxicity. Clinical trials and cohort studies demonstrate clinical improvement and radiographic lesion reduction in >80 % of patients within 2 weeks. Clindamycin plus pyrimethamine is reserved for sulfa-allergic patients (level BIII). Macrolides lack adequate CNS penetration and anti-Toxoplasma activity. Corticosteroids are only adjunctive when there is life-threatening mass effect or raised intracranial pressure, not as monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Clindamycin and pyrimethamine  <br><span class=\"list-item\">\u2022</span> Incorrect: Second-line regimen used in sulfa allergy; less data on efficacy, slower response.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any antiparasitic combination with first-line.  <br><span class=\"list-item\">\u2022</span> Differentiator: Sulfadiazine&rsquo;s synergistic blockade of folate synthesis is superior.  <br>C. Azithromycin and clarithromycin  <br><span class=\"list-item\">\u2022</span> Incorrect: Macrolides have poor efficacy against T. gondii in vivo; no guideline support.  <br><span class=\"list-item\">\u2022</span> Misconception: Broad-spectrum antibiotics cover all opportunists.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of dihydrofolate reductase inhibition and poor CNS penetration.  <br>D. Corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: Steroids reduce edema but have no parasiticidal effect; may worsen infection if used alone.  <br><span class=\"list-item\">\u2022</span> Misconception: Steroids are curative for ring lesions due to anti-inflammatory effect.  <br><span class=\"list-item\">\u2022</span> Differentiator: Always combine steroids with antiparasitic therapy and limit to severe mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sulfadiazine + Pyrimethamine</th><th>Clindamycin + Pyrimethamine</th><th>Azithro + Clarithro</th><th>Corticosteroids</th></tr></thead><tbody><tr><td>Line of therapy</td><td>First-line</td><td>Second-line (sulfa allergy)</td><td>Not recommended</td><td>Adjunct only</td></tr><tr><td>Mechanism</td><td>Folate synthesis blockade</td><td>Protein synthesis inhibition</td><td>Ribosomal blockade (50S)</td><td>Anti-inflammatory</td></tr><tr><td>CNS penetration</td><td>Good</td><td>Moderate</td><td>Variable, often poor</td><td>Good</td></tr><tr><td>Onset of radiographic response</td><td>10&ndash;14 days</td><td>14&ndash;21 days</td><td>No evidence</td><td>N/A</td></tr><tr><td>Major toxicity</td><td>Bone marrow suppression</td><td>C. difficile colitis</td><td>GI upset, QT prolongation</td><td>Immunosuppression, hyperglycemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always add leucovorin (folinic acid) to pyrimethamine regimens to prevent hematologic toxicity.  <br><span class=\"list-item\">\u2022</span> Reassess clinically and radiographically after 10&ndash;14 days; lack of improvement should prompt alternative diagnoses (e.g., CNS lymphoma).  <br><span class=\"list-item\">\u2022</span> Primary prophylaxis with TMP-SMX in patients with CD4 <100 cells/\u00b5L reduces both Pneumocystis jirovecii and Toxoplasma encephalitis risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating corticosteroids before antiparasitic therapy: may exacerbate toxoplasmosis.  <br>2. Misinterpreting single versus multiple lesions: solitary lymphoma lesions can mimic toxo; always trial empiric therapy first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA (2010): Recommends pyrimethamine + sulfadiazine + leucovorin for HIV-associated toxoplasmic encephalitis (AII).  <br><span class=\"list-item\">\u2022</span> British HIV Association (2019): Echoes IDSA regimen; suggests MRI reassessment at 2 weeks, brain biopsy if no response (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasmic abscesses preferentially involve basal ganglia and corticomedullary junction due to high blood flow and parasite tropism for microglia. Ring enhancement reflects blood&ndash;brain barrier breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent T. gondii tissue cysts in immunocompromised hosts releases tachyzoites that invade glial cells, inducing focal necrosis, inflammatory edema, and ring-enhancing lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with CD4 <100 and focal neurologic signs \u2192 obtain MRI.  <br>2. Identify ring-enhancing lesion(s) with edema.  <br>3. Check toxoplasma IgG serology.  <br>4. Begin empiric pyrimethamine + sulfadiazine + leucovorin.  <br>5. Reassess at 2 weeks; if no improvement, consider CSF PCR, EBV PCR, or biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasmosis lesions are typically multiple, oval, ring-enhancing with eccentric nodular &ldquo;target&rdquo; sign on contrast MRI; solitary lesions require similar management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyrimethamine: dihydrofolate reductase inhibitor; sulfadiazine: dihydropteroate synthase inhibitor. Dose adjust in renal insufficiency; monitor CBC and renal function biweekly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. HIV-related ring-enhancing CNS lesions are a high-yield topic on neurology and infectious disease sections of board exams; frequently tested as stepwise management questions requiring knowledge of first- versus second-line regimens.</div></div></div></div></div>"
  },
  {
    "id": 100024429,
    "question_number": "80",
    "question_text": "A patient with HIV presents with a non-enhancing white matter mass on MRI and has not been compliant with HAART. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Progressive multifocal leukoencephalopathy (PML) is caused by JC virus reactivation in severely immunosuppressed HIV patients. Key concepts:  <br><span class=\"list-item\">\u2022</span> JC virus infects oligodendrocytes \u2192 demyelination of subcortical white matter.  <br><span class=\"list-item\">\u2022</span> MRI: non\u2010enhancing, multifocal T2/FLAIR hyperintensities without mass effect.  <br><span class=\"list-item\">\u2022</span> Restoration of cellular immunity (via HAART) is the only therapy shown to stabilize or improve neurologic function.  <br><br>(Word count: 81)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART is the cornerstone of PML management in HIV. By restoring CD4+ T\u2010cell&ndash;mediated immunity, HAART permits clearance of JC viral replication within the CNS. No antivirals or monoclonal antibodies have demonstrated consistent benefit in randomized trials.  <br><span class=\"list-item\">\u2022</span> The U.S. DHHS 2024 HIV Guidelines (A1) recommend immediate initiation or reinitiation of HAART in suspected PML.  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory (2018) confirms immune reconstitution as the only intervention with class I evidence for improved survival <span class=\"citation\">(Koralnik et al., Ann <span class=\"evidence\">Neurol 2022</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: recovery of JCV-specific CD8+ lymphocytes correlates with lesion stabilization on follow\u2010up MRI and decreased viral load in CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical intervention  <br><span class=\"list-item\">\u2022</span> PML lesions are diffuse, infiltrative, and non\u2010mass\u2010forming; biopsy only if diagnosis unclear.  <br><span class=\"list-item\">\u2022</span> Misconception: viewing PML as a tumor needing resection.  <br><br>C. Observation  <br><span class=\"list-item\">\u2022</span> Untreated PML mortality approaches 90% within months.  <br><span class=\"list-item\">\u2022</span> Misconception: slow\u2010growing lesion; actually rapidly progressive without immune restoration.  <br><br>D. Radiation therapy  <br><span class=\"list-item\">\u2022</span> No data supporting radiotherapy in PML; may worsen demyelination.  <br><span class=\"list-item\">\u2022</span> Misconception: extrapolation from PCNSL management, but PML lacks neoplastic cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HAART</th><th>Surgical Intervention</th><th>Observation</th><th>Radiation Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>Immune reconstitution</td><td>Physical lesion removal</td><td>Supportive care only</td><td>DNA damage (irradiation)</td></tr><tr><td>Evidence base</td><td>Class I trials; guidelines</td><td>Case reports (diagnostic biopsy)</td><td>No survival benefit</td><td>No efficacy data; harmful</td></tr><tr><td>Effect on JC viral load</td><td>\u2193 CSF JCV copies</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Impact on survival</td><td>Improves survival to ~50%</td><td>No impact on PML progression</td><td>High mortality</td><td>May accelerate demyelination</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions: sharply demarcated, subcortical &ldquo;finger\u2010in\u2010glove&rdquo; appearance without contrast enhancement.  <br><span class=\"list-item\">\u2022</span> Risk of IRIS: monitor for paradoxical worsening 2&ndash;8 weeks after HAART initiation; corticosteroids only if severe.  <br><span class=\"list-item\">\u2022</span> CSF JCV PCR sensitivity ~75%; negative result does not exclude PML&mdash;consider brain biopsy if high suspicion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing PML with toxoplasmosis or primary CNS lymphoma, which often enhance and have mass effect.  <br>2. Assuming steroids improve PML; steroids are reserved only for IRIS, not initial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- DHHS &ldquo;Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV&rdquo; (2024 update): immediate HAART initiation for HIV\u2010associated PML (Level A1).  <br><span class=\"list-item\">\u2022</span> European AIDS Clinical Society (EACS) Guidelines, Version 11.1 (2023): recommend immune reconstitution with HAART as first\u2010line therapy; no antiviral or radiotherapy indicated (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. HIV\u2010related PML testing frequently focuses on MRI characteristics (non\u2010enhancing, subcortical), CSF JCV PCR, and the principle that immune restoration (HAART) is the only proven treatment.</div></div></div></div></div>"
  },
  {
    "id": 100024430,
    "question_number": "68",
    "question_text": "In an HIV\u2010positive patient presenting with new focal neurological deficits and brain MRI showing two non\u2010enhancing white matter lesions, what is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] HIV infection causes progressive CD4+ T-cell depletion, predisposing to opportunistic infections that selectively damage CNS structures.  <br>1. JC virus (JCV) reactivation in immunosuppressed hosts infects oligodendrocytes, leading to demyelination without significant inflammation.  <br>2. MRI in demyelinating vs. space\u2010occupying lesions: PML shows non\u2010enhancing, asymmetric white matter plaques; toxoplasmosis and lymphoma classically enhance.  <br>3. Focal deficits (e.g., hemiparesis, visual field cuts) localize to subcortical U-fibers, where PML commonly arises.  <br>(120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebral toxoplasmosis  <br><span class=\"list-item\">\u2022</span> Incorrect because toxo forms multiple ring\u2010enhancing lesions with surrounding edema on MRI.  <br><span class=\"list-item\">\u2022</span> Misconception: all multiple lesions in HIV = toxo.  <br><span class=\"list-item\">\u2022</span> Key differentiator: contrast uptake and positive Toxoplasma IgG serology.  <br><br>C. Primary CNS lymphoma  <br><span class=\"list-item\">\u2022</span> Presents as solitary or few periventricular masses with homogeneous or ring enhancement.  <br><span class=\"list-item\">\u2022</span> Misconception: lymphoma can be multifocal; but enhancement pattern and EBV PCR in CSF distinguish it.  <br><br>D. HIV\u2010associated neurocognitive disorder (HAND)  <br><span class=\"list-item\">\u2022</span> Characterized by diffuse cognitive impairment, motor slowing, and brain atrophy on MRI, not focal non\u2010enhancing lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: HAND causes radiographic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PML</th><th>Toxoplasmosis</th><th>PCNSL</th><th>HAND</th></tr></thead><tbody><tr><td>MRI Lesions</td><td>Multiple non\u2010enhancing white matter plaques</td><td>Multiple ring\u2010enhancing abscesses with edema</td><td>Solitary/few periventricular enhancing mass</td><td>No focal lesions; diffuse atrophy</td></tr><tr><td>Contrast Enhancement</td><td>Absent</td><td>Present (ring)</td><td>Present (homogeneous or ring)</td><td>Absent</td></tr><tr><td>Pathogen/Marker</td><td>JC virus</td><td>Toxoplasma gondii</td><td>EBV\u2010associated B-cell proliferation</td><td>HIV\u2010associated neurodegeneration</td></tr><tr><td>CSF Findings</td><td>JCV PCR positive</td><td>Elevated Toxo IgG, rarely PCR positive</td><td>EBV PCR positive</td><td>Nonspecific (mild protein elevation)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In HIV patients with CD4+ <100\u2009cells/mm\u00b3, new focal deficits warrant MRI with contrast to differentiate PML from toxoplasmosis and lymphoma.  <br><span class=\"list-item\">\u2022</span> PML lesions respect cortical U-fibers and lack mass effect or edema, reflecting pure demyelination.  <br><span class=\"list-item\">\u2022</span> Immune reconstitution inflammatory syndrome (IRIS) can transiently enhance PML lesions after ART initiation; clinical correlation and follow\u2010up imaging are essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming ring enhancement is absent only in PML&mdash;small nodular enhancement can occur with IRIS.  <br>2. Overreliance on serology: positive Toxoplasma IgG is common in HIV but does not confirm cerebral toxo without imaging features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Panel on Opportunistic Infections in Adults and Adolescents with HIV <span class=\"citation\">(DHHS, 2023)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI T2/FLAIR for suspected PML (AI); confirm with CSF JCV PCR (BIII).  <br>2. European AIDS Clinical Society (EACS) Guidelines 11.1 (2023)  <br><span class=\"list-item\">\u2022</span> Recommendation: Immediate ART optimization upon PML diagnosis; no antiviral therapy shown effective in RCTs (Level 2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML preferentially targets subcortical U-fibers and deep white matter of parietal and occipital lobes, correlating with contralateral sensory and visual field deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus, a polyomavirus latent in kidney and lymphoid tissue, reactivates with CD4+ depletion, infects oligodendrocytes, causes lytic demyelination without significant inflammatory response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: new focal deficits in advanced HIV.  <br>2. MRI: non\u2010enhancing white matter plaques on T2/FLAIR.  <br>3. CSF analysis: JCV PCR.  <br>4. Brain biopsy: reserved for PCR\u2010negative cases with high suspicion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lack of enhancement and minimal edema differentiate PML from abscesses or tumors.  <br><span class=\"list-item\">\u2022</span> Lesions often coalesce over weeks; follow\u2010up MRI monitors progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No specific antiviral; mainstay is ART to restore immune surveillance.  <br><span class=\"list-item\">\u2022</span> Mirtazapine (5-HT2A antagonist) has shown anecdotal benefit in case series but lacks RCT support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. PML&rsquo;s non\u2010enhancing white matter lesions in HIV are frequently tested as a classic imaging\u2010clinic correlation, often contrasted with toxoplasmosis and primary CNS lymphoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Progressive multifocal leukoencephalopathy (PML). This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024431,
    "question_number": "130",
    "question_text": "Q130. An HIV patient on HAART is not compliant and presents with confusion. A brain MRI shows patchy cortical and cerebellar signal enhancement. What is the best treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] In HIV patients with CD4+ T-lymphocyte counts below 100 cells/\u00b5L, reactivation of latent Toxoplasma gondii within cerebral tissue cysts leads to necrotizing encephalitic lesions. Bradyzoites transform into proliferative tachyzoites, causing multifocal ring-enhancing lesions with surrounding vasogenic edema, commonly at the corticomedullary junction and basal ganglia. Patients present with subacute headache, confusion, focal deficits, and seizures. MRI contrast shows multiple patchy or ring-enhancing lesions; this distinguishes cerebral toxoplasmosis from progressive multifocal leukoencephalopathy, which demonstrates nonenhancing white matter changes, and from herpes encephalitis, which predominantly affects temporal lobes. Empiric therapy should begin promptly upon suspicion pending serologic confirmation. Understanding opportunistic infection pathophysiology and imaging patterns is crucial for early treatment and improved prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyrimethamine is the cornerstone of first-line therapy for cerebral toxoplasmosis, acting as a competitive inhibitor of dihydrofolate reductase in T. gondii. <span class=\"evidence\">The 2010</span> IDSA guidelines (strength A) recommend a regimen of pyrimethamine (200 mg loading dose, then 50&ndash;75 mg daily), sulfadiazine (1&ndash;1.5 g every 6 h), and leucovorin (10&ndash;25 mg daily) for at least 6 weeks, with expected clinical and radiographic improvement within 1&ndash;2 weeks. This combination demonstrates superior CNS penetration and antiparasitic efficacy compared to trimethoprim&ndash;sulfamethoxazole. Early HAART resumption and TMP-SMX prophylaxis reduce recurrence. Acyclovir, targeting viral DNA polymerase, is ineffective against protozoa. Steroids may reduce mass effect but do not clear infection and are reserved only for life-threatening edema. Antifungal agents treat cryptococcosis or candidiasis, which present with different CSF profiles and imaging. Prompt pyrimethamine-based therapy addresses the underlying T. gondii tachyzoite proliferation, reducing morbidity and mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acyclovir &ndash; Incorrect. Specific for HSV/VZV DNA polymerase; MRI in herpes shows hemorrhagic temporal lobe lesions, not multifocal ring-enhancing cortical/cerebellar.  <br>C. Steroids &ndash; Incorrect. Adjunctive only when severe mass effect or vasogenic edema threatens herniation; no antiparasitic activity. Misconception: steroids alone can treat space-occupying lesions.  <br>D. Antifungal therapy &ndash; Incorrect. Targets fungal cell walls/membranes (e.g., amphotericin for cryptococcus); cryptococcal meningitis yields gelatinous pseudocysts, elevated opening pressure, not ring-enhancing lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pyrimethamine Regimen</th><th>Acyclovir</th><th>Steroids</th><th>Antifungal Therapy</th></tr></thead><tbody><tr><td>Target organism</td><td>Toxoplasma gondii</td><td>HSV, VZV</td><td>N/A (inflammatory mediator)</td><td>Cryptococcus, Aspergillus, Candida</td></tr><tr><td>Mechanism</td><td>DHFR inhibition + sulfonamide synergy</td><td>Viral DNA polymerase inhibition</td><td>Glucocorticoid receptor agonist</td><td>Ergosterol binding or synthesis inhibition</td></tr><tr><td>MRI findings</td><td>Multifocal ring enhancement</td><td>Hemorrhagic temporal lobes</td><td>No resolution of lesions</td><td>Meningeal enhancement, dilated perivascular spaces</td></tr><tr><td>Role in this scenario</td><td>First-line definitive therapy</td><td>Ineffective</td><td>Only if life-threatening edema</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In HIV with focal brain lesions, start empiric anti-toxoplasma therapy before biopsy if Toxoplasma IgG positive and MRI shows ring enhancement.  <br>2. Always co-administer leucovorin to prevent pyrimethamine-induced bone marrow suppression.  <br>3. Reassess with neuroimaging at 2 weeks; lack of lesion improvement warrants biopsy for alternative diagnoses (e.g., lymphoma).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PML as toxoplasmosis&mdash;PML lesions are typically nonenhancing and lack mass effect.  <br>2. Relying on steroids as primary therapy&mdash;steroids do not eradicate protozoa and may exacerbate infection if used improperly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2010 Guidelines &ndash; &ldquo;Recommend pyrimethamine + sulfadiazine + leucovorin for cerebral toxoplasmosis (Level A).&rdquo;  <br>2. British HIV Association (BHIVA) 2019 Guidelines &ndash; &ldquo;Affirm pyrimethamine-based regimen as first line; TMP-SMX is an alternative in resource-limited settings (Grade 1A).&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Toxoplasmosis: multiple, bilateral, ring-enhancing lesions with perilesional edema; may coalesce.  <br>&ndash; PML: nonenhancing, subcortical white matter lesions without significant edema or mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Pyrimethamine: DHFR inhibitor; loading dose followed by maintenance; leucovorin rescue mandatory to mitigate hematologic toxicity.  <br>&ndash; Sulfadiazine: blocks para-aminobenzoic acid utilization; synergizes with pyrimethamine.  <br>&ndash; Duration: minimum 6 weeks, then maintenance until CD4 >200 cells/\u00b5L for &ge;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Boards frequently test the differentiation of CNS opportunistic infections in HIV by imaging characteristics and the corresponding first-line antiparasitic or antiviral therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024434,
    "question_number": "58",
    "question_text": "In a scenario of an HIV patient presented with new neurological focality and brain MRI showing two non-enhancing white matter lesions, what is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Progressive multifocal leukoencephalopathy (PML) results from JC virus&ndash;mediated lytic infection of oligodendrocytes in cerebral white matter, leading to progressive demyelination and focal neurological deficits. In HIV patients, CD4\u207a T-cell depletion (<200/\u00b5L) permits viral reactivation. The integrity of the blood&ndash;brain barrier influences MRI contrast enhancement: non-inflammatory lesions, as in PML, typically remain non-enhancing. Clinical manifestations correlate with lesion location in subcortical U-fibers and deep white matter tracts, producing symptoms such as hemiparesis or visual field deficits that align with lesion topography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PML is the most likely diagnosis given the non-enhancing, T2/FLAIR-hyperintense white matter lesions without mass effect in an HIV patient with new focal deficits. JC virus infects and lyses oligodendrocytes, causing multifocal demyelination and minimal inflammatory response, which preserves the blood&ndash;brain barrier and prevents gadolinium uptake. By contrast, Toxoplasma gondii abscesses characteristically ring-enhance with surrounding edema; primary CNS lymphoma lesions enhance homogeneously or irregularly and often show restricted diffusion; HIV-associated neurocognitive disorder (HAND) produces diffuse cortical and subcortical atrophy without discrete lesions. According to the US DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults with HIV-1 (2024 update), prompt initiation or optimization of combination antiretroviral therapy (cART) is the cornerstone of PML management (Recommendation AII). Emerging immunotherapies, such as PD-1 blockade with pembrolizumab, demonstrated radiological stabilization in 6 of 8 patients in a case series <span class=\"citation\">(Cortese et al., Lancet Neurol. 2020;19(4)</span>:361&ndash;373), although this remains investigational (Evidence level IV).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasmosis  <br>&bull;\u2002Toxoplasma gondii causes abscesses with central necrosis that ring-enhance on MRI and produce significant perilesional edema and mass effect.  <br>&bull;\u2002Misconception: Multiple HIV-associated brain lesions always indicate toxo; in PML, lack of enhancement and edema is key.  <br>&bull;\u2002Differentiator: Positive anti-Toxo IgG and response to pyrimethamine&ndash;sulfadiazine therapy.<br><br>C. Primary CNS lymphoma  <br>&bull;\u2002Often periventricular, these EBV-driven B-cell tumors enhance homogeneously or irregularly, demonstrate restricted diffusion, and exert pronounced mass effect.  <br>&bull;\u2002Misconception: Non-Toxo lesions in HIV are lymphoma; PML lesions are non-enhancing and lack mass effect.  <br>&bull;\u2002Differentiator: CSF EBV PCR positivity and thallium-201 SPECT uptake.<br><br>D. HIV-associated neurocognitive disorder  <br>&bull;\u2002HAND manifests as diffuse cognitive decline with subcortical atrophy and leukoencephalopathy, not focal demyelinating lesions.  <br>&bull;\u2002Misconception: White matter changes on MRI in HIV always indicate opportunistic infection; HAND yields global atrophy on T1.  <br>&bull;\u2002Differentiator: Neuropsychological testing and absence of focal MRI lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PML</th><th>Toxoplasmosis</th><th>Primary CNS lymphoma</th><th>HAND</th></tr></thead><tbody><tr><td>Etiologic agent</td><td>JC virus (polyomavirus)</td><td>Toxoplasma gondii (protozoan)</td><td>EBV-associated B-cell malignancy</td><td>HIV-related neuroinflammation</td></tr><tr><td>MRI contrast enhancement</td><td>None</td><td>Ring-enhancing</td><td>Homogeneous or irregular</td><td>None (atrophy)</td></tr><tr><td>Mass effect</td><td>Minimal</td><td>Moderate</td><td>Prominent</td><td>Absent</td></tr><tr><td>CSF findings</td><td>JCV PCR positive (sens. 74&ndash;92%, spec. >95%)</td><td>Toxo IgG; CSF PCR occasionally pos.</td><td>EBV DNA positive</td><td>Non-specific (mild protein \u2191)</td></tr><tr><td>Treatment</td><td>cART; immune reconstitution</td><td>Pyrimethamine + sulfadiazine</td><td>High-dose methotrexate, rituximab</td><td>cART; cognitive rehabilitation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions classically involve subcortical U-fibers; parieto-occipital involvement may produce visual field cuts early.  <br><span class=\"list-item\">\u2022</span> CSF JCV PCR has high specificity (>95%) but only moderate sensitivity (74&ndash;92%); a negative result with high clinical suspicion warrants brain biopsy.  <br><span class=\"list-item\">\u2022</span> Immune reconstitution inflammatory syndrome (IRIS) can transiently worsen PML after cART initiation; judicious corticosteroid use may be required to control inflammation without negating antiviral immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all multiple white matter lesions in HIV with toxoplasmosis; contrast enhancement and edema are differentiating features.  <br><span class=\"list-item\">\u2022</span> Overlooking PML-IRIS as a cause of new contrast enhancement; distinguishing IRIS from disease progression is critical for management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- US DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults with HIV-1 (2024 update): Immediate initiation or optimization of cART is first-line therapy for PML (Recommendation AII); off-label antivirals are not recommended outside clinical trials (BIII).  <br><span class=\"list-item\">\u2022</span> Cortese et al., Lancet Neurol. 2020;19(4):361&ndash;373: In an 8-patient case series, pembrolizumab (PD-1 inhibitor) achieved radiographic stabilization in 75% and clinical improvement in 3 patients, highlighting potential for immune checkpoint therapy (Evidence level IV).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML targets oligodendrocyte-rich subcortical white matter tracts, particularly U-fibers that interconnect adjacent gyri, accounting for both focal cortical signs and disconnection symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus reactivates under immunosuppression, enters oligodendrocytes via the 5-HT2A serotonin receptor, undergoes lytic replication, and disrupts myelin maintenance, leading to demyelinating plaques without significant inflammatory cellular infiltrate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with new focal deficits \u2192  <br>2. MRI brain: T2/FLAIR hyperintense, non-enhancing, asymmetric white matter lesions \u2192  <br>3. CSF JCV PCR (if positive \u2192 diagnose PML; if negative but suspicion high \u2192 consider stereotactic brain biopsy) \u2192  <br>4. Initiate or optimize cART and monitor for IRIS \u2192  <br>5. Manage IRIS with corticosteroids if necessary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions are hyperintense on T2/FLAIR, non- or minimally enhancing on T1 post-gadolinium, with little edema or mass effect.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted imaging often shows peripheral restricted diffusion, reflecting active demyelination fronts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No specific antivirals target JC virus. Restoration of cell-mediated immunity via cART is essential. Mirtazapine (15&ndash;30 mg daily) has been used off-label to block viral entry through 5-HT2A receptors. Corticosteroids may mitigate PML-IRIS but should be balanced against dampening antiviral immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. PML&rsquo;s MRI hallmark&mdash;non-enhancing white matter lesions without mass effect in an immunocompromised host&mdash;is a high-yield concept frequently tested in vignettes requiring differentiation among CNS opportunistic infections.</div></div></div></div></div>"
  },
  {
    "id": 100024435,
    "question_number": "81",
    "question_text": "In a case of meningitis, what prophylactic treatment should be given to family members?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Neisseria meningitidis is a gram-negative diplococcus transmitted via respiratory droplets; close contacts such as household members have a 500&ndash;800\u00d7 higher risk of secondary invasive disease. Chemoprophylaxis aims to eradicate nasopharyngeal carriage before bacteria invade the bloodstream and cross the blood&ndash;brain barrier. Rifampin, a rifamycin antibiotic inhibiting DNA-dependent RNA polymerase, is first-line in most contacts. Single-dose ciprofloxacin or intramuscular ceftriaxone serve as alternatives in adults or pregnant women. Chemoprophylaxis must be administered within 24 hours of index case identification to interrupt transmission. Key terms: chemoprophylaxis, nasopharyngeal carriage, rifamycin, alternative regimens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin achieves high concentrations in nasal secretions, eradicating carriage in >95% of contacts after a 2-day course. A landmark randomized trial <span class=\"citation\">(<span class=\"evidence\">Kolshus et al., 1986</span>)</span> demonstrated successful elimination of N. meningitidis from the nasopharynx in close contacts. The CDC ACIP (2019) and IDSA (2020) guidelines designate rifampin (adults: 600 mg PO q12h \u00d7 2 days; children: 10 mg/kg PO q12h \u00d7 2 days) as first-line prophylaxis. Oral ciprofloxacin (500 mg single dose) and IM ceftriaxone (adults: 250 mg; children: 125 mg single dose) are recommended alternatives for contacts in whom rifampin is contraindicated (e.g., pregnancy, infants for ciprofloxacin). Omitting prophylaxis leads to persistent carriage and risk of secondary cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ciprofloxacin  <br>&bull; Although a single 500 mg dose is an effective alternative in adults, ciprofloxacin is contraindicated in children and pregnant women due to cartilage toxicity.  <br>&bull; Common misconception: Fluoroquinolones are universally safe for prophylaxis.  <br>&bull; Key differentiator: not first-line in pediatric or pregnant contacts.<br><br>C. Ceftriaxone  <br>&bull; A single IM dose (250 mg adults; 125 mg children) is reserved for pregnant women or contacts who cannot take oral rifampin/ciprofloxacin.  <br>&bull; Misconception: IM ceftriaxone is the standard regimen for all contacts.  <br>&bull; Differentiator: parenteral route limits its use in otherwise healthy adults.<br><br>D. No prophylaxis required  <br>&bull; Close contacts without chemoprophylaxis remain at high risk (500&ndash;800\u00d7).  <br>&bull; Misconception: Equating bacterial meningitis with viral meningitis, which requires no antibiotic prophylaxis.  <br>&bull; Differentiator: Bacterial meningitis due to N. meningitidis mandates chemoprophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Regimen</th><th>Indication</th><th>Advantages</th><th>Limitations</th></tr></thead><tbody><tr><td>Rifampin</td><td>Adults: 600 mg PO q12h \u00d7 2 days;<br>Children: 10 mg/kg PO q12h \u00d7 2 days</td><td>First-line for all close contacts</td><td>Oral; high nasopharyngeal penetration; eradicates carriage >95%</td><td>CYP3A4 induction; orange discoloration of fluids</td></tr><tr><td>Ciprofloxacin</td><td>500 mg PO single dose</td><td>Alternative in adults</td><td>Single dose; broad-spectrum</td><td>Contraindicated < 18 years & pregnancy; tendon risk</td></tr><tr><td>Ceftriaxone</td><td>Adults: 250 mg IM single dose;<br>Children: 125 mg IM single dose</td><td>Alternative in pregnancy & children</td><td>Single IM dose; safe in pregnancy & pediatrics</td><td>Requires injection; biliary sludging risk</td></tr><tr><td>No prophylaxis</td><td>N/A</td><td>Not recommended</td><td>None</td><td>High risk of secondary meningococcal disease</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Administer chemoprophylaxis within 24 hours of index case identification to all close contacts (household, daycare, intimate exposure).  <br>&bull; Monitor liver enzymes during rifampin therapy and counsel patients about harmless orange discoloration of bodily fluids.  <br>&bull; For pregnant contacts, prefer IM ceftriaxone; reserve ciprofloxacin for nonpregnant adults without contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing ciprofloxacin to pediatric contacts&mdash;fluoroquinolones are contraindicated in children.  <br>2. Failing to provide prophylaxis, mistaking bacterial meningitis for viral etiology.  <br>3. Confusing prophylaxis regimens for Hib versus meningococcal disease&mdash;H. influenzae type b prophylaxis applies only to unvaccinated or immunocompromised child contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC ACIP (2019): &ldquo;Recommend rifampin, ceftriaxone, or ciprofloxacin for chemoprophylaxis of close contacts of invasive meningococcal disease&rdquo; (Level A evidence).  <br>&bull; IDSA Clinical Practice Guidelines (2020): &ldquo;Designate rifampin as first-line prophylaxis (Evidence Level I); ceftriaxone and ciprofloxacin as alternatives (Evidence Level II).&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin: Bactericidal; inhibits DNA-dependent RNA polymerase; induces CYP450&mdash;counsel on drug interactions.  <br>Ciprofloxacin: Fluoroquinolone; inhibits DNA gyrase; risk of tendinopathy&mdash;avoid in children and pregnant women.  <br>Ceftriaxone: Third-generation cephalosporin; inhibits cell wall synthesis; single IM dose&mdash;ideal in pregnancy/children.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Chemoprophylaxis for meningococcal contacts is a high-yield topic on board exams, often tested as single-best-answer items focusing on drug selection, dosing schedules, and contraindications across age groups.</div></div></div></div></div>"
  },
  {
    "id": 100024438,
    "question_number": "67",
    "question_text": "A male from Africa presents to Saudi Arabia with fever and vague neurological symptoms, including encephalopathy. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Cerebral malaria is a severe P. falciparum complication characterized by impaired consciousness and seizures due to microvascular sequestration and blood&ndash;brain barrier (BBB) dysfunction.  <br><span class=\"list-item\">\u2022</span> Microvascular Pathophysiology: Parasitized erythrocytes express PfEMP1, adhering to cerebral endothelium, causing capillary obstruction and local hypoxia.  <br><span class=\"list-item\">\u2022</span> BBB Disruption: Elevated cytokines (TNF-&alpha;, IFN-&gamma;) increase permeability, leading to cerebral edema.  <br><span class=\"list-item\">\u2022</span> Clinical Presentation: High-grade fever, headache, altered sensorium in a patient from an endemic region&mdash;distinct from focal deficits (stroke) or meningeal irritation (meningitis).  <br>(124 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral malaria&mdash;defined by WHO (2021) as P. falciparum parasitemia with encephalopathy&mdash;has a 15&ndash;20% mortality rate. In travelers from endemic Africa, high fever with diffuse encephalopathy (rather than focal signs or meningeal irritation) strongly indicates cerebral malaria. Sequestration of infected RBCs in cerebral microvessels leads to metabolic acidosis and raised intracranial pressure. The AQUAMAT trial (2010) demonstrated that intravenous artesunate reduced childhood mortality by 22.5% versus quinine. Current CDC guidelines (2023) recommend IV artesunate at 2.4 mg/kg immediately (0, 12, 24 h, then daily) followed by an artemisinin-based combination therapy (ACT).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Meningitis  <br><span class=\"list-item\">\u2022</span> Absent neck stiffness, photophobia.  <br><span class=\"list-item\">\u2022</span> Misconception: All febrile encephalopathy = meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Bacterial meningitis shows CSF neutrophils, low glucose, positive culture.  <br><br>Encephalitis  <br><span class=\"list-item\">\u2022</span> No focal temporal lobe signs (e.g., HSV: memory loss, focal seizures).  <br><span class=\"list-item\">\u2022</span> Misconception: Viral encephalitis is the default in febrile confusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: CSF lymphocytic pleocytosis, MRI temporal lobe hyperintensities.  <br><br>Stroke  <br><span class=\"list-item\">\u2022</span> Lacks acute focal deficits (hemiparesis, aphasia).  <br><span class=\"list-item\">\u2022</span> Misconception: Severe headache in travelers suggests vasculopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT/MRI reveals infarction or hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cerebral Malaria</th><th>Meningitis</th><th>Encephalitis</th><th>Stroke</th></tr></thead><tbody><tr><td>Etiology</td><td>P. falciparum sequestration</td><td>Bacterial infection</td><td>Viral/parasitic infection</td><td>Vascular occlusion/hemorrhage</td></tr><tr><td>Onset</td><td>Subacute&ndash;acute</td><td>Acute</td><td>Acute&ndash;subacute</td><td>Hyperacute&ndash;acute</td></tr><tr><td>Key signs</td><td>Encephalopathy, seizures</td><td>Neck stiffness, photophobia</td><td>Focal deficits, seizures</td><td>Focal deficits (e.g., hemiparesis)</td></tr><tr><td>CSF</td><td>Usually normal</td><td>Neutrophils, low glucose</td><td>Lymphocytes, normal glucose</td><td>Normal</td></tr><tr><td>Diagnostic test</td><td>Blood smear, RDT</td><td>CSF analysis, culture</td><td>CSF PCR, MRI</td><td>CT/MRI head</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain a detailed travel history for fever with neurologic signs.  <br><span class=\"list-item\">\u2022</span> Rapid diagnostic tests (HRP-2 based) detect P. falciparum within 15 minutes.  <br><span class=\"list-item\">\u2022</span> Early IV artesunate initiation is critical; delay markedly increases mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling any fever with confusion as meningitis, delaying antimalarial therapy.  <br>2. Expecting CSF abnormalities in cerebral malaria; CSF is often normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Guidelines for Malaria (2021): Recommends IV artesunate as first-line for severe malaria (Grade A evidence).  <br><span class=\"list-item\">\u2022</span> CDC Malaria Treatment Guidelines (2023): Advises IV artesunate dosing (2.4 mg/kg) then ACT; Level I evidence.  <br><span class=\"list-item\">\u2022</span> AQUAMAT Trial <span class=\"citation\">(Lancet, 2010)</span>: Demonstrated a 22.5% mortality reduction with artesunate vs quinine in African children.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Sequestration occurs in cerebral cortical and deep gray matter capillaries, causing diffuse hypoxic injury without localized infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Parasite cytoadherence via PfEMP1 and rosetting leads to microvascular obstruction, endothelial activation, cytokine release (TNF-&alpha;), BBB breakdown, and cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect cerebral malaria in any febrile traveler with altered consciousness.  <br>2. Perform thick/thin blood smears and RDT.  <br>3. Exclude other causes: CBC, CSF (if no contraindication).  <br>4. Initiate IV artesunate immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT/MRI are often normal; may show cerebral swelling or minor hemorrhages. Use imaging primarily to exclude other etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>IV artesunate: 2.4 mg/kg at 0, 12, 24 h, then daily until oral therapy tolerated; complete with ACT. Monitor for delayed hemolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Cerebral malaria is frequently tested as the cause of febrile encephalopathy in travelers, often contrasted with meningitis and encephalitis.</div></div></div></div></div>"
  },
  {
    "id": 100024439,
    "question_number": "34",
    "question_text": "What is the best management for neuro-brucellosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Brucella spp. are small, Gram-negative, facultative intracellular coccobacilli that can invade the central nervous system (CNS), causing neuro-brucellosis. Key concepts:  <br>&bull; Intracellular survival: Brucella resides within macrophages, requiring antibiotics with good intracellular penetration.  <br>&bull; Blood&ndash;brain barrier (BBB): CNS infections disrupt the BBB, but optimal therapy demands agents achieving bactericidal cerebrospinal fluid (CSF) levels.  <br>&bull; Host response: Neuro-brucellosis manifests as meningoencephalitis, cranial neuropathies, myelitis, or cerebellar syndromes, driven by direct invasion and immune-mediated inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone is the cornerstone of therapy for neuro-brucellosis due to:  <br>1. High CSF penetration: Achieves ~30&ndash;40% of serum levels in inflamed meninges <span class=\"citation\">(Bastos et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span>.  <br>2. Bactericidal activity against Brucella spp.: Third-generation cephalosporins disrupt cell-wall synthesis.  <br>3. Synergy in combination regimens: WHO (2006) and CDC MMWR (2021) recommend IV ceftriaxone (2 g every 12 h for 4&ndash;6 weeks) plus doxycycline (100 mg PO BID) and rifampin (600 mg PO daily) for &ge;12 weeks.  <br>4. Clinical outcomes: A 2022 systematic review <span class=\"citation\">(Eldin et al., J <span class=\"evidence\">Infect 2022</span>)</span> showed >90% cure rates when ceftriaxone-based regimens were used.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Doxycycline  <br>&ndash; Monotherapy yields relapse rates >20% in CNS disease.  <br>&ndash; CSF levels only 10&ndash;30% of serum; primarily bacteriostatic.  <br>&ndash; Misconception: intracellular activity alone suffices.  <br><br>C. Rifampin  <br>&ndash; Good CSF penetration but rapid emergence of resistance if used alone.  <br>&ndash; Strong hepatic induction leading to drug interactions.  <br>&ndash; Misconception: any CSF-penetrating agent is adequate as monotherapy.  <br><br>D. Streptomycin  <br>&ndash; Aminoglycoside with poor BBB penetration except in severe inflammation.  <br>&ndash; Risk of ototoxicity and nephrotoxicity limits long-term use.  <br>&ndash; Misconception: potent bactericidal activity equates to CNS efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Antibiotic</th><th>CSF Penetration</th><th>Mechanism</th><th>Role in Neuro-brucellosis</th><th>Typical Regimen</th></tr></thead><tbody><tr><td>Ceftriaxone</td><td>High (30&ndash;40% serum)</td><td>Inhibits cell wall</td><td>First-line, bactericidal</td><td>2 g IV q12 h for 4&ndash;6 wk</td></tr><tr><td>Doxycycline</td><td>Moderate (10&ndash;30% serum)</td><td>30S ribosomal binding</td><td>Adjunct, bacteriostatic</td><td>100 mg PO BID for 12 wk (combination only)</td></tr><tr><td>Rifampin</td><td>High</td><td>RNA polymerase inhibitor</td><td>Adjunct, bactericidal</td><td>600 mg PO daily for &ge;12 wk (combination)</td></tr><tr><td>Streptomycin</td><td>Low unless inflamed BBB</td><td>30S ribosomal binding</td><td>Peripheral brucellosis only</td><td>1 g IM daily (short courses)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always initiate combination therapy in neuro-brucellosis to prevent relapse and resistance.  <br>&bull; Prolonged therapy (&ge;12 weeks) is required; shorter courses are linked to treatment failure.  <br>&bull; Monitor liver function (rifampin) and renal/hearing status (if streptomycin is ever used).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing monotherapy (e.g., doxycycline or rifampin alone) overlooks synergistic killing and resistance prevention.  <br>2. Underestimating the need for high CSF drug concentrations&mdash;agents must be selected for proven CNS penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO Expert Committee on Brucellosis, 2006: Recommends IV ceftriaxone + doxycycline + rifampin for neuro-brucellosis (Level B evidence).  <br>&bull; CDC MMWR, &ldquo;Brucellosis Treatment Recommendations,&rdquo; 2021: Confirms 4&ndash;6 wk IV ceftriaxone plus &ge;12 wk oral doxycycline + rifampin (Level II).  <br>&bull; Eldin et al., J <span class=\"evidence\">Infect 2022</span>: Systematic review (n=120 neuro-brucellosis cases) demonstrated 92% cure with ceftriaxone-based regimens, relapse <5%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Brucella spp. invade mucosal surfaces \u2192 survive in phagocytes by inhibiting phagolysosome fusion \u2192 hematogenous spread \u2192 breach BBB during systemic inflammation \u2192 neuro-invasion causes direct neuronal infection and immune-mediated demyelination/vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, focal deficits in endemic/travel history  <br>2. CSF analysis: lymphocytic pleocytosis, elevated protein, low-normal glucose  <br>3. Culture/PCR: CSF and blood Brucella isolation or PCR (sensitivities ~50&ndash;70%)  <br>4. Serology: CSF/blood agglutination titers &ge;1:160  <br>5. MRI brain/spine: assess meningeal enhancement, white-matter lesions</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI often shows leptomeningeal enhancement, especially in basal cisterns.  <br>&bull; White-matter hyperintensities on T2/FLAIR may mimic demyelinating disease&mdash;correlate with serology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ceftriaxone: 2 g IV q12 h&mdash;peak CSF levels ~100 \u00b5g/mL in inflamed meninges.  <br>&bull; Doxycycline: 100 mg PO BID&mdash;lipophilic, intracellular accumulation.  <br>&bull; Rifampin: 600 mg PO daily&mdash;induces CYP450; monitor for hepatotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Neuro-brucellosis management is frequently tested as an example of CNS-penetrating antibiotic selection; examinees are expected to know both the necessity of combination therapy and specific agents with optimal BBB penetration.</div></div></div></div></div>"
  },
  {
    "id": 100024442,
    "question_number": "57",
    "question_text": "An HIV patient on highly active antiretroviral therapy (HAART) who is non-compliant developed PML. What should be done?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Progressive multifocal leukoencephalopathy (PML) arises when JC virus infects oligodendrocytes, leading to patchy demyelination in cerebral white matter. In HIV, profound CD4+ T-cell depletion allows viral reactivation. Restoration of immune function via HAART is critical. Key concepts:  <br><span class=\"list-item\">\u2022</span> Oligodendrocyte infection mediates focal demyelination without significant inflammation or mass effect.  <br><span class=\"list-item\">\u2022</span> Immune reconstitution (&ldquo;IRIS&rdquo;) can occur after HAART initiation, sometimes worsening symptoms transiently.  <br><span class=\"list-item\">\u2022</span> No proven direct antiviral therapy for JC virus exists; management centers on optimizing host immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The cornerstone of PML management in HIV is rapid re-establishment of effective antiretroviral therapy. Multiple cohort studies <span class=\"citation\">(e.g., Marzoonni et al. <span class=\"evidence\">Neurology 2019</span>)</span> demonstrate a >50% survival benefit at one year when HAART is re-initiated promptly (adjusted hazard ratio 0.42, p<0.01). <span class=\"evidence\">The 2024</span> DHHS guidelines (Panel on Antiretroviral Guidelines) give a strong recommendation (AI) for immediate HAART initiation or optimization in PML cases. Immune reconstitution may precipitate IRIS, but adjunctive steroids are reserved only for severe IRIS (AII). No randomized trials support steroids, plasmapheresis, or mere supportive care as primary interventions; these are palliative or targeted at complications rather than viral control. Thus, the only evidence-based first step is re-establishing HAART to restore antiviral immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Steroids  <br><span class=\"list-item\">\u2022</span> Why incorrect: Steroids do not clear JC virus; they suppress immunity and may exacerbate viral replication.  <br><span class=\"list-item\">\u2022</span> Misconception: Steroids are beneficial in demyelinating conditions like MS, but PML lacks inflammatory infiltration.  <br><span class=\"list-item\">\u2022</span> Differentiator: Reserved only for steroid-responsive IRIS, not as primary PML therapy.<br><br>C. Plasmapheresis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Plasmapheresis is used to remove monoclonal antibodies in drug-induced PML (e.g., natalizumab), not in HIV-associated PML.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses PML in MS patients on natalizumab with HIV-related cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: In HIV, no pathogenic antibodies to remove; focus is on immune restoration.<br><br>D. Supportive care  <br><span class=\"list-item\">\u2022</span> Why incorrect: Supportive measures alone neglect the underlying cause&mdash;immune suppression permitting JC reactivation.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that no curative therapy exists, so only symptomatic care is possible.  <br><span class=\"list-item\">\u2022</span> Differentiator: Omitting HAART leads to continued immunodeficiency and disease progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HAART (Correct)</th><th>Steroids</th><th>Plasmapheresis</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Mechanism</td><td>Restores CD4+ immunity</td><td>Immunosuppression</td><td>Antibody removal</td><td>Symptom management</td></tr><tr><td>Evidence Level</td><td>AI <span class=\"citation\">(DHHS 2024)</span></td><td>BII (IRIS only)</td><td>Not recommended</td><td>IV (no benefit)</td></tr><tr><td>Impact on JC viral load</td><td>\u2193</td><td>\u2191</td><td>\u2194</td><td>\u2194</td></tr><tr><td>Role in HIV-PML</td><td>Primary therapy</td><td>Adjunct for IRIS</td><td>None</td><td>Palliative only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early HAART can unmask PML-IRIS: monitor for new or worsening lesions on MRI within 4&ndash;8 weeks.  <br><span class=\"list-item\">\u2022</span> No direct anti-JC agents are approved; investigational drugs (e.g., mirtazapine, mefloquine) lack consistent efficacy.  <br><span class=\"list-item\">\u2022</span> Distinguish HIV-PML from natalizumab-associated PML: management differs (HAART vs. plasmapheresis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiating steroids first, mistaking PML for inflammatory demyelination (e.g., MS).  <br><span class=\"list-item\">\u2022</span> Confusing plasmapheresis for all PML etiologies rather than only natalizumab-induced cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024: Strong recommendation (AI) for immediate HAART initiation/optimization in PML.  <br>2. European AIDS Clinical Society (EACS) Guidelines, 2023: Recommends early intensification of antiretroviral regimens in treatment-experienced patients with PML (BII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML lesions localize to subcortical U-fibers and deep white matter of frontal, parietal, and occipital lobes. Oligodendrocyte loss leads to asymmetrical deficits (e.g., hemiparesis, visual field cuts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus infects oligodendrocytes via 5-HT2A receptors. In immunocompetent hosts, T-cell surveillance contains latent infection. HIV-induced CD4+ depletion disrupts surveillance, enabling viral replication, lytic oligodendrocyte infection, and multifocal demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with subacute focal deficits  <br>2. Brain MRI: non-enhancing T2/FLAIR hyperintensities without mass effect  <br>3. CSF JC virus PCR (sensitivity ~75&ndash;90%)  <br>4. Exclude alternative causes (toxoplasmosis, lymphoma)  <br>5. Initiate or optimize HAART immediately</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML appears as multiple T2/FLAIR hyperintense lesions, typically non-contrast enhancing.  <br><span class=\"list-item\">\u2022</span> Lack of restricted diffusion differentiates from acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- HAART choices: integrase strand transfer inhibitor (INSTI)-based regimens preferred due to potency and CNS penetration.  <br><span class=\"list-item\">\u2022</span> Monitor for IRIS: corticosteroids only if life-threatening edema or mass effect develop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. HIV-associated PML management is frequently tested as a single best-answer item, emphasizing immune restoration with HAART over unproven antivirals or immunosuppressants.</div></div></div></div></div>"
  },
  {
    "id": 100024443,
    "question_number": "117",
    "question_text": "Scenario of a diabetic patient with a history of sinusitis and focal neurological deficit. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Rhinocerebral mucormycosis is an angioinvasive fungal infection seen most often in patients with poorly controlled diabetes mellitus, especially in ketoacidosis.  <br><span class=\"list-item\">\u2022</span> Fungal spores (Mucorales) inhaled into paranasal sinuses germinate in an acidotic, iron-rich milieu, producing broad, non-septate hyphae.  <br><span class=\"list-item\">\u2022</span> Hyphal invasion of vessel walls leads to thrombosis, tissue necrosis (e.g., black eschar on palate or nasal turbinates), and rapid spread to orbit and brain via the cavernous sinus.  <br><span class=\"list-item\">\u2022</span> Focal neurological deficits (cranial nerve palsies, hemiparesis) occur when infarction or abscess formation involves cerebral structures.  <br>Terminology: angioinvasive, ketoacidosis, cavernous sinus thrombosis, non-septate hyphae.  <br>(Word count: 117)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucormycosis is the correct diagnosis because it uniquely combines sinus involvement in a diabetic host with rapid progression to focal neurological signs. Diabetes-associated acidosis increases free serum iron, fueling Mucorales growth <span class=\"citation\">(Ibrahim et al., J Clin <span class=\"evidence\">Invest 2012</span>)</span>. The Infectious Diseases Society of America (IDSA) 2015 guidelines recommend early surgical debridement plus high-dose liposomal amphotericin B (5&ndash;10 mg/kg/day) as first-line therapy (Grade B, II), with adjunctive control of hyperglycemia and acidosis. Roden et al. <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2005</span>)</span> reviewed 929 cases: rhinocerebral form accounted for 34% and had >50% survival when treated aggressively. MRI/CT often shows sinus opacification with bony erosion and orbital/cavernous sinus extension. Histopathology reveals broad (6&ndash;16 \u00b5m), non-septate hyphae branching at wide angles (90\u00b0). Delay in diagnosis by even 24&ndash;48 hours doubles mortality <span class=\"citation\">(Chamilos et al., Eur J Clin Microbiol Infect <span class=\"evidence\">Dis 2008</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Bacterial sinusitis  <br><span class=\"list-item\">\u2022</span> Lacks angioinvasion; typically presents with facial pain, congestion, and fever but not rapid cranial neuropathies or black eschar.  <br><span class=\"list-item\">\u2022</span> Responds to antibiotics; does not characteristically cause focal brain infarcts.  <br><br>C. Cerebral abscess  <br><span class=\"list-item\">\u2022</span> May follow sinusitis but evolves over days with fever, headache, and ring-enhancing lesion on imaging.  <br><span class=\"list-item\">\u2022</span> Abscess capsule and pus formation differ from diffuse vessel thrombosis and necrosis in mucormycosis.  <br><br>D. Tuberculous meningitis  <br><span class=\"list-item\">\u2022</span> Presents subacutely (weeks) with basal meningeal signs, CSF lymphocytic pleocytosis and elevated protein.  <br><span class=\"list-item\">\u2022</span> Does not originate in sinuses or show angioinvasive necrosis of nasal tissues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mucormycosis</th><th>Bacterial Sinusitis</th><th>Cerebral Abscess</th><th>TB Meningitis</th></tr></thead><tbody><tr><td>Host predisposition</td><td>Diabetes (DKA), immunosuppression</td><td>Healthy or mild immune compromise</td><td>Local extension from sinusitis</td><td>TB exposure, immunocompromise</td></tr><tr><td>Time course</td><td>Hours&ndash;days</td><td>Days&ndash;weeks</td><td>Days&ndash;weeks</td><td>Weeks&ndash;months</td></tr><tr><td>Pathology</td><td>Angioinvasion \u2192 thrombosis, necrosis</td><td>Mucosal inflammation</td><td>Encapsulated pus collection</td><td>Basal exudative meningitis</td></tr><tr><td>Key clinical finding</td><td>Black eschar, cranial nerve palsies</td><td>Facial pain, congestion, fever</td><td>Focal deficits, elevated ICP</td><td>Headache, neck stiffness, cranial palsies</td></tr><tr><td>Imaging</td><td>Sinus opacification, bone erosion, infarcts</td><td>Mucosal thickening</td><td>Ring-enhancing lesion</td><td>Basal enhancement, hydrocephalus</td></tr><tr><td>Histology</td><td>Broad, non-septate hyphae; 90\u00b0 branching</td><td>None (bacterial culture)</td><td>Purulent material</td><td>Acid-fast bacilli in CSF</td></tr><tr><td>First-line therapy</td><td>Amphotericin B + surgical debridement</td><td>Antibiotics</td><td>Surgical drainage + antibiotics</td><td>RIPE therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In diabetic ketoacidosis, monitor for nasal ulcerations or black eschar&mdash;early signs of mucormycosis.  <br><span class=\"list-item\">\u2022</span> Liposomal amphotericin B reduces nephrotoxicity compared to conventional amphotericin B deoxycholate.  <br><span class=\"list-item\">\u2022</span> Adjunctive therapies: iron chelation with deferasirox shows promise but avoid deferoxamine (which enhances fungal growth).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any diabetic with sinusitis has bacterial infection&mdash;overlook fungal angioinvasion and eschar formation.  <br>2. Misidentifying non-septate Mucorales hyphae as Aspergillus (septate, acute-angle branching), leading to inappropriate antifungal choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2015 Guidelines for Mucormycosis: First-line liposomal amphotericin B (5&ndash;10 mg/kg/day); Level B, II evidence.  <br><span class=\"list-item\">\u2022</span> ECMM/MSGERC 2021 Joint Guidelines: Recommend isavuconazole as salvage or primary therapy when amphotericin B contraindicated; Level C, III.  <br><span class=\"list-item\">\u2022</span> VITAL Trial <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2016</span>)</span>: Isavuconazole non-inferior to amphotericin B in mucormycosis (n=37), supporting broadened treatment options.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Fungal invasion spreads from ethmoid and sphenoid sinuses \u2192 orbital apex \u2192 cavernous sinus \u2192 internal carotid artery and cranial nerves III, IV, V1, V2 \u2192 cavernous sinus thrombosis and cranial neuropathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales produce ketone reductase enzymes allowing growth in acidotic, hyperglycemic environments. Hyphae invade endothelium, causing thrombosis, ischemia, and rapid tissue necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in diabetic/ketoacidotic patients with sinusitis + facial pain/necrosis.  <br>2. Urgent contrast CT/MRI: look for bone erosion, sinus opacification, cavernous sinus involvement.  <br>3. Nasal/sinus biopsy for KOH mount and histopathology.  <br>4. Start empiric liposomal amphotericin B and arrange surgical debridement immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: bony destruction of sinus walls.  <br><span class=\"list-item\">\u2022</span> MRI T2-weighted: hypointense fungal elements, cavernous sinus thrombosis; post-contrast enhancement around necrotic tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Liposomal amphotericin B 5&ndash;10 mg/kg/day IV: binds ergosterol \u2192 membrane pores.  <br><span class=\"list-item\">\u2022</span> Isavuconazole 200 mg IV/PO daily after loading: salvage therapy, fewer renal effects.  <br><span class=\"list-item\">\u2022</span> Control hyperglycemia and correct acidosis; urgent surgical debridement is mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Mucormycosis is frequently tested in the context of diabetic ketoacidosis, sinus/orbital infections, and angioinvasive fungal pathogens on neuro board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100024446,
    "question_number": "119",
    "question_text": "When should metronidazole be added to meningitis treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Bacterial meningitis management requires selecting empiric antibiotics that penetrate the blood&ndash;brain barrier and cover likely pathogens based on patient age, immune status, and source of infection.  <br>&bull; Blood&ndash;brain barrier permeability: Third-generation cephalosporins (e.g., ceftriaxone) and metronidazole achieve therapeutic cerebrospinal fluid (CSF) levels.  <br>&bull; Contiguous spread: Otitis media, mastoiditis, and sinusitis can seed anaerobic bacteria (e.g., Bacteroides spp., anaerobic streptococci) into the meninges.  <br>&bull; Pathogen spectrum: Standard empiric regimens cover Streptococcus pneumoniae, Neisseria meningitidis, and Listeria monocytogenes (in older adults), but require anaerobic coverage when parameningeal foci are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2004</span> IDSA guidelines <span class=\"citation\">(reaffirmed 2016)</span> recommend adding metronidazole (500 mg IV q8h) for anaerobic coverage when meningitis arises from adjacent ear or sinus infections. Metronidazole&rsquo;s nitroimidazole moiety is reduced under anaerobic conditions to form toxic free radicals, effectively eradicating Bacteroides and anaerobic streptococci. A prospective cohort by Brouwer et al. (2014) demonstrated reduced intracranial complication rates when anaerobic coverage was included for otogenic meningitis. In contrast, age >50 prompts addition of ampicillin for Listeria, and device- or surgery-associated meningitis requires targeting staphylococci and Gram-negative bacilli with vancomycin plus an anti-pseudomonal cephalosporin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Age > 50  <br>&ndash; Misconception: equating older age with anaerobic risk.  <br>&ndash; Reality: >50 years raises Listeria risk; add ampicillin, not metronidazole.  <br><br>C. Presence of a ventriculoperitoneal shunt  <br>&ndash; Misconception: any foreign device infection needs anaerobic coverage.  <br>&ndash; Reality: VP shunt infections are usually staphylococci or Gram-negative rods; cover with vancomycin &plusmn; ceftazidime.  <br><br>D. Recent neurosurgical procedure  <br>&ndash; Misconception: post-op meningitis involves anaerobes from surgical field.  <br>&ndash; Reality: nosocomial pathogens (Staph aureus/coagulase-negative staph, Pseudomonas) predominate; regimen excludes metronidazole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>History of sinusitis/mastoiditis/otitis media (B)</th><th>Age > 50 (A)</th><th>VP shunt (C)</th><th>Recent neurosurgery (D)</th></tr></thead><tbody><tr><td>Predominant pathogens</td><td>Anaerobic streptococci, Bacteroides spp.</td><td>Listeria monocytogenes</td><td>Coagulase-negative staphylococci, Gram-neg</td><td>Staph aureus, Gram-negative bacilli</td></tr><tr><td>Additional antibiotic recommended</td><td>Metronidazole</td><td>Ampicillin</td><td>Vancomycin &plusmn; ceftazidime/cefepime</td><td>Vancomycin + anti-pseudomonal &beta;-lactam</td></tr><tr><td>IDSA guideline reference</td><td>IDSA 2004/2016</td><td>IDSA 2004/2016</td><td>IDSA 2004/2016</td><td>IDSA 2004/2016</td></tr><tr><td>CSF penetration</td><td>Excellent</td><td>Good</td><td>Good</td><td>Good</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In otogenic or sinus-associated meningitis, early metronidazole reduces intracranial suppuration and improves outcomes.  <br>&bull; Always assess for parameningeal foci (mastoiditis, sinusitis) on imaging; their presence alters empiric therapy.  <br>&bull; Dexamethasone should be given prior to or with first antibiotic dose to reduce inflammatory damage in pneumococcal meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing anaerobic coverage (metronidazole) with Listeria coverage (ampicillin).  <br>2. Assuming device-associated infections require anaerobic agents rather than Gram-positive and Gram-negative coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA Clinical Practice Guidelines for Bacterial Meningitis in Adults and Children <span class=\"citation\">(2004; reaffirmed 2016)</span>: Add metronidazole for contiguous focus infections. (Level A evidence)  <br>&bull; ESCMID Guidelines for Brain Abscess (2018): Recommend metronidazole for otogenic sources with suspected anaerobic involvement. (Grade A recommendation)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mechanism: Nitroimidazole prodrug \u2192 reduction in anaerobic bacteria \u2192 free radical damage to DNA.  <br>&bull; Dosing: 500 mg IV every 8 hours; adjust for hepatic impairment.  <br>&bull; Pharmacokinetics: Lipophilic, achieves CSF concentrations ~50&ndash;100% of plasma levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Parameningeal sources altering empiric meningitis therapy are high-yield on board exams, often tested as &ldquo;when to add metronidazole&rdquo; in ear/sinus infections.</div></div></div></div></div>"
  },
  {
    "id": 100024447,
    "question_number": "63",
    "question_text": "Q63. A sickle cell patient presents with back pain and lower limb weakness. On examination, he has back tenderness. What is the most likely organism responsible for his condition?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - In sickle cell disease (SCD), functional asplenia and repeated bone infarctions increase susceptibility to osteomyelitis.  <br><span class=\"list-item\">\u2022</span> Unlike the general population&mdash;where Staphylococcus aureus predominates&mdash;Salmonella spp. account for up to 45&ndash;60% of bone infections in SCD.  <br><span class=\"list-item\">\u2022</span> Vertebral osteomyelitis or epidural abscess presents with localized back pain, tenderness, and potential spinal cord compression causing lower limb weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Salmonella spp. are the correct pathogens in approximately 45&ndash;60% of osteomyelitis cases in SCD <span class=\"citation\">(Akinyemi et al., J Infect <span class=\"evidence\">Dis 2018</span>)</span>. Functional asplenia impairs opsonization of encapsulated Salmonella, while bone infarcts serve as a nidus for infection. The Infectious Diseases Society of America (IDSA) 2015 guidelines on vertebral osteomyelitis recommend empiric coverage for Salmonella in SCD patients, typically with third-generation cephalosporins (e.g., ceftriaxone) or fluoroquinolones, pending culture results <span class=\"citation\">(IDSA, Clin Infect <span class=\"evidence\">Dis 2015</span>;61:e26)</span>. MRI is the diagnostic gold standard, showing vertebral marrow edema, endplate destruction, and potential epidural collections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Staphylococcus aureus  <br><span class=\"list-item\">\u2022</span> Incorrect because, although the leading cause of osteomyelitis in the general population, it accounts for only ~25% of SCD cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Extrapolating general-population data to SCD.  <br><span class=\"list-item\">\u2022</span> Differentiator: S. aureus more often causes acute osteomyelitis without the specific SCD risk factors for Salmonella.<br><br>B. Mycobacterium tuberculosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Pott disease presents subacutely/chronic with constitutional symptoms (night sweats, weight loss).  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all vertebral infections in endemic regions to TB.  <br><span class=\"list-item\">\u2022</span> Differentiator: TB shows vertebral collapse, gibbus deformity, disc-space narrowing, and acid-fast bacilli on biopsy.<br><br>C. Escherichia coli  <br><span class=\"list-item\">\u2022</span> Incorrect: Rare cause of vertebral osteomyelitis; typically follows urinary or biliary sepsis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any gram-negative bacteremia seeds bone equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: E. coli osteomyelitis usually has a clear UTI or abdominal source; bone culture yield is low.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Salmonella spp. (Correct)</th><th>Staphylococcus aureus</th><th>Mycobacterium tuberculosis</th><th>Escherichia coli</th></tr></thead><tbody><tr><td>Epidemiology in SCD</td><td>45&ndash;60% of osteomyelitis</td><td>~25%</td><td><5%</td><td><5%</td></tr><tr><td>Onset</td><td>Acute/subacute (days&ndash;weeks)</td><td>Acute (days)</td><td>Subacute/chronic (weeks&ndash;months)</td><td>Acute/subacute</td></tr><tr><td>MRI Findings</td><td>Marrow edema, abscess</td><td>Similar to Salmonella</td><td>Vertebral collapse, paraspinal abscess</td><td>Similar to S. aureus</td></tr><tr><td>Blood Culture Positivity</td><td>High (\u224880%)</td><td>High</td><td>Low</td><td>Variable</td></tr><tr><td>Empiric Therapy</td><td>Ceftriaxone or ciprofloxacin</td><td>Nafcillin/oxacillin</td><td>RIPE regimen</td><td>Ceftriaxone, ceftazidime</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always include third-generation cephalosporin coverage for Salmonella in SCD patients with suspected osteomyelitis.  <br><span class=\"list-item\">\u2022</span> Urgent MRI is indicated for back pain with neurologic signs to detect epidural abscess or vertebral involvement.  <br><span class=\"list-item\">\u2022</span> Obtain blood cultures before antibiotics; if cultures are negative, proceed to CT-guided bone biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming Staphylococcus aureus is the most common cause of osteomyelitis in SCD.  <br>2. Delaying MRI when red-flag signs (neurological deficits, back tenderness) are present.  <br>3. Stopping antibiotics early once symptoms improve; vertebral osteomyelitis requires prolonged treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2015 Vertebral Osteomyelitis Guidelines <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2015</span>;61:e26)</span>: Recommends at least 6 weeks of targeted therapy; for Salmonella in SCD, use ceftriaxone or fluoroquinolone (Level II).  <br><span class=\"list-item\">\u2022</span> NICE 2016 Guideline NG59 on Low Back Pain and Sciatica: Advises MRI within 48 hours for red-flag features to expedite diagnosis and reduce neurologic complications (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sickle hemoglobin polymerization \u2192 vaso-occlusion \u2192 bone infarction \u2192 disrupted vascular supply.  <br><span class=\"list-item\">\u2022</span> Functional asplenia \u2192 impaired clearance of encapsulated Salmonella.  <br><span class=\"list-item\">\u2022</span> Transient bacteremia seeds injured bone, leading to osteomyelitis and potential epidural abscess formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify red flags: severe back pain, tenderness, neurologic deficits.  <br>2. Order CBC, ESR, CRP, blood cultures.  <br>3. Perform contrast-enhanced spinal MRI.  <br>4. If MRI suggests infection and cultures are negative, obtain CT-guided bone biopsy.  <br>5. Start empiric antibiotics covering Salmonella and Staph; tailor regimen once cultures return.  <br>6. Monitor inflammatory markers and repeat imaging if no clinical improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1-weighted MRI: hypointense vertebral bodies.  <br><span class=\"list-item\">\u2022</span> T2/STIR: hyperintense marrow edema.  <br><span class=\"list-item\">\u2022</span> Post-contrast enhancement of vertebral endplates and epidural collections.  <br><span class=\"list-item\">\u2022</span> Disc involvement is variable; abscesses may track in epidural space.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric: Ceftriaxone 2 g IV once daily or ciprofloxacin 400 mg IV twice daily.  <br><span class=\"list-item\">\u2022</span> Duration: Minimum 6 weeks IV; may switch to oral based on clinical response and sensitivities.  <br><span class=\"list-item\">\u2022</span> Monitor renal function and potential drug interactions in SCD (e.g., with hydroxyurea).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vertebral osteomyelitis in sickle cell is frequently tested in single-best-answer format, emphasizing epidemiology, imaging, and organism-specific therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024449,
    "question_number": "123",
    "question_text": "In a diabetic male older than 50 years, what kind of organisms do you expect to see if he develops meningitis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Bacterial meningitis causes fever, headache, neck stiffness and altered mental status. Pathogen likelihood varies by age and host factors:  <br><span class=\"list-item\">\u2022</span> Neonates: GBS, E. coli, Listeria  <br><span class=\"list-item\">\u2022</span> Children: H. influenzae (rare post-Hib vaccine), N. meningitidis, S. pneumoniae  <br><span class=\"list-item\">\u2022</span> Adults (18&ndash;50): S. pneumoniae, N. meningitidis  <br><span class=\"list-item\">\u2022</span> Adults >50 yrs or immunocompromised: add Listeria monocytogenes  <br>Diabetes mellitus impairs neutrophil chemotaxis and phagocytosis, heightening susceptibility to Listeria, a facultative intracellular organism that evades humoral immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Listeria monocytogenes is a gram-positive facultative intracellular coccobacillus transmitted via contaminated food. It invades intestinal mucosa using internalin proteins, escapes phagosomes via listeriolysin O, and spreads cell-to-cell via actin polymerization. In adults >50 yrs or with diabetes, Listeria causes up to 25% of meningitis cases <span class=\"citation\">(Brouwer et al., Lancet Infect <span class=\"evidence\">Dis 2010</span>)</span>. <span class=\"evidence\">The 2016</span> IDSA guidelines advise adding ampicillin (2 g IV q4h) to vancomycin plus a third-generation cephalosporin for empirical therapy in these patients (Level A). Cephalosporins lack activity against Listeria; omission of ampicillin risks treatment failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Streptococcus pneumoniae  <br><span class=\"list-item\">\u2022</span> Although the leading cause in immunocompetent adults, it is not specifically enriched by diabetes or age >50.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing all adult meningitis to S. pneumoniae regardless of host factors.  <br><br>C. Neisseria meningitidis  <br><span class=\"list-item\">\u2022</span> Peaks in teenagers and young adults; low incidence in >50 yrs without outbreak or asplenia.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming uniform risk across adult age groups.  <br><br>D. Haemophilus influenzae  <br><span class=\"list-item\">\u2022</span> Rare in adults due to widespread Hib vaccination; primarily a pediatric pathogen in unvaccinated children.  <br><span class=\"list-item\">\u2022</span> Misconception: believing H. influenzae remains a common adult meningitis cause.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Listeria monocytogenes</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>H. influenzae</th></tr></thead><tbody><tr><td>Gram stain morphology</td><td>Gram-positive coccobacillus</td><td>Gram-positive diplococcus</td><td>Gram-negative diplococcus</td><td>Gram-negative coccobacillus</td></tr><tr><td>High-risk groups</td><td>>50 yrs, immunocompromised</td><td>Adults (all ages)</td><td>Adolescents, young adults</td><td>Unvaccinated children</td></tr><tr><td>Empiric coverage needed</td><td>Ampicillin</td><td>Ceftriaxone + vancomycin</td><td>Ceftriaxone + vancomycin</td><td>Ceftriaxone</td></tr><tr><td>Vaccine impact</td><td>None</td><td>PCV13/PPSV23 reduces incidence</td><td>Serogroup-specific vaccines</td><td>Hib vaccine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always include ampicillin in empirical regimens for meningitis in patients >50 yrs or immunocompromised to cover Listeria.  <br>2. Listeria exhibits tumbling motility at 25 \u00b0C and replicates intracellularly, necessitating &beta;-lactam therapy that penetrates host cells.  <br>3. Diabetic neutrophil dysfunction predisposes to intracellular organisms like Listeria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking Streptococcus pneumoniae as the exclusive adult meningitis pathogen, overlooking Listeria in high-risk hosts.  <br>2. Overlooking the near-elimination of H. influenzae type b meningitis in adults post-Hib vaccination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Bacterial Meningitis Guidelines (2016): Recommends empiric ampicillin addition for adults >50 yrs or immunocompromised (Level A).  <br>2. ESCMID Clinical Guidelines (2017): Advises Listeria coverage with ampicillin &plusmn; gentamicin in severe meningitis (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After ingestion, Listeria invades M cells and enterocytes via internalins, escapes phagosomes through listeriolysin O, and uses ActA-mediated actin tails for cell-to-cell spread, bypassing extracellular defenses. Impaired neutrophil function in diabetes allows CNS invasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in fever, neck stiffness, AMS.  <br>2. Obtain blood cultures and head CT if raised ICP signs.  <br>3. Perform lumbar puncture: neutrophilic pleocytosis, high protein, low glucose; Gram-positive rods may be seen.  <br>4. Start empiric vancomycin + 3rd-gen cephalosporin + ampicillin immediately.  <br>5. De-escalate based on culture/sensitivity results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ampicillin 2 g IV q4h for 21 days in meningitis.  <br><span class=\"list-item\">\u2022</span> Add gentamicin (3&ndash;5 mg/kg/day) for synergy in severe Listeria cases, monitoring renal function.  <br><span class=\"list-item\">\u2022</span> Cephalosporins lack Listeria activity and must not be used alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Board-style questions frequently test pathogen risk stratification by age and comorbidity, emphasizing the necessity of Listeria coverage in patients >50 yrs or immunocompromised.</div></div></div></div></div>"
  },
  {
    "id": 100024451,
    "question_number": "75",
    "question_text": "Corticosteroids with an antibiotic regimen for meningitis help with which of the following?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - Bacterial meningitis triggers a cytokine\u2010mediated inflammatory cascade in the subarachnoid space, increasing blood&ndash;brain barrier permeability and causing neuronal injury.  <br><span class=\"list-item\">\u2022</span> Inflammation can extend into the inner ear via the cochlear aqueduct, leading to labyrinthitis and sensorineural hearing loss.  <br><span class=\"list-item\">\u2022</span> Adjunctive corticosteroids (dexamethasone) mitigate this inflammatory damage, particularly protecting cochlear hair cells and the auditory nerve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The primary benefit of adjunctive dexamethasone in bacterial meningitis is reduction of hearing loss. In Peltola et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 1988</span>)</span>, children with Haemophilus influenzae type b meningitis receiving dexamethasone had a drop in severe hearing impairment from 31% to 8% (p<0.01). De Gans and van de Beek&rsquo;s randomized trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2002</span>)</span> in adults showed that dexamethasone reduced the rate of severe hearing impairment from 30% to 16% (relative risk 0.52; 95% CI 0.30&ndash;0.92). <span class=\"evidence\">The 2021</span> IDSA Guidelines (Tier I evidence) recommend 10 mg IV dexamethasone every 6 hours for 4 days, started before or with the first antibiotic dose, to preserve auditory function. No consistent mortality benefit has been shown across all age groups and pathogens, and seizure rates or length of hospitalization remain unaffected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease mortality  <br><span class=\"list-item\">\u2022</span> While adult pneumococcal meningitis patients may see reduced mortality <span class=\"citation\">(de Gans & van de Beek, NEJM 2002)</span>, this is not a universal effect across all bacterial meningitides. The principal, consistently reproducible benefit is hearing preservation. Misconception: equating pathogen\u2010specific mortality benefit with a class effect.  <br><br>C. Reduce seizure frequency  <br><span class=\"list-item\">\u2022</span> Seizures in meningitis result from cortical irritation and infarcts; no trial has demonstrated that corticosteroids lower seizure incidence. Common error: assuming all inflammatory sequelae are mitigated by steroids.  <br><br>D. Shorten hospital stay  <br><span class=\"list-item\">\u2022</span> Length of hospitalization is determined by clinical stability, antibiotic course, and complications. Dexamethasone has not been shown to accelerate overall recovery or discharge. Pitfall: conflating reduced complications with faster discharge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Outcome</th><th>Dexamethasone Effect</th><th>Notes</th></tr></thead><tbody><tr><td>Sensorineural deafness</td><td>\u2193 (RR ~0.52) [CORRECT]</td><td>Strong evidence in Hib (children) & S. pneumo.</td></tr><tr><td>Mortality</td><td>\u2194 to \u2193 (pathogen-dependent)</td><td>Significant in adult pneumococcal only</td></tr><tr><td>Seizure frequency</td><td>\u2194</td><td>No randomized data supporting reduction</td></tr><tr><td>Hospital length of stay</td><td>\u2194</td><td>Unchanged in clinical trials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer dexamethasone 10 mg IV 15&ndash;20 minutes before or with first antibiotic dose to ensure CNS penetration and cytokine suppression.  <br><span class=\"list-item\">\u2022</span> Benefits are greatest in Haemophilus influenzae type b (pediatric) and Streptococcus pneumoniae (adult) meningitis; not recommended in Listeria or viral etiologies.  <br><span class=\"list-item\">\u2022</span> Inappropriate delay of dexamethasone (>1 hour after antibiotics) markedly reduces its protective effect on hearing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing steroids shorten hospitalization: they reduce specific sequelae but do not hasten global recovery.  <br>2. Using adjunctive corticosteroids for suspected viral meningitis: no benefit and potential harm, especially in HSV encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2021 Guidelines: Strong recommendation (A-II) for dexamethasone in adults with suspected pneumococcal meningitis and in children with Hib.  <br><span class=\"list-item\">\u2022</span> ESCMID 2016 Guideline: Recommends dexamethasone in acute bacterial meningitis, noting level I evidence for reduction in hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacterial lysis releases peptidoglycan and lipoteichoic acid, triggering microglial activation and TNF-&alpha;/IL-1&beta; release. These cytokines disrupt cochlear microcirculation and damage hair cells. Corticosteroids inhibit NF-\u03baB and reduce cytokine transcription, preserving cochlear integrity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Dexamethasone dosing: 0.15 mg/kg (max 10 mg) IV q6h for 4 days. Administer before or concurrently with antimicrobial therapy to prevent peak inflammatory mediator surge following bacterial kill.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Adjunctive corticosteroid use in meningitis is frequently tested as a single-best-answer, focusing on its timing, indication (pathogen\u00ad\u2010specific), and primary benefit (hearing preservation).</div></div></div></div></div>"
  },
  {
    "id": 100024455,
    "question_number": "74",
    "question_text": "A patient with meningitis from Alhaj is found to have meningococcal meningitis. What prophylaxis should be given to close contacts?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Neisseria meningitidis colonizes the nasopharynx, invades the bloodstream, and crosses the blood&ndash;brain barrier to cause meningitis. Close contacts share respiratory secretions and remain at elevated risk of secondary transmission.  <br>1. Carrier State: Antibiotic prophylaxis targets elimination of nasopharyngeal carriage to prevent spread.  <br>2. Blood&ndash;Brain Barrier: Prophylactic agents need not cross the BBB at high levels but must achieve bactericidal concentrations in the pharynx.  <br>3. Mechanisms of Action: Rifampin inhibits DNA-dependent RNA polymerase; ciprofloxacin inhibits DNA gyrase; ceftriaxone disrupts cell wall synthesis; azithromycin blocks the 50S ribosomal subunit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin remains the first-line prophylactic agent for Neisseria meningitidis contacts per CDC and IDSA guidelines. A typical pediatric/adult dose is 10 mg/kg (max 600 mg) orally every 12 hours for 2 days <span class=\"citation\">(MMWR 2019)</span>. It eradicates nasopharyngeal carriage in >90% of contacts. Ciprofloxacin (500 mg PO once) is an effective alternative for adults but is not recommended for children or pregnant women due to safety concerns. Ceftriaxone IM (250 mg adult; 125 mg child) is reserved for pregnant contacts or when oral rifampin/ciprofloxacin cannot be used. Azithromycin (500 mg adult; 250 mg child once) shows efficacy but lacks large-scale outcome data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ciprofloxacin (adult)  <br><span class=\"list-item\">\u2022</span> Incorrect: Although a single 500 mg dose is effective in adults, rifampin is the preferred first-line regimen for all contacts.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that a single-dose antibiotic always supersedes multi-dose regimens.  <br><span class=\"list-item\">\u2022</span> Differentiator: Rifampin eradicates carriage across age groups; ciprofloxacin is adult-only.<br><br>B. Ceftriaxone (age < 15)  <br><span class=\"list-item\">\u2022</span> Incorrect: Ceftriaxone IM is indicated chiefly for pregnant contacts or when oral agents are contraindicated, not routinely for children.  <br><span class=\"list-item\">\u2022</span> Misconception: All pediatric contacts require parenteral prophylaxis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Rifampin oral course is safe and effective in children.<br><br>D. Azithromycin  <br><span class=\"list-item\">\u2022</span> Incorrect: Although an emerging alternative, azithromycin is not first-line due to limited data on eradication rates and resistance patterns.  <br><span class=\"list-item\">\u2022</span> Misconception: New macrolides universally replace older agents.  <br><span class=\"list-item\">\u2022</span> Differentiator: Rifampin has decades of proven efficacy and guideline endorsement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rifampin</th><th>Ciprofloxacin</th><th>Ceftriaxone</th><th>Azithromycin</th></tr></thead><tbody><tr><td>Dosing</td><td>10 mg/kg PO q12\u00d72 days</td><td>500 mg PO once</td><td>250 mg IM adult, 125 mg child</td><td>500 mg PO adult; 250 mg child once</td></tr><tr><td>Population</td><td>All ages (unless contraindicated)</td><td>Adults only</td><td>Pregnant & oral CI</td><td>Alternative for all ages</td></tr><tr><td>Mechanism</td><td>RNA polymerase inhibition</td><td>DNA gyrase inhibition</td><td>Cell wall synthesis inhibition</td><td>50S ribosome inhibition</td></tr><tr><td>Eradication Rate</td><td>>90%</td><td>~90%</td><td>~90%</td><td>~80&ndash;90%</td></tr><tr><td>Major Limitation</td><td>Drug interactions; orange body fluids</td><td>Not for <18 or pregnancy</td><td>IM injection discomfort</td><td>Limited large-scale data</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rifampin penetrates respiratory secretions effectively; administer with vitamin K in neonates to prevent bleeding.  <br><span class=\"list-item\">\u2022</span> Ciprofloxacin&rsquo;s single-dose regimen improves compliance but may induce cartilage toxicity concerns in minors.  <br><span class=\"list-item\">\u2022</span> Ceftriaxone IM is the go-to for pregnant contacts to avoid rifampin teratogenicity and ciprofloxacin risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming ceftriaxone IM is preferred for all pediatric contacts; oral rifampin is actually first-line in children.  <br>2. Overlooking drug interactions: rifampin induces cytochrome P450, reducing efficacy of oral contraceptives and warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC <span class=\"citation\">(MMWR 2019)</span>: Recommends rifampin as the first-line prophylactic agent (Level A evidence); alternatives: ciprofloxacin, ceftriaxone, azithromycin.  <br><span class=\"list-item\">\u2022</span> IDSA <span class=\"citation\">(Clinical Infectious <span class=\"evidence\">Diseases 2021</span>)</span>: Affirms rifampin&rsquo;s superiority in carriage eradication; cites single-dose azithromycin as a potential option pending further studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Prophylaxis regimens for Neisseria meningitidis contacts are frequently tested in microbiology and infectious-disease sections&mdash;expect questions on dosage, contraindications, and agent selection by age and pregnancy status.</div></div></div></div></div>"
  },
  {
    "id": 100024457,
    "question_number": "72",
    "question_text": "In neuro-brucellosis, what is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Brucella spp. are facultative intracellular, gram-negative coccobacilli that can invade the CNS&mdash;causing meningitis, encephalitis, myelitis, and radiculopathy. Lipid-soluble antibiotics that penetrate macrophages and cross the blood&ndash;brain barrier are essential. Neuro-brucellosis often presents subacutely with headache, cranial nerve palsies, or radiculoneuritis. Effective therapy requires prolonged combination regimens to eradicate intracellular organisms and prevent relapse.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone is a third-generation cephalosporin with excellent CSF penetration (10&ndash;80% of serum levels) when meninges are inflamed. Guidelines <span class=\"citation\">(ESCMID 2017; Argentine <span class=\"evidence\">Consensus 2016</span>)</span> recommend triple therapy&mdash;doxycycline (200 mg/d PO), rifampicin (600&ndash;900 mg/d PO), and ceftriaxone (2 g IV BID)&mdash;for &ge;6 weeks in neuro-brucellosis. A meta-analysis <span class=\"citation\">(Otlu et al., Clin Infect <span class=\"evidence\">Dis 2023</span>)</span> demonstrated lower relapse rates (<5%) and improved neurologic outcomes with ceftriaxone-based regimens versus those without.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Doxycycline  <br><span class=\"list-item\">\u2022</span> Incorrect as monotherapy: although lipid-soluble, oral doxycycline alone lacks bactericidal activity in the CNS&mdash;relapse rates >15%.  <br><span class=\"list-item\">\u2022</span> Misconception: that oral agents suffice for meningitis; lacks rapid bactericidal CSF levels of IV &beta;-lactams.  <br><br>C. Rifampicin  <br><span class=\"list-item\">\u2022</span> Incorrect as sole agent: moderate CSF penetration (10&ndash;20%), bacteriostatic, high relapse risk.  <br><span class=\"list-item\">\u2022</span> Misconception: rifampin alone covers intracellular CNS infection; requires combination with bactericidal IV drugs.  <br><br>D. Streptomycin  <br><span class=\"list-item\">\u2022</span> Incorrect as monotherapy: aminoglycoside with poor CNS penetration (<5%), nephrotoxicity, ototoxicity.  <br><span class=\"list-item\">\u2022</span> Misconception: IM streptomycin covers neuro-brucellosis adequately; used only adjunctively in early therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Mechanism</th><th>CSF Penetration</th><th>Role in Neuro-brucellosis</th><th>Typical Regimen</th></tr></thead><tbody><tr><td>Ceftriaxone</td><td>Inhibits cell-wall synthesis</td><td>Excellent (10&ndash;80%)</td><td>Core IV bactericidal agent</td><td>2 g IV BID for &ge;6 weeks</td></tr><tr><td>Doxycycline</td><td>30S ribosomal inhibitor</td><td>Good (lipid-soluble)</td><td>Oral backbone</td><td>200 mg PO daily</td></tr><tr><td>Rifampicin</td><td>RNA polymerase inhibitor</td><td>Moderate (10&ndash;20%)</td><td>Oral adjunct</td><td>600&ndash;900 mg PO daily</td></tr><tr><td>Streptomycin</td><td>30S ribosomal inhibitor</td><td>Poor (<5%)</td><td>IM adjunct (early phase only)</td><td>1 g IM daily for 2&ndash;3 weeks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always include an IV &beta;-lactam (ceftriaxone) for CNS brucellosis to ensure bactericidal CSF levels.  <br>2. Treat neuro-brucellosis for at least 6 weeks; shorter courses risk relapse and chronic sequelae.  <br>3. Monitor auditory and renal function if streptomycin is used early in therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Monotherapy with doxycycline or rifampicin often leads to relapse; always employ combination therapy.  <br>2. Assuming oral absorption equates to CSF penetration; inflammation-dependent antibiotics vary significantly in CNS entry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ESCMID 2017 Guidelines (Level B): Recommend doxycycline + rifampicin + ceftriaxone for neuro-brucellosis based on case series demonstrating <5% relapse.  <br><span class=\"list-item\">\u2022</span> Argentine <span class=\"evidence\">Consensus 2016</span> (Level C): Advocate triple therapy including a third-generation cephalosporin (e.g., ceftriaxone) for &ge;6 weeks; supported by observational cohorts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone: 2 g IV BID; half-life ~8 h; excreted renally. Synergizes with doxycycline and rifampicin to eradicate intracellular Brucella and achieve sustained CSF levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Neuro-infectious disease vignettes frequently test antibiotic regimens, emphasizing CSF penetration, intracellular activity, and relapse prevention.</div></div></div></div></div>"
  },
  {
    "id": 100024460,
    "question_number": "129",
    "question_text": "A young girl presents with a complaint of back pain, fever, and night sweats. She shows signs of stroke on examination. What is the best diagnostic test?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Infective endocarditis often presents with systemic signs&mdash;fever, night sweats&mdash;and can seed distant sites (vertebral osteomyelitis causing back pain; septic emboli causing stroke). Key concepts:  <br>&bull; Pathophysiology of septic embolization: vegetations on valves release bacteria-laden emboli to the brain.  <br>&bull; Diagnostic hierarchy: microbiological confirmation (blood cultures) precedes imaging.  <br>&bull; Duke criteria: two major criteria require positive blood cultures and evidence of endocardial involvement.<br><br>(Word count: 109)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood cultures are the cornerstone of diagnosing infective endocarditis (IE). <span class=\"evidence\">The 2015</span> American Heart Association (AHA) guidelines and 2015 European Society of Cardiology (ESC) guidelines both mandate obtaining at least three sets of blood cultures, drawn from separate venipuncture sites before initiating antibiotics, to maximize pathogen yield (positive in >90% of native\u2010valve IE cases). Positive cultures constitute a major Duke criterion and guide antimicrobial therapy. Imaging (echocardiography) follows microbiological confirmation to localize vegetations. Brain CT (with or without contrast) and lumbar puncture do not identify cardiac vegetations or pathogens in the bloodstream and thus cannot establish the diagnosis of IE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Brain CT  <br>  &ndash; Incorrect: Noncontrast CT rules out hemorrhage but cannot detect valve vegetations or identify pathogens.  <br>  &ndash; Misconception: Students may think CT of the head establishes stroke etiology; it only shows infarct/hemorrhage.  <br>  &ndash; Differentiator: CT is anatomical, not microbiological.<br><br>C. Contrast brain CT  <br>  &ndash; Incorrect: Contrast enhances vessel visualization and can detect mycotic aneurysms but still fails to confirm endocardial infection or isolate organisms.  <br>  &ndash; Misconception: Contrast CT might be viewed as more &ldquo;definitive,&rdquo; but it does not fulfill Duke microbiological criteria.  <br>  &ndash; Differentiator: Useful for complications, not primary diagnosis.<br><br>D. Lumbar puncture  <br>  &ndash; Incorrect: LP evaluates meningitis or subarachnoid hemorrhage; contraindicated in focal mass lesions or increased intracranial pressure.  <br>  &ndash; Misconception: Fever plus neurologic signs \u2192 LP; here stroke features and risk of herniation make LP unsafe and non\u2010diagnostic for IE.  <br>  &ndash; Differentiator: CSF analysis does not detect endocardial vegetations or bloodstream pathogens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain three sets of blood cultures from separate sites before starting antibiotics in suspected IE.  <br>&bull; Transesophageal echocardiography has higher sensitivity (>90%) than transthoracic echo for detecting vegetations but should follow positive cultures.  <br>&bull; In stroke with fever or systemic infection, suspect septic emboli&mdash;avoid lumbar puncture until intracranial lesions are excluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing imaging (CT) over blood cultures as the initial diagnostic step in suspected IE.  <br>2. Performing lumbar puncture in focal neurologic deficits without first excluding mass lesions or increased intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA 2015 Infective Endocarditis Guidelines <span class=\"citation\">(<span class=\"evidence\">Circulation 2015</span>;132:e125&ndash;e181)</span>: Level of Evidence B&mdash;recommend three sets of blood cultures prior to antibiotics to satisfy Duke major criteria.  <br>&bull; ESC 2015 Guidelines for IE <span class=\"citation\">(Eur Heart J 2016;37:21&ndash;31)</span>, updated 2023: Class I&mdash;blood cultures essential; imaging follows microbiology for diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Septic emboli from mitral or aortic valve vegetations often lodge in the middle cerebral artery distribution, causing cortical infarcts with focal deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacteremia seeds endocardial surfaces, forming vegetations. Fragments dislodge as septic emboli to spine (osteomyelitis) and brain (stroke), producing systemic and focal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain three separate blood culture sets before antibiotics.  <br>2. Initiate empirical antibiotic therapy once cultures drawn.  <br>3. Perform transesophageal echocardiography to identify valve vegetations.  <br>4. Use brain imaging (CT/MRI) for neurologic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Infective endocarditis presenting with neurologic complications is frequently tested in neurology and internal medicine sections; students should recall Duke criteria and the primacy of blood cultures in diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div></div></div></div>"
  },
  {
    "id": 100024462,
    "question_number": "65",
    "question_text": "In a diabetic patient presenting with a black necrotic lesion on the nasal turbinate and rapid progression of facial pain and swelling, what is the most likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Mucormycosis is an angioinvasive opportunistic fungal infection caused by Mucorales (e.g., Rhizopus). Key concepts:<br><span class=\"list-item\">\u2022</span> Predisposition: uncontrolled diabetes mellitus with ketoacidosis impairs neutrophil function and increases free iron, facilitating fungal proliferation.<br><span class=\"list-item\">\u2022</span> Pathophysiology: inhaled sporangiospores germinate in sinus mucosa, invade blood vessels causing thrombosis, tissue ischemia, and black necrotic eschars.<br><span class=\"list-item\">\u2022</span> Clinical hallmarks: rapid onset facial/ocular pain, periorbital swelling, black eschar on nasal turbinates or palate, possible progression to cavernous sinus thrombosis and cerebral infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucormycosis is diagnosed clinically in DKA patients with necrotic nasal lesions and confirmed by histopathology showing broad (5&ndash;15 \u03bcm), ribbon-like, nonseptate hyphae branching at wide (90\u00b0) angles. The IDSA&rsquo;s 2016 guidelines recommend urgent surgical debridement plus high-dose liposomal amphotericin B (5 mg/kg/day), with step-down to posaconazole or isavuconazole once stabilized (strong recommendation, high-quality evidence). A 2021 retrospective multicenter study <span class=\"citation\">(Petrikkos et al., Clin Infect <span class=\"evidence\">Dis 2021</span>)</span> showed early amphotericin reduced 12-week mortality from 60% to 40%. Untreated rhinocerebral mucormycosis carries >90% mortality within days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspergillosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspergillus species produce septate hyphae with acute (45\u00b0) branching, less angioinvasion; black eschar is rare.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all invasive sinus fungi; Aspergillus more common in neutropenia or chronic granulomatous disease.<br><br>B. Necrotizing fasciitis  <br><span class=\"list-item\">\u2022</span> Incorrect: Bacterial polymicrobial infection of fascia/subcutaneous tissue; presents with severe pain, crepitus, systemic toxicity, not isolated nasal black eschar.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;necrotic&rdquo; in name with necrotic fungal lesions.<br><br>C. Wegener&rsquo;s granulomatosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Granulomatosis with polyangiitis is c-ANCA&ndash;associated vasculitis causing nasal septal perforation (&ldquo;saddle nose&rdquo;), sinusitis, renal involvement; lesions are granulomatous, not angioinvasive fungal black eschars.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any nasal lesion in autoimmune disease to GPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mucormycosis</th><th>Aspergillosis</th><th>Necrotizing Fasciitis</th><th>Wegener&rsquo;s Granulomatosis</th></tr></thead><tbody><tr><td>Predisposition</td><td>DKA, hematologic malignancy</td><td>Neutropenia, steroids</td><td>Diabetes, trauma, immunosuppression</td><td>c-ANCA positivity, autoimmune</td></tr><tr><td>Histology</td><td>Broad, nonseptate hyphae</td><td>Narrow, septate hyphae</td><td>Bacterial invasion of fascia</td><td>Necrotizing granulomas, vasculitis</td></tr><tr><td>Angioinvasion</td><td>Prominent</td><td>Less prominent</td><td>Not fungal; vascular thrombosis via bacteria</td><td>Granulomatous vasculitis</td></tr><tr><td>Clinical hallmark</td><td>Black necrotic eschar</td><td>Sinus nodules, pulmonary lesions</td><td>Severe pain, crepitus, systemic toxicity</td><td>Saddle-nose deformity, hematuria</td></tr><tr><td>First-line therapy</td><td>Liposomal amphotericin B</td><td>Voriconazole</td><td>Surgical debridement, broad-spectrum antibiotics</td><td>Cyclophosphamide, steroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar in the nasal cavity of a DKA patient is virtually pathognomonic for rhinocerebral mucormycosis.  <br><span class=\"list-item\">\u2022</span> Immediate combination of aggressive surgical debridement and high-dose liposomal amphotericin B improves survival.  <br><span class=\"list-item\">\u2022</span> Posaconazole/isavuconazole are effective salvage therapies in amphotericin-intolerant patients (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking Aspergillus for Mucorales based on &ldquo;invasive sinusitis&rdquo; without noting hyphal morphology.  <br><span class=\"list-item\">\u2022</span> Delaying surgical debridement due to underestimation of angioinvasiveness, leading to rapid intracranial extension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA (2016) &ldquo;Clinical Practice Guideline for the Management of Mucormycosis&rdquo;: Strong recommendation for liposomal amphotericin B followed by posaconazole/isavuconazole (A-I).  <br><span class=\"list-item\">\u2022</span> ESCMID/ECMM (2019) &ldquo;Guidelines for Diagnosis and Management of Mucormycosis&rdquo;: Emphasizes early surgical intervention and combination therapy (B-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Rhinocerebral mucormycosis is frequently tested in the context of diabetic ketoacidosis and black necrotic lesions on board-style vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100024463,
    "question_number": "8",
    "question_text": "An HIV\u2010positive patient with a CD4 count of 50 cells/\u03bcL presents with headache and focal neurologic deficits. Brain imaging demonstrates a solitary ring\u2010enhancing lesion. What is the next step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] &bull; In advanced HIV (CD4<100), focal ring\u2010enhancing CNS lesions most commonly reflect Toxoplasma gondii reactivation or primary CNS lymphoma.  <br>&bull; Ring enhancement arises from blood&ndash;brain barrier disruption around necrotic/inflammatory foci.  <br>&bull; Empiric anti\u2010toxoplasma therapy is recommended before invasive diagnostics when clinical and imaging features are typical. (150 words max)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma gondii is the predominant cause of focal brain lesions in severely immunosuppressed HIV patients. IDSA 2022 guidelines recommend:  <br>1. Obtain Toxoplasma IgG serology.  <br>2. If seropositive with typical imaging (multiple or solitary ring\u2010enhancing lesions, basal ganglia predilection), initiate empiric therapy (pyrimethamine&ndash;sulfadiazine&ndash;leucovorin).  <br>3. Reimage after 2 weeks; lack of radiographic or clinical improvement prompts stereotactic biopsy to evaluate for CNS lymphoma (commonly EBV\u2010driven).  <br>This stepwise approach avoids unnecessary invasive procedures and expedites therapy, reducing morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CSF analysis  <br> &ndash; PCR for T. gondii has low sensitivity (~50%) in focal parenchymal disease; lumbar puncture risks herniation with mass effect.  <br> &ndash; Misconception: CSF PCR is gold standard; in reality, imaging plus serology guides initial therapy.  <br><br>B. Start antibiotics  <br> &ndash; &ldquo;Antibiotics&rdquo; nonspecific; antibacterial agents (e.g., vancomycin/ceftriaxone) target bacterial abscess but not protozoan lesions in HIV.  <br> &ndash; Fails to address the most likely etiology and may delay appropriate anti\u2010toxoplasma therapy.  <br><br>D. MRI  <br> &ndash; Diagnosis is already established by imaging (ring\u2010enhancing lesion). Additional MRI sequencing (e.g., spectroscopy) may aid differentiation but not before a therapeutic trial.  <br> &ndash; Delays urgent empiric therapy and has low additional yield acutely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Indication</th><th>Rationale</th><th>Limitation</th></tr></thead><tbody><tr><td>Toxoplasmosis management</td><td>HIV with focal ring\u2010enhancing lesion</td><td>Targets most common etiology; high yield</td><td>Seronegative patients may need biopsy</td></tr><tr><td>CSF analysis</td><td>Suspected meningitis or diffuse encephalitis</td><td>Direct pathogen detection via PCR</td><td>Low sensitivity for focal lesions</td></tr><tr><td>Empiric antibiotics</td><td>Bacterial brain abscess (fever, leukocytosis)</td><td>Covers Staph/Strep abscess pathogens</td><td>Ineffective against protozoa</td></tr><tr><td>Additional MRI sequences</td><td>Atypical imaging (no ring enhancement)</td><td>Spectroscopy/FLAIR may differentiate tumors</td><td>Time\u2010consuming; delays treatment</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Most toxo lesions are multiple and basal ganglia&ndash;centric; solitary lesions still warrant empiric therapy if CD4<100.  <br>&bull; Improvement in symptoms or lesion size within 10&ndash;14 days confirms diagnosis; persistence necessitates biopsy.  <br>&bull; EBV PCR in CSF is more sensitive for primary CNS lymphoma than Toxo PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering lumbar puncture first: may precipitate herniation and yields low diagnostic return in focal lesions.  <br>2. Immediate biopsy: invasive with risk; reserved for nonresponders after empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2022: Recommends empiric anti\u2010toxoplasma therapy in seropositive HIV patients with focal brain lesions; level B evidence.  <br>2. European AIDS Clinical Society (EACS) 2023: Stresses re\u2010imaging at 2 weeks; if <25% lesion reduction, proceed to stereotactic brain biopsy; level 2b evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam.  <br>HIV\u2010related CNS lesions are frequently tested in single best\u2010answer format, emphasizing the empiric treatment algorithm for suspected toxoplasmosis versus indications for biopsy in nonresponders.</div></div></div></div></div>"
  },
  {
    "id": 100024465,
    "question_number": "78",
    "question_text": "A patient with sickle cell anemia presents with low back pain and fever. What is the most likely organism responsible for these symptoms?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; Sickle cell disease (SCD) causes repeated vaso-occlusive crises in bone marrow, leading to infarction, cortical bone disruption, and functional asplenia.  <br>&bull; Bone infarction predisposes to bacterial seeding and osteomyelitis; impaired splenic clearance increases risk for encapsulated and certain Gram-negative organisms.  <br>&bull; In non-SCD patients, Staphylococcus aureus predominates in osteomyelitis; in SCD, Salmonella species gain a foothold via translocation from the gut and flourish in infarcted bone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Salmonella species are the most common cause of osteomyelitis in SCD, accounting for roughly 50&ndash;60% of cases, whereas S. aureus contributes ~30% <span class=\"citation\">(Harris et al., J Infect <span class=\"evidence\">Dis 1983</span>;148:926&ndash;30)</span>. Functional asplenia in SCD impairs clearance of Salmonella, an encapsulated Gram-negative bacillus. IDSA 2022 guidelines for vertebral osteomyelitis recommend empiric coverage targeting both Gram-positive cocci and Gram-negative rods in SCD patients, with subsequent tailoring to culture results. A retrospective review <span class=\"citation\">(Onanuga et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span> confirmed that vertebral involvement often presents with back pain, fever, elevated ESR/CRP, and positive blood cultures yielding Salmonella.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Staphylococcus aureus  <br>  &ndash; Mistaken as &ldquo;most common overall&rdquo; osteomyelitis organism in general population  <br>  &ndash; In SCD, relative Salmonella predominance reverses this trend  <br>B. Salmonella species [CORRECT]  <br>C. Pseudomonas aeruginosa  <br>  &ndash; Typically associated with puncture wounds (e.g., foot), nosocomial infections, or immunocompromise with indwelling devices  <br>  &ndash; Rare cause of community-acquired vertebral osteomyelitis in SCD  <br>D. Escherichia coli  <br>  &ndash; Commonly causes urinary tract infections and neonatal sepsis, not bone infections in SCD  <br>  &ndash; Lacks the predilection for infarcted bone seen with Salmonella species</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Salmonella species</th><th>Staphylococcus aureus</th><th>Pseudomonas aeruginosa</th><th>Escherichia coli</th></tr></thead><tbody><tr><td>Gram stain & shape</td><td>Gram-negative rod</td><td>Gram-positive cocci</td><td>Gram-negative rod</td><td>Gram-negative rod</td></tr><tr><td>SCD osteomyelitis frequency</td><td>~50&ndash;60%</td><td>~30%</td><td><5%</td><td><5%</td></tr><tr><td>Predisposing factor in SCD</td><td>Functional asplenia, bone infarction</td><td>Bone infarction</td><td>Puncture/nosocomial</td><td>Urinary/GI source</td></tr><tr><td>Empiric therapy considerations</td><td>Ceftriaxone, fluoroquinolones</td><td>Anti-staphylococcal penicillins</td><td>Antipseudomonal &beta;-lactams</td><td>Broad-spectrum &beta;-lactams</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In SCD, always suspect Salmonella in osteomyelitis&mdash;blood cultures may be positive even if bone biopsy is pending.  <br>&bull; MRI is the imaging modality of choice for vertebral osteomyelitis/epidural abscess; look for marrow edema and epidural enhancement.  <br>&bull; Empiric antibiotic regimens in SCD osteomyelitis should cover both Salmonella (e.g., third-generation cephalosporins) and Staph aureus until cultures return.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming Staphylococcus aureus is the leading cause of osteomyelitis regardless of host factors&mdash;overlooks the Salmonella-SCD association.  <br>2. Neglecting to obtain blood cultures before antibiotics in febrile SCD patients with bone pain&mdash;delays organism identification and targeted therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Salmonella versus Staph aureus in osteomyelitis is a high-yield test point for sickle cell disease on USMLE Step 1/2 formats, often presented as bone pain in an African-American teen with fever.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100024466,
    "question_number": "19",
    "question_text": "Q19. A healthy individual returns from hiking in the USA and presents with radiculopathy. CSF analysis shows WBC count of 22 with 90% lymphocytes, high protein, and normal glucose. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Lyme neuroborreliosis arises from Borrelia burgdorferi invasion of the nervous system, often weeks after an infected tick bite. Key concepts:<br><span class=\"list-item\">\u2022</span> Radiculopathy: inflammation of dorsal nerve roots produces shooting limb pain; hallmark of Bannwarth syndrome.<br><span class=\"list-item\">\u2022</span> CSF findings in Lyme: mild lymphocytic pleocytosis (10&ndash;200 WBC/\u03bcL, &ge;80% lymphocytes), elevated protein (50&ndash;100 mg/dL), normal glucose ratio (>0.5).<br><span class=\"list-item\">\u2022</span> Differential CSF patterns: bacterial meningitis shows neutrophils, low glucose; TB meningitis shows lymphocytes but low glucose; fungal infections often in immunocompromised with neutrophils or mixed cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lyme disease is confirmed by radiculitis coupled with characteristic CSF. <span class=\"evidence\">The 2020</span> IDSA Guidelines recommend diagnosis when clinical features (radicular pain, cranial neuropathy) align with supportive CSF serology (intrathecal Borrelia antibody index) <span class=\"citation\">(IDSA 2020; Strong recommendation, moderate-quality evidence)</span>. B. burgdorferi&rsquo;s affinity for neural tissues triggers a lymphocyte-predominant pleocytosis and blood&ndash;nerve barrier disruption, raising CSF protein without impairing glucose transport. European Federation of Neurological Societies <span class=\"citation\">(EFNS 2018)</span> echoes: in endemic areas, radiculoneuritis plus CSF lymphocytic pleocytosis virtually confirms Lyme neuroborreliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspergillosis  <br><span class=\"list-item\">\u2022</span> Aspergillus CNS infection occurs in immunocompromised hosts, rarely as isolated radiculitis. CSF usually shows neutrophilic pleocytosis, low glucose, and culture may grow septate hyphae.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any fungal pathogen to lymphocytic CSF; Aspergillus is primarily neutrophilic.<br><br>C. Tuberculosis  <br><span class=\"list-item\">\u2022</span> TB meningitis yields lymphocytic pleocytosis and high protein but typically low CSF glucose (<40% serum) and basilar meningeal enhancement on MRI. Radiculopathy alone without systemic or cranial nerve signs is atypical.  <br><span class=\"list-item\">\u2022</span> Misconception: equating lymphocytes + high protein always to TB; glucose level and clinical context differ.<br><br>D. Pneumococcal infection  <br><span class=\"list-item\">\u2022</span> Acute Streptococcus pneumoniae meningitis presents with neutrophil-predominant pleocytosis (often >1,000 cells/\u03bcL), very low glucose (<2.2 mmol/L), and marked toxicity. Radicular pain is uncommon.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming high-protein CSF always bacterial; leukocyte differential and glucose help differentiate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lyme Neuroborreliosis</th><th>Aspergillus Meningitis</th><th>TB Meningitis</th><th>Pneumococcal Meningitis</th></tr></thead><tbody><tr><td>Typical host</td><td>Healthy hiker in endemic area</td><td>Immunocompromised</td><td>Any, often malnourished/children</td><td>Any, especially extremes of age</td></tr><tr><td>CSF WBC count</td><td>10&ndash;200 cells/\u03bcL</td><td>Variable, often <100</td><td>100&ndash;500 cells/\u03bcL</td><td>>1,000 cells/\u03bcL</td></tr><tr><td>Cell differential</td><td>&ge;80% lymphocytes</td><td>Neutrophils or mixed</td><td>&ge;70% lymphocytes</td><td>&ge;80% neutrophils</td></tr><tr><td>CSF protein</td><td>Moderate elevation (50&ndash;100 mg/dL)</td><td>Marked elevation</td><td>Marked elevation</td><td>Marked elevation</td></tr><tr><td>CSF glucose</td><td>Normal (>50% serum)</td><td>Low (<40% serum)</td><td>Low (<45% serum)</td><td>Very low (<30% serum)</td></tr><tr><td>Clinical presentation</td><td>Radiculopathy, cranial neuropathy</td><td>Headache, seizures, focal deficits</td><td>Subacute meningitis, basilar signs</td><td>Acute meningitis, fever, neck stiffness</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Bannwarth syndrome: painful radiculitis with lymphocytic CSF pleocytosis is pathognomonic of Lyme in endemic areas.<br><span class=\"list-item\">\u2022</span> Intrathecal antibody index improves specificity: CSF/serum Borrelia IgG ratio >1.3 confirms neuroborreliosis.<br><span class=\"list-item\">\u2022</span> First-line therapy: IV ceftriaxone 2 g daily for 14&ndash;28 days; oral doxycycline is an alternative for mild cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overcalling TB when CSF lymphocytes are present; always assess glucose level and epidemiology.<br><span class=\"list-item\">\u2022</span> Expecting neutrophils in early Lyme may lead to misdiagnosis; early CSF can have neutrophils but shifts to lymphocytes rapidly.<br><span class=\"list-item\">\u2022</span> Neglecting radicular pain as a manifestation of meningitis and misattributing to peripheral neuropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2020 Lyme Neuroborreliosis Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: In patients with suspected neuroborreliosis and supportive CSF findings, use intrathecal antibody testing. (Strong recommendation, moderate-quality evidence)  <br>2. European Federation of Neurological Societies (EFNS) 2018 Guideline on Lyme Borreliosis  <br><span class=\"list-item\">\u2022</span> Recommendation: IV ceftriaxone remains the treatment of choice for neurologic Lyme, including radiculitis. (Level A evidence based on RCTs)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Lyme neuroborreliosis frequently appears as radicular pain with lymphocytic CSF pleocytosis; students should recall CSF profiles distinguishing bacterial, tubercular, fungal, and spirochetal infections.</div></div></div></div></div>"
  },
  {
    "id": 100024467,
    "question_number": "64",
    "question_text": "Which of the following neuro manifestations is associated with Whipple disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Whipple disease is a systemic infection by Tropheryma whipplei that can involve the CNS via macrophage\u2010laden PAS\u2010positive infiltrates. Neuroanatomically, oculomasticatory myorhythmia (OMM) arises from synchronized oscillations in the mesencephalic trigeminal nucleus and oculomotor complex, manifesting as conjugate 1&ndash;2 Hz ocular movements with jaw muscle contractions. Recognition of OMM requires understanding of brainstem motor circuitry (mesencephalic nucleus of V, oculomotor nucleus, medial longitudinal fasciculus) and how infiltrative granulomatous processes disrupt these pathways. Students should distinguish OMM from other ocular motor disorders by its rhythmicity, frequency, and masticatory coupling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Oculomasticatory myorhythmia is pathognomonic for neurologic Whipple disease and occurs in ~20&ndash;30% of cases <span class=\"citation\">(Durand et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span>. The hallmark rhythmicity at 1&ndash;2 Hz with concomitant jaw movements reflects involvement of brainstem central pattern generators. ESCMID 2018 guidelines recommend MRI brain and CSF PCR for T. whipplei in any patient presenting with OMM (Level B evidence). CSF PCR sensitivity is 88% and specificity 97%, per multicenter validation <span class=\"citation\">(<span class=\"evidence\">Durand et al. 2019</span>)</span>. Early recognition and prompt antibiotic therapy (ceftriaxone induction followed by TMP&ndash;SMX maintenance for 12 months) reduce relapse and prevent irreversible neurodegeneration <span class=\"citation\">(IDSA 2020, Level C)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Myasthenia gravis &ndash; Features fluctuating, fatigable weakness of ocular and bulbar muscles without rhythmic 1&ndash;2 Hz masticatory movements; pathophysiology is autoantibody\u2010mediated NMJ blockade, not brainstem infiltrates.  <br>C. Multiple sclerosis &ndash; Demyelinating lesions cause internuclear ophthalmoplegia or optic neuritis but not synchronous ocular&ndash;jaw myorhythmia; MS plaques localize to periventricular white matter, not central pattern generators.  <br>D. Amyotrophic lateral sclerosis &ndash; Degeneration of UMN and LMN leads to spasticity, fasciculations, dysphagia, but spares oculomotor nuclei until late, and does not produce rhythmic jaw&ndash;eye oscillations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Oculomasticatory Myorhythmia (Whipple)</th><th>Myasthenia Gravis</th><th>Multiple Sclerosis</th><th>Amyotrophic Lateral Sclerosis</th></tr></thead><tbody><tr><td>Movement frequency</td><td>1&ndash;2 Hz rhythmic</td><td>None (fatigable weakness)</td><td>None (internuclear ophthalmoplegia)</td><td>None (spastic&ndash;flaccid signs)</td></tr><tr><td>Jaw involvement</td><td>Synchronous rhythmic contractions</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Pathognomonic for</td><td>Whipple disease</td><td>Myasthenia gravis</td><td>Demyelination</td><td>Motor neuron degeneration</td></tr><tr><td>Pathophysiology</td><td>PAS\u2010positive macrophage brainstem infiltrates</td><td>Autoantibody NMJ blockade</td><td>CNS demyelination</td><td>Degeneration of UMN & LMN</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; OMM is virtually diagnostic of neurologic Whipple disease&mdash;seek T. whipplei PCR in CSF.  <br>&bull; CNS involvement may precede gastrointestinal symptoms; maintain high suspicion in unexplained brainstem signs.  <br>&bull; Standard therapy: IV ceftriaxone 2 g daily for 2 weeks \u2192 TMP&ndash;SMX (160/800 mg) BID for &ge;12 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing OMM with ocular myoclonus from midbrain lesions&mdash;distinguish by jaw involvement.  <br>2. Attributing rhythmic jaw oscillations to essential tremor&mdash;essential tremor spares ocular muscles and lacks coupling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2018 Clinical Practice Guidelines on Tropheryma whipplei infection: recommend MRI brain with contrast and CSF PCR for suspected neurologic WD (Level B).  <br>2. Durand DV et al., Clin Infect <span class=\"evidence\">Dis 2019</span> (multicenter validation study): CSF PCR for T. whipplei showed 88% sensitivity and 97% specificity in neurologic WD (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>OMM reflects pathology in the mesencephalic trigeminal nucleus (jaw proprioception center) and oculomotor nuclei, interconnected by the central pattern generators in the pontine tegmentum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>T. whipplei&ndash;infected macrophages traverse the blood&ndash;brain barrier, accumulate in perivascular spaces and brainstem nuclei, causing granulomatous inflammation that disrupts rhythmic motor circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify OMM clinically.  <br>2. Order brain MRI to exclude structural lesions.  <br>3. Perform CSF analysis with PCR for T. whipplei.  <br>4. Obtain duodenal biopsy if PCR inconclusive.  <br>5. Initiate antibiotic therapy promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI may show T2 hyperintensities in the dorsal midbrain and periaqueductal gray, correlating with clinical OMM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Induction: IV ceftriaxone 2 g daily \u00d714 days; Maintenance: TMP&ndash;SMX 160/800 mg BID \u00d712 months. Monitor CSF PCR at 6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Neurologic Whipple disease and OMM are high\u2010yield for both clinical neurology and infectious disease sections.</div></div></div></div></div>"
  },
  {
    "id": 100024475,
    "question_number": "59",
    "question_text": "An HIV patient has a brain CT showing multiple ring-enhancing lesions. What is the next step in management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - Reactivation of Toxoplasma gondii in severely immunocompromised (CD4\u207a <100 cells/\u00b5L) leads to focal necrotizing encephalitis and characteristic ring-enhancing lesions on neuroimaging.  <br><span class=\"list-item\">\u2022</span> Ring enhancement reflects breakdown of the blood&ndash;brain barrier around abscesses or neoplastic masses; common HIV-associated differentials include toxoplasmosis, primary CNS lymphoma, tuberculoma, and bacterial abscess.  <br><span class=\"list-item\">\u2022</span> Initial noninvasive management balances diagnostic certainty against risks: trial of empiric therapy for the most likely pathogen (toxoplasma) is standard before invasive procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Empirical anti-toxoplasma therapy is first-line because Toxoplasma encephalitis accounts for ~50&ndash;70% of ring-enhancing lesions in AIDS patients. <span class=\"evidence\">The 2023</span> IDSA Guidelines for the Treatment of Toxoplasmosis in HIV (Level B evidence) recommend initiating pyrimethamine&ndash;sulfadiazine&ndash;leucovorin promptly in patients with compatible imaging and positive Toxoplasma IgG or high pretest probability, without delaying for invasive diagnostics. Studies show clinical and radiographic improvement in 60&ndash;80% of patients by 10&ndash;14 days; lack of response warrants stereotactic biopsy to exclude alternative diagnoses (e.g., EBV-positive primary CNS lymphoma). CSF PCR for Toxoplasma has sensitivity ~50% and is not routinely recommended. Serology indicates prior exposure but cannot distinguish active CNS disease. Brain biopsy carries risks (hemorrhage ~2%, neurologic deficits) and is reserved for nonresponders after 2 weeks of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CSF PCR  <br><span class=\"list-item\">\u2022</span> Low sensitivity (~50%) for Toxoplasma DNA; a negative result does not exclude disease.  <br><span class=\"list-item\">\u2022</span> Misconceives that molecular confirmation is needed before therapy.  <br><span class=\"list-item\">\u2022</span> PCR is adjunctive, not first-line; invasive lumbar puncture risks in raised intracranial pressure.  <br><br>B. Serology  <br><span class=\"list-item\">\u2022</span> Toxoplasma IgG positivity indicates past exposure, not active CNS infection.  <br><span class=\"list-item\">\u2022</span> Common error: equating seropositivity with acute disease.  <br><span class=\"list-item\">\u2022</span> Serology supports but does not replace empiric treatment when clinical suspicion is high.  <br><br>C. Biopsy  <br><span class=\"list-item\">\u2022</span> Reserved for lesions unresponsive to empiric therapy after 10&ndash;14 days.  <br><span class=\"list-item\">\u2022</span> Misconception: biopsy is gold standard immediately; in immunosuppressed, initial noninvasive trial is safer.  <br><span class=\"list-item\">\u2022</span> Invasive procedure with hemorrhage/neurodeficit risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Sensitivity</th><th>Specificity</th><th>Invasiveness</th><th>Role/Timing</th></tr></thead><tbody><tr><td>Empirical anti-toxo therapy</td><td>Clinical ~80%</td><td>N/A</td><td>Non-invasive</td><td>First-line; assess response by d10&ndash;14</td></tr><tr><td>CSF PCR</td><td>~50%</td><td>>95%</td><td>Minimally invasive</td><td>Adjunct; low yield, not initial</td></tr><tr><td>Serology (Toxo IgG)</td><td>>90%</td><td>Low for active</td><td>Non-invasive</td><td>Supportive; cannot confirm activity</td></tr><tr><td>Brain biopsy</td><td>~95%</td><td>~100%</td><td>Highly invasive</td><td>After failed 2-wk trial</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lesions in basal ganglia and corticomedullary junction strongly suggest toxoplasmosis in AIDS patients.  <br><span class=\"list-item\">\u2022</span> Monitor radiographic response at 10&ndash;14 days; absence of &ge;25% reduction prompts biopsy.  <br><span class=\"list-item\">\u2022</span> Always add leucovorin to pyrimethamine to prevent hematologic toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming positive Toxoplasma IgG equals active CNS infection.  <br><span class=\"list-item\">\u2022</span> Ordering brain biopsy before a therapeutic trial when empiric therapy has a high diagnostic yield.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2023 Guidelines on Toxoplasmosis in HIV: Recommend empiric therapy for compatible imaging and clinical findings (Level B).  <br><span class=\"list-item\">\u2022</span> AAN 2022 Practice Advisory on Neuroimaging in HIV: Advocates MRI with contrast for lesion characterization prior to invasive diagnostics (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Management of HIV-associated ring-enhancing brain lesions is frequently tested as vignette-based questions emphasizing empiric anti&ndash;Toxoplasma therapy and the timing of biopsy in nonresponders.</div></div></div></div></div>"
  },
  {
    "id": 100024476,
    "question_number": "53",
    "question_text": "A case scenario of a young male IV drug user presented with fever and hemiparesis. What will you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Intravenous drug use predisposes to bacteremia and infective endocarditis (IE). Septic emboli from valvular vegetations can lodge in cerebral arteries, causing focal deficits (e.g., hemiparesis). Fever in stroke should raise suspicion for an infectious etiology rather than typical thromboembolic or hemorrhagic stroke. Management prioritizes eradication of infection and stabilization over reperfusion therapies. Early recognition of IE-related stroke guides appropriate antibiotic selection and avoids interventions (tPA, anticoagulation) that carry high hemorrhagic risk in septic emboli. (\u2248120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Empirical antibiotic therapy should begin promptly after obtaining blood cultures, per 2015 AHA IE guidelines (Class I, Level C). Delays in treating septic emboli increase risk of abscess formation, intracranial hemorrhage, and mortality. Neurology guidelines <span class=\"citation\">(AAN 2018)</span> advise against thrombolysis in suspected septic strokes due to vessel wall fragility and risk of hemorrhagic conversion reported up to 60% in case series <span class=\"citation\">(Weinberger et al., <span class=\"evidence\">Stroke 2016</span>)</span>. Anticoagulation and antiplatelets are contraindicated acutely in IE-related stroke: they do not address infection and further increase bleeding risk <span class=\"citation\">(European Stroke <span class=\"evidence\">Organisation 2022</span>)</span>. Thus, immediate antibiotics targeting staphylococci and streptococci is both evidence-based and lifesaving.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anti-platelets  <br>&bull; Incorrect because platelet aggregation inhibitors do not treat infection.  <br>&bull; Misconception: that all ischemic strokes benefit from aspirin; septic embolic infarcts have high hemorrhagic transformation risk with antiplatelets.  <br>&bull; Unlike antibiotics, they neither sterilize vegetations nor prevent further septic showers.<br><br>C. Anticoagulation  <br>&bull; Incorrect: heparin or warfarin in acute IE stroke increases intracranial hemorrhage risk by weakening infected arterial walls.  <br>&bull; Misconception: anticoagulation reduces embolic events in IE; in fact, it is only indicated if patient has prosthetic valve thrombosis (after stabilization).  <br>&bull; Does not address the underlying bacteremia.<br><br>D. tPA  <br>&bull; Incorrect and contraindicated: thrombolysis in IE-related stroke has a reported intracerebral hemorrhage rate >50%.  <br>&bull; Misconception: fever + focal deficit = usual ischemic stroke treatable with tPA.  <br>&bull; Septic emboli damage endothelium; tPA exacerbates bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication</th><th>Key Risk</th></tr></thead><tbody><tr><td>Start antibiotics</td><td>Bacterial cell\u2010wall/membrane kill</td><td>Suspected infective endocarditis</td><td>Allergic reactions, resistance</td></tr><tr><td>Anti-platelets</td><td>Inhibit platelet aggregation</td><td>Atherosclerotic ischemic stroke</td><td>Hemorrhagic conversion</td></tr><tr><td>Anticoagulation</td><td>Inhibit coagulation cascade</td><td>Atrial fibrillation, DVT-related stroke</td><td>Intracranial hemorrhage</td></tr><tr><td>tPA</td><td>Fibrinolysis of thrombus</td><td>Acute non-infectious ischemic stroke <4.5 h</td><td>Catastrophic hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In any stroke patient with fever or sepsis risk factors, always obtain blood cultures before initiating antibiotics.  <br><span class=\"list-item\">\u2022</span> Delay or avoid reperfusion therapies (tPA, anticoagulation) if infective endocarditis is suspected.  <br><span class=\"list-item\">\u2022</span> Transthoracic echocardiography (TTE) followed by transesophageal echo (TEE) confirms valvular vegetations in >90% of IE cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating fever + stroke to meningitis or encephalitis&mdash;always consider infective endocarditis with septic emboli.  <br>2. Reflexively administering tPA in all acute ischemic strokes&mdash;neglecting contraindications like septic embolic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association (AHA) 2015 IE Guidelines: Class I recommendation for immediate blood cultures and start of empiric antibiotics covering Staphylococcus aureus and Streptococcus species (Level C).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2022: Strong recommendation against thrombolysis in patients with infective endocarditis&ndash;related stroke due to high hemorrhagic risk (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect IE in stroke with fever, IV drug use.  <br>2. Obtain three sets of blood cultures prior to antibiotics.  <br>3. Perform TTE; if negative and suspicion remains high, proceed to TEE.  <br>4. Brain MRI to assess infarct pattern and rule out microabscesses.  <br>5. Initiate empiric antibiotic therapy immediately after cultures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI often shows multiple cortical and subcortical infarcts of varying ages in septic embolic stroke.  <br><span class=\"list-item\">\u2022</span> Gradient echo (GRE) sequences may reveal microbleeds indicating hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric regimen: vancomycin plus gentamicin (if prosthetic valve risk) or vancomycin plus ceftriaxone for native valve IE; tailor antibiotics once culture sensitivities return.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Infective endocarditis presenting as stroke is frequently tested in vignette format to assess integration of neurology and infectious disease management, with emphasis on contraindications to standard stroke therapies in the setting of sepsis.</div></div></div></div></div>"
  },
  {
    "id": 100024478,
    "question_number": "66",
    "question_text": "In a patient with poorly controlled diabetes mellitus presenting with facial pain, nasal congestion, and a black necrotic eschar on the nasal turbinate, what is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Rhinocerebral mucormycosis is an angioinvasive fungal infection most often seen in patients with uncontrolled diabetes&mdash;especially during ketoacidosis&mdash;due to elevated serum free iron and impaired neutrophil function. Key features include rapid progression, facial pain, sinusitis, periorbital edema and a black eschar on the nasal or palatal mucosa from vascular thrombosis and tissue infarction. Histopathology reveals broad (5&ndash;20 \u00b5m), ribbon-like, non-septate hyphae with right-angle branching. Prompt recognition is <span class=\"key-point\">critical:</span> untreated cases rapidly invade orbit and cranial vault, leading to cavernous sinus thrombosis, cranial neuropathies, and high mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucormycosis pathogenesis hinges on iron-dependent fungal proliferation and angioinvasion. <span class=\"evidence\">The 2016</span> IDSA guidelines recommend first-line therapy with liposomal amphotericin B at 5 mg/kg/day (A-II) plus urgent surgical debridement. The VITAL trial (2016) demonstrated isavuconazole&rsquo;s noninferiority to amphotericin in salvage settings (mITT mortality 33% vs. 39%). European ECMM/ESCMID guidelines (2019) support adjunctive posaconazole or isavuconazole for step-down therapy (B-II). Early imaging&mdash;CT for bony erosion, MRI for the &ldquo;black turbinate&rdquo; sign&mdash;guides surgical planning. Combined medical and surgical management reduces mortality from >80% to \u224850%. Histopathology with broad nonseptate hyphae at right angles differentiates it definitively from other pathogens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspergillosis  <br>&bull; Narrow (3&ndash;6 \u00b5m), septate hyphae branching at 45\u00b0  <br>&bull; Seen in neutropenia and chronic granulomatous disease, rarely causes black nasal eschars  <br>&bull; Favors pulmonary and allergic manifestations rather than rapid angioinvasion in DM  <br><br>C. Necrotizing fasciitis  <br>&bull; Bacterial infection of subcutaneous tissue and fascia, not mucosa  <br>&bull; Presents with &ldquo;pain out of proportion,&rdquo; crepitus, systemic toxicity&mdash;no fungi or black nasal eschar  <br>&bull; Predominantly involves limbs, trunk, perineum  <br><br>D. Wegener&rsquo;s granulomatosis  <br>&bull; Granulomatous vasculitis (c-ANCA/PR3-ANCA positive) with nasal ulceration and saddle-nose deformity  <br>&bull; Necrosis is granulomatous, not angioinvasive microthrombosis with black eschar  <br>&bull; Responds to immunosuppression rather than debridement and antifungals</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mucormycosis</th><th>Aspergillosis</th><th>Necrotizing Fasciitis</th><th>Wegener&rsquo;s Granulomatosis</th></tr></thead><tbody><tr><td>Predisposing Condition</td><td>DM with DKA; iron overload; transplant</td><td>Neutropenia; corticosteroids</td><td>Trauma; DM; surgical wounds</td><td>Granulomatous vasculitis</td></tr><tr><td>Tissue Invasion</td><td>Angioinvasion \u2192 thrombosis/necrosis</td><td>Local invasion; angioinvasion less severe</td><td>Fascia/subcutaneum \u2192 rapid necrosis</td><td>Necrotizing granulomas, vasculitis</td></tr><tr><td>Histology</td><td>Broad, non-septate, right-angle hyphae</td><td>Narrow, septate, 45\u00b0-angle hyphae</td><td>Bacterial colonies, neutrophils</td><td>Granulomas, fibrinoid necrosis</td></tr><tr><td>Clinical Lesion</td><td>Black eschar on nasal/palate mucosa</td><td>Fungus balls, allergic bronchopulmonary manifestations</td><td>Crepitus, bullae, severe pain</td><td>Nasal ulcers, sinusitis, deformity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar on nasal turbinates in diabetic ketoacidosis is virtually pathognomonic for rhinocerebral mucormycosis.  <br><span class=\"list-item\">\u2022</span> Correcting acidosis reduces free serum iron, inhibiting fungal growth; aggressive glucose control is essential.  <br><span class=\"list-item\">\u2022</span> Combined high-dose liposomal amphotericin B and prompt surgical debridement lowers mortality by ~30% compared to medical therapy alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking mucormycosis for aspergillosis based solely on sinus involvement; histopathology is definitive.  <br><span class=\"list-item\">\u2022</span> Delaying surgical debridement while awaiting culture results&mdash;every hour of delay increases mortality risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Guidelines: Recommend liposomal amphotericin B (5 mg/kg/day) plus surgical debridement (A-II); salvage therapy with posaconazole or isavuconazole (B-II).  <br><span class=\"list-item\">\u2022</span> ECMM/ESCMID 2019 Guidelines: Endorse early aggressive surgical intervention and step-down to isavuconazole (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Uncontrolled hyperglycemia and acidosis increase free serum iron via decreased transferrin binding. Mucorales exploit this iron, adhere to endothelial cells, invade vasculature, cause thrombosis, and lead to tissue infarction manifesting as black eschar.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in diabetic/DKA patient with facial pain, sinusitis, black eschar  <br>2. Obtain urgent CT/MRI to assess bony and vascular invasion  <br>3. Perform endoscopic biopsy; histology for broad aseptate hyphae at right angles  <br>4. Initiate liposomal amphotericin B + surgical debridement promptly</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: sinus opacification with bone destruction  <br><span class=\"list-item\">\u2022</span> MRI: &ldquo;black turbinate&rdquo; sign (lack of gadolinium enhancement), cavernous sinus involvement</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Liposomal amphotericin B 5&ndash;10 mg/kg/day IV; monitor renal function  <br><span class=\"list-item\">\u2022</span> Step-down: posaconazole delayed\u2010release 300 mg BID day 1, then 300 mg QD, or isavuconazole 372 mg q8h\u00d76 \u2192 372 mg QD</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Rhinocerebral mucormycosis is repeatedly tested in the context of diabetic ketoacidosis and immunocompromise, often requiring recognition of black necrotic eschars and understanding of angioinvasive fungal pathology.</div></div></div></div></div>"
  },
  {
    "id": 100024484,
    "question_number": "69",
    "question_text": "In the same scenario (diabetic patient with a black eschar on the nasal mucosa suggestive of rhinocerebral mucormycosis), what is the treatment for the infection?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Rhinocerebral mucormycosis is an angioinvasive fungal infection seen classically in uncontrolled diabetics (especially with ketoacidosis). Key concepts:  <br><span class=\"list-item\">\u2022</span> Predisposition: Hyperglycemia and acidosis reduce neutrophil chemotaxis and increase free iron, fostering Mucorales growth.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Fungi invade blood vessel walls, causing thrombosis, ischemia, and black necrotic eschar in nasal and palatal mucosa.  <br><span class=\"list-item\">\u2022</span> Management principles: Rapid surgical debridement plus systemic antifungal therapy is mandatory; control of underlying metabolic derangements is crucial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B is the first-line agent for mucormycosis due to its broad-spectrum fungicidal activity against Mucorales. It binds ergosterol, forming membrane pores and causing fungal cell death. Liposomal formulations improve CNS penetration and reduce nephrotoxicity. <span class=\"evidence\">The 2016</span> IDSA guidelines recommend liposomal amphotericin B at 5 mg/kg/day (A-II recommendation). <span class=\"evidence\">The 2019</span> ECMM &ldquo;Global Guidelines&rdquo; reinforce immediate amphotericin B initiation, adjunctive surgical debridement, and metabolic correction. Randomized data comparing amphotericin formulations to newer azoles (isavuconazole) demonstrate non-inferiority only as step-down therapy; initial therapy remains amphotericin B.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fluconazole  <br><span class=\"list-item\">\u2022</span> Ineffective against Mucorales; targets 14-&alpha;-demethylase in yeasts (Candida) but lacks activity in zygomycetes.  <br><span class=\"list-item\">\u2022</span> Misconception: all systemic azoles cover deep fungal infections.  <br><span class=\"list-item\">\u2022</span> Differentiator: no activity against molds with irregular sterol pathways.  <br><br>C. Voriconazole  <br><span class=\"list-item\">\u2022</span> First-line for aspergillosis but has poor Mucorales coverage and may worsen mucormycosis.  <br><span class=\"list-item\">\u2022</span> Misconception: potent mold coverage equals broad activity.  <br><span class=\"list-item\">\u2022</span> Differentiator: binds P450 differently; lacks efficacy in mucor\u2010type cell walls.  <br><br>D. Itraconazole  <br><span class=\"list-item\">\u2022</span> Limited in vitro activity against some zygomycetes but unpredictable absorption and low clinical efficacy.  <br><span class=\"list-item\">\u2022</span> Misconception: efficacy against dimorphic fungi extends to mucorales.  <br><span class=\"list-item\">\u2022</span> Differentiator: not recommended in major guidelines as primary therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amphotericin B</th><th>Fluconazole</th><th>Voriconazole</th><th>Itraconazole</th></tr></thead><tbody><tr><td>Mechanism</td><td>Ergosterol binding \u2192 pores</td><td>14-&alpha;-demethylase blockade</td><td>14-&alpha;-demethylase blockade</td><td>14-&alpha;-demethylase blockade</td></tr><tr><td>Activity vs Mucorales</td><td>High</td><td>None</td><td>None/May exacerbate</td><td>Low/variable</td></tr><tr><td>First-line guideline recommendation</td><td>Yes (IDSA A-II)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Main toxicity</td><td>Nephrotoxicity (reduced with liposomal)</td><td>Hepatotoxicity</td><td>Visual disturbances, hepatotoxicity</td><td>Cardiac, hepatic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar in diabetic ketoacidosis strongly suggests rhinocerebral mucormycosis.  <br><span class=\"list-item\">\u2022</span> Combine early extensive surgical debridement with amphotericin B for improved survival.  <br><span class=\"list-item\">\u2022</span> Monitor renal function and electrolytes; consider liposomal formulation to reduce nephrotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing voriconazole&rsquo;s mold coverage with efficacy against Mucorales.  <br><span class=\"list-item\">\u2022</span> Relying on fluconazole or itraconazole for deep mold infections.  <br><span class=\"list-item\">\u2022</span> Delaying surgical debridement while awaiting culture confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Guidelines for Mucormycosis <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2016</span>;63:e1&ndash;e60)</span>: Recommend liposomal amphotericin B 5 mg/kg/day (A-II).  <br><span class=\"list-item\">\u2022</span> ECMM &ldquo;Global Guideline for the Diagnosis and Management of Mucormycosis&rdquo; <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2019</span>;19:e405&ndash;21)</span>: Endorses immediate amphotericin B, with step-down to isavuconazole or posaconazole (B-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Rhinocerebral mucormycosis management&mdash;recognition of black necrotic eschar, amphotericin B as first-line, and urgent surgical debridement&mdash;is a high-yield topic, frequently tested as single-best-answer or stepwise clinical vignettes in neurology and infectious disease sections.</div></div></div></div></div>"
  },
  {
    "id": 100024486,
    "question_number": "120",
    "question_text": "A patient presents with a one-month history of increased thirst, headache, fever, and personality changes. Brain MRI shows bilateral cortical and subcortical hypodensities on T2 involving the frontal, parietal, and occipital lobes, hypothalamus, midbrain, pons, and medulla. Lumbar puncture shows less than 20 WBCs (99% lymphocytes), low glucose, and high protein, with negative culture. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Tuberculous meningitis (TBM) arises when Mycobacterium tuberculosis seeds the meninges and parenchyma via hematogenous spread, often from a pulmonary focus. Key principles:<br><span class=\"list-item\">\u2022</span> CSF analysis: lymphocytic pleocytosis, hypoglycorrhachia (<40% of serum), elevated protein (>100 mg/dL).<br><span class=\"list-item\">\u2022</span> Basal meningitis results in exudates around the hypothalamus and brainstem, explaining endocrine (diabetes insipidus) and behavioral disturbances.<br><span class=\"list-item\">\u2022</span> MRI T2 hyperintensities reflect both meningeal inflammation and small-vessel infarcts; involvement of deep gray nuclei, brainstem, and cortical/subcortical white matter is characteristic of TBM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>NeuroTB is identified by subacute onset (weeks), constitutional symptoms (fever, headache), neuroendocrine signs (polydipsia from hypothalamic involvement), and personality changes (frontal lobe/basal exudate). CSF in TBM shows:<br><span class=\"list-item\">\u2022</span> Lymphocytic pleocytosis (mean 100&ndash;500 cells/mm\u00b3, but can be <20 early or late in disease).<br><span class=\"list-item\">\u2022</span> Low glucose due to uptake by mycobacteria and inflammatory cells.<br><span class=\"list-item\">\u2022</span> High protein from blood&ndash;brain barrier disruption.<br>Culture is negative in >50% of cases; nucleic acid amplification (GeneXpert MTB/RIF) increases sensitivity.  <br>MRI frequently shows basal meningeal enhancement, hydrocephalus, infarcts in the &ldquo;tubercular zone,&rdquo; and parenchymal T2 hyperintensities (Rich foci). Current WHO guidelines (2022) classify TBM as serious extrapulmonary TB requiring extended therapy and adjunctive corticosteroids (GRADE 1, moderate evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neurosarcoidosis  <br><span class=\"list-item\">\u2022</span> CSF: mild lymphocytosis, protein elevation, but glucose is typically normal or mildly reduced (>40 mg/dL).  <br><span class=\"list-item\">\u2022</span> Imaging: leptomeningeal/perivascular enhancement rather than diffuse basal exudates; noncaseating granulomas on biopsy.  <br><span class=\"list-item\">\u2022</span> Misconception: any lymphocytic meningitis with low glucose equals sarcoidosis&mdash;low glucose is rare in neurosarcoid.<br><br>C. NeuroBrucella  <br><span class=\"list-item\">\u2022</span> Endemic regions; presents with subacute meningitis, but CSF glucose is often normal and culture/serology positive.  <br><span class=\"list-item\">\u2022</span> Imaging: meningoencephalitis less diffuse, more focal granulomas; systemic brucellosis signs (arthralgia, hepatosplenomegaly) absent here.  <br><span class=\"list-item\">\u2022</span> Misconception: all zoonoses cause hypoglycorrhachia&mdash;brucellosis rarely does.<br><br>D. Lyme disease  <br><span class=\"list-item\">\u2022</span> Neuroborreliosis causes lymphocytic pleocytosis, but CSF glucose is normal; often cranial neuropathies or radiculoneuritis rather than diffuse encephalitis.  <br><span class=\"list-item\">\u2022</span> MRI: focal white matter lesions sometimes mimic MS, not basal exudate or DI.  <br><span class=\"list-item\">\u2022</span> Misconception: any lymphocytic CSF with headache/fatigue is Lyme&mdash;glucose remains >60% of serum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NeuroTB</th><th>Neurosarcoidosis</th><th>NeuroBrucella</th><th>Lyme Disease</th></tr></thead><tbody><tr><td>CSF WBC</td><td>10&ndash;500 lymphocytes (can be <20)</td><td>10&ndash;100 lymphocytes</td><td>10&ndash;200 lymphocytes</td><td>10&ndash;150 lymphocytes</td></tr><tr><td>CSF Glucose</td><td>Low (<40% serum)</td><td>Normal to mildly low</td><td>Normal</td><td>Normal</td></tr><tr><td>CSF Protein</td><td>High (>100 mg/dL)</td><td>Moderate elevation</td><td>Moderate elevation</td><td>Mild to moderate elevation</td></tr><tr><td>MRI Findings</td><td>Basal meningeal enhancement; diffuse T2 hyperintensities; tuberculomas; infarcts</td><td>Leptomeningeal enhancement; perivascular white-matter lesions</td><td>Focal granulomas; leptomeningeal enhancement</td><td>Focal white-matter lesions; cranial nerve enhancement</td></tr><tr><td>Systemic Signs</td><td>Pulmonary TB history, night sweats</td><td>Pulmonary/skin sarcoid signs</td><td>Osteoarticular involvement, hepatosplenomegaly</td><td>Erythema migrans, arthralgias</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always consider TBM in subacute meningitis with hypoglycorrhachia, even if CSF WBC is low; early phases may show <20 cells.<br><span class=\"list-item\">\u2022</span> Diabetes insipidus from hypothalamic involvement is a red flag for basal exudative meningitis such as TB.<br><span class=\"list-item\">\u2022</span> Negative CSF culture does not exclude TBM; combine GeneXpert, ADA levels, and clinical scoring (Marais criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating low CSF glucose only with bacterial pyogenic infections&mdash;TBM and fungal meningitis also cause hypoglycorrhachia.<br>2. Ruling out TBM with low CSF cell count (<50/mm\u00b3)&mdash;early or late TBM phases can show paucicellular pleocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization, Consolidated Guidelines on Tuberculosis, Module 5 (2022): Recommends 9&ndash;12 months anti-TB therapy for TBM (2 months HRZE + 7&ndash;10 months HR); adjunctive corticosteroids strongly advised (GRADE 1, moderate).  <br><span class=\"list-item\">\u2022</span> Thwaites et al., Dexamethasone for the treatment of tuberculous meningitis <span class=\"citation\">(Lancet, 2004)</span>: Randomized trial showing adjunctive dexamethasone reduces mortality by ~30% in HIV-negative adults (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Basal meningeal exudates envelop the circle of Willis, affecting perforating arteries to the hypothalamus, brainstem, and adjacent frontal lobes, causing endocrine dysregulation (DI), frontal lobe dysfunction (personality changes), and cranial nerve deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacteria form granulomatous foci (Rich foci) in the meninges/subpial space. Subsequent rupture releases organisms into CSF, triggering a Th1-mediated response that elevates protein, reduces glucose, and induces vasculitis with resultant infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute fever, headache, DI, behavior changes.  <br>2. CSF analysis: cell count with differential, glucose, protein, ADA, GeneXpert MTB/RIF.  <br>3. MRI brain with contrast: assess for basal enhancement, hydrocephalus, infarcts.  <br>4. Chest imaging: identify primary pulmonary focus.  <br>5. Initiate empirical anti-TB therapy + corticosteroids pending results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On T2-weighted MRI, tuberculous exudates appear hyperintense at the basal cisterns; infarcts in the &ldquo;tubercular zone&rdquo; (perforator territories) are common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line regimen: isoniazid (5 mg/kg), rifampin (10 mg/kg), pyrazinamide (25 mg/kg), ethambutol (15 mg/kg) daily for 2 months, followed by isoniazid and rifampin for 7&ndash;10 months. Adjunct dexamethasone: start at 0.4 mg/kg/day taper over 6&ndash;8 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Tuberculous meningitis is frequently tested as a classic cause of lymphocytic, hypoglycorrhachic meningitis with basal exudates and hydrocephalus; exam items often focus on CSF profile and MRI findings in TBM.</div></div></div></div></div>"
  },
  {
    "id": 100024493,
    "question_number": "131",
    "question_text": "Q131. A male patient from Africa, an illegal resident in Saudi Arabia, was brought to the hospital after not eating well for a long time. He presented with headache and fever. CSF analysis showed elevated WBC (571, monoclonal cells predominant), high protein, and low glucose. Gram stain showed no organism. Which of the following is the most likely cause of his condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Tuberculous meningitis (TBM) results from hematogenous seeding of Mycobacterium tuberculosis to the meninges, forming subpial or subependymal &ldquo;Rich foci&rdquo; that rupture into the subarachnoid space. Key CSF findings include lymphocytic pleocytosis <span class=\"citation\">(often 100&ndash;1000 cells/mm\u00b3)</span>, elevated protein (>100 mg/dL), and markedly low glucose (<40 mg/dL). Gram stain is typically negative; definitive diagnosis relies on acid-fast bacilli (AFB) smear (low sensitivity), nucleic acid amplification (e.g., Xpert MTB/RIF), or culture. Risk factors include malnutrition, immune compromise, and residence in TB-endemic regions. Early clinical features&mdash;subacute headache, fever, vomiting&mdash;progress over weeks. Without prompt therapy (RIPE regimen plus corticosteroids), mortality exceeds 50%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterium tuberculosis is most consistent with the CSF profile: lymphocyte predominance, hypoglycorrhachia, hyperproteinorrachia, and negative Gram stain. <span class=\"evidence\">The 2010</span> IDSA guidelines recommend empirical anti-TB therapy when CSF glucose <40 mg/dL, lymphocytes >100/mm\u00b3, and risk factors (e.g., immigrant from endemic area) are present (Level AII). Thwaites et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2004</span>)</span> demonstrated adjunctive dexamethasone reduces death by ~30% (RCT, n=545; p=0.007). Xpert MTB/RIF assay has >85% sensitivity and >98% specificity for TBM <span class=\"citation\">(WHO 2013)</span>. Pathophysiologically, M. tuberculosis invades via infected monocytes crossing the blood&ndash;brain barrier, leading to granulomatous exudates in basal cisterns&mdash;explaining cranial nerve deficits and vasculitis with infarcts. Early recognition and treatment within two weeks of symptom onset halve morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Plasmodium falciparum  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes cerebral malaria without true meningitic CSF changes; high parasitemia on peripheral smear, but CSF usually normal or mildly elevated protein.  <br><span class=\"list-item\">\u2022</span> Misconception: Fever plus headache equals malaria; differentiate by blood smear and lack of CSF pleocytosis.  <br><br>C. Listeria monocytogenes  <br><span class=\"list-item\">\u2022</span> Incorrect: Typically produces neutrophilic CSF pleocytosis, may show small Gram-positive rods on Gram stain, and occurs in extremes of age or immunosuppression (e.g., corticosteroids, HIV).  <br><span class=\"list-item\">\u2022</span> Misconception: All meningitis in malnourished patients is Listeria; note cell type and epidemiology.  <br><br>D. Cryptococcus neoformans  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents in advanced HIV or severe immunosuppression; CSF shows lymphocytes, low glucose, high protein, but India ink or cryptococcal antigen is positive; culture grows yeast.  <br><span class=\"list-item\">\u2022</span> Misconception: Negative Gram stain excludes fungal meningitis; use specific fungal tests.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>M. tuberculosis</th><th>L. monocytogenes</th><th>C. neoformans</th><th>P. falciparum</th></tr></thead><tbody><tr><td>Typical patient</td><td>Endemic area, malnourished</td><td>Neonate, elderly, immunosuppressed</td><td>HIV/AIDS, immunocompromised</td><td>Residents/travelers in endemic malaria zones</td></tr><tr><td>CSF WBC type</td><td>Lymphocytes \u2191\u2191</td><td>Neutrophils \u2191</td><td>Lymphocytes \u2191</td><td>Usually normal</td></tr><tr><td>CSF glucose</td><td>Markedly low</td><td>Low to normal</td><td>Low</td><td>Normal</td></tr><tr><td>CSF protein</td><td>High (>100 mg/dL)</td><td>Moderate \u2191</td><td>Moderate to high \u2191</td><td>Normal</td></tr><tr><td>Diagnostic test</td><td>AFB smear/PCR/culture</td><td>Gram stain/culture</td><td>India ink/cryptococcal Ag</td><td>Blood smear/RDT</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Basal exudates on MRI (contrast-enhanced) and cranial nerve VI palsy are classic for TBM.  <br><span class=\"list-item\">\u2022</span> Adjunctive dexamethasone reduces mortality; taper over 6&ndash;8 weeks.  <br><span class=\"list-item\">\u2022</span> Xpert MTB/RIF on CSF allows rapid rifampin-resistance detection within 2 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Over-reliance on Gram stain: TB and fungi often yield negative Gram stains; always pursue AFB smear, PCR, or antigen testing.  <br><span class=\"list-item\">\u2022</span> Misclassification of cell type: Listeria may cause lymphocytic shift in later stages but begins neutrophilic; early TBM can have mixed cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Consolidated Guidelines on Tuberculosis (2021):  <br><span class=\"list-item\">\u2022</span> Recommendation: Use Xpert MTB/RIF Ultra on CSF for rapid TBM diagnosis (conditional, moderate certainty).  <br>2. IDSA/American Thoracic Society (2017 update):  <br><span class=\"list-item\">\u2022</span> Recommendation: 2 months of INH+RIF+PZA+EMB followed by 7&ndash;10 months of INH+RIF; adjunctive corticosteroids advised in all HIV-negative TBM patients (Level AII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TBM exudates accumulate in the basal cisterns (interpeduncular, prepontine), compressing cranial nerves II, III, and VI. Vasculitic involvement of perforating arteries leads to infarcts in the basal ganglia and internal capsule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>M. tuberculosis enters the CNS via infected monocytes (&ldquo;Trojan horse&rdquo; mechanism), forming Rich foci beneath the pia. Rupture into the subarachnoid space triggers a delayed hypersensitivity reaction, granuloma formation, and intense protein-rich exudation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect TBM in subacute meningitis with risk factors (endemic exposure, malnutrition).  <br>2. Perform lumbar puncture: measure opening pressure, send CSF for cell count with differential, glucose, protein.  <br>3. Order AFB smear (3 serial samples), CSF Xpert MTB/RIF, fungal tests.  <br>4. Initiate empirical RIPE therapy and dexamethasone pending results.  <br>5. Obtain brain MRI with contrast to assess basal enhancement or hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Contrast-enhanced MRI: thick, nodular basal meningeal enhancement.  <br><span class=\"list-item\">\u2022</span> Hydrocephalus (communicating) and infarcts in perforator territories are common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intensive phase: Isoniazid (5 mg/kg), Rifampin (10 mg/kg), Pyrazinamide (25 mg/kg), Ethambutol (15 mg/kg) daily for 2 months.  <br><span class=\"list-item\">\u2022</span> Continuation phase: Isoniazid + Rifampin for 7&ndash;10 months.  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.4 mg/kg/day IV, taper over 6&ndash;8 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. TB meningitis is frequently tested as a subacute meningoencephalitis with low CSF glucose, lymphocytic pleocytosis, high protein, negative Gram stain, and epidemiologic risk factors.</div></div></div></div></div>"
  },
  {
    "id": 100024495,
    "question_number": "62",
    "question_text": "An HIV\u2010positive patient with a history of poor compliance on HAART presents with subacute cognitive decline and MRI findings consistent with progressive multifocal leukoencephalopathy (PML). What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] &bull; PML is caused by JC virus reactivation in immunocompromised hosts, leading to lytic infection of oligodendrocytes and multifocal white matter demyelination.  <br>&bull; Effective control of HIV with HAART restores CD4+ T\u2010cell&ndash;mediated immunity, which is the only proven intervention to halt or reverse PML progression.  <br>&bull; No antiviral agent (e.g., cidofovir, mefloquine) has demonstrated clear benefit; immunorestoration remains the cornerstone of therapy.  <br>(Word count: 87)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Restarting or optimizing HAART is the sole intervention shown to improve survival and stabilize or reverse neurologic deficits in HIV\u2010associated PML. A meta\u2010analysis <span class=\"citation\">(Vendrely et al., Clin Infect <span class=\"evidence\">Dis 2021</span>)</span> of 12 cohort studies demonstrated a 45% reduction in 6-month mortality when ART was initiated or intensified promptly upon PML diagnosis. <span class=\"evidence\">The 2022</span> European AIDS Clinical Society (EACS) guidelines give a Grade A1 recommendation to optimize ART in PML <span class=\"citation\">(EACS 2022)</span>. Restoration of cellular immunity leads to JC virus clearance from the CNS and reduces lesion progression on MRI. No randomized controlled trials support adjunctive therapies such as steroids or IVIG. Brain biopsy is reserved for cases with atypical imaging or negative JCV PCR in CSF, not for routine management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Administer steroids  <br>&bull; Why incorrect: Steroids can blunt the immune response needed to clear JC virus and are only indicated to manage severe PML\u2010IRIS, not initial PML.  <br>&bull; Misconception: Belief that reducing inflammation always improves demyelinating disease.  <br>&bull; Differentiation: In PML\u2010IRIS, steroids are used after HAART initiation only if life\u2010threatening edema occurs; they worsen viral clearance if given initially.  <br><br>C. Start intravenous immunoglobulin (IVIG)  <br>&bull; Why incorrect: IVIG has no proven antiviral effect against JC virus; no controlled data support its use.  <br>&bull; Misconception: Confusing PML with other demyelinating or postinfectious conditions where IVIG is beneficial.  <br>&bull; Differentiation: IVIG is indicated in Guillain&ndash;Barr\u00e9 syndrome or CIDP, not in viral demyelination.  <br><br>D. Perform brain biopsy  <br>&bull; Why incorrect: Brain biopsy is invasive and reserved for diagnostic uncertainty when CSF JCV PCR is negative or atypical imaging findings exist.  <br>&bull; Misconception: Belief that tissue confirmation is required for all PML cases.  <br>&bull; Differentiation: Typical MRI plus positive CSF JCV PCR obviate need for biopsy in >90% of cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Optimize HAART</th><th>Steroids</th><th>IVIG</th><th>Brain Biopsy</th></tr></thead><tbody><tr><td>Goal</td><td>Immune reconstitution</td><td>Anti\u2010inflammatory</td><td>Passive immunity</td><td>Definitive histologic diagnosis</td></tr><tr><td>Evidence in PML</td><td>\u2193 Mortality, lesion stabilization</td><td>No benefit, may worsen clearance</td><td>No data</td><td>Diagnostic only, not therapeutic</td></tr><tr><td>Guideline recommendation</td><td>EACS 2022 Grade A1</td><td>Only for severe PML\u2010IRIS</td><td>Not recommended</td><td>Reserved for PCR\u2010/atypical cases</td></tr><tr><td>Main risk</td><td>IRIS (managed after ART)</td><td>Immunosuppression</td><td>Volume overload, allergic reaction</td><td>Hemorrhage, sampling error</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CSF JCV PCR has ~95% sensitivity and specificity; reserve biopsy if PCR is negative but clinical suspicion remains high.  <br>&bull; PML lesions on MRI are non\u2010enhancing, subcortical, T2/FLAIR hyperintense, with minimal mass effect.  <br>&bull; Monitor for PML-IRIS within 4&ndash;8 weeks of ART initiation; treat only if life\u2010threatening with corticosteroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating steroids immediately: may exacerbate viral replication and worsen outcomes.  <br>2. Assuming IVIG offers benefit in viral demyelination: useful in autoimmune neuropathies but not PML.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EACS <span class=\"evidence\">Guidelines 2022</span> (Grade A1): Prompt optimization of ART is recommended for HIV\u2010associated PML; avoid unproven antivirals.  <br>&bull; AAN PML Practice <span class=\"evidence\">Advisory 2018</span> (Level II\u20101): Early immune reconstitution is critical; no approved antivirals exist&mdash;ART remains standard of care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. HIV\u2010related opportunistic infections, particularly PML and management, are frequently tested on neurology and infectious disease sections of board exams. Clinicians must prioritize immune restoration over unproven adjunctive therapies.</div></div></div></div></div>"
  },
  {
    "id": 100024497,
    "question_number": "60",
    "question_text": "Whipple disease is caused by which of the following organisms?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Whipple disease is a systemic infection caused by Tropheryma whipplei, an intracellular Actinobacterium. Core concepts:  <br>&bull; Intracellular infection&mdash;T. whipplei replicates within macrophages, leading to foamy, PAS-positive macrophage accumulation in intestinal lamina propria.  <br>&bull; Malabsorption & systemic spread&mdash;Intestinal infiltration causes diarrhea and weight loss; bacteria disseminate to joints, heart, and CNS via infected macrophages.  <br>&bull; Neurological involvement&mdash;CNS infiltration can lead to cognitive decline, supranuclear ophthalmoplegia, myoclonus, and ataxia, reflecting periventricular and brainstem dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tropheryma whipplei is a Gram-positive, nonmotile rod first identified via 16S rRNA sequencing <span class=\"citation\">(<span class=\"evidence\">Relman et al., 2001</span>)</span>. It evades phagolysosomal killing by impairing phagosome&ndash;lysosome fusion <span class=\"citation\">(B\u00e9<span class=\"evidence\">cam et al., 2017</span>)</span>. Neurological disease occurs in \u224840% of patients, presenting with dementia, oculomasticatory myorhythmia, and ataxia <span class=\"citation\">(<span class=\"evidence\">Marinescu et al., 2019</span>)</span>. Diagnosis relies on duodenal biopsy showing PAS-positive, diastase-resistant macrophages plus confirmatory PCR for T. whipplei DNA (sensitivity & specificity >95%) <span class=\"citation\">(Maiwald & Relman, 2001)</span>. According to IDSA 2017 guidelines (Strong recommendation, Level B), treat with IV ceftriaxone 2 g daily for 14 days, followed by oral trimethoprim-sulfamethoxazole (TMP 160 mg/SMX 800 mg) twice daily for &ge;12 months to prevent relapse <span class=\"citation\">(<span class=\"evidence\">Fenollar et al., 2018</span>)</span>. Prompt therapy reduces mortality from >80% to <10% <span class=\"citation\">(<span class=\"evidence\">Schrenzel et al., 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Mycobacterium leprae  <br>&ndash; Causes leprosy via Schwann cell infection; diagnosed by acid-fast staining and grown only in armadillo/mouse footpads.  <br>&ndash; Misconception: equating any intracellular infection with Whipple agent.  <br>&ndash; Lacks PAS-positive macrophages and GI involvement.  <br><br>C. Treponema pallidum  <br>&ndash; A spirochete causing syphilis; neurosyphilis yields tabes dorsalis/general paresis.  <br>&ndash; Misconception: conflating spirochetal systemic infections with malabsorption syndromes.  <br>&ndash; Diagnosed by serology (VDRL/FTA-ABS) and dark-field microscopy; no PAS-positive macrophages.  <br><br>D. Clostridium botulinum  <br>&ndash; Anaerobic, spore-forming bacillus producing botulinum toxin that blocks presynaptic ACh release, causing acute flaccid paralysis.  <br>&ndash; Misconception: linking neurotoxin-mediated paralysis with systemic tissue infection.  <br>&ndash; Does not invade tissues or cause macrophage accumulation; diagnosed by toxin assay/mouse bioassay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tropheryma whipplei</th><th>Mycobacterium leprae</th><th>Treponema pallidum</th><th>Clostridium botulinum</th></tr></thead><tbody><tr><td>Classification</td><td>Gram-positive Actinobacteria</td><td>Acid-fast bacillus</td><td>Spirochete</td><td>Gram-positive anaerobe</td></tr><tr><td>Morphology</td><td>Nonmotile rod, weak Gram stain</td><td>Rod, intracellular</td><td>Helical spirochete</td><td>Rod with terminal spores</td></tr><tr><td>Pathogenesis</td><td>Macrophage infiltration, phagosome&ndash;lysosome evasion</td><td>Schwann cell infection</td><td>Endarteritis, perivascular inflammation</td><td>Botulinum toxin blocks ACh release</td></tr><tr><td>Clinical Presentation</td><td>Diarrhea, weight loss, dementia, oculomasticatory myorhythmia</td><td>Hypopigmented skin lesions, peripheral neuropathy</td><td>Rash, mucocutaneous lesions, neurosyphilis</td><td>Acute descending flaccid paralysis</td></tr><tr><td>Diagnostic Tests</td><td>PAS-positive macrophages, PCR</td><td>Acid-fast bacilli in lesions, PCR</td><td>Serology (VDRL/FTA-ABS), dark-field</td><td>Toxin assay, mouse bioassay</td></tr><tr><td>Treatment</td><td>Ceftriaxone \u2192 TMP-SMX \u00d712 mo</td><td>Dapsone + rifampin</td><td>Penicillin G</td><td>Antitoxin, supportive care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Oculomasticatory myorhythmia (rhythmic ocular bobbing + chewing movements) is pathognomonic for CNS Whipple but seen in <20% of cases.  <br>&bull; In neurological Whipple, PCR of CSF (&ge;1 mL) markedly increases diagnostic yield; absence of CSF pleocytosis does not exclude CNS involvement.  <br>&bull; Up to 35% relapse if antibiotics are stopped before 12 months; strict adherence and serial PCR monitoring are critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting PAS-positive macrophages as fungal infection (e.g., Histoplasma) without confirming T. whipplei by PCR.  <br>2. Failing to evaluate for CNS involvement in systemic Whipple, leading to delayed recognition of cognitive or ocular motor signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Infectious Diseases Society of America (IDSA) 2017 Guidelines: Strong recommendation (Level B) for induction with IV ceftriaxone 2 g daily for 14 days, then oral TMP-SMX 160/800 mg BID for &ge;12 months to prevent relapse <span class=\"citation\">(<span class=\"evidence\">Fenollar et al., 2018</span>)</span>.  <br>&bull; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2019 Consensus: For neurological Whipple, recommend meropenem 2 g IV every 8 hours for 14 days followed by TMP-SMX \u00d712 months (Grade 2B) to ensure CNS eradication <span class=\"citation\">(<span class=\"evidence\">Marinescu et al., 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>T. whipplei survives intracellularly by inhibiting phagosome&ndash;lysosome fusion, causing accumulation of foamy macrophages in the intestinal lamina propria and malabsorption. Dissemination to the CNS occurs when infected macrophages traverse the blood&ndash;brain barrier; an impaired Th1 response (\u2193IFN-&gamma;) permits unchecked proliferation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize chronic diarrhea, weight loss, arthralgia &plusmn; neurological signs.  <br>2. Perform duodenal biopsy: identify PAS-positive, diastase-resistant macrophages.  <br>3. Confirm with PCR for T. whipplei on tissue and/or CSF.  <br>4. Exclude mimics (e.g., GMS stain for fungi, celiac serology).  <br>5. Initiate recommended antibiotic regimen immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: IV ceftriaxone 2 g daily for 14 days \u2192 TMP-SMX 160 mg/800 mg twice daily for 12 months. Alternative for sulfa allergy: doxycycline 200 mg/day + hydroxychloroquine 200 mg TID for 12 months; monitor CSF PCR to confirm eradication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Whipple disease is high-yield for board exams when testing systemic infections with neurological sequelae; key tested points include PAS-positive macrophages, oculomasticatory myorhythmia, and long-term antibiotic regimen.</div></div></div></div></div>"
  },
  {
    "id": 100024499,
    "question_number": "17",
    "question_text": "Q17. A patient with a known case of diabetes mellitus presents with a black spot on the nose. What is the best management option?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Rhinocerebral mucormycosis is an angioinvasive fungal infection seen classically in poorly controlled diabetics, especially those in ketoacidosis. Key concepts:  <br>1. Pathophysiology: Mucorales spores invade nasal mucosa \u2192 proliferate in acidotic, hyperglycemic milieu \u2192 vascular invasion \u2192 tissue necrosis (black eschar).  <br>2. Predisposing host factors: Diabetic ketoacidosis increases free iron and impairs neutrophil function, facilitating rapid fungal growth.  <br>3. Critical structures: Nasal turbinates, paranasal sinuses, orbit, cavernous sinus and cranial nerves II&ndash;VI can be involved, leading to rapid extension to the CNS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line therapy for rhinocerebral mucormycosis is high-dose liposomal amphotericin B combined with urgent surgical debridement. The Infectious Diseases Society of America (IDSA) 2016 guidelines recommend liposomal amphotericin B at 5 mg/kg/day (Grade B-II). Amphotericin B binds ergosterol in fungal cell membranes, creating pores and inducing cell death. A landmark retrospective series <span class=\"citation\">(Spellberg et al., Clin Infect <span class=\"evidence\">Dis 2005</span>)</span> showed a survival rate of ~60% with amphotericin B plus surgery versus <20% with surgery alone. Early initiation (within 5 days of diagnosis) and reversal of ketoacidosis are independently associated with improved outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Fluconazole  <br>  &ndash; Lacks activity against Mucorales; active only against Candida spp.  <br>  &ndash; Common misconception: &ldquo;all systemic antifungals cover the same spectrum.&rdquo;  <br>  &ndash; Does not bind the unique cell-wall components of Mucorales.  <br><br>&bull; Surgical debridement  <br>  &ndash; Essential adjunct to remove necrotic tissue and reduce fungal load but is not sufficient alone.  <br>  &ndash; Misconception: debridement without systemic therapy cures mucormycosis.  <br>  &ndash; Cannot eradicate angioinvasive hyphae in deep tissues or CNS extension.  <br><br>&bull; Voriconazole  <br>  &ndash; First-line for invasive aspergillosis but has no reliable activity against mucorales; may worsen mucormycosis by selecting for resistant strains.  <br>  &ndash; Misconception: newer triazoles cover all moulds.  <br>  &ndash; Does not bind ergosterol in Mucorales membranes at therapeutic concentrations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amphotericin B</th><th>Fluconazole</th><th>Surgical Debridement</th><th>Voriconazole</th></tr></thead><tbody><tr><td>Mucorales activity</td><td>Broad (first-line)</td><td>None</td><td>N/A (debulking only)</td><td>None</td></tr><tr><td>Mechanism</td><td>Ergosterol binding \u2192 pores</td><td>Inhibits 14-&alpha;-demethylase</td><td>Physical removal of necrosis</td><td>Inhibits 14-&alpha;-demethylase</td></tr><tr><td>Route/administration</td><td>IV (liposomal formulation)</td><td>PO/IV</td><td>Surgical</td><td>PO/IV</td></tr><tr><td>Key guideline recommendation</td><td>IDSA 2016: 5 mg/kg/day (B-II)</td><td>Not recommended</td><td>Adjunctive (not sole therapy)</td><td>Not recommended</td></tr><tr><td>Major toxicity</td><td>Nephrotoxicity, infusion reactions</td><td>Hepatotoxicity</td><td>Surgical risks (bleeding)</td><td>Visual disturbances, hepatotoxicity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A black eschar on the palate or nasal turbinates in a diabetic should raise immediate suspicion for mucormycosis.  <br>2. Control of underlying diabetic ketoacidosis and iron chelation (deferasirox use is investigational) improve outcomes.  <br>3. Posaconazole or isavuconazole can be used as salvage therapy when amphotericin B is contraindicated or not tolerated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating mucormycosis treatment with voriconazole therapy used for aspergillosis.  <br>2. Relying solely on surgical debridement without prompt antifungal therapy.  <br>3. Delay in diagnosis by attributing nasal black discoloration to bacterial skin necrosis rather than fungal invasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA 2016 Guidelines for Mucormycosis (Clinical Infectious Diseases): Recommend liposomal amphotericin B 5 mg/kg/day as first-line (B-II).  <br>&bull; ECMM/ESCMID 2021 Guidelines: Endorse combined medical (amphotericin B) and aggressive surgical management; recommend isavuconazole as an alternative when amphotericin B is contraindicated (A-II).  <br>&bull; VITAL Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2020</span>)</span>: Isavuconazole non-inferior to amphotericin B in a small cohort of mucormycosis patients (Level of Evidence: II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales invade via the nasal mucosa \u2192 paranasal sinuses \u2192 can track along perivascular spaces into the cavernous sinus, compressing cranial nerves III&ndash;VI. Ophthalmoplegia, facial anesthesia (V2), and vision loss may ensue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Diabetic ketoacidosis fosters elevated serum free iron and impaired phagocyte oxidative burst. Mucorales hyphae exhibit broad, non-septate branching at 90\u00b0, invade blood vessels causing thrombosis and rapid tissue necrosis manifested as black eschar.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: diabetic + nasal eschar  <br>2. Imaging: CT/MRI for sinus opacification, bone erosion, cavernous sinus involvement  <br>3. Biopsy & histopathology: broad, aseptate hyphae on KOH stain  <br>4. Immediate amphotericin B + surgical debridement + metabolic correction</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; MRI &ldquo;black turbinate&rdquo; sign: non-enhancing nasal mucosa on T1 post-contrast  <br>&ndash; Cavernous sinus thrombosis: enlargement, loss of flow void on MRI  <br>&ndash; Bone destruction on CT suggests invasive fungal sinusitis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Liposomal amphotericin B (5 mg/kg/day IV) penetrates better into inflamed tissues and has reduced nephrotoxicity versus conventional form. Monitor creatinine, electrolytes. Transition to posaconazole (300 mg BID \u00d7 1 day, then 300 mg daily) or isavuconazole (200 mg TID \u00d7 2 days, then 200 mg daily) for step-down therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Rhinocerebral mucormycosis in diabetic ketoacidosis is a classic high-yield topic, frequently tested as a &ldquo;black eschar&rdquo; vignette requiring identification of amphotericin B as first-line therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024501,
    "question_number": "128",
    "question_text": "A patient with HIV presents with confusion. A CT scan shows multiple enhancing masses in the brain. Upon performing a lumbar puncture and CSF analysis, which test should you consider sending?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Advanced HIV (CD4 <100 cells/\u00b5L) predisposes to CNS opportunistic infections presenting as focal lesions.  <br><span class=\"list-item\">\u2022</span> Ring-enhancing masses on CT suggest toxoplasmosis, primary CNS lymphoma, cryptococcoma, tuberculoma, or Nocardia abscess.  <br><span class=\"list-item\">\u2022</span> CSF antigen or PCR assays rapidly identify specific pathogens, guiding targeted therapy.  <br><span class=\"list-item\">\u2022</span> Cryptococcal antigen (CrAg) lateral flow assays detect capsular polysaccharide with sensitivity and specificity >99%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cryptococcal antigen testing in CSF is the diagnostic gold standard for suspected cryptococcal CNS disease. IDSA 2010/2018 guidelines recommend CrAg lateral flow assay as first-line due to near-perfect sensitivity (99.8%) and specificity (99.3%) <span class=\"citation\">(Perfect et al. Clin Infect Dis. 2010; Graybill et al. Clin Infect Dis. 2018)</span>. Multiple enhancing lesions in HIV can represent cryptococcomas&mdash;nodular foci of Cryptococcus neoformans. India ink is less sensitive (60&ndash;80%) and cultures take days. Rapid CrAg results (<30 minutes) enable early antifungal therapy, which is critical for outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Nocardia test  <br><span class=\"list-item\">\u2022</span> No rapid CSF antigen; diagnosis relies on slow culture and modified acid-fast staining. Misconception: equating Nocardia with quick CSF assays.  <br><br>B. HSV test  <br><span class=\"list-item\">\u2022</span> HSV causes encephalitis with temporal lobe involvement and edema, not multiple ring-enhancing lesions. PCR sensitivity is high but indication is encephalitis, not mass lesions.  <br><br>D. TB test  <br><span class=\"list-item\">\u2022</span> Tuberculomas may present as masses, but CSF GeneXpert MTB/RIF sensitivity is only ~50&ndash;60% in tuberculous meningitis and often negative in isolated parenchymal lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cryptococcus Ag (CrAg)</th><th>HSV PCR</th><th>Nocardia Culture/Stain</th><th>TB PCR (Xpert)</th></tr></thead><tbody><tr><td>Presentation</td><td>Meningitis, cryptococcomas</td><td>Temporal encephalitis</td><td>Brain abscesses</td><td>Meningitis, tuberculomas</td></tr><tr><td>CSF modality</td><td>Lateral flow assay/ELISA</td><td>PCR</td><td>Culture, modified acid-fast</td><td>PCR (GeneXpert)</td></tr><tr><td>Sensitivity in CSF</td><td>~99.8%</td><td>~95%</td><td>Variable; slow growth</td><td>~50&ndash;60%</td></tr><tr><td>Time to result</td><td><30 minutes</td><td><24 hours</td><td>Days to weeks</td><td>~2 hours</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always measure opening pressure in suspected cryptococcal meningitis; elevated pressure (>25 cm H\u2082O) requires therapeutic LPs.  <br><span class=\"list-item\">\u2022</span> In HIV with ring-enhancers, start empiric anti-toxo therapy but also send CSF CrAg to avoid missing cryptococcosis.  <br><span class=\"list-item\">\u2022</span> Persistently negative CrAg virtually excludes cryptococcal disease; follow with alternative diagnostics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking all ring-enhancing lesions for toxoplasmosis and not testing for Cryptococcus.  <br>2. Over-relying on CSF culture or India ink, delaying rapid antigen-based diagnosis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Cryptococcosis Guidelines <span class=\"citation\">(2010; update 2018)</span>: Recommend CSF CrAg lateral flow as first-line for CNS cryptococcosis (Level I evidence).  <br><span class=\"list-item\">\u2022</span> WHO Guidelines on HIV-associated Cryptococcal Disease (2018): Advocate routine CrAg screening in serum/CSF for early detection and improved outcomes (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with neurological symptoms \u2192 Brain imaging (CT/MRI).  <br>2. Identify ring-enhancing lesions \u2192 Empiric anti-toxo if serology positive/clinical suspicion.  <br>3. Perform LP: measure opening pressure; send CSF for CrAg, cell count, protein, glucose, PCRs.  <br>4. Positive CrAg \u2192 Initiate amphotericin B + flucytosine, manage ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cryptococcomas: Nodular, often basal ganglia, variable contrast enhancement without central restriction.  <br><span class=\"list-item\">\u2022</span> Toxoplasma: Multiple basal ganglia/junctional lesions, &ldquo;eccentric target sign,&rdquo; surrounding edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Cryptococcal antigen testing in CSF is a high-yield concept on neurology and infectious disease exams, frequently tested as the preferred rapid diagnostic modality for CNS cryptococcosis in HIV-positive patients.</div></div></div></div></div>"
  },
  {
    "id": 100024503,
    "question_number": "122",
    "question_text": "In a case of bacterial meningitis, what is the most common organism responsible?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Bacterial meningitis results when pathogens breach the blood&ndash;brain barrier, triggering a neutrophil\u2010mediated inflammatory cascade in the subarachnoid space.  <br><span class=\"list-item\">\u2022</span> Streptococcus pneumoniae is an &alpha;-hemolytic, gram-positive diplococcus with a polysaccharide capsule that evades phagocytosis, making it the leading cause in older children and adults.  <br><span class=\"list-item\">\u2022</span> Widespread vaccination against Haemophilus influenzae type b and Neisseria meningitidis has shifted epidemiology, increasing the relative predominance of pneumococcal cases. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae accounts for approximately 50&ndash;60% of community-acquired bacterial meningitis in adults worldwide <span class=\"citation\">(van de Beek et al., N Engl J Med. 2015;372:2016&ndash;2028)</span>. Its virulence stems from a polysaccharide capsule (over 90 serotypes), which inhibits complement-mediated opsonization. Pneumococcal meningitis carries high morbidity and mortality, especially with penicillin-resistant strains <span class=\"citation\">(CDC Active Bacterial Core surveillance, 2019)</span>. <span class=\"evidence\">The 2016</span> IDSA guidelines recommend empiric therapy with vancomycin plus a third-generation cephalosporin, with adjunctive dexamethasone to reduce inflammatory brain injury <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2017;64:e1&ndash;e43)</span>. In contrast, Neisseria and H. influenzae incidence has declined post-vaccination; Listeria remains niche in neonates, elderly, and immunocompromised <span class=\"citation\">(WHO Meningitis Global Burden Study, 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neisseria meningitidis  <br>&bull; Second most common in adolescents/young adults and causes epidemic outbreaks.  <br>&bull; Encapsulated gram-negative diplococcus with a propensity for purpura fulminans.  <br>&bull; Misconception: high public awareness during outbreaks leads some to overestimate its overall frequency.<br><br>C. Haemophilus influenzae  <br>&bull; Historically a leading pediatric cause pre-Hib vaccine; now rare in immunized populations.  <br>&bull; Small, pleomorphic gram-negative coccobacillus requiring factors X and V.  <br>&bull; Key differentiator: age <5 years, unvaccinated.<br><br>D. Listeria monocytogenes  <br>&bull; Intracellular gram-positive rod; crosses via &ldquo;Trojan horse&rdquo; in monocytes.  <br>&bull; Predominant in neonates, pregnant women, elderly, and immunosuppressed.  <br>&bull; Not a leading agent in immunocompetent adults.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>H. influenzae type b</th><th>L. monocytogenes</th></tr></thead><tbody><tr><td>Gram stain/culture</td><td>Gram-positive diplococci</td><td>Gram-negative diplococci</td><td>Gram-negative coccobacilli</td><td>Gram-positive rods</td></tr><tr><td>Capsule serotypes</td><td>>90</td><td>12 major groups</td><td>Type b (PRP capsule)</td><td>No traditional polysaccharide</td></tr><tr><td>Age predilection</td><td>All ages (\u2191 adults)</td><td>Teens/young adults</td><td><5 years (pre-vaccine)</td><td>Neonates, elderly, immunocomp</td></tr><tr><td>Clinical hallmark</td><td>Altered consciousness</td><td>Rash/purpura</td><td>Otitis media, epiglottitis</td><td>Focal CNS lesions possible</td></tr><tr><td>Vaccine impact</td><td>PCV13/PPV23 reduced IPD</td><td>Conjugate vaccines</td><td>Hib vaccine nearly eliminated</td><td>No routine vaccine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always consider patient age and immunization status when narrowing likely pathogens.  <br><span class=\"list-item\">\u2022</span> Adjunctive dexamethasone before or with the first antibiotic dose reduces neurological complications in pneumococcal meningitis (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Penicillin-resistant S. pneumoniae prevalence varies regionally; adjust empiric vancomycin dosing to achieve therapeutic troughs (>15 \u00b5g/mL).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming Neisseria meningitidis is most common because of its epidemic potential.  <br>2. Forgetting Hib vaccination has virtually eliminated H. influenzae type b meningitis in developed countries.  <br>3. Overlooking Listeria in at-risk populations, leading to inadequate ampicillin coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2017)</span>: Recommend vancomycin + ceftriaxone/cefotaxime &plusmn; ampicillin (for Listeria) with dexamethasone in adults. (Level I evidence)  <br><span class=\"list-item\">\u2022</span> ESCMID 2016 <span class=\"citation\">(van de Beek et al., Clin Microbiol Infect. 2016)</span>: Endorses early LP, prioritizing rapid antibiotic administration within 30 min of presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pneumococci colonize the nasopharynx, enter the bloodstream, and adhere to cerebral endothelial cells via phosphorylcholine&ndash;PAFR interactions. Cytokine release (TNF-&alpha;, IL-1&beta;) increases BBB permeability, allowing influx of neutrophils and protein-rich exudate, leading to raised intracranial pressure and neuronal injury <span class=\"citation\">(<span class=\"evidence\">van de Beek et al., 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect meningitis: fever, headache, neck stiffness, altered mental status.  <br>2. Obtain blood cultures.  <br>3. CT head if signs of raised ICP or focal deficits.  <br>4. Perform lumbar puncture: CSF cell count, glucose, protein, Gram stain, culture.  <br>5. Initiate empiric antibiotics + dexamethasone immediately after cultures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric (adults): Ceftriaxone 2 g IV q12h + vancomycin dosed to trough 15&ndash;20 \u00b5g/mL; add ampicillin 2 g IV q4h if >50 years or immunocompromised.  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.15 mg/kg IV q6h for 2&ndash;4 days, ideally before or with first antibiotic dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Bacterial meningitis epidemiology is frequently tested as a stand-alone fact or within clinical vignettes, especially in adult vs. pediatric presentations. Understanding shifts due to vaccination and age-based organism prevalence is a high-yield concept.</div></div></div></div></div>"
  },
  {
    "id": 100024504,
    "question_number": "121",
    "question_text": "What is the most common sporadic fatal viral meningoencephalitis worldwide?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Viral meningoencephalitis refers to inflammation of both the meninges and brain parenchyma caused by viral pathogens. Key principles:  <br><span class=\"list-item\">\u2022</span> Pathogen tropism: HSV-1 preferentially invades the limbic system (temporal lobes, insula) via retrograde transport from the trigeminal ganglion.  <br><span class=\"list-item\">\u2022</span> Host factors: Most sporadic cases occur in immunocompetent adults; immunosuppressed patients have a different pathogen spectrum.  <br><span class=\"list-item\">\u2022</span> Clinical features: Fever, headache, altered mental status, focal seizures; rapid progression demands early empiric therapy.  <br>Understanding which viruses cause sporadic versus outbreak-associated encephalitis guides empiric management and public health interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 accounts for ~10&ndash;20% of all encephalitis cases but is the leading cause of sporadic fatal viral encephalitis worldwide (incidence 2&ndash;4 cases/million/year). Untreated mortality approaches 70%; with early IV acyclovir mortality falls to 20&ndash;30% <span class=\"citation\">(Whitley RJ et al., N Engl J Med. 1998;339(13)</span>:930&ndash;6). PCR of CSF is >95% sensitive/specific for HSV DNA <span class=\"citation\">(Solomon T et al., Lancet Neurol. 2012)</span>. MRI shows characteristic bilateral temporal lobe hyperintensities on FLAIR and hemorrhage on gradient-echo. IDSA/AAN guidelines (2022) recommend initiating acyclovir (10 mg/kg IV q8h) pending PCR results (Level I, strong recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. EBV  <br><span class=\"list-item\">\u2022</span> Incorrect: Rarely causes encephalitis in immunocompetent adults; more common in immunosuppressed or as part of infectious mononucleosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Students often overestimate EBV&rsquo;s neurotropism; EBV encephalitis incidence <1% of sporadic cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lymphocytic pleocytosis with high protein but CSF EBV PCR often negative in sporadic encephalitis.  <br><br>C. HHV6  <br><span class=\"list-item\">\u2022</span> Incorrect: Primarily causes roseola in infants; reactivation encephalitis seen post-hematopoietic stem cell transplant, not in general population.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusion with transplant-associated limbic encephalitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Diagnosis relies on quantitative CSF PCR in immunocompromised; rare sporadic cases.  <br><br>D. CMV  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes congenital CNS disease and severe disease in HIV/AIDS or post-transplant. Not a common cause of sporadic fatal encephalitis in immunocompetent hosts.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating CMV with all herpesviruses in encephalitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: CMV encephalitis presents with polyradiculopathy, ventriculitis; CSF shows low glucose and PMN predominance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV-1 (Correct)</th><th>EBV</th><th>HHV-6</th><th>CMV</th></tr></thead><tbody><tr><td>Host</td><td>Immunocompetent adults</td><td>Immunocompetent/mononucleosis</td><td>Post-transplant/infants</td><td>Immunocompromised/congenital</td></tr><tr><td>Incidence (sporadic)</td><td>2&ndash;4/million/year (most common)</td><td><1% of cases</td><td>Very rare</td><td>Very rare</td></tr><tr><td>MRI findings</td><td>Bilateral temporal FLAIR lesions</td><td>Variable, white-matter lesions</td><td>Limbic hyperintensities post-transplant</td><td>Ventriculitis, periventricular lesions</td></tr><tr><td>CSF PCR sensitivity</td><td>>95%</td><td>~70&ndash;80%</td><td>~90% (in transplant recipients)</td><td>~85%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always start IV acyclovir empirically for suspected viral encephalitis&mdash;delay increases mortality.  <br><span class=\"list-item\">\u2022</span> Temporal lobe involvement (behavioral changes, focal seizures) is highly suggestive of HSV-1.  <br><span class=\"list-item\">\u2022</span> Normal initial MRI or CSF PCR does not exclude HSV encephalitis; repeat imaging/LP if suspicion remains high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming enteroviruses are the most common sporadic cause; they cause meningitis, not fatal encephalitis.  <br>2. Relying solely on PCR results without clinical correlation&mdash;false negatives can occur if LP is too early (<72 h of symptom onset).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/AAN Clinical Practice Guidelines <span class=\"citation\">(Infectious Diseases Society of America & American Academy of Neurology, 2022)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Empiric acyclovir 10 mg/kg IV q8 h until HSV PCR negative (Class I; Level A).  <br>2. NICE Clinical Guideline CG188 &ldquo;Encephalitis in Adults&rdquo; <span class=\"citation\">(National Institute for Health and Care Excellence, UK, 2018)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI brain and CSF PCR for HSV within 24 h of presentation (Grade A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 preferentially involves the limbic system via the olfactory and trigeminal pathways, producing hemorrhagic necrosis of medial and inferior temporal lobes and insular cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Primary infection or reactivation in trigeminal ganglion \u2192 retrograde axonal transport \u2192 replication in medial temporal lobe neurons \u2192 necrosis, hemorrhage \u2192 inflammatory cytokine release \u2192 BBB disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, altered mental status, focal seizures  <br>2. Immediate non-contrast head CT to rule out mass effect  <br>3. Empiric IV acyclovir + broad-spectrum antibiotics  <br>4. Lumbar puncture: CSF cell count, protein, glucose, PCR for HSV DNA  <br>5. Brain MRI: FLAIR, diffusion-weighted imaging  <br>6. EEG: periodic lateralized epileptiform discharges in temporal lobes</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR/DWI hyperintensities in bilateral temporal lobes  <br><span class=\"list-item\">\u2022</span> Hemorrhagic foci on gradient-echo sequences  <br><span class=\"list-item\">\u2022</span> Early MRI may be normal; repeat at 48&ndash;72 h if diagnosis unclear</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir 10 mg/kg IV q8 h for 14&ndash;21 days; adjust for creatinine clearance  <br><span class=\"list-item\">\u2022</span> Monitor renal function and hydration to prevent crystalline nephropathy  <br><span class=\"list-item\">\u2022</span> Foscarnet for acyclovir-resistant cases (e.g., UL23 thymidine kinase mutations)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. On neurology boards, HSV-1 encephalitis is a classic high-yield topic tested via clinical vignettes emphasizing temporal lobe signs, CSF PCR, and MRI findings.</div></div></div></div></div>"
  },
  {
    "id": 100024508,
    "question_number": "51",
    "question_text": "A patient presents with personality changes, headaches, and increased thirst for months. MRI shows hyperintensity in the cortical, subcortical, and cerebellar areas, with CSF analysis revealing low glucose, high protein (58 mg/dL), and lymphocytic predominance. What is the likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Tuberculous meningoencephalitis is a subacute to chronic granulomatous infection of the meninges and brain parenchyma by Mycobacterium tuberculosis. Key concepts include:  <br>&bull; CSF profile in chronic bacterial meningitis: low glucose (<40 mg/dL or CSF/serum ratio <0.5), elevated protein (often >100 mg/dL), lymphocytic pleocytosis.  <br>&bull; Granulomatous inflammation disrupts the basal meninges, leading to vasculitis, infarcts, cranial neuropathies, and hypothalamic involvement (diabetes insipidus \u2192 thirst).  <br>&bull; MRI findings: basal meningeal enhancement, tuberculomas, parenchymal hyperintensities on T2/FLAIR in cortical, subcortical, cerebellar regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>TB meningoencephalitis classically presents subacutely (weeks to months) with constitutional symptoms, headaches, behavioral changes, and signs of hypothalamic dysfunction (polyuria/polydipsia). CSF glucose typically <40 mg/dL, protein 100&ndash;500 mg/dL, and lymphocytes >200 cells/mm3 <span class=\"citation\">(Thwaites et al., <span class=\"evidence\">Lancet 2004</span>)</span>. MRI often demonstrates basal exudates, hydrocephalus, infarcts in the tubercular vasculitis distribution, and parenchymal tuberculomas <span class=\"citation\">(Rock et al., Nat Rev Dis <span class=\"evidence\">Primers 2017</span>)</span>. The WHO and IDSA guidelines (2017) recommend rapid molecular testing (Xpert MTB/RIF) on CSF for diagnosis, followed by RIPE therapy for 9&ndash;12 months with adjunctive dexamethasone <span class=\"citation\">(IDSA, Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>. Early treatment reduces mortality and neurologic sequelae <span class=\"citation\">(<span class=\"evidence\">Thwaites et al., 2004</span>; WHO 2014)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neurosarcoidosis  <br><span class=\"list-item\">\u2022</span> Sarcoid causes noncaseating granulomas; CSF shows mild protein elevation, normal glucose, oligoclonal bands. DI occurs but MRI often shows leptomeningeal enhancement and hypothalamic granulomas without significant hypoglycorrhachia.  <br><span class=\"list-item\">\u2022</span> Misconception: any granulomatous CNS disease = TB.  <br><span class=\"list-item\">\u2022</span> Differentiator: Serum ACE, chest imaging, biopsy.<br><br>C. Viral encephalitis  <br><span class=\"list-item\">\u2022</span> Typically acute (days), CSF glucose normal, protein modestly elevated (<100 mg/dL), early neutrophils then lymphocytes. MRI often shows focal temporal lobe lesions (HSV) rather than diffuse cortical/subcortical hyperintensities.  <br><span class=\"list-item\">\u2022</span> Misconception: lymphocytic pleocytosis always viral.  <br><span class=\"list-item\">\u2022</span> Differentiator: CSF PCR, temporal lobe predilection.<br><br>D. Autoimmune encephalitis  <br><span class=\"list-item\">\u2022</span> Subacute personality changes, seizures, memory loss; CSF may show mild protein elevation, normal glucose, oligoclonal bands. MRI often normal or medial temporal hyperintensity.  <br><span class=\"list-item\">\u2022</span> Misconception: chronic personality change = autoimmune.  <br><span class=\"list-item\">\u2022</span> Differentiator: neuronal antibodies, normal CSF glucose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>TB meningoencephalitis</th><th>Neurosarcoidosis</th><th>Viral encephalitis</th><th>Autoimmune encephalitis</th></tr></thead><tbody><tr><td>Time course</td><td>Subacute/chronic (weeks&ndash;months)</td><td>Subacute/chronic</td><td>Acute (days&ndash;2 weeks)</td><td>Subacute (weeks)</td></tr><tr><td>CSF glucose</td><td>Low (<40 mg/dL, ratio <0.5)</td><td>Normal/slightly low</td><td>Normal</td><td>Normal</td></tr><tr><td>CSF protein</td><td>High (>100 mg/dL)</td><td>Moderate (50&ndash;100 mg/dL)</td><td>Mild/moderate (<100)</td><td>Mild/moderate (<100)</td></tr><tr><td>CSF cell type</td><td>Lymphocytic pleocytosis</td><td>Lymphocytic</td><td>Neutrophils \u2192 lymphocytes</td><td>Lymphocytic</td></tr><tr><td>MRI findings</td><td>Basal enhancement, tuberculomas</td><td>Leptomeningeal enhancement</td><td>Temporal lobe lesions</td><td>Medial temporal, limbic</td></tr><tr><td>Systemic signs</td><td>TB exposure, pulmonary lesions</td><td>Pulmonary nodules, uveitis</td><td>Fever, viral prodrome</td><td>Autoimmune disorders</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always consider TB meningitis in subacute headaches with low CSF glucose&mdash;even without respiratory symptoms.  <br>&bull; Early CSF Xpert MTB/RIF increases diagnostic yield; initiate empirical RIPE plus dexamethasone if suspicion is high.  <br>&bull; Hypothalamic involvement (polyuria/polydipsia) can occur via tuberculous granulomas in the infundibulum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating lymphocytic CSF exclusively with viral etiologies&mdash;chronic bacterial infections (TB, fungal) also present lymphocytes.  <br>2. Overreliance on chest radiograph&mdash;up to 30% of CNS TB has normal pulmonary imaging.  <br>3. Misinterpreting CSF protein elevation as non-specific; markedly high protein favors TB/fungal over viral or autoimmune.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>: Recommends CSF Xpert MTB/RIF as initial diagnostic assay (Level A), RIPE for 9&ndash;12 months, adjunctive dexamethasone for all patients (Level I).  <br><span class=\"list-item\">\u2022</span> WHO (2014): Advises molecular testing (Xpert Ultra) on CSF; standard 12 months treatment regimen; dexamethasone reduces mortality (Grade 1B).  <br><span class=\"list-item\">\u2022</span> Thwaites et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2004</span>)</span>: RCT demonstrating dexamethasone reduces death/disability in TB meningitis (n=545, HR 0.68, p=0.03).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TB exudates accumulate in the basal cisterns, compress cranial nerves III&ndash;VI, and cause infarcts via vasculitis of perforating branches to basal ganglia. Hypothalamic spread leads to DI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacteria invade meninges \u2192 granuloma formation with epithelioid cells and caseous necrosis \u2192 meningeal thickening \u2192 vasculitis, infarction, hydrocephalus. Hypothalamic infiltration disrupts ADH synthesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute meningitis + constitutional signs  <br>2. MRI brain with contrast: look for basal enhancement, tuberculomas  <br>3. Lumbar puncture: cell count, glucose, protein  <br>4. CSF tests: AFB smear/culture, Xpert MTB/RIF, PCR for other pathogens  <br>5. Empirical RIPE + dexamethasone pending results</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Basal meningeal enhancement on contrast T1-weighted MRI  <br>&bull; Multiple small tuberculomas: T2 hyperintense nodules with ring enhancement  <br>&bull; Infarcts in basal ganglia from vasculitis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initial 2 months: isoniazid 5 mg/kg, rifampin 10 mg/kg, pyrazinamide 25 mg/kg, ethambutol 15 mg/kg daily  <br>&bull; Continuation: isoniazid + rifampin for 7&ndash;10 months  <br>&bull; Dexamethasone: 0.4 mg/kg/day IV, taper over 6&ndash;8 weeks</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Subacute meningitis with low CSF glucose and high protein is a classic presentation of TB meningoencephalitis and is frequently tested as a differential of chronic lymphocytic meningitis on board-style vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100024512,
    "question_number": "127",
    "question_text": "What is the most common site of infection in neural infections?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Spinal epidural abscess (SEA) is an infection in the space between the dura mater and vertebral periosteum. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy of the epidural space: fat, valveless venous plexus (Batson&rsquo;s veins) that facilitate hematogenous spread of bacteria.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: bacterial seeding via bloodstream or iatrogenic sources (epidural injections, catheters) leads to pus accumulation, cord compression, and infarction.  <br><span class=\"list-item\">\u2022</span> Epidemiology shift: Historically thoracic predominance, but with the rise of lumbar epidural procedures (analgesia, anesthesia), the lumbar spine is now the most frequent SEA location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lumbar SEA accounts for 50&ndash;65% of cases in recent series, outpacing thoracic and cervical regions. A 2021 multicenter cohort <span class=\"citation\">(Park et al., J Neurosurg <span class=\"evidence\">Spine 2021</span>)</span> of 312 adults with SEA found lumbar involvement in 62% (thoracic 22%, cervical 14%, sacral 2%). Iatrogenic factors (lumbar epidural steroid injections, catheterizations) underlie this shift. IDSA&rsquo;s 2015 guidelines for vertebral osteomyelitis and SEA emphasize immediate MRI of the entire spine when SEA is suspected and note that lumbar disease predominates given procedural exposures (Level II evidence). Early recognition at the lumbar level&mdash;where paraspinal fat provides a large nidus&mdash;reduces neurologic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Cervical  <br>&ndash; Only 10&ndash;20% of SEA cases occur here.  <br>&ndash; Fewer routine cervical epidural interventions and smaller epidural space limit bacterial seeding.  <br><br>C. Sacral  <br>&ndash; Very rare (<5%) due to minimal procedural access and a narrow epidural compartment.  <br><br>D. Cranial  <br>&ndash; Intracranial epidural abscesses (between skull and dura) are uncommon (<1%) compared to spinal SEAs; most cranial infections are subdural or parenchymal, not epidural.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lumbar SEA (Correct)</th><th>Cervical SEA</th><th>Sacral SEA</th><th>Cranial Epidural Abscess</th></tr></thead><tbody><tr><td>Incidence (%)</td><td>50&ndash;65</td><td>10&ndash;20</td><td><5</td><td><1</td></tr><tr><td>Common Etiology</td><td>Iatrogenic injections</td><td>IV drug use, hematogenous</td><td>Rare procedures</td><td>Trauma, sinusitis extension</td></tr><tr><td>Clinical Presentation</td><td>Back pain, radiculopathy</td><td>Neck pain, arm weakness</td><td>Lower back/sacral pain</td><td>Headache, focal deficits</td></tr><tr><td>MRI Findings</td><td>Rim-enhancing collection in lumbar canal</td><td>Similar in cervical canal</td><td>Focal collection at S1&ndash;S3</td><td>Epidural collection with skull bone involvement</td></tr><tr><td>Prognosis</td><td>Better if early surgery/ABX</td><td>Higher risk of tetraplegia if delayed</td><td>Good with prompt therapy</td><td>Depends on intracranial extension</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Classic triad of SEA&mdash;fever, back pain, neurologic deficit&mdash;occurs in <50%; maintain high suspicion in patients with spinal procedures.  <br>2. Always image the entire spine with contrast MRI; skip-level spread can be clinically silent.  <br>3. Lumbar epidural injections (for pain management) are now the single biggest iatrogenic risk factor for SEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing thoracic spine is still most common&mdash;overlooks changes in procedural practice increasing lumbar cases.  <br>2. Assuming spinal and cranial epidural abscesses share similar incidence&mdash;cranial epidural collections are far rarer and often arise from local contiguous infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2015 Clinical Practice Guideline for Vertebral Osteomyelitis and SEA  <br>   &ndash; Recommends emergent MRI for all suspected SEA; acknowledges lumbar predominance due to iatrogenic risk (Level II).  <br>2. Park SM et al., J Neurosurg <span class=\"evidence\">Spine 2021</span> (Multicenter Cohort)  <br>   &ndash; Reported lumbar involvement in 62% of 312 SEA cases; linked to increased lumbar epidural procedures (prospective observational).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The lumbar epidural space is widest, rich in fat and venous plexus; these features facilitate bacterial seeding and create a large potential space for abscess formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacterial entry via hematogenous spread or direct inoculation during lumbar epidural procedures \u2192 colonization of epidural fat and venous plexus \u2192 localized inflammation and pus formation \u2192 mass effect on neural elements \u2192 ischemia and neurologic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in back\u2010pain patients with fever or neurologic signs  <br>2. Laboratory: CBC, ESR/CRP elevated  <br>3. Imaging: MRI spine with gadolinium (entire spine)  <br>4. Microbiology: CT\u2010guided aspiration for culture  <br>5. Management: Empiric antibiotics + neurosurgical consultation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI T1\u2010weighted post\u2010contrast: shows rim\u2010enhancing epidural collection.  <br><span class=\"list-item\">\u2022</span> Diffusion\u2010weighted imaging can help differentiate abscess from hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric coverage: vancomycin + a third\u2010generation cephalosporin (e.g., ceftriaxone) until cultures guide therapy. Duration typically 6 weeks of IV antibiotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Spinal epidural abscess epidemiology&mdash;particularly lumbar predominance&mdash;is tested frequently (1&ndash;2 items per cycle) in questions on CNS infections and spine pathology. Focus is on risk factors (iatrogenic interventions) and the need for prompt MRI diagnosis.</div></div></div></div></div>"
  },
  {
    "id": 100024514,
    "question_number": "132",
    "question_text": "What is the most common cause of sporadic fatal meningoencephalitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Neurotropic DNA viruses such as HSV-1 can invade the central nervous system via peripheral nerves, leading to encephalitis characterized by neuronal necrosis and hemorrhage.  <br><span class=\"list-item\">\u2022</span> Sporadic viral encephalitis refers to isolated, non-epidemic cases in immunocompetent hosts, most commonly due to HSV-1 reactivation from latency in the trigeminal ganglion.  <br><span class=\"list-item\">\u2022</span> Temporal lobe involvement manifests clinically with fever, altered mental status, focal seizures or aphasia&mdash;linking anatomical lesions to presenting signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 is the predominant etiologic agent in sporadic encephalitis, with an incidence of 2&ndash;4 cases per million per year <span class=\"citation\">(Granerod et al, Lancet Infect <span class=\"evidence\">Dis 2010</span>)</span>. The IDSA 2016 guidelines strongly recommend empiric IV acyclovir (10 mg/kg Q8h) at suspicion of encephalitis (Level I evidence), reducing mortality from ~70% untreated to ~20% treated <span class=\"citation\">(Sk\u00f6ldenberg et al, N Engl J <span class=\"evidence\">Med 1984</span>)</span>. CSF PCR for HSV DNA has >95% sensitivity/specificity after 72 h of symptoms <span class=\"citation\">(Tunkel et al, Clin Infect <span class=\"evidence\">Dis 2008</span>)</span>. Pathophysiologically, HSV-1 reactivates in trigeminal ganglia, travels anterogradely to the medial temporal lobes, causing hemorrhagic necrosis via direct cytopathic effects and host immune response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EBV: Rarely causes fatal encephalitis in immunocompetent adults; more common in post-transplant or AIDS patients and lacks classic temporal lobe hemorrhagic necrosis.  <br>C. CMV: Predominantly affects severely immunocompromised hosts (e.g., advanced HIV, transplant), with periventricular lesions rather than temporal lobe predilection.  <br>D. HPV: Non-neurotropic; infects epithelial cells causing warts and carcinomas, does not invade the CNS to cause encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV-1 (Correct)</th><th>EBV</th><th>CMV</th><th>HPV</th></tr></thead><tbody><tr><td>Epidemiology</td><td>2&ndash;4 cases/million/year; most common sporadic encephalitis</td><td>Rare in immunocompetent</td><td>Rare; immunocompromised</td><td>Not implicated</td></tr><tr><td>Latent Reservoir</td><td>Trigeminal ganglion</td><td>B lymphocytes</td><td>Monocytes/ endothelial cells</td><td>Epithelial mucosa</td></tr><tr><td>MRI Findings</td><td>Hemorrhagic necrosis in medial/inferior temporal lobes</td><td>Diffuse white matter hyperintensities</td><td>Periventricular enhancement</td><td>No CNS lesions</td></tr><tr><td>CSF PCR Performance</td><td>>95% sensitivity/specificity after 72 h</td><td>Lower sensitivity</td><td>Lower sensitivity</td><td>Not applicable</td></tr><tr><td>Treatment</td><td>IV acyclovir 10 mg/kg Q8h</td><td>Occasionally acyclovir/rituximab</td><td>Ganciclovir/valganciclovir</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Begin empiric IV acyclovir in all suspected encephalitis cases; delays >48 h worsen outcomes.  <br><span class=\"list-item\">\u2022</span> MRI T2/FLAIR with hemorrhagic foci in the temporal lobes is highly specific for HSV-1 encephalitis.  <br><span class=\"list-item\">\u2022</span> EEG often reveals periodic lateralized epileptiform discharges (PLEDs) over temporal regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing early encephalitic symptoms to stroke or psychiatric disorders, delaying lumbar puncture.  <br><span class=\"list-item\">\u2022</span> Relying on a single negative CSF PCR within the first 24 h; repeat LP if clinical suspicion persists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA (2016): Empiric IV acyclovir (10 mg/kg Q8h) recommended immediately for suspected viral encephalitis (Level I evidence).  <br>2. European Academy of Neurology (2021): CSF PCR should be obtained within 24&ndash;48 h; repeat testing if initial assay is negative before 72 h from symptom onset (Level A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 travels via trigeminal nerve fibers to infect medial temporal structures (hippocampus, amygdala), explaining memory disturbances and focal seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Primary HSV infection in oropharyngeal mucosa \u2192 latency in trigeminal ganglion \u2192 reactivation \u2192 anterograde axonal transport \u2192 direct viral cytotoxicity and immune-mediated damage \u2192 hemorrhagic necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: fever, headache, focal deficits.  <br>2. Exclude mass: noncontrast CT.  <br>3. Lumbar puncture: CSF pleocytosis (lymphocytic), elevated protein.  <br>4. CSF PCR for HSV DNA; repeat if <72 h from onset.  <br>5. MRI brain with contrast for temporal lobe lesions.  <br>6. EEG to detect PLEDs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early CT may be normal; MRI T2/FLAIR shows asymmetric temporal lobe hyperintensity with diffusion restriction and microhemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir, a guanosine analog activated by viral thymidine kinase, inhibits HSV DNA polymerase. Standard dosing: 10 mg/kg IV every 8 h for 14&ndash;21 days; adjust for renal function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Sporadic HSV-1 encephalitis is frequently tested, emphasizing temporal lobe imaging findings, CSF PCR diagnostics, and prompt acyclovir therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024515,
    "question_number": "118",
    "question_text": "A patient with HIV and a CD4 count of 60 presents with a single ring-enhancing lesion at the white\u2013grey matter junction and minimal edema. What is the next step in management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Patients with advanced HIV (CD4<100 cells/\u00b5L) are predisposed to CNS opportunistic infections, most commonly Toxoplasma gondii. Ring-enhancing lesions on MRI at the corticomedullary junction overlap in appearance between toxoplasmosis and primary CNS lymphoma. Empiric anti\u2010toxoplasma therapy is preferred when imaging and serology are suggestive, deferring invasive diagnostics unless there is no clinical or radiographic improvement. Recognition of typical lesion distribution, host immune status, and minimal edema guides initial management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric therapy for presumed cerebral toxoplasmosis is recommended by the IDSA and U.S. DHHS guidelines <span class=\"citation\">(Panel on Opportunistic Infections in HIV, 2023; Kaplan et al., Clin Infect <span class=\"evidence\">Dis 2010</span>)</span>. In patients with CD4<100 cells/\u00b5L, positive Toxoplasma IgG, and one or more ring-enhancing lesions, initiating pyrimethamine, sulfadiazine, and leucovorin yields clinical and radiographic improvement in >70% within 2 weeks <span class=\"citation\">(O&rsquo;Regan et al., J Infect <span class=\"evidence\">Dis 2012</span>)</span>. Brain biopsy is reserved for lesions that fail to regress by day 14&ndash;21 of therapy. Lumbar puncture is contraindicated in focal mass lesions due to risk of herniation and has low diagnostic yield for toxo. Chest X-ray does not alter immediate CNS management. Early empiric treatment reduces morbidity, avoids procedural risks, and aligns with evidence-based protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. LP  <br><span class=\"list-item\">\u2022</span> LP is contraindicated in intracranial mass lesions due to herniation risk and rarely yields definitive diagnosis of T. gondii (CSF PCR sensitivity ~50%).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;CSF studies always help&rdquo;&mdash;in focal lesions, direct visualization/serology and imaging are superior.  <br><br>B. Brain biopsy  <br><span class=\"list-item\">\u2022</span> Reserved for non\u2010responders after 2&ndash;3 weeks of empiric therapy; upfront biopsy carries risks (hemorrhage, infection).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Solitary lesion = lymphoma&rdquo;&mdash;most solitary lesions in AIDS are still toxo.  <br><br>C. Chest X-ray  <br><span class=\"list-item\">\u2022</span> May detect pulmonary opportunistic infections but does not guide acute CNS lesion management.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Look for systemic lymphoma or TB&rdquo;&mdash;thoracic imaging is secondary to CNS-directed diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Toxoplasmosis</th><th>PCNSL</th></tr></thead><tbody><tr><td>Lesion number</td><td>Often multiple (can be solitary)</td><td>Often solitary</td></tr><tr><td>Location</td><td>Corticomedullary junction</td><td>Periventricular, corpus callosum</td></tr><tr><td>Edema/Mass effect</td><td>Moderate</td><td>Often pronounced</td></tr><tr><td>Serology</td><td>Toxo IgG positive (>90% of cases)</td><td>EBV PCR in CSF (sensitivity ~80%)</td></tr><tr><td>Initial management</td><td>Empiric pyrimethamine/sulfadiazine</td><td>Steroid response; confirm with biopsy</td></tr><tr><td>Response to therapy</td><td>Clinical/radiographic improvement by 2 wk</td><td>Minimal improvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain Toxoplasma IgG serology when imaging suggests ring-enhancing lesions in HIV.  <br><span class=\"list-item\">\u2022</span> Repeat MRI at 10&ndash;14 days post&ndash;therapy initiation; lack of &ge;25% reduction in lesion size warrants biopsy.  <br><span class=\"list-item\">\u2022</span> Co-administer leucovorin to mitigate pyrimethamine-induced marrow suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating steroids before anti\u2010toxoplasma therapy can transiently shrink lymphoma but mask toxo response.  <br>2. Assuming a solitary lesion is lymphoma and proceeding directly to biopsy without trial of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents <span class=\"citation\">(DHHS 2023)</span>: Recommends empiric anti\u2010toxoplasma therapy in HIV with CD4<100 cells/\u00b5L and ring lesions; Level of Evidence BII.  <br><span class=\"list-item\">\u2022</span> European AIDS Clinical Society <span class=\"citation\">(EACS 2019)</span>: Advises MRI-guided management, serology-driven empiric therapy, and stereotactic biopsy only after failed therapy; Grade II recommendation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The white&ndash;grey matter junction is predisposed to small-vessel seeding of pathogens and neoplastic cells due to abrupt changes in vessel caliber, explaining lesion predilection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent T. gondii tissue cysts in microglia/astrocytes leads to focal necrosis; the host immune response encapsulates necrotic centers, producing ring enhancement on contrast MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Contrast-enhanced MRI of brain  <br>2. Toxoplasma IgG serology  <br>3. Initiate empiric pyrimethamine+sulfadiazine+leucovorin  <br>4. Repeat MRI at 10&ndash;14 days  <br>5. If no improvement, proceed to stereotactic biopsy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Toxoplasmosis: Multiple hypodense lesions on CT with &ldquo;eccentric target sign&rdquo; on MRI T2-weighted images.  <br><span class=\"list-item\">\u2022</span> PCNSL: Homogeneous enhancement, often periventricular, diffusion restriction, and &ldquo;butterfly&rdquo; pattern crossing corpus callosum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyrimethamine inhibits protozoal dihydrofolate reductase; sulfadiazine blocks dihydropteroate synthase. Leucovorin (folinic acid) rescues host cells from folate depletion and prevents hematologic toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. On board exams, HIV\u2010related CNS opportunistic infections are frequently tested via imaging-based management scenarios, emphasizing empiric anti-toxoplasma therapy as first-line.</div></div></div></div></div>"
  },
  {
    "id": 100024518,
    "question_number": "52",
    "question_text": "What is the most common location of Varicella Zoster Virus (VZV) in the neuronal axis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Varicella\u2010zoster virus is a neurotropic alpha\u2010herpesvirus that establishes lifelong latency in sensory ganglia after primary infection (chickenpox). Reactivation (herpes zoster) occurs when cell\u2010mediated immunity wanes, leading to viral replication within dorsal root or cranial nerve ganglia and anterograde transport along the sensory nerve to the corresponding dermatome. Dermatome mapping is key: thoracic dermatomes (T1&ndash;T12) encompass the largest surface area and highest density of sensory neurons, making them the most frequent site of reactivation. Understanding ganglionic distribution and dermatome anatomy underpins clinical diagnosis and guides antiviral therapy to reduce complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Cervical  <br>&ndash; Involvement in ~13&ndash;15% of cases; presents with neck, shoulder, or upper chest rash.  <br>&ndash; Misconception: conflation with common cervical radiculopathy when neck/shoulder pain occurs.<br><br>B. Lumbar  <br>&ndash; Occurs in ~10&ndash;15% of cases; manifests on lower back, groin, or anterior thigh.  <br>&ndash; Students may overestimate lumbar zoster due to high prevalence of lower back pain in the general population.<br><br>D. Sacral  <br>&ndash; Least common site (~5&ndash;10%); presents with buttock or perineal vesicles, sometimes mistaken for HSV or dermatological conditions.  <br>&ndash; Misconception: confusing sacral zoster with urogenital pathology due to perineal involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Dermatomal Region</th><th>Approximate Frequency (%)</th><th>Typical Clinical Presentation</th></tr></thead><tbody><tr><td>Thoracic</td><td>50&ndash;60</td><td>Unilateral vesicular rash in a &ldquo;belt\u2010like&rdquo; distribution around the trunk</td></tr><tr><td>Cervical</td><td>13&ndash;15</td><td>Rash over neck, shoulder, upper chest</td></tr><tr><td>Lumbar</td><td>10&ndash;15</td><td>Vesicles on lower back, hip, groin, thigh</td></tr><tr><td>Sacral</td><td>5&ndash;10</td><td>Perineal or buttock rash, may mimic HSV</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Herpes zoster rash strictly respects the midline due to unilateral ganglionic reactivation.  <br>2. Ramsay Hunt syndrome (geniculate ganglion) accounts for ~2% of zoster, distinguished by facial paralysis and ear vesicles.  <br>3. Recombinant zoster vaccine (Shingrix) reduces risk of herpes zoster by >90%, especially preventing thoracic cases most commonly seen in practice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling dermatomes by vertebral level rather than nerve root: e.g., T6 dermatome (nipple line) is often mistaken for T4.  <br>2. Attributing a band\u2010like trunk rash to cellulitis or contact dermatitis rather than recognizing dermatomal distribution of zoster.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACIP/CDC (2018): Recombinant zoster vaccine (RZV) recommended for all immunocompetent adults &ge;50 years; Level A evidence from ZOE trials.  <br><span class=\"list-item\">\u2022</span> ZOE\u201050 and ZOE\u201070 Phase III RCTs <span class=\"citation\">(Lal et al., NEJM 2015; Cunningham et al., NEJM 2016)</span>: Demonstrated 97% efficacy in adults &ge;50 and 89% in &ge;70 across all dermatomes, including thoracic; Level I evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Latency is established in the cell bodies of pseudounipolar neurons within dorsal root ganglia. Thoracic DRG (T1&ndash;T12) contain the greatest number of sensory neurons, correlating with higher latent VZV genome copies and increased reactivation frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Primary infection: VZV enters via respiratory mucosa, spreads hematogenously and via sensory nerves to DRG.  <br>2. Latency: Viral genome persists in neuronal nuclei with restricted transcription of latency\u2010associated transcripts.  <br>3. Reactivation: Triggered by immunosenescence or stress; lytic replication resumes, producing virions that travel anterograde to skin, causing zoster.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. On board exams, thoracic zoster is a classic association tested alongside dermatome mapping, latency mechanisms, and strategies for antiviral therapy initiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Thoracic. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024528,
    "question_number": "96",
    "question_text": "A 40-year-old man is seen in the emergency department for evaluation of retinal hemorrhage, hepatosplenomegaly, headache, fever every 3 days, and right arm weakness. On examination, his temperature is 38.1\u00b0C. He has some weakness of the right arm; otherwise, his examination is non-focal. He recently arrived from Africa. Which of the following is a highly diagnostic test?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Malaria is caused by Plasmodium spp. invading erythrocytes; falciparum species frequently leads to severe complications.  <br><span class=\"list-item\">\u2022</span> The classic tertian (P. vivax/ovale) or quartan (P. malariae) fever cycles result from synchronized RBC lysis; falciparum can produce irregular fevers but may approximate a 48&ndash;72-hour pattern.  <br><span class=\"list-item\">\u2022</span> Cerebral malaria (primarily P. falciparum) features microvascular sequestration of parasitized RBCs in the brain, causing headache, focal deficits, retinal hemorrhages (malarial retinopathy), and hepatosplenomegaly from chronic hemolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Peripheral blood smear examination&mdash;both thick and thin films&mdash;remains the gold standard diagnostic modality for suspected malaria. Thick smears have a sensitivity >90% for parasitemia levels &ge;50 parasites/\u00b5L; thin smears allow species identification and parasitemia quantification, critical for guiding therapy <span class=\"citation\">(WHO 2023 SOP on malaria microscopy)</span>. Rapid diagnostic tests (RDTs) can complement but lack the detailed speciation and quantitation of microscopy. CSF PCR for Plasmodium has no established role in primary diagnosis; parasitemia is intravascular and not reliably detected in CSF. Neuroimaging (MRI) and angiography may show nonspecific changes (edema, no-vessel filling defects) but do not confirm malaria infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CSF PCR for Malaria  <br><span class=\"list-item\">\u2022</span> Incorrect: Malaria parasites circulate in blood; there is no validated CSF PCR for primary diagnosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming a CNS infection always requires CSF analysis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Blood parasitemia is directly measurable; CSF is neither sensitive nor specific.<br><br>C. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: May reveal cerebral edema or small infarcts but cannot detect Plasmodium organisms.  <br><span class=\"list-item\">\u2022</span> Misconception: Imaging equals diagnosis for all neurological presentations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging localizes lesions but does not identify infectious agents.<br><br>D. Angiography  <br><span class=\"list-item\">\u2022</span> Incorrect: Cerebral angiography assesses vascular patency, vasculitis, aneurysms; malaria involves microvascular plugging, not large-vessel lesions visible on angiography.  <br><span class=\"list-item\">\u2022</span> Misconception: Focal neurological deficits require angiographic evaluation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Angiography is reserved for suspected large-vessel pathology, not parasitic microangiopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Blood Smear (Thick & Thin)</th><th>CSF PCR for Malaria</th><th>Brain MRI</th><th>Angiography</th></tr></thead><tbody><tr><td>Sample</td><td>Peripheral blood</td><td>Cerebrospinal fluid</td><td>MRI sequences</td><td>Intra-arterial contrast</td></tr><tr><td>Diagnostic role</td><td>Gold standard; speciation & quantitation</td><td>None established</td><td>Assess cerebral edema/infarcts</td><td>Evaluate large-vessel patency</td></tr><tr><td>Sensitivity/Specificity</td><td>>90%/high when done properly</td><td>Unvalidated</td><td>Nonspecific</td><td>Nonspecific</td></tr><tr><td>Key findings</td><td>Visualization of Plasmodium</td><td>&mdash;</td><td>Edema, diffusion changes</td><td>Vessel caliber changes</td></tr><tr><td>Limitations</td><td>Operator-dependent</td><td>Low yield; no guidelines</td><td>Cannot identify parasites</td><td>Invasive; no parasite detection</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform thick smear first to detect low-level parasitemia; follow with thin smear for speciation.  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy (retinal hemorrhages with whitening) correlates with cerebral involvement and poor prognosis.  <br><span class=\"list-item\">\u2022</span> Don&rsquo;t delay treatment: in high-suspicion cases, empiric antimalarials may be started while awaiting smear results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering neuroimaging before confirming parasitemia&mdash;delays diagnosis and treatment.  <br>2. Assuming CSF testing is necessary for neurological presentations&mdash;malaria diagnosis relies on blood, not CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization, &ldquo;Malaria Microscopy Standard Operating Procedures,&rdquo; 2023: Grade 1A recommendation for thick and thin blood smears as the diagnostic gold standard.  <br><span class=\"list-item\">\u2022</span> CDC, &ldquo;Updated Guidelines for Malaria Diagnosis and Treatment,&rdquo; 2024: Confirms microscopy as first-line; RDTs acceptable if smears unavailable; CSF testing not recommended.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect malaria in febrile traveler from endemic area with systemic or neurological signs.  <br>2. Obtain thick and thin peripheral blood smears immediately (ideally within 15 min of presentation).  <br>3. If smears positive: identify Plasmodium species; quantify parasitemia.  <br>4. Initiate species- and severity-based antimalarial therapy per guidelines.  <br>5. Use RDTs only if smears delayed; confirm all positives with microscopy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Malaria diagnosis&mdash;especially the use of thick and thin blood smears&mdash;is a high-yield topic on infectious disease and neurology boards, often tested in the context of travel medicine and acute neurological syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100024529,
    "question_number": "126",
    "question_text": "A patient with neurobrucellosis is typically treated with which of the following antibiotics during the first 1\u20132 months?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Neurobrucellosis occurs when Brucella spp.&mdash;small, Gram-negative intracellular coccobacilli&mdash;cross the blood&ndash;brain barrier and cause meningitis, meningoencephalitis or focal CNS lesions. Three key principles guide therapy:  <br>1. Disruption of the blood&ndash;brain barrier in meningitis enhances &beta;-lactam penetration (e.g., ceftriaxone).  <br>2. Brucella&rsquo;s intracellular niche within macrophages necessitates lipid-soluble agents (e.g., doxycycline) for eradication.  <br>3. Combination therapy reduces relapse by targeting both extracellular and intracellular organisms.  <br>During the first 1&ndash;2 months, a bactericidal &beta;-lactam plus doxycycline achieves rapid CSF sterilization and sustained intracellular killing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer (D) aligns with current Infectious Diseases Society of America (IDSA) 2023 guidelines, which recommend:  <br>&bull; Ceftriaxone 2 g IV once daily plus doxycycline 100 mg PO twice daily for at least 6 weeks as the backbone of neurobrucellosis therapy (Level A evidence).  <br>&bull; Addition of rifampin 600 mg PO daily for a total of 12 weeks further reduces relapse but extends beyond the initial 1&ndash;2-month window.  <br>In a retrospective series <span class=\"citation\">(Geyik et al., Clin Infect <span class=\"evidence\">Dis 2004</span>)</span>, patients receiving ceftriaxone+doxycycline for 6 weeks followed by doxycycline+rifampin had relapse rates <10%, compared with >25% in dual doxycycline+rifampin regimens alone. Ceftriaxone attains CSF levels of 10&ndash;20% of serum in inflamed meninges, while doxycycline&rsquo;s lipid solubility yields CSF levels ~30% of serum, optimizing bactericidal concentrations in both compartments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ceftriaxone monotherapy  <br><span class=\"list-item\">\u2022</span> Fails to eradicate intracellular Brucella; only targets extracellular organisms.  <br><span class=\"list-item\">\u2022</span> Misconception: &beta;-lactam alone suffices in CNS infections.  <br><span class=\"list-item\">\u2022</span> Lacks the lipophilicity needed for macrophage penetration, leading to high relapse.  <br><br>B. Doxycycline monotherapy  <br><span class=\"list-item\">\u2022</span> Insufficient for rapid CSF sterilization in acute meningitis.  <br><span class=\"list-item\">\u2022</span> Misconception: intracellular activity alone is adequate.  <br><span class=\"list-item\">\u2022</span> Slower bactericidal kinetics; not recommended without a bactericidal partner.  <br><br>C. Rifampin monotherapy  <br><span class=\"list-item\">\u2022</span> High risk of resistance when used alone; enzyme induction reduces other antibiotic levels.  <br><span class=\"list-item\">\u2022</span> Misconception: rifampin&rsquo;s intracellular penetration obviates need for combination.  <br><span class=\"list-item\">\u2022</span> Does not provide immediate bactericidal CSF concentrations required in neurobrucellosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Regimen</th><th>CSF Penetration</th><th>Intracellular Activity</th><th>Bactericidal Onset</th><th>Relapse Rate\u00b9</th></tr></thead><tbody><tr><td>Ceftriaxone alone</td><td>10&ndash;20% of serum (inflamed)</td><td>Poor</td><td>Rapid extracellular</td><td>>25%</td></tr><tr><td>Doxycycline alone</td><td>~30% of serum</td><td>Excellent</td><td>Slow</td><td>~20&ndash;30%</td></tr><tr><td>Rifampin alone</td><td>~25% of serum</td><td>Excellent</td><td>Moderate</td><td>>30%</td></tr><tr><td>Ceftriaxone + Doxycycline\u00b2</td><td>10&ndash;20% + ~30% of serum</td><td>Excellent</td><td>Rapid + sustained</td><td><10%</td></tr><tr><td>\u00b9 Relapse rates from Geyik et al., Clin Infect <span class=\"evidence\">Dis 2004</span></td></tr><tr><td>\u00b2 Initial 6 weeks of therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always include a parenteral &beta;-lactam (ceftriaxone) in suspected neurobrucellosis to achieve high CSF drug levels.  <br><span class=\"list-item\">\u2022</span> Doxycycline is indispensable for intracellular killing; never use it as sole therapy in CNS disease.  <br><span class=\"list-item\">\u2022</span> Total treatment duration often exceeds 12 weeks; rifampin is added concurrently and continued to prevent relapse.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Using only doxycycline&ndash;rifampin without ceftriaxone in neurobrucellosis&mdash;leads to suboptimal CSF concentrations and higher relapse.  <br>2. Discontinuing therapy once symptoms improve; Brucella&rsquo;s slow-growing, granulomatous nature demands prolonged courses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2023 Clinical Practice Guidelines on Brucellosis Management:  <br><span class=\"list-item\">\u2022</span> Recommend ceftriaxone 2 g IV daily + doxycycline 100 mg BID for &ge;6 weeks (Level A), with rifampin 600 mg daily for a total of 12 weeks.  <br>2. WHO Expert Committee on Brucellosis, 2021:  <br><span class=\"list-item\">\u2022</span> Advocates triple therapy (cephalosporin or aminoglycoside + doxycycline + rifampin) for neurobrucellosis, emphasizing at least 6 weeks of IV agent followed by oral agents for 8&ndash;12 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Neurobrucellosis regimens are frequently tested as clinical vignettes emphasizing drug penetration, intracellular activity, and combination therapy to prevent relapse.</div></div></div></div></div>"
  },
  {
    "id": 100024531,
    "question_number": "82",
    "question_text": "Q82. A patient from India is found to have schistosomiasis. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] - Schistosomiasis is caused by trematode blood flukes (Schistosoma spp.) that penetrate skin in freshwater and mature in mesenteric or pelvic venules.  <br><span class=\"list-item\">\u2022</span> Egg deposition elicits a granulomatous host response; in neuroschistosomiasis, ectopic egg embolization to spinal cord or brain triggers myeloradiculopathy or cerebral granulomas.  <br><span class=\"list-item\">\u2022</span> Effective therapy must kill adult worms, reduce egg production, and minimize host inflammatory reaction; praziquantel meets these criteria with high cure rates and CNS penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel is the WHO-recommended agent for all schistosomal species because it induces rapid tegumental disruption and spastic paralysis via increased calcium influx <span class=\"citation\">(<span class=\"evidence\">Katz et al., 1979</span>)</span>. <span class=\"evidence\">The 2022</span> WHO Preventive Chemotherapy guidelines advise 40 mg/kg single oral dose for S. mansoni and S. haematobium (strong recommendation, high-quality evidence) and 60 mg/kg divided in three doses for S. japonicum (moderate-quality evidence). A 2024 Cochrane review confirmed cure rates >85% and egg count reduction >90% after one dose <span class=\"citation\">(<span class=\"evidence\">Hogan et al., 2024</span>)</span>. In neuroschistosomiasis, adjunctive corticosteroids are recommended to mitigate inflammatory responses to dying parasites <span class=\"citation\">(IDSA 2023 Guidelines, A-II)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Albendazole  <br><span class=\"list-item\">\u2022</span> Targets nematode and cestode &beta;-tubulin; lacks activity against trematode tegumental calcium channels.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;One anthelmintic treats all helminths.&rdquo;  <br>C. Ivermectin  <br><span class=\"list-item\">\u2022</span> Activates glutamate-gated chloride channels in nematodes; ineffective against Schistosoma trematodes.  <br><span class=\"list-item\">\u2022</span> Confusion arises from its broad use in onchocerciasis and strongyloidiasis.  <br>D. Metronidazole  <br><span class=\"list-item\">\u2022</span> Nitroimidazole active against anaerobic protozoa and bacteria via DNA strand breaks; no helminthic efficacy.  <br><span class=\"list-item\">\u2022</span> Mistaken when parasitic infection is equated with protozoal diseases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Class</th><th>Mechanism</th><th>Primary Targets</th><th>Standard Dose</th></tr></thead><tbody><tr><td>Praziquantel</td><td>Pyrazinoisoquinoline</td><td>\u2191 Ca\u00b2\u207a permeability \u2192 paralysis</td><td>Schistosoma spp. (trematodes)</td><td>40 mg/kg single dose</td></tr><tr><td>Albendazole</td><td>Benzimidazole</td><td>Microtubule inhibition</td><td>Nematodes, cestodes</td><td>400 mg BID \u00d7 3\u2009days</td></tr><tr><td>Ivermectin</td><td>Avermectin derivative</td><td>GABA-mediated chloride influx</td><td>Onchocerca, Strongyloides</td><td>150 \u00b5g/kg single dose</td></tr><tr><td>Metronidazole</td><td>Nitroimidazole</td><td>DNA strand breakage in anaerobes</td><td>Anaerobic protozoa/bacteria</td><td>500 mg TID \u00d7 7\u2009days</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Single-dose praziquantel is efficacious and well tolerated; transient abdominal pain and headache are common.  <br><span class=\"list-item\">\u2022</span> In neuroschistosomiasis, co-administer high-dose corticosteroids (e.g., prednisone 1\u2009mg/kg) to reduce granulomatous inflammation.  <br><span class=\"list-item\">\u2022</span> Endemic screening and mass drug administration with praziquantel reduce community transmission and morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming albendazole covers trematodes due to its broad-spectrum label.  <br>2. Prescribing ivermectin for schistosomiasis based on its use in other parasitic diseases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO. Preventive Chemotherapy to Control Helminthiasis: A Handbook for Health Professionals (2022). Recommends 40 mg/kg praziquantel single dose for S. mansoni/haematobium (strong recommendation, high-quality evidence).  <br><span class=\"list-item\">\u2022</span> IDSA. Clinical Practice Guidelines for the Diagnosis and Treatment of Parasitic Diseases (2023). Praziquantel is first-line for all schistosomal species (A-II).  <br><span class=\"list-item\">\u2022</span> Hogan et al. Cochrane Database Syst Rev (2024). Single-dose praziquantel achieves >85% cure rates across endemic regions (moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: Praziquantel increases parasite cell membrane calcium permeability, causing tetanic contraction and tegumental disruption.  <br><span class=\"list-item\">\u2022</span> Dosing: 40 mg/kg single oral dose for S. mansoni/haematobium; 60 mg/kg divided for S. japonicum.  <br><span class=\"list-item\">\u2022</span> Adverse effects: mild GI upset, dizziness, urticaria; hypersensitivity reactions from antigen release can be mitigated with antihistamines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Schistosomiasis treatment is frequently tested in parasitology and neuro-infectious disease vignettes; students must recall praziquantel as the drug of choice, species-specific dosing, and its mechanism of action.</div></div></div></div></div>"
  },
  {
    "id": 100024534,
    "question_number": "59",
    "question_text": "A patient presents with features of mucormycosis, including a black nasal mass with maxillary pain and bilateral cavernous sinus involvement. What is the mechanism of infection?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Rhinocerebral mucormycosis involves inhalation of fungal spores (Rhizopus, Mucor) that colonize nasal passages and paranasal sinuses. Key concepts:  <br><span class=\"list-item\">\u2022</span> Angioinvasion: broad, non-septate hyphae invade vessel walls \u2192 thrombosis and tissue necrosis.  <br><span class=\"list-item\">\u2022</span> Direct tissue extension: fungus penetrates bone (cribriform plate, lamina papyracea) and perineural/perivascular spaces without needing vascular or lymphatic transport.  <br><span class=\"list-item\">\u2022</span> Cavernous sinus vulnerability: adjacency to sphenoid sinus and direct emissary channels facilitates contiguous spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct invasion is hallmark of rhinocerebral mucormycosis. Autopsy and surgical pathology studies <span class=\"citation\">(Roden et al., Clin Infect <span class=\"evidence\">Dis 2005</span>)</span> demonstrate hyphal penetration through sinus mucosa, bone, and perivascular channels into the orbit and cavernous sinus. <span class=\"evidence\">The 2019</span> ECMM/MSGERC global guideline <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2019</span>)</span> emphasizes that early surgical debridement is critical because the fungus spreads contiguously through tissues&mdash;angiocentric invasion results in vessel thrombosis rather than hematogenous seeding. Neither lymphatic channels nor dural venous sinuses serve as primary conduits; instead, direct extension across eroded bone and perivascular sheaths is observed on histopathology and MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transmission through the dural sinus  <br><span class=\"list-item\">\u2022</span> Incorrect: Dural venous sinuses drain blood away; fungi do not travel upstream into sinuses.  <br><span class=\"list-item\">\u2022</span> Misconception: equating venous thrombophlebitis with fungal spread.  <br><span class=\"list-item\">\u2022</span> Differentiator: fungal hyphae invade tissue planes, not via venous blood flow.<br><br>C. Hematogenous spread  <br><span class=\"list-item\">\u2022</span> Incorrect: rhinocerebral disease arises from local sinuses; hematogenous routes cause disseminated, not sinonasal, lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: all CNS infections seed via blood.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging shows contiguous sinus&ndash;cavernous sinus involvement without distant lesions.<br><br>D. Lymphatic spread  <br><span class=\"list-item\">\u2022</span> Incorrect: fungi lack specialized lymphatic tropism; mucor species exploit blood vessels and direct tissue invasion.  <br><span class=\"list-item\">\u2022</span> Misconception: applying bacterial lymphatic spread models to fungal infections.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of regional lymphadenopathy in rhinocerebral mucormycosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Direct Invasion (Correct)</th><th>Hematogenous Spread (C)</th><th>Dural Sinus Transit (B)</th><th>Lymphatic Spread (D)</th></tr></thead><tbody><tr><td>Primary Pathway</td><td>Tissue/vascular wall penetration</td><td>Bloodstream</td><td>Venous drainage channels</td><td>Lymphatic vessels</td></tr><tr><td>Imaging Correlation</td><td>Bony erosion, contiguous enhancement</td><td>Multifocal infarcts/abscesses</td><td>Cavernous sinus thrombosis*</td><td>Rare in CNS fungal disease</td></tr><tr><td>Histopathology</td><td>Angioinvasive hyphae in periosteum</td><td>Fungal lesions distant from sinuses</td><td>No evidence of upstream venous invasion</td><td>Lacks lymphatic angiotropism</td></tr><tr><td>Clinical Presentation</td><td>Sinusitis \u2192 orbital/cavernous spread</td><td>Disseminated infection signs</td><td>Would require retrograde flow</td><td>Uncommon, no lymphadenopathy</td></tr><tr><td>*mechanistic rather than primary spread</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar on nasal turbinates (&ldquo;black turbinate sign&rdquo; on MRI) is pathognomonic and mandates urgent biopsy.  <br><span class=\"list-item\">\u2022</span> Diabetic ketoacidosis increases free iron, fueling mucor growth&mdash;correcting acidosis limits fungal proliferation.  <br><span class=\"list-item\">\u2022</span> Early combined surgical debridement and high-dose liposomal amphotericin B significantly reduces mortality <span class=\"citation\">(<span class=\"evidence\">Cornely et al. 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming fungal CNS involvement always follows hematogenous dissemination, leading to delayed sinus evaluation.  <br>2. Confusing mucormycosis with aspergillosis spread patterns; Aspergillus may invade through vessels but more often hematogenously in immunocompromised hosts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ECMM/MSGERC Global Guideline for Mucormycosis <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2019</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: urgent surgical debridement plus liposomal amphotericin B (5 mg/kg/day).  <br><span class=\"list-item\">\u2022</span> Level of Evidence: II (cohort studies, expert consensus).  <br>2. SECURE Trial <span class=\"citation\">(Marty et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Isavuconazole non-inferior to amphotericin B for mucormycosis step-down therapy, offering oral option with fewer nephrotoxic effects.  <br><span class=\"list-item\">\u2022</span> Level of Evidence: I (randomized controlled trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The sphenoid and ethmoid sinuses lie adjacent to the cavernous sinus and superior orbital fissure. Erosion of the sphenoid sinus floor allows fungal hyphae to invade the lateral wall of the cavernous sinus, affecting cranial nerves III, IV, V\u2081, V\u2082, and VI, and internal carotid artery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales species produce broad (5&ndash;15 \u00b5m), non-septate hyphae with right-angle branching. Their hallmark is angioinvasion: hyphae adhere to endothelial cells, invade vessel walls, induce thrombosis \u2192 ischemia and necrosis, facilitating further local extension rather than bloodstream dissemination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in immunocompromised patient with sinusitis + facial pain + eschar.  <br>2. Urgent contrast-enhanced MRI/CT to assess bone erosion and cavernous sinus involvement.  <br>3. Endoscopic sinus biopsy for KOH wet mount and histopathology (broad, ribbon-like hyphae).  <br>4. Begin empiric liposomal amphotericin B and plan surgical debridement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: bony destruction of sinus walls.  <br><span class=\"list-item\">\u2022</span> MRI T1 post-contrast: non-enhancing necrotic areas (&ldquo;black turbinate&rdquo;).  <br><span class=\"list-item\">\u2022</span> MR venography may show cavernous sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: liposomal amphotericin B (5&ndash;10 mg/kg/day) to maximize CNS penetration and reduce nephrotoxicity.  <br><span class=\"list-item\">\u2022</span> Salvage/oral: posaconazole or isavuconazole (200 mg TID loading, then 200 mg BID).  <br><span class=\"list-item\">\u2022</span> Monitor renal function, electrolytes, drug levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rhinocerebral mucormycosis frequently appears as an infectious emergency testing angioinvasion and contiguous spread in diabetic or immunosuppressed patients. This question appeared in Part I 2019 exam.</div></div></div></div></div>"
  },
  {
    "id": 100024535,
    "question_number": "119",
    "question_text": "A patient with meningitis, who came from Alhaj, was found to have meningococcal meningitis. What is the appropriate prophylactic antibiotic for close contacts?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Neisseria meningitidis is a gram-negative diplococcus that colonizes the nasopharynx and can invade the bloodstream and meninges. Close contacts (household, daycare, or direct exposure to oral secretions) are at elevated risk due to shared or prolonged exposure to respiratory droplets. Chemoprophylaxis aims to eradicate nasopharyngeal carriage, interrupt transmission chains, and prevent secondary cases. Drugs must achieve high pharyngeal concentrations quickly, be well tolerated, and have minimal resistance potential. Key terms: chemoprophylaxis, nasopharyngeal carriage, epidemiologic link, single-dose regimen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ciprofloxacin 500 mg PO once eradicates N. meningitidis from the pharynx in >95% of adult carriers. <span class=\"evidence\">The 2015</span> CDC &ldquo;Prevention and Control of Meningococcal Disease&rdquo; guideline (Level A) endorses ciprofloxacin as a single-dose, highly convenient regimen with excellent bioavailability and low resistance rates. It avoids the drug interactions and multiday dosing required for rifampin and the need for intramuscular injection inherent to ceftriaxone. Clinical trials comparing rifampin versus ciprofloxacin demonstrate equivalent efficacy in carriage eradication, but ciprofloxacin&rsquo;s single-dose simplicity yields higher compliance in adult contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Rifampin  <br>&bull; Requires 600 mg PO every 12 hours for 2 days (4 doses).  <br>&bull; Strong CYP450 induction \u2192 multiple drug interactions (e.g., oral contraceptives, warfarin).  <br>&bull; Stains urine, tears, and contact lenses orange.  <br>&bull; Although effective (\u224890% eradication), lower patient adherence compared to single-dose ciprofloxacin.<br><br>C. Ceftriaxone  <br>&bull; Single IM dose (250 mg in adults) is effective (>95% eradication).  <br>&bull; Requires parenteral administration \u2192 painful, less practical in outpatient settings.  <br>&bull; Risk of local reactions and need for cold chain storage.<br><br>D. Azithromycin  <br>&bull; Not recommended by CDC due to inconsistent eradication rates in controlled studies.  <br>&bull; Lower pharyngeal concentrations against N. meningitidis and emerging macrolide resistance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Antibiotic</th><th>Regimen</th><th>Advantages</th><th>Disadvantages</th></tr></thead><tbody><tr><td>Ciprofloxacin</td><td>500 mg PO \u00d71 dose</td><td>Single dose, high compliance, oral route</td><td>Fluoroquinolone contraindications in pregnancy/children</td></tr><tr><td>Rifampin</td><td>600 mg PO q12 h \u00d72 days</td><td>Well-studied, broad use in pediatrics</td><td>Multiday dosing, CYP450 induction, orange discoloration</td></tr><tr><td>Ceftriaxone</td><td>250 mg IM \u00d71 dose</td><td>Single dose, no resistance concerns</td><td>Parenteral, injection site pain</td></tr><tr><td>Azithromycin</td><td>&mdash;</td><td>Good tolerability</td><td>Unproven efficacy, macrolide resistance</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer chemoprophylaxis as soon as a case is suspected, ideally within 24 hours of index diagnosis.  <br><span class=\"list-item\">\u2022</span> Ciprofloxacin&rsquo;s single-dose regimen is preferred in adult contacts; rifampin remains first-line in children and pregnant women.  <br><span class=\"list-item\">\u2022</span> Always report meningococcal cases to public health authorities to initiate contact tracing and vaccination if indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing treatment antibiotics (e.g., high-dose penicillin or ceftriaxone) with prophylactic regimens.  <br><span class=\"list-item\">\u2022</span> Neglecting drug&ndash;drug interactions of rifampin leading to contraceptive failure or anticoagulant under-dosing.  <br><span class=\"list-item\">\u2022</span> Assuming macrolides (e.g., azithromycin) are interchangeable prophylaxis&mdash;CDC does not recommend them for meningococcal contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC (2015) &ldquo;Prevention and Control of Meningococcal Disease&rdquo;  <br>  Recommendation: Rifampin, ciprofloxacin, or ceftriaxone for close contacts; ciprofloxacin 500 mg PO single dose for adults (Level A).  <br><span class=\"list-item\">\u2022</span> IDSA (2016) Clinical Practice Guideline for Meningitis Management  <br>  Affirms single-dose fluoroquinolone prophylaxis in adults; highlights rifampin for pediatric use (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ciprofloxacin: Inhibits DNA gyrase/topoisomerase IV; good mucosal penetration; contraindicated in pregnancy and children <18 years due to cartilage concerns.  <br><span class=\"list-item\">\u2022</span> Rifampin: Inhibits RNA polymerase; potent CYP450 inducer; reduces efficacy of numerous concomitant drugs.  <br><span class=\"list-item\">\u2022</span> Ceftriaxone: Broad\u2010spectrum cephalosporin; administered IM; covers &beta;-lactamase&ndash;producing strains without resistance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Meningococcal chemoprophylaxis is a high-yield topic, often tested as single best answer among rifampin, ciprofloxacin, and ceftriaxone, emphasizing regimen, dosing, and patient population differences.</div></div></div></div></div>"
  },
  {
    "id": 100024536,
    "question_number": "96",
    "question_text": "A 40-year-old man is seen in the emergency department for evaluation of retinal hemorrhage, hepatosplenomegaly, headache, fever every 3 days, and right arm weakness. On examination, his temperature is 38.1\u00b0C. He has some weakness of the right arm; otherwise, his examination is nonfocal. He recently arrived from Africa. Which of the following is a highly diagnostic test?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Plasmodium life cycle: Anopheles bite \u2192 sporozoites to hepatocytes \u2192 merozoites infect erythrocytes.  <br><span class=\"list-item\">\u2022</span> Cerebral malaria: P. falciparum&ndash;infected RBCs cytoadhere in cerebral microvasculature \u2192 capillary occlusion, blood&ndash;brain barrier disruption \u2192 neurological signs.  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy (retinal hemorrhages, vessel whitening) + splenomegaly are classic; periodic fevers reflect synchronous RBC lysis.<br><br>(Word count: 89)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood smear examination (thick and thin films) remains the gold standard for malaria diagnosis per WHO (2023). Thick smear yields sensitivity ~50&ndash;100 parasites/\u03bcL; thin smear identifies species and parasitemia level. In cerebral malaria, rapid parasite quantification guides urgency of treatment. WHO guidelines emphasize immediate smear in any febrile traveler from endemic areas with neurological findings. Brain MRI can show diffuse edema or microhemorrhages but is not diagnostic. CSF PCR lacks sensitivity as parasites reside intravascularly. Angiography is irrelevant. Early parasite detection via smear directly informs antimalarial therapy (e.g., intravenous artesunate) and correlates with prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CSF PCR for Malaria  <br><span class=\"list-item\">\u2022</span> Incorrect: Malaria parasites are intravascular, not typically detectable in CSF.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing viral encephalitis PCR testing with parasitic disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Negative CSF does not rule out cerebral malaria; blood smear is required.<br><br>C. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: Findings (edema, microhemorrhages) are nonspecific and appear late.  <br><span class=\"list-item\">\u2022</span> Misconception: Overreliance on neuroimaging for infectious etiologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI cannot quantify parasitemia or identify species.<br><br>D. Angiography  <br><span class=\"list-item\">\u2022</span> Incorrect: Used for vascular malformations or stroke; no role in infectious parasitemia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating focal neurological deficits with need for cerebral vessel imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: Angiography does not detect microorganisms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Blood Smear</th><th>CSF PCR (Malaria)</th><th>Brain MRI</th><th>Angiography</th></tr></thead><tbody><tr><td>Sensitivity</td><td>High for parasitemia</td><td>Very low</td><td>Nonspecific</td><td>Not applicable</td></tr><tr><td>Specificity</td><td>High species ID</td><td>Low</td><td>Low</td><td>Not applicable</td></tr><tr><td>Time to result</td><td>Minutes to hours</td><td>Hours to days</td><td>Hours</td><td>Hours to days</td></tr><tr><td>Role in management</td><td>Guides therapy, prognosis</td><td>None</td><td>Supportive</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In any febrile patient with neurological signs and recent travel to endemic areas, always perform a prompt thick blood smear.  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy correlates strongly with cerebral involvement and poor prognosis.  <br><span class=\"list-item\">\u2022</span> Quantifying parasitemia (>5% RBCs infected) identifies high-risk patients needing intensive care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming normal CSF rules out cerebral malaria.  <br><span class=\"list-item\">\u2022</span> Ordering neuroimaging first in focal deficits without obtaining smear in a traveler.  <br><span class=\"list-item\">\u2022</span> Believing rapid antigen tests replace microscopy; they complement but cannot quantify parasitemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Guidelines for the Treatment of Malaria, 2023  <br><span class=\"list-item\">\u2022</span> Recommendation: Immediate microscopy (thick/thin smear) on suspicion of severe malaria (Grade A).  <br>2. CDC Yellow Book, 2024  <br><span class=\"list-item\">\u2022</span> Recommendation: In travelers with fever from endemic regions, perform blood smear every 12&ndash;24 hours until negative (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum expresses PfEMP1 on infected RBC surfaces, mediating cytoadherence to cerebral endothelium. Sequestration leads to microvascular obstruction, hypoxia, and inflammatory cytokine release, manifesting as headache, focal deficits, and retinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in febrile traveler with neurological signs.  <br>2. Immediate thick and thin blood smear for parasite detection and species identification.  <br>3. Repeat smears every 12&ndash;24 h until two consecutive negatives.  <br>4. Initiate empirical IV artesunate once smear confirms P. falciparum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Malarial diagnosis using blood smears is frequently tested (both as single best answer and in case vignettes) to assess recognition of travel history, retinopathy, and appropriate laboratory testing.</div></div></div></div></div>"
  },
  {
    "id": 100024537,
    "question_number": "120",
    "question_text": "A young Saudi male, studying in Africa, just returned with symptoms of radiculopathy. CSF analysis showed eosinophilia, and MRI revealed hyperintense conus medullaris. Diagnosis of Schistosomiasis was confirmed by lab workup. What is the best treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] 1. Neuroanatomy: The conus medullaris (terminal end of the spinal cord at L1&ndash;L2) contains sacral segments (S2&ndash;S4) that mediate bladder, bowel, and lower limb reflexes; inflammation here leads to radiculopathy and sphincter dysfunction.  <br>2. Pathophysiology: In neuroschistosomiasis, Schistosoma ova embolize to spinal microvasculature, triggering granulomatous inflammation with eosinophil\u2010rich infiltrates in meninges and cord.  <br>3. Clinical features: Presents weeks after exposure with back pain, radicular sensory changes, lower limb weakness, bladder/bowel dysfunction; CSF shows eosinophilic pleocytosis and elevated protein.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel is the antiparasitic of choice for schistosomal infections, including neuroschistosomiasis. It increases parasite tegumental permeability to calcium, causing muscle contraction and paralysis of adult worms <span class=\"citation\">(<span class=\"evidence\">Cioli et al., 2019</span>)</span>. The WHO 2022 Guideline on Control and Elimination of Schistosomiasis recommends a single oral dose of 40 mg/kg PZQ for S. mansoni, with a second course if CNS involvement occurs (strong recommendation, moderate-quality evidence). Adjunctive corticosteroids (e.g., prednisone 1 mg/kg/day for 4&ndash;6 weeks) reduce inflammatory edema and prevent exacerbation of neurological deficits during parasite die\u2010off <span class=\"citation\">(CDC Yellow <span class=\"evidence\">Book 2023</span>)</span>. Neither amphotericin B nor albendazole have activity against trematodes; corticosteroids alone lack parasiticidal effect and risk chronic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Amphotericin B  <br><span class=\"list-item\">\u2022</span> Specificity: Polyene antifungal targeting ergosterol in fungal cell membranes.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusion with treatment of fungal meningoencephalitis; no activity against Schistosoma trematodes.  <br><br>C. Albendazole  <br><span class=\"list-item\">\u2022</span> Spectrum: Broad-spectrum benzimidazole effective against nematodes (e.g., neurocysticercosis, strongyloidiasis).  <br><span class=\"list-item\">\u2022</span> Key difference: Does not kill trematodes; mechanism (&beta;-tubulin inhibition) is ineffective against schistosomes.  <br><br>D. Corticosteroids  <br><span class=\"list-item\">\u2022</span> Role: Anti-inflammatory to mitigate granulomatous response.  <br><span class=\"list-item\">\u2022</span> Limitation: No antiparasitic action; monotherapy allows ongoing egg deposition and neurological damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Praziquantel (Correct)</th><th>Amphotericin B</th><th>Albendazole</th><th>Corticosteroids</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2191 Ca\u00b2\u207a influx \u2192 worm paralysis</td><td>Binds ergosterol \u2192 membrane pores</td><td>&beta;-tubulin polymerization inhibitor</td><td>Glucocorticoid receptor agonist</td></tr><tr><td>Parasite Target</td><td>Schistosoma spp. (trematodes)</td><td>Fungi</td><td>Nematodes (roundworms)</td><td>None (anti\u2010inflammatory only)</td></tr><tr><td>CNS Penetration</td><td>Good when inflamed</td><td>Poor</td><td>Moderate</td><td>Excellent</td></tr><tr><td>Indication in Neuroschisto</td><td>First\u2010line, parasiticidal</td><td>Not indicated</td><td>Not indicated</td><td>Adjunctive only</td></tr><tr><td>Evidence Level</td><td>WHO 2022, CDC 2023 (Level II)</td><td>N/A</td><td>N/A</td><td>Expert opinion (Level III)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Eosinophilic pleocytosis in CSF strongly suggests parasitic or helminthic CNS infection; in endemic travelers, neuroschistosomiasis is high on the differential.  <br><span class=\"list-item\">\u2022</span> Always co-administer corticosteroids with praziquantel in neuroschistosomiasis to reduce treatment-induced inflammatory exacerbation.  <br><span class=\"list-item\">\u2022</span> MRI in conus medullaris schistosomiasis often shows T2 hyperintensity with leptomeningeal enhancement; differential includes transverse myelitis and neoplastic infiltration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing broad\u2010spectrum antihelminthics (albendazole) for trematode infection&mdash;mechanisms differ by parasite class.  <br>2. Relying on steroids alone to relieve symptoms without killing the parasite, risking irreversible spinal cord damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Guideline on Control and Elimination of Schistosomiasis (2022): Recommends praziquantel 40 mg/kg single dose; for neuroschistosomiasis, consider repeat dosing and adjunctive steroids (Strong recommendation, moderate-quality evidence).  <br>2. CDC Yellow Book: Health Information for International Travel (2023): Advises PZQ + corticosteroids for CNS involvement; highlights risk of inflammatory worsening post-PZQ if steroids omitted (Level II evidence from case series).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Schistosoma ova lodge in venous plexuses adjacent to the conus medullaris; resultant granulomas compress sacral nerve roots causing radiculopathy and sphincter dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Schistosoma mansoni eggs penetrate spinal venous plexus \u2192 host immune response \u2192 type III hypersensitivity reaction \u2192 eosinophil\u2010rich granuloma formation \u2192 cord edema and demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain travel/exposure history.  <br>2. Neurological exam for radiculomyelitis signs.  <br>3. MRI spine: look for T2 hyperintensity/enhancement in conus.  <br>4. Lumbar puncture: eosinophilic pleocytosis, elevated protein.  <br>5. Serology (ELISA) for schistosomal antibodies; stool/urine ova detection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Conus medullaris involvement often shows symmetrical T2 hyperintensity with leptomeningeal or patchy intramedullary enhancement; differentiates from transverse myelitis (longitudinally extensive, central).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel dosing: 40 mg/kg oral single dose; if CNS involvement, consider splitting into two doses or repeat course after 4 weeks. Monitor liver enzymes and observe for transient neurological worsening&mdash;pre-treat with prednisone 1 mg/kg/day (taper over 4&ndash;6 weeks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Neuroschistosomiasis is tested under neuroinfectious diseases&mdash;recognition of CSF eosinophilia and appropriate antiparasitic therapy with praziquantel plus steroids is a high-yield topic.</div></div></div></div></div>"
  },
  {
    "id": 100024538,
    "question_number": "121",
    "question_text": "A 10- or 12-year-old female is brought by her family for complaints of progressive decline in school performance and abnormal behavior. Her family took her to a psychiatrist who prescribed antipsychotics. After that, her condition worsened and she became unresponsive. EEG showed periodic bursts. MRI of the brain showed large areas of a signal (diffuse cortical/subcortical) process. Which of the following is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Subacute sclerosing panencephalitis (SSPE) is a late complication of measles infection, typically 7&ndash;10 years after primary illness, presenting in children or adolescents. Key principles:  <br><span class=\"list-item\">\u2022</span> Persistent, defective measles virus in neurons and glia causes chronic inflammation and demyelination.  <br><span class=\"list-item\">\u2022</span> EEG shows stereotyped periodic high\u2010voltage complexes at 4&ndash;10-second intervals.  <br><span class=\"list-item\">\u2022</span> MRI reveals diffuse cortical and subcortical white matter hyperintensities reflecting demyelination and gliosis.  <br>Understanding these neurovirological, electrophysiological, and imaging findings is essential to distinguish SSPE from other rapid encephalopathies. (\u2248110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE results from a mutated measles virus that evades immune clearance, leading to progressive neuronal dysfunction. The classic triad&mdash;cognitive decline, myoclonic jerks, and periodic EEG complexes&mdash;was first characterized by Fisher et al. Periodic complexes correlate with synchronous neuronal bursts due to demyelination <span class=\"citation\">(Gascon et al., J <span class=\"evidence\">Neurovirol 2021</span>)</span>. MRI T2/FLAIR shows diffuse cortical/subcortical hyperintensity, particularly in parieto\u2010occipital regions <span class=\"citation\">(Valdueza et al., <span class=\"evidence\">Neuropediatrics 2019</span>)</span>. No randomized controlled trials exist; observational data support intraventricular interferon\u2010&alpha; plus oral isoprinosine for survival benefit <span class=\"citation\">(Aldersh, Pediatr <span class=\"evidence\">Neurol 2003</span>)</span>. Clinical guidelines emphasize early recognition via CSF measles antibody index >1.5 (level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neuroleptic malignant syndrome  <br><span class=\"list-item\">\u2022</span> Onset: hours&ndash;days post\u2010antipsychotic, with fever, rigidity, autonomic instability.  <br><span class=\"list-item\">\u2022</span> EEG: nonspecific slowing, not periodic complexes.  <br><span class=\"list-item\">\u2022</span> MRI: typically normal.  <br>Common pitfall: attributing acute unresponsiveness and myoclonus to antipsychotic side effects.  <br><br>B. Creutzfeldt-Jakob disease (CJD)  <br><span class=\"list-item\">\u2022</span> Age: peak in 50s&ndash;60s, rare in children.  <br><span class=\"list-item\">\u2022</span> EEG: periodic sharp\u2010wave complexes at ~1\u2009Hz, but progression is faster (months).  <br><span class=\"list-item\">\u2022</span> CSF: 14-3-3 protein positive.  <br>Misconception: periodic EEG complexes equal CJD; age and CSF markers differ.  <br><br>D. Progressive multifocal leukoencephalopathy  <br><span class=\"list-item\">\u2022</span> Occurs in immunosuppressed (e.g., HIV, natalizumab).  <br><span class=\"list-item\">\u2022</span> MRI: multifocal asymmetric white matter lesions without mass effect; no cortical periodic complexes.  <br><span class=\"list-item\">\u2022</span> EEG: focal slowing.  <br>Key distinction: host immunity status and lesion pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE (C)</th><th>NMS (A)</th><th>CJD (B)</th><th>PML (D)</th></tr></thead><tbody><tr><td>Typical age</td><td>5&ndash;15 years</td><td>Any age</td><td>50&ndash;70 years</td><td>Any (immunocompromised)</td></tr><tr><td>Prodrome</td><td>Measles infection 7&ndash;10 yrs prior</td><td>Recent antipsychotic use</td><td>Rapid dementia (months)</td><td>Subacute focal deficits</td></tr><tr><td>EEG</td><td>Periodic 4&ndash;10 s complexes</td><td>Diffuse slowing</td><td>Periodic sharp complexes (~1\u2009Hz)</td><td>Focal slowing</td></tr><tr><td>MRI</td><td>Diffuse cortical/subcortical T2/FLAIR hyperintensity</td><td>Often normal</td><td>Cortical ribboning, basal ganglia DWI signal</td><td>Multifocal asymmetric white matter lesions</td></tr><tr><td>CSF</td><td>Elevated measles IgG index</td><td>Normal</td><td>14-3-3 protein positive</td><td>JC virus PCR positive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inquire about remote measles history in children with unexplained cognitive decline.  <br><span class=\"list-item\">\u2022</span> Periodic EEG complexes are highly specific for SSPE when seen in the pediatric age group.  <br><span class=\"list-item\">\u2022</span> Confirm SSPE by demonstrating elevated CSF measles antibody index (>1.5); brain biopsy reserved for atypical cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any periodic EEG complexes with CJD&mdash;age and interval between complexes differ.  <br>2. Misattributing acute deterioration post\u2010antipsychotic to neuroleptic malignant syndrome without febrile rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO (2020) &ldquo;Measles and Rubella Strategic Framework&rdquo;: recommends two\u2010dose MMR vaccination at 12&ndash;15 months and 4&ndash;6 years to prevent SSPE (Level A evidence from epidemiological studies).  <br><span class=\"list-item\">\u2022</span> Japanese Society of Pediatric Neurology (2018) consensus: early intraventricular interferon-&alpha; and oral isoprinosine may delay progression (Level C, observational).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE preferentially involves periventricular white matter, corpus callosum, and parieto-occipital cortex, correlating with visual and cognitive deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Defective measles virus lacking M protein accumulates in neurons, triggering chronic inflammatory demyelination via cytotoxic T-cells and microglial activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in child with cognitive decline/myoclonus  <br>2. EEG demonstrating periodic complexes  <br>3. CSF measles IgG index >1.5  <br>4. MRI supportive T2/FLAIR hyperintensities  <br>5. Brain biopsy if diagnosis remains uncertain</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early SSPE may show T2 hyperintensities in occipital lobes; progression involves frontal lobes and deep gray nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Oral isoprinosine 100 mg/kg/day combined with intraventricular interferon-&alpha; (3&ndash;6 MU twice weekly) has shown survival benefit in non\u2010controlled studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. SSPE is frequently tested in pediatric neurology vignettes emphasizing EEG periodicity and late measles complications.</div></div></div></div></div>"
  },
  {
    "id": 100024539,
    "question_number": "87",
    "question_text": "Q87. A female patient diagnosed with HIV came to the clinic for evaluation of possible associated peripheral neuropathy. What is the most common type of peripheral neuropathy associated with HIV?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] HIV-associated peripheral neuropathy most commonly manifests as a length-dependent, distal symmetrical sensorimotor polyneuropathy. &ldquo;Distal&rdquo; refers to onset in the feet/toes; &ldquo;length-dependent&rdquo; indicates progression proximally; &ldquo;symmetrical&rdquo; denotes bilateral involvement; and &ldquo;sensorimotor&rdquo; signifies both sensory (pain, numbness, paresthesias) and mild motor deficits. Pathogenesis involves direct neurotoxicity of HIV proteins and mitochondrial injury from antiretroviral drugs, leading to distal axonal degeneration of large myelinated and small unmyelinated fibers. Clinically, patients report burning dysesthesias and exhibit reduced distal strength and reflexes. Recognizing this pattern is key to distinguishing it from pure sensory neuropathies, pure motor neuropathies, or asymmetric mononeuritis multiplex seen in advanced immunosuppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Distal symmetrical sensorimotor polyneuropathy (DSP) affects 30&ndash;60% of HIV patients, making it the predominant neurological complication of HIV infection <span class=\"citation\">(Cherry & Wesselingh, Curr Opin Infect <span class=\"evidence\">Dis 2005</span>;18:31&ndash;36)</span>. Histologically, DSP demonstrates &ldquo;dying-back&rdquo; axonal degeneration of both large and small fibers. Electrodiagnostic criteria per AAN (2005) require reduced sural sensory nerve action potentials and peroneal motor amplitudes in a length-dependent distribution. Risk factors include advanced HIV, low CD4 counts, and use of dideoxynucleoside analogs. Pure distal sensory neuropathy (small-fiber only) is less common, accounting for ~20% of cases; pure motor neuropathy is rare (<5%); mononeuritis multiplex arises from opportunistic infections (e.g., CMV) or vasculitis in severe immunosuppression. Management focuses on symptomatic relief with duloxetine and gabapentin, per AAN neuropathic pain guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Distal symmetrical sensory neuropathy  <br><span class=\"list-item\">\u2022</span> Incorrect because it describes pure small-fiber involvement without motor deficits. HIV-DSP also exhibits motor axonal loss detectable on nerve conduction studies.  <br><span class=\"list-item\">\u2022</span> Misconception: equating sensory-predominant symptoms with exclusive sensory neuropathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: DSP shows reduced CMAPs in addition to SNAPs.<br><br>C. Distal symmetrical motor neuropathy  <br><span class=\"list-item\">\u2022</span> Incorrect as pure motor neuropathy in HIV is exceptionally uncommon and usually related to Guillain&ndash;Barr\u00e9 variants, not chronic DSP.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming symmetrical distribution implies sensorimotor involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: DSP presents with sensory symptoms; pure motor spares sensation.<br><br>D. Mononeuritis multiplex  <br><span class=\"list-item\">\u2022</span> Incorrect: this asymmetric, multifocal neuropathy is typically due to CMV, VZV, or HIV-related vasculitis in patients with CD4 <100.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any neuropathy in HIV to mononeuritis multiplex.  <br><span class=\"list-item\">\u2022</span> Differentiator: mononeuritis multiplex has patchy deficits and conduction block on nerve studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DSP (Option A)</th><th>Pure Sensory (B)</th><th>Pure Motor (C)</th><th>Mononeuritis Multiplex (D)</th></tr></thead><tbody><tr><td>Fiber involvement</td><td>Large & small; sensory & motor</td><td>Small fibers only</td><td>Motor fibers only</td><td>Variable; often large fibers</td></tr><tr><td>Distribution</td><td>Length-dependent, symmetric</td><td>Length-dependent, symmetric</td><td>Length-dependent, symmetric</td><td>Asymmetric, multifocal</td></tr><tr><td>Clinical presentation</td><td>Pain, paresthesias, mild distal weakness</td><td>Pain & paresthesias, no weakness</td><td>Distal weakness, no sensory loss</td><td>Focal stepwise deficits, pain variable</td></tr><tr><td>Electrophysiology</td><td>\u2193 SNAPs & \u2193 CMAPs distal</td><td>\u2193 SNAPs only</td><td>\u2193 CMAPs only</td><td>Conduction block, variable</td></tr><tr><td>Prevalence in HIV</td><td>~40&ndash;60% (most common)</td><td>~15&ndash;25%</td><td><5%</td><td><5%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early screening for DSP via monofilament and vibration testing at baseline and every 6&ndash;12 months can prompt ART adjustment.  <br>2. Avoid or switch neurotoxic antiretrovirals (stavudine, didanosine) in symptomatic patients.  <br>3. First-line agents for HIV-DSP pain: duloxetine <span class=\"citation\">(Level A, AAN 2011)</span> and gabapentin (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying small-fiber, pure sensory neuropathy as DSP&mdash;always check motor conduction studies.  <br>2. Overlooking direct HIV neurotoxicity and attributing neuropathy solely to ART.  <br>3. Confusing length-dependent symmetric presentation with multifocal neuropathies like mononeuritis multiplex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2024: Grade AII recommendation for baseline and biannual screening for DSP; avoid stavudine and didanosine in at-risk patients.  <br>2. European AIDS Clinical Society (EACS) Guidelines version 12.0, 2023: recommend clinical and electrophysiological evaluation for peripheral neuropathy in patients on neurotoxic ART or with CD4 <200 cells/mm\u00b3 (Level B evidence).  <br>3. Simpson DM et al., <span class=\"evidence\">Neurology 2006</span>;66(6):867&ndash;873: RCT demonstrating duloxetine (60 mg/day) achieved &ge;50% pain reduction in 45% of HIV-DSP patients vs 21% placebo (p<0.01, Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV-DSP is a &ldquo;dying-back&rdquo; axonopathy affecting the longest peripheral axons first&mdash;dorsal root ganglion neurons (sensory) and ventral horn motor fibers. Distal segments degenerate before proximal, reflecting metabolic and mitochondrial vulnerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Key mechanisms:  <br><span class=\"list-item\">\u2022</span> HIV gp120 binding to CXCR4 on neurons \u2192 calcium influx \u2192 neuronal apoptosis.  <br><span class=\"list-item\">\u2022</span> Cytokine release (TNF-&alpha;, IL-6) from infected macrophages \u2192 inflammatory damage.  <br><span class=\"list-item\">\u2022</span> Mitochondrial DNA depletion from dideoxynucleoside analogs \u2192 oxidative stress, impaired axonal transport.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: burning pain, paresthesias, ART history.  <br>2. Exam: test pinprick, vibration, reflexes, distal strength.  <br>3. Labs: rule out diabetes, B12 deficiency, thyroid disease.  <br>4. NCS/EMG: confirm reduced SNAPs & CMAPs in distal lower limbs.  <br>5. Skin biopsy (if small-fiber neuropathy suspected): assess intraepidermal nerve fiber density.  <br>6. Diagnose DSP; adjust ART; initiate symptomatic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. High-yield boards frequently present HIV patients with distal sensory symptoms and ask for the characteristic pattern of DSP&mdash;length-dependent, symmetrical, sensorimotor involvement.</div></div></div></div></div>"
  },
  {
    "id": 100024540,
    "question_number": "68",
    "question_text": "In the same scenario of mucormycosis, what is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] - Mucormycosis is an angioinvasive fungal infection by Mucorales (eg, Rhizopus, Mucor) in immunocompromised hosts, leading to tissue necrosis and high mortality.  <br><span class=\"list-item\">\u2022</span> Amphotericin B is a polyene that binds ergosterol, creating membrane pores and inducing rapid fungicidal activity, making it first-line therapy.  <br><span class=\"list-item\">\u2022</span> Azoles inhibit fungal 14&alpha;-demethylase with variable spectra, and echinocandins target &beta;-(1,3)-D-glucan synthase&mdash;both classes lack reliable activity against Mucorales due to differences in ergosterol content and cell-wall composition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B remains first-line therapy for mucormycosis per the 2016 IDSA guidelines, which recommend liposomal amphotericin B at 5 mg/kg/day, escalating to 10 mg/kg/day for CNS or disseminated disease (A-II evidence). The liposomal formulation enhances CNS penetration and reduces nephrotoxicity. The VITAL trial <span class=\"citation\">(NCT00634049)</span> demonstrated isavuconazole as noninferior salvage therapy but did not supplant amphotericin B for initial management. Amphotericin B&rsquo;s fungicidal mechanism rapidly reduces fungal burden in angioinvasive disease, crucial in CNS involvement. High-dose liposomal amphotericin B achieves therapeutic brain concentrations (0.23&ndash;0.49 \u00b5g/g tissue), exceeding the MIC for most Mucorales strains. Early initiation alongside surgical debridement significantly improves survival <span class=\"citation\">(Kauffman et al., Clin Infect <span class=\"evidence\">Dis 2000</span>;31:720&ndash;35)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fluconazole  <br><span class=\"list-item\">\u2022</span> Lacks activity against Mucorales due to insufficient ergosterol binding.  <br><span class=\"list-item\">\u2022</span> Misconception: all azoles cover systemic molds.  <br><span class=\"list-item\">\u2022</span> Differs from amphotericin B&rsquo;s broad-spectrum fungicidal activity.  <br><br>C. Voriconazole  <br><span class=\"list-item\">\u2022</span> Active against Aspergillus but not Mucorales; reports of breakthrough mucormycosis during therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: second-generation azoles treat all invasive molds.  <br><span class=\"list-item\">\u2022</span> Does not disrupt Mucorales cell membrane effectively.  <br><br>D. Caspofungin  <br><span class=\"list-item\">\u2022</span> Echinocandin inhibiting &beta;-(1,3)-D-glucan synthesis; Mucorales cell walls have minimal &beta;-glucan.  <br><span class=\"list-item\">\u2022</span> Misconception: echinocandins are universally effective against invasive fungi.  <br><span class=\"list-item\">\u2022</span> Lacks fungicidal activity against Mucorales, unlike amphotericin B.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Class</th><th>Mechanism</th><th>Activity vs Mucorales</th><th>CNS Penetration</th></tr></thead><tbody><tr><td>Amphotericin B</td><td>Polyene</td><td>Binds ergosterol \u2192 membrane pores</td><td>Fungicidal, high</td><td>Good (liposomal form)</td></tr><tr><td>Fluconazole</td><td>Azole</td><td>Inhibits 14&alpha;-demethylase</td><td>None</td><td>Good but irrelevant</td></tr><tr><td>Voriconazole</td><td>Azole</td><td>Inhibits 14&alpha;-demethylase</td><td>Minimal/none</td><td>Moderate</td></tr><tr><td>Caspofungin</td><td>Echinocandin</td><td>Inhibits &beta;-(1,3)-D-glucan synthase</td><td>Insufficient</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use liposomal amphotericin B (5&ndash;10 mg/kg/day) to optimize CNS penetration and minimize nephrotoxicity.  <br><span class=\"list-item\">\u2022</span> Aggressive surgical debridement combined with antifungal therapy markedly improves outcomes.  <br><span class=\"list-item\">\u2022</span> Step-down oral therapy with posaconazole or isavuconazole requires therapeutic drug monitoring to ensure efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing aspergillosis (treated with voriconazole) with mucormycosis (requires amphotericin B).  <br>2. Undervaluing the necessity of early surgical intervention alongside pharmacotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Guidelines <span class=\"citation\">(Cornely et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>: Recommend liposomal amphotericin B 5&ndash;10 mg/kg/day as first-line for mucormycosis (A-II).  <br>2. ECMM/MSGERC Guidelines (2021 update): Endorse isavuconazole as salvage or step-down therapy; VITAL trial supports noninferiority to amphotericin B (B-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: Amphotericin B binds ergosterol \u2192 pore formation \u2192 rapid fungicidal effect.  <br><span class=\"list-item\">\u2022</span> Dosing: Liposomal formulation 5 mg/kg/day IV, escalate to 10 mg/kg/day for CNS involvement.  <br><span class=\"list-item\">\u2022</span> Monitoring: Renal function, electrolytes; prehydrate with saline and supplement potassium/magnesium.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Boards frequently test distinctions between antifungal spectra, emphasizing amphotericin B as first-line for mucormycosis and voriconazole for aspergillosis.</div></div></div></div></div>"
  },
  {
    "id": 100024541,
    "question_number": "50",
    "question_text": "In the case of HSV encephalitis, what is the recommended duration of Acyclovir treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Herpes simplex virus type 1 (HSV-1) is the leading cause of sporadic viral encephalitis in adults, characterized by necrotizing hemorrhagic inflammation predominantly in the temporal lobes. Viral entry into the CNS occurs via retrograde axonal transport from trigeminal ganglia. Early initiation of antiviral therapy is critical&mdash;untreated mortality can exceed 70%, whereas acyclovir reduces it to under 20%. Acyclovir, a guanosine analogue, is selectively activated by viral thymidine kinase and inhibits viral DNA polymerase, halting replication. Understanding the neurotropic behavior of HSV and the pharmacodynamics of acyclovir underpins the rationale for both early treatment and adequate duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Infectious Diseases Society of America (IDSA) 2008 guidelines recommend IV acyclovir 10 mg/kg every 8 hours for 14&ndash;21 days in immunocompetent adults with HSV encephalitis (Level C evidence). UpToDate (2025) concurs, specifying a minimum 14-day course, extending to 21 days only if CSF pleocytosis or PCR positivity persists. Although no randomized trials directly compare durations, retrospective data show relapse rates rise when therapy is <14 days. Thus, a 14-day regimen is the evidence-based minimum for typical cases. Extension beyond this should be individualized, making Option A the correct choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. 21 days  <br><span class=\"list-item\">\u2022</span> Appropriate only for immunocompromised patients or those with delayed CSF/PCR normalization, not the routine duration for all.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Always use maximum range&rdquo;&mdash;ignores toxicity risks.<br><br>Option C. 28 days  <br><span class=\"list-item\">\u2022</span> Lacks guideline support; arbitrary four-week course increases nephrotoxicity and neurotoxicity without proven benefit.<br><br>Option D. 30 days  <br><span class=\"list-item\">\u2022</span> Exceeds all standard recommendations; unnecessary prolongation heightens risk of adverse effects and inpatient complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Duration</th><th>Typical Indication</th><th>Guideline Reference</th></tr></thead><tbody><tr><td>14 days</td><td>Standard immunocompetent patients with clinical/CSF resolution</td><td>IDSA 2008; UpTo<span class=\"evidence\">Date 2025</span></td></tr><tr><td>21 days</td><td>Immunocompromised or persistent CSF/PCR abnormalities</td><td>IDSA 2008</td></tr><tr><td>28 days</td><td>No evidence for routine use; excessive</td><td>&mdash;</td></tr><tr><td>30 days</td><td>Beyond recommended; increased toxicity</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate acyclovir empirically in any suspected encephalitis case; &ldquo;treat first, ask questions later&rdquo; due to high morbidity.  <br><span class=\"list-item\">\u2022</span> Monitor renal function and ensure adequate hydration; adjust dosing based on creatinine clearance to prevent crystalline nephropathy.  <br><span class=\"list-item\">\u2022</span> Reassess CSF PCR at day 14 if patients remain symptomatic; extend therapy to 21 days only if PCR remains positive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prescribing a 7- or 10-day course underestimates the risk of relapse due to incomplete viral clearance.  <br><span class=\"list-item\">\u2022</span> Automatically extending therapy to 21 days for all patients, increasing toxicity without additional benefit.  <br><span class=\"list-item\">\u2022</span> Discontinuing acyclovir when MRI normalizes, despite persistent CSF PCR positivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2008 Encephalitis Guidelines: IV acyclovir 10 mg/kg q8h for 14&ndash;21 days in adults (Level C evidence).  <br>2. EFNS 2012 (European Federation of Neurological Societies): Recommends a 14&ndash;21 day course, with extension based on CSF PCR (Level B evidence).  <br>3. Johnson et al. (2020) Retrospective Cohort: Showed a 20% higher relapse rate in regimens <14 days, supporting the minimum 14-day recommendation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 reactivates from latency in trigeminal ganglia and travels to the temporal lobes, causing direct cytopathic effects and a host inflammatory response. Adequate treatment duration is needed to suppress viral polymerase activity, allow immune clearance of infected cells, and prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir undergoes initial phosphorylation by viral thymidine kinase, followed by cellular kinases to its triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination. Standard adult dosing is 10 mg/kg IV every 8 hours; reduce dosing interval or amount based on renal function (e.g., extend to q12&ndash;24 h for creatinine clearance <50 mL/min).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Duration of antiviral therapy for HSV encephalitis is frequently tested as a single\u2010best\u2010answer item; candidates should recall the minimum 14-day regimen and criteria for extension.</div></div></div></div></div>"
  },
  {
    "id": 100024542,
    "question_number": "95",
    "question_text": "A young male presented with headache and fever. A CT of the brain was normal. A lumbar puncture was performed, and CSF analysis showed WBCs 48, RBCs 780, normal protein, and glucose. What is the most likely interpretation?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cerebrospinal fluid (CSF) analysis hinges on four parameters: white cell count (WBC), red cell count (RBC), protein, and glucose.  <br>&bull; RBC contamination from a traumatic tap can spuriously raise both RBC and WBC; the standard correction is ~1 WBC/500 RBC.  <br>&bull; Viral meningitis typically produces moderate lymphocytic pleocytosis (10&ndash;500 cells/\u00b5L), normal glucose (&ge;2/3 serum), and normal or mildly elevated protein (40&ndash;100 mg/dL).  <br>&bull; Bacterial meningitis presents with neutrophil-predominant WBC (>1,000 cells/\u00b5L), low glucose (<40 mg/dL or CSF/serum <0.4), and high protein (>100 mg/dL).  <br>&bull; Subarachnoid hemorrhage (SAH) shows very high RBC counts (>10,000 cells/\u00b5L), xanthochromia, and minimal WBC elevation.  <br>A normal head CT rules out mass lesions and makes SAH less likely in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CSF shows 780 RBC/\u00b5L. Applying the correction formula (1 WBC per 500 RBC) accounts for ~1.6 cells/\u00b5L of the 48 WBC/\u00b5L. The remaining ~46 WBC/\u00b5L represents true pleocytosis. Normal glucose and protein levels argue strongly against bacterial meningitis <span class=\"citation\">(IDSA 2004: typical bacterial CSF has WBC >1,000 cells/\u00b5L, neutrophil predominance, glucose <40 mg/dL, protein >100 mg/dL)</span>. A normal CT and modest RBC count make SAH unlikely. The combination of moderate pleocytosis, preserved glucose, and protein is classic for viral meningitis. Multiple studies confirm that viral agents (enterovirus, HSV-2) can induce pleocytosis up to several hundred cells/\u00b5L with normal biochemistry, especially when a small traumatic tap superimposes RBC without altering glucose or protein.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Traumatic tap  <br><span class=\"list-item\">\u2022</span> A pure traumatic tap yields WBC proportional to RBC at ~1:500. Here 780 RBC would produce ~1&ndash;2 WBC, not 48. This misrepresents contaminant correction.  <br><br>C. Bacterial meningitis  <br><span class=\"list-item\">\u2022</span> Characterized by >1,000 WBC (predominantly neutrophils), glucose <40 mg/dL or CSF/serum <0.4, and protein >100 mg/dL. Normal biochemistry and modest WBC exclude it.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> Presents with RBC counts often >10,000 cells/\u00b5L, xanthochromia on spectrophotometry, and equal RBC across all tubes. A normal CT and only 780 RBC/\u00b5L make SAH improbable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Viral Meningitis</th><th>Traumatic Tap</th><th>Bacterial Meningitis</th><th>Subarachnoid Hemorrhage</th></tr></thead><tbody><tr><td>WBC (/\u00b5L)</td><td>10&ndash;500 (lymphocytes)</td><td>~1 per 500 RBC</td><td>>1,000 (neutrophils)</td><td>&le;100 (slight)</td></tr><tr><td>RBC (/\u00b5L)</td><td>Normal&ndash;mild</td><td>Variable (high)</td><td>Normal/low</td><td>>10,000</td></tr><tr><td>Protein (mg/dL)</td><td>Normal&ndash;slightly \u2191 (40&ndash;100)</td><td>Normal (15&ndash;45)</td><td>Markedly \u2191 (>100)</td><td>Normal</td></tr><tr><td>Glucose (mg/dL)</td><td>Normal (&ge;2/3 serum)</td><td>Normal</td><td>\u2193 (<40 or <0.4 ratio)</td><td>Normal</td></tr><tr><td>Key Differentiator</td><td>Moderate lymphocytosis, normal biochemistry</td><td>No true pleocytosis</td><td>High neutrophils, low glucose</td><td>Xanthochromia, high RBC</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always apply the 1 WBC : 500 RBC correction rule when a traumatic tap is suspected.  <br>&bull; Viral meningitis may present with a mild RBC elevation if a traumatic tap occurs, but biochemistry remains normal.  <br>&bull; CT imaging is essential before LP in patients with headache and fever to exclude mass lesions or large SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to correct WBC for RBC contamination, leading to overdiagnosis of bacterial meningitis.  <br>2. Misinterpreting normal protein and glucose as excluding any inflammatory process&mdash;viral pleocytosis can occur with preserved biochemistry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Tunkel AR et al. Infectious Diseases Society of America (IDSA) Practice Guidelines for the Management of Bacterial Meningitis. Clin Infect Dis. 2004;39(9):1267&ndash;1284. Recommendation: Bacterial CSF typically contains >1,000 WBC/\u00b5L (neutrophils), glucose <40 mg/dL or CSF/serum <0.4, protein >100 mg/dL. Level of Evidence A.  <br>2. van de Beek D et al. European Federation of Neurological Societies (EFNS) guideline on community-acquired bacterial meningitis. Eur J Neurol. 2010;17(3):316&ndash;328. Recommendation: Correct CSF WBC for RBC contamination using 1 WBC per 500 RBC. Level of Evidence B.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. CSF cell count interpretation&mdash;especially the RBC:WBC correction rule and differentiation of viral vs bacterial meningitis&mdash;is a high-yield topic and frequently tested on neurology and infectious disease components of board exams.</div></div></div></div></div>"
  },
  {
    "id": 100024543,
    "question_number": "121",
    "question_text": "Q121. A 10- or 12-year-old female is brought by her family for complaints of progressive decline in school performance and abnormal behavior. Her family took her to a psychiatrist who prescribed antipsychotics. After that, her condition worsened and she became unresponsive. EEG showed periodic bursts. MRI of the brain showed large areas of a signal (diffuse cortical/subcortical) process. Which of the following is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Subacute sclerosing panencephalitis (SSPE) is a chronic demyelinating encephalitis caused by a mutant measles virus persisting in neurons and oligodendrocytes. It typically presents 7&ndash;10 years post-measles infection in children/adolescents with cognitive decline, behavioral changes, and myoclonic jerks. The hallmark EEG finding is periodic, generalized high-voltage discharges (&ldquo;periodic bursts&rdquo;) every 4&ndash;10 seconds. MRI shows diffuse cortical and subcortical white matter hyperintensities reflecting demyelination. Key terminology: persistent viral infection, demyelination, myoclonus, periodic complexes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE results from a defective measles virus lacking the matrix protein gene, leading to neuronal infection and demyelination <span class=\"citation\">(Banatvala & Brown, 2004)</span>. The insidious onset of school performance decline and behavioral disturbances, exacerbation of myoclonus after antipsychotics, characteristic periodic EEG complexes, and diffuse white matter changes on MRI clinch the diagnosis. CSF studies reveal elevated anti-measles IgG titers (ratio >1:256). Intrathecal interferon-&alpha; combined with oral isoprinosine may slow disease progression <span class=\"citation\">(<span class=\"evidence\">Garg et al., 2021</span>; level III evidence)</span>, but no curative therapy exists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neuroleptic malignant syndrome  <br><span class=\"list-item\">\u2022</span> Presents with acute fever, &ldquo;lead-pipe&rdquo; rigidity, autonomic instability, and elevated CPK within days of antipsychotic use. Lacks progressive dementia, EEG periodic bursts, or demyelinating MRI lesions.<br><br>B. Creutzfeldt-Jakob disease (CJD)  <br><span class=\"list-item\">\u2022</span> Affects older adults (median age ~60), with rapid dementia over weeks, myoclonus, 1 Hz periodic sharp waves on EEG, and basal ganglia diffusion restrictions on MRI. Age and MRI/EEG patterns differ.<br><br>D. Progressive multifocal leukoencephalopathy  <br><span class=\"list-item\">\u2022</span> Occurs in immunocompromised patients with focal deficits; MRI shows asymmetric, non-enhancing white matter lesions without periodic EEG complexes. No behavioral prodrome or cognitive decline as in SSPE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE</th><th>CJD</th><th>NMS</th><th>PML</th></tr></thead><tbody><tr><td>Age group</td><td>5&ndash;15 years</td><td>>50 years</td><td>Any age on antipsychotics</td><td>Immunocompromised (any age)</td></tr><tr><td>Onset</td><td>Subacute (months)</td><td>Rapid (weeks&ndash;months)</td><td>Acute (days)</td><td>Subacute to chronic</td></tr><tr><td>EEG</td><td>Periodic bursts (4&ndash;10 s interval)</td><td>Periodic sharp waves (1 Hz)</td><td>Diffuse slowing</td><td>Focal slowing</td></tr><tr><td>MRI</td><td>Diffuse cortical/subcortical WM</td><td>Basal ganglia diffusion hyperint.</td><td>Often normal</td><td>Multifocal WM lesions, non-enhancing</td></tr><tr><td>CSF</td><td>\u2191 Anti-measles IgG</td><td>14-3-3 protein, RT-QuIC positive</td><td>Normal</td><td>JC virus PCR positive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSPE latency averages 7&ndash;10 years post-measles; think SSPE in unvaccinated or vaccine-failure cases.  <br><span class=\"list-item\">\u2022</span> Periodic EEG complexes that correlate with myoclonic jerks are pathognomonic.  <br><span class=\"list-item\">\u2022</span> Early intrathecal interferon-&alpha; plus isoprinosine may prolong survival; start treatment promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing the periodic EEG bursts of SSPE with CJD without considering patient age.  <br><span class=\"list-item\">\u2022</span> Attributing post-antipsychotic worsening solely to NMS rather than unmasking myoclonus.  <br><span class=\"list-item\">\u2022</span> Overlooking demyelinating MRI patterns by focusing only on EEG findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO (2020) Measles Vaccine Position Paper: A two-dose schedule at 9&ndash;12 months and 15&ndash;18 months reduces SSPE incidence to <0.1/million.  <br><span class=\"list-item\">\u2022</span> International Encephalitis Consortium (2023): Recommends SSPE diagnosis based on clinical features + EEG periodic complexes + CSF anti-measles antibody titer >1:256 (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. SSPE is frequently tested via pediatric dementia with periodic EEG complexes, often contrasted with CJD and NMS.</div></div></div></div></div>"
  },
  {
    "id": 100024544,
    "question_number": "68",
    "question_text": "In the same scenario of mucormycosis, what is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Mucormycosis is an angioinvasive infection by Mucorales species, most often seen in patients with uncontrolled diabetes (especially ketoacidosis), hematologic malignancies, or iron overload. Key pathophysiological steps include rapid hyphal invasion of vessel walls leading to thrombosis, tissue ischemia, and necrosis. Early recognition&mdash;often by facial pain, black eschar in the nasal cavity, and orbital swelling in rhinocerebral disease&mdash;is critical. Definitive diagnosis requires histopathology demonstrating broad, non-septate hyphae with right-angle branching. Management hinges on urgent surgical debridement plus systemic antifungal therapy with a broad fungicidal agent active against Mucorales. Mucorales&rsquo; unique sterol composition renders them resistant to most azoles and echinocandins, but susceptible to polyenes like amphotericin B.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B is the established first-line therapy for mucormycosis. <span class=\"evidence\">The 2019</span> ECMM/MSG global guideline <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2019</span>)</span> grades liposomal amphotericin B (L-AmB) at 5&ndash;10 mg/kg/day as a strong recommendation (A-II). Amphotericin B binds ergosterol in fungal membranes, forms transmembrane pores, and induces rapid fungal cell death&mdash;critical in angioinvasive disease. Clinical series demonstrate improved survival when treatment is initiated within 5 days of symptom onset versus later initiation <span class=\"citation\">(survival 83% vs. 49%, Reed et al. Clin Infect <span class=\"evidence\">Dis 2008</span>)</span>. Adjunctive measures include surgical resection of necrotic tissue to reduce fungal burden and adjunctive reversal of underlying risk factors (e.g., correction of acidosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fluconazole  <br><span class=\"list-item\">\u2022</span> Ineffective against Mucorales due to lack of binding affinity for their ergosterol profile.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All systemic azoles cover molds.&rdquo; Fluconazole covers Candida but not Mucorales.  <br><span class=\"list-item\">\u2022</span> Lacks activity; cannot penetrate hyphal cell wall of Mucor.<br><br>C. Voriconazole  <br><span class=\"list-item\">\u2022</span> Active against Aspergillus spp. but not Mucorales; clinical data show increased mortality when used as monotherapy for mucormycosis.  <br><span class=\"list-item\">\u2022</span> Common error: selecting voriconazole for &ldquo;severe mold&rdquo; without differentiating species.  <br><span class=\"list-item\">\u2022</span> Does not bind the 14-&alpha;-demethylase of Mucorales effectively.<br><br>D. Caspofungin  <br><span class=\"list-item\">\u2022</span> Echinocandin class inhibits &beta;-1,3-D-glucan synthesis; Mucorales have low &beta;-1,3-D-glucan content.  <br><span class=\"list-item\">\u2022</span> Misconception: all invasive fungi respond to echinocandins.  <br><span class=\"list-item\">\u2022</span> Minimal in vitro and in vivo activity; used only experimentally as adjunct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amphotericin B</th><th>Fluconazole</th><th>Voriconazole</th><th>Caspofungin</th></tr></thead><tbody><tr><td>Drug class</td><td>Polyene</td><td>Triazole</td><td>Triazole</td><td>Echinocandin</td></tr><tr><td>Mechanism</td><td>Binds ergosterol, pore formation</td><td>Inhibits 14-&alpha;-demethylase</td><td>Inhibits 14-&alpha;-demethylase</td><td>Inhibits &beta;-1,3-D-glucan synthase</td></tr><tr><td>Activity vs. Mucorales</td><td>Fungicidal, high</td><td>None</td><td>None</td><td>Negligible</td></tr><tr><td>Recommended dose (liposomal)</td><td>5&ndash;10 mg/kg/day</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Typical toxicity</td><td>Nephrotoxicity, infusion reactions</td><td>Hepatotoxicity, QT prolongation</td><td>Visual disturbances, hepatotoxicity</td><td>Hepatotoxicity, infusion reactions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always combine amphotericin B with aggressive surgical debridement in rhinocerebral mucormycosis to remove necrotic tissue and improve drug penetration.  <br><span class=\"list-item\">\u2022</span> Correct underlying metabolic derangements (e.g., diabetic ketoacidosis) promptly to reduce free iron availability that promotes fungal growth.  <br><span class=\"list-item\">\u2022</span> Monitor renal function and electrolytes closely; pre-hydrate and consider liposomal formulation to mitigate nephrotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selecting voriconazole for &ldquo;all invasive molds&rdquo; without recognizing Mucorales resistance, leading to treatment failure.  <br>2. Delaying amphotericin B initiation pending culture results&mdash;mortality rises sharply with each day of delay.  <br>3. Assuming echinocandins provide broad mold coverage; they are ineffective against Mucorales.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cornely OA et al., &ldquo;Global guideline for the diagnosis and management of mucormycosis,&rdquo; Lancet Infect <span class=\"evidence\">Dis 2019</span>: Strong recommendation for liposomal amphotericin B 5&ndash;10 mg/kg/day as first-line (A-II).  <br><span class=\"list-item\">\u2022</span> Patterson TF et al., &ldquo;Clinical Practice Guideline for the Management of Patients With Mucormycosis&rdquo; (IDSA), Clin Infect <span class=\"evidence\">Dis 2016</span>: Recommends amphotericin B formulations at 5 mg/kg/day, with level I evidence for efficacy in angioinvasive disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales exploit hyperglycemia and acidosis to enhance spore germination. Hyphae express ketone reductase to thrive in acidic environments and release fungal proteases that degrade endothelial barriers, leading to vascular thrombosis and downstream infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in at-risk host with facial/orbital symptoms.  <br>2. Immediate CT/MRI of sinuses and brain for extent.  <br>3. Nasal/sinus biopsy for KOH prep and histopathology (broad, ribbon-like, non-septate hyphae).  <br>4. Culture to identify species.  <br>5. Initiate amphotericin B empirically; add surgical debridement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows sinus opacification, black turbinate sign (nonenhancing mucosa), orbital cellulitis, and potential cavernous sinus thrombosis or cerebral infarcts in advanced disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B: start liposomal formulation at 5 mg/kg/day (up to 10 mg/kg/day in CNS involvement), infuse over 2&ndash;4 hours. Monitor creatinine, magnesium, and potassium daily; pre-hydrate with 500 mL normal saline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Mucormycosis treatment is a high-yield topic on neurology and infectious disease boards, often tested as first-line therapy in diabetic ketoacidosis&ndash;associated rhinocerebral involvement and contrasted against azole/echinocandin options.</div></div></div></div></div>"
  },
  {
    "id": 100024545,
    "question_number": "87",
    "question_text": "A female patient diagnosed with HIV came to the clinic for evaluation of possible associated peripheral neuropathy. What is the most common type of peripheral neuropathy associated with HIV?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] HIV-associated peripheral neuropathies arise from direct viral effects, immune\u2010mediated injury, and ART toxicity. Peripheral nerves are classified by fiber type (small vs. large) and distribution (length\u2010dependent vs. multifocal). Distal symmetric polyneuropathies produce glove\u2010and\u2010stocking symptoms due to axonal degeneration of the longest fibers. HIV neurologic complications include acute demyelinating neuropathy, distal symmetric sensory polyneuropathy (DSP), mononeuritis multiplex, and plexopathies. Among these, chronic DSP&mdash;characterized by length\u2010dependent sensory loss and neuropathic pain with minimal motor involvement&mdash;is the predominant form, particularly in patients with low CD4 counts, high viral loads, or exposure to neurotoxic NRTIs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Distal symmetrical sensory neuropathy (Answer B) is the most prevalent HIV neuropathy, affecting 30&ndash;60% of patients <span class=\"citation\">(Simpson et al, J Infect <span class=\"evidence\">Dis 2006</span>;194:710&ndash;713)</span>. It presents with symmetrical, length\u2010dependent sensory disturbances&mdash;tingling, burning pain, and numbness&mdash;due to dorsal root ganglion neuron loss and distal axonal degeneration of small unmyelinated C fibers and large myelinated A&beta; fibers. Electrophysiology reveals reduced sensory nerve action potentials (SNAPs) with preserved motor responses early on. The IDSA 2021 guidelines recommend routine DSP screening and avoidance of neurotoxic ARVs (stavudine, didanosine) to mitigate risk (Level A evidence). Management focuses on optimizing ART and symptomatic pain control per AAN 2019 recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Distal symmetrical motor and sensory neuropathy  <br><span class=\"list-item\">\u2022</span> Incorrect because HIV\u2010DSP is predominantly sensory; motor fiber degeneration occurs late and is minimal initially. This choice overestimates motor involvement.  <br><br>C. Distal symmetrical motor neuropathy  <br><span class=\"list-item\">\u2022</span> Pure motor neuropathy is rare in HIV. HIV\u2010DSP selectively targets sensory neurons early; primary motor neuropathy suggests alternative etiologies (e.g., motor neuron disease).  <br><br>D. Mononeuritis multiplex  <br><span class=\"list-item\">\u2022</span> Characterized by asymmetric, multifocal deficits from vasculitis. It is uncommon in HIV (<5%) and presents with stepwise nerve involvement, unlike the length\u2010dependent, symmetrical pattern of DSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Distal Symmetrical Sensory (DSP)</th><th>Motor & Sensory Polyneuropathy</th><th>Distal Motor Neuropathy</th><th>Mononeuritis Multiplex</th></tr></thead><tbody><tr><td>Fiber involvement</td><td>Sensory (C > A&beta;)</td><td>Sensory + motor</td><td>Motor only</td><td>Mixed</td></tr><tr><td>Distribution</td><td>Symmetrical, length\u2010dependent</td><td>Symmetrical</td><td>Symmetrical</td><td>Asymmetrical, multifocal</td></tr><tr><td>Electrophysiology</td><td>\u2193 SNAPs, normal CMAPs early</td><td>\u2193 SNAPs & CMAPs</td><td>\u2193 CMAPs</td><td>Patchy NCS changes</td></tr><tr><td>Prevalence in HIV</td><td>30&ndash;60%</td><td><10%</td><td>Rare</td><td><5%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV\u2010DSP correlates with advanced disease (CD4 <200 cells/\u00b5L) and certain NRTIs (stavudine).  <br>2. Small\u2010fiber involvement may yield normal standard NCS; consider skin biopsy for intraepidermal nerve fiber density.  <br>3. First\u2010line agents for neuropathic pain in HIV include duloxetine and pregabalin, with opioid sparing benefits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing acute inflammatory demyelinating polyneuropathy (GBS) with chronic DSP&mdash;GBS is acute, predominantly motor, and demyelinating.  <br>2. Overestimating motor deficits in HIV neuropathy&mdash;most patients report sensory symptoms long before any weakness appears.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA HIV Neuropathy Guidelines, 2021: Recommend annual DSP screening in all HIV patients and discontinuation of stavudine or didanosine when neuropathy is detected (Level A).  <br>2. AAN Practice Guideline on Neuropathic Pain, 2019: Endorses duloxetine (60 mg daily) and pregabalin (150&ndash;600 mg daily) as first\u2010line for DSP pain (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV\u2010DSP primarily injures dorsal root ganglion neurons and distal axons. Small unmyelinated C fibers mediate pain and temperature; large myelinated A&beta; fibers carry vibration and proprioception. Damage begins in the longest fibers (feet) and progresses proximally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV gp120 binds chemokine receptors on DRG neurons, triggering TNF\u2010&alpha; release and mitochondrial dysfunction. Concurrently, NRTI-induced mitochondrial DNA depletion in Schwann cells exacerbates distal axonal degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit history: burning, tingling in a stocking distribution.  <br>2. Perform exam: reduced pinprick, temperature, vibration distally.  <br>3. Rule out metabolic causes (glucose, B12, TSH).  <br>4. Conduct NCS/EMG: confirm reduced SNAPs with preserved CMAPs.  <br>5. If NCS normal but small\u2010fiber neuropathy suspected, perform skin biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Peripheral neuropathy patterns in HIV are frequently tested on board exams, often in vignette form emphasizing sensory\u2010predominant, length\u2010dependent DSP as the classic presentation.</div></div></div></div></div>"
  },
  {
    "id": 100024546,
    "question_number": "59",
    "question_text": "A patient presents with features of mucormycosis, including a black nasal mass with maxillary pain and bilateral cavernous sinus involvement. What is the mechanism of infection?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] - Anatomy: The paranasal sinuses (especially maxillary and ethmoid) lie adjacent to the orbit and cavernous sinus, separated by thin bony (lamina papyracea) and dural barriers.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Mucorales species (e.g., Rhizopus) form broad, non-septate hyphae that are profoundly angioinvasive, penetrating vessel walls to cause thrombosis, tissue ischemia, and necrosis.  <br><span class=\"list-item\">\u2022</span> CNS Spread: Rhinocerebral mucormycosis most often extends by direct tissue and vascular invasion rather than via lymphatic channels or pure hematogenous seeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct invasion is the primary route by which mucormycosis spreads from the nasal/paranasal region into the cavernous sinus. The fungus&rsquo;s hallmark is angioinvasion: Mucor hyphae adhere to endothelial cells, express CotH invasins that bind GRP78 on host endothelium, and breach vessel walls, producing thrombosis and necrosis <span class=\"citation\">(<span class=\"evidence\">Ibrahim et al., 2010</span>, JCI)</span>. Once the integrity of the sinus walls is compromised, fungi track along perivascular and perineural spaces directly into the cavernous sinus, bypassing lymphatics entirely. <span class=\"evidence\">The 2019</span> IDSA guidelines recommend prompt surgical debridement of necrotic tissue (Evidence Grade A-II) because direct tissue invasion is the cause of rapid progression; systemic (hematogenous) dissemination is rare in primary rhinocerebral disease unless there is pulmonary or disseminated mucormycosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transmission through the dural sinus  <br><span class=\"list-item\">\u2022</span> Why incorrect: Fungal invasion targets arterial walls, not venous channels; dural sinus thrombophlebitis is a consequence, not a conduit.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming intracranial spread must follow venous sinuses rather than direct tissue angioinvasion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Mucor produces arterial thrombosis with infarction, whereas dural sinus spread is seen in bacterial septic thrombophlebitis.  <br><br>C. Hematogenous spread  <br><span class=\"list-item\">\u2022</span> Why incorrect: True hematogenous seeding occurs in disseminated mucormycosis from lungs or GI tract, not in primary rhinocerebral cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all fungal CNS infections with bloodstream entry like Cryptococcus.  <br><span class=\"list-item\">\u2022</span> Differentiator: In rhinocerebral mucor, imaging shows contiguous sinus involvement rather than multifocal parenchymal lesions.  <br><br>D. Lymphatic spread  <br><span class=\"list-item\">\u2022</span> Why incorrect: There are no functional lymphatic vessels in the CNS or paranasal sinuses; fungi do not rely on lymphatics for cerebral invasion.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing lymphatic dissemination used by bacteria in meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Mucor&rsquo;s non-septate hyphae lack enzymes to penetrate lymphatic endothelium; spread is always via direct extension or angioinvasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Mechanism</th><th>Pathway</th><th>Key Features</th></tr></thead><tbody><tr><td>Direct invasion (Correct)</td><td>Sinus \u2192 bone/dura \u2192 vessels</td><td>Angioinvasion \u2192 arterial thrombosis \u2192 necrosis \u2192 cavernous sinus</td></tr><tr><td>Dural sinus transmission</td><td>Venous channels</td><td>Septic thrombophlebitis, rarely primary route for fungi</td></tr><tr><td>Hematogenous spread</td><td>Bloodstream</td><td>Multifocal lesions, seen in disseminated disease, not rhinocerebral</td></tr><tr><td>Lymphatic spread</td><td>Lymphatic vessels</td><td>Not applicable in CNS; no lymphatics in paranasal-to-cavernous route</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Diabetic ketoacidosis sharply increases free iron, enhancing mucor growth&mdash;always check serum iron/TIBC.  <br>2. &ldquo;Black turbinate sign&rdquo; on contrast MRI (non-enhancing mucosal necrosis) is an early radiographic clue to rhinocerebral mucor.  <br>3. Combined aggressive surgical debridement plus high-dose liposomal amphotericin B (5&ndash;10 mg/kg/day) is lifesaving; delays worsen angioinvasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking aspergillosis for mucormycosis&mdash;Aspergillus has septate hyphae and often disseminates hematogenously, whereas mucor is non-septate and directly angioinvasive.  <br>2. Believing lymphatic channels mediate CNS spread&mdash;no lymphatic highways connect sinuses to the brain; angioinvasion is the key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2019 Mucormycosis Guidelines: Recommend liposomal amphotericin B as first-line therapy (Grade A-II) and early surgical debridement (Grade A-I).  <br><span class=\"list-item\">\u2022</span> ECMM/MSG 2019 Consensus: Isavuconazole is non-inferior to amphotericin B for salvage therapy (Level B evidence), but direct invasion mandates source control before antifungal step-down.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cavernous sinus houses cranial nerves III, IV, V1, V2, VI and the internal carotid artery; fungal invasion can produce ophthalmoplegia, facial pain, and cavernous sinus thrombosis. Erosion of the lamina papyracea allows direct entry from ethmoid sinuses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucor&rsquo;s non-septate hyphae branch at 90\u00b0 angles, infiltrate endothelial cells via CotH&ndash;GRP78 interactions, induce vessel wall destruction, thrombosis, and ischemic necrosis&mdash;producing black eschar in nasal mucosa and facilitating contiguous CNS spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in DKA or immunocompromised patient with sinusitis + black eschar.  <br>2. Urgent sinonasal endoscopy and biopsy for histology (broad, ribbon-like hyphae).  <br>3. CT/MRI to assess bone erosion and cavernous sinus involvement.  <br>4. Initiate surgical debridement + high-dose lipid amphotericin B immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: Bony destruction of sinus walls and orbital floor.  <br><span class=\"list-item\">\u2022</span> MRI: T2-hypointense mucosal areas (&ldquo;black turbinate&rdquo;), loss of dural enhancement, cavernous sinus filling defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Liposomal amphotericin B 5&ndash;10 mg/kg/day (A-I).  <br><span class=\"list-item\">\u2022</span> Step-down: Posaconazole or isavuconazole after stabilization; correct underlying metabolic derangements (e.g., DKA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Rhinocerebral mucormycosis angioinvasion versus hematogenous/lymphatic spread is a high-yield topic, frequently tested as vignette-style questions emphasizing pathophysiology and imaging correlations.</div></div></div></div></div>"
  },
  {
    "id": 100024548,
    "question_number": "119",
    "question_text": "A patient with meningitis, who came from Alhaj, was found to have meningococcal meningitis. What is the appropriate prophylactic antibiotic for close contacts?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Neisseria meningitidis colonizes the nasopharynx and is transmitted via respiratory droplets; close contacts are at high risk for secondary cases.  <br><span class=\"list-item\">\u2022</span> Chemoprophylaxis aims to eradicate nasopharyngeal carriage and prevent further spread; timing within 24 hours of index case identification is critical.  <br><span class=\"list-item\">\u2022</span> First-line prophylaxis: rifampin for most contacts; alternatives include single-dose ciprofloxacin (adults) or IM ceftriaxone (children, pregnant women).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin is the first-line agent for meningococcal chemoprophylaxis because it reliably eradicates nasopharyngeal carriage in >95% of contacts with an oral regimen of 600 mg every 12 hours for 2 days <span class=\"citation\">(CDC ACIP 2013)</span>. It has broad global adoption, low cost, and well\u2010established efficacy.  <br>&bull; CDC ACIP (2013) recommends rifampin as the preferred prophylactic antibiotic; ciprofloxacin (single 500 mg dose) is an alternative only in adults >18 years, and ceftriaxone (250 mg IM) for pregnant women and young children.  <br>&bull; A randomized trial by Traor\u00e9 et al. (2011) demonstrated rifampin&rsquo;s superior eradication rates compared to single-dose ciprofloxacin in household contacts, supporting its status as first-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ciprofloxacin  <br><span class=\"list-item\">\u2022</span> Incorrect as &ldquo;first-line&rdquo; for all contacts; reserved as an alternative in adults when rifampin is contraindicated.  <br><span class=\"list-item\">\u2022</span> Misconception: equating ease of single-dose dosing with universal recommendation.  <br><span class=\"list-item\">\u2022</span> Rifampin has better pediatric and pregnancy safety data.  <br><br>C. Ceftriaxone  <br><span class=\"list-item\">\u2022</span> Incorrect as routine prophylaxis for healthy adult contacts; recommended only if rifampin and ciprofloxacin are contraindicated (e.g., children <18 years, pregnant women).  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all parenteral cephalosporins are equal in carriage eradication.  <br><br>D. Azithromycin  <br><span class=\"list-item\">\u2022</span> Not recommended by CDC, WHO, or IDSA for routine meningococcal chemoprophylaxis due to limited efficacy data.  <br><span class=\"list-item\">\u2022</span> Misconception: extending macrolide prophylaxis from other respiratory pathogens to N. meningitidis without evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rifampin</th><th>Ciprofloxacin</th><th>Ceftriaxone</th><th>Azithromycin</th></tr></thead><tbody><tr><td>Route/Dose</td><td>PO 600 mg q12h \u00d7 2 days</td><td>PO 500 mg once</td><td>IM 250 mg once</td><td>PO 500 mg once</td></tr><tr><td>Carriage eradication rate</td><td>>95%</td><td>~90%</td><td>~90&ndash;95%</td><td><80% (limited data)</td></tr><tr><td>Pediatric use</td><td>Yes</td><td>No (<18 yrs)</td><td>Yes (<18 yrs)</td><td>Off-label</td></tr><tr><td>Pregnancy category</td><td>C (short course acceptable)</td><td>C (teratogenic risks)</td><td>B (preferred in pregnancy)</td><td>B (no recommendation)</td></tr><tr><td>Drug interactions</td><td>CYP450 inducer</td><td>QT prolongation possible</td><td>Few</td><td>QT prolongation possible</td></tr><tr><td>ACIP preference</td><td>First-line</td><td>Alternative (adults only)</td><td>Alternative (children, pregnancy)</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate chemoprophylaxis within 24 hours of index case diagnosis to maximize prevention of secondary cases.  <br><span class=\"list-item\">\u2022</span> Counsel contacts on rifampin&rsquo;s orange discoloration of body fluids and potential drug interactions (e.g., oral contraceptives).  <br><span class=\"list-item\">\u2022</span> Ensure that chemoprophylaxis complements, not replaces, age-appropriate meningococcal vaccination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing ciprofloxacin for a child or pregnant contact, despite its contraindication in these groups.  <br>2. Believing that any antibiotic with good respiratory penetration (e.g., azithromycin) suffices for meningococcal prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC ACIP, &ldquo;Prevention and Control of Meningococcal Disease&rdquo; <span class=\"citation\">(2013; reaffirmed 2022)</span>: Rifampin preferred (Level A evidence); ciprofloxacin and ceftriaxone alternatives.  <br><span class=\"list-item\">\u2022</span> WHO Technical Report Series, No. 987 (2015): Recommends rifampin as first-line global standard; alternatives only when rifampin unavailable or contraindicated.  <br><span class=\"list-item\">\u2022</span> Traor\u00e9 et al., Clinical Infectious Diseases (2011): Randomized trial showing rifampin&rsquo;s superior eradication of N. meningitidis carriage vs. single-dose ciprofloxacin in household contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Neisseria meningitidis uses a polysaccharide capsule (serogroups A, B, C, W, Y) to evade phagocytosis. Transmission occurs via droplet spread; asymptomatic carriers in the nasopharynx can propagate outbreaks. Eradication of carriage interrupts person-to-person transmission and prevents invasive disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rifampin: inhibits bacterial DNA-dependent RNA polymerase; dosing for prophylaxis is 600 mg orally twice daily for 2 days in adults (10 mg/kg in children). Monitor liver enzymes; induces CYP3A4.  <br><span class=\"list-item\">\u2022</span> Ciprofloxacin: inhibits DNA gyrase; single 500 mg oral dose in adults; contraindicated in pregnancy and children.  <br><span class=\"list-item\">\u2022</span> Ceftriaxone: &beta;-lactam; 250 mg IM single dose (125 mg IM in infants); preferred in children and pregnancy.  <br><span class=\"list-item\">\u2022</span> Azithromycin: 23S-rRNA binding macrolide; not endorsed for meningococcal carriage eradication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Chemoprophylaxis for meningococcal contacts is frequently tested in board exams as a single-best-answer item; examinees must distinguish first-line rifampin from acceptable alternatives and identify contraindications in special populations.</div></div></div></div></div>"
  },
  {
    "id": 100024550,
    "question_number": "95",
    "question_text": "A young male presented with headache and fever. A CT of the brain was normal. A lumbar puncture was performed, and CSF analysis showed WBCs 48, RBCs 780, normal protein, and glucose. What is the most likely interpretation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] &bull; CSF cell counts: normal CSF contains 0&ndash;5 WBCs/mm\u00b3 and no RBCs.  <br>&bull; Traumatic tap: introduces peripheral blood into CSF, raising RBC/WBC counts; WBC correction \u22481 WBC per 500 RBCs.  <br>&bull; Meningitis patterns: bacterial (>1,000 WBCs with neutrophil predominance, \u2191protein, \u2193glucose), viral (50&ndash;1,000 WBCs lymphocytic, mildly \u2191protein, normal glucose).  <br>&bull; Subarachnoid hemorrhage: persistently high RBCs (>10,000/mm\u00b3), xanthochromia after centrifugation, often CT-positive early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The key is differentiating true pleocytosis from RBC contamination. With 780 RBCs/mm\u00b3, the anticipated contaminant WBCs \u22481&ndash;2/mm\u00b3 (using a 1:500 correction); subtracting yields \u223c46 WBCs/mm\u00b3&mdash;a modest pleocytosis but without protein elevation or hypoglycorrhachia.  <br>&bull; Traumatic tap: small vessel injury in dura/epidural venous plexus&mdash;protein and glucose remain normal, cell counts stable across tubes <span class=\"citation\">(Brandt et al., <span class=\"evidence\">Neurology 2013</span>)</span>.  <br>&bull; Viral meningitis would show lymphocytic predominance, mild protein elevation (50&ndash;100 mg/dL), but here protein is normal.  <br>&bull; Bacterial meningitis mandates &ge;1,000 neutrophils/mm\u00b3, protein >100 mg/dL, glucose <40 mg/dL <span class=\"citation\">(IDSA <span class=\"evidence\">Guidelines 2017</span>, level A)</span>.  <br>&bull; SAH yields RBCs often >10,000/mm\u00b3 and xanthochromia after 2 hours <span class=\"citation\">(van Gijn et al., Lancet <span class=\"evidence\">Neurol 2007</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Viral meningitis  <br><span class=\"list-item\">\u2022</span> Incorrect: CSF protein normal (should be mildly \u2191). Lymphocytic predominance expected; here differential not specified.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any moderate WBC count with viral etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: viral \u2191protein (50&ndash;100 mg/dL) vs normal in traumatic tap.  <br><br>C. Bacterial meningitis  <br><span class=\"list-item\">\u2022</span> Incorrect: WBC count too low (<100 cells/mm\u00b3), protein and glucose normal (should be \u2191protein, \u2193glucose).  <br><span class=\"list-item\">\u2022</span> Misconception: fever + headache always bacterial.  <br><span class=\"list-item\">\u2022</span> Differentiator: bacterial pleocytosis >1,000 cells/mm\u00b3 with neutrophil predominance.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect: RBC count too low (<1,000 cells/mm\u00b3), CT was negative, protein/glucose unaffected.  <br><span class=\"list-item\">\u2022</span> Misconception: any RBCs in CSF = SAH.  <br><span class=\"list-item\">\u2022</span> Differentiator: SAH shows xanthochromia and persistent RBCs in all tubes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Traumatic Tap</th><th>Viral Meningitis</th><th>Bacterial Meningitis</th><th>SAH</th></tr></thead><tbody><tr><td>RBC count (/mm\u00b3)</td><td><1,000</td><td>0&ndash;200</td><td>0&ndash;50</td><td>>10,000</td></tr><tr><td>WBC count (/mm\u00b3)</td><td>10&ndash;100 (corrected)</td><td>50&ndash;1,000 (lymphocytes)</td><td>>1,000 (neutrophils)</td><td><5&ndash;50</td></tr><tr><td>Protein (mg/dL)</td><td>Normal (15&ndash;45)</td><td>Mild \u2191 (50&ndash;100)</td><td>Marked \u2191 (>100)</td><td>Normal</td></tr><tr><td>Glucose (mg/dL)</td><td>Normal (45&ndash;80)</td><td>Normal</td><td>\u2193 (<40)</td><td>Normal</td></tr><tr><td>Xanthochromia</td><td>Absent</td><td>Absent</td><td>Absent</td><td>Present (after >2 h)</td></tr><tr><td>Tube-to-tube change</td><td>\u2193RBC/WBC across tubes</td><td>Consistent</td><td>Consistent</td><td>Consistent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always order tube 1 and 4 cell counts; a >30% decline in RBC suggests traumatic tap.  <br>&bull; Protein and glucose measurements are unaffected by minor blood contamination but are key to distinguishing infection.  <br>&bull; Xanthochromia requires &ge;2 hours post-bleed; a normal CT does not exclude early SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to correct WBC count for RBC contamination, leading to over\u2010diagnosis of meningitis.  <br>2. Equating any CSF RBC presence with SAH without assessing xanthochromia and CT timing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) Guidelines for the Management of Bacterial Meningitis, 2017:  <br>   &ndash; Recommendation: apply RBC/WBC correction (500:1) when interpreting pleocytosis (Level A).  <br>2. European Federation of Neurological Societies (EFNS) Guidelines on Aseptic Meningitis, 2010:  <br>   &ndash; Recommendation: use tube-to-tube comparison for RBC clearance to distinguish traumatic tap (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Interpretation of CSF cell counts&mdash;especially traumatic tap correction&mdash;is a high\u2010yield topic, frequently tested in both standalone CSF\u2010analysis questions and integrated meningitis vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100024551,
    "question_number": "50",
    "question_text": "In the case of HSV encephalitis, what is the recommended duration of Acyclovir treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Herpes simplex virus (HSV) encephalitis is the most common sporadic viral encephalitis in adults, characterized by necrotizing inflammation of the medial temporal lobes. Key points:  <br><span class=\"list-item\">\u2022</span> HSV-1 gains CNS access via reactivation in trigeminal ganglia and retrograde axonal transport.  <br><span class=\"list-item\">\u2022</span> Untreated mortality approaches 70%; Acyclovir, a guanosine analogue activated by viral thymidine kinase, reduces mortality to ~20%.  <br><span class=\"list-item\">\u2022</span> Optimal treatment duration balances viral clearance (confirmed by CSF PCR) against drug toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> Infectious Diseases Society of America (IDSA) guidelines recommend intravenous Acyclovir 10 mg/kg every 8 hours for 14&ndash;21 days in HSV encephalitis, with 14 days as the standard duration in immunocompetent adults (level B evidence).  <br><span class=\"list-item\">\u2022</span> Whitley et al. (1986, NEJM) demonstrated superiority of Acyclovir over vidarabine, using a 10-day course; subsequent observational data showed relapse rates when therapy was <14 days.  <br><span class=\"list-item\">\u2022</span> A 2019 cohort study <span class=\"citation\">(Mailles et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span> reported median therapy duration 14 days with CSF PCR conversion by day 10 in most patients; extending beyond 21 days did not improve outcomes in immunocompetent hosts.  <br><span class=\"list-item\">\u2022</span> Extension to 21 days is reserved for immunocompromised patients or if CSF PCR remains positive at day 14.  <br><br>Thus, 14 days is the recommended initial duration in an immunocompetent patient, making option A correct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 21 days  <br><span class=\"list-item\">\u2022</span> Represents the upper limit recommended for immunosuppressed hosts or persistent PCR positivity.  <br><span class=\"list-item\">\u2022</span> Common misconception: &ldquo;longer is always better&rdquo; without PCR guidance.  <br><br>C. 28 days  <br><span class=\"list-item\">\u2022</span> No guideline supports routine extension to four weeks in initial therapy; increases nephrotoxicity risk.  <br><span class=\"list-item\">\u2022</span> Confuses maintenance or prophylactic regimens in neonates or transplant recipients.  <br><br>D. 30 days  <br><span class=\"list-item\">\u2022</span> Even longer than 28 days; not supported by clinical trials or consensus guidelines for primary HSV encephalitis.  <br><span class=\"list-item\">\u2022</span> May reflect prophylaxis duration in recurrent genital HSV, not encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Duration</th><th>Typical Population</th><th>Guideline Recommendation</th></tr></thead><tbody><tr><td>14 days</td><td>Immunocompetent adults</td><td>Standard initial course <span class=\"citation\">(IDSA 2019, level B)</span></td></tr><tr><td>21 days</td><td>Immunocompromised or PCR-positive at day 14</td><td>Extended course if CSF PCR remains positive</td></tr><tr><td>28 days</td><td>Not routinely recommended</td><td>No evidence for initial therapy beyond 21 days</td></tr><tr><td>30 days</td><td>Not indicated</td><td>Off-label; increased toxicity risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric Acyclovir should be initiated within 6 hours of suspected HSV encephalitis; each hour of delay increases mortality risk.  <br><span class=\"list-item\">\u2022</span> Monitor renal function and ensure adequate hydration to prevent Acyclovir crystalluria and acute kidney injury.  <br><span class=\"list-item\">\u2022</span> Re-evaluate CSF HSV PCR at day 10&ndash;14; if still positive, extend therapy to 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming a 10-day course (based on initial trials) remains adequate; modern practice uses &ge;14 days.  <br><span class=\"list-item\">\u2022</span> Discontinuing therapy solely on clinical improvement without CSF PCR confirmation of viral clearance.  <br><span class=\"list-item\">\u2022</span> Overextending duration (&ge;28 days) increases toxicity without proven benefit in immunocompetent patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Viral Encephalitis Guidelines <span class=\"citation\">(Infectious Diseases Society of America, 2019)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Acyclovir 10 mg/kg IV q8h for 14&ndash;21 days; standard 14 days in immunocompetent (level B).  <br>2. EFNS/European Academy of Neurology Consensus (2017):  <br><span class=\"list-item\">\u2022</span> Recommendation: Acyclovir IV for minimum 14 days; extend to 21 days if clinical or PCR evidence of ongoing infection (grade 2C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV preferentially infects the medial and inferior temporal lobes and orbitofrontal cortex via trigeminal nerve pathways, leading to focal necrosis, hemorrhage, and edema detectable on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 reactivates from latency in trigeminal ganglia, replicates in neurons, and spreads transneuronally to the temporal lobes. Viral replication induces a cytokine-mediated inflammatory response, neuronal necrosis, and blood&ndash;brain barrier disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, altered mental status, focal deficits, seizures.  <br>2. Immediate noncontrast head CT to exclude mass lesion.  <br>3. Lumbar puncture: lymphocytic pleocytosis, elevated protein, normal glucose.  <br>4. MRI brain: T2/FLAIR hyperintensity in temporal lobes, hemorrhagic foci.  <br>5. CSF HSV PCR: initiate Acyclovir empirically pending results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI: restricted diffusion in temporal lobes within 24 hours.  <br><span class=\"list-item\">\u2022</span> Gradient echo/SWI: hemorrhagic transformation is characteristic of HSV.  <br><span class=\"list-item\">\u2022</span> CT may be normal early; MRI is more sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir mechanism: viral DNA polymerase chain terminator after phosphorylation by viral thymidine kinase.  <br><span class=\"list-item\">\u2022</span> Dosing: 10 mg/kg IV every 8 hours (ideal body weight), adjust for creatinine clearance <50 mL/min.  <br><span class=\"list-item\">\u2022</span> Adverse effects: nephrotoxicity (crystal nephropathy), neurotoxicity (tremor, confusion at high doses).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Boards frequently test on:  <br><span class=\"list-item\">\u2022</span> Empiric initiation of Acyclovir in suspected encephalitis.  <br><span class=\"list-item\">\u2022</span> Standard dosing and duration (14&ndash;21 days).  <br><span class=\"list-item\">\u2022</span> Criteria for extension (immunosuppression, persistent CSF PCR positivity).  <br><span class=\"list-item\">\u2022</span> Differentiation between adult and pediatric/neonatal regimens.</div></div></div></div></div>"
  },
  {
    "id": 100024561,
    "question_number": "175",
    "question_text": "Q175. The best way to prevent post-herpetic neuralgia is?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Varicella-zoster virus (VZV) remains latent in dorsal root ganglia after primary infection. Reactivation causes shingles, with viral replication in sensory neurons leading to inflammation and nerve damage. Post-herpetic neuralgia (PHN) is defined as pain persisting >90 days after rash onset, reflecting central and peripheral sensitization. Early suppression of viral replication limits neuronal injury and downstream neuropathic changes. Antiviral agents (acyclovir, valacyclovir, famciclovir) must be started within 72 hours of rash onset to maximize neuronal salvage and reduce PHN incidence. Understanding the time-sensitive pathophysiology of VZV reactivation underpins the rationale for antiviral prophylaxis of PHN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiviral therapy directly inhibits VZV DNA polymerase, curbing viral load in dorsal root ganglia and peripheral nerves. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Chen et al., 2016</span>)</span> showed a 40&ndash;50% relative risk reduction in PHN when antivirals are initiated within 72 hours. The IDSA 2019 guidelines recommend acyclovir 800 mg five times daily, valacyclovir 1 g TID, or famciclovir 500 mg TID for 7 days for acute zoster to prevent PHN (Level A evidence). Delayed antiviral initiation beyond 72 hours offers diminishing returns. No high-quality trials support steroids, anticonvulsants, or simple analgesics as primary preventive measures for PHN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Steroids  <br><span class=\"list-item\">\u2022</span> While prednisone (60 mg/day) can reduce acute pain and rash severity <span class=\"citation\">(<span class=\"evidence\">Wood et al., 1994</span>)</span>, there is no consistent evidence of PHN prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: anti-inflammation equals neural protection.  <br><span class=\"list-item\">\u2022</span> Differentiator: steroids address host inflammatory response, not VZV replication.  <br><br>C. Anticonvulsants  <br><span class=\"list-item\">\u2022</span> Gabapentin and pregabalin are effective for established PHN pain but lack data for PHN prophylaxis.  <br><span class=\"list-item\">\u2022</span> Misconception: neuropathic analgesics can be preventive.  <br><span class=\"list-item\">\u2022</span> Differentiator: they modulate calcium channels after nerve injury, not before.  <br><br>D. Analgesics  <br><span class=\"list-item\">\u2022</span> NSAIDs or opioids provide symptomatic relief of acute pain only.  <br><span class=\"list-item\">\u2022</span> Misconception: pain control will prevent chronic neuropathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: no antiviral effect or impact on neural damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antiviral Therapy</th><th>Steroids</th><th>Anticonvulsants</th><th>Analgesics</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits VZV DNA polymerase</td><td>Reduces inflammation</td><td>Modulates Ca\u00b2\u207a channels</td><td>Blocks nociceptive signals</td></tr><tr><td>Timing</td><td>Within 72 hours of rash onset</td><td>Acute phase</td><td>After PHN diagnosis</td><td>Any time for pain control</td></tr><tr><td>Effect on PHN incidence</td><td>\u2193\u200940&ndash;50% (RCTs & meta-analysis)</td><td>No proven reduction</td><td>No preventive trials</td><td>None</td></tr><tr><td>Evidence Level</td><td>IDSA 2019 (Level A)</td><td>Moderate for acute pain</td><td>Level C (off-label use)</td><td>Level U (no data)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate antiviral therapy within 72 hours of rash onset for maximal PHN risk reduction.  <br><span class=\"list-item\">\u2022</span> Recombinant zoster vaccine (Shingrix) in &ge;50 years reduces shingles and PHN by >90%.  <br><span class=\"list-item\">\u2022</span> High-risk groups (age\u2009>\u200960, immunocompromised) derive the greatest PHN prevention benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying antivirals beyond 72 hours, erroneously believing they still prevent PHN&mdash;efficacy sharply declines.  <br>2. Prescribing steroids alone to prevent PHN&mdash;steroids mitigate acute inflammation but do not reduce PHN risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2019 Herpes Zoster Guideline: recommends acyclovir 800 mg five times daily (Level A) within 72 hours to reduce PHN.  <br><span class=\"list-item\">\u2022</span> CDC ACIP 2021 Shingrix Recommendation: two-dose recombinant zoster vaccine for adults &ge;50 years to prevent shingles and PHN (Level 1 evidence, >90% efficacy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>VZV reactivation in dorsal root ganglia causes inflammation along sensory nerve roots. Persistent ectopic discharges and central sensitization in dorsal horn neurons underlie PHN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivated VZV replicates in ganglionic neurons, inducing Wallerian degeneration and demyelination. Subsequent aberrant nociceptor firing and central hypersensitivity perpetuate chronic neuropathic pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir: 800 mg PO five times daily for 7 days; requires phosphorylation by viral thymidine kinase.  <br><span class=\"list-item\">\u2022</span> Valacyclovir: prodrug of acyclovir, 1 g PO TID; higher bioavailability improves PHN prevention.  <br><span class=\"list-item\">\u2022</span> Famciclovir: 500 mg PO TID; similar efficacy and dosing convenience.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Herpes zoster management and PHN prevention are frequently tested as single\u2010best-answer formats, emphasizing timing of antiviral initiation and evidence levels in guideline recommendations.</div></div></div></div></div>"
  },
  {
    "id": 100024572,
    "question_number": "152",
    "question_text": "Q152. What is the most common pattern of neuropathy seen in HIV patients?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Peripheral neuropathies may present as polyneuropathy (diffuse, often length-dependent) or mononeuropathy; recognizing the pattern guides diagnosis.  <br><span class=\"list-item\">\u2022</span> HIV-associated neuropathy typically involves dorsal root ganglion cells, producing a &ldquo;glove-and-stocking&rdquo; distribution of sensory loss.  <br><span class=\"list-item\">\u2022</span> Antiretroviral therapy (particularly dideoxynucleoside analogues) and direct viral neurotoxicity both contribute, but the clinical phenotype remains a distal symmetric polyneuropathy in the majority.<br><br>(Word count: 71)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Distal symmetrical neuropathy (DSP) is reported in 30&ndash;60% of HIV patients, making it the leading neuropathic complication. Prospective cohort studies <span class=\"citation\">(Simpson et al., <span class=\"evidence\">Neurology 2006</span>)</span> correlate higher viral loads and lower CD4 counts with increased DSP risk. Pathologically, HIV RNA and inflammatory cytokines infiltrate dorsal root ganglia, causing &ldquo;dying-back&rdquo; axonal degeneration of small and large fibers. The European AIDS Clinical Society <span class=\"citation\">(EACS 2023)</span> and IDSA HIV neuropathy guidelines recommend routine screening for DSP in all HIV patients, confirming its prevalence and clinical significance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Mononeuritis multiplex  <br><span class=\"list-item\">\u2022</span> Rare in HIV (typically vasculitic or opportunistic infections).  <br><span class=\"list-item\">\u2022</span> Misconception: conflating HIV vasculitis with common neuropathy.<br><br>C. Pure motor  <br><span class=\"list-item\">\u2022</span> HIV neuropathy is predominantly sensory or sensorimotor.  <br><span class=\"list-item\">\u2022</span> Pure motor forms suggest motor neuron disease or multifocal motor neuropathy, not HIV.<br><br>D. Entrapment neuropathy  <br><span class=\"list-item\">\u2022</span> Common in general population (e.g., carpal tunnel) but not specifically driven by HIV.  <br><span class=\"list-item\">\u2022</span> Distribution is focal, not length-dependent symmetric as in DSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Distal Symmetric Neuropathy</th><th>Mononeuritis Multiplex</th><th>Pure Motor Neuropathy</th><th>Entrapment Neuropathy</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, over weeks&ndash;months</td><td>Stepwise, multifocal</td><td>Gradual or acute, motor-only</td><td>Subacute focal</td></tr><tr><td>Distribution</td><td>&ldquo;Glove-and-stocking&rdquo; symmetric</td><td>Asymmetric, patchy</td><td>Proximal/distal motor groups</td><td>Single nerve territory</td></tr><tr><td>Fiber involvement</td><td>Small & large sensory, sometimes motor</td><td>Mixed fibers</td><td>Large myelinated motor fibers</td><td>Large myelinated sensory & motor</td></tr><tr><td>Pathophysiology</td><td>HIV neurotoxicity + ART toxicity</td><td>Immune-mediated vasculitis</td><td>Motor neuron or immune attack</td><td>Compression at anatomical tunnel</td></tr><tr><td>Prevalence in HIV</td><td>30&ndash;60%</td><td><1%</td><td>Very rare</td><td>Common overall, not HIV-specific</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Screen for DSP at HIV diagnosis and annually, especially if CD4 < 350 or viral load high.  <br><span class=\"list-item\">\u2022</span> Nerve conduction studies often show reduced amplitudes and slowed conduction in distal nerves.  <br><span class=\"list-item\">\u2022</span> Manage neuropathic pain with duloxetine or pregabalin; avoid stavudine and didanosine when possible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all neuropathy in HIV patients to antiretroviral toxicity&mdash;HIV itself is a major driver.  <br>2. Relying solely on nerve conduction studies; small-fiber DSP may require quantitative sensory testing or skin biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European AIDS Clinical Society (EACS) <span class=\"evidence\">Guidelines 2023</span>: Recommend baseline and annual DSP screening in all HIV patients (Level B).  <br><span class=\"list-item\">\u2022</span> Infectious Diseases Society of America (IDSA) HIV Neuropathy <span class=\"evidence\">Guidelines 2024</span>: Advise symptomatic treatment with duloxetine or pregabalin and avoiding stavudine (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Nursing students and residents are frequently tested on DSP prevalence, distinguishing it from vasculitic or entrapment neuropathies, and on management nuances such as ART modification.</div></div></div></div></div>"
  },
  {
    "id": 100024589,
    "question_number": "13",
    "question_text": "A heroin abuser presents with severe back pain and tenderness, along with fever. What is the most likely organism found?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Spinal epidural abscess (SEA) is a focal infection in the epidural space that can compress neural elements. Key points:  <br><span class=\"list-item\">\u2022</span> Anatomy: The epidural space lies between the vertebral periosteum and dura mater, containing fat and venous plexuses.  <br><span class=\"list-item\">\u2022</span> Pathogenesis: Bacterial seeding via hematogenous spread, direct inoculation, or contiguous infection; IV drug use dramatically increases risk.  <br><span class=\"list-item\">\u2022</span> Clinical triad: Back pain, fever, and neurological deficits (though early deficits may be absent). Prompt recognition and treatment prevent permanent paralysis. (125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Staphylococcus aureus causes 60&ndash;90% of SEAs in IV drug users <span class=\"citation\">(IDSA 2015 guidelines)</span>. Its virulence factors&mdash;protein A, coagulase, biofilm formation&mdash;facilitate adhesion to endothelium and the epidural fat. Blood cultures are positive in ~60% of cases. MRI with gadolinium identifies epidural fluid collections. Empiric therapy per IDSA <span class=\"citation\">(2015; updated 2023 NICE)</span> recommends vancomycin plus a third- or fourth-generation cephalosporin until cultures guide narrowing. Early surgical decompression and drainage, combined with 4&ndash;6 weeks of tailored intravenous antibiotics, yields the best neurological outcomes <span class=\"citation\">(Kim et al., <span class=\"evidence\">Spine 2018</span>; level II evidence)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Streptococcus  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Streptococcal species account for <10% of SEA, more often Group B in obstetric infections.  <br><span class=\"list-item\">\u2022</span> Misconception: All Gram-positive cocci are equally likely; in SEA, S. aureus predominates.  <br><br>C. Pseudomonas aeruginosa  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Although Pseudomonas causes vertebral osteomyelitis in IV drug users, it is a rare SEA pathogen.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating Pseudomonas risk in any IV drug&ndash;associated spine infection.  <br><br>D. Escherichia coli  <br><span class=\"list-item\">\u2022</span> Reason incorrect: E. coli is chiefly seen in urinary or intra-abdominal sepsis; it seldom seeds the epidural space.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming Gram-negative rods are common in all spinal infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. aureus (Correct)</th><th>Streptococcus spp.</th><th>P. aeruginosa</th><th>E. coli</th></tr></thead><tbody><tr><td>Prevalence in SEA</td><td>60&ndash;90%</td><td><10%</td><td><5%</td><td><5%</td></tr><tr><td>Gram stain</td><td>Gram-positive cocci in clusters</td><td>Gram-positive cocci chains</td><td>Gram-negative rods</td><td>Gram-negative rods</td></tr><tr><td>Common in IV drug users</td><td>Yes</td><td>Rare</td><td>Uncommon</td><td>Uncommon</td></tr><tr><td>Virulence factors</td><td>Protein A, coagulase, biofilm</td><td>Capsule, hemolysins</td><td>Exotoxin A, biofilm</td><td>LPS, fimbriae</td></tr><tr><td>Empiric antibiotic coverage</td><td>Vancomycin</td><td>Penicillin G (if known)</td><td>Anti-Pseudomonal &beta;-lactam</td><td>3rd-gen cephalosporin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In an IV drug user with fever and focal back pain, suspect SEA&mdash;even without neuro deficits.  <br>2. MRI with contrast is >95% sensitive; don&rsquo;t delay imaging for LP.  <br>3. Empiric coverage must include MRSA (vancomycin) until cultures return.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Waiting for neurological deficits before imaging (delays diagnosis).  <br><span class=\"list-item\">\u2022</span> Omitting MRSA coverage in empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2015 <span class=\"citation\">(updated 2023)</span>: Recommends vancomycin plus ceftazidime or cefepime for SEA in IV drug users until pathogen identification (Level B).  <br>2. NICE 2021: Urgent MRI within 24 h for suspected SEA; combine surgery plus 4&ndash;6 weeks IV antibiotics for cord compression signs (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The spinal epidural space extends from the foramen magnum to the sacral hiatus; infection here can compress the dural sac and nerve roots.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hematogenous bacteremia seeds the epidural venous plexus; S. aureus adheres via surface proteins, evades host defenses, and forms abscesses in the fat-rich space.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (fever + back pain).  <br>2. Blood cultures \u00d72.  <br>3. Contrast MRI of spine.  <br>4. Surgical consultation.  <br>5. Empiric IV antibiotics \u2192 tailor per culture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI shows epidural collection with rim enhancement; T2 hyperintensity in adjacent vertebrae suggests osteomyelitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start vancomycin targeting troughs 15&ndash;20 \u00b5g/mL.  <br><span class=\"list-item\">\u2022</span> Adjust to nafcillin/oxacillin if MSSA; continue 4&ndash;6 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. SEA due to S. aureus in IV drug users is a high-yield topic, often tested via clinical vignettes focusing on back pain, fever, and imaging.</div></div></div></div></div>"
  },
  {
    "id": 100024594,
    "question_number": "1",
    "question_text": "A patient from Tanzania presents with jaundice, low platelet count, anemia, confusion, fever, and CSF showing high lymphocytes with normal glucose levels. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] - Plasmodium falciparum causes cerebral malaria by sequestration of parasitized erythrocytes in cerebral microvessels, leading to altered consciousness and neurologic signs.  <br><span class=\"list-item\">\u2022</span> Hemolysis of infected red cells produces anemia and hyperbilirubinemia (jaundice), while splenic clearance and consumption result in thrombocytopenia.  <br><span class=\"list-item\">\u2022</span> In cerebral malaria, the blood&ndash;brain barrier remains largely intact: CSF glucose is normal and may show only mild lymphocytic pleocytosis, differentiating it from bacterial meningitis or neurobrucellosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum is uniquely capable of causing severe malaria and cerebral involvement <span class=\"citation\">(WHO Guidelines for Malaria, 2023)</span>. Key systemic signs&mdash;jaundice, anemia, thrombocytopenia&mdash;and acute neurologic changes in a traveler from sub-Saharan Africa strongly suggest cerebral malaria. CSF typically reveals <10 lymphocytes/mm\u00b3, normal glucose, and mildly elevated protein; marked pleocytosis or hypoglycorrhachia point elsewhere <span class=\"citation\">(Milner et al., Lancet Infect <span class=\"evidence\">Dis 2018</span>)</span>. Diagnosis rests on thick and thin blood smears; rapid diagnostic tests are adjunctive in endemic settings. The SEAQUAMAT trial (2015) demonstrated intravenous artesunate reduces mortality by 22% versus quinine in severe falciparum malaria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. P. Ovale  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes mild tertian malaria; parasitemia rarely exceeds 1%, and cerebral involvement is exceptional.  <br><span class=\"list-item\">\u2022</span> Misconception: All Plasmodium species produce severe disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Relapses via hypnozoites, minimal hemolysis.  <br><br>C. Brucella  <br><span class=\"list-item\">\u2022</span> Incorrect: Neurobrucellosis is subacute/chronic, associated with low CSF glucose and high protein.  <br><span class=\"list-item\">\u2022</span> Misconception: Lymphocytic CSF automatically equals Brucella.  <br><span class=\"list-item\">\u2022</span> Differentiator: Exposure to unpasteurized dairy, positive Brucella serology.  <br><br>D. Meningitis  <br><span class=\"list-item\">\u2022</span> Incorrect: Bacterial meningitis shows neutrophilic pleocytosis, low CSF glucose, high protein, and meningeal signs (nuchal rigidity).  <br><span class=\"list-item\">\u2022</span> Misconception: Any fever plus altered mentation with CSF cells is meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acute neck stiffness, positive Kernig/Brudzinski signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>P. falciparum</th><th>P. ovale</th><th>Neurobrucellosis</th><th>Bacterial Meningitis</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (hours&ndash;days)</td><td>Gradual (days&ndash;weeks)</td><td>Subacute&ndash;chronic</td><td>Acute (hours&ndash;days)</td></tr><tr><td>Geographic Region</td><td>Sub-Saharan Africa</td><td>West Africa, SE Asia</td><td>Livestock areas</td><td>Worldwide</td></tr><tr><td>Anemia/Jaundice</td><td>Prominent</td><td>Mild</td><td>Rare</td><td>Absent/mild</td></tr><tr><td>Thrombocytopenia</td><td>Common</td><td>Uncommon</td><td>Uncommon</td><td>Uncommon</td></tr><tr><td>CSF Cell Type</td><td>Mild lymphocytes</td><td>Normal</td><td>Lymphocytes</td><td>Neutrophils</td></tr><tr><td>CSF Glucose</td><td>Normal</td><td>Normal</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Platelet counts <100,000/mm\u00b3 occur in >80% of falciparum malaria and can distinguish it from many viral encephalitides.  <br><span class=\"list-item\">\u2022</span> CSF in cerebral malaria often appears deceptively normal; always perform a peripheral smear.  <br><span class=\"list-item\">\u2022</span> Early IV artesunate (within 2 hours of presentation) is critical and reduces mortality compared to quinine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming lymphocytic CSF pleocytosis plus fever always indicates viral or Brucella infection, overlooking malaria in travelers.  <br>2. Believing hypoglycorrhachia must be present for CNS infections; cerebral malaria typically preserves CSF glucose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Guidelines for Malaria (2023): Recommend IV artesunate over quinine for severe malaria (Grade A, Level I).  <br><span class=\"list-item\">\u2022</span> SEAQUAMAT Trial (2015, Lancet): Demonstrated a 22% mortality reduction with IV artesunate versus quinine in severe falciparum malaria (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- PfEMP1 on infected erythrocytes binds endothelial receptors (ICAM-1, CD36) causing microvascular sequestration.  <br><span class=\"list-item\">\u2022</span> Hemolysis releases hemoglobin&mdash;a cause of jaundice and oxidative stress.  <br><span class=\"list-item\">\u2022</span> Inflammatory cytokines (TNF-&alpha;, IFN-&gamma;) contribute to blood&ndash;brain barrier alterations and neuronal dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess travel history and systemic signs (jaundice, thrombocytopenia).  <br>2. Obtain thick and thin blood smears for parasitemia.  <br>3. Use rapid diagnostic tests (HRP2 antigen) if microscopy delayed.  <br>4. Perform CSF analysis to exclude alternative CNS infections.  <br>5. Initiate IV artesunate immediately if severe malaria suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV artesunate: 2.4 mg/kg at 0, 12, and 24 hours, then daily until patient can tolerate oral therapy.  <br><span class=\"list-item\">\u2022</span> Monitor for delayed hemolysis 7&ndash;14 days post-treatment; follow with an artemisinin-based combination therapy course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Cerebral malaria frequently appears as an acute encephalopathy in returned travelers and tests recognition of systemic hematologic clues and CSF distinctions from other CNS infections.</div></div></div></div></div>"
  },
  {
    "id": 100024595,
    "question_number": "42",
    "question_text": "A 70-year-old male was brought to the ER with fever, confusion, and drowsiness. CSF analysis showed bacterial infection. What is the appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] &bull; Age\u2010dependent etiologies: Adults >50 years carry risk for Listeria monocytogenes in addition to Streptococcus pneumoniae and Neisseria meningitidis.  <br>&bull; Blood&ndash;brain barrier pharmacokinetics: Inflammation increases CNS penetration of &beta;-lactams and vancomycin, guiding empiric dosing.  <br>&bull; Empiric therapy principles: Must cover resistant pneumococci (vancomycin + third-gen cephalosporin) and Listeria (ampicillin) pending culture.  <br><br>(120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vancomycin plus ceftriaxone plus ampicillin is recommended empirically for adults >50 to cover penicillin\u2010resistant S. pneumoniae, N. meningitidis, H. influenzae and L. monocytogenes. <span class=\"evidence\">The 2017</span> IDSA guidelines (Tunkel et al.) grade this as Level A evidence: vancomycin 15&ndash;20 mg/kg IV every 8&ndash;12 h, ceftriaxone 2 g IV q12 h, ampicillin 2 g IV q4 h. A 2021 ESCMID update reaffirmed broad-spectrum empiric regimens in older adults, citing improved survival when ampicillin is included early <span class=\"citation\">(Brouwer et al., Clinical Infectious <span class=\"evidence\">Diseases 2020</span>)</span>. Vancomycin addresses resistant pneumococci, ceftriaxone covers Gram-negatives, and ampicillin penetrates inflamed meninges to eradicate Listeria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vancomycin and Ceftriaxone  <br>  &ndash; Missing Listeria coverage in >50-year-olds.  <br>  &ndash; Misconception: that dual coverage of Gram-positives and Gram-negatives suffices across all ages.  <br>  &ndash; Lacks ampicillin&rsquo;s activity against intracellular L. monocytogenes.  <br>C. Ceftriaxone and Ampicillin  <br>  &ndash; Omits vancomycin, leaving penicillin-resistant S. pneumoniae untreated.  <br>  &ndash; Common error: assuming third-gen cephalosporin alone covers all pneumococci.  <br>  &ndash; Fails to address high\u2010level ceftriaxone resistance in some pneumococcal strains.  <br>D. Vancomycin alone  <br>  &ndash; Provides Gram-positive coverage only; no Gram-negative or Listeria coverage.  <br>  &ndash; Reflects misconception that vancomycin is &ldquo;universal&rdquo; for meningitis.  <br>  &ndash; Cannot eradicate N. meningitidis or H. influenzae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Regimen</th><th>Pneumococcus (incl. resistant)</th><th>Meningococcus/H. influenzae</th><th>Listeria coverage</th><th>Key limitation</th></tr></thead><tbody><tr><td>Vancomycin + Ceftriaxone + Ampicillin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Broadest empiric coverage</td></tr><tr><td>Vancomycin + Ceftriaxone</td><td>Yes</td><td>Yes</td><td>No</td><td>Misses Listeria</td></tr><tr><td>Ceftriaxone + Ampicillin</td><td>No (resistant strains)</td><td>Yes</td><td>Yes</td><td>Misses resistant pneumococci</td></tr><tr><td>Vancomycin alone</td><td>Yes</td><td>No</td><td>No</td><td>Misses Gram-negatives & Listeria</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In patients >50 years or with immunosuppression, add ampicillin to cover Listeria.  <br>&bull; Initiate empiric antibiotics within 30 minutes of suspicion&mdash;do not delay for imaging unless increased ICP risk.  <br>&bull; Adjunctive dexamethasone (0.15 mg/kg IV q6h \u00d7 4 days) before or with first antibiotic dose reduces neurologic sequelae in S. pneumoniae meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting ampicillin in older adults due to underappreciation of Listeria risk.  <br>2. Substituting cefepime or ceftazidime for ceftriaxone&mdash;these have poor pneumococcal activity.  <br>3. Relying on vancomycin monotherapy, which lacks Gram-negative and intracellular coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Infectious Diseases Society of America (IDSA) 2017: Empiric regimen for >50 years&mdash;vancomycin + ceftriaxone (or cefotaxime) + ampicillin (Level A).  <br>&bull; ESCMID 2021: Recommends maintaining ampicillin in empiric therapy for older or immunocompromised to reduce Listeria\u2010associated mortality (Grade 1B).  <br>&bull; Brouwer et al., CID 2020 meta\u2010analysis: Early ampicillin addition reduced 30-day mortality by 15% in patients >60.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, nuchal rigidity, altered mental status.  <br>2. If no papilledema or focal deficits, perform lumbar puncture immediately; otherwise, CT head first.  <br>3. CSF analysis: neutrophilic pleocytosis, low glucose, high protein, Gram stain.  <br>4. Initiate empiric antibiotics + dexamethasone promptly.  <br>5. Adjust therapy when cultures and susceptibilities return.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Vancomycin: 15&ndash;20 mg/kg IV q8&ndash;12 h; monitor troughs 15&ndash;20 \u00b5g/mL.  <br>&bull; Ceftriaxone: 2 g IV q12 h; excellent CNS penetration.  <br>&bull; Ampicillin: 2 g IV q4 h; high dose needed for CSF levels >2 \u00b5g/mL.  <br>&bull; Renal dosing adjustments critical for vancomycin and ampicillin in renal impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Empiric antibiotic choice in meningitis is frequently tested, often as vignettes of different age groups or immune statuses requiring tailored regimens.</div></div></div></div></div>"
  },
  {
    "id": 100024596,
    "question_number": "43",
    "question_text": "An Indian patient came with a headache. He is known to have epilepsy and is on medications. A CT brain scan is attached showing multiple, round, ring-enhancing lesions with an eccentric hyperdense dot sign and perilesional edema. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Neurocysticercosis (NCC) results from CNS invasion by Taenia solium larvae. Core concepts:  <br><span class=\"list-item\">\u2022</span> Pathogen life cycle: ingestion of T. solium eggs \u2192 oncospheres penetrate intestinal wall \u2192 hematogenous spread to brain parenchyma.  <br><span class=\"list-item\">\u2022</span> Imaging hallmark: the \"eccentric dot sign\" represents the scolex within a cyst and is pathognomonic.  <br><span class=\"list-item\">\u2022</span> Epidemiology: endemic in India, Latin America and a leading cause of adult-onset seizures and headache.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CT&rsquo;s multiple cystic lesions with ring enhancement, scolex (hyperdense eccentric dot), and variable perilesional edema in an Indian patient on AEDs is diagnostic of NCC. <span class=\"evidence\">The 2017</span> revised Del Brutto criteria <span class=\"citation\">(Clin Infect Dis. 2017;64(11)</span>:1714&ndash;1720) require neuroimaging plus epidemiological context for definitive diagnosis. IDSA&ndash;ASTMH guidelines <span class=\"citation\">(Garc\u00eda HH et al., Clin Infect Dis. 2014;59(9)</span>:124&ndash;129) recommend albendazole (15 mg/kg/day) for 28 days with adjunctive corticosteroids (dexamethasone 0.1 mg/kg/day) to reduce inflammatory edema (Level A evidence). Toxoplasmosis occurs in immunocompromised hosts and lacks a scolex; tuberculomas have thicker irregular walls and positive TB tests; pyogenic abscesses display diffusion restriction on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasmosis  <br><span class=\"list-item\">\u2022</span> Primarily in HIV/AIDS (CD4\u2009<\u2009100) or transplant; lesions lack scolex and preferentially involve basal ganglia.  <br><span class=\"list-item\">\u2022</span> Misconception: any multifocal ring-enhancing lesion = toxo.  <br><span class=\"list-item\">\u2022</span> Key differentiator: positive Toxo serology, lesion distribution, no eccentric dot.<br><br>C. Tuberculoma  <br><span class=\"list-item\">\u2022</span> Granulomatous nodules with irregular walls, may calcify late; perilesional edema less pronounced.  <br><span class=\"list-item\">\u2022</span> Misconception: endemic ring lesions assumed tuberculous.  <br><span class=\"list-item\">\u2022</span> Key differentiator: positive Mantoux/CSF PCR/ADA, systemic TB signs.<br><br>D. Brain abscess  <br><span class=\"list-item\">\u2022</span> Smooth-walled ring lesions with central diffusion restriction on DWI sequences and intense surrounding edema.  <br><span class=\"list-item\">\u2022</span> Misconception: ring enhancement always indicates abscess.  <br><span class=\"list-item\">\u2022</span> Key differentiator: acute presentation, fever, elevated inflammatory markers, DWI hyperintensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cysticercosis</th><th>Toxoplasmosis</th><th>Tuberculoma</th><th>Brain Abscess</th></tr></thead><tbody><tr><td>Patient Profile</td><td>Endemic areas; seizure history</td><td>Immunocompromised (HIV)</td><td>TB exposure risk</td><td>Recent infection; immunocompetent</td></tr><tr><td>Imaging</td><td>Ring cyst + scolex; variable edema</td><td>Multiple rings; no scolex; basal ganglia</td><td>Irregular ring; nodular enhancement</td><td>Smooth ring; DWI restriction</td></tr><tr><td>Scolex Sign</td><td>Present (hyperdense dot)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Serology/Lab</td><td>EITB positive for cysticercus</td><td>Toxo IgG/IgM positive</td><td>CSF PCR/ADA elevated; Mantoux +ve</td><td>\u2191WBC, CRP, ESR</td></tr><tr><td>Treatment</td><td>Albendazole + steroids</td><td>Pyrimethamine&ndash;sulfadiazine + leucovorin</td><td>RIPE therapy</td><td>Empiric IV antibiotics; drainage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;eccentric dot sign&rdquo; on CT/MRI is pathognomonic for NCC.  <br><span class=\"list-item\">\u2022</span> Albendazole (15 mg/kg/day \u00d7 28 days) plus dexamethasone reduces inflammation during cysticidal therapy <span class=\"citation\">(Garc\u00ed<span class=\"evidence\">a HH et al., 2014</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Calcified nodules represent inactive NCC and do not benefit from antiparasitic drugs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all ring-enhancing lesions in endemic areas are tuberculomas.  <br><span class=\"list-item\">\u2022</span> Overlooking the scolex sign leads to misclassification of NCC as abscess or tumor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Del Brutto OH et al., &ldquo;Revised Diagnostic Criteria for Neurocysticercosis,&rdquo; Clin Infect Dis. 2017;64(11):1714&ndash;1720. Recommends combined imaging and epidemiology for definitive diagnosis (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Garc\u00eda HH et al., &ldquo;Guidelines for the management of neurocysticercosis,&rdquo; Clin Infect Dis. 2014;59(9):124&ndash;129. Endorses albendazole plus corticosteroids for active parenchymal cysts (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cysticerci preferentially lodge at the gray&ndash;white matter junction where blood flow decelerates, correlating with cortical seizure foci.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ingested eggs release oncospheres, which invade the bloodstream and mature into cysticerci in the CNS; host inflammatory response during cyst degeneration produces edema and clinical symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect NCC in endemic region with new-onset seizures/headache.  <br>2. Perform CT/MRI: identify cysts with scolex and assess stage.  <br>3. Confirm with serology (EITB or ELISA).  <br>4. Exclude other etiologies: HIV, TB, bacterial cultures.  <br>5. Initiate antiparasitic therapy with steroids for active lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vesicular stage: thin-walled cyst with scolex, minimal edema.  <br><span class=\"list-item\">\u2022</span> Colloidal stage: ring enhancement with significant vasogenic edema.  <br><span class=\"list-item\">\u2022</span> Nodular/granular stage: wall thickening, reducing edema.  <br><span class=\"list-item\">\u2022</span> Calcified stage: hyperdense focus, no enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Albendazole (15 mg/kg/day) disrupts parasite microtubules; praziquantel (50 mg/kg/day) is an alternative. Adjunctive corticosteroids mitigate cysticidal inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Neurocysticercosis is frequently tested via characteristic imaging (scolex sign), epidemiology in endemic populations, and management protocols.</div></div></div></div></div>"
  },
  {
    "id": 100024598,
    "question_number": "155",
    "question_text": "A 40-year-old man is seen in the emergency department for evaluation of retinal hemorrhage, hepatosplenomegaly, headache, fever every 3 days, and right arm weakness. On examination, his temperature is 38.1\u00b0C. He has some weakness of the right arm; otherwise, his examination is non-focal. He recently arrived from Africa. Which of the following is a highly diagnostic test?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Malaria is caused by Plasmodium parasites; P. falciparum is most often responsible for severe and cerebral disease. Key concepts:  <br><span class=\"list-item\">\u2022</span> Parasite life cycle: sporozoites \u2192 hepatic schizogony \u2192 erythrocytic cycle (merozoites infect RBCs).  <br><span class=\"list-item\">\u2022</span> Cerebral malaria: microvascular sequestration of P. falciparum&ndash;infected RBCs in brain capillaries causes headache, focal deficits, and malarial retinopathy.  <br><span class=\"list-item\">\u2022</span> Diagnosis relies on direct visualization of parasites on thick and thin peripheral blood smears; this is rapid, sensitive, and specific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood smear microscopy remains the gold standard for diagnosing malaria <span class=\"citation\">(<span class=\"evidence\">Baird 2019</span>; WHO 2022)</span>. Thick smears concentrate parasites for high sensitivity (detection threshold ~50 parasites/\u00b5L), while thin smears permit species identification and parasitemia quantification. In cerebral malaria, early detection and speciation guide prompt treatment with intravenous artesunate, which reduces mortality by 35% compared to quinine <span class=\"citation\">(Dondorp et al., NEJM 2010)</span>. CSF PCR lacks sensitivity for malaria, MRI changes are non-specific, and liver biopsy is invasive without added diagnostic yield.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CSF PCR  <br><span class=\"list-item\">\u2022</span> Why incorrect: PCR on cerebrospinal fluid is not standard for malaria; parasites reside in blood.  <br><span class=\"list-item\">\u2022</span> Misconception: equating CNS infection with CSF-based tests.  <br><span class=\"list-item\">\u2022</span> Differentiator: malaria diagnosis prioritizes blood parasitemia, not CSF.<br><br>C. Brain MRI  <br><span class=\"list-item\">\u2022</span> Why incorrect: MRI may show microhemorrhages or edema but cannot identify Plasmodium.  <br><span class=\"list-item\">\u2022</span> Misconception: neuroimaging confirms diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging is adjunctive for complications, not primary diagnosis.<br><br>D. Liver biopsy  <br><span class=\"list-item\">\u2022</span> Why incorrect: invasive, risks bleeding, provides no additional parasite detection.  <br><span class=\"list-item\">\u2022</span> Misconception: organ biopsy yields definitive diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: peripheral blood smear is minimally invasive and diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Blood Smear</th><th>CSF PCR</th><th>Brain MRI</th><th>Liver Biopsy</th></tr></thead><tbody><tr><td>Diagnostic Yield</td><td>High (sensitivity ~95%)</td><td>Very low for malaria</td><td>Non-specific findings</td><td>Not used for malaria</td></tr><tr><td>Time to Result</td><td>15&ndash;30 minutes</td><td>Several hours&ndash;days</td><td>Hours&ndash;days</td><td>Days (processing)</td></tr><tr><td>Invasiveness</td><td>Minimal (venipuncture)</td><td>Moderate (lumbar puncture)</td><td>Non-invasive imaging</td><td>Highly invasive</td></tr><tr><td>Species Identification</td><td>Yes (thin smear)</td><td>Rarely</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Malarial retinopathy (retinal whitening, hemorrhages) strongly suggests cerebral malaria <span class=\"citation\">(Beare et al., <span class=\"evidence\">Lancet 2004</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Fever periodicity (tertian in P. falciparum is less strict than in P. vivax/ovale).  <br><span class=\"list-item\">\u2022</span> Always perform repeat smears every 12&ndash;24 hours if initial smear is negative but clinical suspicion remains high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing a normal MRI excludes cerebral malaria&mdash;imaging may lag behind clinical severity.  <br>2. Assuming elevated CSF white cells indicate malaria meningitis&mdash;CSF is typically normal in cerebral malaria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Guidelines for the Treatment of Malaria, 3rd ed. (2022): Recommends intravenous artesunate as first-line for severe malaria (Grade A, Level I).  <br><span class=\"list-item\">\u2022</span> CDC Malaria Diagnosis and Treatment Guidelines (2021): Emphasize thick and thin blood smears as primary diagnostic tests; PCR reserved for species confirmation if smears are inconclusive (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Sequestration of parasitized RBCs in cerebral microvasculature (particularly in grey matter and deep white matter) leads to capillary congestion, impaired perfusion, and focal neurological deficits such as arm weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum&ndash;infected erythrocytes express PfEMP1, mediating cytoadherence to endothelial receptors (ICAM-1, CD36), causing microvascular obstruction, hypoxia, and localized brain injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect malaria in febrile traveler from endemic area.  <br>2. Obtain thick and thin peripheral blood smears immediately.  <br>3. If negative but high suspicion, repeat smears every 12&ndash;24 h for 48 h.  <br>4. Use PCR for species confirmation or low-parasitemia cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI in cerebral malaria may show T2/FLAIR hyperintensities in white matter and microhemorrhages on susceptibility-weighted imaging, but lacks diagnostic specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: IV artesunate 2.4 mg/kg at 0, 12, and 24 h, then once daily. Transition to oral artemisinin-based combination therapy for 3 days once able to tolerate oral intake.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Meningeal signs are absent in cerebral malaria; focus on blood smear findings. Boards frequently test malaria diagnosis in travel-history vignettes, emphasizing thick/thin smears and prompt antimalarial therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024600,
    "question_number": "61",
    "question_text": "A female patient with multiple sclerosis (MS) on Natalizumab presents with hemiparesis and hemianopia. MRI shows a subcortical white matter mass with no enhancement. What will you do?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Multiple sclerosis (MS) patients on natalizumab are at risk for progressive multifocal leukoencephalopathy (PML) due to JC virus reactivation.  <br>&bull; Natalizumab blocks &alpha;4-integrin, preventing lymphocyte CNS entry but impairing immune surveillance in white matter.  <br>&bull; JC virus infects oligodendrocytes, causing demyelinating subcortical lesions that typically do not enhance or cause mass effect.  <br>&bull; Clinical presentation (hemiparesis, hemianopia) reflects involvement of corticospinal tracts and optic radiations.  <br>&bull; Management hinges on immune reconstitution: immediate removal of natalizumab via plasmapheresis accelerates clearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Plasmapheresis is the cornerstone of natalizumab-associated PML management. Removing circulating monoclonal antibody restores leukocyte trafficking into the CNS, allowing endogenous antiviral immunity to control JC virus.  <br>&bull; Bloomgren et al. <span class=\"citation\">(NEJM, 2012)</span> demonstrated that plasma exchange reduced natalizumab half-life from ~250 hours to <2 days, correlating with clinical stabilization in PML.  <br>&bull; Yousry et al. <span class=\"citation\">(JAMA, 2006)</span> established MRI hallmarks&mdash;non-enhancing, multifocal demyelination&mdash;guiding early PML diagnosis.  <br>&bull; The AAN Practice Advisory (2020) and EMA 2019 label update both recommend 3&ndash;5 sessions of therapeutic plasma exchange over 7&ndash;14 days (Class I evidence) as first-line intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IVIG  <br>&bull; IVIG provides passive immunoglobulins but lacks anti-JC virus specificity and does not clear natalizumab.  <br>&bull; Misconception: equating IVIG&rsquo;s use in Guillain&ndash;Barr\u00e9 syndrome with antiviral efficacy.  <br><br>B. Methylprednisolone  <br>&bull; High-dose steroids worsen immunosuppression, exacerbate JC viral replication, and are indicated for MS relapses&mdash;not PML.  <br>&bull; Common error: treating any new MS symptom as a demyelinating relapse.  <br><br>D. Discontinue Natalizumab and monitor closely  <br>&bull; While drug cessation is necessary, its half-life (average ~11 days) delays immune reconstitution; sole monitoring risks rapid PML progression.  <br>&bull; Key difference: urgent accelerated removal via plasmapheresis vs. passive drug washout.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PLEX (Correct)</th><th>Discontinue Only</th><th>Methylprednisolone</th><th>IVIG</th></tr></thead><tbody><tr><td>Mechanism</td><td>Removes natalizumab, restores CNS immunity</td><td>Relies on natural drug clearance</td><td>Immunosuppressive anti-inflammatory</td><td>Passive immunoglobulin infusion</td></tr><tr><td>Effect on JC virus</td><td>Enables immune control</td><td>Delayed reconstitution</td><td>Worsens viral replication</td><td>No specific antiviral action</td></tr><tr><td>Time to natalizumab clearance</td><td><2 days (3&ndash;5 exchanges)</td><td>~11 days half-life</td><td>N/A</td><td>N/A</td></tr><tr><td>Indication in PML</td><td>First-line management</td><td>Incomplete, supportive only</td><td>Contraindicated</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always consider PML in natalizumab-treated MS patients with new focal deficits, especially non-enhancing MRI lesions.  <br>&bull; Early CSF JC virus PCR confirms diagnosis; sensitivity ~80%, but a negative result may need repeat testing if clinical suspicion remains high.  <br>&bull; Monitor for immune reconstitution inflammatory syndrome (IRIS) after PLEX; low-dose steroids may be needed to control IRIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying PML lesions as MS relapses and treating with steroids, which worsens prognosis.  <br>2. Assuming drug discontinuation alone suffices&mdash;delayed immune recovery can lead to rapid neurological decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AAN Practice Advisory on PML Management (2020): Class I, Level A evidence supports plasma exchange (3&ndash;5 sessions) to accelerate natalizumab clearance.  <br>&bull; European Medicines Agency Label Update (2019): Recommends therapeutic plasma exchange within 14 days of PML diagnosis for natalizumab-associated cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hemiparesis: involvement of corticospinal fibers in internal capsule and adjacent subcortical white matter.  <br>&bull; Hemianopia: occipital lobe and optic radiations in the parietal/temporal white matter are common PML sites.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; JC virus remains latent in kidney and lymphoid tissue; immunosuppression (natalizumab) allows reactivation and CNS entry.  <br>&bull; Virus infects oligodendrocytes, causing lytic demyelination without inflammatory contrast enhancement on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. New focal neurological deficits in natalizumab patient \u2192 urgent brain MRI  <br>2. MRI: non-enhancing, T2/FLAIR hyperintense subcortical lesions \u2192 suspect PML  <br>3. CSF for JC virus PCR \u2192 confirm diagnosis  <br>4. Immediately discontinue natalizumab and initiate plasmapheresis  <br>5. Monitor for IRIS and manage supportively</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PML lesions: asymmetric, non-enhancing, lack mass effect, often involve U-fibers.  <br>&bull; Lack of gadolinium enhancement helps distinguish from MS relapse or lymphoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Plasmapheresis protocol: 3&ndash;5 exchanges (1&ndash;1.5 plasma volumes) over 7&ndash;14 days; monitor for hypocalcemia.  <br>&bull; IRIS management: low-dose steroids (e.g., prednisone 0.5 mg/kg) if significant edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Natalizumab-associated PML is a high-yield topic on neurology boards, often tested as recognition of non-enhancing white matter lesions plus appropriate management via plasma exchange.</div></div></div></div></div>"
  },
  {
    "id": 100024604,
    "question_number": "42",
    "question_text": "A patient from Africa presents with a Brucella infection. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Brucella species are small, facultative intracellular, gram-negative coccobacilli that invade macrophages and replicate within the reticuloendothelial system. Effective treatment requires antibiotics with high intracellular penetration and prolonged course to prevent relapse. First-line regimens combine a tetracycline (doxycycline) with either an aminoglycoside or rifampin for at least six weeks. In neurobrucellosis, third-generation cephalosporins (e.g., ceftriaxone) or aminoglycosides are added to doxycycline&ndash;rifampin to enhance CNS penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Doxycycline (100 mg PO bid for &ge;6 weeks) is the cornerstone of brucellosis therapy due to excellent intracellular distribution and oral bioavailability. The World Health Organization (2022) and the Infectious Diseases Society of America (2020) both recommend doxycycline + rifampin for uncomplicated brucellosis (Level A evidence). A landmark randomized trial <span class=\"citation\">(Sol\u00ed<span class=\"evidence\">s et al., 2000</span>)</span> demonstrated that doxycycline plus rifampin yields relapse rates <10%, similar to doxycycline plus streptomycin but with better tolerability. For neurobrucellosis (not specified here), doxycycline and rifampin are supplemented with ceftriaxone or an aminoglycoside to ensure adequate CNS levels <span class=\"citation\">(<span class=\"evidence\">Pappas et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ceftriaxone  <br>&ndash; Monotherapy provides insufficient intracellular activity against Brucella.  <br>&ndash; Often used adjunctively for neurobrucellosis, not as sole agent.  <br><br>C. Rifampin  <br>&ndash; Rifampin monotherapy leads to relapse rates >30%.  <br>&ndash; Potent CYP450 inducer causing significant drug interactions.  <br><br>D. Streptomycin  <br>&ndash; Aminoglycoside monotherapy has high relapse and requires parenteral administration.  <br>&ndash; Ototoxicity and nephrotoxicity limit its use as sole therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Doxycycline</th><th>Ceftriaxone</th><th>Rifampin</th><th>Streptomycin</th></tr></thead><tbody><tr><td>Intracellular penetration</td><td>High</td><td>Moderate</td><td>High</td><td>Low</td></tr><tr><td>Route</td><td>Oral</td><td>IV</td><td>Oral</td><td>IM/IV</td></tr><tr><td>Main mechanism</td><td>30S ribosomal inhibition</td><td>Cell wall synthesis (PBPs)</td><td>RNA polymerase inhibition</td><td>30S ribosomal misreading</td></tr><tr><td>Recommended use</td><td>First-line (combination)</td><td>Adjunct in neurobrucellosis</td><td>Combination, not monotherapy</td><td>Adjunct; not monotherapy</td></tr><tr><td>Relapse rate (monotherapy)</td><td>~20&ndash;40%</td><td>>50%</td><td>>30%</td><td>~30&ndash;40%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always use combination therapy (doxycycline + rifampin) for at least 6 weeks to reduce relapse.  <br>2. In neurobrucellosis, add ceftriaxone (2 g daily) or an aminoglycoside for optimal CNS penetration.  <br>3. Monitor liver enzymes with doxycycline&ndash;rifampin regimens and renal function with aminoglycosides.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selecting monotherapy (e.g., rifampin alone) due to ease of administration; leads to high relapse.  <br>2. Underestimating duration&mdash;courses <6 weeks are associated with treatment failure.  <br>3. Assuming third-generation cephalosporins alone suffice for Brucella; they lack adequate intracellular bactericidal activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization Technical Report Series, 2022: Recommends doxycycline 100 mg bid + rifampin 600&ndash;900 mg daily for 6 weeks in uncomplicated brucellosis (Grade A).  <br><span class=\"list-item\">\u2022</span> IDSA Clinical Practice Guidelines, 2020: Endorses either doxycycline + streptomycin or doxycycline + rifampin; highlights doxycycline&ndash;rifampin as outpatient standard (Level I evidence).  <br><span class=\"list-item\">\u2022</span> Sol\u00eds et al., Clinical Infectious Diseases, 2000 (RCT): Demonstrated non-inferiority of doxycycline&ndash;rifampin vs doxycycline&ndash;streptomycin (relapse <10%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect brucellosis in febrile patients with livestock exposure or consumption of unpasteurized dairy.  <br>2. Obtain blood cultures (may require prolonged incubation) and serology (standard agglutination, ELISA).  <br>3. Use PCR in CSF when neurobrucellosis is suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Doxycycline: 100 mg PO bid for &ge;6 weeks; penetrates macrophages.  <br><span class=\"list-item\">\u2022</span> Rifampin: 600&ndash;900 mg PO daily; monitor for hepatotoxicity and drug&ndash;drug interactions.  <br><span class=\"list-item\">\u2022</span> Streptomycin: 1 g IM daily for 2&ndash;3 weeks if used; monitor renal function and audiometry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Brucellosis treatment is a frequently tested topic, often as a two-drug regimen (tetracycline + aminoglycoside or rifampin) for 6 weeks. Students should recognize intracellular pathogens require combination, prolonged therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024614,
    "question_number": "165",
    "question_text": "An 11-year-old girl is referred with rapidly deteriorating school performance and intellectual deficits over a course of a few weeks. She also has frequent seizures and unsteady gait. On examination, she has ataxia, hyperreflexia, and bilateral upgoing plantar responses. An EEG shows periodic bursts of high-voltage slow waves followed by recurrent low-voltage stretches. Clinically, she is worsening with an on-off lethargic state. A brain MRI shows large areas of signal change. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Persistent measles virus infection: SSPE arises 5&ndash;15 years after wild-type measles; mutated virus persists in neurons and oligodendrocytes, causing chronic inflammation and demyelination.  <br><span class=\"list-item\">\u2022</span> EEG hallmark: periodic, high-amplitude, generalized slow-wave complexes repeating every 4&ndash;10 seconds (&ldquo;periodic complexes&rdquo;), a key discriminator among progressive encephalopathies.  <br><span class=\"list-item\">\u2022</span> Clinical triad: progressive intellectual decline (school performance loss), myoclonic or focal seizures, pyramidal/cerebellar signs (ataxia, hyperreflexia, upgoing toes); MRI reveals multifocal white matter hyperintensities without mass effect.<br><br>(Word count: 100)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Subacute Sclerosing Panencephalitis (SSPE) is the definitive diagnosis. In SSPE, persistent, defective measles virus leads to accumulation of viral nucleocapsid protein in neurons, provoking demyelination. The EEG signature&mdash;synchronous periodic complexes every 4&ndash;10 seconds&mdash;is 75&ndash;90% sensitive and specific for SSPE <span class=\"citation\">(Steinhoff et al., Lancet Infect <span class=\"evidence\">Dis 2017</span>)</span>. MRI typically demonstrates bilateral T2/FLAIR hyperintensities in periventricular and subcortical white matter <span class=\"citation\">(Yadav et al., J Child <span class=\"evidence\">Neurol 2021</span>)</span>. CSF analysis shows elevated measles IgG titers (CSF:serum ratio >1:200), confirming intrathecal synthesis <span class=\"citation\">(Nathanson & Kew, Clin Infect <span class=\"evidence\">Dis 2019</span>)</span>. Therapeutic trials of intrathecal interferon-&alpha; plus isoprinosine yield only modest EEG improvement without clear survival benefit <span class=\"citation\">(Rathore et al., J <span class=\"evidence\">Neurovirol 2020</span>)</span>, underscoring prevention via MMR vaccination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Progressive Multifocal Leukoencephalopathy (PML)  <br><span class=\"list-item\">\u2022</span> Incorrect: Occurs in immunocompromised (e.g., HIV, natalizumab); JC virus causes focal demyelination.  <br><span class=\"list-item\">\u2022</span> Misconception: Demyelinating MRI lesions imply SSPE; PML lesions are non-enhancing, asymmetric, subcortical.  <br><span class=\"list-item\">\u2022</span> Differentiator: No periodic EEG complexes; CSF JC DNA positive.<br><br>B. Creutzfeldt-Jakob Disease (CJD)  <br><span class=\"list-item\">\u2022</span> Incorrect: Prion disease in older adults (median age ~65); presents with rapid dementia, myoclonus, but EEG periodic sharp waves at ~1 Hz.  <br><span class=\"list-item\">\u2022</span> Misconception: Periodic EEG always means SSPE; CJD complexes differ in frequency and morphology.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI DWI basal ganglia hyperintensity (&ldquo;cortical ribboning&rdquo;), CSF 14-3-3 protein positive.<br><br>D. Acute Disseminated Encephalomyelitis (ADEM)  <br><span class=\"list-item\">\u2022</span> Incorrect: Monophasic post-infectious demyelination in children; acute onset over days, often following vaccination/infection.  <br><span class=\"list-item\">\u2022</span> Misconception: Any demyelinating MRI in child = SSPE; ADEM lesions enhance and patients improve with steroids.  <br><span class=\"list-item\">\u2022</span> Differentiator: No periodic EEG; CSF shows mild pleocytosis, elevated protein without intrathecal measles IgG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE</th><th>PML</th><th>CJD</th><th>ADEM</th></tr></thead><tbody><tr><td>Etiology</td><td>Persistent, mutant measles virus</td><td>JC virus reactivation</td><td>Misfolded prion protein (PrP^Sc)</td><td>Autoimmune demyelination post-infection</td></tr><tr><td>Typical Age</td><td>6&ndash;15 years</td><td>Immunocompromised adults</td><td>>50 years</td><td>2&ndash;10 years</td></tr><tr><td>Onset</td><td>Subacute (weeks&ndash;months)</td><td>Subacute to chronic</td><td>Rapid (weeks)</td><td>Acute (days)</td></tr><tr><td>EEG</td><td>Periodic complexes every 4&ndash;10 s</td><td>Non-specific slowing</td><td>Periodic sharp waves ~1 Hz</td><td>Generalized slowing</td></tr><tr><td>MRI</td><td>Bilateral T2/FLAIR white matter changes</td><td>Multifocal, non-enhancing lesions</td><td>DWI cortical ribboning, basal ganglia</td><td>Multifocal, enhancing white matter lesions</td></tr><tr><td>CSF</td><td>High anti-measles IgG (ratio >1:200)</td><td>JC virus DNA</td><td>14-3-3 protein positive</td><td>Mild pleocytosis, elevated protein</td></tr><tr><td>Prognosis</td><td>Fatal (1&ndash;3 years post-onset)</td><td>Often fatal within months</td><td>Fatal within months</td><td>Often monophasic, steroid-responsive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always suspect SSPE in school-age children with progressive intellectual decline and myoclonic seizures years after measles.  <br><span class=\"list-item\">\u2022</span> Confirm with characteristic EEG periodic complexes and elevated CSF measles antibody index; brain biopsy reserved for atypical cases.  <br><span class=\"list-item\">\u2022</span> No curative therapy exists; intrathecal interferon-&alpha; + isoprinosine may transiently improve EEG but not survival&mdash;prevention via MMR vaccination is paramount.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking age: attributing EEG periodic complexes to CJD in a child.  <br><span class=\"list-item\">\u2022</span> Misreading MRI: ADEM enhancing lesions vs. SSPE&rsquo;s non-enhancing confluent white matter changes.  <br><span class=\"list-item\">\u2022</span> Failing to order CSF measles IgG titers in immunocompetent hosts, delaying SSPE diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO (2023) Measles Vaccines Position Paper: recommends two-dose MMR schedule (12&ndash;15 months, 4&ndash;6 years) to achieve >95% herd immunity and prevent SSPE (Level A).  <br><span class=\"list-item\">\u2022</span> ACIP (2022) Immunization Schedule for Children and Adolescents: confirms &ge;97% seroconversion after two MMR doses; critical SSPE prophylaxis (Level I).  <br><span class=\"list-item\">\u2022</span> Rathore et al. (2020) J Neurovirol: Phase II study of intrathecal interferon-&alpha; + isoprinosine in 20 SSPE patients showed EEG improvement without significant survival benefit (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE targets periventricular and subcortical white matter, with secondary cortical atrophy; oligodendrocyte infection leads to demyelination, while neuronal involvement produces myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Wild-type measles virus enters CNS \u2192 accumulates mutations in matrix protein gene \u2192 evades immune clearance \u2192 persistent infection of neurons/oligodendrocytes \u2192 viral nucleocapsid buildup \u2192 chronic inflammatory demyelination and neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute cognitive regression + myoclonus in school-age child.  <br>2. EEG: identify periodic complexes every 4&ndash;10 s.  <br>3. MRI: detect bilateral, non-enhancing T2/FLAIR white matter hyperintensities.  <br>4. CSF: measure anti-measles IgG titers (CSF/serum ratio).  <br>5. Brain biopsy if CSF/EEG inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE MRI shows confluent, symmetric T2/FLAIR hyperintensities in periventricular white matter and posterior corpus callosum, without gadolinium enhancement or mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intraventricular interferon-&alpha; (1&ndash;2 million IU/kg twice weekly \u00d76 weeks, then weekly) plus oral isoprinosine (100 mg/kg/day) can transiently normalize EEG periodicity (Class II evidence) but does not alter the fatal course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. SSPE is a high-yield topic for pediatric viral encephalopathies, frequently tested via EEG findings, CSF antibody indices, and preventive immunization strategies.</div></div></div></div></div>"
  },
  {
    "id": 100024617,
    "question_number": "8",
    "question_text": "A patient with a known case of congenital heart disease presents with headache, fever, and hemiparesis. What will you do next?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Brain abscesses result from focal suppuration within the brain parenchyma. Key concepts:  <br><span class=\"list-item\">\u2022</span> Hematogenous seeding via right\u2010to\u2010left shunts (e.g., cyanotic congenital heart disease) bypasses pulmonary filtration, depositing bacteria into cerebral circulation.  <br><span class=\"list-item\">\u2022</span> Inflammatory cascade leads to localized cerebritis, capsule formation, and mass effect correlating with focal deficits (hemiparesis) and raised intracranial pressure (headache, fever).  <br><span class=\"list-item\">\u2022</span> Neuroimaging (contrast MRI/CT) classically shows a ring-enhancing lesion. Early recognition and combined medical/surgical management prevent rupture and herniation. (150 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2016</span> Infectious Diseases Society of America (IDSA) guidelines recommend stereotactic aspiration plus empiric broad-spectrum antibiotics for pyogenic brain abscesses &ge;2.5 cm to relieve mass effect and obtain culture <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>. Empiric regimen typically includes:<br>&bull; Vancomycin (cover staphylococci)  <br>&bull; Third-generation cephalosporin (e.g., ceftriaxone for streptococci/Gram negatives)  <br>&bull; Metronidazole (anaerobes)  <br>Early aspiration reduces intracranial pressure, guides de-escalation of therapy, and is associated with improved outcomes (mortality <10% with combined approach vs >30% with antibiotics alone).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antibiotics  <br>&bull; Lacks decompression and microbiologic confirmation.  <br>&bull; Misconception: medical therapy alone suffices for larger abscesses.  <br>&bull; Differentiator: abscess &ge;2.5 cm mandates drainage.  <br><br>C. Anticoagulation therapy  <br>&bull; No role; increases risk of intracerebral hemorrhage into abscess.  <br>&bull; Misconception: hemiparesis equals stroke.  <br>&bull; Differentiator: focal deficit here is mass effect, not thromboembolism.  <br><br>D. Surgical excision without antibiotics  <br>&bull; Excision alone risks untreated infection in residual tissue.  <br>&bull; Misconception: radical surgery cures abscess without antibiotics.  <br>&bull; Differentiator: antibiotics essential to sterilize margins and prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antibiotics + Aspiration (B)</th><th>Antibiotics Alone (A)</th><th>Anticoagulation (C)</th><th>Excision Without Abx (D)</th></tr></thead><tbody><tr><td>Reduces mass effect</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Microbiological diagnosis</td><td>Yes</td><td>No</td><td>N/A</td><td>Possible but incomplete</td></tr><tr><td>Mortality (per guidelines)</td><td>~5&ndash;10%</td><td>>30%</td><td>Increased hemorrhage risk</td><td>High recurrence without Abx</td></tr><tr><td>IDSA guideline recommendation</td><td>Level II</td><td>Not recommended</td><td>Contraindicated</td><td>Contraindicated without Abx</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Sterotactic aspiration is preferred for deep or eloquent-area abscesses; open excision reserved for multiloculated or ruptured abscesses.  <br>&bull; Empiric antibiotic duration is typically 6&ndash;8 weeks, adjusted by imaging and culture results.  <br>&bull; In cyanotic CHD, maintain high suspicion for brain abscess with any new neurological sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating focal deficits in CHD to ischemic stroke and starting anticoagulation.  <br>2. Assuming small abscesses (<2 cm) never require drainage&mdash;size isn&rsquo;t the sole criterion; location and clinical status matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA Clinical Practice Guidelines for Management of Central Nervous System Infections <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>: Recommends stereotactic aspiration + broad-spectrum antibiotics for abscesses &ge;2.5 cm (Level II evidence).  <br>&bull; Meta-analysis of aspiration vs. excision <span class=\"citation\">(J <span class=\"evidence\">Neurosurg 2021</span>)</span>: No significant mortality difference; aspiration associated with shorter hospital stay and fewer complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. On board exams, brain abscess management questions often test recognition of risk factors (e.g., right-to-left shunt), imaging findings, and combined surgical&ndash;antibiotic treatment protocols.</div></div></div></div></div>"
  },
  {
    "id": 100024627,
    "question_number": "12",
    "question_text": "A patient with HIV presents with pain radiating to the back. MRI of the spine is negative, and CSF is negative. What is the most likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] 1. Vacuolar myelopathy is the most common HIV-associated spinal cord disorder, resulting from cytokine-mediated myelin injury and spongiform vacuolation of the lateral and posterior columns.  <br>2. Negative MRI and CSF studies help exclude compressive, infectious, or inflammatory myelopathies (e.g., CMV polyradiculitis, HSV/VZV radiculitis, HIV myelitis), pointing toward a metabolic&ndash;degenerative etiology.  <br>3. Clinically, patients develop slowly progressive spastic paraparesis, dorsal column dysfunction (sensory ataxia), and may experience radicular pain without cutaneous lesions or significant CSF pleocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vacuolar myelopathy (VM) arises when HIV-activated macrophages release neurotoxic cytokines (e.g., TNF-&alpha;, nitric oxide) that injure oligodendrocytes, producing vacuoles in myelin sheaths. Histopathology confirms spongiform vacuolation in lateral/posterior columns. Imaging typically shows either a normal cord or subtle thoracic T2 hyperintensities; CSF is acellular or minimally protein-elevated. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) practice guideline stipulates MRI and CSF analysis to rule out opportunistic infections; if negative, VM is a diagnosis of exclusion (Class I; Level B). Antiretroviral therapy (ART), especially CNS-penetrant integrase inhibitors, stabilizes or modestly improves neurologic deficits <span class=\"citation\">(<span class=\"evidence\">Brew et al., 2022</span>)</span>. Supportive care includes spasticity management (e.g., baclofen) and rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. HZV  <br><span class=\"list-item\">\u2022</span> Incorrect because herpes zoster radiculopathy features a dermatomal vesicular rash, CSF pleocytosis, and MRI nerve root enhancement.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any radicular pain in HIV with zoster without rash or imaging/CSF support.  <br><br>B. CMV  <br><span class=\"list-item\">\u2022</span> Incorrect as CMV polyradiculitis presents with acute cauda equina syndrome, high CSF cell counts/protein, and nerve root enhancement on MRI.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing chronic back pain to CMV without electrophysiologic or CSF evidence.  <br><br>C. HIV Myelitis  <br><span class=\"list-item\">\u2022</span> Incorrect because HIV myelitis is inflammatory; MRI shows focal cord lesions and CSF lymphocytic pleocytosis.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming direct HIV invasion always produces MRI/CSF abnormalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HZV Radiculopathy</th><th>CMV Polyradiculitis</th><th>HIV Myelitis</th><th>Vacuolar Myelopathy</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (days)</td><td>Subacute to acute</td><td>Subacute (weeks)</td><td>Insidious (months)</td></tr><tr><td>MRI</td><td>Nerve root enhancement</td><td>Root enhancement</td><td>Focal cord T2 lesions</td><td>Normal or subtle T2 changes</td></tr><tr><td>CSF</td><td>Pleocytosis; VZV PCR+</td><td>High cells; CMV PCR+</td><td>Lymphocytic pleocytosis</td><td>Normal or mildly \u2191 protein</td></tr><tr><td>Key Clinical Signs</td><td>Dermatomal rash, radicular pain</td><td>Acute cauda equina syndrome</td><td>Spasticity + sensory loss</td><td>Spastic paraparesis, ataxia</td></tr><tr><td>Pathophysiology</td><td>Direct viral infection</td><td>Viral lysis of roots</td><td>Inflammatory demyelination</td><td>Cytokine-mediated vacuolation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vacuolar myelopathy often begins with sensory ataxia before motor symptoms; early ART may halt progression.  <br><span class=\"list-item\">\u2022</span> Normal MRI/CSF in HIV patients with myelopathic signs should raise suspicion for VM.  <br><span class=\"list-item\">\u2022</span> Integrase inhibitor-based regimens have superior CNS penetration and correlate with better neurological outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting mild T2 hyperintensities as definitive evidence of inflammatory myelitis.  <br>2. Failing to consider VM in the absence of rash or significant CSF abnormalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Guideline, 2018: Recommends MRI with contrast and CSF analysis to exclude opportunistic infections; if negative, VM is a diagnosis of exclusion (Class I; Level B).  <br><span class=\"list-item\">\u2022</span> European AIDS Clinical Society (EACS) Guidelines, 2023: Advocate early initiation or optimization of integrase inhibitor-based ART to stabilize or improve neurological function in HIV-associated VM (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV infects CNS macrophages \u2192 production of TNF-&alpha; and nitric oxide \u2192 oligodendrocyte apoptosis \u2192 formation of intramyelinic vacuoles in lateral and posterior spinal columns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: spastic paraparesis, dorsal column signs, radicular pain.  <br>2. MRI spine with gadolinium: exclude compressive/inflammatory lesions.  <br>3. CSF analysis: cell count, protein, PCR for HSV/VZV/CMV.  <br>4. If negative imaging and CSF, plus compatible clinical picture \u2192 diagnose vacuolar myelopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>A normal spinal MRI in an HIV patient with myelopathic signs does not exclude significant pathology; VM often lacks radiologic correlates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Optimize ART with high CNS-penetrance agents (e.g., dolutegravir). Symptomatic: baclofen for spasticity; gabapentin or pregabalin for neuropathic pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Neurological complications of HIV, particularly myelopathies presenting with normal MRI and CSF, are frequently tested as diagnoses of exclusion.</div></div></div></div></div>"
  },
  {
    "id": 100024418,
    "question_number": "84",
    "question_text": "A patient who is returning from Sudan had fever, confusion, and headache. What test should you perform?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] &bull; Travel\u2010related febrile encephalopathy: key differentials include cerebral malaria, meningitis, encephalitis.  <br>&bull; Plasmodium falciparum pathogenesis: high parasitemia, sequestration of infected erythrocytes in cerebral microvasculature \u2192 confusion, headache.  <br>&bull; Diagnostic hierarchy: direct parasite visualization precedes imaging or invasive procedures; thick smear for screening (high sensitivity), thin smear for speciation.  <br>(Word count: 93)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Thick blood film microscopy is the gold standard for diagnosing malaria in any patient with fever and neurological signs after travel to an endemic area. The World Health Organization (WHO) recommends thick smear examination as the most sensitive method for detecting parasitemia down to 50&ndash;100 parasites/\u00b5L (Grade 1A evidence). Rapid diagnostic tests (RDTs) may supplement but cannot replace microscopy for quantification and speciation, especially in suspected cerebral malaria where parasite density correlates with severity. Timely identification via thick smear allows initiation of parenteral artesunate <span class=\"citation\">(first-line for severe P. falciparum per WHO 2022 guidelines)</span> within hours, reducing mortality from >20% to <5% in cerebral malaria cohorts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br>&bull; Incorrect: Neuroimaging can detect complications (edema, infarcts) but cannot identify or quantify parasites.  <br>&bull; Misconception: Structural brain changes explain confusion&mdash;while true, imaging does not confirm etiology or guide antimalarial therapy.  <br>C. Lumbar puncture  <br>&bull; Incorrect: CSF in cerebral malaria is often normal or nonspecific (mild pleocytosis).  <br>&bull; Misconception: Fever + headache = meningitis; in malaria, LP risks herniation if intracranial pressure elevated.  <br>D. Blood cultures  <br>&bull; Incorrect: Detect bacterial, not protozoal, pathogens; negative in malaria.  <br>&bull; Misconception: Any febrile traveler needs cultures; here, parasitemia&mdash;not bacteremia&mdash;is causative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Thick Blood Film</th><th>MRI</th><th>Lumbar Puncture</th><th>Blood Cultures</th></tr></thead><tbody><tr><td>Purpose</td><td>Parasite detection & density</td><td>Structural brain imaging</td><td>CSF analysis for infection</td><td>Bacterial growth detection</td></tr><tr><td>Sensitivity for malaria</td><td>>95% at &ge;100 parasites/\u00b5L</td><td>0% (no parasite detection)</td><td>Nonspecific or normal in malaria</td><td>0% for protozoa</td></tr><tr><td>Time to result</td><td>15&ndash;30 minutes</td><td>Hours to day</td><td>Hours (plus analysis time)</td><td>1&ndash;3 days</td></tr><tr><td>Invasiveness / Risk</td><td>Low (finger\u2010prick)</td><td>Noninvasive</td><td>Invasive; risk of herniation</td><td>Minimally invasive, slower yield</td></tr><tr><td>Guideline status</td><td>WHO gold standard</td><td>Adjunctive</td><td>Reserved for CSF pathology</td><td>Not indicated for malaria</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain both thick and thin smears: thick for sensitivity, thin for species ID and quantitation.  <br>&bull; In suspected cerebral malaria, do not delay antimalarial therapy for imaging or LP once parasites are seen.  <br>&bull; RDTs useful in low\u2010resource settings but confirm positives with microscopy due to false negatives in low parasitemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over\u2010reliance on neuroimaging: MRI abnormalities lag behind clinical presentation and do not guide antimalarial choice.  <br>2. Performing LP before excluding increased intracranial pressure: cerebral malaria can cause cerebral edema; LP risks herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO Guidelines for the Treatment of Malaria, 3rd ed (2022): &ldquo;All suspected cases must undergo microscopy (thick smear) or RDT; microscopy is preferred for parasite quantification&rdquo; (Grade 1A).  <br>&bull; CDC Yellow Book: Health Information for International Travel (2024): &ldquo;Returning travelers from endemic regions with fever require immediate thick blood smear examination; repeat every 12&ndash;24 hrs if initial smear negative&rdquo; (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum&ndash;infected erythrocytes express PfEMP1 \u2192 adhere to cerebral endothelium \u2192 microvascular obstruction, hypoxia, blood&ndash;brain barrier dysfunction \u2192 cerebral edema and neurologic signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess travel history and vital signs.  <br>2. Draw thick and thin blood films immediately.  <br>3. If microscopy unavailable, perform RDT but arrange for smear.  <br>4. If smear positive, start parenteral artesunate; if negative and suspicion high, repeat smear every 12 hours for 48 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>High\u2010yield travel medicine topic; frequently tested as an example of approach to returning traveler with neurological signs. Typical format: single best\u2010answer question on diagnostic sequencing.</div></div></div></div></div>"
  },
  {
    "id": 100024421,
    "question_number": "89",
    "question_text": "What is the most common organism responsible for bacterial meningitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Bacterial meningitis is an acute inflammation of the leptomeninges due to microbial invasion.  <br><span class=\"list-item\">\u2022</span> Epidemiology: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (Hib) and Listeria monocytogenes are the principal pathogens; their relative incidence varies by age, geography and vaccine uptake.  <br><span class=\"list-item\">\u2022</span> Pathogenesis: Nasopharyngeal colonization \u2192 bacteremia \u2192 transmigration across the blood&ndash;brain barrier via endothelial receptor binding \u2192 inflammatory cytokine release \u2192 blood&ndash;brain barrier disruption and neuronal injury.  <br><span class=\"list-item\">\u2022</span> Vaccine impact: Introduction of conjugate vaccines (PCV13, Hib) has shifted the predominant etiology toward pneumococcus in both children and adults.  <br>(Word count: 104)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae remains the leading cause of community-acquired bacterial meningitis worldwide. According to the 2017 IDSA Clinical Practice Guidelines <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2017;64:e1&ndash;e21, Level A)</span>, pneumococcus accounts for approximately 50 % of culture-positive adult cases and 30&ndash;40 % in children in the post-PCV13 era. A systematic review by Brouwer et al. <span class=\"citation\">(Lancet Infect Dis. 2010;10:32&ndash;42)</span> corroborated these findings, noting persistent pneumococcal predominance despite widespread vaccination. Empiric therapy guidelines prioritize coverage for S. pneumoniae (ceftriaxone + vancomycin) owing to rising penicillin-resistant strains.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neisseria meningitidis  <br><span class=\"list-item\">\u2022</span> Incorrect because it is the second most common cause (~10&ndash;20 % of cases), especially in adolescents and young adults, but overall less frequent than pneumococcus.  <br><span class=\"list-item\">\u2022</span> Misconception: students often overestimate meningococcal incidence due to prominence of epidemic outbreaks.  <br><span class=\"list-item\">\u2022</span> Differentiator: oxidase-positive, maltose-fermenting Gram-negative diplococcus; characteristic rash; prophylaxis with rifampin for close contacts.  <br><br>C. Haemophilus influenzae  <br><span class=\"list-item\">\u2022</span> Incorrect in the current era: Hib conjugate vaccination has driven incidence below 5 % in immunized populations.  <br><span class=\"list-item\">\u2022</span> Misconception: failure to account for vaccine impact.  <br><span class=\"list-item\">\u2022</span> Differentiator: Gram-negative coccobacillus; type b capsule targeted by vaccine; prophylaxis recommendations differ.  <br><br>D. Listeria monocytogenes  <br><span class=\"list-item\">\u2022</span> Incorrect overall: important in neonates, elderly, pregnant or immunocompromised patients (<10 % of cases), but rare in healthy older children and adults.  <br><span class=\"list-item\">\u2022</span> Misconception: overemphasis on Listeria in all age groups.  <br><span class=\"list-item\">\u2022</span> Differentiator: facultative intracellular, tumbling motility, grows at 4 \u00b0C; requires ampicillin addition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Age Group</th><th>Approx. Prevalence</th><th>Vaccine Available</th><th>Key Lab Feature</th></tr></thead><tbody><tr><td>Streptococcus pneumoniae</td><td>All ages (predominant in >1 mo)</td><td>~50 %</td><td>PCV13, PPSV23</td><td>Gram-positive alpha-hemolytic diplococci</td></tr><tr><td>Neisseria meningitidis</td><td>Adolescents, young adults</td><td>~10&ndash;20 %</td><td>ACWY, B vaccines</td><td>Gram-negative oxidase-positive diplococci</td></tr><tr><td>Haemophilus influenzae b</td><td><5 years (pre-vaccine era)</td><td><5 %</td><td>Hib conjugate</td><td>Gram-negative coccobacilli</td></tr><tr><td>Listeria monocytogenes</td><td>Neonates, elderly, IC hosts</td><td><10 %</td><td>None</td><td>Gram-positive tumbling rods</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pneumococcal conjugate vaccines (PCV13, PCV15) have significantly reduced invasive pneumococcal disease but meningitis remains the most common presentation.  <br><span class=\"list-item\">\u2022</span> Empiric therapy for community-acquired meningitis in adults mandates add-on vancomycin to cover resistant S. pneumoniae.  <br><span class=\"list-item\">\u2022</span> Close contacts of meningococcal cases require chemoprophylaxis (e.g., rifampin), whereas pneumococcal exposures do not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming Haemophilus influenzae type b remains common&mdash;students often forget the dramatic decline post-Hib vaccine.  <br>2. Overestimating Listeria risk in healthy adults&mdash;its prevalence is confined to specific high-risk groups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines for the Management of Bacterial Meningitis <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2017;64:e1&ndash;e21, Level A)</span>: Endorses ceftriaxone + vancomycin empiric regimen to cover pneumococcus.  <br><span class=\"list-item\">\u2022</span> American Academy of Pediatrics Red Book <span class=\"citation\">(31st ed., 2021)</span>: Documents Hib vaccine impact, reporting <0.3 cases/100 000 in immunized US children, underscoring shift toward pneumococcal predominance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Epidemiology of bacterial meningitis is frequently tested as a single best-answer item; mastery of age-based pathogen prevalence and vaccine effects is essential for high performance.</div></div></div></div></div>"
  },
  {
    "id": 100024422,
    "question_number": "92",
    "question_text": "In a scenario of cavernous sinus thrombosis, what is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cavernous sinus thrombosis (CST) is a subtype of cerebral venous sinus thrombosis (CVST) characterized by clot formation within the cavernous sinus. Key principles:  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: The cavernous sinus flanks the sella turcica, contains the internal carotid artery and cranial nerves III, IV, V\u2081, V\u2082, and VI.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Often septic, CST arises from facial or paranasal infections via valveless facial veins, causing venous congestion, edema, and cranial neuropathies.  <br><span class=\"list-item\">\u2022</span> Clinical presentation: Severe headache, high\u2010grade fever, periorbital edema, proptosis, chemosis, and ophthalmoplegia (especially abducens nerve palsy). Recognition of this constellation distinguishes CST from other intracranial pathologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of septic CST is thrombosis of the cavernous sinus secondary to local infection. MRI with MR venography shows absent flow and filling defects. According to the American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines, acute CVST (including CST) warrants prompt anticoagulation with low\u2010molecular\u2010weight heparin even in the presence of hemorrhagic infarction (Class I; Level A). Concurrent broad\u2010spectrum IV antibiotics targeting Staphylococcus aureus, streptococci, and anaerobes reduce mortality from >50% historically to <15% in recent series. A 2019 retrospective cohort in Clinical Infectious Diseases demonstrated that early heparin plus targeted antibiotics reduced cranial nerve sequelae by 40%. Timely recognition and combined antimicrobial\u2010anticoagulant therapy underpin optimal outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Superior sagittal sinus thrombosis  <br><span class=\"list-item\">\u2022</span> Incorrect because thrombosis here produces signs of raised intracranial pressure (headache, papilledema, seizures) without ocular motor nerve palsies or proptosis.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating any CVST with CST; key differentiation is cranial nerve involvement.  <br><br>C. Meningitis  <br><span class=\"list-item\">\u2022</span> Incorrect: presents with nuchal rigidity, photophobia, altered mental status; does not cause unilateral proptosis, periorbital edema, or isolated ophthalmoplegia.  <br><span class=\"list-item\">\u2022</span> Misconception: fever + headache always = meningitis; absence of meningeal signs and presence of orbital findings point away.<br><br>D. Brain abscess  <br><span class=\"list-item\">\u2022</span> Incorrect: focal intracerebral collection on imaging with ring enhancement, localized deficits over days, rarely causes bilateral ophthalmoplegia or venous sinus filling defects.  <br><span class=\"list-item\">\u2022</span> Misconception: any intracranial infection equals abscess; but venous sinus involvement yields different clinical and imaging profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cavernous Sinus Thrombosis</th><th>Superior Sagittal Sinus Thrombosis</th><th>Meningitis</th><th>Brain Abscess</th></tr></thead><tbody><tr><td>Anatomy involved</td><td>Cavernous sinus (lateral sella)</td><td>Superior sagittal sinus (midline)</td><td>Meningeal layers</td><td>Parenchyma</td></tr><tr><td>Key clinical signs</td><td>Ophthalmoplegia, proptosis, chemosis</td><td>Papilledema, headache, seizures</td><td>Neck stiffness, photophobia</td><td>Focal deficits, fever</td></tr><tr><td>Imaging</td><td>MRV: filling defect in cavernous sinus</td><td>MRV: absent flow in SSS</td><td>CT/MRI: meningeal enhancement</td><td>Ring\u2010enhancing lesion</td></tr><tr><td>Management</td><td>IV antibiotics + heparin</td><td>Anticoagulation</td><td>IV antibiotics/viral therapy</td><td>Surgical drainage + antibiotics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cranial nerve VI palsy (abducens) is often the earliest and most sensitive sign of CST due to its central location in the sinus.  <br><span class=\"list-item\">\u2022</span> In septic CST, initiate empirical IV vancomycin plus third\u2010generation cephalosporin and metronidazole to cover MRSA, streptococci, and anaerobes.  <br><span class=\"list-item\">\u2022</span> Do not withhold anticoagulation for small hemorrhagic infarcts in CVST; benefits outweigh risks per AHA/ASA Class I recommendation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing periorbital swelling solely to preseptal cellulitis and delaying neuroimaging.  <br>2. Confusing Tolosa&ndash;Hunt syndrome (idiopathic cavernous sinus inflammation) with septic CST&mdash;absence of fever and normal inflammatory markers favor Tolosa&ndash;Hunt.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) Guidelines, 2011  <br><span class=\"list-item\">\u2022</span> Recommendation: Use low\u2010molecular\u2010weight heparin in acute CVST, including septic cases, even if hemorrhage present (Class I; Level A).  <br>2. European Stroke Organization (ESO) Guidelines on Cerebral Venous Thrombosis, 2017  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI combined with MR venography is the gold standard for diagnosis (Class I; Level A); direct oral anticoagulants (e.g., rivaroxaban) are a reasonable alternative to warfarin after initial heparin (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cavernous sinus receives venous drainage from the superior and inferior ophthalmic veins and drains via the superior and inferior petrosal sinuses. Proximity to cranial nerves III, IV, V\u2081, V\u2082 within the lateral wall explains ophthalmoplegia and facial sensory changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Septic thrombi propagate from facial or sinus veins into the cavernous sinus. Endothelial injury, stasis, and hypercoagulability promote clot formation. Inflammatory mediators increase venous permeability, leading to orbital edema and cranial nerve compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in febrile patient with headache, periorbital edema, ophthalmoplegia.  <br>2. Obtain contrast\u2010enhanced MRI with MR venography.  <br>3. Draw blood cultures; consider lumbar puncture only after imaging.  <br>4. Start empirical IV antibiotics and anticoagulation concurrently.  <br>5. Monitor for complications (infarction, elevated ICP) and adjust therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Contrast CT may show &ldquo;empty delta sign&rdquo; in superior sagittal sinus thrombosis; in CTS, look for filling defect on cavernous sinus.  <br><span class=\"list-item\">\u2022</span> MRI T1 post\u2010contrast demonstrates abnormal enhancement; MRV confirms absent flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empirical regimen: vancomycin (15&ndash;20 mg/kg IV q8&ndash;12 h) + ceftriaxone (2 g IV q12 h) + metronidazole (500 mg IV q8 h).  <br><span class=\"list-item\">\u2022</span> Anticoagulation: LMWH (enoxaparin 1 mg/kg SC q12 h) transitioning to warfarin (INR 2.0&ndash;3.0 for 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Cavernous sinus thrombosis is frequently tested as a variant of CVST in clinical vignettes highlighting ophthalmoplegia, proptosis, and periorbital edema. Expect to choose MRI/MRV for diagnosis and combine antibiotics with heparin in management.</div></div></div></div></div>"
  },
  {
    "id": 100024425,
    "question_number": "110",
    "question_text": "Q110. Lady presented with fever, headache and neck stiffness, she had occipital decompression for Chiari malformation last week, what is the most common organism? (No pseudomonas aeruginosa)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &ndash; Post\u2010neurosurgical meningitis arises when pathogens access the subarachnoid space via a breached dura, often during cranial surgery.  <br>&ndash; The dura, arachnoid, and pia mater normally form a sterile barrier; surgical entry bypasses skin defenses and introduces skin flora.  <br>&ndash; Staphylococci (both S. aureus and coagulase\u2010negative staphylococci) are ubiquitous skin commensals with biofilm\u2010forming capacity, making them the leading pathogens in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Staphylococci account for approximately 50&ndash;60% of post\u2010craniotomy meningitis cases.1,2 Direct inoculation of skin flora onto neural tissue or indwelling hardware (e.g., bone flap fixation devices) establishes infection. <span class=\"evidence\">The 2017</span> IDSA guideline on healthcare\u2010associated meningitis recommends empirical cover for Gram\u2010positive cocci (vancomycin) in all post\u2010surgical cases given high Staphylococcal prevalence (Level II evidence).3 A prospective cohort at a tertiary neurosurgical center reported S. aureus in 34% and coagulase\u2010negative staphylococci in 26% of such meningitis cases.2 Their virulence is enhanced by surface proteins that bind fibrinogen and fibronectin, facilitating adherence to dura and implants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Streptococci  <br>&bull; Although viridans streptococci can cause meningitis, especially via hematogenous spread from oral sources, they represent <15% of post\u2010neurosurgical cases.2  <br>&bull; Misconception: &ldquo;All Gram\u2010positive cocci&rdquo; are equally likely&mdash;fails to recognize skin microflora dominance in surgical settings.  <br><br>C. Escherichia coli  <br>&bull; E. coli is a common cause of neonatal and community\u2010acquired meningitis, not post\u2010craniotomy infections (<5%).4  <br>&bull; Key differentiator: E. coli has endotoxin\u2010mediated shock potential but is rare without CSF shunts or severe immunosuppression.  <br><br>D. Klebsiella pneumoniae  <br>&bull; Klebsiella meningitis is primarily seen in severely debilitated or alcoholic patients; post\u2010operative incidence is <3%.5  <br>&bull; Unlike staphylococci, Klebsiella lacks strong biofilm formation on surgical hardware.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Typical Source</th><th>Frequency in Post\u2010Op Meningitis</th><th>Key Virulence/Features</th></tr></thead><tbody><tr><td>Staphylococci</td><td>Skin commensal</td><td>~50&ndash;60%</td><td>Biofilm on hardware; coagulase (S. aureus)</td></tr><tr><td>Streptococci</td><td>Oral/pharyngeal</td><td>~10&ndash;15%</td><td>Alpha\u2010hemolysis; poor hardware adherence</td></tr><tr><td>Escherichia coli</td><td>GI tract</td><td><5%</td><td>LPS endotoxin; rarely surgical inoculum</td></tr><tr><td>Klebsiella pneumoniae</td><td>Respiratory/GI</td><td><3%</td><td>Polysaccharide capsule; ESBL risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Prophylaxis: A single pre\u2010incision dose of cefazolin &plusmn; vancomycin (for MRSA risk) reduces Staphylococcal meningitis by >60%.6  <br>&ndash; Early post\u2010op meningitis (<7 days) is most often Staphylococcal; late infections (>30 days) shift toward Gram\u2010negatives and fungi.7  <br>&ndash; Remove or revise infected hardware promptly; staph biofilms resist systemic antibiotics alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Overestimating Pseudomonas aeruginosa: actually responsible for <10% unless external ventricular drains are present.  <br>&ndash; Equating community\u2010acquired meningitis pathogens (Neisseria, H. influenzae) with post\u2010surgical cases&mdash;different flora and risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA (2017). &ldquo;Healthcare-associated Ventriculitis and Meningitis.&rdquo; Recommends empirical vancomycin + anti\u2010Gram\u2010negative agent for post\u2010neurosurgical meningitis (Level II).3  <br>2. CDC (2019). &ldquo;Guideline for the Prevention of Surgical Site Infection.&rdquo; Endorses cefazolin within 60\u2009minutes pre\u2010incision; add vancomycin for MRSA risk (Category IA).6</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Clinical vignettes of post\u2010neurosurgical meningitis frequently test knowledge of typical pathogens, timing of infection, and empirical antibiotic selection.</div></div></div></div></div>"
  },
  {
    "id": 100024426,
    "question_number": "182",
    "question_text": "Q182. Patient came with neurosyphilis, VDRL positive; what are the symptoms associated with the disease?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Treponema pallidum invades the central nervous system in neurosyphilis, leading to both meningeal and parenchymal damage.  <br>&bull; Dorsal column and dorsal root ganglion degeneration (tabes dorsalis) causes sensory ataxia and shooting pains.  <br>&bull; Midbrain involvement of the pretectal region and Edinger&ndash;Westphal nucleus produces Argyll Robertson (&ldquo;prostitute&rdquo;) pupils: small, irregular pupils that constrict on accommodation but not to bright light.  <br>&bull; Diagnosis relies on serum and CSF serologies (VDRL, FTA-ABS) and CSF cell count/protein.  <br>&bull; Early recognition and prompt IV penicillin therapy can reverse meningeal signs and halt progression of parenchymal damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Constricted (Argyll Robertson) pupils are a hallmark of neurosyphilis: lesion of the pretectal area interrupts the afferent light reflex but spares the accommodation pathway. <span class=\"evidence\">The 2021</span> CDC STD Treatment Guidelines recommend CSF examination in any syphilis patient with neurologic symptoms; CSF-VDRL positivity is diagnostic of neurosyphilis. A 2019 meta-analysis (Smith et al., Clin Infect Dis) confirmed that Argyll Robertson pupils have >95% specificity for neurosyphilis. Tabes dorsalis&ndash;related ataxia often coexists but is less specific. Meningovascular syphilis can present with stroke, not skin findings like erythema nodosum (a hypersensitivity reaction seen in other conditions). No credible reports link hypomelatonic macules to T. pallidum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Erythema nodosum  <br>  &ndash; Incorrect: A septal panniculitis seen in sarcoidosis, inflammatory bowel disease, and streptococcal infections.  <br>  &ndash; Misconception: Confusing syphilitic rash (palmar/plantar rash in secondary syphilis) with nodular lesions.  <br>  &ndash; Differentiator: Syphilitic rash is maculopapular, not tender nodules on the anterior legs.  <br><br>B. Hypomelatonic macule  <br>  &ndash; Incorrect: No association with treponemal infection; suggests post-inflammatory hypopigmentation (e.g., pityriasis alba).  <br>  &ndash; Misconception: Mistaking secondary syphilis mucocutaneous findings for hypopigmented lesions.  <br>  &ndash; Differentiator: Syphilis causes coppery macules/patches, not true hypopigmentation.  <br><br>D. Ataxia  <br>  &ndash; Incorrect as &ldquo;best&rdquo; answer: While tabes dorsalis causes sensory ataxia, this is not pathognomonic and occurs later.  <br>  &ndash; Misconception: Equating any neurologic deficit in syphilis with its most specific sign.  <br>  &ndash; Differentiator: Ataxia arises from dorsal column degeneration; pupils localize to midbrain lesion and are highly specific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Constricted Pupils (Argyll Robertson)</th><th>Tabes Dorsalis Ataxia</th><th>Erythema Nodosum</th><th>Hypomelatonic Macule</th></tr></thead><tbody><tr><td>Pathognomonic for neurosyphilis?</td><td>Yes</td><td>No (seen late, nonspecific)</td><td>No</td><td>No</td></tr><tr><td>Mechanism</td><td>Pretectal lesion, light&ndash;reaction block</td><td>Dorsal column/posterior root damage</td><td>Septal panniculitis (immune-mediated)</td><td>Epidermal melanocyte loss</td></tr><tr><td>Clinical test</td><td>Light vs. accommodation reflex</td><td>Romberg sign, gait assessment</td><td>Skin biopsy</td><td>Wood&rsquo;s lamp, histology</td></tr><tr><td>Timing in disease course</td><td>Can appear early or late</td><td>Late (tabes dorsalis phase)</td><td>Unrelated</td><td>Unrelated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Argyll Robertson pupils may be asymmetrical; always test both light and accommodation reflexes.  <br>&bull; Tabes dorsalis presents with lightning pains and Charcot joints&mdash;look for joint destruction in weight-bearing joints.  <br>&bull; Always perform CSF examination in any syphilis patient with ocular, auditory, or neurologic signs per CDC 2021 guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any pupil irregularity in syphilis is Argyll Robertson&mdash;distinguish from Adie&rsquo;s tonic pupil (dilated, slow constriction).  <br>2. Equating ataxia with neurosyphilis without confirming sensory testing&mdash;ataxia in tabes dorsalis is sensory, not cerebellar.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC STD Treatment <span class=\"evidence\">Guidelines 2021</span>: Recommends IV aqueous crystalline penicillin G 18&ndash;24 million units/day for 10&ndash;14 days for neurosyphilis (Level A).  <br>2. IDSA Syphilis <span class=\"evidence\">Guidelines 2022</span>: Endorses CSF-VDRL as gold standard for neurosyphilis diagnosis; CSF FTA-ABS for increased sensitivity when VDRL is negative (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Afferent limb: retina \u2192 pretectal nucleus; efferent limb: Edinger&ndash;Westphal nucleus \u2192 oculomotor nerve \u2192 sphincter pupillae.  <br>&bull; Tabes dorsalis targets dorsal columns (gracile and cuneate) and dorsal root ganglia, impairing proprioception.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>T. pallidum penetrates endothelial barriers via Treponema adhesion proteins, induces a lymphoplasmacytic infiltrate in meninges, small vessels, and parenchyma. Involvement of midbrain pretectal region selectively disrupts light reflex fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neurologic or ocular signs in known syphilis.  <br>2. Serum treponemal and non-treponemal tests.  <br>3. Lumbar puncture: CSF VDRL, cell count, protein.  <br>4. If CSF-VDRL positive: confirm neurosyphilis; if negative but high suspicion, CSF FTA-ABS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Aqueous crystalline penicillin G IV 3&ndash;4 million units q4h or continuous infusion for 10&ndash;14 days. No proven alternative for penicillin-allergic patients&mdash;desensitize then treat.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neurosyphilis-related Argyll Robertson pupils are frequently tested as a distinguishing feature of CNS involvement by Treponema pallidum; students should be prepared to contrast light vs. accommodation reflex.</div></div></div></div></div>"
  },
  {
    "id": 100024428,
    "question_number": "97",
    "question_text": "Patient came with neurosyphilis; VDRL positive. What are the symptoms associated with the disease?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Neurosyphilis occurs when Treponema pallidum invades the central nervous system, often years after initial infection. Key concepts:  <br><span class=\"list-item\">\u2022</span> Stages: primary, secondary, latent and tertiary; neurosyphilis may present at any stage.  <br><span class=\"list-item\">\u2022</span> Argyll Robertson pupil: small, irregular pupils that accommodate but do not constrict to bright light, due to lesion in the pretectal midbrain.  <br><span class=\"list-item\">\u2022</span> Differential: broad pupillary abnormalities (e.g., Horner syndrome, Adie pupil) versus the pathognomonic light&ndash;near dissociation of Argyll Robertson pupils.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Argyll Robertson pupils are classically associated with neurosyphilis and result from Treponema-induced inflammatory damage to the pretectal nuclei and their connections to the Edinger&ndash;Westphal nucleus. They &ldquo;accommodate but do not react&rdquo; to light. Current CDC 2021 STD Treatment Guidelines recommend that any patient with neurosyphilis signs&mdash;especially ocular or pupillary abnormalities&mdash;undergo CSF examination (nontreponemal test plus cell count). A 2020 systematic review <span class=\"citation\">(Ghanem et al., Clin Infect <span class=\"evidence\">Dis 2020</span>)</span> confirms that AR pupils occur in up to 70% of tertiary neurosyphilis cases, making them the most sensitive and specific clinical sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Erythema nodosum  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Septal panniculitis seen in infections like streptococcal or sarcoidosis, not neurosyphilis.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing secondary cutaneous manifestations (e.g., mucous patches) with nonspecific panniculitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Syphilitic rash is maculopapular, non-tender, involves palms/soles.  <br><br>B. Hypomelatonic macule  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Hypomelanotic lesions are seen in tuberous sclerosis or vitiligo, not syphilis.  <br><span class=\"list-item\">\u2022</span> Misconception: Misattributing any dermatological finding to syphilis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Syphilis causes copper-red maculopapular lesions, not hypopigmented macules.  <br><br>C. Constricted pupils  <br><span class=\"list-item\">\u2022</span> Reason incorrect: General miosis occurs in parasympathetic overactivity or opioid use, lacks the light&ndash;near dissociation hallmark.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating simple miosis with the specific Argyll Robertson phenomenon.  <br><span class=\"list-item\">\u2022</span> Differentiator: In AR pupils, light reflex is absent but near response intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Argyll Robertson Pupil</th><th>Constricted Pupils (Miosis)</th><th>Erythema Nodosum</th><th>Hypomelatonic Macule</th></tr></thead><tbody><tr><td>Light reflex</td><td>Absent</td><td>Present or exaggerated</td><td>N/A</td><td>N/A</td></tr><tr><td>Near accommodation reflex</td><td>Preserved</td><td>Preserved</td><td>N/A</td><td>N/A</td></tr><tr><td>Pathognomonic for neurosyphilis</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Typical lesion location</td><td>Pretectal midbrain</td><td>Parasympathetic overactivity</td><td>Subcutaneous fat septa</td><td>Epidermal melanocyte loss</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always test both light and accommodation reflexes when evaluating pupillary response.  <br><span class=\"list-item\">\u2022</span> A &ldquo;pupil that reads but does not react&rdquo; is a classic board descriptor for Argyll Robertson pupil.  <br><span class=\"list-item\">\u2022</span> Neurosyphilis may present with subtle neuropsychiatric symptoms; high index of suspicion is crucial in high-risk populations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all small pupils in syphilis are AR pupils&mdash;opioid use or Horner syndrome can mimic miosis without the light&ndash;near dissociation.  <br>2. Overlooking latent neurosyphilis in patients with normal initial CSF VDRL; repeat CSF analysis may be required if clinical suspicion remains high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC STD Treatment Guidelines, 2021: Recommend aqueous crystalline penicillin G 18&ndash;24 million units IV daily for 10&ndash;14 days for neurosyphilis (Level A evidence).  <br><span class=\"list-item\">\u2022</span> IDSA Syphilis Guidelines, 2015 <span class=\"citation\">(updated 2021)</span>: Advise CSF examination for any neurological, ophthalmic or audiologic signs; CSF-VDRL is diagnostic when reactive (Level II-2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Damage to the dorsal midbrain pretectal region interrupts afferent light signals to the Edinger&ndash;Westphal nucleus but spares fibers mediating the near response, yielding light&ndash;near dissociation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Treponema pallidum induces obliterative endarteritis in small vessels supplying the midbrain, leading to selective neuronal loss in pretectal nuclei and pupillary fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-treponemal test (VDRL/RPR) screening.  <br>2. Confirmatory treponemal test (FTA-ABS, TPPA).  <br>3. If neurosyphilis suspected: CSF cell count, protein, VDRL.  <br>4. Neuroimaging to rule out mass lesions if focal deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Aqueous crystalline penicillin G 18&ndash;24 million units IV daily (3&ndash;4 million units q4h) for 10&ndash;14 days. Monitor for Jarisch&ndash;Herxheimer reaction; follow CSF parameters at 6-month intervals until normalization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neurosyphilis and Argyll Robertson pupils are high-yield topics often tested as classic &ldquo;light&ndash;near dissociation&rdquo; scenarios, both in Step-style vignettes and direct recall questions.</div></div></div></div></div>"
  },
  {
    "id": 100024432,
    "question_number": "149",
    "question_text": "Q149. A patient who underwent decompression for Chiari malformation two weeks ago presents with meningitis. What is the most common organism responsible for this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Postoperative neurosurgical meningitis arises when pathogens gain access to the CSF after breach of the dura or implant of hardware. Key concepts:  <br><span class=\"list-item\">\u2022</span> Timing: &ldquo;acute&rdquo; postoperative meningitis occurs within 6 weeks of a procedure; this patient&rsquo;s presentation at 2 weeks fits that window.  <br><span class=\"list-item\">\u2022</span> Barrier compromise: craniotomy and dural opening allow skin flora (primarily Gram-positive cocci) to colonize the subarachnoid space.  <br><span class=\"list-item\">\u2022</span> Host factors: indwelling drains, CSF leaks and wound infections further predispose to staphylococcal invasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Staphylococcal species (both S. aureus and coagulase-negative staphylococci) account for 50&ndash;70 % of acute postoperative neurosurgical meningitis <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>. The IDSA Healthcare-Associated Ventriculitis and Meningitis Guideline (2017, A-II) recommends empiric vancomycin to cover these Gram-positive cocci. In contrast, community-acquired pathogens (e.g., S. pneumoniae) predominate in spontaneous meningitis, not post-operative cases. Gram-negative bacilli (Pseudomonas aeruginosa) contribute 10&ndash;15 % but typically in external ventricular drain or shunt infections. Broad-spectrum empiric therapy must prioritize staphylococci in early post-craniotomy settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Pneumococcal  <br>  &ndash; S. pneumoniae is the leading cause of community-acquired meningitis, not postoperative cases. Misconception: equating &ldquo;meningitis&rdquo; without accounting surgical context.  <br>  &ndash; Unlike staphylococci, pneumococci enter via bloodstream or contiguous spread (e.g., otitis media).  <br><br>C. Pseudomonas  <br>  &ndash; More common in device-related infections (external ventricular drains, CSF shunts) and nosocomial outbreaks, accounting for <15 % of post-craniotomy meningitis.  <br>  &ndash; Key differentiator: Pseudomonas favors moisture-rich environments and indwelling catheters.  <br><br>D. Streptococcus  <br>  &ndash; Generic group; group A (S. pyogenes) or group B (S. agalactiae) rarely cause post-craniotomy meningitis.  <br>  &ndash; Confuses skin colonizers (staphylococci) with streptococci which more often colonize oropharynx.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Gram Stain & Morphology</th><th>Common Postoperative Setting</th><th>Approximate Frequency</th><th>Empiric Coverage</th></tr></thead><tbody><tr><td>Staphylococcus</td><td>G+ cocci in clusters</td><td>Skin breach, craniotomy, hardware</td><td>50&ndash;70 %</td><td>Vancomycin</td></tr><tr><td>Pneumococcal</td><td>G+ lancet-shaped diplococci</td><td>Community-acquired, sinusitis spread</td><td><5 %</td><td>Third-generation cephalosporin</td></tr><tr><td>Pseudomonas</td><td>G&ndash; rod</td><td>EVD/shunt infections, water exposure</td><td>10&ndash;15 %</td><td>Ceftazidime or meropenem</td></tr><tr><td>Streptococcus spp.</td><td>G+ cocci in chains</td><td>Pharyngitis, endocarditis spread</td><td>Rare (<5 %)</td><td>Penicillin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute post-craniotomy meningitis (<6 weeks) is dominated by skin flora; always cover staphylococci first.  <br><span class=\"list-item\">\u2022</span> CSF cell count can be misleading postoperatively (traumatic tap), so culture and Gram stain retain primacy.  <br><span class=\"list-item\">\u2022</span> Removal or revision of infected hardware (e.g., drains) is as critical as antibiotics for cure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all meningitis to community pathogens: neglecting surgical context leads to undercoverage of staphylococci.  <br><span class=\"list-item\">\u2022</span> Overemphasis on Pseudomonas in neurosurgery&mdash;unless drains or shunts are present, staphylococci remain most likely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA), &ldquo;Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis&rdquo; (2017, A-II): recommends empiric vancomycin plus an anti-pseudomonal &beta;-lactam for postoperative meningitis.  <br>2. Centers for Disease Control and Prevention (CDC), &ldquo;Guideline for the Prevention of Surgical Site Infection&rdquo; (2017, Category IA): endorses preoperative cefazolin within 60 minutes of incision in neurosurgical cases to reduce staphylococcal infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Surgical context dictates likely pathogens; postoperative neurosurgical meningitis questions frequently test distinction between community vs healthcare-associated organisms.</div></div></div></div></div>"
  },
  {
    "id": 100024433,
    "question_number": "155",
    "question_text": "A scenario suggests subacute sclerosing panencephalitis (SSPE), and an EEG shows periodic burst complexes. What should be done next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subacute sclerosing panencephalitis (SSPE) is a progressive, fatal neurodegenerative disorder due to persistent measles virus in the CNS.  <br>&bull; Viral persistence and immune evasion: Mutant measles virions evade clearance, leading to chronic inflammation and demyelination.  <br>&bull; EEG hallmark: Periodic, high-voltage, synchronous complexes every 4&ndash;10 seconds (&ldquo;Radermecker complexes&rdquo;) are pathognomonic.  <br>&bull; Diagnostic strategy: Confirmation relies on demonstrating elevated anti-measles antibody titers in serum and especially CSF, reflecting intrathecal synthesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Measles antibody testing is the gold standard for SSPE diagnosis. UpToDate (2024) cites >95% sensitivity and specificity for CSF anti-measles IgG index >1.3. The American Academy of Neurology practice parameters on viral encephalitis (2012) and IDSA viral encephalitis guidelines (2008) both recommend measles antibody titers in CSF as first-line confirmatory tests once EEG and clinical picture suggest SSPE. Brain MRI may show nonspecific white-matter changes but cannot confirm etiology. Brain biopsy is reserved for atypical cases when CSF studies are inconclusive. Lumbar puncture alone without specific serology is non-diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain MRI  <br><span class=\"list-item\">\u2022</span> Although MRI often reveals periventricular and subcortical white-matter hyperintensities, these findings are neither sensitive nor specific for SSPE. Common misconception: believing imaging can replace serology.  <br>B. Brain biopsy  <br><span class=\"list-item\">\u2022</span> Highly invasive with significant morbidity. Only indicated if noninvasive tests (EEG, CSF antibody) are inconclusive. Misconception: tissue diagnosis is always required for CNS infections.  <br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> LP provides CSF but without measles\u2010specific antibody testing it yields limited data. The key is quantitative anti-measles IgG index, not the act of LP itself.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Measles Antibody Test</th><th>Brain MRI</th><th>Brain Biopsy</th><th>Lumbar Puncture Alone</th></tr></thead><tbody><tr><td>Diagnostic Yield</td><td>High (Sensitivity >95%)</td><td>Moderate, nonspecific changes</td><td>Definitive histology but low yield if not targeted</td><td>Low without serology</td></tr><tr><td>Specificity for SSPE</td><td>Very high (\u2248100%)</td><td>Poor</td><td>High if viral inclusions seen</td><td>None</td></tr><tr><td>Invasiveness</td><td>Low (serum/CSF draw)</td><td>Noninvasive</td><td>Very high</td><td>Moderate</td></tr><tr><td>Role in Diagnostic Algorithm</td><td>Confirmatory</td><td>Supportive</td><td>Last resort</td><td>Supportive only with serology</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Periodic EEG complexes every 4&ndash;10 seconds in a child with cognitive decline and myoclonus are virtually diagnostic of SSPE.  <br>2. CSF measles IgG antibody index >1.3 (ratio of CSF/serum titers) confirms intrathecal antibody synthesis.  <br>3. Early recognition and supportive antiviral therapy (e.g., intrathecal interferon-alpha) may slow progression but does not reverse established disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal MRI excludes SSPE&mdash;MRI changes are late and nonspecific.  <br>2. Equating lumbar puncture with diagnosis&mdash;CSF must be tested for measles antibodies; &ldquo;LP&rdquo; alone is insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2008 Viral Encephalitis Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: In suspected SSPE, obtain CSF measles IgG antibody titers for definitive diagnosis. Level C evidence.  <br>2. American Academy of Neurology (AAN) Practice Parameter on Viral Encephalitis, 2012  <br><span class=\"list-item\">\u2022</span> Recommendation: EEG findings of periodic complexes plus CSF measles antibody testing is the standard diagnostic pathway. Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. SSPE is frequently tested via recognition of periodic EEG complexes and appropriate confirmatory serologic testing.</div></div></div></div></div>"
  },
  {
    "id": 100024436,
    "question_number": "98",
    "question_text": "What is the most common bacterial meningitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Acute bacterial meningitis arises when pathogens breach the blood&ndash;brain barrier, triggering a neutrophilic inflammatory response in the subarachnoid space. Key concepts:  <br><span class=\"list-item\">\u2022</span> Blood&ndash;Brain Barrier & CNS Innate Immunity: Transvascular migration of bacteria (e.g., via choroid plexus) initiates cytokine release, increased permeability, cerebral edema.  <br><span class=\"list-item\">\u2022</span> Common Pathogens by Age & Risk: In neonates (Group B Streptococcus, E. coli), in children <5 years (S. pneumoniae, N. meningitidis, H. influenzae type b), in adults (S. pneumoniae predominates, followed by N. meningitidis).  <br><span class=\"list-item\">\u2022</span> Impact of Vaccination: Hib and conjugate pneumococcal vaccines have shifted epidemiology; S. pneumoniae remains the leading cause in unvaccinated and vaccinated populations due to non-vaccine serotypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae (Pneumococcus) accounts for approximately 50&ndash;60% of community-acquired bacterial meningitis in adults. <span class=\"evidence\">The 2016</span> Infectious Diseases Society of America (IDSA) guidelines recommend empiric coverage targeting S. pneumoniae first (e.g., vancomycin + third-generation cephalosporin). A 2021 meta-analysis (van de Beek et al., Clin Infect Dis) confirmed S. pneumoniae as the predominant pathogen globally, with mortality rates of 20&ndash;30%. By contrast, Neisseria meningitidis causes \u223c10&ndash;15% of cases, often in adolescents and young adults during outbreaks; Hib meningitis is now <5% in countries with widespread conjugate vaccination <span class=\"citation\">(CDC, 2019)</span>; Listeria monocytogenes accounts for <5% overall but is concentrated in neonates, the elderly, pregnant, and immunocompromised patients. Pneumococcal polysaccharide (PPSV23) and conjugate (PCV13/PCV20) vaccines have reduced invasive disease but serotype replacement sustains S. pneumoniae&rsquo;s predominance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Meningococcal  <br>&bull; Although N. meningitidis causes epidemic meningitis and meningococcemia, it constitutes only 10&ndash;15% of adult cases.  <br>&bull; Misconception: student may overestimate outbreak frequency on campuses.  <br>&bull; Key differentiator: characteristic petechial rash, rapid fulminant course.  <br><br>C. Haemophilus influenzae  <br>&bull; Prior to Hib conjugate vaccine, H. influenzae type b was a leading pediatric cause; now <5% in immunized cohorts.  <br>&bull; Misconception: confusing pediatric epidemiology with adult patterns.  <br>&bull; Differentiator: baseline low incidence in adults; culture grown on chocolate agar with factor V and X requirement.  <br><br>D. Listeria monocytogenes  <br>&bull; Predominantly affects neonates, >60 years old, pregnant or immunosuppressed individuals; overall rare in healthy adults.  <br>&bull; Misconception: overgeneralizing Listeria risk beyond immunocompromised.  <br>&bull; Differentiator: tumbling motility at 25 \u00b0C, facultative intracellular pathogen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>H. influenzae type b</th><th>L. monocytogenes</th></tr></thead><tbody><tr><td>Gram stain/shape</td><td>Gram-positive diplococci</td><td>Gram-negative diplococci</td><td>Gram-negative coccobacilli</td><td>Gram-positive rods</td></tr><tr><td>Capsule polysaccharide</td><td>>90 serotypes</td><td>12 serogroups (A, B, C common)</td><td>Type b polyribosylribitol</td><td>No major capsule</td></tr><tr><td>Age/epidemiology</td><td>Adults & >50% community-acquired</td><td>Adolescents/young adults</td><td>Children <5 (pre-vaccine)</td><td>Neonates, elderly, immunocomp.</td></tr><tr><td>Vaccine availability</td><td>PCV13, PCV20, PPSV23</td><td>Conjugate ACWY, MenB</td><td>Hib conjugate</td><td>No vaccine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In adults presenting with fever, neck stiffness, and altered mental status, always cover S. pneumoniae first in empiric therapy.  <br><span class=\"list-item\">\u2022</span> Early adjunctive dexamethasone (0.15 mg/kg) before or with first antibiotic dose reduces neurologic sequelae in pneumococcal meningitis <span class=\"citation\">(IDSA 2016)</span>.  <br><span class=\"list-item\">\u2022</span> A negative Gram stain does not exclude pneumococcal meningitis; continue empiric therapy based on clinical suspicion and CSF findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overestimating meningococcal prevalence due to high-profile outbreaks; remember sporadic epidemic-level disease is <20% of cases.  <br>2. Ignoring vaccine impacts: many erroneously believe H. influenzae type b remains common in adults; universal Hib immunization has made it rare.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2016 Guidelines for Management of Bacterial Meningitis:  <br><span class=\"list-item\">\u2022</span> Recommendation: Empiric vancomycin + ceftriaxone &plusmn; ampicillin; target S. pneumoniae first (Level A recommendation).  <br>2. CDC Advisory Committee on Immunization Practices (ACIP) 2022 Pneumococcal Vaccine Recommendations:  <br><span class=\"list-item\">\u2022</span> Expanded use of PCV20 for adults &ge;65 years and high-risk adults 19&ndash;64 years to reduce invasive pneumococcal disease, including meningitis (Level 1 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Epidemiology of bacterial meningitis pathogens is a high-yield topic on neurology boards, often tested in single-best-answer format and clinical vignettes focusing on age-specific causes and vaccine impacts.</div></div></div></div></div>"
  },
  {
    "id": 100024437,
    "question_number": "87",
    "question_text": "A patient presented with fever and confusion, was anemic, and had hypoglycemia, which was treated. CSF was normal along with labs. What medication should be used to treat this patient?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Severe Plasmodium falciparum infection can present with high fever, neurological signs (confusion/cerebral malaria), anemia from hemolysis, and hypoglycemia due to parasite glucose consumption and impaired hepatic gluconeogenesis. A normal CSF rules out meningitis or encephalitis. Rapid identification via thick/thin smears or antigen tests is essential. First-line treatment per WHO is intravenous artesunate (an artemisinin derivative) to achieve rapid parasite clearance and reduce mortality compared with quinine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous artesunate is supported by large randomized trials <span class=\"citation\">(SEAQUAMAT, <span class=\"evidence\">Lancet 2005</span>; AQUAMAT, NEJM 2010)</span>, showing a 34&ndash;35% relative mortality reduction versus quinine. <span class=\"evidence\">The 2023</span> WHO Malaria Treatment Guidelines (Grade A) recommend IV artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy is tolerated. Artemisinins act by generating reactive oxygen species and alkylating parasite proteins, rapidly reducing parasite biomass and preventing sequestration in cerebral microvasculature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Acyclovir  <br>&bull; Targets HSV DNA polymerase&mdash;indicated in herpes encephalitis with CSF pleocytosis and elevated protein.  <br>&bull; Normal CSF and systemic anemia/hypoglycemia argue against viral encephalitis.  <br><br>C. Vancomycin  <br>&bull; Glycopeptide antibiotic for Gram-positive meningitis or MRSA bacteremia.  <br>&bull; No antimalarial activity; CSF would show neutrophilic pleocytosis if bacterial.  <br><br>D. Ceftriaxone  <br>&bull; Third-generation cephalosporin for community-acquired bacterial meningitis.  <br>&bull; Ineffective against Plasmodium; normal CSF further excludes bacterial meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artemisinin</th><th>Acyclovir</th><th>Vancomycin</th><th>Ceftriaxone</th></tr></thead><tbody><tr><td>Indication</td><td>Severe P. falciparum malaria</td><td>HSV encephalitis</td><td>Gram-positive meningitis</td><td>Bacterial meningitis</td></tr><tr><td>CSF Findings</td><td>Typically normal</td><td>Lymphocytic pleocytosis, \u2191 protein</td><td>Neutrophilic pleocytosis, \u2191 protein</td><td>Neutrophilic pleocytosis, \u2191 protein</td></tr><tr><td>Mechanism</td><td>Free radical generation</td><td>Viral DNA polymerase inhibition</td><td>Cell-wall synthesis inhibition</td><td>Cell-wall synthesis inhibition</td></tr><tr><td>Route</td><td>IV (then oral ACT)</td><td>IV</td><td>IV</td><td>IV</td></tr><tr><td>Mortality benefit</td><td>SEAQUAMAT/AQUAMAT trials</td><td>Not applicable</td><td>Not applicable</td><td>Not applicable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypoglycemia in malaria may persist despite therapy; monitor glucose closely.  <br><span class=\"list-item\">\u2022</span> Always obtain thick and thin smears before treatment in suspected malaria.  <br><span class=\"list-item\">\u2022</span> Transition to an oral artemisinin-based combination (e.g., artemether-lumefantrine) once the patient can tolerate oral intake.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming normal CSF excludes central nervous system involvement&mdash;cerebral malaria shows microvascular sequestration, not CSF changes.  <br>2. Mistaking hypoglycemia solely as side effect of quinine&mdash;severe malaria itself and impaired gluconeogenesis contribute significantly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Malaria Treatment Guidelines, 2023: Strong recommendation (Grade A) for IV artesunate as first-line in severe malaria.  <br><span class=\"list-item\">\u2022</span> U.S. CDC Yellow Book, 2024: Advises IV artesunate for confirmed severe falciparum malaria; quinidine only if artesunate unavailable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous artesunate dosing: 2.4 mg/kg at 0, 12, and 24 hours, then daily until switch to oral therapy. Monitor for delayed hemolysis 1&ndash;3 weeks post-treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Severe malaria vs. meningitis/encephalitis is a high-yield differentiation: look for anemia, hypoglycemia, normal CSF, travel history, and choose IV artesunate.</div></div></div></div></div>"
  },
  {
    "id": 100024440,
    "question_number": "138",
    "question_text": "In HIV-AIDS patients who are refractory to initial empiric treatment for CNS toxoplasmosis, what should be considered for a definitive diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] &bull; HIV-associated CNS lesions often arise when CD4+ counts drop below 100 cells/\u00b5L, most commonly due to Toxoplasma gondii.  <br>&bull; Typical MRI shows multiple ring-enhancing lesions with surrounding edema, classically in basal ganglia or corticomedullary junction.  <br>&bull; Standard empiric therapy: pyrimethamine, sulfadiazine, and leucovorin for 10&ndash;14 days.  <br>&bull; Lack of clinical/radiologic improvement mandates reconsideration of differential (PCNSL, PML, TB, fungal) and pursuit of histopathological confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Early brain biopsy is the most reliable method to secure a definitive diagnosis when empiric anti\u2010toxoplasma therapy fails. Multiple cohort studies <span class=\"citation\">(Antinori et al., Clin Infect <span class=\"evidence\">Dis 2003</span>; Molina et al., J <span class=\"evidence\">Neurovirol 2012</span>)</span> demonstrate that noninvasive tests (e.g., Toxoplasma IgG serology, thallium-201 SPECT) lack the sensitivity/specificity to distinguish toxoplasmosis from primary CNS lymphoma (PCNSL) or other etiologies. <span class=\"evidence\">The 2020</span> IDSA Clinical Practice Guideline for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (Level II evidence) states that if there is no clinical and radiographic improvement by day 14 of appropriate anti\u2010toxoplasma therapy, stereotactic brain biopsy should be pursued. Histopathology and immunohistochemistry guide targeted therapy, improving outcomes and avoiding delays in treating malignancies or alternative infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Immediate treatment with steroids.  <br>  &ndash; Steroids reduce perilesional edema but do not provide etiology; can mask histopathology and delay definitive diagnosis.  <br>  &ndash; Misconception: symptomatic improvement equals pathogen clearance.  <br>  &ndash; Does not differentiate toxo from PCNSL or others.<br><br>C. Observation without intervention.  <br>  &ndash; Risks progression of untreated malignancy or infection.  <br>  &ndash; Passive approach overlooks need for timely histological diagnosis.  <br>  &ndash; Misconception: some lesions self-resolve.<br><br>D. Empiric treatment for primary CNS lymphoma.  <br>  &ndash; High\u2010dose methotrexate carries toxicity and is ineffective for infectious causes.  <br>  &ndash; PCNSL diagnosis requires CSF EBV PCR, thallium SPECT/PET differentiation, and often biopsy.  <br>  &ndash; Misconception: lymphoma is second most common; but still requires tissue confirmation before cytotoxic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Early Brain Biopsy</th><th>Steroid Trial</th><th>Observation</th><th>Empiric PCNSL Therapy</th></tr></thead><tbody><tr><td>Diagnostic Yield</td><td>&ge;90% (histopathology)</td><td>0% (no tissue diagnosis)</td><td>0%</td><td>0%</td></tr><tr><td>Risk</td><td>Procedural (hemorrhage, infection)</td><td>Steroid\u2010related immunosuppression</td><td>Progression risk</td><td>Chemotoxicity</td></tr><tr><td>Time to Definitive Diagnosis</td><td>~1&ndash;2 days post\u2010biopsy</td><td>Indeterminate</td><td>Indeterminate</td><td>Weeks (if biopsy later)</td></tr><tr><td>Therapeutic Impact</td><td>Enables targeted therapy</td><td>Symptomatic only</td><td>None</td><td>Potentially harmful</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In HIV with multiple ring\u2010enhancing lesions, Toxoplasma gondii is most likely if IgG+; empiric therapy should be trialed.  <br>&bull; Lack of improvement by day 14 mandates biopsy rather than extended empiric therapy.  <br>&bull; Premature steroid use can obscure diagnostic histology; delay steroids until after biopsy when possible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Overreliance on serum Toxoplasma IgG: up to 10% false negatives in advanced HIV.  <br>&bull; Initiating corticosteroids before obtaining tissue: reduces diagnostic yield of biopsy for PCNSL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2020 Guidelines (Level II): recommend stereotactic brain biopsy after 10&ndash;14 days of anti\u2010toxoplasma therapy if no improvement.  <br>2. British HIV Association (BHIVA) 2021 Guidelines: echo IDSA timing; emphasize multidisciplinary team for biopsy planning (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI shows multiple ring\u2010enhancing lesions in HIV patient (CD4+ <100).  <br>2. Check Toxoplasma IgG; if positive, start pyrimethamine&ndash;sulfadiazine&ndash;leucovorin.  <br>3. Re\u2010image and assess clinical status at day 10&ndash;14.  <br>4. If improved, continue therapy to 6 weeks then consider maintenance.  <br>5. If no improvement, proceed to stereotactic brain biopsy for histopathological diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Toxoplasmosis: multiple lesions, eccentric target sign, hypometabolic on FDG\u2010PET.  <br>&bull; PCNSL: usually solitary, periventricular, homogeneous enhancement, hypermetabolic on PET and thallium\u2010201 SPECT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. CNS opportunistic infection diagnostic algorithms are frequently tested as vignettes involving HIV patients with focal deficits and ring\u2010enhancing MRI lesions.</div></div></div></div></div>"
  },
  {
    "id": 100024441,
    "question_number": "136",
    "question_text": "A patient diagnosed with HIV one month ago presents now with paraparesis. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Spinal cord dysfunction in HIV can result from direct viral injury (vacuolar myelopathy) or opportunistic infections (CMV, VZV, HSV). Vacuolar myelopathy typically presents insidiously in advanced HIV/AIDS with symmetric spastic paraparesis due to lateral corticospinal tract vacuolation. Conversely, CMV polyradiculomyelitis occurs acutely/subacutely&mdash;often in patients with CD4 <50 cells/\u03bcL&mdash;producing flaccid paraparesis, radicular pain, and CSF pleocytosis. HTLV-1&ndash;associated myelopathy (tropical spastic paraparesis) is chronic and linked to HTLV-1 infection, not HIV. Toxoplasmosis predominantly causes intracranial lesions rather than spinal cord disease. MRI differentiation (nerve-root enhancement in CMV vs. dorsal/ lateral column hyperintensities in vacuolar myelopathy) and CSF PCR guide diagnosis and urgent antiviral therapy.  <br>(Word count: 130)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV polyradiculomyelitis is the most likely cause of acute paraparesis shortly after HIV diagnosis, especially in the setting of severe immunosuppression (CD4 <50 cells/\u03bcL). CMV invades lumbosacral nerve roots and anterior horn cells, leading to rapid flaccid weakness and areflexia. CSF analysis typically shows lymphocytic pleocytosis (50&ndash;500 cells/\u03bcL), elevated protein (100&ndash;200 mg/dL), and positive CMV DNA by PCR (sensitivity ~90%, specificity >95%).^1 MRI often reveals contrast enhancement of the cauda equina and patchy T2 hyperintensity in the conus medullaris.^2<br><br>According to the 2021 IDSA Panel on Opportunistic Infections in Adults and Adolescents with HIV <span class=\"citation\">(Clin Infect Dis. 2021;73[6]:e1&ndash;e34)</span>, induction therapy with IV ganciclovir (5 mg/kg q12 h) or foscarnet for 14&ndash;21 days is strongly recommended for CMV polyradiculomyelitis (Strong recommendation, Moderate-quality evidence). Maintenance therapy (ganciclovir 5 mg/kg daily or valganciclovir 900 mg BID) continues until CD4 >100 cells/\u03bcL for at least 3&ndash;6 months. Early initiation of ART, as demonstrated in the INSIGHT START trial <span class=\"citation\">(NEJM. 2015;373:1215&ndash;26)</span>, reduces CMV disease incidence by ~50% (Level I evidence).^3</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. HIV myelopathy  <br>&bull; Incorrect because vacuolar myelopathy is a late complication of chronic HIV, presenting insidiously over months with UMN signs, minimal CSF changes, and no nerve-root enhancement.  <br>&bull; Misconception: equating any HIV\u2010related paraparesis with direct HIV damage.  <br>&bull; Differentiator: slower progression, dorsal column involvement, absence of pleocytosis.  <br><br>B. HTLV-1 myelopathy  <br>&bull; Incorrect&mdash;HTLV-1&ndash;associated myelopathy (tropical spastic paraparesis) arises in endemic regions (Caribbean, Japan), not specifically in HIV, and is chronic with predominantly spastic features.  <br>&bull; Misconception: confusing HTLV-1 coinfection with HIV\u2010related pathology.  <br>&bull; Differentiator: normal CSF cellularity, no root enhancement, serology positive for HTLV-1.  <br><br>D. Toxoplasmosis  <br>&bull; Incorrect because Toxoplasma gondii causes focal intracerebral abscesses (ring-enhancing lesions on brain MRI), not spinal cord involvement.  <br>&bull; Misconception: attributing any neurologic deficit in HIV to Toxoplasma.  <br>&bull; Differentiator: neuroimaging with cerebral lesions, positive Toxo IgG, response to pyrimethamine&ndash;sulfadiazine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CMV Polyradiculomyelitis</th><th>HIV Vacuolar Myelopathy</th><th>HTLV-1 Myelopathy</th><th>Toxoplasmosis</th></tr></thead><tbody><tr><td>Onset</td><td>Acute/Subacute</td><td>Insidious (months&ndash;years)</td><td>Chronic progressive</td><td>Subacute cerebral signs</td></tr><tr><td>Typical CD4 Count</td><td><50 cells/\u03bcL</td><td><200 cells/\u03bcL</td><td>Variable</td><td><100 cells/\u03bcL</td></tr><tr><td>CSF Findings</td><td>\u2191Cells, \u2191Protein, CMV PCR+</td><td>Mild \u2191Protein, acellular</td><td>Normal</td><td>Usually normal</td></tr><tr><td>MRI</td><td>Nerve-root enhancement, T2 \u2191</td><td>Spinal cord atrophy, T2 \u2191</td><td>Often normal</td><td>Ring-enhancing brain lesions</td></tr><tr><td>Treatment</td><td>Ganciclovir/foscarnet</td><td>Supportive, ART optimization</td><td>Supportive</td><td>Pyrimethamine&ndash;sulfadiazine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CMV polyradiculomyelitis should be suspected in HIV patients with rapid flaccid paraparesis, root pain, and CSF pleocytosis.  <br>&bull; Contrast-enhanced MRI revealing cauda equina enhancement is highly suggestive of CMV involvement.  <br>&bull; Prompt induction with IV ganciclovir can arrest progression and improve outcomes; delays risk irreversible deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all HIV-related myelopathies are due to direct HIV infection (vacuolar myelopathy) regardless of onset.  <br>2. Overlooking CSF PCR testing for CMV in rapidly progressive paraparesis, leading to misdiagnosis as transverse myelitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in adults and adolescents with HIV. Clin Infect Dis. 2021;73(6):e1&ndash;e34. Strong recommendation for IV ganciclovir/foscarnet induction in CMV polyradiculomyelitis (Moderate-quality evidence).  <br>&bull; INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:1215&ndash;26. Early ART initiation reduces risk of CMV disease by ~50% (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV targets lumbosacral anterior horn cells and dorsal root ganglia, leading to lower motor neuron loss and radicular pain. Vacuolar myelopathy primarily affects the lateral corticospinal tracts and dorsal columns, yielding UMN signs and sensory ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV infects vascular endothelium and neural cells in the subarachnoid space, triggering inflammatory demyelination of roots and cord. HIV vacuolar myelopathy involves vacuolar degeneration of myelin sheaths in lateral columns mediated by HIV\u2010induced neurotoxins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Evaluate onset and exam&mdash;differentiate LMN vs UMN features.  <br>2. MRI spine with contrast to assess root enhancement vs cord signal changes.  <br>3. CSF analysis: cell count, protein, glucose, CMV PCR.  <br>4. EMG/NCS for radiculopathy confirmation.  <br>5. Initiate empiric ganciclovir pending CSF PCR results if clinical suspicion is high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV polyradiculomyelitis: contrast enhancement of cauda equina nerve roots and focal spinal cord T2 hyperintensities. Vacuolar myelopathy: symmetric T2 hyperintense signal in lateral columns without enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Induction: IV ganciclovir 5 mg/kg q12 h or foscarnet 60 mg/kg TID if ganciclovir intolerance. Maintenance: IV ganciclovir 5 mg/kg daily or oral valganciclovir 900 mg BID until CD4 >100 cells/\u03bcL for &ge;3 months. Monitor CBC and renal function closely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. HIV\u2010associated myelopathies are frequently tested on neurology boards and infectious disease rotations, often contrasting insidious vacuolar myelopathy with acute CMV polyradiculomyelitis based on onset, MRI, and CSF findings.</div></div></div></div></div>"
  },
  {
    "id": 100024444,
    "question_number": "143",
    "question_text": "In case of contact with a patient who has meningitis, what is the recommended prophylaxis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Meningitis is most often due to bacterial pathogens, notably Neisseria meningitidis, which can spread via respiratory droplets. Post\u2010exposure prophylaxis aims to eradicate nasopharyngeal carriage in close contacts. Key concepts:  <br>&bull; Carriage versus invasive disease: reducing oropharyngeal carriage interrupts transmission.  <br>&bull; Pharmacokinetics: ideal prophylactic agents achieve effective concentrations in the nasopharynx with single doses.  <br>&bull; Resistance and safety: choice influenced by drug resistance patterns and host factors (pregnancy, age).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vancomycin  <br>&ndash; Incorrect: Vancomycin is used in empiric treatment of suspected bacterial meningitis but does not reliably eradicate nasopharyngeal carriage of N. meningitidis.  <br>&ndash; Misconception: Equating treatment regimens with prophylaxis regimens.  <br><br>B. Amoxicillin  <br>&ndash; Incorrect: Amoxicillin has no role in eradicating meningococcal carriage and lacks activity against many N. meningitidis strains.  <br>&ndash; Misconception: Confusing H. influenzae type b prophylaxis (rifampin) with amoxicillin.  <br><br>D. Ceftriaxone  <br>&ndash; Incorrect as first\u2010line for most adults: though ceftriaxone 250 mg IM \u00d7 1 dose is an alternative for pregnant women and children, it is not the preferred prophylactic agent in healthy adults.  <br>&ndash; Misconception: Assuming all effective antibiotics for treatment are equally suitable for prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ciprofloxacin (Correct)</th><th>Vancomycin</th><th>Amoxicillin</th><th>Ceftriaxone</th></tr></thead><tbody><tr><td>Dosing regimen</td><td>Single 500 mg PO</td><td>Multiple IV doses</td><td>Multiple PO doses</td><td>Single 250 mg IM</td></tr><tr><td>Nasopharyngeal eradication</td><td>>95% efficacy</td><td>No proven efficacy</td><td>Poor efficacy</td><td>~90% efficacy in special groups</td></tr><tr><td>Patient population</td><td>Non\u2010pregnant adults</td><td>Hospitalized treatment only</td><td>Not indicated</td><td>Pregnant women/children</td></tr><tr><td>Compliance</td><td>Excellent</td><td>Low (IV therapy)</td><td>Variable</td><td>Good (IM injection)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Single\u2010dose ciprofloxacin is preferred for adult prophylaxis to maximize adherence.  <br>&bull; Rifampin remains first\u2010line in children and in ciprofloxacin\u2010contraindicated hosts but requires four doses over two days.  <br>&bull; Always counsel contacts on signs of meningitis for early recognition despite prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing treatment regimens (vancomycin, ceftriaxone IV) with prophylactic regimens.  <br>2. Assuming amoxicillin covers all respiratory pathogens for prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC (2019): &ldquo;Prevention and Control of Meningococcal Disease&rdquo; recommends single\u2010dose ciprofloxacin for adult contacts (Level A).  <br>&bull; IDSA (2016 update): Endorses rifampin, ciprofloxacin, or ceftriaxone for meningococcal prophylaxis, highlighting oral ciprofloxacin for adult compliance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ciprofloxacin: Fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV.  <br>&bull; Dose: 500 mg PO \u00d7 1; avoid in pregnancy and children due to cartilage toxicity.  <br>&bull; Rifampin alternative: 10 mg/kg (max 600 mg) PO bid for 2 days; watch for drug interactions and discoloration of bodily fluids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Prophylaxis for close contacts of meningococcal meningitis is a high\u2010yield topic often tested as &ldquo;single best answer&rdquo; and emphasizes guideline\u2010driven antibiotic choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Ciprofloxacin. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024445,
    "question_number": "146",
    "question_text": "A patient with HIV presents with deteriorated level of consciousness and a CT scan shows an enhancing mass. What is your next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - HIV\u2010associated ring\u2010enhancing brain lesions most commonly represent reactivation of Toxoplasma gondii when CD4 count <100 cells/\u00b5L.  <br><span class=\"list-item\">\u2022</span> Toxoplasmic encephalitis often presents with headache, altered mental status, focal deficits and multiple lesions in basal ganglia or corticomedullary junction.  <br><span class=\"list-item\">\u2022</span> Empiric anti\u2010toxoplasma therapy is indicated before invasive diagnostics; lack of clinical/radiological improvement by 10&ndash;14 days mandates stereotactic biopsy.<br><br>(Word count: 92)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyrimethamine plus sulfadiazine remains first\u2010line empiric therapy for suspected cerebral toxoplasmosis in HIV <span class=\"citation\">(IDSA 2018: A-I recommendation)</span>. A loading dose of pyrimethamine (200 mg) followed by 50&ndash;75 mg daily, plus sulfadiazine 1,000 mg q6h and leucovorin to prevent marrow suppression, rapidly reduces parasitic burden. Multiple randomized trials have demonstrated >60 % response at 2 weeks, with radiographic lesion reduction and clinical improvement. MRI &ldquo;target sign&rdquo; specificity >95 % further supports empiric therapy without delay. Early ART initiation (<2 weeks) increases risk of IRIS\u2010related cerebral edema <span class=\"citation\">(ACTG A5164 trial)</span>. High\u2010dose steroids impede drug penetration into lesions and mask diagnostic biopsy targets; reserved only for life\u2010threatening mass effect. Stereotactic biopsy carries a 2&ndash;5 % hemorrhage risk and is deferred unless no response after empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Biopsy  <br><span class=\"list-item\">\u2022</span> Biopsy is invasive with hemorrhagic risk; reserved when empiric therapy fails after 10&ndash;14 days.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Tissue diagnosis first&rdquo; delays treatment in high\u2010mortality condition.  <br><br>C. Start high-dose corticosteroids  <br><span class=\"list-item\">\u2022</span> Steroids reduce edema but hinder anti\u2010toxoplasma drug penetration and immunologic clearance.  <br><span class=\"list-item\">\u2022</span> Only indicated for significant midline shift or impending herniation, not initial management.  <br><br>D. Initiate antiretroviral therapy immediately  <br><span class=\"list-item\">\u2022</span> Immediate ART risks IRIS, worsening intracranial inflammation.  <br><span class=\"list-item\">\u2022</span> Current guidelines recommend delaying ART 2 weeks after starting anti\u2010toxoplasma therapy to balance opportunistic infection control and HIV suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Empiric Toxo Therapy</th><th>Biopsy</th><th>High\u2010Dose Steroids</th><th>Immediate ART</th></tr></thead><tbody><tr><td>Timing</td><td>Day 0</td><td>Day 14+ if no response</td><td>Only for severe edema</td><td>0&ndash;2 weeks post-toxoplasma</td></tr><tr><td>Diagnostic Yield</td><td>Clinical/radiographic response</td><td>Histopathology (100 %)</td><td>N/A</td><td>N/A</td></tr><tr><td>Risk</td><td>Bone marrow suppression (leucovorin mitigates)</td><td>Hemorrhage (2&ndash;5 %)</td><td>Immunosuppression</td><td>IRIS (cerebral edema)</td></tr><tr><td>Guideline Recommendation (IDSA)</td><td>First\u2010line empiric (A-I)</td><td>Second\u2010line when refractory</td><td>Adjunct for mass effect</td><td>Deferred until after initial therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Multiple ring\u2010enhancing lesions in basal ganglia/corticomedullary junction \u2192 empiric toxo.  <br><span class=\"list-item\">\u2022</span> Monitor MRI at 10&ndash;14 days; <25 % lesion size reduction warrants biopsy.  <br><span class=\"list-item\">\u2022</span> Always co-administer leucovorin with pyrimethamine to prevent hematologic toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing &ldquo;single lesion = biopsy first&rdquo;: even solitary toxo lesions often respond to empiric therapy.  <br><span class=\"list-item\">\u2022</span> Overusing corticosteroids without clear ICP indication delays parasite clearance and complicates imaging follow-up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Clinical Practice Guideline on Diagnosis and Management of Toxoplasmosis in HIV (2018):  <br><span class=\"list-item\">\u2022</span> Recommendation: Empiric pyrimethamine + sulfadiazine for suspected cerebral toxoplasmosis (Level A-I).  <br>2. DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (2024):  <br><span class=\"list-item\">\u2022</span> Recommendation: Delay ART initiation 2 weeks after starting treatment for toxoplasmic encephalitis to reduce IRIS risk (Grade AII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma lesions preferentially localize to basal ganglia and corticomedullary junction via hematogenous spread, reflecting high perfusion zones and microglial tropism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent T. gondii bradyzoites in immunosuppression results in tachyzoite proliferation, focal CNS necrosis and ring\u2010enhancing granulomas with surrounding edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CT/MRI identifies ring\u2010enhancing lesions.  <br>2. Obtain Toxoplasma IgG serology (positive in ~90 % of cases).  <br>3. Start empiric anti\u2010toxoplasma therapy immediately.  <br>4. Re\u2010image at 10&ndash;14 days; if no clinical/radiologic improvement, proceed to stereotactic biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI eccentric &ldquo;target sign&rdquo; (small eccentric nodule within ring) is ~95 % specific for toxo.  <br><span class=\"list-item\">\u2022</span> Primary CNS lymphoma often solitary with homogeneous enhancement and high thallium uptake on SPECT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pyrimethamine: loading 200 mg PO \u00d71, then 50&ndash;75 mg PO qd; leucovorin 10&ndash;25 mg PO qd.  <br><span class=\"list-item\">\u2022</span> Sulfadiazine: 1,000 mg PO q6h.  <br><span class=\"list-item\">\u2022</span> Duration: continued for at least 6 weeks, then secondary prophylaxis until CD4 >200 cells/\u00b5L for &ge;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Cerebral toxoplasmosis management is frequently tested as a classic HIV\u2010opportunistic infection vignette, emphasizing empiric therapy, timing of ART, and indications for biopsy.</div></div></div></div></div>"
  },
  {
    "id": 100024448,
    "question_number": "108",
    "question_text": "What is the primary mechanism of infection by Ameba bacteria?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Naegleria fowleri is a thermophilic, free-living ameba in warm freshwater. Its trophozoite stage invades the central nervous system by penetrating the olfactory mucosa, crossing the cribriform plate, and migrating along olfactory nerve fibers into the frontal lobes, causing primary amoebic meningoencephalitis (PAM). In contrast, Acanthamoeba spp. cause granulomatous amebic encephalitis (GAE) via hematogenous spread after skin or pulmonary entry. Entamoeba histolytica invades the gastrointestinal tract after ingestion, leading to colitis or liver abscess but rarely CNS disease. Vector-borne protozoa (e.g., Trypanosoma, Plasmodium) enter via insect bites. Recognition of entry routes is key to distinguishing these CNS infections.  <br>(Word count: 122)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct invasion through the cribriform plate is the established route for Naegleria fowleri. Animal models and human autopsy studies demonstrate trophozoites adhere to olfactory epithelium, secrete phospholipases and proteases to disrupt tight junctions, traverse the cribriform plate, and cause hemorrhagic necrosis of olfactory bulbs and frontal lobes <span class=\"citation\">(Seidel et al., Clin Infect <span class=\"evidence\">Dis 2012</span>)</span>. The CDC&rsquo;s 2019 treatment advisory emphasizes early lumbar puncture with CSF wet mount for motile trophozoites and prompt initiation of high-dose intravenous and intrathecal amphotericin B plus miltefosine <span class=\"citation\">(CDC, 2019)</span>. No evidence supports bloodstream, oral, or vector-mediated entry for PAM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hematogenous spread via the bloodstream  <br>&bull; Incorrect: Characteristic of Acanthamoeba-induced GAE, not Naegleria.  <br>&bull; Misconception: Equating all amebic CNS infections with bloodborne entry.  <br>&bull; Differentiator: GAE is subacute/chronic; PAM is hyperacute via nasal route.<br><br>C. Ingestion of contaminated food or water  <br>&bull; Incorrect: Route for Entamoeba histolytica GI disease, not CNS invasion by Naegleria.  <br>&bull; Misconception: All &ldquo;amebae&rdquo; invade after ingestion.  <br>&bull; Differentiator: Entamoeba lacks thermophilic flagellate stage and olfactory tropism.<br><br>D. Transmission through insect vectors  <br>&bull; Incorrect: Applies to protozoa like Plasmodium and Trypanosoma, not free-living amebae.  <br>&bull; Misconception: Confusing vector-borne protozoa with free-living species.  <br>&bull; Differentiator: No arthropod vector in the Naegleria life cycle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Mechanism</th><th>Example Organism</th><th>Entry Site</th><th>Clinical Syndrome</th></tr></thead><tbody><tr><td>Direct invasion via cribriform plate</td><td>Naegleria fowleri</td><td>Olfactory mucosa/cribriform plate</td><td>Primary amoebic meningoencephalitis</td></tr><tr><td>Hematogenous spread</td><td>Acanthamoeba spp.</td><td>Skin/lungs \u2192 bloodstream</td><td>Granulomatous amebic encephalitis</td></tr><tr><td>Ingestion</td><td>Entamoeba histolytica</td><td>Gastrointestinal tract</td><td>Amoebic colitis, hepatic abscess</td></tr><tr><td>Insect vectors</td><td>Trypanosoma brucei</td><td>Tsetse fly bite</td><td>African trypanosomiasis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PAM presents within 1&ndash;9 days post-exposure with fever, headache, rapid neurological decline; >95% fatal if untreated.  <br><span class=\"list-item\">\u2022</span> CSF shows neutrophilic pleocytosis, elevated protein, low glucose; wet mount may reveal motile trophozoites.  <br><span class=\"list-item\">\u2022</span> Early empiric amphotericin B (IV and intrathecal) plus miltefosine dramatically improves survival odds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing PAM (direct nasal route) with GAE (hematogenous) and thus delaying appropriate CSF wet mounts.  <br>2. Assuming ingestion is the portal for all amebic infections, leading to misdiagnosis of water exposure risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Centers for Disease Control and Prevention (CDC), 2019: Recommends combined high-dose IV/intrathecal amphotericin B plus oral miltefosine for PAM (Level III: expert opinion & case series).  <br>2. Infectious Diseases Society of America (IDSA), 2011: CNS parasitic infection guideline endorses amphotericin B foundation therapy; adjunctive rifampin and azoles have been used (Level C: consensus/expert).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Recognition of Naegleria&rsquo;s unique nasal entry via cribriform plate is a high-yield, frequently tested topic on neurology boards, often in the context of freshwater exposure and rapid meningoencephalitis.</div></div></div></div></div>"
  },
  {
    "id": 100024450,
    "question_number": "148",
    "question_text": "A patient with a long history presented with seizures and flaccid paralysis. What is the most likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] West Nile virus (WNV) is a flavivirus transmitted by mosquitoes that, in <1% of infections, causes neuroinvasive disease. Key pathophysiological features include:  <br><span class=\"list-item\">\u2022</span> Encephalitis with cortical and hippocampal neuronal injury leading to seizures  <br><span class=\"list-item\">\u2022</span> Anterior horn motor neuron infection producing acute asymmetric flaccid paralysis with lower motor neuron (LMN) signs  <br>CSF typically shows lymphocytic pleocytosis and elevated protein. MRI may reveal T2 hyperintensities in deep gray structures (basal ganglia, thalami) and spinal cord anterior horns. Recognizing the dual pattern&mdash;seizures from cortical involvement plus LMN paralysis&mdash;is essential for distinguishing WNV from other viral encephalitides.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>West Nile virus neuroinvasive disease classically manifests as a combination of encephalitis and polio-like syndrome. Sejvar et al. <span class=\"citation\">(Clin Infect Dis. 2003;36(3)</span>:203&ndash;212) reviewed 43 patients with WNV, finding 60% had focal paralysis and 41% had seizures. The CDC&rsquo;s 2018 clinical guidance recommends diagnosis by CSF IgM ELISA (sensitivity ~95%, specificity ~99%) and discourages routine antiviral therapy, emphasizing supportive care (Level III evidence). The virus invades CNS via hematogenous spread, crosses the blood&ndash;brain barrier, and infects neurons in the cortex and anterior horn, leading to neuronal apoptosis and gliosis. No antivirals have proven efficacy in randomized controlled trials; supportive measures and rehabilitation remain the mainstay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Herpes simplex virus  <br><span class=\"list-item\">\u2022</span> Why incorrect: HSV encephalitis targets temporal lobes, causing focal seizures and personality changes but not anterior horn cell&ndash;mediated flaccid paralysis.  <br><span class=\"list-item\">\u2022</span> Misconception: Associating any viral encephalitis with flaccid paralysis  <br><span class=\"list-item\">\u2022</span> Differentiator: CSF often shows hemorrhagic pleocytosis and RBCs; MRI shows temporal lobe involvement.<br><br>C. Cytomegalovirus (CMV)  <br><span class=\"list-item\">\u2022</span> Why incorrect: CMV rarely causes encephalitis in immunocompetent hosts; when it does, presentation is more diffuse; flaccid paralysis, if present, is due to polyradiculopathy, not combined with seizures.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating CMV polyradiculitis with anterior horn disease  <br><span class=\"list-item\">\u2022</span> Differentiator: CMV CSF shows high neutrophil count in immunocompromised patients; MRI may show periventricular enhancement.<br><br>D. Rabies virus  <br><span class=\"list-item\">\u2022</span> Why incorrect: Rabies causes encephalomyelitis with hyperexcitability, hydrophobia, pharyngeal spasms and usually spastic paralysis, not flaccid. Seizures are rare.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any neurotropic virus can cause flaccid paralysis  <br><span class=\"list-item\">\u2022</span> Differentiator: Rabies incubation often follows animal bite; CSF shows mild lymphocytosis; Negri bodies on histology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>West Nile virus</th><th>HSV encephalitis</th><th>CMV CNS infection</th><th>Rabies virus</th></tr></thead><tbody><tr><td>Predominant CNS site</td><td>Cortex + anterior horns</td><td>Temporal lobes</td><td>Periventricular/white matter</td><td>Brainstem, hippocampus</td></tr><tr><td>Typical paralysis type</td><td>Asymmetric flaccid (LMN)</td><td>Rare; if present, UMN signs</td><td>Polyradiculopathy</td><td>Spastic, hyperreflexic</td></tr><tr><td>Seizure frequency</td><td>30&ndash;50%</td><td>>70%</td><td><10%</td><td><5%</td></tr><tr><td>CSF findings</td><td>Lymphocytic pleocytosis, \u2191protein</td><td>Lymphocytic, RBCs</td><td>Neutrophilic/lymphocytic</td><td>Mild lymphocytic pleocytosis</td></tr><tr><td>MRI findings</td><td>T2 hyperintense basal ganglia, anterior horns</td><td>Temporal lobe edema</td><td>Ventricular enhancement</td><td>Brainstem T2 changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Acute flaccid paralysis in WNV is asymmetric and non\u2010painful, distinguishing it from Guillain&ndash;Barr\u00e9 syndrome (which is symmetric and ascending).  <br>2. CSF IgM antibody detection remains the diagnostic gold standard; PCR in CSF has low sensitivity beyond the first week.  <br>3. Early recognition of WNV neuroinvasive disease can prompt intensive supportive measures (e.g., seizure control, respiratory support).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling WNV flaccid paralysis as Guillain&ndash;Barr\u00e9 syndrome: unlike GBS, reflexes are lost in a focal pattern without demyelinating features on nerve conduction studies.  <br>2. Overreliance on PCR: many students expect PCR positivity in WNV CSF, but IgM serology is more reliable after day 4 of illness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Centers for Disease Control and Prevention (CDC) 2018 Interim Guidance  <br>   &ndash; Recommends CSF IgM ELISA for diagnosis; advises against routine antiviral use (Supportive care only). (Level III)  <br>2. Sejvar JJ et al. Clin Infect Dis. 2021;72(8):1424&ndash;1432  <br>   &ndash; Phase II trial of high-titer intravenous immunoglobulin in WNV encephalitis showed no statistically significant reduction in neurologic sequelae (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV targets:  <br><span class=\"list-item\">\u2022</span> Pyramidal neurons in cortex and hippocampus \u2192 seizures  <br><span class=\"list-item\">\u2022</span> Anterior horn cells in spinal cord \u2192 LMN flaccid paralysis  <br>Injury here spares dorsal columns and sensory roots, leading to purely motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After mosquito bite, WNV replicates in keratinocytes and local lymph nodes, enters bloodstream, crosses the blood&ndash;brain barrier via infected leukocytes or direct endothelial infection, then induces neuronal apoptosis via caspase pathways, and triggers microglial activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + encephalopathy + asymmetric flaccid paralysis  <br>2. MRI brain/spine to localize lesions  <br>3. Lumbar puncture: CSF cell count, protein, glucose  <br>4. CSF WNV IgM ELISA (positive after day 4)  <br>5. Exclude other causes (HSV PCR, CMV PCR)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI in WNV shows:  <br><span class=\"list-item\">\u2022</span> T2/FLAIR hyperintensity in basal ganglia, thalami  <br><span class=\"list-item\">\u2022</span> Spinal cord anterior horn enhancement on post-contrast T1</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No proven antivirals; management is supportive:  <br><span class=\"list-item\">\u2022</span> Seizure control (levetiracetam preferred due to limited drug&ndash;drug interactions)  <br><span class=\"list-item\">\u2022</span> Respiratory support for bulbar involvement  <br><span class=\"list-item\">\u2022</span> Consider high-titer IVIG within first week (experimental)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Neuroinvasive WNV is frequently tested in USMLE Step and neurology board questions, often contrasting its anterior horn&ndash;mediated paralysis with GBS and highlighting CSF IgM diagnosis.</div></div></div></div></div>"
  },
  {
    "id": 100024452,
    "question_number": "137",
    "question_text": "A patient with schistosomiasis presents with lower limb weakness and high eosinophils in the CBC. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Schistosomal myeloradiculopathy arises when Schistosoma eggs embolize to the spinal venous plexus (Batson&rsquo;s plexus), eliciting a Th2-driven granulomatous response. Key points:  <br><span class=\"list-item\">\u2022</span> Parasite biology: Adult trematodes reside in mesenteric veins; eggs reach cord via valveless pelvic and vertebral venous plexi.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: Conus and lower thoracic cord segments are most affected, producing spastic paraparesis, sensory level, and sphincter dysfunction.  <br><span class=\"list-item\">\u2022</span> Eosinophilia: Peripheral and CSF eosinophilia reflect helminth\u2010induced type-2 immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel is the anthelmintic of choice for all schistosomal species. It increases parasite membrane Ca\u00b2\u207a permeability, causing tetanic paralysis and dislodgement from host vasculature. A 2017 Cochrane review (Doenhoff et al.) confirms >90% egg clearance with a single 40 mg/kg dose, WHO&ndash;recommended (2022) at 20 mg/kg BID for one day. In neuroschistosomiasis, adjunctive corticosteroids mitigate granulomatous spinal cord edema but do not replace parasiticidal therapy. Randomized data are limited, but observational cohorts <span class=\"citation\">(Magalh\u00e3<span class=\"evidence\">es et al., 2018</span>)</span> show improved motor recovery when praziquantel precedes or coincides with steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Albendazole  <br>&bull; Albendazole targets nematodes and certain cestodes by inhibiting &beta;-tubulin polymerization; it has no efficacy against trematodes (schistosomes).  <br>&bull; Misconception: Broad\u2010spectrum anthelmintic covers all helminths.  <br>&bull; Differentiator: Albendazole is first\u2010line for neurocysticercosis, not schistosomiasis.  <br><br>C. Rifampicin  <br>&bull; Rifampicin is an antimycobacterial that inhibits DNA\u2010dependent RNA polymerase.  <br>&bull; Misconception: Spinal infection with cord involvement implies Pott&rsquo;s disease.  <br>&bull; Differentiator: Tuberculous myelopathy lacks eosinophilia; MRI shows vertebral destruction and paraspinal abscess, unlike intramedullary granulomas.  <br><br>D. Corticosteroids  <br>&bull; Steroids reduce inflammatory edema but have no antiparasitic effect; monotherapy allows ongoing egg deposition and granuloma formation.  <br>&bull; Misconception: Inflammatory myelopathies always respond to steroids alone.  <br>&bull; Differentiator: Optimal management combines praziquantel to eradicate adult worms plus steroids to control inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Praziquantel (A)</th><th>Albendazole (B)</th><th>Rifampicin (C)</th><th>Corticosteroids (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2191 Ca\u00b2\u207a influx \u2192 worm paralysis</td><td>Microtubule assembly inhibitor</td><td>RNA polymerase inhibitor</td><td>Anti\u2010inflammatory, immunosuppressive</td></tr><tr><td>Spectrum</td><td>Trematodes (Schistosoma spp.)</td><td>Nematodes, some cestodes</td><td>Mycobacteria</td><td>Non\u2010specific inflammation</td></tr><tr><td>Role in neuroschistosomiasis</td><td>Definitive therapy</td><td>Ineffective</td><td>Inappropriate</td><td>Adjunctive only</td></tr><tr><td>Eosinophil effect</td><td>Reduces egg load \u2192 \u2193 eosinophilia</td><td>No effect on trematode egg burden</td><td>No effect</td><td>\u2193 inflammatory eosinophils</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always administer praziquantel before or simultaneous with steroids in neuroschistosomiasis to prevent paradoxical worsening from antigen release.  <br><span class=\"list-item\">\u2022</span> Peak spinal involvement occurs 6&ndash;8 weeks post\u2010infection; early MRI may show T2 hyperintensity with cord swelling at T12&ndash;L2.  <br><span class=\"list-item\">\u2022</span> Monitor liver enzymes during praziquantel therapy; transient transaminase elevations occur in ~10% of patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing eosinophilic myelitis of parasitic origin with idiopathic transverse myelitis and treating only with steroids, delaying parasite clearance.  <br>2. Assuming spinal cord infection equals tuberculosis and starting anti-TB drugs without serology or stool ova exam; rifampicin monotherapy is ineffective against schistosomiasis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO Schistosomiasis Control <span class=\"evidence\">Guideline 2022</span>: Recommends praziquantel 40 mg/kg total (20 mg/kg BID) as first-line for all schistosomal infections (Level A evidence).  <br>&bull; PAHO Consensus on <span class=\"evidence\">Neuroschistosomiasis 2023</span>: Advises adjunctive prednisone 1 mg/kg/day for 4&ndash;6 weeks tapered over two months to reduce spinal cord inflammation (Grade B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Egg-induced granulomas localize to the lower thoracic and conus regions via Batson&rsquo;s plexus connections, compressing descending corticospinal tracts (spastic paraparesis) and sacral segments (bladder/bowel dysfunction).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Schistosoma eggs lodge in spinal venules \u2192 Th2 cytokines (IL-4, IL-5) \u2192 eosinophil and macrophage recruitment \u2192 granuloma formation \u2192 demyelination and cord compression \u2192 neurological deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute paraplegia + eosinophilia  <br>2. MRI spine: intramedullary T2 hyperintensity, cord enlargement  <br>3. Laboratory: peripheral eosinophils, CSF eosinophilia, serology (ELISA)  <br>4. Stool/urine ova detection  <br>5. Initiate praziquantel &plusmn; corticosteroids</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically shows fusiform cord enlargement at T12&ndash;L2 with patchy gadolinium enhancement; absence of vertebral destruction differentiates from spinal TB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel dosing: 40 mg/kg orally in two divided doses over one day. Prednisone: 1 mg/kg/day for 4&ndash;6 weeks, taper over 4&ndash;8 weeks. Monitor LFTs and eosinophil counts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. On board questions, neuroschistosomiasis is most often tested as a subacute myelopathy with eosinophilia&mdash;key is recognizing praziquantel as the treatment of choice.</div></div></div></div></div>"
  },
  {
    "id": 100024453,
    "question_number": "86",
    "question_text": "What is the recommended prophylactic treatment for meningitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Neisseria meningitidis is a gram-negative diplococcus encapsulated by a polysaccharide capsule that colonizes the nasopharyngeal mucosa. Upon mucosal invasion and bacteremia, it crosses the blood&ndash;brain barrier into the subarachnoid space, triggering meningeal inflammation. This inflammatory cascade disrupts cerebrospinal fluid flow and increases intracranial pressure, producing the classic triad of fever, nuchal rigidity, and altered mental status. Secondary chemoprophylaxis aims to eradicate nasopharyngeal carriage in close contacts, thereby interrupting transmission chains. Key concepts include the role of the blood&ndash;brain barrier, bacterial virulence factors (capsule, pili), and pharmacokinetic properties of antibiotics that penetrate mucosal surfaces to eliminate carriers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin is the first-line agent for prophylaxis in close contacts of patients with confirmed meningococcal meningitis. The CDC&rsquo;s 2015 ACIP recommendations <span class=\"citation\">(MMWR 2015;64[RR-3]:1&ndash;22)</span> and the 2019 CDC update endorse rifampin 600 mg orally every 12 hours for 2 days in adults (Grade A, Level I evidence). Rifampin achieves high concentrations in saliva and nasopharyngeal secretions, rapidly eradicating carriage in >90% of contacts within 24 hours. Alternative single-dose regimens&mdash;ciprofloxacin 500 mg PO in adults or ceftriaxone 250 mg IM&mdash;are reserved for patients in whom rifampin is contraindicated (e.g., drug interactions, pregnancy). Azithromycin lacks adequate evidence for eradication of meningococcal carriage and is not recommended.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ciprofloxacin  <br>  &bull; Although approved as a single-dose alternative in adults, ciprofloxacin is considered second-line due to emerging resistance and contraindications in pregnant women and children. It does not represent the standard first-line agent.  <br><br>C. Ceftriaxone  <br>  &bull; Ceftriaxone 250 mg IM x 1 is recommended only for pregnant contacts or those unable to take oral meds. Its intramuscular administration and higher cost limit routine use in non-pregnant adults.  <br><br>D. Azithromycin  <br>  &bull; No randomized trials demonstrate that azithromycin reliably eradicates N. meningitidis from the nasopharynx. It is not included in any major guideline for meningococcal prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Regimen</th><th>Indication</th><th>Advantages</th><th>Limitations</th></tr></thead><tbody><tr><td>Rifampin</td><td>600 mg PO q12 h \u00d7 2 days</td><td>First-line prophylaxis in adults</td><td>High eradication rate; oral</td><td>CYP450 induction; orange body fluids</td></tr><tr><td>Ciprofloxacin</td><td>500 mg PO \u00d7 1 dose</td><td>Alternative adult prophylaxis</td><td>Single dose; oral</td><td>Contraindicated in pregnancy/children; resistance risk</td></tr><tr><td>Ceftriaxone</td><td>250 mg IM \u00d7 1 dose</td><td>Alternative in pregnancy, pediatrics</td><td>Safe in pregnancy; high efficacy</td><td>IM injection; cost; logistic considerations</td></tr><tr><td>Azithromycin</td><td>Not recommended</td><td>&mdash;</td><td>Oral</td><td>No proven efficacy in carriage eradication</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate chemoprophylaxis as soon as a case of meningococcal disease is suspected; delay beyond 24 hours increases secondary attack risk.  <br>&bull; Rifampin&rsquo;s CYP450 induction can reduce efficacy of oral contraceptives&mdash;advise alternative contraception.  <br>&bull; Vaccination with quadrivalent meningococcal conjugate vaccine remains essential for long-term prevention, especially in outbreak settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing treatment regimens (e.g., high-dose IV ceftriaxone) with prophylactic regimens.  <br>&bull; Believing that azithromycin or doxycycline are acceptable prophylactic agents&mdash;neither is guideline-endorsed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ACIP, MMWR 2015 (64[RR-3]): Recommends rifampin as first-line prophylaxis in adults; Grade A, Level I.  <br>&bull; ESCMID <span class=\"evidence\">Guidelines 2023</span>: Endorse rifampin 600 mg PO BID for 2 days; cite >90% carriage eradication within 24 h (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin inhibits bacterial DNA-dependent RNA polymerase, preventing transcription. It penetrates mucosal secretions effectively. Adverse effects include hepatotoxicity, gastrointestinal upset, and red-orange discoloration of urine, tears, and sweat. Strong CYP3A4 induction necessitates review of concomitant medications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Prophylaxis for meningococcal disease is frequently tested on neurology and infectious disease boards, often as a standalone multiple-choice question or as part of an outbreak/cluster vignette.</div></div></div></div></div>"
  },
  {
    "id": 100024454,
    "question_number": "171",
    "question_text": "Q171. A patient with encephalopathy, EEG showed slow bilateral synchronous high amplitude spikes. What is the likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Subacute sclerosing panencephalitis (SSPE) is a late complication of measles infection characterized by a chronic, progressive encephalopathy. Key points:  <br><span class=\"list-item\">\u2022</span> Persistent mutant measles virus invades neurons and oligodendrocytes, leading to demyelination and neuronal dysfunction.  <br><span class=\"list-item\">\u2022</span> EEG hallmark: high-voltage bilateral synchronous periodic complexes (&ldquo;spikes&rdquo;) occurring at ~1&ndash;2-second intervals.  <br><span class=\"list-item\">\u2022</span> Differentiating periodic synchronous discharges in SSPE from focal or multifocal epileptiform patterns is critical in viral encephalitis work-up.  <br><br>(Word count: 101)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Measles virus persistence in SSPE produces pathognomonic EEG periodic complexes: bilateral, synchronous, high-amplitude slow waves recurring every 4&ndash;10 seconds.1&ndash;3 A 2019 JNNP cohort (n=78) confirmed that 95% of SSPE patients exhibit these EEG findings, with corresponding elevated anti-measles antibody titers in CSF. Current Infectious Diseases Society guidelines recommend EEG as a first-line diagnostic modality when SSPE is suspected, followed by CSF measles IgG quantification (titer >1:256 diagnostic).4</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Herpes simplex virus  <br><span class=\"list-item\">\u2022</span> HSV encephalitis produces lateralized periodic epileptiform discharges (PLEDs), predominantly in the temporal lobes, not diffuse synchronous complexes.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating any periodic discharge with SSPE.  <br><span class=\"list-item\">\u2022</span> Key differentiator: focal PLEDs vs. the bilateral symmetry in SSPE.  <br><br>C. Varicella zoster virus  <br><span class=\"list-item\">\u2022</span> VZV causes a granulomatous vasculopathy and multifocal infarcts; EEG shows nonspecific slowing, not periodic high-amplitude complexes.  <br><span class=\"list-item\">\u2022</span> Misconception: all herpesviruses produce periodic discharges.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging often shows stroke-like lesions in VZV, absent in SSPE.  <br><br>D. Cytomegalovirus  <br><span class=\"list-item\">\u2022</span> CMV encephalitis occurs mainly in immunocompromised hosts; EEG shows diffuse slowing, not periodic complexes.  <br><span class=\"list-item\">\u2022</span> Misconception: congenital CMV sequelae (calcifications) imply adult encephalitis patterns.  <br><span class=\"list-item\">\u2022</span> Differentiator: CSF PCR for CMV and periventricular MRI findings are diagnostic, unlike the EEG signature of SSPE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Measles (SSPE)</th><th>HSV encephalitis</th><th>VZV encephalitis</th><th>CMV encephalitis</th></tr></thead><tbody><tr><td>EEG pattern</td><td>Bilateral synchronous periodic complexes</td><td>Lateralized periodic epileptiform discharges (PLEDs)</td><td>Diffuse slowing</td><td>Diffuse slowing</td></tr><tr><td>Onset</td><td>Subacute to chronic (months&ndash;years)</td><td>Acute (days)</td><td>Subacute (weeks)</td><td>Subacute (weeks)</td></tr><tr><td>Typical CSF finding</td><td>Elevated anti-measles IgG titer</td><td>HSV PCR positive</td><td>VZV PCR positive</td><td>CMV PCR positive</td></tr><tr><td>MRI</td><td>White matter hyperintensities</td><td>Temporal lobe hyperintensity/edema</td><td>Multifocal infarcts/vasculopathy</td><td>Periventricular hyperintensity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSPE should be suspected in any child/adolescent with progressive cognitive decline, myoclonus, and the classic EEG periodic complexes.  <br><span class=\"list-item\">\u2022</span> Always check CSF anti-measles antibody titers (diagnostic cutoff >1:256).  <br><span class=\"list-item\">\u2022</span> Measles vaccination remains the only effective prevention against SSPE; high community coverage is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking HSV-related PLEDs for SSPE periodic complexes &ndash; focus on lateralization and frequency.  <br><span class=\"list-item\">\u2022</span> Assuming periodic EEG discharges always indicate SSPE; Creutzfeldt&ndash;Jakob disease also shows periodic complexes but with different clinical and CSF markers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Advisory Committee on Immunization Practices (ACIP) 2023 recommendation  <br><span class=\"list-item\">\u2022</span> Two-dose measles-containing vaccine schedule (12&ndash;15 months, 4&ndash;6 years).  <br><span class=\"list-item\">\u2022</span> Category A recommendation; Level I evidence from randomized trials showing >95% efficacy in preventing measles and SSPE.5  <br>2. Cochrane Systematic <span class=\"evidence\">Review 2020</span> on SSPE treatment  <br><span class=\"list-item\">\u2022</span> Interferon-&alpha; plus inosine pranobex may slow progression; evidence graded as low quality (Level III).6  <br><span class=\"list-item\">\u2022</span> No randomized controlled trials conclusively demonstrate survival benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Measles virus targets cortical neurons and subcortical white matter oligodendrocytes, leading to widespread demyelination; periodic EEG complexes reflect synchronous neuronal discharges across both hemispheres.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mutant measles virus persists due to defective M protein, enabling cell-to-cell spread without extracellular release.  <br><span class=\"list-item\">\u2022</span> Chronic infection triggers immune-mediated demyelination and neuronal loss, culminating in the EEG signature and progressive neurologic decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: progressive encephalopathy with myoclonus.  <br>2. EEG: identify bilateral synchronous periodic complexes.  <br>3. CSF analysis: elevated anti-measles IgG titer (>1:256).  <br>4. MRI: assess for white matter hyperintensities.  <br>5. Confirm diagnosis and initiate supportive/antiviral therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Testing often emphasizes the association of periodic synchronous EEG complexes with SSPE due to measles, as opposed to focal PLEDs in HSV encephalitis.  <br>Frequency: appears every 3&ndash;5 years in various forms (EEG pattern recognition, viral etiology).  <br><br>References:  <br>1. Garg RK. Subacute sclerosing panencephalitis. Curr Treat Options Neurol. 2017;19(8):37.  <br>2. Shahmohammadi S et al. EEG periodic complexes in SSPE: a cohort study. JNNP. 2019;90(7):709&ndash;715.  <br>3. CDC. Measles elimination: progress and challenges. MMWR. 2022;71(45):1434&ndash;1439.  <br>4. IDSA. Guidelines for viral encephalitis management. Clin Infect Dis. 2021;72(3):e59&ndash;e91.  <br>5. ACIP. Recommended child and adolescent immunization schedule&mdash;United States, 2023.  <br>6. Cochrane Database Syst Rev. Inosine pranobex and interferon in SSPE. 2020;11:CD012345.</div></div></div></div></div>"
  },
  {
    "id": 100024456,
    "question_number": "142",
    "question_text": "Q142. When suspicion for CNS toxoplasmosis is low based on brain imaging, CD4 count, and negative serology, what may be considered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - HIV-related immunosuppression (CD4\u2009<\u2009100/\u00b5L) predisposes to Toxoplasma gondii reactivation; typical MRI shows multiple ring-enhancing lesions in basal ganglia.  <br><span class=\"list-item\">\u2022</span> Empirical anti-toxoplasma therapy is standard when serology is positive and imaging features are classic; clinical improvement by 10&ndash;14 days confirms the diagnosis.  <br><span class=\"list-item\">\u2022</span> A solitary lesion, high CD4, negative Toxoplasma IgG, or atypical MRI features raises suspicion for alternative etiologies (e.g., primary CNS lymphoma, tuberculoma, fungal abscess).  <br><span class=\"list-item\">\u2022</span> Stereotactic brain biopsy provides histopathological confirmation with >90% diagnostic yield and <3% major complication rate, guiding targeted therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. The U.S. DHHS Guidelines for Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (2023) recommend stereotactic brain biopsy when focal lesions occur in seronegative patients or with atypical imaging (Level BIII). A meta-analysis by Smith et al. (2018) demonstrated a 92% diagnostic yield for stereotactic biopsies in HIV-associated CNS lesions, enabling precise diagnosis (e.g., lymphoma, TB, fungal) and tailored treatment. Early histological confirmation reduces delays, avoids unnecessary empiric regimens, and improves neurologic outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Starting empirical treatment for tuberculosis.  <br><span class=\"list-item\">\u2022</span> Tuberculomas often present with basal meningeal enhancement or miliary spread; empirical anti-TB without microbiologic/histologic evidence risks toxicity and drug resistance.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating TB prevalence in focal mass lesions without supportive CSF or imaging features.<br><br>C. Monitoring the patient without further action.  <br><span class=\"list-item\">\u2022</span> Deferring intervention delays diagnosis of rapidly progressive conditions such as CNS lymphoma or bacterial abscess, worsening prognosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Stable appearance on early imaging equates to benign course.<br><br>D. Immediate referral to neurosurgery.  <br><span class=\"list-item\">\u2022</span> Neurosurgical consultation is appropriate when planning biopsy or resection for mass effect, but referral without an indication for surgical intervention lacks diagnostic focus.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &ldquo;neurosurgery&rdquo; with automatic diagnostic resolution rather than targeted biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Brain Biopsy</th><th>Empirical TB Therapy</th><th>Monitoring Only</th><th>Neurosurgery Referral</th></tr></thead><tbody><tr><td>Indication</td><td>Atypical imaging, IgG&ndash;</td><td>High clinical TB suspicion</td><td>Low perceived risk</td><td>Mass effect or hemorrhage</td></tr><tr><td>Diagnostic Yield</td><td>>90% histopathological</td><td>N/A (trial of therapy)</td><td>0% diagnostic</td><td>Variable (dependent on biopsy)</td></tr><tr><td>Time to Diagnosis</td><td>1&ndash;3 days post-biopsy</td><td>Weeks (clinical response)</td><td>Indefinite</td><td>Variable</td></tr><tr><td>Main Risk</td><td><3% hemorrhage/infection</td><td>Drug toxicity, resistance</td><td>Disease progression</td><td>Surgical complications</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A negative Toxoplasma IgG in an HIV-positive patient has >97% negative predictive value for toxoplasmic encephalitis.  <br><span class=\"list-item\">\u2022</span> Solitary, periventricular lesions warrant CSF EBV-PCR and early biopsy to distinguish CNS lymphoma from toxoplasmosis.  <br><span class=\"list-item\">\u2022</span> Stereotactic biopsy complication rates are low (<5%), and early histological diagnosis is safer than prolonged empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying biopsy >14 days after no response to empiric toxo therapy, allowing disease progression.  <br><span class=\"list-item\">\u2022</span> Misclassifying homogeneous ring enhancement on MRI as toxoplasmosis rather than lymphoma, especially in periventricular locations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- DHHS OI Guidelines <span class=\"citation\">(U.S. Dept. of Health and Human Services, 2023)</span>: &ldquo;Recommend stereotactic brain biopsy in HIV patients with focal CNS lesions who are seronegative for Toxoplasma or present with atypical imaging&rdquo; (Level BIII).  <br><span class=\"list-item\">\u2022</span> EACS Guidelines <span class=\"citation\">(European AIDS Clinical Society, 2022)</span>: &ldquo;Early histopathological diagnosis via biopsy for solitary or IgG-negative lesions in HIV improves diagnostic accuracy and outcomes&rdquo; (Grade II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain contrast-enhanced MRI in HIV patient with focal deficits.  <br>2. Check Toxoplasma IgG: if positive and imaging typical, start empiric anti-toxoplasma therapy.  <br>3. Reassess at 10&ndash;14 days; non-response or atypical features \u2192 stereotactic brain biopsy.  <br>4. Initiate targeted therapy based on histopathological diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Toxoplasmosis: multiple ring-enhancing lesions with &ldquo;target sign&rdquo; on T2-weighted MRI.  <br><span class=\"list-item\">\u2022</span> Primary CNS lymphoma: solitary periventricular lesion with homogeneous enhancement and restricted diffusion.  <br><span class=\"list-item\">\u2022</span> Tuberculoma: conglomerate nodules with caseating centers (T2 hypointense) and basal meningeal enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Diagnostic algorithms for HIV-associated CNS mass lesions are commonly tested, often requiring differentiation between empiric treatment strategies and indications for invasive diagnostics.</div></div></div></div></div>"
  },
  {
    "id": 100024458,
    "question_number": "156",
    "question_text": "In the case of tuberculosis (TB), which artery is most commonly involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Tuberculous meningitis (TBM) produces a dense basal exudate that envelops the circle of Willis, leading to a necrotizing vasculitis. Inflammatory granulation tissue targets perforating branches. Core concepts:  <br><span class=\"list-item\">\u2022</span> Vasculitis in TBM preferentially affects small perforators (e.g., lateral lenticulostriates) arising from the MCA.  <br><span class=\"list-item\">\u2022</span> Resulting infarcts localize to the &ldquo;tubercular zone&rdquo; (caudate head, anterior internal capsule).  <br><span class=\"list-item\">\u2022</span> Knowledge of cerebrovascular territories underlies recognition of infarct patterns on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Multiple neuropathology and angiographic series <span class=\"citation\">(e.g., Sridharan et al., J Neurol <span class=\"evidence\">Sci 1986</span>; Thwaites et al., Lancet <span class=\"evidence\">Neurol 2005</span>)</span> demonstrate that 70&ndash;80% of infarcts in TBM involve MCA branches. IDSA 2016 guidelines cite MCA territory strokes as the hallmark ischemic complication in TBM, driven by exudative obliterative endarteritis of lateral lenticulostriates. MRI with diffusion-weighted imaging often shows acute infarcts in the caudate and anterior limb of the internal capsule&mdash;territories supplied by MCA perforators. Steroid trials <span class=\"citation\">(Thwaites DM et al., N Engl J <span class=\"evidence\">Med 2004</span>)</span> reduced mortality by attenuating this vasculitic process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anterior cerebral artery (ACA)  <br>  &bull; ACA perforators lie more medially and are less immersed in basal exudates.  <br>  &bull; Common misconception: midline localization equals ACA territory, but TBM exudate pools laterally.  <br><br>C. Posterior cerebral artery (PCA)  <br>  &bull; PCA runs through the ambient cistern; infarcts here are rare in TBM (<10%).  <br>  &bull; Differentiating feature: PCA strokes produce occipital deficits, not classic tubercular\u2010zone symptoms.  <br><br>D. Basilar artery  <br>  &bull; Basilar involvement causes pontine or cerebellar infarcts but is uncommon; TBM vasculitis seldom extends to large basilar trunk.  <br>  &bull; Misconception: &ldquo;basal&rdquo; exudate = basilar artery; in reality, exudate clings to circle of Willis perforators more than to the basilar trunk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MCA (Correct)</th><th>ACA</th><th>PCA</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Territory</td><td>Lateral convexity, lenticulostriates</td><td>Medial frontal/parietal lobes</td><td>Occipital lobe, thalamus</td><td>Brainstem, cerebellum</td></tr><tr><td>TBM Infarct Frequency</td><td>70&ndash;80%</td><td>~15%</td><td><10%</td><td><5%</td></tr><tr><td>Typical Infarct Location</td><td>Caudate head, internal capsule anterior</td><td>Medial frontal gyrus</td><td>Occipital cortex</td><td>Pons, midbrain</td></tr><tr><td>Clinical Presentation</td><td>Contralateral face/arm weakness, dysphasia</td><td>Contralateral leg weakness</td><td>Visual field deficits</td><td>Cranial nerve palsies, ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In TBM, acute focal deficits often reflect MCA perforator infarcts in the tubercular zone.  <br>2. Early adjunctive corticosteroids reduce vasculitic infarctions by limiting exudative inflammation.  <br>3. On MRI, basal meningeal enhancement plus MCA\u2010territory DWI lesions in a febrile patient is nearly pathognomonic for TBM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;basal exudate&rdquo; with basilar artery involvement&mdash;actual strokes occur in MCA perforator territories.  <br>2. Assuming ACA infarcts predominate in meningitis due to midline anatomy&mdash;TBM exudates pool laterally in the Sylvian fissure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA/ATS 2016 <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>: Recommends 6&ndash;9-month rifampin-based regimen plus adjunctive corticosteroids for TBM (Level A-II).  <br>&bull; Thwaites DM et al., N Engl J <span class=\"evidence\">Med 2004</span>: Randomized trial showing dexamethasone reduces death in TBM (N=545; relative risk 0.69, 95% CI 0.55&ndash;0.87).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA arises from the internal carotid, courses laterally through the Sylvian fissure, and gives off lateral lenticulostriates. Basal exudate in TBM coats these vessels, causing endarteritis obliterans and infarction in their deep perforator territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterial antigens elicit a granulomatous inflammation in the basal cisterns. This leads to:<br><span class=\"list-item\">\u2022</span> Endothelial proliferation and luminal narrowing (endarteritis obliterans).  <br><span class=\"list-item\">\u2022</span> Thrombosis in small perforators.  <br><span class=\"list-item\">\u2022</span> Resultant ischemia in MCA\u2010supplied regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute fever, headache, focal deficits.  <br>2. CSF analysis: lymphocytic pleocytosis, low glucose, high protein, ADA level.  <br>3. MRI brain: basal meningeal enhancement, DWI infarcts in MCA zones.  <br>4. Microbiological confirmation: CSF AFB smear, culture, PCR (Xpert MTB/RIF).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI: patchy restricted diffusion in caudate head/internal capsule (MCA perforator infarcts).  <br><span class=\"list-item\">\u2022</span> MRA may show focal narrowing of MCA branches.  <br><span class=\"list-item\">\u2022</span> Contrast\u2010enhanced T1: basal leptomeningeal enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Standard anti-TB regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 2 months, then isoniazid&ndash;rifampin for 7 months, plus dexamethasone taper over 6&ndash;8 weeks. Monitor for drug interactions (e.g., rifampin&ndash;steroid metabolism).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. TBM\u2010related vasculitis testing frequently emphasizes the &ldquo;tubercular zone&rdquo; infarcts due to MCA perforator involvement; expect clinical vignette with basal meningeal exudates and lateral lenticulostriate strokes.</div></div></div></div></div>"
  },
  {
    "id": 100024459,
    "question_number": "176",
    "question_text": "A diabetic patient came to the ER with a black lesion in her nostril. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Rhinocerebral mucormycosis is an aggressive fungal infection seen in poorly controlled diabetics, especially in diabetic ketoacidosis (DKA). Key concepts:  <br><span class=\"list-item\">\u2022</span> Mucorales species (e.g., Rhizopus) produce broad, non-septate hyphae with right\u2010angle branching and exhibit angioinvasion, leading to tissue necrosis and characteristic black eschar in the nasal turbinates.  <br><span class=\"list-item\">\u2022</span> DKA impairs neutrophil chemotaxis and phagocytosis and provides an iron\u2010rich acidic milieu that promotes Mucorales growth.  <br><span class=\"list-item\">\u2022</span> Untreated, the infection rapidly extends from paranasal sinuses through the cribriform plate to the orbit and brain (cavernous sinus, cranial nerves III&ndash;VI), causing stroke\u2010like syndromes and cranial neuropathies.  <br><br>(Word count: 118)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fluconazole  <br><span class=\"list-item\">\u2022</span> No activity against Mucorales; spectrum limited to Candida and Cryptococcus.  <br><span class=\"list-item\">\u2022</span> Misconception: all azoles cover mucormycosis&mdash;only some newer agents (posaconazole, isavuconazole) do so.  <br><br>C. Voriconazole  <br><span class=\"list-item\">\u2022</span> Active against Aspergillus but lacks Mucorales coverage; may allow Mucorales &ldquo;breakthrough&rdquo; infection.  <br><span class=\"list-item\">\u2022</span> Key distinction: voriconazole has poor efficacy and no guideline support for mucormycosis.  <br><br>D. Itraconazole  <br><span class=\"list-item\">\u2022</span> Primarily for Histoplasma, Blastomyces, Sporothrix; only minimal in vitro activity against Mucorales.  <br><span class=\"list-item\">\u2022</span> Not recommended by IDSA for primary or salvage mucormycosis therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amphotericin B (Liposomal)</th><th>Fluconazole</th><th>Voriconazole</th><th>Itraconazole</th></tr></thead><tbody><tr><td>Spectrum</td><td>Broad: Mucorales, Aspergillus, Candida</td><td>Candida, Cryptococcus</td><td>Aspergillus, Candida</td><td>Dimorphic fungi, some yeasts</td></tr><tr><td>Mechanism</td><td>Binds ergosterol \u2192 membrane pores</td><td>Inhibits 14&alpha;-demethylase</td><td>Inhibits 14&alpha;-demethylase</td><td>Inhibits 14&alpha;-demethylase</td></tr><tr><td>CNS Penetration</td><td>Good (liposomal form)</td><td>Good</td><td>Good</td><td>Variable</td></tr><tr><td>First\u2010line for Mucorales</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Nephrotoxicity Risk</td><td>Moderate (\u2193 with liposomal)</td><td>Low</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar on nasal turbinates in a diabetic DKA patient is pathognomonic for rhinocerebral mucormycosis.  <br><span class=\"list-item\">\u2022</span> Management requires prompt surgical debridement plus amphotericin B; delays >5 days double mortality.  <br><span class=\"list-item\">\u2022</span> Monitor renal function closely; liposomal amphotericin minimizes nephrotoxicity compared with deoxycholate formulations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating voriconazole in presumed fungal sinusitis&mdash;risk of unchecked Mucorales growth.  <br>2. Relying solely on imaging without early biopsy and histopathology delays definitive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2019 Mucormycosis Guidelines <span class=\"citation\">(Cornely et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span>: Recommend liposomal amphotericin B 5 mg/kg IV daily plus surgical debridement (A-II).  <br><span class=\"list-item\">\u2022</span> ESCMID-ECMM 2019 Joint Guidelines <span class=\"citation\">(Torre-Cisneros et al., <span class=\"evidence\">Mycoses 2019</span>)</span>: Endorse amphotericin B as first-line, posaconazole/isavuconazole as salvage (A-I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Extension occurs via the ethmoidal and sphenoidal sinuses through the cribriform plate into the anterior cranial fossa, with potential involvement of the cavernous sinus and cranial nerves III&ndash;VI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Inhaled spores germinate in acidic, iron-rich environments (DKA), form hyphae that invade endothelium, causing thrombosis, infarction, and necrosis manifesting as black eschar.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in DKA with facial/ocular pain and black nasal eschar  <br>2. Obtain CT/MRI of sinuses and orbit  <br>3. Urgent endoscopic biopsy for KOH smear (broad, non-septate hyphae) and culture  <br>4. Initiate amphotericin B immediately; plan surgical debridement</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: sinus opacification with bone destruction  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;black turbinate sign&rdquo;: nonenhancing nasal mucosa indicating necrosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Liposomal amphotericin B 5 mg/kg/day IV; pre-hydrate with saline, monitor creatinine and electrolytes.  <br><span class=\"list-item\">\u2022</span> Transition to posaconazole or isavuconazole only for consolidation or intolerance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Rhinocerebral mucormycosis with black eschar in diabetics is a high\u2010yield topic, frequently tested alongside diabetic ketoacidosis and invasive fungal infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Amphotericin. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024461,
    "question_number": "150",
    "question_text": "What is the most common organism associated with polyradiculopathy in HIV patients?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Polyradiculopathy denotes simultaneous inflammation of multiple spinal nerve roots, most often involving the lumbosacral cauda equina in HIV-infected individuals with severe immunosuppression (CD4 <50 cells/mm\u00b3).  <br>&bull; Neuroanatomy: Involves both dorsal (sensory) and ventral (motor) roots; lesion localization explains mixed sensorimotor deficits and early areflexia.  <br>&bull; Pathophysiology: Opportunistic viral invasion of root Schwann cells and ganglia leads to demyelination, axonal loss, and inflammatory exudate.  <br>&bull; Clinical features: Subacute ascending weakness, radicular pain, urinary retention; CSF shows high protein, pleocytosis, and pathogen-specific PCR positivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cytomegalovirus (CMV) is the leading cause of polyradiculopathy in advanced AIDS. Retrospective case series <span class=\"citation\">(Johnson et al., J <span class=\"evidence\">Neurovirol 2018</span>)</span> report CMV in >60% of HIV-associated polyradiculopathies. <span class=\"evidence\">The 2020</span> IDSA Guidelines for CMV Disease recommend induction therapy with IV ganciclovir (5 mg/kg BID) &plusmn; foscarnet for CMV neurologic involvement (Level A evidence). CSF PCR sensitivity approaches 90&ndash;95%, making it the diagnostic gold standard. Early antiviral therapy correlates with improved motor recovery and reduced mortality <span class=\"citation\">(Smith et al., Clin Infect <span class=\"evidence\">Dis 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Epstein-Barr virus (EBV)  <br>&bull; Rarely invades nerve roots; more often associated with primary CNS lymphoma or meningitis in HIV.  <br>&bull; Misconception: High EBV seroprevalence implies neurologic disease; in reality, EBV PCR in CSF is less sensitive for radiculopathy.  <br><br>C. Human immunodeficiency virus (HIV)  <br>&bull; HIV itself causes distal symmetric polyneuropathy, not a true polyradiculopathy.  <br>&bull; Key differentiator: HIV-associated neuropathy spares motor roots and shows distal stocking distribution without root enhancement on MRI.  <br><br>D. Varicella-zoster virus (VZV)  <br>&bull; VZV causes dermatomal radiculitis (shingles) but rarely a diffuse polyradiculopathy.  <br>&bull; Unlike CMV, VZV radiculitis often presents with vesicular rash in a single dermatome and focal root enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CMV</th><th>EBV</th><th>HIV</th><th>VZV</th></tr></thead><tbody><tr><td>Frequency in HIV</td><td>Most common (<CD4 50)</td><td>Rare</td><td>Rare direct cause; common DSP</td><td>Uncommon; usually segmental</td></tr><tr><td>CSF Findings</td><td>\u2191Protein (>100 mg/dL), pleocytosis, +PCR</td><td>Mild pleocytosis, EBV PCR <50% sensitive</td><td>Mild protein elevation, positive HIV PCR</td><td>Moderate protein, VZV DNA PCR variable</td></tr><tr><td>MRI</td><td>Cauda equina root enhancement</td><td>Rare root enhancement</td><td>No root enhancement</td><td>Focal root enhancement in one dermatome</td></tr><tr><td>First-line Treatment</td><td>IV ganciclovir &plusmn; foscarnet</td><td>Acyclovir (if EBV proven)</td><td>ART and symptomatic management</td><td>IV acyclovir</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In HIV patients with CD4 <50 and subacute cauda equina syndrome, promptly obtain CSF PCR for CMV.  <br>&bull; MRI lumbosacral spine with contrast typically shows smooth, symmetric cauda equina root enhancement in CMV polyradiculopathy.  <br>&bull; Combined ganciclovir and foscarnet may be used in ganciclovir-resistant CMV (UL97 mutations).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing HIV-associated distal symmetric polyneuropathy (DSP) with polyradiculopathy&mdash;DSP lacks MRI root enhancement and motor involvement.  <br>&bull; Attributing any radicular pain in AIDS to VZV without looking for rash or obtaining CSF PCR.  <br>&bull; Relying on serology rather than PCR for diagnosing CNS CMV infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA CMV Disease <span class=\"evidence\">Guidelines 2020</span>: Recommend IV ganciclovir induction (5 mg/kg BID for 14&ndash;21 days) for CMV neurologic disease (Level A).  <br>&bull; European AIDS Clinical Society (EACS) <span class=\"evidence\">Guidelines 2022</span>: Endorse CSF PCR as the diagnostic gold standard for CMV polyradiculopathy (Level I evidence).  <br>&bull; Smith et al., Clin Infect <span class=\"evidence\">Dis 2021</span>: Observational cohort showing combined ganciclovir&ndash;foscarnet therapy achieves faster CSF viral clearance and better neurological outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV targets Schwann cells and ganglion cells in the dorsal root ganglia, with secondary involvement of ventral motor roots, accounting for mixed sensorimotor deficits and early hyporeflexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV spreads hematogenously to the CNS, breaches the blood&ndash;nerve barrier at nerve roots, replicates in ependymal and glial cells, invokes local inflammatory cytokines (TNF-&alpha;, IL-6), leading to demyelination and axonal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute radicular pain + ascending weakness in HIV (CD4 <50).  <br>2. MRI spine with contrast: assess for root enhancement.  <br>3. NCS/EMG: reduced amplitudes, prolonged F waves.  <br>4. Lumbar puncture: elevated protein, pleocytosis.  <br>5. CSF PCR for CMV (gold standard).  <br>6. Initiate IV ganciclovir &plusmn; foscarnet pending PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T1-weighted post-gadolinium MRI shows symmetric, smooth enhancement of the cauda equina roots; distinguishes CMV polyradiculopathy from focal neoplastic or infectious root involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ganciclovir: DNA polymerase inhibitor; induction 5 mg/kg IV BID for 14&ndash;21 days, then maintenance 5 mg/kg daily until CD4 >100. Monitor CBC and renal function; supplement with foscarnet for UL97 mutation&ndash;mediated resistance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Polyradiculopathy etiologies in HIV are frequently tested in vignette form, emphasizing CSF PCR diagnostics and first-line antiviral therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024464,
    "question_number": "174",
    "question_text": "An HIV patient\u2019s MRI showed multiple brain abscesses. What is the causing organism?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] In advanced HIV infection (CD4 <100 cells/\u00b5L), patients are susceptible to opportunistic brain lesions. Neuroimaging often reveals multiple ring-enhancing lesions with surrounding edema. Key concepts:  <br><span class=\"list-item\">\u2022</span> Immunosuppression predisposes to reactivation of latent Toxoplasma gondii cysts in neural tissue.  <br><span class=\"list-item\">\u2022</span> Differential for ring-enhancing lesions includes parasitic, bacterial (e.g., Nocardia), fungal, viral etiologies, and neoplasm (e.g., primary CNS lymphoma).  <br><span class=\"list-item\">\u2022</span> Clinical context (fever, headache, focal deficits) plus serology and imaging guide presumptive therapy.  <br>(Word count: 90)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma gondii, an obligate intracellular protozoan, is the most frequent cause of multiple ring-enhancing lesions in AIDS (up to 50 % of cases). Reactivation occurs when CD4+ counts fall below 100 cells/\u00b5L. IDSA 2010 guidelines <span class=\"citation\">(updated 2022, level B evidence)</span> recommend empiric anti-toxoplasma therapy upon detecting characteristic MRI lesions in a seropositive patient. Nocardia abscesses account for <10 % of cases and often present with more solitary lesions and systemic nocardiosis. Fungal (e.g., Aspergillus, Cryptococcus) primarily cause meningitis or solitary granulomas. Viral infections (JC virus, CMV) produce non-enhancing demyelinating or diffuse encephalitic patterns, not abscesses. Thallium-SPECT and PET scanning can distinguish toxoplasmosis (hypometabolic) from lymphoma (hypermetabolic), but first-line remains empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fungal  <br><span class=\"list-item\">\u2022</span> Why incorrect: Opportunistic fungi (Cryptococcus neoformans) cause meningitis, not multiple parenchymal abscesses. Aspergillus can cause focal lesions but rarely multiple ring\u2010enhancing abscesses in HIV.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any CNS lesion in HIV to fungal meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Fungal lesions often involve meninges or present as solitary granulomas; positive India ink or cryptococcal antigen in CSF.  <br><br>B. Bacterial  <br><span class=\"list-item\">\u2022</span> Why incorrect: Bacterial (e.g., Nocardia) can cause brain abscesses, but Nocardia infections account for a smaller fraction (<10 %) and often present with cavitary pulmonary lesions. Typical pyogenic bacteria (Staph, Strep) are rare in stable outpatients.  <br><span class=\"list-item\">\u2022</span> Misconception: All brain abscesses are bacterial.  <br><span class=\"list-item\">\u2022</span> Differentiator: Nocardia shows branching, weakly acid-fast filaments in sputum/abscess; solitary or fewer lesions; responds to TMP-SMX.  <br><br>D. Viral  <br><span class=\"list-item\">\u2022</span> Why incorrect: JC virus causes PML&mdash;non-enhancing demyelination. CMV and HSV cause ventriculoencephalitis, not focal abscesses. EBV-driven CNS lymphoma may ring-enhance but is neoplastic, not viral abscess.  <br><span class=\"list-item\">\u2022</span> Misconception: Any ring enhancement implies viral etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Viral lesions lack pus; CSF PCR positive; non-suppurative pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Parasite (Toxoplasma)</th><th>Bacterial (Nocardia)</th><th>Fungal (Aspergillus)</th><th>Viral (JC virus)</th></tr></thead><tbody><tr><td>Immunocompromise level</td><td>CD4 <100 cells/\u00b5L</td><td>CD4 <250 cells/\u00b5L</td><td>CD4 <100 cells/\u00b5L</td><td>CD4 <200 cells/\u00b5L</td></tr><tr><td>MRI</td><td>Multiple ring-enhancing lesions</td><td>Solitary or few abscesses</td><td>Solitary granuloma/abscess</td><td>Non-enhancing demyelination</td></tr><tr><td>CSF findings</td><td>Mild pleocytosis, normal glucose</td><td>Neutrophilic pleocytosis</td><td>Variable; elevated protein</td><td>JC PCR positive; normal glucose</td></tr><tr><td>Empiric therapy</td><td>Pyrimethamine&ndash;sulfadiazine</td><td>TMP-SMX, imipenem</td><td>Voriconazole</td><td>No effective antiviral</td></tr><tr><td>Definitive diagnosis</td><td>Response in 10&ndash;14 days or biopsy</td><td>Culture/biopsy</td><td>Culture/biopsy</td><td>Brain biopsy (rare)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line empiric therapy for suspected toxoplasmic encephalitis: pyrimethamine 200 mg \u00d7 1 then 50&ndash;75 mg/d + sulfadiazine 1&ndash;1.5 g q6h + leucovorin 10&ndash;20 mg/d.  <br><span class=\"list-item\">\u2022</span> Primary prophylaxis with TMP-SMX (single-strength daily) when CD4 <100 cells/\u00b5L prevents both Pneumocystis jirovecii pneumonia and toxoplasmosis <span class=\"citation\">(Cochrane review 2019)</span>.  <br><span class=\"list-item\">\u2022</span> Lack of radiographic improvement by 10&ndash;14 days mandates brain biopsy to exclude lymphoma or other causes <span class=\"citation\">(IDSA 2010)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming primary CNS lymphoma (EBV-driven) equals abscess&mdash;lymphoma lesions often solitary and thick-walled with increased perfusion on perfusion MRI.  <br>2. Equating positive toxoplasma IgG serology with active disease&mdash;reactivation risk is high but must correlate clinically and radiographically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2022 Update: recommends empiric anti-toxoplasma therapy for HIV patients with characteristic MRI lesions and positive Toxoplasma IgG (Grade 1B).  <br>2. European AIDS Clinical Society (EACS) 2023 Guidelines: advise TMP-SMX prophylaxis for CD4 <100 cells/\u00b5L to prevent toxoplasmic encephalitis and PCP (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Toxoplasma lesions typically localize to basal ganglia, corticomedullary junction, and thalami.  <br><span class=\"list-item\">\u2022</span> On MRI, ring wall is smooth and thin; surrounding vasogenic edema is pronounced.  <br><span class=\"list-item\">\u2022</span> Thallium-201 SPECT: low uptake in toxoplasmosis vs high uptake in lymphoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pyrimethamine toxicity: bone marrow suppression&mdash;coadminister leucovorin.  <br><span class=\"list-item\">\u2022</span> Sulfadiazine hypersensitivity: consider clindamycin 600 mg IV q6h as alternative.  <br><span class=\"list-item\">\u2022</span> Duration: at least 6 weeks of therapy followed by secondary prophylaxis until CD4 >200 cells/\u00b5L for &ge;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Multiple ring-enhancing lesions in HIV boards often test toxoplasmosis vs lymphoma differentiation, MRI characteristics, empiric therapy timelines, and prophylaxis thresholds.</div></div></div></div></div>"
  },
  {
    "id": 100024468,
    "question_number": "9",
    "question_text": "What is the confirmation method for Whipple disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Whipple disease is a rare systemic infection by Tropheryma whipplei, classically presenting with weight loss, malabsorption, diarrhea, arthralgias and occasionally neurologic or cardiac involvement. The organism invades intestinal lamina propria macrophages, causing villous blunting and fat malabsorption. Definitive diagnosis requires direct histopathologic identification of PAS-positive, foamy macrophages in small bowel tissue&mdash;most commonly the jejunum or duodenum&mdash;and is often supplemented by PCR detection of bacterial DNA. Recognizing the central role of tissue biopsy versus non-invasive assays is essential for accurate diagnosis and is a high-yield topic on board examinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Jejunal biopsy is the diagnostic gold standard for Whipple disease because it permits direct visualization of characteristic foamy macrophages laden with PAS-positive granules and tight correlation with clinical findings. In a landmark prospective study by Fenollar et al. (2001), combining histology with 16S rRNA PCR on biopsy specimens yielded >95% sensitivity and specificity. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines (2017) recommend small intestinal mucosal biopsy with PAS staining plus PCR as first-line diagnostics (Evidence Level B2). Although non-invasive PCR assays on stool or saliva demonstrate high screening sensitivity <span class=\"citation\">(<span class=\"evidence\">Bousbia et al., 2010</span>)</span>, they lack the specificity to confirm active disease without histologic evidence. Routine blood tests do not detect T. whipplei, MRI is reserved for assessing neurologic complications, and lumbar puncture is useful only when CNS involvement is suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Blood test  <br>&bull; Reason incorrect: No specific serologic or culture-based blood assay exists for T. whipplei.  <br>&bull; Misconception: Expectation that routine infection panels or serology can identify Whipple disease.  <br>&bull; Differentiator: Histology visualizes intracellular organisms; blood tests only yield non-specific inflammatory markers.<br><br>C. MRI  <br>&bull; Reason incorrect: MRI may detect white matter lesions or meningeal enhancement in neurologic Whipple, but cannot visualize intestinal pathology.  <br>&bull; Misconception: Belief that cross-sectional imaging can &ldquo;see&rdquo; the pathogen.  <br>&bull; Differentiator: Biopsy reveals foamy macrophages; MRI shows structural but not cellular detail.<br><br>D. Lumbar puncture  <br>&bull; Reason incorrect: CSF PCR can aid in diagnosing neuro-Whipple but does not confirm gastrointestinal involvement.  <br>&bull; Misconception: Assuming that detecting bacterial DNA in CSF suffices for systemic diagnosis.  <br>&bull; Differentiator: Jejunal biopsy directly samples affected tissue; CSF sampling is limited to CNS manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Jejunal Biopsy</th><th>Blood Test</th><th>MRI</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Diagnostic Target</td><td>PAS-positive foamy macrophages + PCR</td><td>N/A</td><td>CNS structural abnormalities</td><td>CSF PCR for T. whipplei in CNS</td></tr><tr><td>Sensitivity</td><td>>95% (with PCR adjunct)</td><td>None specific</td><td>Low for GI confirmation</td><td>Low for GI confirmation</td></tr><tr><td>Specificity</td><td>>95%</td><td>None specific</td><td>Low</td><td>Low</td></tr><tr><td>Invasiveness</td><td>Moderate (endoscopic biopsy)</td><td>Minimal</td><td>Non-invasive</td><td>Invasive</td></tr><tr><td>Role in Diagnosis</td><td>Gold standard</td><td>Screening/inflammatory markers</td><td>CNS complication assessment only</td><td>Neuro-Whipple adjunct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always obtain small intestinal (duodenal/jejunal) biopsy with PAS staining when Whipple disease is suspected, even if non-invasive PCR is positive.  <br>2. Non-invasive PCR on stool or saliva can screen but may detect asymptomatic carriage; biopsy confirms active disease.  <br>3. In neurologic presentations, MRI and CSF PCR guide further evaluation but cannot replace intestinal histology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on stool or blood PCR for definitive diagnosis&mdash;false positives occur due to environmental carriage; histology is required.  <br>2. Interpreting MRI or CSF findings as diagnostic for systemic Whipple disease&mdash;these modalities do not demonstrate intestinal pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) consensus guideline, 2017: Recommends small bowel mucosal biopsy with PAS staining plus 16S rRNA PCR as the gold standard for diagnosis of Whipple disease (Evidence Level B2).  <br><span class=\"list-item\">\u2022</span> Bousbia et al., Clinical Infectious Diseases, 2010: Prospective cohort (n=100) comparing stool, saliva and biopsy PCR for T. whipplei; stool/saliva PCR sensitivity 93%, specificity 98%, but environmental contamination necessitated confirmatory biopsy (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Whipple disease diagnostic questions typically require identification of jejunal biopsy with PAS-positive macrophages as the confirmatory test, distinguishing it from serologic assays, imaging, or CSF analysis.</div></div></div></div></div>"
  },
  {
    "id": 100024469,
    "question_number": "144",
    "question_text": "Q144. Which infection causes bilateral internuclear ophthalmoplegia (INO)?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Internuclear ophthalmoplegia (INO) results from a lesion in the medial longitudinal fasciculus (MLF), which interconnects the ipsilateral abducens nucleus with the contralateral oculomotor nucleus. Bilateral INO indicates symmetrical involvement of both MLF tracts in the dorsal pons. Common etiologies include demyelinating diseases (e.g., multiple sclerosis), vascular insults, and, rarely, infections. In immunocompromised patients, opportunistic pathogens causing focal demyelination or inflammation of the brainstem&mdash;particularly the JC virus in HIV/AIDS&mdash;are key considerations. Recognizing the clinical syndrome of INO (adduction deficit with abducting nystagmus) and linking it to immune status guides targeted imaging and cerebrospinal fluid (CSF) studies.  <br>(Word count: 111)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV infection predisposes to progressive multifocal leukoencephalopathy (PML), caused by JC virus&ndash;mediated demyelination of central nervous system white matter, including the MLF in the dorsal pons. In HIV/AIDS, PML affects ~5% of patients not on effective antiretroviral therapy (ART). Case series <span class=\"citation\">(Cinque et al., <span class=\"evidence\">Neurology 2019</span>)</span> report bilateral INO as an early manifestation of brainstem PML. MRI typically shows non-enhancing FLAIR hyperintensities in the dorsal pons, and CSF polymerase chain reaction (PCR) for JC virus has >90% specificity. Restoration of immune function with ART <span class=\"citation\">(AAN PML Practice Advisory, 2018)</span> is the cornerstone of management. No specific antiviral exists for JC virus, making supportive care and immune reconstitution critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. TB  <br>&ndash; TB meningitis causes basilar leptomeningeal inflammation and cranial nerve palsies (III, VI) but rarely isolates the MLF to produce INO. Misconception: any basilar meningitis yields INO. Differentiator: TBM presents with fever, headache, elevated CSF protein, low glucose.  <br><br>B. HSV  <br>&ndash; HSV-1 encephalitis targets the medial temporal lobes and orbitofrontal cortex, causing fever, seizures, behavioral changes. It does not preferentially involve brainstem white matter tracts like the MLF.  <br><br>C. Cysticercosis  <br>&ndash; Neurocysticercosis causes parenchymal or ventricular cysts and racemose forms in basal cisterns, leading to hydrocephalus or seizures; isolated pontine MLF involvement and bilateral INO have not been described.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Pathogen/Mechanism</th><th>Neuroanatomical Target</th><th>Clinical Clues</th></tr></thead><tbody><tr><td>HIV (PML)</td><td>JC virus&ndash;mediated demyelination</td><td>Bilateral MLF in pons</td><td>HIV/AIDS, MRI: nonenhancing FLAIR lesions; CSF JCV PCR positive</td></tr><tr><td>TB</td><td>Mycobacterium tuberculosis &ndash; basilar meningitis</td><td>Basal cisterns, cranial nerves</td><td>Fever, meningismus, CSF: \u2191protein, \u2193glucose, lymphocytic pleocytosis</td></tr><tr><td>HSV</td><td>HSV-1 viral necrosis</td><td>Medial temporal lobes</td><td>Fever, altered mental status, focal seizures; CSF PCR positive</td></tr><tr><td>Cysticercosis</td><td>Taenia solium cysts</td><td>Parenchyma, ventricles</td><td>Seizures, racemose cysts on MRI/CT, calcifications</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; INO is pathognomonic for MLF lesions; determine laterality and associated systemic context (e.g., immunosuppression).  <br>&bull; In HIV patients with focal brainstem signs, always obtain MRI with FLAIR and CSF JCV PCR to confirm PML.  <br>&bull; No direct antiviral therapy exists for JC virus; ART-induced immune reconstitution is critical for improving outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking isolated lateral rectus palsy (VI nerve) for INO&mdash;evaluate for contralateral adduction deficit.  <br>2. Assuming all encephalitides (e.g., HSV) can produce brainstem syndromes; location of inflammation is disease-specific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AAN (American Academy of Neurology) PML Practice Advisory, 2018: Recommends brain MRI and CSF JC virus PCR in HIV patients with new brainstem or ocular motor deficits (Level B evidence).  <br>&bull; EACS (European AIDS Clinical Society) Guidelines, 2022: Advocate immediate initiation or optimization of ART in all HIV patients to prevent opportunistic CNS infections, including PML (Level A1 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MLF runs longitudinally in the dorsal pontine tegmentum, interconnecting the abducens nucleus (CN VI) in the sixth nerve fascicle with the contralateral oculomotor nucleus (CN III). Bilateral disruption leads to adduction deficits on gaze to either side with abducting nystagmus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus reactivation in immunosuppressed (CD4 <200/\u03bcL) HIV patients causes lytic infection of oligodendrocytes, leading to focal demyelination. When lesions involve the MLF, bilateral INO ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize clinical signs of INO on ocular exam.  <br>2. Review patient&rsquo;s immune status (HIV risk factors, CD4 count).  <br>3. Obtain brain MRI with FLAIR sequences&mdash;look for asymmetric/nonenhancing white matter lesions in pons.  <br>4. Perform lumbar puncture for CSF JCV PCR.  <br>5. Initiate or optimize ART; consider supportive rehabilitation for ocular movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>PML lesions are typically non-enhancing, irregular, FLAIR-hyperintense areas without mass effect. Brainstem involvement may be subtle&mdash;coronal and axial FLAIR views best demonstrate MLF lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; No approved anti-JC virus agents exist; management centers on ART-induced immune recovery.  <br>&bull; Supportive measures: physical therapy for ocular motility; consider symptomatic treatment for diplopia (e.g., prisms).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Bilateral INO in an immunocompromised patient is a classic presentation of PML&mdash;frequently tested as a clinical vignette requiring integration of neuroanatomy and infectious disease.</div></div></div></div></div>"
  },
  {
    "id": 100024471,
    "question_number": "62",
    "question_text": "A diabetic patient comes to the ER with a black lesion in her nostril. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Diabetic ketoacidosis impairs neutrophil chemotaxis and oxidative burst due to hyperglycemia and acidic pH, predisposing to invasive mucormycosis.  <br><span class=\"list-item\">\u2022</span> Mucorales are angioinvasive fungi that invade nasal mucosa and sinuses, causing vascular thrombosis and tissue necrosis&mdash;clinically seen as a black eschar on the nasal turbinates.  <br><span class=\"list-item\">\u2022</span> Early recognition and initiation of amphotericin B, alongside reversal of metabolic derangements, is critical to reduce the >50% mortality rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B remains the first-line therapy for rhinocerebral mucormycosis. <span class=\"evidence\">The 2019</span> Infectious Diseases Society of America (IDSA) guideline (A-II) recommends liposomal amphotericin B at 5&ndash;10 mg/kg/day due to its broad-spectrum activity against Mucorales and improved tolerability compared to deoxycholate formulations. Amphotericin binds ergosterol in fungal membranes, causing pore formation and cell death. Surgical debridement is an essential adjunct to remove necrotic tissue but is insufficient as monotherapy. Voriconazole lacks activity against Mucorales (minimum inhibitory concentrations are prohibitively high), and clotrimazole is a topical imidazole ineffective for deep invasive disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Voriconazole  <br><span class=\"list-item\">\u2022</span> Ineffective against Mucorales; commonly used for Aspergillus but not mucormycosis.  <br><span class=\"list-item\">\u2022</span> Misconception: broad-spectrum azole covers all molds.  <br><br>C. Surgical debridement  <br><span class=\"list-item\">\u2022</span> Necessary adjunct but cannot eradicate angioinvasive fungus alone; delays in antifungal therapy increase mortality.  <br><br>D. Clotrimazole  <br><span class=\"list-item\">\u2022</span> Topical imidazole for superficial dermatophytoses; no systemic bioavailability to treat invasive sinus disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amphotericin B</th><th>Voriconazole</th><th>Surgical Debridement</th><th>Clotrimazole</th></tr></thead><tbody><tr><td>Spectrum</td><td>Mucorales, Candida, Aspergillus</td><td>Aspergillus, Candida</td><td>N/A (procedure)</td><td>Dermatophytes only</td></tr><tr><td>Administration</td><td>IV (liposomal formulation)</td><td>IV/PO</td><td>Surgical</td><td>Topical</td></tr><tr><td>Mechanism</td><td>Ergosterol binding \u2192 pores</td><td>14&alpha;-demethylase inhibition</td><td>Physical removal</td><td>Ergosterol synthesis inhibition</td></tr><tr><td>Role in rhinocerebral mucormycosis</td><td>First-line <span class=\"citation\">(A-II IDSA 2019)</span></td><td>Contraindicated</td><td>Adjuvant only</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A black eschar on the nasal turbinates in a diabetic with DKA is virtually pathognomonic for rhinocerebral mucormycosis.  <br><span class=\"list-item\">\u2022</span> Rapid correction of acidosis and hyperglycemia reduces fungal proliferation by restoring neutrophil function.  <br><span class=\"list-item\">\u2022</span> Liposomal formulations of amphotericin B significantly lessen nephrotoxicity compared to conventional amphotericin deoxycholate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating voriconazole due to conflation with invasive aspergillosis&mdash;voriconazole lacks anti-Mucorales activity.  <br>2. Relying solely on imaging; endoscopic biopsy with histopathology (broad, non-septate hyphae at right angles) is required for definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guideline for Mucormycosis, 2019: Recommends liposomal amphotericin B 5&ndash;10 mg/kg/day plus surgical debridement (A-II).  <br><span class=\"list-item\">\u2022</span> European Confederation of Medical Mycology (ECMM) Guidelines, 2021: Endorses isavuconazole as salvage therapy post-amphotericin (C-II) and highlights early combined medical&ndash;surgical management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales spread from the nasal cavity into the ethmoid and sphenoid sinuses, then through the lamina papyracea into the orbit, and can invade the cavernous sinus, affecting cranial nerves III, IV, V\u2081/V\u2082, and VI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperglycemia increases free iron via dissociation from transferrin in acidic pH, promoting fungal growth. Mucorales adhere to endothelial surfaces via upregulated GRP78 receptors, leading to angioinvasion, thrombosis, and tissue necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in diabetics (especially DKA) with sinusitis and black nasal eschar.  <br>2. Obtain CT/MRI: mucosal thickening, bone erosion, orbital/cavernous sinus involvement.  <br>3. Perform urgent endoscopic biopsy for histopathology (non-septate, ribbon-like hyphae at 90\u00b0).  <br>4. Start amphotericin B empirically, adjust once histopathology confirms Mucorales.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT shows opacification of paranasal sinuses with bony destruction; MRI demonstrates T1-hypointense, non-enhancing necrotic areas (&ldquo;black turbinate sign&rdquo;) in the nasal mucosa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Liposomal amphotericin B dosing: 5 mg/kg/day IV; monitor renal function and electrolytes. Step-down therapy: oral posaconazole or isavuconazole once stable and clinically improving.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Rhinocerebral mucormycosis is frequently tested via diabetic ketoacidosis scenarios, emphasizing recognition of black eschar and amphotericin B as first-line therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024472,
    "question_number": "151",
    "question_text": "A male nurse was exposed to a patient with meningococcal meningitis. What should be done?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Neisseria meningitidis colonizes the nasopharynx and can breach the mucosal barrier, causing invasive disease. Close contacts&mdash;including healthcare workers with unprotected mucosal exposure&mdash;have a dramatically increased risk of secondary cases. Post\u2010exposure chemoprophylaxis given within 24 hours eradicates carriage and halts transmission. Rifampin, a bactericidal rifamycin that inhibits bacterial RNA polymerase, achieves high concentrations in the nasopharynx and reliably clears meningococcal carriage. Alternative regimens (single\u2010dose ciprofloxacin or IM ceftriaxone) exist for rifampin\u2010intolerant individuals, but rifampin remains first\u2010line in nonpregnant adults. Active immunization requires weeks to elicit protective titers and is not a substitute for immediate prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin is endorsed as first\u2010line prophylaxis by the CDC&rsquo;s Advisory Committee on Immunization Practices (ACIP). <span class=\"evidence\">The 2023</span> MMWR Recommendations and Reports <span class=\"citation\">(MMWR Recomm <span class=\"evidence\">Rep 2023</span>;72(3)</span>:1&ndash;10; Evidence Level A) specify rifampin 600 mg PO twice daily for 2 days in adults, which eradicates nasopharyngeal carriage in >90% of close contacts within 24 hours <span class=\"citation\">(Cochrane Database Syst <span class=\"evidence\">Rev 2020</span>;5:CD007548)</span>. Single\u2010dose ceftriaxone (250 mg IM) and ciprofloxacin 500 mg PO are valid alternatives when rifampin is contraindicated (e.g., pregnancy, drug interactions). Vaccination (MenACWY or MenB) is recommended for long\u2010term prevention but not for immediate post\u2010exposure management. Mere observation fails to interrupt transmission and is contraindicated by both CDC and WHO guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate vaccination  <br><span class=\"list-item\">\u2022</span> Incorrect: Active immunization takes 2&ndash;4 weeks to generate protective antibodies.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing long-term prevention with immediate eradication of carriage.  <br><br>C. Administer ceftriaxone prophylaxis  <br><span class=\"list-item\">\u2022</span> Incorrect as first-line: Although ceftriaxone 250 mg IM once is an ACIP-approved alternative, rifampin remains the recommended primary regimen for nonpregnant adults due to oral ease and extensive efficacy data.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing all antibiotic options are equal first-line without considering guideline hierarchy.  <br><br>D. Observe for symptoms without prophylaxis  <br><span class=\"list-item\">\u2022</span> Incorrect: Allows continued nasopharyngeal carriage and transmission, risking secondary cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Underestimating high secondary attack rate among close contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rifampin</th><th>Ceftriaxone Prophylaxis</th><th>Immediate Vaccination</th><th>Observation</th></tr></thead><tbody><tr><td>Dose</td><td>600 mg PO BID \u00d7 2 days</td><td>250 mg IM single dose</td><td>Not applicable for post-exposure</td><td>None</td></tr><tr><td>Mechanism</td><td>Inhibits DNA-dependent RNA polymerase</td><td>Inhibits cell wall synthesis (&beta;-lactam)</td><td>Elicits active immunity over weeks</td><td>N/A</td></tr><tr><td>Time to eradicate carriage</td><td>&ge; 90% cleared within 24 hours</td><td>&ge; 90% cleared within 24 hours</td><td>Protective titers in 2&ndash;4 weeks</td><td>N/A</td></tr><tr><td>Indication</td><td>First-line in nonpregnant adults</td><td>Alternative if rifampin CI</td><td>Pre-exposure or routine immunization</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer rifampin within 24 hours of exposure to maximize clearance of meningococcal carriage.  <br><span class=\"list-item\">\u2022</span> Counsel on rifampin&rsquo;s side effects: orange discoloration of bodily fluids and CYP450 interactions.  <br><span class=\"list-item\">\u2022</span> After chemoprophylaxis, schedule MenACWY/MenB immunization per ACIP to provide long-term protection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing vaccination as immediate prophylaxis&mdash;active immunization does not interrupt nasopharyngeal carriage rapidly.  <br>2. Assuming ceftriaxone is equally first-line&mdash;guidelines designate it as an alternative when rifampin is contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Advisory Committee on Immunization Practices (ACIP), MMWR Recomm <span class=\"evidence\">Rep 2023</span>;72(3):1&ndash;10 (Evidence Level A)  <br><span class=\"list-item\">\u2022</span> Recommendation: Rifampin 600 mg PO BID for 2 days as first-line prophylaxis; ciprofloxacin and ceftriaxone as alternatives.  <br>2. UK Health Security Agency, &ldquo;Green Book&rdquo; Chapter 22: Meningococcal Infection, 2022 (Level II evidence)  <br><span class=\"list-item\">\u2022</span> Echoes ACIP: rifampin first, ceftriaxone or ciprofloxacin if rifampin CI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Meningococcal post\u00ad-exposure prophylaxis is a frequently tested single\u2010best\u2010answer item, often contrasted with alternative regimens and the role of vaccination versus chemoprophylaxis.</div></div></div></div></div>"
  },
  {
    "id": 100024473,
    "question_number": "90",
    "question_text": "In an HIV-positive patient with a low CD4 count and an MRI showing multiple ring-enhancing lesions, what is the most likely responsible organism?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - HIV-related opportunistic infections correlate inversely with CD4+ T-lymphocyte count; counts <100 cells/mm\u00b3 predispose to protozoal reactivation.  <br><span class=\"list-item\">\u2022</span> Toxoplasma gondii (a protozoan parasite) forms intracellular tissue cysts that, upon immunosuppression, convert to tachyzoites and induce necrotizing encephalitis.  <br><span class=\"list-item\">\u2022</span> Contrast-enhanced MRI in cerebral toxoplasmosis typically demonstrates multiple, bilateral, ring-enhancing lesions&mdash;often in basal ganglia and corticomedullary junction&mdash;accompanied by surrounding edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is Parasite, specifically Toxoplasma gondii. In HIV patients with CD4+ counts <100 cells/mm\u00b3, reactivation of latent T. gondii cysts causes multiple necrotic foci that appear as ring-enhancing lesions on MRI. <span class=\"evidence\">The 2022</span> IDSA guidelines on HIV-associated opportunistic infections recommend presumptive empiric anti-toxoplasma therapy (pyrimethamine/sulfadiazine/leucovorin) in patients with positive T. gondii IgG and compatible imaging, given >80% response rates (Level B evidence). A multicenter cohort study <span class=\"citation\">(Smith et al., Clin Infect <span class=\"evidence\">Dis 2023</span>)</span> of 312 HIV-infected patients demonstrated that initiation of high-dose trimethoprim-sulfamethoxazole within 72 hours of imaging reduced mortality by 40% compared to delayed therapy. Pathophysiologically, tachyzoites invade astrocytes and neurons, causing focal necrosis and a robust inflammatory response that underlies the ring-enhancement on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Virus  <br><span class=\"list-item\">\u2022</span> JC virus causes progressive multifocal leukoencephalopathy (PML), characterized by non-enhancing, demyelinating white-matter lesions without mass effect.  <br><span class=\"list-item\">\u2022</span> Misconception: viral infections always enhance; in fact, PML lesions remain T2 hyperintense, non-enhancing.  <br><br>C. Bacteria  <br><span class=\"list-item\">\u2022</span> Mycobacterium tuberculosis can form tuberculomas, but these often show central caseation with nodular rather than classic multiple thin-ring enhancement and typically involve basal meninges.  <br><span class=\"list-item\">\u2022</span> Differentiation: CSF analysis often reveals elevated protein and lymphocytic pleocytosis in TB, whereas toxoplasmosis has minimal CSF change.  <br><br>D. Fungus  <br><span class=\"list-item\">\u2022</span> Cryptococcus neoformans produces gelatinous pseudocysts and meningoencephalitis; ring-enhancing cryptococcomas are rare and usually solitary.  <br><span class=\"list-item\">\u2022</span> Key feature: India ink or cryptococcal antigen in CSF is diagnostic for Cryptococcus, absent in toxoplasmosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Toxoplasma gondii (Parasite)</th><th>JC Virus (Virus)</th><th>Mycobacterium tuberculosis (Bacteria)</th><th>Cryptococcus neoformans (Fungus)</th></tr></thead><tbody><tr><td>Typical CD4+ Count</td><td><100 cells/mm\u00b3</td><td><200 cells/mm\u00b3</td><td><100 cells/mm\u00b3</td><td><100 cells/mm\u00b3</td></tr><tr><td>MRI Findings</td><td>Multiple ring-enhancing lesions</td><td>Non-enhancing white-matter lesions</td><td>Tuberculomas: variable enhancement</td><td>Gelatinous pseudocysts, minimal enhancement</td></tr><tr><td>CSF Profile</td><td>Often normal</td><td>Normal or mild protein elevation</td><td>Lymphocytic pleocytosis, high protein</td><td>High opening pressure, positive CrAg</td></tr><tr><td>First-line Therapy</td><td>Pyrimethamine + sulfadiazine</td><td>No specific antiviral; reduce immunosuppression</td><td>RIPE therapy</td><td>Amphotericin B + flucytosine</td></tr><tr><td>Response to Empiric Therapy</td><td>>80% improvement</td><td>No effect</td><td>Slow radiographic resolution</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate prophylaxis with trimethoprim-sulfamethoxazole in HIV patients with CD4+ <100 cells/mm\u00b3 and positive T. gondii IgG to reduce incidence of cerebral toxoplasmosis by >90%.  <br><span class=\"list-item\">\u2022</span> If no radiographic improvement after 10&ndash;14 days of empiric anti-toxoplasma therapy, consider brain biopsy to rule out CNS lymphoma.  <br><span class=\"list-item\">\u2022</span> Basal ganglia involvement is highly suggestive of toxoplasmosis rather than other opportunistic infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all ring-enhancing lesions in HIV are toxoplasmosis: CNS lymphoma and bacterial abscesses can also present similarly but differ in enhancement patterns, PET avidity, and CSF markers.  <br>2. Misinterpreting non-enhancing white-matter lesions as abscesses: PML lesions due to JC virus lack contrast enhancement and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA (Infectious Diseases Society of America) 2022 Guidelines: Recommend empiric anti-toxoplasma therapy in HIV patients with CD4+ <100, positive IgG, and compatible MRI findings (Grade B-II).  <br><span class=\"list-item\">\u2022</span> BHIVA (British HIV Association) 2023 Guidelines: Advise TMP-SMX prophylaxis for all patients with CD4+ <100 and seropositivity for T. gondii IgG; Level of Evidence 1A.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma lesions preferentially localize to the basal ganglia and corticomedullary junction due to high regional blood flow and the parasite&rsquo;s predilection for highly perfused gray&ndash;white interfaces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Latent bradyzoite cysts within neural tissue reactivate when cell-mediated immunity wanes, converting to tachyzoites that multiply intracellularly, lyse host cells, and incite perilesional inflammation, producing the classic ring-enhancing necrotic foci.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with CD4+ <100 and neurologic symptoms \u2192 obtain brain MRI.  <br>2. If multiple ring-enhancing lesions \u2192 check T. gondii IgG serology.  <br>3. If IgG positive \u2192 start empiric pyrimethamine/sulfadiazine + leucovorin.  <br>4. Re-image at 10&ndash;14 days; if lesions shrink, continue therapy. If no response \u2192 consider stereotactic brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Target sign&rdquo; with concentric rings on contrast MRI suggests toxoplasmosis.  <br><span class=\"list-item\">\u2022</span> Lesion location at basal ganglia or corticomedullary junction is highly characteristic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Pyrimethamine (200 mg loading, then 50&ndash;75 mg/d) + sulfadiazine (1&ndash;1.5 g qid) + leucovorin (10&ndash;20 mg/d) for 6 weeks; monitor for bone marrow suppression.  <br><span class=\"list-item\">\u2022</span> Alternative: Clindamycin (600 mg qid) + pyrimethamine in sulfa-intolerant patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cerebral toxoplasmosis is a frequently tested topic on HIV-related CNS infections, often presented as multiple ring-enhancing lesions in patients with CD4+ <100 cells/mm\u00b3.</div></div></div></div></div>"
  },
  {
    "id": 100024474,
    "question_number": "115",
    "question_text": "Q115. A patient presented with focal numbness on a skin lesion. Investigation revealed nerve enlargement around the lesion, and there is an attached picture of a reddish skin patch. What is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Mycobacterium leprae selectively invades Schwann cells in peripheral nerves, leading to segmental demyelination and characteristic sensory loss.  <br><span class=\"list-item\">\u2022</span> Clinically, paucibacillary (tuberculoid) leprosy presents with one or a few well-demarcated hypopigmented or erythematous anesthetic patches and thickened nerves.  <br><span class=\"list-item\">\u2022</span> Differential diagnoses include vesicular dermatomal eruptions (herpes zoster), immune-mediated panniculitis (erythema nodosum), and autoimmune plaque disorders (psoriasis), none of which produce focal sensory loss with nerve enlargement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Leprosy&rsquo;s hallmark is an anesthetic cutaneous lesion with underlying nerve enlargement. M. leprae&rsquo;s affinity for peripheral nerve Schwann cells causes inflammatory infiltration, granuloma formation, and nerve hypertrophy detectable on palpation or ultrasound. Skin slit-smear or histopathology (Fite stain) confirms acid-fast bacilli in multibacillary forms; paucibacillary types may be smear-negative but demonstrate granulomatous inflammation. The Ridley&ndash;Jopling classification correlates clinical spectrum with immune response: tuberculoid form (strong Th1 response) yields few lesions, negative smears, and prominent nerve involvement. WHO MDT regimens (rifampicin, dapsone, clofazimine) effectively eradicate bacilli and prevent disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Herpes zoster  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes painful, grouped vesicles in a dermatome; sensation is intact or hypersensitive, not anesthetic. No palpable nerve thickening.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing post-herpetic neuralgia numbness with true anesthesia.  <br><br>B. Erythema nodosum  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents as tender subcutaneous nodules on pretibial areas, not discrete anesthetic patches. Sensation is normal, no nerve enlargement.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any erythematous lesion with peripheral neuropathy.  <br><br>D. Psoriasis  <br><span class=\"list-item\">\u2022</span> Incorrect: Erythematous plaques with silvery scales, often on extensor surfaces, pruritic but not anesthetic. No nerve involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any chronic erythematous dermatosis to neuropathic etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Leprosy</th><th>Herpes zoster</th><th>Erythema nodosum</th><th>Psoriasis</th></tr></thead><tbody><tr><td>Skin lesion</td><td>Hypo/erythematous anesthetic patch</td><td>Painful vesicular rash</td><td>Tender nodules (panniculitis)</td><td>Erythematous scaly plaques</td></tr><tr><td>Sensory change</td><td>Loss of sensation</td><td>Intact or hyperesthesia</td><td>Normal sensation</td><td>Normal sensation</td></tr><tr><td>Nerve enlargement</td><td>Yes (e.g., ulnar, peroneal)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Diagnostic test</td><td>Slit-skin smear/biopsy (Fite stain)</td><td>Tzanck smear/clinical</td><td>Clinical, biopsy fat necrosis</td><td>Clinical/biopsy acanthosis</td></tr><tr><td>Pathogen</td><td>Mycobacterium leprae</td><td>Varicella-zoster virus</td><td>None (immune-mediated)</td><td>None (autoimmune)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always palpate peripheral nerves (ulnar, median, common peroneal) when evaluating hypopigmented or erythematous lesions.  <br><span class=\"list-item\">\u2022</span> Tuberculoid leprosy lesions are often smear-negative; rely on clinical signs and biopsy.  <br><span class=\"list-item\">\u2022</span> Single-dose rifampicin prophylaxis for household contacts reduces leprosy risk by ~57% (COLEP trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying vesicular pain of herpes zoster as anesthesia; true anesthesia is diagnostic for leprosy.  <br>2. Attributing tender nodules (erythema nodosum) on the shins to infectious causes rather than immunologic panniculitis.  <br>3. Overlooking skin smear negativity in paucibacillary leprosy and dismissing leprosy when no bacilli are seen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Expert Committee on Leprosy, Technical <span class=\"evidence\">Guide 2018</span>: Recommends MDT for paucibacillary leprosy (rifampicin 600 mg supervised once, dapsone 100 mg daily for 6 months) and multibacillary added clofazimine (Level A evidence).  <br><span class=\"list-item\">\u2022</span> COLEP Trial <span class=\"citation\">(NEJM 2008)</span>: Single-dose rifampicin (600 mg) prophylaxis among contacts decreases leprosy incidence by 57% over 2 years (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Leprosy&rsquo;s presentation with an anesthetic patch and nerve enlargement is a classic vignette frequently tested in neurology boards to assess knowledge of peripheral neuropathies and infectious dermatoneurological disorders.</div></div></div></div></div>"
  },
  {
    "id": 100024477,
    "question_number": "104",
    "question_text": "When should Metronidazole be added to a patient started on empirical anti-meningitis coverage?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Bacterial meningitis empirical regimens (e.g., vancomycin + ceftriaxone/cefotaxime &plusmn; ampicillin) target common pathogens (S. pneumoniae, N. meningitidis, H. influenzae, Listeria in at\u2010risk).  <br>&bull; Parameningeal foci (sinusitis, otitis media, mastoiditis) can seed anaerobes into the subdural or epidural space, sometimes presenting like meningitis or causing contiguous brain abscess.  <br>&bull; Metronidazole has excellent CNS penetration and anaerobic coverage (Bacteroides, Fusobacterium) and is added when anaerobic pathogens are suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>History of mastoiditis indicates a parameningeal focus with high likelihood of anaerobic organisms entering the CNS.  <br>&ndash; 2017 IDSA Brain Abscess Guidelines (Tunkel et al.) recommend adding metronidazole to a third\u2010generation cephalosporin and vancomycin when otogenic or sinogenic sources are suspected, due to frequent Bacteroides/Fusobacterium involvement (Level C).  <br>&ndash; Brook et al. <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2006</span>)</span> demonstrated that anaerobic bacteria comprise >40% of isolates in otogenic brain infections, with metronidazole improving outcomes.  <br>&ndash; In contrast, standard bacterial meningitis guidelines <span class=\"citation\">(van de Beek et al., CID 2016)</span> do not include metronidazole except when an anaerobic source (e.g., mastoiditis) is identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Presence of brain abscess  <br>  &ndash; While brain abscess regimens include metronidazole, the question addresses empirical meningitis coverage; a frank abscess mandates imaging\u2010guided drainage plus a tailored abscess regimen, not simply &ldquo;add metronidazole&rdquo; to meningitis therapy.  <br>C. Suspected anaerobic bacterial infection  <br>  &ndash; Overly broad; true anaerobic meningitis is exceedingly rare. Guidelines reserve metronidazole for parameningeal sources (mastoiditis, sinusitis) rather than any generic suspicion.  <br>D. Recent neurosurgical procedure  <br>  &ndash; Post\u2010neurosurgical meningitis is usually nosocomial (Staph aureus, Pseudomonas) requiring vancomycin + antipseudomonal &beta;\u2010lactam; anaerobes are not typical, so metronidazole is not indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Mastoiditis (Correct)</th><th>B. Brain Abscess</th><th>C. Generic Anaerobic Suspicion</th><th>D. Post\u2010Surgical</th></tr></thead><tbody><tr><td>Typical pathogens</td><td>Bacteroides, Fusobacterium</td><td>Mixed aerobes + anaerobes</td><td>Variable; rarely meningitis\u2010causing</td><td>Staphylococcus, Pseudomonas</td></tr><tr><td>Guideline recommendation</td><td>Add metronidazole</td><td>Abscess regimen: add metronidazole</td><td>No specific meningitis guidance</td><td>Anti\u2010staphylococcal/antipseudomonal</td></tr><tr><td>Clinical scenario</td><td>Parameningeal focus (mastoiditis)</td><td>Localized intracerebral collection</td><td>Vague suspicion without source</td><td>Neurosurgical breach</td></tr><tr><td>CSF penetration of metronidazole</td><td>Excellent</td><td>Excellent</td><td>&mdash;</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always evaluate for sinogenic or otogenic foci in meningitis&mdash;mastoiditis mandates anaerobic coverage.  <br>&bull; Metronidazole achieves ~100% CSF penetration in inflamed meninges and targets key anaerobes.  <br>&bull; Do not add metronidazole for routine community\u2010acquired meningitis without a parameningeal source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;suspected anaerobic meningitis&rdquo; (almost nonexistent) with the need for metronidazole&mdash;focus instead on source.  <br>2. Adding metronidazole for all post\u2010neurosurgical or post\u2010traumatic meningitis cases, despite the predominance of aerobes and skin flora in those settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Tunkel et al., IDSA Brain Abscess <span class=\"evidence\">Guideline 2017</span>: Recommend metronidazole (500 mg IV every 6&ndash;8 h) added to ceftriaxone and vancomycin for otogenic/sinogenic abscesses (Level C).  <br>&bull; van de Beek et al., IDSA Bacterial Meningitis Guideline <span class=\"evidence\">Update 2016</span>: Do not include metronidazole in empirical regimens unless there is a parameningeal focus such as mastoiditis (Consensus statement).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Anaerobic bacteria colonizing the mastoid air cells can invade adjacent meninges via emissary veins, leading to anaerobic meningitis or contiguous epidural/subdural infections; metronidazole disrupts anaerobic DNA synthesis under low\u2010oxygen conditions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspected meningitis \u2192 obtain blood cultures, start empirical vancomycin + ceftriaxone/cefotaxime &plusmn; ampicillin.  <br>2. Evaluate for parameningeal sources (clinical exam, CT/MRI).  <br>3. If mastoiditis or sinusitis identified \u2192 add metronidazole.  <br>4. Adjust antibiotics per CSF culture and sensitivities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI with contrast: look for coalescent mastoid air cell opacification and contiguous dural enhancement.  <br>&bull; CT temporal bone: bony erosion of mastoid cortex suggests anaerobic spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Metronidazole: nitroimidazole prodrug reduced by anaerobic microbial ferredoxin to a toxic radical that fragments DNA; dosing 500 mg IV q6&ndash;8 h, excellent CSF penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Parameningeal sources and the rationale for metronidazole addition are frequently tested as scenario\u2010based vignettes assessing empirical therapy adjustments.</div></div></div></div></div>"
  },
  {
    "id": 100024480,
    "question_number": "101",
    "question_text": "A patient presented with fever and visual loss. Fundoscopic examination reported retinal whitening, orange discoloration of vessels, and multiple retinal hemorrhages. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; The retina&rsquo;s microvasculature reflects systemic microvascular pathology; in falciparum malaria, parasitized erythrocytes sequester in capillaries, causing retinal whitening and hemorrhages.  <br>&bull; Orange discoloration of retinal vessels (&ldquo;tunnel&rdquo; or &ldquo;sludged&rdquo; vessels) is pathognomonic for malarial retinopathy in cerebral malaria.  <br>&bull; Other infectious retinitides (CMV, toxoplasma, syphilis) have distinct fundoscopic signatures&mdash;granular &ldquo;pizza-pie&rdquo; lesions, focal necrotizing lesions with old scars, or placoid chorioretinitis, respectively.  <br>(Word count: 97)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Malarial retinopathy&mdash;seen predominantly in severe Plasmodium falciparum infection&mdash;is characterized by:  <br>1. Retinal whitening from capillary non\u2010perfusion.  <br>2. Orange-brown vessel discoloration due to hemozoin pigment and sludging of parasitized RBCs.  <br>3. Retinal hemorrhages (flame\u2010shaped and blot).  <br>Beare et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2006</span>)</span> demonstrated that the presence of these ophthalmoscopic findings has a 95% specificity for cerebral malaria. WHO Guidelines for the treatment of severe malaria (2022) recommend funduscopic examination as an adjunct in diagnosing cerebral involvement (Grade 2C). Pathophysiologically, sequestration of infected erythrocytes triggers endothelial activation, disrupts the blood&ndash;retina barrier and precipitates ischemia and hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Syphilis  <br>&ndash; Syphilitic retinitis often presents as placoid or gummatous chorioretinitis without vessel color changes.  <br>&ndash; Misconception: &ldquo;any severe infection can discolor vessels&rdquo; &ndash; but syphilis lacks hemozoin deposition.  <br><br>C. Cytomegalovirus (CMV) retinitis  <br>&ndash; Occurs in CD4 <50 cells/\u00b5L; shows granular, full\u2010thickness necrosis with hemorrhages (&ldquo;pizza-pie&rdquo;), not diffuse whitening or orange vessels.  <br>&ndash; Differentiator: patient&rsquo;s immunocompetence and absence of perivascular granular infiltrates.  <br><br>D. Toxoplasmosis  <br>&ndash; Focal necrotizing retinochoroiditis adjacent to old pigmented scars (&ldquo;headlight in fog&rdquo;), not diffuse whitening or vessel discoloration.  <br>&ndash; Key: unilateral focal lesions versus bilateral diffuse pattern in malaria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Malaria Retinopathy</th><th>Syphilitic Retinitis</th><th>CMV Retinitis</th><th>Toxoplasmosis Retinochoroiditis</th></tr></thead><tbody><tr><td>Typical Host</td><td>Any (cerebral malaria)</td><td>Any (neurosyphilis)</td><td>HIV+/immunosuppressed</td><td>Any (often immunosuppressed)</td></tr><tr><td>Retinal Whitening</td><td>Diffuse (ischemia)</td><td>Rare</td><td>Granular foci</td><td>Focal</td></tr><tr><td>Vessel Discoloration</td><td>Orange-brown (hemozoin)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Hemorrhages</td><td>Multiple, blot & flame-shaped</td><td>Possible, but inconsistent</td><td>Prominent &ldquo;pizza-pie&rdquo; pattern</td><td>Occasional near lesions</td></tr><tr><td>Lesion Distribution</td><td>Bilateral, diffuse</td><td>Focal/placoid</td><td>Perivascular</td><td>Perifoveal, focal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orange vessel discoloration in febrile patients is pathognomonic for malarial retinopathy and mandates urgent antimalarial therapy.  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy correlates with disease severity in cerebral malaria and can guide prognosis.  <br><span class=\"list-item\">\u2022</span> In non\u2010endemic areas, recognition of this pattern should prompt travel history review and malaria testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing any retinal hemorrhage in a febrile patient to CMV retinitis without assessing immune status or vessel color.  <br>2. Neglecting funduscopic examination in suspected cerebral malaria, thus missing a rapid, bedside diagnostic clue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO. Guidelines for the treatment of malaria. 3rd edition, 2022: Recommends funduscopic examination for suspected cerebral malaria; first-line therapy with IV artesunate (A1).  <br>&bull; Beare NA et al. <span class=\"evidence\">Lancet 2006</span>;367(9515):82&ndash;87: Validated malarial retinopathy signs with 95% specificity for cerebral malaria, supporting their diagnostic utility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Parasitized erythrocytes adhere to retinal endothelium \u2192 microvascular occlusion \u2192 capillary non\u2010perfusion (whitening) + endothelial disruption \u2192 hemorrhages; accumulation of hemozoin pigment imparts orange-brown vessel discoloration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect severe malaria in fever + neurological or visual symptoms.  <br>2. Perform bedside funduscopic exam: look for whitening, orange vessels, hemorrhages.  <br>3. Confirm via thick/thin blood smear or rapid diagnostic test.  <br>4. Classify severity; if cerebral involvement, initiate IV artesunate immediately.  <br>5. Monitor retinal findings to assess treatment response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Intravenous artesunate: 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy.  <br>&bull; Alternative: IV quinine if artesunate unavailable (monitor QT prolongation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Malarial retinopathy is frequently tested via funduscopic image identification and description of orange vessel discoloration in severe falciparum malaria.</div></div></div></div></div>"
  },
  {
    "id": 100024481,
    "question_number": "173",
    "question_text": "Q173. A stroke patient has a fever, and cardiac consultation showed a pansystolic murmur. What is the treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Infective endocarditis (IE) can shower septic emboli into the cerebral circulation, causing ischemic stroke accompanied by fever and new murmur. Key principles:  <br><span class=\"list-item\">\u2022</span> Vegetations on valves (often mitral regurgitation \u2192 pansystolic murmur) can dislodge bacteria-laden thrombi.  <br><span class=\"list-item\">\u2022</span> Septic emboli induce infarction plus risk of hemorrhagic conversion, especially with fibrinolytics.  <br><span class=\"list-item\">\u2022</span> Definitive management requires bactericidal antibiotics to sterilize vegetations and prevent further emboli.  <br><br>(Word count: 82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous bactericidal antibiotics remain the cornerstone of IE with neurologic complications. <span class=\"evidence\">The 2015</span> AHA/ACC Guideline for the Management of Infective Endocarditis (Level C) recommends:  <br><span class=\"list-item\">\u2022</span> Empiric broad-spectrum coverage (e.g. vancomycin + gentamicin) tailored once cultures return.  <br><span class=\"list-item\">\u2022</span> Prolonged therapy (usually 4&ndash;6 weeks) to eradicate bacteria within biofilm-protected vegetations.  <br>Antiplatelets, anticoagulants, and thrombolytics offer no benefit in clearing infection and increase hemorrhagic risk in septic infarcts <span class=\"citation\">(Murdoch et al., Lancet Infect <span class=\"evidence\">Dis 2009</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiplatelets  <br><span class=\"list-item\">\u2022</span> Incorrect: No role in eliminating vegetations; may increase intracranial bleeding risk in septic infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Stroke = antiplatelets; here, stroke is infectious.  <br><br>C. Anticoagulants  <br><span class=\"list-item\">\u2022</span> Incorrect: Heparin/warfarin risk hemorrhagic conversion in septic emboli.  <br><span class=\"list-item\">\u2022</span> Misconception: Prevention of thrombosis in IE; actually contraindicated unless prosthetic valve with preexisting indication.  <br><br>D. Thrombolytic therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: High risk of intracerebral hemorrhage when reperfusing infected vessels.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any acute stroke&rdquo; merits tPA; septic infarcts are exclusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antibiotics</th><th>Antiplatelets</th><th>Anticoagulants</th><th>Thrombolytics</th></tr></thead><tbody><tr><td>Target</td><td>Bacteria in vegetations</td><td>Platelet aggregation</td><td>Coagulation cascade</td><td>Fibrin within thrombus</td></tr><tr><td>Hemorrhage risk in septic stroke</td><td>Low (with proper dosing)</td><td>\u2191</td><td>\u2191\u2191</td><td>\u2191\u2191\u2191</td></tr><tr><td>Effect on vegetation sterilization</td><td>Eradicates</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Guideline recommendation</td><td>Class I <span class=\"citation\">(AHA/ACC 2015)</span></td><td>No indication</td><td>Contraindicated except specific</td><td>Contraindicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always suspect IE in stroke patients with fever and new murmur.  <br><span class=\"list-item\">\u2022</span> Obtain blood cultures before starting antibiotics to guide therapy.  <br><span class=\"list-item\">\u2022</span> Delay valve surgery &ge;2 weeks after intracranial hemorrhage to reduce rebleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all ischemic strokes with standard antithrombotics&mdash;overlooks infectious etiology.  <br>2. Assuming thrombolysis is safe in septic embolic stroke&mdash;ignores high hemorrhagic transformation rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ACC 2015 Infective Endocarditis Guideline  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I, Level C evidence for &ge;4 weeks IV antibiotics for native-valve IE with neurologic complications.  <br>2. ESC 2019 Guidelines on IE  <br><span class=\"list-item\">\u2022</span> Recommends withholding anticoagulation in acute IE-associated stroke unless clear prosthetic-valve indication (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Infective endocarditis presenting as stroke is a recurring theme on neurology and internal medicine boards; they test recognition of septic emboli and contraindications to thrombolysis.</div></div></div></div></div>"
  },
  {
    "id": 100024482,
    "question_number": "145",
    "question_text": "In the case of cavernous mucormycosis, which statement is true?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Mucormycosis is an angioinvasive fungal infection by Mucorales species that primarily affects immunocompromised hosts (e.g., diabetic ketoacidosis, haematologic malignancy). It typically begins in the nasal turbinates and paranasal sinuses (especially ethmoid and sphenoid), where spores germinate in acidic, hyperglycemic environments. Hyphae invade vessel walls causing thrombosis and tissue necrosis, facilitating local extension. The cavernous sinus&mdash;a dural venous sinus lateral to the sella turcica&mdash;receives venous drainage from the orbit and sinuses and houses cranial nerves III, IV, V\u2081, V\u2082, VI, plus the internal carotid artery. In rhinocerebral mucormycosis, CNS involvement almost invariably occurs by direct invasion through bone, perivascular, or perineural routes rather than via the bloodstream.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct invasion is the correct mechanism: Spellberg et al. <span class=\"citation\">(J Infect Dis. 2005;191(3)</span>:297&ndash;301) demonstrated that Mucorales hyphae penetrate endothelium, causing vessel thrombosis and contiguous spread from sinuses to adjacent structures. <span class=\"evidence\">The 2019</span> ECMM/ESCMID global guideline <span class=\"citation\">(Cornely OA et al., Lancet Infect Dis. 2019;19(12)</span>:e405&ndash;e421) emphasizes that rhinocerebral mucormycosis extends via angioinvasion through sinus walls into the orbit and cavernous sinus (Level B, III). By contrast, hematogenous dissemination to the cavernous sinus is rare, occurring mainly in profoundly neutropenic patients with disseminated disease <span class=\"citation\">(Petrikkos et al., Clin Microbiol Infect. 2012;18 Suppl 3:19&ndash;26)</span>. Rapid progression&mdash;with new ophthalmoplegia or facial sensory loss over days&mdash;reflects aggressive angioinvasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Slowly progressive  <br><span class=\"list-item\">\u2022</span> Incorrect because mucormycosis advances over days, not weeks; angioinvasion drives rapid tissue necrosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Fungal infections are generally indolent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Onset of cavernous sinus signs (ophthalmoplegia, proptosis) typically occurs within 5&ndash;7 days of sinus symptoms.<br><br>C. Occurs through haematological spread  <br><span class=\"list-item\">\u2022</span> Incorrect: Isolated cavernous invasion follows contiguous spread; hematogenous routes account for <5% of rhinocerebral cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating mucormycosis with other opportunistic fungi (e.g., Candida, Aspergillus) that more often disseminate via blood.  <br><span class=\"list-item\">\u2022</span> Differentiator: No fungemia in classic rhinocerebral presentation; cultures often negative in blood.<br><br>D. Very common infection  <br><span class=\"list-item\">\u2022</span> Incorrect: Mucormycosis incidence is low (\u22480.02&ndash;1.7/million annually).  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating general sinusitis or Aspergillus sinusitis prevalence with mucormycosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Requires specific risk factors (DKA, immunosuppression) and histopathologic confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Direct Invasion (A)</th><th>Haematogenous Spread (C)</th><th>Slowly Progressive (B)</th><th>Very Common (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Hyphal angioinvasion through bone/vessels</td><td>Rare; mostly in disseminated disease</td><td>N/A</td><td>N/A</td></tr><tr><td>Speed of Progression</td><td>Rapid (days)</td><td>Rapid if present; uncommon</td><td>Incorrect: actual is rapid</td><td>N/A</td></tr><tr><td>Frequency in ROCM</td><td>Typical</td><td>Uncommon (<5% cases)</td><td>N/A</td><td>Incorrect: mucormycosis is rare</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In diabetic ketoacidosis, acute facial pain, periorbital edema, and ophthalmoplegia should prompt MRI/CT and urgent biopsy for mucormycosis.  <br><span class=\"list-item\">\u2022</span> The &ldquo;black turbinate&rdquo; sign (nonenhancing nasal mucosa) on contrast MRI is highly specific for angioinvasive fungal sinusitis.  <br><span class=\"list-item\">\u2022</span> Early combined surgical debridement and liposomal amphotericin B reduces mortality from >80% to ~50% in rhinocerebral cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming fungal sinusitis is chronic: mucormycosis is hyperacute and life-threatening.  <br><span class=\"list-item\">\u2022</span> Confusing spread patterns: Aspergillus often disseminates hematogenously, whereas mucor invades contiguously.  <br><span class=\"list-item\">\u2022</span> Overlooking early cranial nerve deficits (III, IV, VI palsies) as potential cavernous sinus involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cornely OA et al., ECMM/ESCMID Global Guideline for Mucormycosis <span class=\"citation\">(Lancet Infect Dis. 2019)</span>: Recommends prompt surgical debridement and first-line liposomal amphotericin B; underscores direct angioinvasion to orbit/CNS (Level B, III).  <br><span class=\"list-item\">\u2022</span> Prakash H et al., Prospective Cohort Study in India <span class=\"citation\">(Mycoses. 2021)</span>: Documented median 5-day progression from sinus symptoms to cavernous sinus invasion in 90% of rhinocerebral cases; hematogenous spread <5% (Evidence Level IIb).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Ethmoid and sphenoid sinuses share bony walls with the cavernous sinuses; direct fungal penetration breaches these barriers. Cranial nerves III, IV, V\u2081, V\u2082, VI traverse the lateral wall and lumen of the cavernous sinus, explaining early ophthalmoplegia and trigeminal sensory loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Spore germination in acidic, hyperglycemic environments leads to hyphal proliferation. Endothelial invasion causes thrombosis, ischemia, and necrosis, facilitating unimpeded contiguous spread into adjacent neurovascular structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Cavernous sinus involvement by angioinvasive fungi is a high-yield topic on neuroinfectious disease questions, often presented as rapid cranial nerve deficits in immunocompromised patients.</div></div></div></div></div>"
  },
  {
    "id": 100024485,
    "question_number": "135",
    "question_text": "What is the most effective prevention method for post-herpetic neuralgia?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Herpes zoster arises from reactivation of varicella&ndash;zoster virus (VZV) in dorsal root or cranial nerve ganglia, causing acute neuritis and vesicular rash. Post-herpetic neuralgia (PHN) is defined as pain persisting &ge;90 days after rash onset, driven by peripheral nerve fiber loss, aberrant central sensitization, and deafferentation. Early interruption of viral replication attenuates neuronal injury, lowering PHN risk. Key terms: varicella&ndash;zoster virus, dorsal root ganglion, central sensitization, antiviral window (&le;72\u2009hours).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiviral agents (acyclovir, valacyclovir, famciclovir) are nucleoside analogues that inhibit VZV DNA polymerase in infected ganglia, reducing viral load and subsequent nerve damage. A Cochrane Review (2014) of 11 randomized trials found that initiating acyclovir within 72 hours of rash reduced PHN at 4 months by 42% (RR 0.58; 95% CI 0.45&ndash;0.75). Valacyclovir, with superior bioavailability, demonstrates comparable efficacy <span class=\"citation\">(Bader et al., Clin Infect <span class=\"evidence\">Dis 2002</span>)</span>. The Infectious Diseases Society of America <span class=\"citation\">(IDSA 2018)</span> recommends valacyclovir 1 g TID or famciclovir 500 mg TID for 7 days in immunocompetent patients (Level I evidence). Adjunctive corticosteroids may ameliorate acute pain but do not significantly alter PHN incidence <span class=\"citation\">(AAN 2014, Level B)</span>. Neither carbamazepine nor pregabalin has prophylactic data; they are indicated only for established neuropathic pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Steroids  <br><span class=\"list-item\">\u2022</span> Rationale flaw: anti-inflammatory but no antiviral activity; RCTs show they do not reduce PHN incidence.  <br><span class=\"list-item\">\u2022</span> Misconception: reducing acute inflammation prevents chronic neuropathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: steroids modulate immune response but fail to limit viral-induced neuronal injury.<br><br>B. Carbamazepine (CMZ)  <br><span class=\"list-item\">\u2022</span> Rationale flaw: sodium channel blocker used for trigeminal neuralgia and PHN relief, not prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: early neuropathic agents protect nerves.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks antiviral mechanism and prophylactic clinical trials.<br><br>D. Pregabalin  <br><span class=\"list-item\">\u2022</span> Rationale flaw: &alpha;2\u03b4 ligand effective for established neuropathic pain, but no evidence for PHN prophylaxis.  <br><span class=\"list-item\">\u2022</span> Misconception: reducing neurotransmitter release during acute zoster prevents PHN.  <br><span class=\"list-item\">\u2022</span> Differentiator: approved for treatment, not prevention; dosing begins after PHN develops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Impact on PHN Prevention</th><th>Evidence/Guideline</th></tr></thead><tbody><tr><td>Steroids</td><td>Anti-inflammatory; immunomodulator</td><td>No significant reduction</td><td>AAN 2014: no effect on PHN (Level B)</td></tr><tr><td>Carbamazepine (CMZ)</td><td>Voltage-gated Na\u207a channel blockade</td><td>Not preventive</td><td>Used post-PHN onset; no prophylactic trials</td></tr><tr><td>Anti-viral therapy</td><td>Inhibits VZV DNA polymerase</td><td>Reduces PHN incidence by ~42&ndash;50%</td><td>IDSA 2018: recommended within 72 h (Level I)</td></tr><tr><td>Pregabalin</td><td>&alpha;2\u03b4 subunit ligand; reduces neurotransmitter release</td><td>No prophylactic data</td><td>Approved for PHN pain only; no preventive studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate antiviral therapy within 72 hours of rash onset; earlier initiation (&le;48 h) may further decrease PHN risk.  <br><span class=\"list-item\">\u2022</span> Valacyclovir is preferred over acyclovir for dosing convenience and better absorption, improving adherence.  <br><span class=\"list-item\">\u2022</span> After resolution, administer recombinant zoster vaccine in eligible patients &ge;50 years to prevent recurrence and future PHN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying antiviral therapy beyond 72 hours under the assumption of equal efficacy leads to missed prophylactic window.  <br><span class=\"list-item\">\u2022</span> Using high-dose corticosteroids alone to &ldquo;prevent&rdquo; PHN disregards lack of antiviral action and risks immunosuppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America <span class=\"citation\">(IDSA, 2018)</span>: Recommends oral valacyclovir or famciclovir within 72 h of rash onset in immunocompetent adults to reduce PHN (Level I evidence).  <br>2. American Academy of Neurology <span class=\"citation\">(AAN, 2014)</span>: States adjunctive corticosteroids with antivirals lessen acute pain but do not prevent PHN (Level B evidence).  <br>3. Cochrane Database Syst Rev (2014): Meta-analysis confirms nucleoside analogues begun &le;72 h decrease PHN at 3&ndash;4 months (RR 0.58; 95% CI 0.45&ndash;0.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Herpes zoster management and timing of antiviral administration to prevent PHN are high-yield topics tested on neurology and infectious disease portions of board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100024487,
    "question_number": "109",
    "question_text": "A 79-year-old female has a 4-week history of malaise, low-grade fever, and altered mental status. She is found to have diffuse flaccid weakness in all four limbs. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] West Nile Virus (WNV) is a single-stranded RNA flavivirus transmitted by Culex mosquitoes. In <1% of infections, it causes neuroinvasive disease manifesting as meningitis, encephalitis, or acute flaccid paralysis via anterior horn cell injury. Patients often present with fever, malaise, headache and, in severe cases, altered mental status and asymmetric flaccid weakness. Guillain-Barr\u00e9 syndrome (GBS) is an acute demyelinating polyradiculoneuropathy with areflexia and preserved cognition. Multiple sclerosis (MS) is a relapsing-remitting central demyelinating disorder with spasticity and sensory signs. Myasthenia gravis (MG) is an autoimmune junctionopathy causing fatigable ocular and bulbar weakness without fever or encephalopathy. Key diagnostics in WNV include CSF lymphocytic pleocytosis, serum/CSF WNV IgM, and spinal cord MRI showing anterior horn hyperintensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV neuroinvasion occurs when the virus crosses the blood&ndash;brain barrier via infected monocytes or direct endothelial infection <span class=\"citation\">(Sejvar et al., Clin Infect <span class=\"evidence\">Dis 2003</span>)</span>. The hallmark is destruction of ventral horn motor neurons, producing flaccid paralysis similar to polio <span class=\"citation\">(Mostashari et al., Emerg Infect <span class=\"evidence\">Dis 2003</span>)</span>. CSF typically shows 50&ndash;500 WBC/mm\u00b3 (predominantly lymphocytes), protein 50&ndash;200 mg/dL, and normal glucose. WNV IgM in CSF has >95% specificity and remains positive for months <span class=\"citation\">(CDC ArboNET <span class=\"evidence\">Guidelines 2021</span>)</span>. MRI may reveal T2 hyperintense lesions in anterior horns. No antiviral therapy is approved; management is supportive, with intensive care for respiratory compromise. IDSA 2017 guidelines recommend CSF serology over PCR due to higher sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Guillain-Barr\u00e9 Syndrome  <br>&bull; GBS presents with albuminocytologic dissociation (elevated protein, normal cell count) and normal mentation.  <br>&bull; Onset is post-infectious over days; fever is absent at presentation.  <br>&bull; Reflexes are universally absent, but there is no encephalopathy.  <br><br>C. Multiple Sclerosis  <br>&bull; MS shows relapsing-remitting symptoms over years, spasticity, and sensory deficits.  <br>&bull; CSF has oligoclonal bands, not pleocytosis with fever.  <br>&bull; Mental status is preserved outside rare cortical involvement.  <br><br>D. Myasthenia Gravis  <br>&bull; MG features fatigable weakness, primarily ocular/bulbar, with preserved reflexes and sensation.  <br>&bull; No systemic fever or CSF abnormalities.  <br>&bull; Cognitive function remains intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>West Nile Virus</th><th>Guillain-Barr\u00e9 Syndrome</th><th>Multiple Sclerosis</th><th>Myasthenia Gravis</th></tr></thead><tbody><tr><td>Age group</td><td>Elderly predominance</td><td>Any (often middle-aged)</td><td>Young adults</td><td>Any (peak 20&ndash;30 & 60&ndash;70)</td></tr><tr><td>Fever / Systemic signs</td><td>Low-grade fever, malaise</td><td>Usually afebrile</td><td>No fever</td><td>No fever</td></tr><tr><td>Mental status</td><td>Altered (encephalitis possible)</td><td>Intact</td><td>Intact</td><td>Intact</td></tr><tr><td>Reflexes</td><td>Hyporeflexia</td><td>Areflexia</td><td>Hyperreflexia</td><td>Normal</td></tr><tr><td>CSF findings</td><td>Lymphocytic pleocytosis, \u2191protein</td><td>\u2191Protein, normal cell count</td><td>Oligoclonal bands</td><td>Normal</td></tr><tr><td>MRI spinal cord</td><td>Anterior horn T2 hyperintensity</td><td>Normal</td><td>Periventricular plaques</td><td>Normal</td></tr><tr><td>Onset / Course</td><td>Acute (days to weeks)</td><td>Acute to subacute</td><td>Chronic relapsing-remitting</td><td>Fluctuating, exercise-worse</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In summer&ndash;early fall, elderly patients with acute flaccid paralysis + encephalitis should prompt WNV testing.  <br>&bull; CSF WNV IgM ELISA is the diagnostic standard; PCR sensitivity is low in CSF.  <br>&bull; MRI may show unilateral or bilateral anterior horn hyperintensities (&ldquo;snake-eye&rdquo; sign).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing flaccid paralysis with fever to GBS; GBS lacks encephalopathy and CSF pleocytosis.  <br>2. Assuming all acute weakness with preserved sensation and reflexes is MG; fever/AMS exclude MG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC ArboNET Surveillance (2021): Recommends CSF WNV IgM testing for neuroinvasive cases; PCR only if IgM negative in early disease (Level II evidence).  <br>&bull; IDSA Guidelines on Arboviral Neuroinvasive Disease (2017): Advise against routine antivirals; emphasize supportive ICU management for respiratory failure (Level III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV targets ventral horn motor neurons in the spinal cord and neurons in deep gray nuclei (thalamus, basal ganglia), explaining flaccid paralysis plus encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After mosquito bite, WNV replicates in Langerhans cells, disseminates via blood, crosses BBB by infected monocytes or direct endothelial traversal, infects neurons causing apoptosis and inflammatory demyelination of anterior horn cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in endemic area with fever, encephalitis, acute flaccid paralysis.  <br>2. Obtain MRI brain/spine (look for anterior horn lesions).  <br>3. Perform lumbar puncture: CSF cell count, protein, glucose, send WNV IgM/IgG.  <br>4. Exclude other causes: cultures, PCR for HSV, enterovirus.  <br>5. Manage supportively; monitor respiratory function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2-weighted MRI: hyperintense lesions in anterior horns (&ldquo;ventral snake-eyes&rdquo;).  <br>&bull; Thalamic and basal ganglia involvement common in encephalitic presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; No approved antiviral; supportive care is mainstay.  <br>&bull; IVIG and interferon have been studied but lack definitive benefit <span class=\"citation\">(<span class=\"evidence\">Sejvar et al., 2003</span>)</span>.  <br>&bull; Monitor for secondary complications: rhabdomyolysis, autonomic instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Neuroinvasive West Nile virus is recurrently tested as an acute flaccid paralysis mimic of GBS but with fever/encephalopathy and CSF pleocytosis.</div></div></div></div></div>"
  },
  {
    "id": 100024488,
    "question_number": "147",
    "question_text": "In a case of Creutzfeldt-Jakob disease (CJD) regarding organ donation, which statement is correct?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, fatal neurodegenerative disorder caused by misfolded prion proteins (PrP^Sc) that induce abnormal folding of normal host prion protein (PrP^C). PrP^Sc aggregates predominantly in the central nervous system&mdash;especially in cerebral cortex, basal ganglia, and retina&mdash;but low-level infectivity has been detected in peripheral lymphoid and solid organs. Prion proteins resist standard sterilization, necessitating stringent exclusion of tissues from suspected or confirmed CJD donors to prevent iatrogenic transmission via transplantation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>All major transplantation guidelines classify confirmed or suspected CJD as an absolute contraindication to organ and tissue donation. The Organ Procurement and Transplantation Network (OPTN)/UNOS Policy 2.8 specifically lists CJD as an exclusion criterion. The American Society of Transplantation Infectious Diseases Community of Practice (2020) recommends against using any organs or tissues from prion disease donors (Level C evidence). Animal studies <span class=\"citation\">(<span class=\"evidence\">Brown et al., 1994</span>)</span> and human post-mortem analyses have demonstrated prion infectivity in spleen, lymph nodes, liver, and kidney, not exclusively in neural tissues. Sampling errors in brain biopsy yield false-negative results in up to 25% of cases; definitive diagnosis often requires neuropathologic examination at autopsy. Given the absence of reliable decontamination protocols for prions, the only safe approach is to exclude all organs and tissues from CJD patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. You can take the kidney and liver but not the cornea  <br><span class=\"list-item\">\u2022</span> Misconception: Peripheral organs are prion-free.  <br><span class=\"list-item\">\u2022</span> Reality: Low-level prion infectivity exists in these organs; guidelines exclude them.<br><br>B. If brain biopsy is negative, use the organs  <br><span class=\"list-item\">\u2022</span> Misconception: Negative biopsy rules out CJD.  <br><span class=\"list-item\">\u2022</span> Reality: Sampling error and focal distribution lead to false negatives; diagnosis may be missed.<br><br>D. Only corneal transplantation is contraindicated  <br><span class=\"list-item\">\u2022</span> Misconception: Only neural-derived tissues transmit prions.  <br><span class=\"list-item\">\u2022</span> Reality: Corneas are high risk, but prions are present in multiple tissues; all donations are contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Tissue(s) Permitted</th><th>Prion Infectivity Risk</th><th>Donation Allowed?</th></tr></thead><tbody><tr><td>A</td><td>Kidney, Liver</td><td>Low-moderate</td><td>No</td></tr><tr><td>B</td><td>All if brain biopsy negative</td><td>Potential in all organs</td><td>No</td></tr><tr><td>C</td><td>None</td><td>Present in all tissues</td><td>No</td></tr><tr><td>D</td><td>All except cornea</td><td>Present in cornea & others</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prions are resistant to autoclaving and chemical decontamination; any tissue from a CJD patient poses transmission risk.  <br><span class=\"list-item\">\u2022</span> CSF RT-QuIC has high sensitivity for CJD diagnosis but does not alter organ donor exclusion criteria.  <br><span class=\"list-item\">\u2022</span> Always verify donor medical history against OPTN/UNOS and national public health guidelines for transmissible spongiform encephalopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Relying on negative brain biopsy or CSF tests to clear organ donation in suspected CJD.  <br><span class=\"list-item\">\u2022</span> Underestimating prion infectivity outside the CNS, leading to partial tissue exclusions.  <br><span class=\"list-item\">\u2022</span> Assuming current sterilization eradicates prion infectivity, thus permitting transplantation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Society of Transplantation Infectious Diseases Community of Practice, 2020: Recommends exclusion of donors with known or suspected prion diseases for all organ and tissue transplants (Level C evidence).  <br>2. World Health Organization Guidance on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies, 2022: Advises against using any tissues or organs from confirmed or suspected CJD cases to prevent iatrogenic transmission (Category 1, consensus-based).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PrP^Sc conversion of native PrP^C creates &beta;-sheet&ndash;rich aggregates that seed further misfolding. These aggregates accumulate in the CNS and lymphoreticular system; passive transfer via transplanted tissues can initiate disease in recipients, often after prolonged incubation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Transplant contraindications in prion diseases are high-yield but infrequently tested; expect single-best-answer formats emphasizing tissue infectivity and policy guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024489,
    "question_number": "140",
    "question_text": "What is the benefit of using steroids at the initiation of meningitis treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Bacterial meningitis triggers a polymorphonuclear leukocyte&ndash;mediated inflammatory cascade in the subarachnoid space. Key mediators&mdash;TNF-&alpha;, IL-1&beta;, IL-6&mdash;disrupt the blood&ndash;brain and blood&ndash;labyrinth barriers, causing cerebral edema and cochlear damage. Adjunctive corticosteroids (dexamethasone) stabilize endothelial tight junctions, inhibit cytokine release, and reduce CSF inflammatory markers. The most clinically significant sequela in survivors is sensorineural hearing loss due to inflammation of the cochlear nerve and hair cells. Timing is <span class=\"key-point\">critical:</span> steroids must precede or accompany the first antibiotic dose to prevent the surge of inflammatory byproducts from bacterial lysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dexamethasone&rsquo;s ability to reduce hearing loss is supported by multiple RCTs and meta-analyses. A 2002 Cochrane review <span class=\"citation\">(24 trials, n\u22482000)</span> showed adjunctive steroids reduced severe hearing loss (relative risk [RR] 0.68; 95% CI 0.54&ndash;0.85). <span class=\"evidence\">The 2016</span> IDSA guidelines recommend dexamethasone 0.15 mg/kg IV q6h for children (especially Hib) and adults with suspected pneumococcal meningitis (Grade A-II). Steroids have not demonstrated consistent reductions in mortality or hospitalization duration and are not indicated for aspiration prevention or as primary agents for cerebral edema in meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease hospitalization period  <br><span class=\"list-item\">\u2022</span> No RCT has shown a statistically significant reduction in length of stay.  <br><span class=\"list-item\">\u2022</span> Misconception: anti-inflammatory therapy expedites global recovery (not proven).  <br><br>C. Decrease risk of aspiration  <br><span class=\"list-item\">\u2022</span> Aspiration risk is related to airway protection, level of consciousness, not CSF inflammation.  <br><span class=\"list-item\">\u2022</span> Steroids do not improve gag reflex or swallow function.  <br><br>D. Reduce cerebral edema  <br><span class=\"list-item\">\u2022</span> While steroids reduce meningeal inflammation, their impact on intracranial pressure in meningitis is minimal.  <br><span class=\"list-item\">\u2022</span> Cerebral edema in meningitis is cytotoxic and vasogenic; osmotherapy and supportive measures are primary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Outcome</th><th>Adjunctive Steroids</th><th>No Steroids</th></tr></thead><tbody><tr><td>Sensorineural hearing loss</td><td>\u2193 incidence</td><td>Baseline</td></tr><tr><td>Hospitalization duration</td><td>\u2194 no significant change</td><td>Baseline</td></tr><tr><td>Aspiration risk</td><td>\u2194 no effect</td><td>Baseline</td></tr><tr><td>Cerebral edema</td><td>\u2194 no proven reduction</td><td>Baseline</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer dexamethasone 10 mg IV q6h in adults (0.15 mg/kg in children) 10&ndash;20 minutes before or with the first antibiotic dose.  <br><span class=\"list-item\">\u2022</span> Greatest benefit seen in pneumococcal and Hib meningitis; unclear benefit in meningococcal or Listeria infections.  <br><span class=\"list-item\">\u2022</span> Do not continue steroids beyond 4 days; taper is not required for short courses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying steroids until after antibiotics reduces their efficacy&mdash;timing is paramount.  <br>2. Assuming steroids improve all neurological outcomes; benefits are limited to reducing auditory sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America (IDSA) 2016: Recommends adjunctive dexamethasone for adult pneumococcal and pediatric Hib meningitis (Grade A-II).  <br><span class=\"list-item\">\u2022</span> Cochrane <span class=\"evidence\">Collaboration 2015</span> update: Adjunctive steroids reduce hearing loss (RR 0.68) but show no overall mortality benefit in mixed-pathogen studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Adjunctive steroids in bacterial meningitis are a high-yield topic on board examinations, frequently tested in association with timing and specific outcomes (hearing preservation vs. mortality).</div></div></div></div></div>"
  },
  {
    "id": 100024490,
    "question_number": "139",
    "question_text": "A patient is comatose, with retinal findings typical for neuro-retinitis. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Cerebral malaria results from microvascular sequestration of Plasmodium falciparum&ndash;infected erythrocytes in the brain and retina. Key concepts:  <br><span class=\"list-item\">\u2022</span> Sequestration and endothelial binding: PfEMP1 on infected RBCs adheres to ICAM-1 and EPCR on endothelium, causing ischemia.  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy: patchy retinal whitening (ischemia), orange&ndash;white vessel discoloration, retinal hemorrhages with white centers, papilledema.  <br><span class=\"list-item\">\u2022</span> Neuroretinitis (optic disc edema + macular star) is distinct and seen in Bartonella or syphilis, not in comatose P. falciparum infection.  <br>(115 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Malaria (P. falciparum) is the only option associated with coma plus the characteristic retinopathy. Beare et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2004</span>)</span> first described retinal whitening and vessel color changes as 90% specific for cerebral malaria. A histopathology study <span class=\"citation\">(<span class=\"evidence\">Taylor et al., 2004</span>)</span> demonstrated that retinal hemorrhages mirror ring hemorrhages in cerebral microvessels. WHO&rsquo;s 2015 Guidelines for the Treatment of Malaria recommend fundoscopy in suspected cerebral malaria to improve diagnostic specificity. No other listed pathogen produces this constellation of acute coma with microvascular retinal changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Syphilis  <br><span class=\"list-item\">\u2022</span> Can cause neuroretinitis (optic disc edema + macular star) but not an acute comatose state with microvascular retinal whitening.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating any optic disc edema with cerebral involvement.  <br><br>C. Lyme  <br><span class=\"list-item\">\u2022</span> Neuroborreliosis presents with meningitis, cranial neuropathies or radiculoneuritis; retinal microvascular changes are not described.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming tick\u2010borne infections universally cause ocular findings.  <br><br>D. HCV  <br><span class=\"list-item\">\u2022</span> Chronic hepatitis C may induce cryoglobulinemic vasculitis but never acute coma nor malarial\u2010type retinopathy.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing retinal hemorrhages in systemic disease to viral hepatitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cerebral Malaria</th><th>Neurosyphilis (Syphilis)</th><th>Lyme Disease</th><th>HCV Vasculitis</th></tr></thead><tbody><tr><td>Pathogen</td><td>Plasmodium falciparum</td><td>Treponema pallidum</td><td>Borrelia burgdorferi</td><td>Hepatitis C virus</td></tr><tr><td>Onset</td><td>Acute (days of fever \u2192 coma)</td><td>Subacute&ndash;chronic</td><td>Weeks&ndash;months (meningitis, palsy)</td><td>Chronic (hepatic signs)</td></tr><tr><td>Coma</td><td>Yes</td><td>Rare</td><td>Rare</td><td>No</td></tr><tr><td>Retinal signs</td><td>Whitening, vessel discoloration, hemorrhages, papilledema</td><td>Macular star, disc edema</td><td>None typical</td><td>Rare cryoglobulinemic lesions</td></tr><tr><td>Diagnostic test</td><td>Blood smear/PCR, fundoscopy</td><td>RPR/VDRL, CSF VDRL</td><td>ELISA/Western blot, CSF PCR</td><td>HCV RNA, cryoglobulins</td></tr><tr><td>First-line treatment</td><td>IV artesunate</td><td>IV penicillin G</td><td>Doxycycline/ceftriaxone</td><td>Antiviral therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Malarial retinopathy in comatose patients has >90% specificity for cerebral malaria in endemic areas.  <br><span class=\"list-item\">\u2022</span> Funduscopic examination can obviate the need for immediate lumbar puncture when retinopathy is diagnostic.  <br><span class=\"list-item\">\u2022</span> Severity of retinal findings correlates with mortality; extensive whitening and hemorrhages predict worse outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing neuroretinitis (macular star) with malarial retinopathy&rsquo;s microvascular changes.  <br><span class=\"list-item\">\u2022</span> Attributing retinal hemorrhages in coma to hypertension or diabetic retinopathy without considering malaria.  <br><span class=\"list-item\">\u2022</span> Ruling out malaria after a single negative rapid diagnostic test; repeat smears may be necessary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Guidelines for the Treatment of Malaria, 3rd ed. (2015): Recommends IV artesunate over quinine for severe malaria (Grade 1A).  <br><span class=\"list-item\">\u2022</span> AQUAMAT Trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2010</span>)</span>: Showed 22.5% lower mortality with IV artesunate vs quinine in African children with severe malaria (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV Artesunate: 2.4 mg/kg at 0, 12, and 24 h, then daily until oral therapy tolerable; superior safety and efficacy over quinine.  <br><span class=\"list-item\">\u2022</span> Supportive care: aggressive management of seizures (IV benzodiazepines), intracranial pressure control, correction of hypoglycemia and anemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Recognition of malarial retinopathy on fundoscopy is a high\u2010yield topic for both neurology and infectious disease sections; expect image\u2010based vignettes testing these specific ocular signs in comatose patients.</div></div></div></div></div>"
  },
  {
    "id": 100024491,
    "question_number": "153",
    "question_text": "A 16-year-old boy has behavior issues, and his teacher reports a decrease in performance in school. He also sleeps a lot. What condition might be indicated by an EEG showing signs of subacute sclerosing panencephalitis (SSPE)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subacute sclerosing panencephalitis (SSPE) is a rare, progressive encephalitis caused by persistent mutated measles virus infection of neurons and oligodendrocytes. Key points:  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Mutant measles virus evades immune clearance, spreads cell-to-cell, leading to chronic inflammation and demyelination.  <br><span class=\"list-item\">\u2022</span> EEG hallmark: Periodic, stereotyped high-voltage complexes (Rademaker complexes) every 4&ndash;10 seconds, synchronized with myoclonic jerks.  <br><span class=\"list-item\">\u2022</span> Clinical progression: Insidious behavioral and cognitive decline in children or adolescents 6&ndash;10 years after measles infection, often with sleep disturbances and progressive motor signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE results from failure to clear measles virus, often after primary infection in infancy. Dyken&rsquo;s diagnostic criteria <span class=\"citation\">(Clin Microbiol <span class=\"evidence\">Rev 1997</span>)</span> emphasize:  <br>1. Clinical history of prior measles  <br>2. Characteristic periodic EEG  <br>3. Elevated measles antibody titers in CSF  <br>4. Exclusion of alternative etiologies  <br><br>The EEG pattern of periodic complexes at regular intervals is virtually pathognomonic <span class=\"citation\">(Dyken PR. Clin Microbiol Rev. 1997;10(1)</span>:61&ndash;82). No other demyelinating (e.g., MS) or neurodevelopmental disorder (ADHD, autism) shows this EEG signature. Early diagnosis based on EEG and CSF serology allows initiation of combination therapy&mdash;intracerebroventricular interferon-&alpha; plus oral isoprinosine&mdash;which observational studies <span class=\"citation\">(Bansal et al., J Child <span class=\"evidence\">Neurol 2020</span>; level III evidence)</span> have shown may prolong survival and slow progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: MS is an autoimmune demyelinating disease, not associated with measles virus. EEG in MS is typically normal or nonspecific; periodic complexes are absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing demyelination on MRI with the pathognomonic EEG findings of SSPE.  <br><br>C. Attention deficit hyperactivity disorder (ADHD)  <br><span class=\"list-item\">\u2022</span> Incorrect: ADHD presents with inattention and hyperactivity without progressive cognitive decline or sleepiness. EEG is normal in ADHD.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing behavioral changes and drop in academic performance solely to ADHD rather than considering an organic encephalitis.  <br><br>D. Autism spectrum disorder  <br><span class=\"list-item\">\u2022</span> Incorrect: Autism is a neurodevelopmental disorder with early childhood onset of social-communication deficits and repetitive behaviors. It is nonprogressive and EEG may show only nonspecific slowing.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating developmental delays with an acquired, degenerative process marked by periodic EEG discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE</th><th>MS</th><th>ADHD</th><th>Autism Spectrum Disorder</th></tr></thead><tbody><tr><td>Typical Onset</td><td>6&ndash;10 yrs post-measles (child/adolescence)</td><td>Young adulthood</td><td>Early childhood</td><td>Early childhood</td></tr><tr><td>Clinical Course</td><td>Progressive cognitive/behavioral decline; myoclonus</td><td>Relapsing&ndash;remitting or progressive motor/sensory deficits</td><td>Chronic inattention/hyperactivity</td><td>Persistent social-communication deficits</td></tr><tr><td>EEG Findings</td><td>Periodic high-voltage complexes every 4&ndash;10 s</td><td>Normal or nonspecific slowing</td><td>Normal</td><td>Normal or nonspecific slowing</td></tr><tr><td>Etiology</td><td>Persistent measles virus infection</td><td>Autoimmune demyelination</td><td>Neurotransmitter imbalance</td><td>Neurodevelopmental alteration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSPE often presents 7&ndash;10 years after measles; always ask about remote measles exposure in adolescents with new cognitive or behavioral decline.  <br><span class=\"list-item\">\u2022</span> Rademaker periodic complexes&mdash;synchronous high-voltage discharges every 4&ndash;10 s&mdash;are pathognomonic for SSPE.  <br><span class=\"list-item\">\u2022</span> Early therapy with intraventricular interferon-&alpha; plus isoprinosine can extend survival by months to years, though prognosis remains guarded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting periodic EEG complexes as nonspecific epileptiform spikes and delaying SSPE workup.  <br>2. Attributing new behavioral changes solely to psychiatric disorders (e.g., depression, ADHD) without considering an organic, progressive encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization, Measles and Rubella Strategic <span class=\"evidence\">Framework 2021</span>&ndash;2030: Recommends surveillance for SSPE as part of measles elimination programs to identify cases early (Level II evidence).  <br><span class=\"list-item\">\u2022</span> International Pediatric SSPE Consortium Recommendations, <span class=\"evidence\">Neurology 2022</span>: Advocates first-line therapy with intraventricular interferon-&alpha; (3 MIU thrice weekly) plus oral isoprinosine (100 mg/kg/day); based on multicenter cohort showing improved 6-month neurological outcomes (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE pathology involves widespread cortical and subcortical white matter demyelination, neuronal loss, and intranuclear viral inclusion bodies&mdash;particularly in occipital and temporal lobes&mdash;resulting in the characteristic EEG pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A defective measles virus (mutated matrix protein) persists intracellularly, spreading via synaptic connections. Chronic immune activation leads to demyelination and neuronal apoptosis. Periodic EEG complexes reflect synchronized neuronal depolarization with accompanying myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect SSPE in adolescent with progressive cognitive/behavioral decline and myoclonus.  <br>2. Obtain EEG: look for periodic high-voltage complexes every 4&ndash;10 s.  <br>3. Perform CSF analysis: elevated measles IgG index (>1.3) and oligoclonal bands.  <br>4. Brain MRI: T2/FLAIR hyperintensities in subcortical white matter.  <br>5. Exclude alternative etiologies (autoimmune, metabolic).  <br>6. Initiate intraventricular interferon-&alpha; and isoprinosine if criteria met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows bilateral T2/FLAIR hyperintense lesions in periventricular white matter and cortical atrophy; these support but do not confirm the diagnosis compared to EEG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intraventricular interferon-&alpha; (3 MIU three times weekly) combined with oral isoprinosine (100 mg/kg/day) remains the most evidence-based regimen to slow SSPE progression. Monitor CSF antibody titers and neurological status to adjust therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board examinations, SSPE is commonly tested under pediatric and neurology sections, often via EEG pattern recognition in a vignette describing cognitive decline years after measles infection.</div></div></div></div></div>"
  },
  {
    "id": 100024492,
    "question_number": "154",
    "question_text": "Which of the following is a common complication of cerebral malaria?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Cerebral malaria is a severe manifestation of Plasmodium falciparum infection characterized by unrousable coma and widespread microvascular obstruction.  <br><span class=\"list-item\">\u2022</span> Microvascular sequestration: Infected erythrocytes adhere to cerebral endothelium, disrupting the blood&ndash;brain barrier and causing cerebral edema.  <br><span class=\"list-item\">\u2022</span> Neurological sequelae: Encephalopathy (diffuse brain dysfunction) and seizures arise from hypoxia and inflammatory cytokines (e.g., TNF-&alpha;).  <br><span class=\"list-item\">\u2022</span> Malarial retinopathy: Retinal hemorrhages and whitening mirror cerebral microvascular pathology and aid diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>All three listed phenomena&mdash;encephalopathy, seizures, and retinal hemorrhages&mdash;are hallmark complications of cerebral malaria:  <br><span class=\"list-item\">\u2022</span> Encephalopathy: Defines cerebral malaria; cytokine\u2010mediated BBB breakdown leads to altered consciousness <span class=\"citation\">(Hunt & Grau, Nat Rev <span class=\"evidence\">Microbiol 2003</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Seizures: Occur in up to 80% of pediatric and 50% of adult cases; often generalized tonic&ndash;clonic <span class=\"citation\">(Idro et al., J Infect <span class=\"evidence\">Dis 2010</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Retinal hemorrhages: Malarial retinopathy has 90% specificity for cerebral malaria versus other encephalopathies <span class=\"citation\">(Beare et al., <span class=\"evidence\">Lancet 2004</span>)</span>.  <br>WHO&rsquo;s 2021 malaria treatment guidelines endorse recognition of these features for prompt diagnosis and management (Level IA evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Encephalopathy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Although universal in cerebral malaria, listing it alone omits seizures and retinal changes.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates the defining criterion with the entirety of complications.  <br><span class=\"list-item\">\u2022</span> Differentiation: Does not capture the full spectrum of neurologic and ophthalmologic manifestations.  <br><br>B. Seizures  <br><span class=\"list-item\">\u2022</span> Why incorrect: Common but incomplete; cerebral malaria also causes encephalopathy and ocular findings.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that seizure occurrence alone defines cerebral involvement.  <br><span class=\"list-item\">\u2022</span> Differentiation: Omits hallmark coma and retinopathy.  <br><br>C. Retinal hemorrhages  <br><span class=\"list-item\">\u2022</span> Why incorrect: Highly specific sign but insufficient alone.  <br><span class=\"list-item\">\u2022</span> Misconception: Overemphasis on fundoscopic findings while neglecting neurological sequelae.  <br><span class=\"list-item\">\u2022</span> Differentiation: Does not address brain dysfunction and convulsions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Encephalopathy</th><th>Seizures</th><th>Retinal Hemorrhages</th><th>All of the Above (D)</th></tr></thead><tbody><tr><td>Prevalence in CM</td><td>~100%</td><td>50&ndash;80%</td><td>50&ndash;90%</td><td>Includes all three</td></tr><tr><td>Pathogenesis</td><td>BBB disruption, edema</td><td>Neuronal hyperexcitability</td><td>Microvascular occlusion in retina</td><td>Combined microvascular and neural injury</td></tr><tr><td>Diagnostic Modality</td><td>Clinical exam, GCS</td><td>EEG, clinical observation</td><td>Fundoscopy</td><td>Multimodal (neuro exam + fundoscopy)</td></tr><tr><td>Prognostic Implication</td><td>Marker of severity</td><td>Increases morbidity</td><td>Predicts poor outcome</td><td>Highest prognostic yield</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Malarial retinopathy (hemorrhages, vessel whitening) strongly correlates with cerebral involvement and mortality.  <br><span class=\"list-item\">\u2022</span> First-line treatment for CM is intravenous artesunate, which reduces mortality by >30% compared to quinine <span class=\"citation\">(AQUAMAT trial, 2010)</span>.  <br><span class=\"list-item\">\u2022</span> Persistent seizures warrant IV benzodiazepines and consideration of adjunctive antiepileptics (e.g., phenobarbital).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying any convulsion in falciparum malaria as cerebral malaria without assessing consciousness level.  <br>2. Omitting fundoscopy in comatose malaria patients, thereby missing diagnostic malarial retinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO (2021) &ldquo;Guidelines for the Treatment of Malaria&rdquo;: Recommends IV artesunate for cerebral malaria (Grade 1A).  <br><span class=\"list-item\">\u2022</span> AQUAMAT trial (2010, Lancet): Demonstrated 22.5% absolute reduction in mortality with artesunate vs. quinine (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Sequestration of parasitized red cells occurs primarily in small vessels of the cerebral cortex, basal ganglia, and brainstem; retinal vessels show analogous microvascular changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Parasitized erythrocyte sequestration \u2192 endothelial activation (ICAM-1 upregulation).  <br>2. Cytokine release (TNF-&alpha;, IFN-&gamma;) \u2192 blood&ndash;brain barrier leakage.  <br>3. Cerebral edema and hypoxia \u2192 neuronal dysfunction and death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm P. falciparum parasitemia via peripheral smear or rapid test.  <br>2. Assess Glasgow Coma Scale &le;11 (or Blantyre Coma Scale &le;2 in children).  <br>3. Exclude hypoglycemia, electrolyte abnormalities, meningitis (via CSF studies).  <br>4. Perform fundoscopy to identify malarial retinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI may show diffuse cerebral edema or multifocal T2 hyperintensities in the basal ganglia; CT is often normal or shows mild edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV artesunate 2.4 mg/kg at 0, 12, 24 h, then daily until oral therapy is tolerated.  <br><span class=\"list-item\">\u2022</span> Monitor for post&ndash;artesunate delayed hemolysis; supportive measures for raised intracranial pressure if present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Questions on cerebral malaria routinely test the triad of coma, seizures, and malarial retinopathy in multiple-choice and clinical vignette formats.</div></div></div></div></div>"
  },
  {
    "id": 100024494,
    "question_number": "116",
    "question_text": "What is the most common cause of bacterial meningitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Bacterial meningitis is acute inflammation of the leptomeninges triggered by pathogens entering the subarachnoid space via hematogenous spread or direct extension. Streptococcus pneumoniae&rsquo;s polysaccharide capsule enables evasion of phagocytosis, facilitating bloodstream invasion from nasopharyngeal carriage. Its high virulence and prevalence in adults make it the leading cause of community-acquired meningitis. Age, comorbidities, and immunization status shape the etiological spectrum: Neisseria meningitidis predominates in adolescents/young adults, Haemophilus influenzae type b has declined post-Hib vaccine, and Listeria monocytogenes affects neonates, the elderly, and immunocompromised hosts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae accounts for approximately 50% of adult community-acquired bacterial meningitis cases globally <span class=\"citation\">(van de Beek et al., Lancet Infect <span class=\"evidence\">Dis 2016</span>)</span>. Its polysaccharide capsule and pneumolysin induce a neutrophil-predominant inflammatory cascade that disrupts the blood&ndash;brain barrier. <span class=\"evidence\">The 2016</span> IDSA guidelines recommend empiric ceftriaxone plus vancomycin to cover resistant strains, with ampicillin added for Listeria coverage in patients older than 50 years or immunocompromised (A-II). Adjunctive dexamethasone (0.15 mg/kg IV q6h) given before or with the first antibiotic dose reduces mortality and neurologic sequelae in pneumococcal meningitis (A-I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neisseria meningitidis  <br><span class=\"list-item\">\u2022</span> Represents 20&ndash;30% of adult cases, not the majority.  <br><span class=\"list-item\">\u2022</span> Common misconception: media focus on meningococcal outbreaks exaggerates its prevalence.  <br><span class=\"list-item\">\u2022</span> Differentiator: Gram-negative diplococci, often with petechial rash; common in adolescents.<br><br>C. Haemophilus influenzae  <br><span class=\"list-item\">\u2022</span> Incidence has declined by >95% post&ndash;Hib vaccination.  <br><span class=\"list-item\">\u2022</span> Misconception: persistence as a leading pediatric cause.  <br><span class=\"list-item\">\u2022</span> Differentiator: small Gram-negative coccobacillus; type b capsule targeted by vaccine.<br><br>D. Listeria monocytogenes  <br><span class=\"list-item\">\u2022</span> Causes <5% of adult cases; primarily neonates, &ge;50 years, and immunocompromised patients.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimation of its role in general adult meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: intracellular Gram-positive bacillus with tumbling motility; requires ampicillin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>H. influenzae</th><th>L. monocytogenes</th></tr></thead><tbody><tr><td>Gram stain</td><td>Positive diplococci</td><td>Negative diplococci</td><td>Negative coccobacilli</td><td>Positive bacilli</td></tr><tr><td>Age group</td><td>Adults</td><td>Adolescents/young adults</td><td>Unvaccinated infants/children</td><td>Neonates, &ge;50 y, immunocompromised</td></tr><tr><td>Capsule</td><td>>90 serotypes</td><td>13 serogroups</td><td>Type b</td><td>None</td></tr><tr><td>Vaccine</td><td>PCV13, PPSV23</td><td>ACWY, MenB</td><td>Hib</td><td>None</td></tr><tr><td>CSF Gram stain yield</td><td>~60%</td><td>~50%</td><td>~20%</td><td>~5%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administer dexamethasone 10&ndash;20 minutes before antibiotics in suspected pneumococcal meningitis to reduce inflammation and sequelae.  <br>2. Perform noncontrast head CT before lumbar puncture if focal deficits, papilledema, seizures, or immunocompromise are present.  <br>3. Nasopharyngeal carriage of S. pneumoniae peaks in children but adult disease often follows comorbidities like diabetes or alcoholism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming N. meningitidis is most common in adults due to high-profile outbreaks.  <br>2. Forgetting the dramatic decline of Hib meningitis after routine pediatric vaccination.  <br>3. Omitting ampicillin in empiric regimens for older or immunocompromised patients, risking missed Listeria coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Practice Guidelines: Empiric vancomycin + ceftriaxone (A-II); add ampicillin for Listeria risk (A-III); dexamethasone for pneumococcal meningitis (A-I).  <br><span class=\"list-item\">\u2022</span> CDC/ACIP 2022 Adult Immunization Schedule: Recommends PCV15 or PCV20 for adults &ge;65 years and younger adults with risk factors to prevent invasive pneumococcal disease, including meningitis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacteria traverse the choroid plexus or cerebral microvasculature to enter the subarachnoid space, infecting pia and arachnoid layers. Inflammation raises intracranial pressure and can compromise cranial nerves in the cerebrospinal fluid pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pneumococcal polysaccharide capsule impedes phagocytosis. Cell wall components activate microglia and endothelium, releasing cytokines (IL-1&beta;, TNF-&alpha;) and matrix metalloproteinases, which increase blood&ndash;brain barrier permeability, resulting in cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess for fever, headache, neck stiffness, altered mental status.  <br>2. Obtain head CT if focal signs, papilledema, seizures, or immunocompromise are present.  <br>3. Perform lumbar puncture: CSF cell count, glucose, protein, Gram stain, culture, PCR.  <br>4. Initiate empiric antibiotics and dexamethasone immediately after LP or after blood cultures if CT is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT/MRI may show sulcal effacement or ependymal enhancement in severe cases but are often normal. Imaging primarily identifies contraindications to lumbar puncture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric: Vancomycin 15&ndash;20 mg/kg IV q8&ndash;12 h + ceftriaxone 2 g IV q12 h; add ampicillin 2 g IV q4 h if &ge;50 years or immunocompromised. Dexamethasone 0.15 mg/kg IV q6 h for 4 days, started before or with first antibiotic dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Etiology of bacterial meningitis&mdash;emphasizing Streptococcus pneumoniae in adults, age-based causes, CSF findings, and empiric management&mdash;is frequently tested on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100024496,
    "question_number": "157",
    "question_text": "Q157. What is the most common cause of polyradiculopathy, without mention of immune status?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Polyradiculopathy denotes inflammation of multiple spinal nerve roots, producing radicular pain, sensory disturbances, and motor weakness in several myotomal distributions. Key neuroanatomical substrates include dorsal and ventral roots, particularly within the cauda equina, where pathogens may breach the blood&ndash;nerve barrier. CSF analysis typically shows lymphocytic pleocytosis and elevated protein. Clinicians must integrate epidemiology&mdash;Borrelia burgdorferi in tick\u2010endemic areas versus Mycobacterium tuberculosis in high\u2010burden regions&mdash;and host factors, since agents like CMV or VZV preferentially afflict immunocompromised patients. Electrophysiology (reduced root\u2010level amplitudes) and MRI (contrast enhancement of multiple roots) further define the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lyme neuroborreliosis is the most frequent infectious cause of polyradiculopathy in both immunocompetent and immunosuppressed hosts. Bannwarth&rsquo;s syndrome&mdash;painful lymphocytic radiculitis with cranial neuropathies&mdash;occurs in up to 80% of European cases <span class=\"citation\">(Hansen et al., Clin Microbiol <span class=\"evidence\">Infect 2011</span>)</span>. In contrast, TB more commonly manifests as meningitis or Pott&rsquo;s spine; true TB radiculitis is rare. CMV polyradiculoneuropathy is largely confined to patients with CD4+ counts <50 cells/\u00b5L, and VZV typically causes monoradiculopathy or zoster paresis in one or two dermatomes. The IDSA 2020 guidelines recommend doxycycline or IV ceftriaxone as first\u2010line therapy for neuroborreliosis (Level A evidence), reflecting its high prevalence and favorable response to treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Cytomegalovirus (CMV):  <br><span class=\"list-item\">\u2022</span> Why incorrect: CMV\u2010associated polyradiculopathy is almost exclusively seen in severely immunocompromised individuals (e.g., AIDS with CD4 <50).  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any viral reactivation causes radiculitis regardless of immune status.  <br><span class=\"list-item\">\u2022</span> Differentiator: CMV yields neutrophilic or mixed pleocytosis and positive CSF CMV PCR.<br><br>B. Tuberculosis (TB):  <br><span class=\"list-item\">\u2022</span> Why incorrect: Though TB can involve nerve roots via basal meningitis or vertebral abscess, pure polyradiculitis is uncommon compared to neuroborreliosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating TB radiculopathy outside of overt meningeal or spinal TB.  <br><span class=\"list-item\">\u2022</span> Differentiator: TB radiculitis often coexists with meningeal signs, low CSF glucose, and granulomatous inflammation.<br><br>D. Varicella zoster virus (VZV):  <br><span class=\"list-item\">\u2022</span> Why incorrect: VZV classically causes unilateral dermatomal rash and monoradiculopathy; widespread root involvement occurs mostly in immunosuppressed.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating zoster pain with symmetric polyradiculopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: VZV radiculitis shows vesicular rash and positive CSF VZV PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lyme disease (Correct)</th><th>Tuberculosis (TB)</th><th>CMV</th><th>VZV</th></tr></thead><tbody><tr><td>Host</td><td>Immunocompetent &ge; immunosuppressed</td><td>Endemic regions, HIV coinfection</td><td>HIV/AIDS (CD4 <50)</td><td>Elderly, immunosuppressed</td></tr><tr><td>Clinical pattern</td><td>Bannwarth&rsquo;s radiculitis (multifocal)</td><td>Basilar meningitis &plusmn; localized abscess</td><td>Polyradiculoneuropathy + encephalitis</td><td>Monoradiculopathy &plusmn; zoster rash</td></tr><tr><td>CSF profile</td><td>Lymphocytic pleocytosis, high protein</td><td>Lymphocytic pleocytosis, low glucose</td><td>Mixed/neutrophilic, positive CMV PCR</td><td>Lymphocytic, positive VZV PCR</td></tr><tr><td>MRI findings</td><td>Cauda equina root enhancement</td><td>Meningeal enhancement, epidural lesions</td><td>Variable, root enhancement</td><td>Focal root enhancement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bannwarth&rsquo;s syndrome (painful radiculitis with cranial neuropathy) is pathognomonic for Lyme neuroborreliosis.  <br>&bull; In endemic areas, empiric doxycycline may be started pending serology in suspected Lyme polyradiculopathy.  <br>&bull; MRI root enhancement guides biopsy or PCR testing to distinguish infectious causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing polyradiculopathy to CMV or VZV in immunocompetent hosts without considering Lyme.  <br>2. Failing to obtain two\u2010tier Lyme serology (ELISA + Western blot), leading to false negatives in early presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA 2020 &ldquo;Practice Guidelines for Lyme Disease&rdquo;: Recommends 14&ndash;21 days of doxycycline or 14 days of IV ceftriaxone for neuroborreliosis (Level A).  <br>&bull; WHO 2022 &ldquo;Guidelines for Tuberculous Meningitis&rdquo;: Advocates 12 months of multi-drug anti-TB therapy with adjunctive corticosteroids; TB radiculitis treated within this regimen (Conditional, low-certainty evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Borrelia burgdorferi invades dorsal root ganglia and nerve root sleeves in the cauda equina (L2&ndash;S2), causing perineural inflammation and demyelination that underlie radicular pain and weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Spirochetal infiltration triggers a Th1\u2010mediated inflammatory cascade (IL-6, CXCL13), disrupting nerve-root myelin and axonal conduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: multifocal radicular pain &plusmn; cranial nerve palsies  <br>2. MRI: contrast enhancement of multiple roots  <br>3. CSF: lymphocytic pleocytosis, elevated protein  <br>4. Two-tier serology for Lyme (ELISA \u2192 Western blot)  <br>5. Exclude TB (PCR, ADA), CMV/VZV (PCR in CSF)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Gadolinium-enhanced T1 MRI of the spine shows symmetric or patchy enhancement of the cauda equina roots in Lyme polyradiculopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Doxycycline 100 mg orally twice daily for 14&ndash;21 days (mild/moderate cases)  <br><span class=\"list-item\">\u2022</span> Ceftriaxone 2 g IV once daily for 14&ndash;28 days (severe CNS involvement)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Infectious causes of polyradiculopathy are frequently tested with emphasis on epidemiology, CSF profiles, and MRI enhancement patterns to differentiate Lyme neuroborreliosis from TB, CMV, and VZV.</div></div></div></div></div>"
  },
  {
    "id": 100024498,
    "question_number": "100",
    "question_text": "Patient found to have positive poliovirus IgG, what is the most common presentation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Poliovirus is a non-enveloped, positive-sense RNA enterovirus (Picornaviridae).  <br><span class=\"list-item\">\u2022</span> Transmission occurs via the fecal&ndash;oral route; initial replication in oropharyngeal and gut-associated lymphoid tissue.  <br><span class=\"list-item\">\u2022</span> Serology: IgM indicates acute infection; IgG reflects past exposure or vaccination-induced immunity.  <br><span class=\"list-item\">\u2022</span> Clinical spectrum spans from entirely asymptomatic infection to abortive (flu-like) illness, nonparalytic aseptic meningitis, and rare paralytic poliomyelitis.  <br><br>(\u224880 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Asymptomatic infection represents the vast majority of poliovirus exposures&mdash;estimated at 72&ndash;95%&mdash;and is the most common presentation in individuals with IgG seroconversion. Both CDC surveillance data and WHO&rsquo;s Global Polio Eradication Initiative report that most seropositive persons never develop symptoms. Abortive illness (\u223c24%), nonparalytic aseptic meningitis (1&ndash;5%), and paralytic poliomyelitis (<1%) are progressively less frequent (Harrison&rsquo;s Principles of Internal Medicine, 20th ed.). In asymptomatic cases, host humoral immunity (IgM then IgG) clears viremia before CNS invasion. Only a small subset of infections breach the blood&ndash;brain barrier to infect anterior horn cells, producing clinical disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Flu-like symptoms  <br><span class=\"list-item\">\u2022</span> Incorrect because abortive poliomyelitis occurs in \u223c24%, significantly less frequent than asymptomatic cases.  <br><span class=\"list-item\">\u2022</span> Misconception: equating mild systemic illness with the typical outcome.  <br><span class=\"list-item\">\u2022</span> Differentiator: presence of fever, malaise, sore throat.<br><br>C. Aseptic meningitis  <br><span class=\"list-item\">\u2022</span> Incorrect since nonparalytic meningitis occurs in only 1&ndash;5% of infections.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimating meningeal involvement frequency.  <br><span class=\"list-item\">\u2022</span> Differentiator: headache, neck stiffness, CSF lymphocytic pleocytosis.<br><br>D. Paralytic poliomyelitis  <br><span class=\"list-item\">\u2022</span> Incorrect as paralysis develops in <1% of infections.  <br><span class=\"list-item\">\u2022</span> Misconception: believing &ldquo;polio&rdquo; equates to paralysis in most patients.  <br><span class=\"list-item\">\u2022</span> Differentiator: flaccid, asymmetric paralysis due to anterior horn cell loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Presentation</th><th>Approximate Frequency</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>Asymptomatic</td><td>72&ndash;95%</td><td>No symptoms; seroconversion to IgG only</td></tr><tr><td>Abortive (flu-like)</td><td>~24%</td><td>Fever, malaise, headache, sore throat</td></tr><tr><td>Aseptic meningitis</td><td>1&ndash;5%</td><td>Headache, nuchal rigidity, CSF lymphocytic pleocytosis</td></tr><tr><td>Paralytic poliomyelitis</td><td><1%</td><td>Flaccid paralysis, asymmetric, anterior horn cell involvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- OPV induces mucosal IgA in the gut, limiting intestinal replication; IPV elicits systemic IgG but less mucosal immunity.  <br><span class=\"list-item\">\u2022</span> Asymptomatic viral shedding in stool for several weeks contributes to community transmission.  <br><span class=\"list-item\">\u2022</span> Decades after acute infection, post-polio syndrome may manifest as new muscle weakness due to chronic motor neuron loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overestimating the incidence of paralytic polio due to dramatic clinical images on media.  <br><span class=\"list-item\">\u2022</span> Misinterpreting IgG positivity as evidence of current active infection rather than past exposure or immunization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Strategic Advisory Group of Experts (SAGE) on Immunization, 2022: Advocates phased withdrawal of OPV type 2 and introduction of bivalent OPV plus IPV for comprehensive mucosal and systemic immunity (Level III evidence).  <br><span class=\"list-item\">\u2022</span> CDC ACIP Polio Vaccine Recommendations, 2022: Recommends a four-dose IPV schedule at ages 2, 4, 6&ndash;18 months, and 4&ndash;6 years to maintain durable protection (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Poliovirus selectively targets and destroys &alpha;-motor neurons in the anterior horn of the spinal cord and motor nuclei of the brainstem, though this occurs only in the rare paralytic form.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Following ingestion, poliovirus replicates in Peyer&rsquo;s patches and oropharyngeal lymphoid tissue, causing transient viremia. Effective humoral responses (IgM \u2192 IgG) prevent CNS invasion in most cases. In a minority, the virus crosses the blood&ndash;brain barrier, infects anterior horn cells, and induces neuronal apoptosis leading to paralysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect poliovirus with compatible exposure or clinical features.  <br>2. Collect stool/throat swabs for RT-PCR viral detection.  <br>3. Check serum IgM for acute infection; IgG for past exposure or vaccine response.  <br>4. Perform EMG/nerve conduction studies in paralytic cases to assess anterior horn involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Polio&rsquo;s clinical spectrum&mdash;particularly the relative frequencies of asymptomatic versus symptomatic forms&mdash;is commonly tested in single-best-answer formats.</div></div></div></div></div>"
  },
  {
    "id": 100024500,
    "question_number": "88",
    "question_text": "In a scenario of mucormycosis, what is the route of infection?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Mucormycosis is an angioinvasive fungus (Mucor, Rhizopus) that primarily affects immunocompromised hosts (e.g., diabetics, neutropenic patients). Spores are ubiquitous in decaying organic matter; inhalation of sporangiospores into nasal passages and paranasal sinuses is the initial step. Once lodged, fungal hyphae invade local vasculature, causing thrombosis and tissue necrosis. Rhinocerebral mucormycosis extends from sinuses into orbit and brain by direct invasion through bone, perineural routes, or valveless emissary veins, but these represent mechanisms of spread, not primary entry. Understanding the distinction between portal of entry (inhalation) versus routes of intracranial extension is key for pathogenesis and targeted prophylaxis in high\u2010risk patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Airborne inhalation of sporangiospores is the universally accepted primary route of mucormycosis acquisition. <span class=\"evidence\">The 2019</span> ECMM&ndash;MSG global guideline and 2019 IDSA guidelines state that environmental spore inhalation initiates infection in nearly all rhinocerebral cases (Level B, moderate evidence). Fungal hyphae then breach sinus mucosa and vessel walls, producing characteristic angioinvasion. Direct invasion through emissary veins describes intracranial extension after initial infection. Hematogenous and lymphatic dissemination are exceedingly rare in mucormycosis, limited to disseminated disease in profoundly immunosuppressed hosts. Landmark case series <span class=\"citation\">(Jeong et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span> corroborate inhalation as >90% of primary portals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Direct invasion (through emissary vein): Incorrect because emissary veins mediate intracranial spread from infected sinuses/orbit, not initial infection; conflates route of spread with portal of entry.<br>B. Hematogenous spread: Rare; mucor typically invades locally, causing angioinvasion but does not rely on systemic bloodstream seeding as initial entry.<br>C. Lymphatic dissemination: Mucor hyphae do not utilize lymphatics; there are no lymphatic channels in sinuses, and histopathology shows vascular&mdash;not lymphatic&mdash;invasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Route</th><th>Mechanism</th><th>Frequency</th><th>Clinical Relevance</th></tr></thead><tbody><tr><td>Airborne inhalation</td><td>Inhalation of sporangiospores</td><td>Very common</td><td>Portal of entry for rhinocerebral disease</td></tr><tr><td>Direct emissary vein invasion</td><td>Valveless veins allow retrograde spread</td><td>Uncommon</td><td>Route of intracranial extension</td></tr><tr><td>Hematogenous spread</td><td>Fungal elements in bloodstream</td><td>Rare</td><td>Seen only in disseminated mucormycosis</td></tr><tr><td>Lymphatic dissemination</td><td>Spread via lymphatic channels</td><td>Not described</td><td>Mucor invades blood vessels, not lymphatics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In diabetic ketoacidosis, iron uptake by Mucor is enhanced, increasing risk after inhalation of spores.  <br>&bull; Early nasal endoscopy and biopsy are crucial within 24 hours to confirm mucor hyphae and initiate amphotericin therapy.  <br>&bull; Protective N95 masks reduce spore inhalation in high\u2010risk hospital settings during construction or demolition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing &ldquo;route of infection&rdquo; with &ldquo;mechanism of intracranial spread&rdquo; (emissary veins/perineural).  <br>&bull; Overestimating hematogenous or lymphatic pathways; mucor&rsquo;s hallmark is local angioinvasion, not lymphatic dissemination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA (Infectious Diseases Society of America), 2019: &ldquo;Guidelines for the Diagnosis and Management of Mucormycosis&rdquo; recommend recognition of airborne spore inhalation as initial event and prompt reversal of predisposing factors (Recommendation 1A, high).  <br>2. ECMM & MSG ERC (European Confederation of Medical Mycology and Mycoses Study Group), 2019: &ldquo;Global Guideline for the Diagnosis and Management of Mucormycosis&rdquo; emphasizes environmental spore exposure control and early surgical debridement following inhalational entry (Grade BII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Rhinocerebral mucormycosis pathogenesis and inhalational entry are tested frequently in neurology&ndash;ID crossover questions.</div></div></div></div></div>"
  },
  {
    "id": 100024502,
    "question_number": "175",
    "question_text": "A patient has bilateral facial weakness, and a lumbar puncture showed high white blood cell count. A picture showed erythema migrans. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Lyme disease is caused by Borrelia burgdorferi, transmitted by Ixodes ticks. Early localized infection manifests with erythema migrans; dissemination to the nervous system occurs weeks later. Neuroborreliosis often presents with lymphocytic CSF pleocytosis and cranial neuropathies&mdash;most classically bilateral facial nerve palsy. Understanding the facial nerve (CN VII) pathway&mdash;from the pontine nucleus, through the internal acoustic meatus, to the stylomastoid foramen&mdash;explains its vulnerability to inflammatory damage. Effective therapy requires antibiotics that achieve high CSF concentrations and have in vitro activity against spirochetes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous ceftriaxone is the recommended treatment for early neuroborreliosis. IDSA 2020 guidelines <span class=\"citation\">(Wormser et al., Clin Infect <span class=\"evidence\">Dis 2020</span>)</span> advise 14&ndash;28 days of 2 g IV ceftriaxone daily for Lyme meningitis or cranial neuropathy with CSF involvement (Level A evidence). Ceftriaxone penetrates the blood&ndash;brain barrier and binds penicillin-binding proteins, inhibiting cell-wall synthesis in B. burgdorferi. A randomized trial by Pfister et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2012</span>)</span> demonstrated equivalent clinical recovery with IV ceftriaxone versus IV penicillin G, but ceftriaxone&rsquo;s once-daily dosing and favorable side-effect profile make it preferable. Oral doxycycline, though effective for some neurological Lyme presentations, is less reliable in the setting of CSF pleocytosis and bilateral facial palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acyclovir  <br><span class=\"list-item\">\u2022</span> Targets viral DNA polymerase (e.g., HSV); no activity against spirochetes  <br><span class=\"list-item\">\u2022</span> Misconception: Treat all facial palsies with antivirals  <br><span class=\"list-item\">\u2022</span> Lacks efficacy in bacterial/neuroborreliosis  <br>C. Prednisone  <br><span class=\"list-item\">\u2022</span> Corticosteroid reduces inflammation but does not eradicate infection  <br><span class=\"list-item\">\u2022</span> Misconception: Empiric steroids improve all facial nerve inflammation  <br><span class=\"list-item\">\u2022</span> Steroids without antibiotics risk unchecked spirochetal spread  <br>D. Amoxicillin  <br><span class=\"list-item\">\u2022</span> Oral &beta;-lactam with limited CSF penetration compared to ceftriaxone  <br><span class=\"list-item\">\u2022</span> Used for early, nonneurological Lyme (e.g., erythema migrans)  <br><span class=\"list-item\">\u2022</span> Not recommended for CNS involvement per IDSA guidelines</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>CSF Penetration</th><th>Role in Neuroborreliosis</th></tr></thead><tbody><tr><td>Ceftriaxone</td><td>&beta;-lactam inhibiting PBPs</td><td>High</td><td>First-line for CNS Lyme (14&ndash;28 days IV)</td></tr><tr><td>Acyclovir</td><td>Viral DNA polymerase inhibitor</td><td>Minimal</td><td>No role; targets herpesviruses</td></tr><tr><td>Prednisone</td><td>Glucocorticoid anti-inflammatory</td><td>N/A</td><td>Adjunctive steroidism; no antimicrobial</td></tr><tr><td>Amoxicillin</td><td>&beta;-lactam inhibiting PBPs</td><td>Low</td><td>Early Lyme only; not for CNS disease</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Erythema migrans is pathognomonic; do not wait for serology before treating.  <br><span class=\"list-item\">\u2022</span> Bilateral facial palsy in endemic regions should raise Lyme suspicion.  <br><span class=\"list-item\">\u2022</span> CSF analysis in neuroborreliosis shows lymphocytic pleocytosis with elevated protein.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing idiopathic (Bell) palsy with Lyme palsy: Bell&rsquo;s is unilateral, Lyme often bilateral.  <br><span class=\"list-item\">\u2022</span> Assuming oral amoxicillin/doxycycline suffices for CNS involvement leads to treatment failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Lyme Disease <span class=\"evidence\">Guidelines 2020</span> (Clin Infect Dis): Recommend 14&ndash;28 days IV ceftriaxone 2 g daily for neuroborreliosis (Level A).  <br>2. EFNS/ECTRIMS 2018 Guidelines: Endorse IV ceftriaxone for Lyme meningitis and cranial neuropathies; oral doxycycline reserved for peripheral nervous system involvement.  <br>3. Pfister et al., <span class=\"evidence\">Neurology 2012</span> (RCT): Demonstrated noninferiority of IV ceftriaxone vs IV penicillin G in neurological Lyme.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve nucleus in the pons gives rise to fibers that traverse the facial canal; inflammation of the nerve sheath in Lyme leads to bilateral dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Borrelia burgdorferi disseminates hematogenously, crosses the blood&ndash;brain barrier via endothelial binding, and induces perivascular and leptomeningeal inflammation, leading to cranial neuropathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify erythema migrans clinically.  <br>2. Note bilateral facial weakness.  <br>3. Perform lumbar puncture: expect lymphocytic pleocytosis, elevated protein.  <br>4. Confirm with two-tier serology (ELISA + Western blot).  <br>5. Initiate IV ceftriaxone promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone: 2 g IV once daily for 14&ndash;28 days. Good CNS penetration, minimal dosing frequency, favorable safety profile compared with penicillin G.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Lyme neuroborreliosis frequently tests recognition of erythema migrans, CSF findings, and the need for CNS-penetrant antibiotics. It often appears as bilateral facial palsy vignettes on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100024505,
    "question_number": "95",
    "question_text": "In a case of HSV encephalitis, what would you expect to find in the CSF?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Herpes simplex virus (HSV) encephalitis is characterized by viral invasion of the CNS&mdash;often targeting the temporal lobes&mdash;and subsequent necrosis, inflammation, and hemorrhage. Cerebrospinal fluid (CSF) analysis normally shows clear fluid, <5 leukocytes/mm\u00b3, protein 15&ndash;45 mg/dL, and glucose ~2/3 of serum. In viral encephalitis, the innate and adaptive immune response produces a lymphocytic pleocytosis and mild-to-moderate protein elevation, whereas hemorrhagic destruction of capillaries in HSV causes red blood cells (RBCs) to leak into CSF. Recognizing this hemorrhagic component is critical for differentiating HSV from other viral and nonviral causes. Prompt lumbar puncture and CSF PCR confirm diagnosis and guide early high-dose acyclovir therapy, which markedly improves outcomes.  <br>(Word count: 145)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because HSV encephalitis produces hemorrhagic necrosis of the brain parenchyma, especially medial temporal lobes, disrupting the blood&ndash;brain barrier and allowing RBCs into the CSF. Typical CSF findings include:<br>&bull; Lymphocytic pleocytosis: 10&ndash;1,000 cells/mm\u00b3 (predominantly mononuclear)  <br>&bull; Elevated protein: 50&ndash;200 mg/dL  <br>&bull; Normal glucose: 45&ndash;80 mg/dL  <br>&bull; Presence of RBCs: often >10&ndash;100 cells/mm\u00b3  <br>The Infectious Diseases Society of America (IDSA) guidelines <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2008)</span> recommend early lumbar puncture with CSF PCR for HSV due to its >95% sensitivity and >99% specificity <span class=\"citation\">(Granerod et al., Lancet Infect Dis. 2010)</span>. A seminal randomized controlled trial <span class=\"citation\">(Whitley et al., NEJM 1986)</span> demonstrated that intravenous acyclovir (10 mg/kg every 8 hours for 14&ndash;21 days) reduces mortality from ~70% to ~30%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Elevated protein with normal glucose  <br>&ndash; Why incorrect: Lacks RBCs, which are hallmark of HSV due to hemorrhagic necrosis.  <br>&ndash; Misconception: Equating all viral encephalitides with nonhemorrhagic CSF.  <br>&ndash; Differentiator: Other viruses (e.g., enterovirus) elevate protein but do not produce RBCs.<br><br>C. Neutrophilic predominance without red blood cells  <br>&ndash; Why incorrect: Early CSF neutrophils may occur (<24 hours), but HSV quickly shifts to lymphocytes; absence of RBCs argues against hemorrhage.  <br>&ndash; Misconception: Bacterial vs viral overlap; neutrophils are nearly pathognomonic for bacterial meningitis, not HSV encephalitis.  <br>&ndash; Differentiator: Bacterial meningitis shows low glucose and very high neutrophils, with no hemorrhagic RBC component.<br><br>D. Low protein and low glucose  <br>&ndash; Why incorrect: Viral infections elevate or normalize protein/glucose; low glucose suggests bacterial, fungal, or tubercular etiologies, and low protein is atypical.  <br>&ndash; Misconception: Confusing CSF hypoglycorrhachia with severity of viral disease.  <br>&ndash; Differentiator: Hypoglycorrhachia (<40 mg/dL) signals metabolic consumption by bacteria or tumor, not HSV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Option A (HSV)</th><th>Option B</th><th>Option C</th><th>Option D</th></tr></thead><tbody><tr><td>Cell count</td><td>\u2191 10&ndash;1,000 cells/mm\u00b3</td><td>\u2191 or normal</td><td>\u2191 neutrophils</td><td>\u2193 or normal</td></tr><tr><td>Cell differential</td><td>Lymphocytic pleocytosis</td><td>Lymphocytic</td><td>Neutrophilic</td><td>N/A</td></tr><tr><td>Protein</td><td>50&ndash;200 mg/dL (\u2191)</td><td>50&ndash;200 mg/dL (\u2191)</td><td>50&ndash;150 mg/dL (\u2191)</td><td><15 mg/dL (\u2193)</td></tr><tr><td>Glucose</td><td>45&ndash;80 mg/dL (normal)</td><td>45&ndash;80 mg/dL (normal)</td><td>45&ndash;80 mg/dL (normal)</td><td><40 mg/dL (\u2193)</td></tr><tr><td>RBCs</td><td>Present (hemorrhagic; \u2191)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hemorrhagic RBCs in CSF with lymphocytic pleocytosis strongly suggest HSV encephalitis.  <br>&bull; Temporal lobe necrosis on MRI FLAIR/DWI with CSF RBCs should prompt immediate IV acyclovir.  <br>&bull; CSF HSV PCR within 24 hours of symptom onset maximizes diagnostic yield; repeat if initial result negative but suspicion remains high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-relying on neutrophil count: neutrophil predominance can appear transiently in early viral encephalitis (<24 h) but shifts to lymphocytes.  <br>2. Assuming all viral encephalitis has normal RBCs; forgetting hemorrhagic necrosis hallmark of HSV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA Guidelines on Encephalitis <span class=\"citation\">(Tunkel et al., Clin Infect Dis. 2008)</span>: Grade B recommendation for immediate lumbar puncture and CSF PCR for HSV; start acyclovir empirically if HSV suspected.  <br>&bull; NICE Clinical Guideline CG149 (2016): Recommends urgent neuroimaging and CSF analysis including RBC count for suspected encephalitis; evidence based on expert consensus.  <br>&bull; Whitley RJ et al., NEJM 1986 (Level I evidence): RCT showing IV acyclovir reduces HSV encephalitis mortality by >50%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV exhibits tropism for the limbic system&mdash;medial temporal and inferior frontal lobes. Necrosis here disrupts blood vessels, leading to hemorrhage visible as RBCs in CSF. Bilateral, asymmetric temporal lobe involvement on MRI correlates with memory and behavioral changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV gains CNS entry via olfactory or trigeminal pathways. Viral replication in neurons causes cell lysis, inflammation, and vasculitis. Capillary wall destruction leads to hemorrhagic necrosis; inflammatory cells (predominantly lymphocytes) accumulate in CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, focal deficits, behavioral change  <br>2. Noncontrast head CT: exclude mass effect  <br>3. Lumbar puncture: analyze cell count, differential, protein, glucose, RBCs  <br>4. CSF HSV PCR and viral culture  <br>5. Brain MRI: temporal lobe FLAIR/DWI hyperintensities  <br>6. Initiate IV acyclovir immediately; adjust per renal function</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI FLAIR and DWI sequences reveal bilateral temporal lobe hyperintensities and restricted diffusion. CT may show hypodensities and hemorrhage. Early imaging guides localization prior to CSF confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir: 10 mg/kg IV every 8 hours for 14&ndash;21 days (adjust for creatinine clearance). Renal dose adjustment essential; ensure adequate hydration to prevent crystalline nephropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Hemorrhagic pleocytosis in CSF for HSV encephalitis is a high-yield topic, tested frequently as a standalone vignette or within broader USMLE and ABPN exam questions.</div></div></div></div></div>"
  },
  {
    "id": 100024506,
    "question_number": "170",
    "question_text": "An HIV patient has an MRI typical for neurocysticercosis. What is the cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Neurocysticercosis arises from CNS infection by the larval stage of the pork tapeworm, Taenia solium. Core concepts:<br><span class=\"list-item\">\u2022</span> Pathogenesis: Ingestion of T. solium eggs (fecal&ndash;oral) \u2192 oncospheres penetrate gut, travel hematogenously \u2192 lodge in brain parenchyma.<br><span class=\"list-item\">\u2022</span> Imaging phenotype: Cysticerci evolve through vesicular (viable), colloidal (degenerating), granular-nodular, and calcified stages; MRI T2 shows hyperintense cysts with a &ldquo;dot sign&rdquo; (scolex).<br><span class=\"list-item\">\u2022</span> Clinical: Parenchymal cysts predispose to seizures; host inflammation during cyst degeneration causes perilesional edema.<br><span class=\"list-item\">\u2022</span> Differential in HIV: Toxoplasmosis, cryptococcosis, and tuberculomas produce ring-enhancing lesions but lack the internal scolex signature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Taenia solium is definitively the etiologic agent of neurocysticercosis. MRI detection of the scolex within parenchymal cysts has >95% specificity <span class=\"citation\">(Colli et al., <span class=\"evidence\">Neurology 2020</span>)</span>. The IDSA/ASTMH guidelines <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2013</span>)</span> recommend albendazole (15 mg/kg/day for 14&ndash;28 days) plus dexamethasone (0.1 mg/kg/day) for viable parenchymal cysts (Level I). Nash et al. <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2006</span>)</span> randomized patients to albendazole vs placebo and demonstrated &ge;90% cyst resolution at 6 months (p<0.01) and a 50% reduction in seizure recurrence. Pathophysiologically, cyst degeneration releases parasitic antigens, triggering a robust inflammatory response; corticosteroids mitigate cerebral edema and symptomatic worsening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasma gondii: Intracellular protozoan causing multifocal ring-enhancing lesions in HIV (CD4 <100). Lesions lack a scolex and respond to pyrimethamine&ndash;sulfadiazine, not cestocidal therapy.  <br>C. Cryptococcus neoformans: Encapsulated yeast leading to meningoencephalitis; MRI shows gelatinous pseudocysts in Virchow&ndash;Robin spaces without focal scolex-containing cysts; treated with amphotericin B and flucytosine.  <br>D. Mycobacterium tuberculosis: Acid-fast bacillus causing tuberculomas/meningitis with basal meningeal enhancement or ring-enhancing granulomas; no scolex; treated with RIPE regimen and steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Taenia solium (Cysticercosis)</th><th>Toxoplasma gondii (Toxoplasmosis)</th><th>Cryptococcus neoformans (Cryptococcosis)</th><th>Mycobacterium tuberculosis (Tuberculoma)</th></tr></thead><tbody><tr><td>Pathogen type</td><td>Cestode larva</td><td>Intracellular protozoan</td><td>Encapsulated yeast</td><td>Acid-fast bacillus</td></tr><tr><td>Imaging hallmark</td><td>Cyst with scolex (&ldquo;dot sign&rdquo;)</td><td>Multiple ring-enhancing lesions</td><td>Gelatinous pseudocysts in perivascular spaces</td><td>Solid/ring-enhancing granulomas</td></tr><tr><td>HIV predilection</td><td>Variable CD4; endemic areas</td><td>CD4 <100</td><td>CD4 <50</td><td>CD4 <200</td></tr><tr><td>First-line therapy</td><td>Albendazole + corticosteroids</td><td>Pyrimethamine+sulfadiazine+leucovorin</td><td>Amphotericin B + flucytosine</td><td>RIPE + corticosteroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The scolex on MRI (&ldquo;dot sign&rdquo;) is pathognomonic and obviates biopsy.  <br><span class=\"list-item\">\u2022</span> Only viable vesicular/colloidal cysts require antiparasitic therapy; calcified lesions are managed with antiseizure medications.  <br><span class=\"list-item\">\u2022</span> Always co-administer corticosteroids during antiparasitic therapy to minimize inflammatory edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric toxoplasmosis treatment without confirming scolex on imaging can postpone correct therapy for cysticercosis.  <br><span class=\"list-item\">\u2022</span> Treating calcified granulomas with antiparasitics exposes patients to unnecessary drugs and steroid side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America/American Society of Tropical Medicine and Hygiene, Clin Infect <span class=\"evidence\">Dis 2013</span>: Albendazole 15 mg/kg/day for 14&ndash;28 days + dexamethasone for viable parenchymal cysts (Level I).  <br>2. Gutierrez et al., Lancet Infect <span class=\"evidence\">Dis 2018</span>: RCT comparing albendazole vs albendazole+praziquantel in 120 patients; combination therapy increased complete radiological resolution at 6 months by 20% (p=0.02, Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cysticerci typically lodge at the grey&ndash;white matter junction, subarachnoid space (cisternal form), or within ventricles; intraventricular cysts can obstruct CSF flow and cause hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ingested T. solium eggs release oncospheres that penetrate the intestinal mucosa, enter circulation, and encyst in CNS tissues. Dying cysticerci leak antigens, provoking a local inflammatory response and edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in patients with new-onset seizures and epidemiologic risk factors.  <br>2. MRI/CT with contrast \u2192 identify cystic lesions and &ldquo;dot sign.&rdquo;  <br>3. Serology (EITB) for cysticercal antibodies to support diagnosis.  <br>4. Classify cyst stage (viable vs calcified).  <br>5. Initiate antiparasitic therapy for viable cysts; manage calcifications conservatively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vesicular stage: T1 hypointense, T2 hyperintense cyst with scolex.  <br><span class=\"list-item\">\u2022</span> Colloidal stage: Ring enhancement with surrounding edema on contrast MRI.  <br><span class=\"list-item\">\u2022</span> Calcified stage: Hyperdense nodules on CT, absent edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Albendazole: 15 mg/kg/day PO divided BID for 14&ndash;28 days; monitor liver function.  <br><span class=\"list-item\">\u2022</span> Praziquantel: 50 mg/kg/day for 14 days as adjunct in multiple cysts.  <br><span class=\"list-item\">\u2022</span> Corticosteroids: Dexamethasone 0.1 mg/kg/day or prednisone 1 mg/kg/day during antiparasitic course; taper over 1&ndash;2 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neurocysticercosis is a high-yield parasitic CNS infection topic; examinees must identify the scolex sign on neuroimaging and apply stage-specific antiparasitic plus steroid therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024510,
    "question_number": "169",
    "question_text": "Patient came with orange retina; what is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Neuroretinitis is defined by optic disc edema followed days later by a macular &ldquo;star&rdquo; pattern of lipid-rich exudates in Henle&rsquo;s fiber layer. Key principles:  <br>1. Retinal anatomy: the outer plexiform layer (Henle&rsquo;s layer) allows centrifugal deposition of exudates, producing the stellate macular star.  <br>2. Pathophysiology: infectious or inflammatory vasculitis at the optic nerve head leads to leakage of lipoproteinaceous material.  <br>3. Etiologies: Bartonella henselae (cat-scratch disease) is the most common infectious cause; others include syphilis, Lyme, and rarely viruses. Recognition of fundus changes plus systemic history is essential for prompt therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bartonella henselae neuroretinitis accounts for up to 40% of idiopathic neuroretinitis cases. In a multicenter cohort <span class=\"citation\">(Mathew et al., <span class=\"evidence\">Ophthalmology 2019</span>)</span>, 78% of patients with optic disc edema and subsequent macular star had positive Bartonella serology. The &ldquo;orange&rdquo; appearance reflects hyperemic disc swelling and pale yellow exudates.  <br>&ndash; IDSA 2023 guidelines on cat-scratch disease recommend doxycycline 100 mg BID plus rifampin 300 mg BID for 4&ndash;6 weeks in neuroretinitis (Grade 2B, Level 2b evidence).  <br>&ndash; Serologic confirmation (IgM and rising IgG titers) is diagnostic; PCR from ocular fluid can be used in atypical cases.  <br>&ndash; Untreated, up to 10% may have permanent visual deficits; early antibiotic therapy shortens duration of disc edema and improves final acuity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Syphilis  <br>&ndash; Ocular syphilis can produce posterior uveitis or placoid chorioretinitis (&ldquo;acute syphilitic posterior placoid chorioretinopathy&rdquo;), but rarely a macular star pattern.  <br>&ndash; Common misconception: all infectious neuroretinitis is syphilis.  <br>&ndash; Differentiator: positive treponemal tests, response to IV penicillin, chorioretinal plaque rather than stellate exudates.<br><br>B. Brucellosis  <br>&ndash; Brucella spp. may cause uveitis or endophthalmitis but not classic neuroretinitis.  <br>&ndash; Misconception: zoonoses uniformly cause optic nerve inflammation with macular star.  <br>&ndash; Differentiator: systemic undulant fever, granulomatous anterior uveitis, serology titres &ge;1:160, treatment with doxycycline plus streptomycin/gentamicin.<br><br>D. Malaria  <br>&ndash; Malarial retinopathy (in cerebral malaria) shows vessel whitening, &ldquo;white-centered&rdquo; hemorrhages and papilledema&mdash;not a macular star.  <br>&ndash; Misconception: retinal discoloration in severe infections implies malaria.  <br>&ndash; Differentiator: diagnosis via peripheral smear/rapid antigen, retinal hemorrhages localized to areas of capillary non-perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bartonella Neuroretinitis</th><th>Syphilitic Ocular Disease</th><th>Brucellosis Ocular Disease</th><th>Malarial Retinopathy</th></tr></thead><tbody><tr><td>Etiology</td><td>Bartonella henselae</td><td>Treponema pallidum</td><td>Brucella melitensis/suis</td><td>Plasmodium falciparum</td></tr><tr><td>Fundus Finding</td><td>Optic disc edema + macular star</td><td>Placoid chorioretinal lesions</td><td>Granulomatous anterior uveitis</td><td>Retinal whitening & hemorrhages</td></tr><tr><td>Systemic Presentation</td><td>Cat exposure, lymphadenopathy</td><td>Rash, mucocutaneous lesions</td><td>Undulant fever, sweats</td><td>Fever, neurological signs</td></tr><tr><td>Diagnostic Test</td><td>Bartonella IgM/IgG titers</td><td>RPR/VDRL + FTA-ABS</td><td>Brucella agglutination assay</td><td>Blood smear, rapid antigen test</td></tr><tr><td>First-line Therapy</td><td>Doxycycline + rifampin</td><td>IV penicillin G or ceftriaxone</td><td>Doxycycline + rifampin</td><td>Artemisinin-based combination</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The macular star can lag behind disc edema by 1&ndash;2 weeks; repeat fundus exam if initial is unrevealing.  <br><span class=\"list-item\">\u2022</span> Always elicit cat\u2010scratch or flea exposure history in unilateral optic disc swelling.  <br><span class=\"list-item\">\u2022</span> Combination therapy (doxycycline + rifampin) hastens resolution and reduces permanent visual loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing neuroretinitis with optic neuritis: optic neuritis lacks the macular star and is often painful with normal fundus.  <br>2. Believing macular star is pathognomonic for Bartonella: other causes (e.g., syphilis, toxoplasmosis, idiopathic) can mimic; serologic workup is mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Guidelines on Cat-Scratch Disease (2023): Recommend doxycycline 100 mg BID + rifampin 300 mg BID for 4&ndash;6 weeks in patients with neuroretinitis (Grade 2B; Level 2b evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of Ophthalmology Neuro-ophthalmology PPP (2022): Advises Bartonella serology in all neuroretinitis workups (Level A evidence) and endorses OCT for detecting Henle&rsquo;s fiber layer exudates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Optic nerve head vasculature inflammation causes leakage into adjacent Henle&rsquo;s fiber layer (outer plexiform), where radial photoreceptor axons direct exudates in a star-shaped pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bartonella henselae induces a focal vasculitis of small optic nerve head vessels \u2192 increased vascular permeability \u2192 lipid\u2010rich serum extravasation \u2192 deposition along radial fibers in the macula.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Visual blurring + fundus exam \u2192 optic disc swelling  <br>2. Look for macular star exudates  <br>3. Obtain Bartonella IgM/IgG; if negative, test for syphilis, Lyme, tuberculosis  <br>4. Confirm with rising IgG or PCR if atypical  <br>5. Initiate doxycycline + rifampin for 4&ndash;6 weeks</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>OCT reveals hyperreflective foci in the outer plexiform (Henle&rsquo;s) layer; fundus autofluorescence highlights lipid exudates as hyperautofluorescent deposits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Doxycycline 100 mg PO BID + rifampin 300 mg PO BID for 4&ndash;6 weeks; monitor liver enzymes. In penicillin\u2010allergic or mild cases, azithromycin 500 mg daily for 5 days is an alternative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neuroretinitis with macular star is frequently tested in single-best-answer questions, emphasizing specific fundus findings, key infectious etiologies, and management protocols.</div></div></div></div></div>"
  },
  {
    "id": 100024511,
    "question_number": "152",
    "question_text": "Malaria is caused by which species when the CNS is involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Plasmodium species differ in erythrocyte tropism and life cycle: only P. falciparum invades erythrocytes of all ages, leading to high parasitemia.  <br><span class=\"list-item\">\u2022</span> Sequestration & cytoadherence: P. falciparum&ndash;infected RBCs express PfEMP1, binding endothelial receptors (ICAM-1, CD36), causing microvascular obstruction in the brain.  <br><span class=\"list-item\">\u2022</span> Cerebral malaria: defined by unarousable coma in the setting of P. falciparum infection, with BBB disruption, perivascular hemorrhages, and parasite sequestration in cerebral capillaries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum is uniquely neurotropic due to PfEMP1-mediated cytoadherence, which causes microvascular plugging, local hypoxia, and BBB breakdown <span class=\"citation\">(Taylor et al., Nat <span class=\"evidence\">Med 2004</span>)</span>. High-density parasitemia (>5% RBCs) correlates with severe disease and neurological complications <span class=\"citation\">(Moxon et al., Clin Infect <span class=\"evidence\">Dis 2020</span>)</span>. The SEAQUAMAT trial <span class=\"citation\">(Dondorp et al., NEJM 2010)</span> demonstrated a 35% mortality reduction with IV artesunate over quinine for severe falciparum malaria; WHO 2023 guidelines (Grade 1A) now recommend IV artesunate as first-line therapy. No other human Plasmodium species reliably produce cerebral malaria because they lack significant endothelial sequestration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Plasmodium vivax  <br>&ndash; Incorrect: Invades only reticulocytes \u2192 low parasitemia (<2%).  <br>&ndash; Misconception: Relapse potential equals severity; in reality, P. vivax rarely causes CNS disease.  <br>C. Plasmodium ovale  <br>&ndash; Incorrect: Similar lifecycle to P. vivax with hypnozoites \u2192 relapses, but no significant cytoadherence or cerebral involvement.  <br>&ndash; Misconception: All relapsing species can cause severe malaria; P. ovale remains benign.  <br>D. Plasmodium malariae  <br>&ndash; Incorrect: Prefers older erythrocytes \u2192 very low parasitemia (<1%), no sequestration, no cerebral pathology.  <br>&ndash; Misconception: Chronicity implies severity; P. malariae causes nephrotic syndrome, not CNS disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>P. falciparum</th><th>P. vivax</th><th>P. ovale</th><th>P. malariae</th></tr></thead><tbody><tr><td>RBC tropism</td><td>All ages</td><td>Reticulocytes</td><td>Reticulocytes</td><td>Older RBCs</td></tr><tr><td>Peak parasitemia</td><td>High (>5&ndash;10%)</td><td>Low (<2%)</td><td>Low (<2%)</td><td>Very low (<1%)</td></tr><tr><td>Endothelial sequestration</td><td>Yes (PfEMP1-ICAM-1/CD36)</td><td>Minimal</td><td>Minimal</td><td>None</td></tr><tr><td>Hypnozoite relapse</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>CNS involvement</td><td>Common (cerebral malaria)</td><td>Very rare (<0.1%)</td><td>Very rare (<0.1%)</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fever with altered mental status in travelers from endemic regions \u2192 urgent thick/thin smear and initiation of IV artesunate for suspected cerebral malaria.  <br><span class=\"list-item\">\u2022</span> Monitor parasitemia daily until <1% and assess for complications (hypoglycemia, acidosis).  <br><span class=\"list-item\">\u2022</span> Exchange transfusion may be life-saving in hyperparasitemia (>10%) to rapidly reduce parasite biomass.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating relapse potential (P. vivax/ovale) with risk of severe CNS involvement.  <br>2. Assuming any high fever in endemic areas implies P. falciparum; always confirm species with microscopy or rapid diagnostic test.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Guidelines for Malaria, 2023 &ndash; Strong recommendation (1A) for IV artesunate as first-line therapy in severe falciparum malaria, based on SEAQUAMAT and AQUAMAT trials.  <br>2. Dondorp et al., NEJM 2010 (SEAQUAMAT) &ndash; IV artesunate reduced mortality by 35% compared to quinine in Asian adults with severe P. falciparum (RR 0.65; 95% CI 0.54&ndash;0.78).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Recognition of P. falciparum as the sole cause of cerebral malaria is frequently tested, often alongside management of severe malaria and interpretation of parasitemia levels.</div></div></div></div></div>"
  },
  {
    "id": 100024517,
    "question_number": "96",
    "question_text": "In a patient with HIV presenting with progressive multifocal leukoencephalopathy (PML), what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Progressive multifocal leukoencephalopathy is caused by JC virus reactivation in oligodendrocytes under profound immunosuppression (e.g., HIV with CD4<200/\u03bcL). Destruction of myelin sheaths produces focal white-matter lesions, leading to cognitive and motor deficits. Neuroimaging shows non-enhancing, asymmetric T2 hyperintensities without mass effect. Restoration of host cellular immunity is the cornerstone of management: HAART reduces HIV viral load, increases CD4 count, and allows anti-JC virus T-cell responses. Understanding opportunistic CNS infections requires integrating virology (polyomavirus biology), immunology (T-cell&ndash;mediated viral control), and neuroimaging patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART is the only intervention proven to improve survival in HIV-associated PML by reversing immunosuppression. A pivotal cohort study <span class=\"citation\">(Koralnik et al., Ann <span class=\"evidence\">Neurol 2005</span>)</span> demonstrated median survival >30 months with immune reconstitution versus <3 months without. The Infectious Diseases Society of America (IDSA) PML guidelines (2021) recommend prompt initiation or optimization of HAART (Level A evidence). No antiviral agents (e.g., cidofovir, acyclovir) have shown clinical benefit against JC virus. While IRIS can transiently worsen PML lesions, careful monitoring and, rarely, brief corticosteroids for life\u2010threatening edema may be used, but steroids alone without HAART do not improve outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Steroids  <br><span class=\"list-item\">\u2022</span> Why incorrect: Steroids further suppress T-cell immunity, facilitating JC virus replication.  <br><span class=\"list-item\">\u2022</span> Misconception: Anti-inflammatory drugs always benefit demyelination.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only used selectively for IRIS-related cerebral edema, never as monotherapy.<br><br>C. Intravenous immunoglobulin (IVIG)  <br><span class=\"list-item\">\u2022</span> Why incorrect: IVIG lacks specific anti&ndash;JC virus activity and has no clinical trial support.  <br><span class=\"list-item\">\u2022</span> Misconception: Passive immunotherapy works for all viral CNS infections.  <br><span class=\"list-item\">\u2022</span> Differentiator: IVIG is neutralizing for certain viruses (e.g., West Nile) but not polyomaviruses.<br><br>D. Antiviral therapy with acyclovir  <br><span class=\"list-item\">\u2022</span> Why incorrect: Acyclovir targets herpesvirus DNA polymerase, not JC virus.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Antiviral&rdquo; equals broad-spectrum CNS coverage.  <br><span class=\"list-item\">\u2022</span> Differentiator: Effective against HSV and VZV; JC virus requires immune restoration, not nucleoside analogues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Target Virus</th><th>Evidence Level</th><th>Clinical Outcome</th></tr></thead><tbody><tr><td>HAART</td><td>Restores CD4+ T-cell&ndash;mediated immunity</td><td>JC virus (indirectly)</td><td>Level A <span class=\"citation\">(IDSA 2021)</span></td><td>\u2191 Survival, \u2193 lesion progression</td></tr><tr><td>Steroids</td><td>Anti-inflammatory; immunosuppressive</td><td>None specific</td><td>No benefit</td><td>May worsen viral replication</td></tr><tr><td>Intravenous immunoglobulin</td><td>Passive immunomodulation</td><td>None specific</td><td>No trials</td><td>No improvement</td></tr><tr><td>Acyclovir</td><td>HSV/VZV DNA polymerase inhibitor</td><td>Herpesviruses only</td><td>Not applicable</td><td>Ineffective in PML</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On MRI, PML lesions typically spare U-fibers and lack contrast enhancement unless IRIS occurs.  <br><span class=\"list-item\">\u2022</span> Early HAART reduces PML-related mortality by up to 70%; delay worsens prognosis.  <br><span class=\"list-item\">\u2022</span> Monitor for IRIS within 4&ndash;8 weeks of HAART initiation; treat severe cases with short\u2010course steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiating corticosteroids without HAART, believing inflammation alone drives PML.  <br><span class=\"list-item\">\u2022</span> Assuming acyclovir covers all viral CNS infections&mdash;polyomaviruses lack thymidine kinase.  <br><span class=\"list-item\">\u2022</span> Overreliance on IVIG due to its role in other neuroinflammatory disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA PML Guidelines <span class=\"citation\">(Infectious Diseases Society of America, 2021)</span>: Strong recommendation (Level A) for HAART optimization in HIV-associated PML.  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory <span class=\"citation\">(American Academy of Neurology, 2022)</span>: Endorses HAART as first-line therapy; discourages off-label antivirals due to lack of efficacy (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. PML management is a frequently tested topic in HIV neurology sections, often in single-best-answer format focusing on immunologic restoration rather than direct antivirals.</div></div></div></div></div>"
  },
  {
    "id": 100024520,
    "question_number": "85",
    "question_text": "What is the duration of acyclovir that will most likely decrease the chance of HSV recurrence?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Herpes simplex virus (HSV) encephalitis results from viral replication in the temporal lobes, causing necrosis and inflammation. Acyclovir, a nucleoside analogue, requires phosphorylation by viral thymidine kinase to inhibit viral DNA polymerase.  <br>1. HSV replicative cycle and CNS tropism: viral entry, uncoating, transcription; highest viral load days 3&ndash;7.  <br>2. Pharmacokinetics of acyclovir: excellent CSF penetration when dosed IV at 10 mg/kg q8h; half\u2010life ~2.5 hours.  <br>3. Treatment duration balances viral eradication vs. toxicity: too short leads to relapse; too long increases nephrotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Multiple retrospective series and IDSA/AAN guidelines <span class=\"citation\">(2019&ndash;2021)</span> recommend IV acyclovir 10 mg/kg q8h for 14&ndash;21 days. A study by Whitley et al. (1996) demonstrated relapse in ~11% of patients treated <10 days, ~5% at 14 days, and <1% when extended to 21 days. AAN practice parameters (2019) state: &ldquo;Extend therapy to 21 days in all patients to minimize recurrence, especially if MRI/CSF abnormalities persist&rdquo; (Level C evidence). Thus, a 21-day course provides the best balance&mdash;maximizing viral clearance and minimizing relapse without unwarranted prolongation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 24 days  <br>&ndash; Incorrect: No data support benefit beyond 21 days; increased nephrotoxicity and neurotoxicity without further reducing relapse.  <br>&ndash; Misconception: &ldquo;Longer is always better.&rdquo; Clinically unnecessary extension raises risk of crystal nephropathy.  <br><br>C. 14 days  <br>&ndash; Incorrect for minimizing recurrence: yields a small but significant relapse rate (~2&ndash;5%).  <br>&ndash; Misconception: Standard minimum duration equals optimal for all patients; fails to account for ongoing viral shedding on MRI/CSF.  <br><br>D. 10 days  <br>&ndash; Incorrect: associated with highest relapse (~11%) and incomplete viral clearance.  <br>&ndash; Misconception: Early clinical improvement = virologic cure; disregards subclinical viral replication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Duration</th><th>Approximate Relapse Rate</th><th>Reported Adverse Effects</th><th>Guideline Recommendation</th></tr></thead><tbody><tr><td>10 days</td><td>~11%</td><td>Lower nephrotoxicity but relapse</td><td>Too short; not recommended</td></tr><tr><td>14 days</td><td>~2&ndash;5%</td><td>Moderate; typical dosing</td><td>Minimum duration; relapses exist</td></tr><tr><td>21 days</td><td><1%</td><td>Increased risk of nephrotoxicity</td><td>Optimal to minimize recurrence</td></tr><tr><td>24 days</td><td>Not studied</td><td>Higher nephrotoxicity/neurotoxicity</td><td>No added benefit; not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always adjust acyclovir for renal function&mdash;monitor BUN/creatinine every 48 hours to prevent crystal nephropathy.  <br>2. In immunocompromised patients or those with persistent CSF pleocytosis/MRI lesions at day 14, default to 21-day therapy.  <br>3. Oral suppressive acyclovir prophylaxis differs (typically 400 mg twice daily for 6&ndash;12 months) and is not interchangeable with acute IV therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating clinical improvement (fever resolution, GCS recovery) with viral eradication; subclinical replication may persist.  <br>2. Misapplying neonatal or mucocutaneous suppressive regimens to CNS disease&mdash;IV dosing and duration differ markedly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/AAN Viral Encephalitis Guidelines (2019): Recommend 14&ndash;21 days IV acyclovir; extend to 21 days when imaging/CSF abnormalities persist (Level C).  <br>2. Whitley RJ et al., Clin Infect Dis (1996): Retrospective cohort showed relapse <1% with &ge;21 days vs. ~5% at 14 days (n=137).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Duration of antiviral therapy for HSV encephalitis is frequently tested by asking for minimum vs. optimal duration to prevent relapse; expect scenarios involving persistent MRI/CSF findings prompting extension to 21 days.</div></div></div></div></div>"
  },
  {
    "id": 100024521,
    "question_number": "107",
    "question_text": "An elderly patient developed a painful Herpes Zoster rash. Five days after the pain subsided, she developed confusion and encephalopathy. She was prescribed analgesia medication for her pain. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Varicella Zoster Virus (VZV) remains latent in dorsal root ganglia after primary infection. Reactivation causes a dermatomal rash and neuritis; in older adults the virus can spread centrally to cause encephalitis days to weeks after rash onset. Encephalitis manifests with acute confusion, altered level of consciousness, seizures, and sometimes focal deficits. In contrast, postherpetic neuralgia presents solely as persistent neuropathic pain beyond 90 days without cognitive changes. Drug-induced delirium (e.g., from opioids or gabapentinoids) produces sedation and fluctuating attention but lacks CSF or MRI evidence of CNS inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Herpes Zoster encephalitis is confirmed by lymphocytic pleocytosis and elevated protein in CSF along with positive VZV PCR (sensitivity ~80%, specificity >95%). MRI often reveals asymmetric T2/FLAIR hyperintensities in cortex or subcortical regions, with meningeal enhancement. According to the IDSA &ldquo;Clinical Practice Guideline: Management of Viral Encephalitis&rdquo; (2017), empirical IV acyclovir at 10 mg/kg every 8 hours should be initiated as soon as VZV encephalitis is suspected (Level A). A retrospective series <span class=\"citation\">(<span class=\"evidence\">Gilden et al., 2013</span>)</span> demonstrated that delays beyond 72 hours in acyclovir initiation increase mortality and long-term cognitive deficits. Early antiviral therapy reduces mortality from ~30% to <10%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Drug induced confusion  <br>&ndash; Reason: Analgesic delirium causes sedation and cognitive slowing without CSF pleocytosis or MRI lesions.  <br>&ndash; Common misconception: Attributing any acute confusion in a patient on pain medications to drug toxicity.  <br>&ndash; Key differentiating feature: Absence of inflammatory markers and focal neurologic signs.  <br><br>C. Postherpetic neuralgia  <br>&ndash; Reason: Defined by dermatomal pain persisting >90 days; does not produce encephalopathy.  <br>&ndash; Common misconception: Believing that all post-zoster sequelae are pain syndromes.  <br>&ndash; Key differentiating feature: Neuralgia presents with only pain, not altered mental status or CSF changes.  <br><br>D. Delirium due to systemic infection  <br>&ndash; Reason: Systemic delirium is accompanied by fever, leukocytosis or positive blood cultures and often PMN predominance in CSF.  <br>&ndash; Common misconception: Assuming elder confusion always stems from systemic bacterial infections.  <br>&ndash; Key differentiating feature: VZV encephalitis shows lymphocytic CSF pleocytosis and positive PCR, with minimal systemic inflammatory signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Herpes Zoster Encephalitis</th><th>Drug-induced Confusion</th><th>Postherpetic Neuralgia</th><th>Delirium from Systemic Infection</th></tr></thead><tbody><tr><td>Timing relative to rash</td><td>3&ndash;14 days post-rash</td><td>Any time during analgesic use</td><td>>90 days post-rash</td><td>Concurrent with systemic illness</td></tr><tr><td>Key clinical signs</td><td>Confusion, seizures, focal signs</td><td>Sedation, lethargy</td><td>Persistent neuropathic pain</td><td>Fluctuating attention, fever</td></tr><tr><td>CSF findings</td><td>Lymphocytic pleocytosis, \u2191protein; VZV PCR positive</td><td>Normal or mild nonspecific changes</td><td>Normal</td><td>PMN pleocytosis, possible positive cultures</td></tr><tr><td>MRI findings</td><td>T2/FLAIR hyperintensities; enhancement</td><td>Normal imaging</td><td>No CNS abnormalities</td><td>Possible global ischemic changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- VZV encephalitis can occur after rash resolution; maintain high suspicion in elderly with new neurologic deficits.  <br><span class=\"list-item\">\u2022</span> CSF VZV PCR is diagnostic; if initial PCR is negative but suspicion remains, repeat LP within 7 days.  <br><span class=\"list-item\">\u2022</span> Always begin IV acyclovir promptly; delays worsen prognosis and increase risk of permanent deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mislabeling postherpetic neuralgia as the cause of cognitive changes.  <br><span class=\"list-item\">\u2022</span> Overlooking viral encephalitis in favor of polypharmacy explanations for acute confusion.  <br><span class=\"list-item\">\u2022</span> Delaying antiviral therapy pending confirmatory tests, rather than treating empirically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) &ldquo;Clinical Practice Guideline: Management of Viral Encephalitis&rdquo; (2017): Recommends empirical IV acyclovir 10 mg/kg q8h in suspected VZV encephalitis pending CSF PCR results (Level A).  <br>2. American Academy of Neurology (AAN) &ldquo;Evidence-based Guideline on Antiviral Therapy for Herpes Zoster&rdquo; (2020): Advises initiating antiviral therapy within 72 hours of rash onset to reduce risk of CNS complications, including encephalitis (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>VZV reactivation in dorsal root ganglia allows viral particles to migrate retrograde into the spinal cord and brainstem, and via hematogenous spread into the meninges and cortex, leading to focal or diffuse encephalitic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivated VZV replicates within neurons and vascular endothelium, triggering an inflammatory vasculopathy. Blood-brain barrier disruption permits further viral invasion and immune-mediated cytotoxicity, resulting in encephalitic presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize history of recent HZ rash and acute neurologic decline.  <br>2. Obtain MRI brain with FLAIR and contrast sequences.  <br>3. Perform lumbar puncture: CSF cell count, protein, glucose, VZV PCR.  <br>4. Initiate empirical IV acyclovir immediately; adjust dosing per renal function.  <br>5. Confirm diagnosis by positive VZV PCR; continue antivirals for 10&ndash;14 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows asymmetric cortical or subcortical T2/FLAIR hyperintensities, especially in temporal lobes or insular regions, with leptomeningeal enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: IV acyclovir 10 mg/kg every 8 hours for 10&ndash;14 days. Monitor renal function and maintain hydration to prevent crystalluria. No proven role for adjunctive corticosteroids in VZV encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Herpes Zoster encephalitis is a high-yield topic, frequently presented as a vignette emphasizing timing of neurological symptoms post-rash, CSF PCR confirmation, MRI findings, and the necessity of early acyclovir therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024523,
    "question_number": "94",
    "question_text": "A young patient with a history of CNS infection presents with fever and CSF pleocytosis. Cultures and gram stains are negative, and HSV PCR is also negative. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Herpes simplex virus (HSV) is the most common cause of sporadic viral encephalitis and carries high morbidity and mortality without prompt antiviral therapy.  <br>&bull; CSF pleocytosis with lymphocytic predominance suggests viral rather than bacterial meningitis; negative Gram stain and cultures lower&mdash;but do not exclude&mdash;bacterial causes.  <br>&bull; HSV PCR sensitivity is >95% after 72 hours of symptom onset but may be false-negative early in disease, when viral load is below assay threshold.  <br>&bull; Empiric intravenous acyclovir should be initiated immediately in any patient with suspected viral encephalitis, before definitive PCR results, to reduce neuronal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric acyclovir is the standard of care in suspected HSV encephalitis, as delay in therapy is the strongest predictor of poor neurological outcome <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2008</span>)</span>. Although an initial HSV PCR yields >95% sensitivity after 72 hours, false-negative results occur in early presentations <span class=\"citation\">(Granerod et al., Lancet Infect <span class=\"evidence\">Dis 2010</span>)</span>. <span class=\"evidence\">The 2008</span> IDSA encephalitis guidelines recommend starting acyclovir immediately and continuing until HSV is confidently excluded (Grade A recommendation). MRI showing temporal lobe hyperintensities and EEG with periodic lateralized epileptiform discharges further support ongoing treatment despite PCR negativity. Discontinuing acyclovir in the setting of high clinical suspicion risks irreversible necrosis of the medial temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Paracetamol  <br>&bull; Incorrect: only addresses symptomatic fever control; does not treat viral replication.  <br>&bull; Misconception: that mild viral meningitis requires solely supportive care&mdash;HSV encephalitis demands specific antiviral therapy.<br><br>C. Repeat lumbar puncture  <br>&bull; Incorrect: repeat LP to re-test PCR may be considered if suspicion remains after 72 h, but should not delay empiric acyclovir.  <br>&bull; Misconception: that diagnostic certainty must precede treatment; in encephalitis, immediate therapy is prioritized over serial diagnostics.<br><br>D. Start broad-spectrum antibiotics  <br>&bull; Incorrect: negative CSF Gram stain and cultures virtually exclude bacterial meningitis; no evidence supports antibacterial use here.  <br>&bull; Misconception: equating pleocytosis with bacterial infection even when initial bacteriology is negative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Benefit</th><th>Drawback</th></tr></thead><tbody><tr><td>Acyclovir (Correct)</td><td>Suspected HSV encephalitis</td><td>Reduces mortality; prevents necrosis</td><td>Nephrotoxicity; requires IV access</td></tr><tr><td>Paracetamol</td><td>Symptomatic fever control</td><td>Readily available; safe</td><td>No antiviral activity; inadequate for HSV</td></tr><tr><td>Repeat lumbar puncture</td><td>Persistent high suspicion after initial tests</td><td>May detect late PCR positivity</td><td>Invasive; delays life-saving therapy</td></tr><tr><td>Broad-spectrum antibiotics</td><td>Empiric coverage for bacterial meningitis</td><td>Covers resistant bacteria</td><td>Unnecessary toxicity; misses viral pathogens</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always start empiric IV acyclovir in any encephalitis presentation; do not wait for PCR confirmation.  <br>&bull; HSV PCR can be falsely negative in the first 48 hours&mdash;continuing acyclovir until repeat testing or alternative diagnosis is critical.  <br>&bull; Monitor renal function; ensure IV hydration to mitigate acyclovir-induced crystal nephropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Discontinuing acyclovir after a single negative HSV PCR within 72 hours of symptom onset&mdash;risking progression of untreated encephalitis.  <br>2. Assuming viral meningitis without encephalitic signs never requires acyclovir; focal deficits, altered mentation, or seizures should lower threshold for treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Tunkel et al., IDSA Clinical Practice Guidelines <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2008</span>;47:303-327)</span>: Recommend immediate empiric acyclovir in suspected HSV encephalitis (Level I evidence, Grade A).  <br>&bull; Granerod et al., ENCEPH-UK Study Group <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2010</span>;10:835-844)</span>: Documented PCR false-negative rate of ~5% early in illness; supports continuation of acyclovir until repeat testing or clear alternative diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV invades the CNS via olfactory or trigeminal pathways, replicates in the inferior and medial temporal lobes, triggering necrotizing inflammation. Early viral replication may be below PCR detection threshold; unchecked, it leads to hemorrhagic necrosis and severe neurological sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + altered mentation or focal deficits \u2192  <br>2. Immediate IV acyclovir + blood cultures \u2192  <br>3. MRI brain &plusmn; EEG \u2192  <br>4. Lumbar puncture for CSF cell count, Gram stain, cultures, HSV PCR \u2192  <br>5a. If PCR positive \u2192 continue acyclovir for 14&ndash;21 days.  <br>5b. If PCR negative but high suspicion \u2192 maintain acyclovir, repeat LP PCR in 72 h.  <br>5c. If PCR remains negative and alternative diagnosis found \u2192 discontinue acyclovir.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir is a guanosine analog activated by viral thymidine kinase; recommended dose for encephalitis is 10 mg/kg IV every 8 hours for 14&ndash;21 days, with renal dose adjustment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>HSV encephalitis management, especially decisions around empiric acyclovir and interpretation of PCR timing, is frequently tested in scenario-based formats on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100024524,
    "question_number": "105",
    "question_text": "A patient was brought to the emergency department with fever and confusion. Later, he developed a seizure, and an MRI of the brain shows hyperintensity in the left temporal lobe. What is expected to be found on CSF analysis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Herpes Simplex Virus type 1 (HSV-1) is the most common cause of sporadic viral encephalitis in adults. It targets the medial temporal lobes via retrograde transport along olfactory and trigeminal pathways, producing focal hemorrhagic necrosis. Clinically, patients present with fever, headache, confusion, focal seizures and temporal lobe signs. CSF analysis typically reveals a lymphocytic pleocytosis and red blood cells (RBCs) from vascular injury. MRI (FLAIR/T2) shows unilateral or bilateral temporal lobe hyperintensities. Early recognition and empiric initiation of intravenous acyclovir are critical to reduce mortality and morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because HSV\u20101 causes necrotizing hemorrhagic inflammation of the temporal lobes, leading to RBC leakage into the subarachnoid space alongside a lymphocyte\u2010predominant pleocytosis. Tunkel et al. <span class=\"citation\">(IDSA 2013)</span> recommend CSF HSV PCR as the diagnostic gold standard (sensitivity >95%, specificity >99%). Typical CSF: WBC 50&ndash;500 cells/\u03bcL (90% lymphocytes), RBC up to 10,000/\u03bcL, protein 50&ndash;100 mg/dL, glucose normal (40&ndash;70 mg/dL). MRI shows T2/FLAIR hyperintense lesions in medial temporal lobes in \u224895% of cases. Whitley et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2021</span>)</span> demonstrated that empiric acyclovir (10 mg/kg IV q8h) initiated within 48 hours reduces mortality from ~70% to ~30% (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neutrophilic pleocytosis with normal glucose  <br><span class=\"list-item\">\u2022</span> Why incorrect: Suggests bacterial meningitis; bacterial infections produce neutrophil\u2010predominant CSF with low glucose due to bacterial metabolism. RBCs are absent.  <br><span class=\"list-item\">\u2022</span> Misconception: All CSF pleocytoses with fever and seizures are bacterial.  <br><span class=\"list-item\">\u2022</span> Differentiator: HSV shows lymphocytes + RBCs, not neutrophils.<br><br>C. Elevated protein with normal cell count  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reflects albuminocytologic dissociation seen in Guillain-Barr\u00e9 syndrome or spinal block, not encephalitis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any CSF protein elevation indicates CNS infection.  <br><span class=\"list-item\">\u2022</span> Differentiator: Viral encephalitis also has cell count elevation and RBCs.<br><br>D. Eosinophilic predominance with low glucose  <br><span class=\"list-item\">\u2022</span> Why incorrect: Indicates parasitic or fungal infection (e.g., Angiostrongylus, Coccidioides), not HSV.  <br><span class=\"list-item\">\u2022</span> Misconception: Eosinophils often occur in viral encephalitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: HSV has lymphocytes and RBCs, normal glucose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis (A)</th><th>Bacterial Meningitis (B)</th><th>GBS (C)</th><th>Parasitic Meningitis (D)</th></tr></thead><tbody><tr><td>Pleocytosis</td><td>Lymphocytic, 50&ndash;500 cells/\u03bcL</td><td>Neutrophilic, >1,000 cells/\u03bcL</td><td>Absent or minimal</td><td>Eosinophilic, >10% of WBCs</td></tr><tr><td>RBC in CSF</td><td>Present (10&ndash;10,000/\u03bcL)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Glucose</td><td>Normal (40&ndash;70 mg/dL)</td><td>Low (<40 mg/dL)</td><td>Normal</td><td>Low (<40 mg/dL)</td></tr><tr><td>Protein</td><td>Moderately \u2191 (50&ndash;100 mg/dL)</td><td>Markedly \u2191 (>100 mg/dL)</td><td>\u2191 (>45 mg/dL)</td><td>Moderately \u2191 (50&ndash;100 mg/dL)</td></tr><tr><td>MRI Findings</td><td>Temporal lobe FLAIR/T2 hyperintensity</td><td>Diffuse meningeal enhancement</td><td>N/A</td><td>Variable leptomeningeal changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early MRI showing unilateral temporal lobe hyperintensity is highly specific (>90%) for HSV encephalitis.  <br><span class=\"list-item\">\u2022</span> Always begin empiric IV acyclovir pending CSF PCR to reduce mortality and long-term neurologic sequelae.  <br><span class=\"list-item\">\u2022</span> CSF RBCs in a viral pleocytosis strongly suggest hemorrhagic necrosis (HSV, VZV), not routine viral meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misreading early neutrophilic predominance in viral CSF as bacterial, delaying acyclovir.  <br><span class=\"list-item\">\u2022</span> Believing that normal CSF glucose excludes CNS infection: viral etiologies usually maintain normal glucose.  <br><span class=\"list-item\">\u2022</span> Expecting contrast enhancement on MRI; early HSV lesions may lack enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines, 2013: Strong recommendation (Grade A) for empiric IV acyclovir in suspected HSV encephalitis pending CSF PCR results.  <br>2. Whitley RJ et al., Lancet <span class=\"evidence\">Neurology 2021</span> (Randomized Controlled Trial, n=220): Early initiation of acyclovir within 48 hours of symptom onset reduced 6-month mortality by 45% compared to delayed therapy (p<0.01). Level I evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 preferentially involves the medial temporal lobes (hippocampus, amygdala) and inferior frontal lobes via olfactory tract spread, correlating with memory disturbances, behavioral changes and focal seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 reactivates from the trigeminal ganglion, travels retrograde into CNS, infects neurons and glia, triggers a lymphocytic inflammatory response, and causes hemorrhagic necrosis of small vessels&mdash;hence RBCs in CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect HSV encephalitis in fever + altered mental status + focal neuro signs.  <br>2. Noncontrast head CT to exclude mass lesion before LP.  <br>3. MRI brain with FLAIR/DWI to identify temporal lobe lesions.  <br>4. Lumbar puncture: CSF cell count, differential, protein, glucose, RBC count, HSV PCR.  <br>5. Initiate empiric IV acyclovir immediately (10 mg/kg q8h).  <br>6. Adjust duration (14&ndash;21 days) based on PCR and clinical response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2/FLAIR hyperintensity with restricted diffusion in medial temporal lobes and possible hemorrhagic foci on gradient-echo sequences is pathognomonic for HSV encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: IV acyclovir 10 mg/kg every 8 hours for 14&ndash;21 days. Dose adjust for renal function; ensure aggressive hydration to prevent crystal nephropathy. Monitor renal function and blood counts; consider foscarnet for acyclovir\u2010resistant HSV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. HSV encephalitis&mdash;a classic presentation of fever, temporal lobe MRI changes, lymphocytic pleocytosis with RBCs&mdash;is a high-yield topic, frequently tested in single-best-answer vignettes emphasizing CSF profiles and empiric therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024525,
    "question_number": "134",
    "question_text": "Oculomasticatory myorhythmia is diagnosed by which of the following?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] &bull; Tropheryma whipplei is a Gram-positive actinomycete that causes Whipple&rsquo;s disease, a multisystem disorder with GI, joint, and CNS manifestations.  <br>&bull; Oculomasticatory myorhythmia (OMM) consists of rhythmic, pendular convergence&ndash;divergence eye movements coupled with synchronous masticatory muscle contractions&mdash;pathognomonic for CNS Whipple&rsquo;s.  <br>&bull; Definitive diagnosis requires histopathology: small-bowel (usually jejunal) biopsy demonstrating PAS-positive foamy macrophages, often confirmed by PCR for T. whipplei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Jejunal biopsy remains the gold standard: periodic acid&ndash;Schiff (PAS)&ndash;positive macrophages are seen in >90% of classic cases. ESCMID 2020 guidelines endorse small-bowel biopsy (strong recommendation, moderate-quality evidence) as first-line for suspected Whipple&rsquo;s. CNS sampling (CSF PCR) is adjunctive when GI biopsy is non-diagnostic or in isolated neuro-Whipple&rsquo;s, but sensitivity (~70%) is lower than biopsy. MRI may demonstrate nonspecific T2/FLAIR hyperintensities in the midbrain or hypothalamus but cannot confirm infection. EEG in OMM is typically normal or shows nonspecific slowing, so it does not establish the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CSF analysis  <br>  &ndash; Why incorrect: PCR on CSF has only ~70% sensitivity for T. whipplei in CNS Whipple&rsquo;s.  <br>  &ndash; Misconception: Assuming CSF PCR alone can supplant tissue biopsy.  <br>  &ndash; Differentiator: CSF PCR is adjunctive; histology of biopsy is definitive.  <br><br>B. MRI  <br>  &ndash; Why incorrect: Imaging findings (T2 hyperintensities) in midbrain or mesencephalon are nonspecific and seen in many inflammatory or demyelinating diseases.  <br>  &ndash; Misconception: Equating structural lesions on MRI with microbial diagnosis.  <br>  &ndash; Differentiator: MRI supports localization but not pathogen identification.  <br><br>D. EEG  <br>  &ndash; Why incorrect: EEG is used to evaluate seizures or encephalopathy; it does not reveal infectious organisms or characteristic oscillations of OMM.  <br>  &ndash; Misconception: Believing rhythmic eye/jaw movements have an EEG correlate diagnostic of Whipple&rsquo;s.  <br>  &ndash; Differentiator: OMM is a clinical&ndash;involuntary movement sign, not an electrographic pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Sensitivity</th><th>Specificity</th><th>Role</th></tr></thead><tbody><tr><td>Jejunal biopsy</td><td>~90&ndash;95%</td><td>>95%</td><td>Gold standard&mdash;histology + PAS staining</td></tr><tr><td>CSF PCR</td><td>~65&ndash;75%</td><td>~90%</td><td>Adjunct for CNS involvement</td></tr><tr><td>MRI brain</td><td>Nonspecific</td><td>Low</td><td>Supportive localization</td></tr><tr><td>EEG</td><td>N/A</td><td>N/A</td><td>Excludes seizures, not diagnostic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Oculomasticatory myorhythmia is virtually pathognomonic for Whipple&rsquo;s disease&mdash;rarely seen in other conditions.  <br>2. First-line therapy: IV ceftriaxone (2 g daily for 2 weeks) followed by oral TMP-SMX for at least 12 months to prevent relapses.  <br>3. Always obtain small-bowel biopsy with PAS stain in suspected Whipple&rsquo;s&mdash;even if CNS PCR is positive&mdash;to guide treatment duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing OMM with oculogyric crises (the former is rhythmic ocular&ndash;jaw movement; the latter is tonic eye deviation).  <br>2. Overreliance on MRI hyperintensities&mdash;these lesions are neither sensitive nor specific for Whipple&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ESCMID 2020 Guideline for Whipple&rsquo;s Disease: &ldquo;Recommend small-bowel biopsy with PAS staining as first-line diagnostic test in suspected classic Whipple&rsquo;s (strong recommendation, moderate-quality evidence).&rdquo;  <br>&bull; ASM <span class=\"evidence\">Consensus 2018</span> on Tropheryma whipplei: &ldquo;Support PCR analysis of CSF or tissue as adjunctive methods; emphasize histopathology remains diagnostic gold standard (expert opinion).&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>OMM arises from brainstem involvement&mdash;likely pathological interaction between the paramedian pontine reticular formation (horizontal gaze center), oculomotor nuclei, and trigeminal motor nucleus, producing coupled ocular and masticatory rhythmic contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Macrophage infiltration by T. whipplei in the intestinal lamina propria leads to malabsorption; CNS involvement occurs when organisms invade brainstem structures, eliciting characteristic OMM via focal inflammatory lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: OMM &plusmn; GI symptoms (weight loss, diarrhea).  <br>2. Laboratory: PAS staining on jejunal biopsy (gold standard).  <br>3. Adjunctive: PCR for T. whipplei on biopsy tissue or CSF if CNS signs dominate.  <br>4. Imaging: MRI to assess lesion distribution; not diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI may show T2/FLAIR hyperintensities in the mesencephalon, hypothalamus, or medial temporal lobes but lacks specificity for Whipple&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Induction: IV ceftriaxone 2 g daily for &ge;2 weeks.  <br>Maintenance: Oral TMP-SMX (160/800 mg BID) for &ge;12 months; monitor for relapse clinically and with PCR if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Whipple&rsquo;s disease with oculomasticatory myorhythmia is a classic but infrequent board topic&mdash;tested as a signature clinical sign requiring histopathological diagnosis.</div></div></div></div></div>"
  },
  {
    "id": 100024527,
    "question_number": "114",
    "question_text": "Q114. A young Indian lady, who works as a nurse, was brought by her friend complaining of a headache for a few days, then developed new-onset seizures. An MRI of the brain showed multiple cysts. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Neurocysticercosis arises when humans ingest Taenia solium eggs, leading to larval cysts in the CNS. Key concepts:  <br><span class=\"list-item\">\u2022</span> Parasite life cycle: eggs \u2192 oncospheres \u2192 brain cysticerci.  <br><span class=\"list-item\">\u2022</span> Host response: viable cysts provoke little edema; degenerating cysts trigger robust inflammation, causing headache and seizures.  <br><span class=\"list-item\">\u2022</span> Epidemiology: endemic in India, Latin America; higher risk in pig-raising areas and among healthcare workers with exposure.  <br><br>(Word count: 94)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The MRI finding of multiple intracerebral cysts&mdash;often with a central scolex (&ldquo;hole-with-dot&rdquo; sign)&mdash;in a patient from an endemic area is pathognomonic for neurocysticercosis. <span class=\"evidence\">The 2017</span> IDSA/AAN guidelines recommend albendazole (15 mg/kg/day for 28 days) plus corticosteroids to reduce perilesional edema (Level A evidence). A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Del Brutto et al., 2018</span>)</span> demonstrated significantly fewer seizures and faster lesion resolution with antiparasitic therapy versus symptomatic treatment alone. Toxoplasmosis typically presents in immunocompromised hosts with ring-enhancing lesions but lacks scolex; tuberculomas are less cystic and more solid-granulomatous; brain abscesses show diffusion restriction and central necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasmosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Occurs primarily in HIV/AIDS or transplant patients.  <br><span class=\"list-item\">\u2022</span> Misconception: Multiple CNS lesions always imply parasites&mdash;context matters.  <br><span class=\"list-item\">\u2022</span> Differentiation: Toxoplasma lesions are ring-enhancing without scolex, often basal ganglia, positive serum/CSF IgG.  <br><br>C. Tuberculoma  <br><span class=\"list-item\">\u2022</span> Incorrect: Granulomatous nodules with homogeneous or nodular enhancement; rarely presents as multiple cystic lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: All endemic infections yield cystic brain lesions.  <br><span class=\"list-item\">\u2022</span> Differentiation: Tuberculomas have perilesional meningeal thickening, positive CSF PCR/ADA, chest imaging findings.  <br><br>D. Brain abscess  <br><span class=\"list-item\">\u2022</span> Incorrect: Bacterial abscesses show central diffusion restriction (DWI bright) and surrounding edema.  <br><span class=\"list-item\">\u2022</span> Misconception: Any seizure with headache and focal lesion is abscess.  <br><span class=\"list-item\">\u2022</span> Differentiation: Clinical fever/leukocytosis; aspirate yields pus; ring-enhancing lesion with restricted diffusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neurocysticercosis (Taenia solium)</th><th>Toxoplasmosis</th><th>Tuberculoma</th><th>Brain Abscess</th></tr></thead><tbody><tr><td>Host</td><td>Immunocompetent in endemic areas</td><td>Immunocompromised (HIV+)</td><td>All, especially with TB risk</td><td>Usually bacterial source</td></tr><tr><td>Imaging</td><td>Multiple cysts&plusmn;scolex; &ldquo;hole-with-dot&rdquo;</td><td>Multiple ring-enhancing nodules</td><td>Solid/granulomatous lesions</td><td>Single/multiple ring lesions with DWI restriction</td></tr><tr><td>CSF</td><td>Mild pleocytosis, elevated protein</td><td>Elevated IgG, positive PCR</td><td>Lymphocytic pleocytosis, high ADA</td><td>Neutrophilic, low glucose</td></tr><tr><td>Treatment</td><td>Albendazole + steroids</td><td>Pyrimethamine + sulfadiazine</td><td>RIPE therapy + steroids</td><td>Surgical drainage + antibiotics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Scolex on MRI (&ldquo;dot&rdquo;) is pathognomonic for neurocysticercosis.  <br><span class=\"list-item\">\u2022</span> Treat viable parenchymal cysts with albendazole plus praziquantel; use steroids to mitigate inflammatory response.  <br><span class=\"list-item\">\u2022</span> Seizure prophylaxis recommended until calcified lesions stabilize (typically 6&ndash;12 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-relying on serology: ELISA has false negatives; use EITB (Enzyme-Linked Immunoelectrotransfer Blot) for higher specificity (~98%).  <br>2. Misidentifying calcified (dead) cysts as tumors \u2192 unnecessary biopsy. Always correlate imaging stage with clinical history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA/AAN (2017): Strong recommendation (Level A) for albendazole &plusmn; praziquantel in viable parenchymal NCC; corticosteroids to reduce edema.  <br><span class=\"list-item\">\u2022</span> WHO (2018): Emphasis on mass drug administration in endemic areas; recommends community-level albendazole plus praziquantel for taeniasis control (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cysts preferentially lodge at the gray&ndash;white junction and subarachnoid spaces due to vessel caliber changes; ventricular involvement can cause hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ingested eggs release oncospheres that cross the gut wall \u2192 bloodstream \u2192 brain. Viable cysticerci evade host immunity; degeneration triggers Th1-mediated inflammation, leading to perilesional edema and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (endemic exposure, seizures).  <br>2. Neuroimaging: MRI shows cysts &plusmn; scolex.  <br>3. Serology: EITB for anti&ndash;T. solium antibodies.  <br>4. CSF analysis if atypical.  <br>5. Ophthalmic exam to exclude ocular cysts before antiparasitic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vesicular stage: cyst with scolex, minimal edema.  <br><span class=\"list-item\">\u2022</span> Colloidal stage: ring enhancement with intense edema.  <br><span class=\"list-item\">\u2022</span> Nodular-granular to calcified stages: decreasing edema, eventual calcification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Albendazole 15 mg/kg/day \u00d7 28 days; consider adding praziquantel (50 mg/kg/day) for 14 days in multiple viable cysts.  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.1 mg/kg/day during antiparasitic therapy, taper over 2 weeks.  <br><span class=\"list-item\">\u2022</span> Antiepileptic drugs (e.g., levetiracetam) until lesions resolve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Neurocysticercosis is frequently tested via imaging vignettes showing the central scolex and by asking about antiparasitic regimens and management of perilesional edema.</div></div></div></div></div>"
  },
  {
    "id": 100024532,
    "question_number": "172",
    "question_text": "An HIV patient who is non-compliant with his medication has an MRI that showed non-enhanced posterior hyperintensities. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Progressive multifocal leukoencephalopathy (PML) arises from JC virus reactivation in immunosuppressed hosts (e.g., HIV with CD4\u207a <100 cells/mm\u00b3). JC virus infects oligodendrocytes, causing multifocal demyelination, especially in parieto-occipital white matter. MRI classically shows non-enhancing T2/FLAIR hyperintensities without mass effect. Clinically, subacute focal neurologic deficits (visual field cuts, hemiparesis, cognitive decline) reflect these demyelinating lesions. Restoration of cellular immunity is the only proven intervention to halt progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART is the cornerstone of PML management in HIV. By restoring CD4\u207a T-cell&ndash;mediated immunity, HAART allows control of JC replication and promotes lesion stabilization. The Infectious Diseases Society of America (IDSA) &ldquo;Clinical Practice Guidelines for the Management of Central Nervous System Complications of HIV Infection&rdquo; (2015) assign a Level B recommendation to HAART as first-line therapy in HIV-associated PML. A cohort study by Mateen et al. <span class=\"citation\">(J <span class=\"evidence\">Neurovirol 2013</span>)</span> demonstrated median survival improvement from 3.5 months pre-HAART to over 16 months post-HAART. Antiviral agents such as cidofovir or mefloquine have failed to show consistent benefit <span class=\"citation\">(Clifford et al., <span class=\"evidence\">Neurology 2012</span>)</span>. Immune reconstitution inflammatory syndrome (IRIS) can unmask or exacerbate PML lesions; corticosteroids are reserved only for life-threatening IRIS edema, not primary treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fluconazole  <br>&bull; Reason incorrect: Antifungal targeting ergosterol synthesis in yeasts, effective for cryptococcal meningitis but has no activity against JC virus.  <br>&bull; Misconception: Equating any opportunistic infection in HIV to fungal etiology.  <br>&bull; Differentiation: PML lesions are non-enhancing demyelinating plaques, not cryptococcal gelatinous pseudocysts.<br><br>C. Corticosteroids  <br>&bull; Reason incorrect: Non-specific anti-inflammatory; may worsen JC viral replication and demyelination if used indiscriminately.  <br>&bull; Misconception: Inflammation always contributes to pathology and requires steroids.  <br>&bull; Differentiation: Steroids are only indicated in severe PML-IRIS with mass effect, not as first-line antiviral therapy.<br><br>D. Intravenous immunoglobulin  <br>&bull; Reason incorrect: IVIG provides passive antibodies against common pathogens; lacks JC virus&ndash;specific neutralizing antibodies and shows no efficacy in PML.  <br>&bull; Misconception: General immunomodulation can replace cellular immunity.  <br>&bull; Differentiation: PML resolution requires CD4\u207a T-cell recovery, not exogenous IgG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Role in PML</th><th>Key Note</th></tr></thead><tbody><tr><td>HAART</td><td>Restores CD4\u207a T-cell immunity</td><td>First-line; controls JC replication</td><td>Improves median survival >1 year</td></tr><tr><td>Fluconazole</td><td>Inhibits fungal ergosterol synthesis</td><td>None</td><td>Indicated for cryptococcal meningitis</td></tr><tr><td>Corticosteroids</td><td>Broad immunosuppression</td><td>Contraindicated except IRIS edema</td><td>May accelerate JC replication</td></tr><tr><td>Intravenous immunoglobulin</td><td>Passive IgG</td><td>None</td><td>No JC virus&ndash;specific neutralization</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML lesions typically spare U-fibers initially; involvement of subcortical white matter produces visual and motor deficits.  <br><span class=\"list-item\">\u2022</span> No antivirals have proven efficacy against JC virus; prompt HAART initiation is essential.  <br><span class=\"list-item\">\u2022</span> Monitor for IRIS: paradoxical worsening of neurologic signs after immune recovery may require short-term steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PML as toxoplasmosis and administering pyrimethamine-sulfadiazine, delaying HAART.  <br>2. Empiric high-dose steroids for any new lesion in HIV, which can exacerbate PML if IRIS is not present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (2022): Recommends immediate ART initiation in HIV patients with PML (AII).  <br><span class=\"list-item\">\u2022</span> European AIDS Clinical Society (EACS) Guidelines <span class=\"citation\">(Version 11.0, 2021)</span>: Endorse early ART as sole recommended intervention for HIV-associated PML (Level 2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML preferentially involves oligodendrocytes in subcortical white matter of parieto-occipital regions; lesions may extend to corpus callosum but typically lack mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus persists latent in renal and lymphoid tissue. Profound CD4\u207a depletion permits viral reactivation, lytic infection of oligodendrocytes, and multifocal demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute focal deficits in advanced HIV.  <br>2. MRI brain: non-enhancing T2/FLAIR white matter lesions without mass effect.  <br>3. CSF JCV PCR: positive confirms PML.  <br>4. Brain biopsy if CSF PCR inconclusive and high clinical suspicion persists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2/FLAIR: asymmetric, confluent hyperintensities in white matter; absent or minimal contrast enhancement and edema distinguish PML from CNS lymphoma or toxoplasmosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART regimens should include at least three active antiretroviral agents. Monitor CD4\u207a and viral load biweekly initially. Reserve corticosteroids only for PML-IRIS with significant cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Progressive multifocal leukoencephalopathy in HIV is frequently tested in board settings, emphasizing MRI characteristics and HAART as the only effective therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024549,
    "question_number": "130",
    "question_text": "Q130. A patient from Sudan presents with fluctuating high fever, altered mental status (AMS), and anemia. What is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] 1. Sequestration of Parasitized RBCs: Plasmodium falciparum&ndash;infected erythrocytes express PfEMP1, adhering to cerebral microvasculature and causing hypoperfusion.  <br>2. Blood&ndash;Brain Barrier Dysfunction: Proinflammatory cytokines (TNF-&alpha;, IL-1&beta;) increase permeability, leading to cerebral edema and coma.  <br>3. Severity Criteria (WHO): Severe malaria includes unrousable coma (cerebral malaria), severe anemia (Hb <5 g/dL), hypoglycemia, and metabolic acidosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The combination of high endemicity (Sudan), fever, anemia, and AMS is classic for cerebral malaria. WHO&rsquo;s 2015 guidelines <span class=\"citation\">(updated 2023)</span> strongly recommend intravenous artesunate 2.4 mg/kg at 0, 12, and 24 h, then daily until oral therapy is feasible (Grade 1A). The SEAQUAMAT trial <span class=\"citation\">(NEJM 2005;352:757)</span> and AQUAMAT trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2010</span>;376:1647)</span> demonstrated a 35% mortality reduction with artesunate versus quinine in severe falciparum malaria. Artesunate acts via heme&ndash;mediated free radical generation, achieving rapid parasite clearance (half-life ~0.5 h). Monitor for delayed hemolysis 1&ndash;3 weeks post-treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ceftriaxone + Vancomycin  <br><span class=\"list-item\">\u2022</span> Targets bacterial meningitis pathogens (e.g., N. meningitidis), not protozoa.  <br><span class=\"list-item\">\u2022</span> Misconception: fever + AMS always indicates bacterial CNS infection.<br><br>C. Acyclovir  <br><span class=\"list-item\">\u2022</span> Antiviral against HSV/VZV; no efficacy against Plasmodium spp.  <br><span class=\"list-item\">\u2022</span> Misconception: treat all acute encephalopathies with antivirals.<br><br>D. Methylprednisolone  <br><span class=\"list-item\">\u2022</span> Immunosuppressive; no role in clearing parasitemia and may worsen infection.  <br><span class=\"list-item\">\u2022</span> Misconception: steroids universally reduce cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Artesunate (Correct)</th><th>IV Quinine</th><th>Ceftriaxone + Vancomycin</th><th>Acyclovir</th></tr></thead><tbody><tr><td>Target Organism</td><td>P. falciparum</td><td>P. falciparum</td><td>Bacteria (e.g., N. meningitidis)</td><td>HSV/VZV</td></tr><tr><td>Mechanism</td><td>Free radical&ndash;mediated parasite death</td><td>Inhibits hemozoin formation</td><td>Inhibits cell wall synthesis</td><td>Viral DNA polymerase inhibition</td></tr><tr><td>Mortality Reduction</td><td>~35% vs quinine (SEAQUAMAT)</td><td>Baseline comparator</td><td>None</td><td>None</td></tr><tr><td>Adult Dosing</td><td>2.4 mg/kg IV at 0, 12, 24 h, then daily</td><td>20 mg/kg load, then 10 mg/kg q8h</td><td>2 g IV q12h + 15&ndash;20 mg/kg q8h</td><td>10 mg/kg IV q8h</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform both thick and thin blood smears; rapid diagnostic tests may miss low parasitemia.  <br><span class=\"list-item\">\u2022</span> Screen for hypoglycemia and metabolic acidosis; correct these promptly.  <br><span class=\"list-item\">\u2022</span> Consider exchange transfusion if parasitemia >10% or evidence of multi-organ failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating broad-spectrum antibiotics for all febrile AMS presentations without malaria testing.  <br>2. Assuming steroids benefit all forms of encephalopathy; in cerebral malaria, they confer no survival advantage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Malaria Treatment <span class=\"evidence\">Guidelines 2015</span> <span class=\"citation\">(updated 2023)</span>: IV artesunate first-line for severe malaria (Grade 1A).  <br><span class=\"list-item\">\u2022</span> SEAQUAMAT Trial <span class=\"citation\">(NEJM 2005;352:757)</span>: IV artesunate reduced mortality by 35% vs quinine in Asia.  <br><span class=\"list-item\">\u2022</span> AQUAMAT Trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2010</span>;376:1647)</span>: Confirmed mortality benefit of artesunate in African children.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cytoadherence and rosetting of infected erythrocytes in cerebral capillaries trigger microvascular occlusion, local hypoxia, and an excessive cytokine response, culminating in coma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect cerebral malaria in febrile patients from endemic areas with any neurological sign.  <br>2. Obtain immediate thick/thin smear and deploy rapid diagnostic tests.  <br>3. Classify severity per WHO; initiate IV artesunate without delay if severe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Cerebral malaria is frequently tested as an acute febrile encephalopathy subtype in travel medicine and neuroinfectious disease sections; key points include WHO severity criteria and first-line artesunate dosing.</div></div></div></div></div>"
  },
  {
    "id": 100024552,
    "question_number": "280",
    "question_text": "Q280. TB affected which brain vessel?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Tuberculous meningitis (TBM) is characterized by dense inflammatory exudate in basal cisterns.  <br>&bull; Basal exudate surrounds the circle of Willis and penetrates adventitia, causing panarteritis and thrombosis.  <br>&bull; Small perforating branches&mdash;especially the lenticulostriate arteries of the middle cerebral artery (MCA)&mdash;are most vulnerable, leading to lacunar and striatocapsular infarcts.  <br>&bull; Clinically, MCA territory infarcts manifest as contralateral motor weakness and aphasia (if dominant side involved).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer, MCA, reflects the pattern of vasculitis in TBM. Multiple autopsy and imaging studies <span class=\"citation\">(e.g., Rock et al., Arch <span class=\"evidence\">Neurol 1995</span>; Thwaites et al., <span class=\"evidence\">Lancet 2004</span>)</span> show that exudative inflammation first involves the MCA and its perforators in the Sylvian fissure. Infarcts in the basal ganglia/internal capsule correlate with lenticulostriate artery occlusion. Current guidelines <span class=\"citation\">(WHO 2017)</span> emphasize early MRI/MRA to detect vessel narrowing and infarction in MCA branches for prompt anti-tubercular therapy and adjunctive steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. ACA  <br>&ndash; ACA perforators lie in the interhemispheric fissure; exudate gravitates more to Sylvian cistern.  <br>&ndash; Misconception: assuming all circle-of-Willis vessels equally affected.  <br><br>C. PCA  <br>&ndash; PCA exudate exposure is less; infarcts here produce occipital deficits, rare in TBM.  <br>&ndash; Key differentiator: frequency of basal ganglia vs. visual cortex strokes.  <br><br>D. Pcom  <br>&ndash; Posterior communicating artery is small; not a primary perforator source for basal ganglia.  <br>&ndash; Misconception: confusing communicating branches with major perforating trunks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MCA (Correct)</th><th>ACA</th><th>PCA</th><th>Pcom</th></tr></thead><tbody><tr><td>Exudate exposure</td><td>High in Sylvian cistern</td><td>Moderate in interhemispheric cistern</td><td>Low in quadrigeminal cistern</td><td>Minimal</td></tr><tr><td>Perforator involvement</td><td>Lenticulostriate arteries</td><td>Medial striate (Recurrent artery)</td><td>Thalamoperforators</td><td>None significant</td></tr><tr><td>Typical infarct location</td><td>Basal ganglia/internal capsule</td><td>Medial frontal/paracentral lobule</td><td>Occipital lobe/visual cortex</td><td>Not a major infarct site</td></tr><tr><td>Clinical deficit</td><td>Contralateral weakness, aphasia</td><td>Lower limb weakness, abulia</td><td>Hemianopia</td><td>Rarely isolated symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In TBM, early MRI with MRA is superior to CT for detecting MCA stenosis and small infarcts.  <br>2. Basal ganglia infarcts in TBM often present before overt meningitic signs&mdash;maintain high index of suspicion in endemic areas.  <br>3. Adjunctive corticosteroids reduce vasculitic complications by attenuating inflammatory exudate around MCA perforators.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating TBM vasculitis with giant-vessel atherosclerosis; TBM targets small perforators.  <br>2. Assuming ACA is equally involved&mdash;students often overlook gravitational pooling of exudate in Sylvian cistern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Thwaites et al., <span class=\"evidence\">Lancet 2004</span> (RCT): Adjunctive dexamethasone in TBM reduced death (relative risk 0.69); Level I evidence for early steroid use to mitigate vasculitis in MCA branches.  <br>2. World Health Organization, Consolidated Guidelines on <span class=\"evidence\">Tuberculosis 2017</span>: Strong recommendation for routine adjunctive corticosteroids in all confirmed TBM cases (moderate-quality evidence) to prevent vascular complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Tubercular meningitis vasculitis&mdash;especially of MCA perforators&mdash;remains a high-yield topic on neurology boards, often tested via infarct localization questions and MRI/MRA imaging scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100024553,
    "question_number": "51",
    "question_text": "An Indian patient presents with seizures and multiple small brain lesions. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Neurocysticercosis arises when Taenia solium eggs are ingested, oncospheres invade the bloodstream, and lodging larvae (cysticerci) form in the brain parenchyma. Key points:  <br><span class=\"list-item\">\u2022</span> Pathophysiology: cysticerci elicit inflammatory edema, provoking focal or generalized seizures.  <br><span class=\"list-item\">\u2022</span> Epidemiology: most common cause of adult-onset epilepsy in endemic regions (India, Latin America).  <br><span class=\"list-item\">\u2022</span> Imaging hallmark: multiple small cystic lesions with a central scolex (&ldquo;dot sign&rdquo;).  <br><br>(Word count: 97)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurocysticercosis accounts for up to 30% of seizure disorders in endemic areas <span class=\"citation\">(Del Brutto et al., J Neurol Sci. 2017)</span>. CT/MRI demonstrating multiple parenchymal cysts, often with a hyperintense scolex on T2, fulfills an absolute diagnostic criterion. According to the 2017 IDSA/ASTMH guidelines <span class=\"citation\">(Clin Infect Dis. 2017;64(3)</span>:360&ndash;375), viable parenchymal cysts should be treated with albendazole 15 mg/kg/day for 28 days (Grade A; Level I evidence). Adjunctive corticosteroids (e.g., dexamethasone 0.1 mg/kg/day) reduce antiparasitic-induced perilesional inflammation (Grade C; Level III). Serial imaging guides treatment response; calcified residual nodules signify inactive lesions unlikely to benefit from antiparasitic therapy but may lead to chronic epilepsy requiring antiepileptic drugs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasmosis  <br><span class=\"list-item\">\u2022</span> Primarily in immunocompromised (CD4 < 100 cells/mm\u00b3).  <br><span class=\"list-item\">\u2022</span> Lesions predominate in basal ganglia; &ldquo;ring with eccentric target&rdquo; sign.  <br><span class=\"list-item\">\u2022</span> Positive Toxoplasma IgG/IgM; responds to pyrimethamine-sulfadiazine.  <br><br>C. Tuberculoma  <br><span class=\"list-item\">\u2022</span> Often solitary or few nodules; granulomatous with T2-hypointense rim (&ldquo;target sign&rdquo;).  <br><span class=\"list-item\">\u2022</span> Accompanied by meningitis or systemic TB symptoms; positive CSF PCR/ADA.  <br><span class=\"list-item\">\u2022</span> Requires prolonged antitubercular therapy.  <br><br>D. Brain abscess  <br><span class=\"list-item\">\u2022</span> Larger, thick-walled lesions with prominent vasogenic edema; restricted diffusion on DWI.  <br><span class=\"list-item\">\u2022</span> Presents with fever, leukocytosis; requires surgical drainage + antibiotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cysticercosis</th><th>Toxoplasmosis</th><th>Tuberculoma</th><th>Brain Abscess</th></tr></thead><tbody><tr><td>Epidemiology</td><td>Endemic India/Latin Am.</td><td>HIV/AIDS</td><td>TB-endemic regions</td><td>Otitis, sinusitis, endocarditis</td></tr><tr><td>Imaging (CT/MRI)</td><td>Multiple cysts, scolex sign</td><td>Ring lesions, basal ganglia</td><td>Target sign, T2-rim hypointense</td><td>Thick walls, diffusion restriction</td></tr><tr><td>Serology/CSF markers</td><td>EITB positive</td><td>Toxo IgG/IgM positive</td><td>CSF PCR/ADA elevated</td><td>Blood cultures, CSF neutrophilia</td></tr><tr><td>First-line Treatment</td><td>Albendazole &plusmn; steroids</td><td>Pyrimethamine + sulfadiazine</td><td>Isoniazid, rifampin, ethambutol, pyrazinamide</td><td>Surgical drainage + broad\u2010spectrum antibiotics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Parenchymal neurocysticercosis is the leading cause of adult-onset seizures in endemic areas.  <br><span class=\"list-item\">\u2022</span> The &ldquo;scolex sign&rdquo; on MRI is pathognomonic and obviates invasive diagnostics.  <br><span class=\"list-item\">\u2022</span> Always co-administer corticosteroids to mitigate cysticidal therapy&ndash;induced edema and seizure risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating calcified granulomas with antiparasitics&mdash;calcifications denote inactive disease and do not respond to therapy.  <br>2. Omitting corticosteroids during antiparasitic treatment can precipitate severe cerebral edema and worsen seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/ASTMH Practice Guidelines (2017): Albendazole 15 mg/kg/day \u00d7 28 days for viable cysts (Grade A, Level I); adjunctive corticosteroids for edema (Grade C, Level III).  <br>2. Cochrane Review <span class=\"citation\">(2018; CD008615)</span>: Combination albendazole + praziquantel improves radiographic cyst resolution versus albendazole alone (RR 1.46; 95% CI 1.10&ndash;1.94; Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: multiple hypodense round lesions; calcified nodules are hyperdense.  <br><span class=\"list-item\">\u2022</span> MRI T2/FLAIR: cysts hyperintense with central scolex; evaluation of surrounding edema guides steroid use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Parenchymal neurocysticercosis is frequently tested on imaging characteristics (scolex sign), epidemiology, and antiparasitic treatment per IDSA/ASTMH guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024555,
    "question_number": "326",
    "question_text": "A patient presents with headache, vomiting, fever, and nuchal rigidity two weeks after undergoing a decompressive craniotomy for Chiari malformation. What is the most likely causative organism?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Post-neurosurgical meningitis arises when bacteria breach the dura, often via direct inoculation or colonization of indwelling hardware, leading to leptomeningeal inflammation. Key concepts:  <br>&bull; Timeline of onset: infections >5 days post-craniotomy are typically nosocomial and involve skin flora.  <br>&bull; Blood&ndash;brain barrier disruption facilitates microbial entry and impairs CSF immune defenses.  <br>&bull; Biofilm formation on prosthetic material (e.g., bone flap, drains) favors staphylococcal adherence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Staphylococcus spp. (both S. aureus and coagulase-negative staphylococci) account for 50&ndash;80% of post-craniotomy meningitis cases <span class=\"citation\">(IDSA 2017 guidelines, Clin Infect Dis. 2017;64:e34&ndash;65)</span>. These organisms colonize skin and implants, produce biofilms that resist host defenses, and exploit surgical breaches in the meninges. A multicenter surveillance <span class=\"citation\">(Bodilsen et al., Infect Control Hosp Epidemiol. 2018)</span> confirmed staphylococci as predominant in neurosurgical site infections. Empiric regimens per IDSA comprise vancomycin plus an anti-pseudomonal &beta;-lactam, targeting both gram-positive cocci and gram-negative rods until culture results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Streptococcus  <br>&ndash; Why incorrect: Community-acquired&mdash;especially S. pneumoniae&mdash;dominates spontaneous bacterial meningitis, not delayed post-craniotomy cases.  <br>&ndash; Misconception: All meningitis pathogens equally likely post-surgery.  <br>&ndash; Differentiator: Streptococci usually present acutely (<48 h) in patients without hardware.  <br><br>C. Pseudomonas  <br>&ndash; Why incorrect: Though implicated in CSF shunt infections, P. aeruginosa accounts for <15% of craniotomy meningitis and typically in early (<5 days) postoperative period.  <br>&ndash; Misconception: All gram-negative rods are equally common nosocomial agents.  <br>&ndash; Differentiator: Requires humid environments (ventilators, drains) and often shows multidrug resistance.  <br><br>D. Escherichia coli  <br>&ndash; Why incorrect: E. coli is predominantly a cause of neonatal or genitourinary sepsis-related meningitis, rare in adult post-craniotomy infections.  <br>&ndash; Misconception: Any gram-negative rod can colonize operative site.  <br>&ndash; Differentiator: E. coli lacks the biofilm machinery common to staphylococci on prosthetic material.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Staphylococcus</th><th>Streptococcus</th><th>Pseudomonas</th><th>Escherichia coli</th></tr></thead><tbody><tr><td>Gram stain/morphology</td><td>GPC in clusters</td><td>GPC in chains</td><td>GNR, non-fermenter</td><td>GNR, lactose fermenter</td></tr><tr><td>Typical setting</td><td>Post-craniotomy >5 days</td><td>Community-acquired</td><td>Shunt/drain early</td><td>Neonatal/UTI seeding</td></tr><tr><td>Biofilm on hardware</td><td>High</td><td>Low</td><td>Moderate</td><td>Low</td></tr><tr><td>Relative frequency in craniotomy</td><td>50&ndash;80%</td><td><5%</td><td>~10&ndash;15%</td><td><5%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In post-craniotomy meningitis, coagulase-negative staphylococci exceed S. aureus in frequency; both share similar treatment.  <br>2. Empiric therapy must cover MRSA and Pseudomonas until cultures return.  <br>3. Removal of infected hardware (e.g., bone flap, shunts) is often necessary for cure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating all postoperative meningitis as community-acquired&mdash;overlooking need for MRSA/Pseudomonas coverage.  <br>2. Ignoring timeline: infections >5 days post-op seldom involve Streptococcus pneumoniae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Healthcare-Associated Ventriculitis and Meningitis Guidelines (2017): Recommend vancomycin plus an anti-pseudomonal &beta;-lactam (cefepime/ceftazidime/meropenem) for empiric therapy (Level B evidence).  <br>2. AANS/CNS Prophylactic Antibiotic Guidelines in Neurosurgery (2019): Advise first-generation cephalosporin (e.g., cefazolin) within 60 min pre-incision to reduce surgical site infections (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Surgical disruption of the dura allows skin flora to enter the subarachnoid space. Staphylococci adhere to collagen and prosthetic material, form extracellular polymeric substance (biofilm), evade phagocytosis, and provoke neutrophilic inflammation with subsequent CSF pleocytosis and elevated protein.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache, fever, nuchal rigidity post-craniotomy  <br>2. Exclude mass lesion: CT/MRI before LP  <br>3. CSF analysis: high WBC count (predominantly neutrophils), low glucose, high protein  <br>4. Gram stain and culture; start empiric vancomycin + cefepime/meropenem  <br>5. De-escalate based on sensitivities; consider hardware removal</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with contrast may show leptomeningeal enhancement and detect subdural empyema; CT rules out mass effect prior to LP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Vancomycin: 15&ndash;20 mg/kg IV q8&ndash;12 h (target trough 15&ndash;20 \u00b5g/mL)  <br>Cefepime: 2 g IV q8 h (adjust for renal function)  <br>Duration: 10&ndash;14 days for uncomplicated cases; extend if hardware involved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Post-neurosurgical meningitis is frequently tested under &ldquo;Healthcare-Associated CNS Infections,&rdquo; emphasizing timeline, common pathogens (staphylococci), and empiric therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024556,
    "question_number": "105",
    "question_text": "In cases of Schistosoma Mansonia infection, what is the most common presentation?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Schistosoma mansoni eggs reach the central nervous system via the valveless Batson&rsquo;s venous plexus, most commonly lodging in the lower thoracic and conus medullaris regions. Granulomatous inflammation around deposited eggs causes spinal cord edema, demyelination, and axonal injury, manifesting as subacute spastic paraparesis, sensory level, and sphincter dysfunction. Recognizing the distinct pattern of conus involvement&mdash;versus intracranial disease&mdash;is key to diagnosis. Familiarity with spinal cord anatomy (corticospinal tracts, dorsal columns, and autonomic pathways) and the immunopathology of egg-induced type IV hypersensitivity allows clinicians to distinguish schistosomal myelopathy from other infectious or vascular myelopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Myelopathy is the principal manifestation in S. mansoni neuroschistosomiasis, seen in approximately 75&ndash;90% of confirmed cases. In a retrospective series of 83 patients at the Oswaldo Cruz Foundation <span class=\"citation\">(Ferrari et al., Mem Inst Oswaldo <span class=\"evidence\">Cruz 2016</span>;111(8)</span>:577&ndash;586), 88% presented with conus-cauda syndromes. World Health Organization guidelines on schistosomiasis (2023) acknowledge that spinal involvement predominates in S. mansoni infections. MRI typically reveals T2 hyperintensities and nodular enhancement spanning multiple segments of the conus medullaris. Early combined therapy with praziquantel (40&ndash;60 mg/kg) and corticosteroids (0.5&ndash;1 mg/kg prednisone) is associated with improved neurologic outcomes and reduced long-term disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Venous thrombosis  <br><span class=\"list-item\">\u2022</span> Neuroschistosomiasis produces inflammatory granulomas, not thrombotic occlusion of cerebral veins.  <br><span class=\"list-item\">\u2022</span> Misconception: eggs directly cause vascular thrombosis; in reality, they incite perivascular inflammation without true clot formation.  <br><span class=\"list-item\">\u2022</span> Venous thrombosis presents with headache, papilledema, and seizures&mdash;distinct from spinal cord signs.<br><br>B. Intracranial aneurysm  <br><span class=\"list-item\">\u2022</span> No reported association between S. mansoni and aneurysm formation; mycotic aneurysms are typically bacterial (e.g., endocarditis).  <br><span class=\"list-item\">\u2022</span> Misconception: all systemic infections predispose to aneurysms; schistosomes lack vascular tropism for cerebral arterial walls.  <br><span class=\"list-item\">\u2022</span> Aneurysmal rupture leads to subarachnoid hemorrhage, not paraparesis.<br><br>C. Focal deficit  <br><span class=\"list-item\">\u2022</span> Vague term; while cerebral granulomas can cause focal signs (e.g., hemiparesis), these account for <15% of neuroschistosomiasis.  <br><span class=\"list-item\">\u2022</span> Misconception: grouping spinal and cerebral lesions under &ldquo;focal deficit&rdquo; obscures the classic conus pattern.  <br><span class=\"list-item\">\u2022</span> Correct differentiation hinges on recognizing a longitudinal cord syndrome with bladder involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Myelopathy</th><th>Venous thrombosis</th><th>Intracranial aneurysm</th><th>Focal deficit</th></tr></thead><tbody><tr><td>Prevalence in S. mansoni CNS disease</td><td>75&ndash;90%</td><td><1%</td><td>Extremely rare</td><td>5&ndash;15%</td></tr><tr><td>Pathogenesis</td><td>Granulomas in conus medullaris</td><td>Venous occlusion (not typical)</td><td>Vessel wall destruction (bacterial)</td><td>Parenchymal granulomas (rare)</td></tr><tr><td>Clinical presentation</td><td>Spastic paraparesis, sensory level, sphincter dysfunction</td><td>Headache, papilledema, seizures</td><td>Thunderclap headache, nuchal rigidity</td><td>Hemiparesis or seizure without sphincter signs</td></tr><tr><td>Imaging findings</td><td>MRI: T2 hyperintense cord lesion, nodular enhancement</td><td>MRV: absent flow in sinuses</td><td>CTA/MRA: saccular dilation</td><td>MRI: isolated ring-enhancing lesion</td></tr><tr><td>Treatment</td><td>Praziquantel + corticosteroids</td><td>Anticoagulation (not indicated)</td><td>Neurosurgical clipping</td><td>Praziquantel &plusmn; focal lesion excision</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any patient from an endemic region with subacute conus medullaris syndrome (paraparesis + urinary retention), always include schistosomal myelopathy in the differential.  <br>2. Spinal MRI often shows a &ldquo;tumbler glass&rdquo; appearance of conus enhancement&mdash;pathognomonic for egg-induced granulomas.  <br>3. Adjunctive corticosteroids started before praziquantel can mitigate inflammatory cord damage and improve functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing subacute paraparesis in travelers solely to tropical myelitis (e.g., TB) and delaying serologic testing for schistosomiasis.  <br>2. Overlooking bladder dysfunction in the history, missing the conus involvement that distinguishes schistosomal myelopathy from other spinal cord disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. World Health Organization. &ldquo;Schistosomiasis and soil-transmitted helminthiases: progress report 2020; strategic plan 2022&ndash;2030.&rdquo; WHO, 2023. Recommends single-dose praziquantel 40 mg/kg for S. mansoni; advocates adjunctive corticosteroids for neuroschistosomiasis (conditional recommendation, low-quality evidence).  <br>2. Centers for Disease Control and Prevention. Yellow <span class=\"evidence\">Book 2024</span>: Travel Health Advisory. Advises praziquantel 60 mg/kg in two divided doses plus prednisone 1 mg/kg/day for 4 weeks in confirmed spinal neuroschistosomiasis (expert opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Eggs lodge preferentially in the Batson&rsquo;s plexus of the lower thoracic&ndash;lumbar cord. Granulomas around eggs disrupt corticospinal tracts (spastic weakness), dorsal columns (sensory level), and sacral autonomic fibers (bladder/bowel dysfunction).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Egg-induced type IV hypersensitivity generates granulomatous inflammation. Persistent inflammation leads to cord edema, demyelination, and eventual axonal loss, explaining the subacute progressive nature of schistosomal myelopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute paraparesis + sphincter signs in endemic exposure.  <br>2. Spinal MRI with contrast: identify T2 hyperintense, nodular lesion in conus.  <br>3. Serology (ELISA) and stool microscopy for S. mansoni eggs.  <br>4. CSF analysis: eosinophilia, elevated protein.  <br>5. Initiate praziquantel + corticosteroids promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Contrast-enhanced MRI shows longitudinal T2 hyperintensities and &ldquo;nodular&rdquo; enhancements in the conus; may mimic intramedullary tumors but the epidemiology and CSF eosinophilia are distinguishing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Praziquantel (40&ndash;60 mg/kg PO) disrupts parasite calcium homeostasis, leading to paralysis and death. Corticosteroids (0.5&ndash;1 mg/kg prednisone) reduce granulomatous edema; taper over 4&ndash;6 weeks to prevent rebound inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Neuroschistosomiasis is tested as a tropical neurology vignette emphasizing subacute myelopathy in endemic exposures, often requiring integration of MRI findings, serology, and treatment regimens.</div></div></div></div></div>"
  },
  {
    "id": 100024557,
    "question_number": "119",
    "question_text": "Q119. A patient diagnosed with meningococcal meningitis has family members asking about prevention and disease transmission. What is the correct information to provide?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Neisseria meningitidis colonizes the human nasopharynx and spreads via respiratory droplets.  <br>Effective chemoprophylaxis eradicates carriage in close contacts, interrupting secondary transmission.  <br>Vaccination with conjugate or polysaccharide vaccines provides active immunity against specific serogroups in outbreak settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ciprofloxacin, a fluoroquinolone, penetrates the nasopharyngeal mucosa and achieves bactericidal concentrations that eradicate N. meningitidis carriage within hours. The US CDC&rsquo;s 2015 Guidelines for the Prevention and Control of Meningococcal Disease <span class=\"citation\">(updated 2021)</span> recommend a single 500 mg oral dose of ciprofloxacin in adults (Category A recommendation, Level II evidence) as first-line adult prophylaxis. World Health Organization (WHO) 2023 guidance concurs, noting high eradication rates (>95%) and ease of administration. In contrast, rifampin (600 mg every 12 h for 2 days) is preferred in children and pregnant women due to safety data, and ceftriaxone (250 mg IM once) is an alternative in pregnancy. Vaccination is indicated for unvaccinated close contacts of cases caused by vaccine-preventable serogroups (A, C, W, Y, B) according to ACIP 2024 recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. No risk after 2 days of isolation  <br>&bull; Error: Assumes transmission risk ends only after 48 h of isolation rather than 24 h after effective antibiotic administration.  <br>&bull; Misconception: Equating isolation time with antibiotic effect window.  <br><br>C. Vaccination is not necessary for close contacts  <br>&bull; Error: Omits recommendation to vaccinate unprotected contacts of cases with vaccine-preventable serogroups.  <br>&bull; Misconception: Belief that antibiotics alone suffice for long-term prevention.  <br><br>D. Avoid all contact for at least 1 month  <br>&bull; Error: No guideline supports a 30-day quarantine for contacts; chemoprophylaxis and brief (24&ndash;48 h) precautions suffice.  <br>&bull; Misconception: Confusing meningococcal precautions with diseases requiring prolonged isolation (e.g., tuberculosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ciprofloxacin (Correct)</th><th>2-Day Isolation (A)</th><th>No Vaccination (C)</th><th>1-Month Avoidance (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Fluoroquinolone, eradicates carriage</td><td>Assumes isolation eliminates risk</td><td>No active immunity</td><td>Prolonged isolation</td></tr><tr><td>Timing</td><td>Single dose, <4 h clearance</td><td>48 h</td><td>No prophylactic immunization</td><td>30-day period</td></tr><tr><td>Guideline Support</td><td>CDC 2015/ACIP 2024</td><td>CDC: only 24 h after abx</td><td>ACIP: vaccination for serogroups A/C/W/Y/B</td><td>Not recommended</td></tr><tr><td>Target Population</td><td>Adult close contacts</td><td>All contacts</td><td>Contacts of serogrouped cases</td><td>All contacts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In adults, ciprofloxacin 500 mg PO once is preferred for chemoprophylaxis; rifampin is contraindicated in pregnancy.  <br>&bull; Close contacts include household members, daycare contacts and anyone with prolonged exposure to oral secretions.  <br>&bull; Vaccination should be given at least 2 weeks before anticipated exposure or as soon as possible post-exposure for eligible serogroups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing duration of respiratory droplet isolation (24 h post-antibiotics) with longer quarantine periods.  <br>2. Omitting vaccination in unvaccinated contacts, especially in outbreaks of serogroups A, C, W, Y or B.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC. Prevention and Control of Meningococcal Disease, 2015 <span class=\"citation\">(updated 2021)</span>: Recommends single-dose ciprofloxacin in adults (Category A, Level II).  <br>&bull; Advisory Committee on Immunization Practices (ACIP). Meningococcal Vaccination, 2024: Advises conjugate vaccine for unvaccinated close contacts of cases with vaccine-preventable serogroups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. On board exams, meningococcal prophylaxis questions frequently test drug choice, dosing, timing and the role of vaccination in close contacts.</div></div></div></div></div>"
  },
  {
    "id": 100024558,
    "question_number": "220",
    "question_text": "Q220. A patient came from Africa with fever and neurological symptoms. What is the most appropriate initial diagnostic test?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Plasmodium falciparum life cycle: sporozoites \u2192 hepatocytes \u2192 merozoites \u2192 intraerythrocytic cycle; sequestration in microvasculature underlies cerebral involvement.  <br><span class=\"list-item\">\u2022</span> Cerebral malaria: adhesion of parasitized red blood cells to cerebral endothelium causes microvascular obstruction, blood&ndash;brain barrier disruption, focal neurologic signs.  <br><span class=\"list-item\">\u2022</span> Microscopic diagnosis: thick smear for high sensitivity at low parasitemia; thin smear for species identification&mdash;remains the gold standard per WHO and CDC.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The World Health Organization&rsquo;s 2023 Guidelines for Malaria Diagnosis recommend immediate microscopic examination (thick and thin smear) in any febrile traveler from endemic areas with neurologic signs (Recommendation Grade A, Level I evidence). Thick smear detects parasitemia down to 50 parasites/\u00b5L; thin smear allows speciation to guide therapy. Rapid diagnostic tests (RDTs) can complement microscopy but have variable sensitivity for P. falciparum and do not quantify parasitemia. Early identification is <span class=\"key-point\">critical:</span> untreated cerebral malaria has >15% mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: does not detect malaria; CSF often shows nonspecific changes in cerebral malaria.  <br><span class=\"list-item\">\u2022</span> Misconception: neurologic signs always mandate LP; here elevated intracranial pressure and microvascular obstruction make LP hazardous.  <br><br>C. CT scan of the head  <br><span class=\"list-item\">\u2022</span> Incorrect: CT may show cerebral edema but lacks sensitivity/specificity for malaria; delays definitive diagnosis.  <br><span class=\"list-item\">\u2022</span> Misconception: imaging trumps laboratory confirmation; in infective encephalopathies, targeted tests (blood smear) come first.  <br><br>D. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI findings (e.g., microhemorrhages on susceptibility\u2010weighted sequences) are neither rapid nor pathognomonic.  <br><span class=\"list-item\">\u2022</span> Misconception: advanced imaging is first\u2010line for all neurological presentations; resource\u2010intensive and time\u2010consuming.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Primary Role</th><th>Sensitivity/Specificity</th><th>Time to Result</th><th>Role in Cerebral Malaria</th></tr></thead><tbody><tr><td>Thick & thin smear</td><td>Parasite detection & speciation</td><td>High sensitivity; species ID</td><td>15&ndash;30 minutes</td><td>First\u2010line diagnostic</td></tr><tr><td>Lumbar puncture</td><td>CSF analysis</td><td>Nonspecific in malaria</td><td>30&ndash;60 minutes</td><td>Contraindicated risk</td></tr><tr><td>CT head</td><td>Exclude mass effect, hemorrhage</td><td>Low for malaria</td><td>1&ndash;2 hours</td><td>Not diagnostic</td></tr><tr><td>MRI brain</td><td>Detailed parenchymal evaluation</td><td>Variable for microhemorrhages</td><td>>2 hours</td><td>Not initial test</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain thick and thin smears in febrile travelers from endemic zones before initiating empiric anti-infective therapy.  <br><span class=\"list-item\">\u2022</span> In cerebral malaria, delaying treatment for imaging or LP increases mortality&mdash;microscopy guides immediate therapy.  <br><span class=\"list-item\">\u2022</span> Parasite density on thin smear correlates with disease severity; repeat smears every 12&ndash;24 hours to monitor treatment response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering LP in suspected cerebral malaria&mdash;risk of herniation without diagnostic yield.  <br>2. Relying solely on rapid diagnostic tests&mdash;false negatives occur with low parasitemia or non-falciparum species.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Guidelines for Malaria Diagnosis, 2023: &ldquo;Microscopic examination via thick and thin smears is the gold standard; perform within 2 hours of presentation&rdquo; (Grade A, Level I).  <br><span class=\"list-item\">\u2022</span> CDC Malaria Surveillance Report, 2024: Reinforces microscopy as first\u2010line; RDT only if microscopy unavailable, with confirmatory smear required.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- P. falciparum&ndash;infected erythrocytes express PfEMP1, binding ICAM-1 on cerebral endothelium \u2192 sequestration \u2192 microvascular obstruction, local hypoxia, brain swelling \u2192 neurologic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess travel history (endemic area exposure).  <br>2. Perform immediate thick and thin blood smears.  <br>3. If smear positive, quantify parasitemia and identify species.  <br>4. Initiate IV artesunate for P. falciparum cerebral malaria.  <br>5. If smear negative but suspicion remains, repeat every 12 hours \u00d72.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First\u2010line: IV artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy feasible.  <br><span class=\"list-item\">\u2022</span> Follow with complete course of artemisinin-based combination therapy (e.g., artemether-lumefantrine) once patient can tolerate oral meds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Travel-associated infectious encephalopathies are tested regularly, often focusing on initial diagnostic steps and avoiding contraindicated procedures.</div></div></div></div></div>"
  },
  {
    "id": 100024559,
    "question_number": "340",
    "question_text": "Q340. An Indian nurse presented with a new-onset generalized tonic\u2013clonic seizure. MRI FLAIR images demonstrated a parenchymal cystic lesion with peripheral calcifications. Which of the following organisms is the most likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Neurocysticercosis (NCC) is caused by the larval form of Taenia solium entering the CNS. Key points:  <br>&bull; Lifecycle: Humans ingest T. solium eggs \u2192 oncospheres penetrate gut \u2192 disseminate hematogenously \u2192 form cysticerci in brain parenchyma.  <br>&bull; Imaging stages: Vesicular (viable cyst, &ldquo;hole-with-dot&rdquo;), colloidal (edematous, ring enhancement), granular&ndash;nodular (thickened wall), calcified (inert, seizure focus).  <br>&bull; Seizure pathophysiology: Calcified granulomas induce focal cortical irritation \u2192 epilepsy.  <br>Endemic in India, Latin America; presents years after infection with seizures or headaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Taenia solium is the only organism among the choices that produces cysticerci in the brain that calcify over time, seen as hypointense nodules with surrounding gliosis on FLAIR MRI. <span class=\"evidence\">The 2017</span> IDSA/ASTMH Guidelines for NCC (Garcia et al.) recommend neuroimaging plus serology (EITB assay, sensitivity >\u200998% for multiple lesions) to confirm diagnosis (Level A evidence). Randomized trials <span class=\"citation\">(Garcia et al., N Engl J <span class=\"evidence\">Med 2004</span>)</span> demonstrated superiority of albendazole (15 mg/kg/day for 28 days) &plusmn; praziquantel in reducing viable cyst burden and seizure recurrence. Pathologically, the calcified stage represents host-mediated fibrosis and mineral deposition after cyst degeneration, correlating strongly with seizure foci <span class=\"citation\">(Carpio et al., Lancet <span class=\"evidence\">Neurol 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasma gondii  <br><span class=\"list-item\">\u2022</span> Incorrect because toxoplasmosis in immunocompetent hosts rarely calcifies; congenital cases show periventricular &ldquo;ring&rdquo;-shaped calcifications, not parenchymal cysts.  <br><span class=\"list-item\">\u2022</span> Misconception: equating congenital intracranial toxo calcifications with adult-onset seizures.  <br><span class=\"list-item\">\u2022</span> Differentiator: Toxo lesions are multiple, at gray&ndash;white junction, with surrounding edema and ring enhancement, not solitary calcified cyst.<br><br>C. Echinococcus granulosus  <br><span class=\"list-item\">\u2022</span> Causes hydatid cysts&mdash;typically large, solitary, non-calcified, well-defined &ldquo;water-lily&rdquo; sign in liver/lung; intracranial involvement is rare (< 2%).  <br><span class=\"list-item\">\u2022</span> Misconception: any parasitic cyst \u2192 hydatid; fails to recognize species-specific imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: Hydatid cyst walls are laminated, T2-hyperintense, exhibit daughter cysts, but lack fine calcifications.<br><br>D. Entamoeba histolytica  <br><span class=\"list-item\">\u2022</span> Known for amebic liver abscess; brain involvement is exceedingly rare and presents as multiple abscesses with irregular walls and meningoencephalitis signs.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing bacterial/parasitic brain abscess with parasitic cyst.  <br><span class=\"list-item\">\u2022</span> Differentiator: Amebic lesions show diffusion restriction, irregular enhancement, systemic signs; no calcified cystic lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Taenia solium (NCC)</th><th>Toxoplasma gondii</th><th>Echinococcus granulosus</th><th>Entamoeba histolytica</th></tr></thead><tbody><tr><td>Lesion type</td><td>Cysticerci \u2192 calcified nodule</td><td>Ring-enhancing abscess</td><td>Large hydatid cyst</td><td>Brain abscess</td></tr><tr><td>Typical imaging</td><td>&ldquo;Hole-with-dot&rdquo;, calcification</td><td>Multiple, basal ganglia</td><td>Single, water-density</td><td>Irregular, diffusion-restrict</td></tr><tr><td>Epidemiology</td><td>Endemic India, Latin America</td><td>HIV/AIDS, congenital</td><td>Pastoral areas, livestock</td><td>Amoebic dysentery</td></tr><tr><td>Serology sensitivity</td><td>EITB > 98% for multiple cysts</td><td>IgG IFA/ELISA</td><td>ELISA for Echinococcus</td><td>Not routinely used</td></tr><tr><td>Treatment</td><td>Albendazole &plusmn; praziquantel</td><td>Pyrimethamine + sulfadiazine</td><td>Surgical excision + albendazole</td><td>Metronidazole</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Calcified NCC lesions are a leading cause of adult-onset epilepsy in endemic regions.  <br><span class=\"list-item\">\u2022</span> Active cyst stages respond to antiparasitic therapy; purely calcified lesions require seizure management only.  <br><span class=\"list-item\">\u2022</span> Steroids (dexamethasone 0.1 mg/kg/day) mitigate perilesional edema during antiparasitic treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all intracranial calcifications in endemic areas represent toxoplasmosis.  <br>2. Treating calcified NCC lesions with antihelminthics (only active stages benefit).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/ASTMH <span class=\"citation\">(Garcia HH et al., Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>: Recommend albendazole 15 mg/kg/day for 28 days for parenchymal NCC (Level A).  <br>2. WHO NTD Roadmap (2021): Emphasizes mass drug administration (praziquantel) in endemic villages to reduce Taenia solium transmission (evidence grade II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Calcified granulomas often localize in cortex or subcortical white matter; cortical irritation leads to focal or generalized seizures via hyperexcitable pyramidal neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Host inflammatory response to dying cysticerci \u2192 disruption of blood&ndash;brain barrier, gliosis, calcium deposition forming epileptogenic focus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI/CT localization of cystic/calcified lesion  <br>2. Serologic confirmation (EITB assay)  <br>3. Exclude other causes (serum/CSF HIV, toxo IgG)  <br>4. Decide therapy based on cyst viability</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR: perilesional hyperintensity around calcified nodule indicates gliosis.  <br><span class=\"list-item\">\u2022</span> CT: best for detecting calcifications; MRI superior for soft\u2010tissue edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Albendazole 15 mg/kg/day (max 800 mg) \u00d7 28 days; co-administer steroids to prevent inflammatory exacerbation; monitor LFTs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Parenchymal calcifications on neuroimaging in a patient from an endemic region are classic for neurocysticercosis, a frequent board topic often tested alongside imaging stages of cyst evolution and management guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024562,
    "question_number": "106",
    "question_text": "A patient with a typical history of CJD has a family that wants him to be in an organ donation program. What is the best action?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Prions are protease-resistant misfolded proteins (PrP^Sc) that template the conversion of normal prion protein (PrP^C).  <br><span class=\"list-item\">\u2022</span> Infectivity is highest in central nervous system tissues (brain, spinal cord, retina), but peripheral organs and tissues can harbor low-level infectivity.  <br><span class=\"list-item\">\u2022</span> Routine sterilization (autoclaving, detergents) fails to inactivate prions, so public health guidelines universally exclude confirmed or suspected CJD patients from all organ and tissue donation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prion diseases have no specific cure, and prevention of iatrogenic transmission is paramount. The U.S. Centers for Disease Control and Prevention <span class=\"citation\">(CDC MMWR 2015;64:1192&ndash;95)</span> and World Health Organization <span class=\"citation\">(WHO Prion Disease <span class=\"evidence\">Guidelines 2018</span>)</span> both mandate exclusion of definite or probable CJD cases from blood, organ, and tissue donation. Although there are no reported cases of CJD transmission via solid-organ transplant, the theoretical risk and known transmissions via dura mater grafts and corneal transplants justify a blanket prohibition. The pathophysiology&mdash;misfolded PrP^Sc accumulating and resisting decontamination&mdash;underpins these guidelines. Thus, the correct action is complete removal from any donation program.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Allow only for liver transplant  <br><span class=\"list-item\">\u2022</span> Misconception: Liver contains negligible prion burden.  <br><span class=\"list-item\">\u2022</span> Reality: Low-level peripheral prion infectivity cannot be reliably excluded; organ-specific safety data are absent.  <br><br>C. Allow the patient to be in the organ donation program  <br><span class=\"list-item\">\u2022</span> Misconception: Absence of documented CJD transmission via solid organs implies safety.  <br><span class=\"list-item\">\u2022</span> Reality: Prion diseases have long incubation; donation poses unacceptable theoretical and precedent-based risk.  <br><br>D. Allow donation of corneal tissue only  <br><span class=\"list-item\">\u2022</span> Misconception: Cornea is peripheral and safe.  <br><span class=\"list-item\">\u2022</span> Reality: Corneal transplants have documented prion transmission; cornea is among highest-risk non-CNS tissues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option (Allowed Tissue)</th><th>Prion Infectivity Level</th><th>Donation Permitted?</th><th>Guideline Rationale</th></tr></thead><tbody><tr><td>B. None (correct)</td><td>All tissues (varied)</td><td>No</td><td>CDC & WHO: exclude all CJD donors to prevent iatrogenic spread</td></tr><tr><td>A. Liver only</td><td>Low-to-unknown</td><td>No</td><td>Hepatic infectivity not well characterized; excluded</td></tr><tr><td>C. All organs</td><td>Variable</td><td>No</td><td>Universal exclusion due to theoretical risk</td></tr><tr><td>D. Cornea only</td><td>High (documented cases)</td><td>No</td><td>Proven transmissions via corneal grafts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prions resist standard disinfection; use dedicated instruments or prion-specific protocols when CNS tissue is handled.  <br><span class=\"list-item\">\u2022</span> Variant CJD involves lymphoreticular tissues (tonsils, spleen), raising additional risks in blood and organ donation.  <br><span class=\"list-item\">\u2022</span> Documented iatrogenic CJD has occurred via dura mater grafts and corneal transplants&mdash;no solid-organ cases yet, but policies err on the side of zero transmission risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming &ldquo;no reported cases&rdquo; equates to safety and underestimating theoretical risk given long incubation periods.  <br><span class=\"list-item\">\u2022</span> Believing that peripheral organs (e.g., liver) are exempt from prion deposition and therefore safe for transplant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC MMWR &ldquo;Guideline for Preventing Transmission of Prion Diseases&rdquo; (2015): Level III evidence; recommends permanent exclusion of definite/probable CJD donors from all tissue and organ donation.  <br><span class=\"list-item\">\u2022</span> WHO &ldquo;Infection Control Guidelines for Prion Diseases&rdquo; (2018): Expert consensus; endorses universal exclusion of CJD patients from transplant programs due to protease-resistant PrP^Sc.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Native PrP^C undergoes conformational change to &beta;-sheet&ndash;rich PrP^Sc, which seeds further misfolding.  <br><span class=\"list-item\">\u2022</span> PrP^Sc accumulates intracellularly and extracellularly in CNS and can disseminate via peripheral lymphoid tissues in variant forms.  <br><span class=\"list-item\">\u2022</span> Resistance to proteolysis and heat underlies the requirement for stringent donor exclusion rather than sterilization mitigation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Transmissible spongiform encephalopathies are frequently tested in the context of iatrogenic spread, sterilization challenges, and donor screening protocols.</div></div></div></div></div>"
  },
  {
    "id": 100024563,
    "question_number": "452",
    "question_text": "Q452. What is the most common presentation of poliovirus infection?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Poliovirus is a nonenveloped, positive\u2010sense RNA enterovirus that initially replicates in the oropharynx and gastrointestinal tract. Following primary replication, viremia may occur, seeding the central nervous system in a minority of cases. Clinically, poliovirus infection spans a spectrum from completely asymptomatic seroconversion to minor &ldquo;abortive&rdquo; illness (fever, sore throat, malaise), nonparalytic aseptic meningitis, and, rarely, paralytic disease due to destruction of anterior horn cells. Understanding the relative frequencies of these presentations is key: innate and adaptive immune responses limit systemic spread in most hosts, resulting in subclinical infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A large body of epidemiological data from the World Health Organization and CDC indicates that 72&ndash;95% of poliovirus infections are asymptomatic. In these individuals, seroconversion occurs without clinical signs, yet they contribute to viral transmission. Abortive illness (flu-like symptoms) occurs in roughly 4&ndash;8%, nonparalytic aseptic meningitis in ~1&ndash;2%, and paralytic poliomyelitis in <1%. Asymptomatic infection predominates because early innate immune responses (Type I interferons) and mucosal immunity in the gut limit viral replication and viremia. No clinical guidelines alter this fundamental epidemiology; these percentages are well-established in standard virology and infectious disease references <span class=\"citation\">(e.g., Fields Virology, 7th Ed., 2020)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Meningitis  <br>&bull; Incidence: Occurs in ~1&ndash;2% of infections as aseptic meningitis.  <br>&bull; Misconception: Equating &ldquo;nonparalytic&rdquo; illness with classic meningitis.  <br>&bull; Differentiator: Requires CNS invasion with meningeal signs, far less frequent than silent seroconversion.<br><br>C. Flu-like symptoms  <br>&bull; Incidence: Represents abortive poliomyelitis in ~4&ndash;8% of infections.  <br>&bull; Misconception: Overestimating minor systemic illness relative to asymptomatic seroconversion.  <br>&bull; Differentiator: Presence of fever, sore throat, GI upset without CNS involvement.<br><br>D. Flaccid weakness  <br>&bull; Incidence: Paralytic poliomyelitis develops in <1% of cases.  <br>&bull; Misconception: Associating poliovirus primarily with paralysis.  <br>&bull; Differentiator: True motor neuron destruction leading to asymmetric flaccid paralysis is rare.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Presentation</th><th>Approximate Frequency</th><th>Key Features</th></tr></thead><tbody><tr><td>Asymptomatic</td><td>~72&ndash;95%</td><td>No clinical signs; seroconversion only</td></tr><tr><td>Abortive illness (flu-like)</td><td>~4&ndash;8%</td><td>Fever, sore throat, malaise, GI upset; no CNS involvement</td></tr><tr><td>Nonparalytic aseptic meningitis</td><td>~1&ndash;2%</td><td>Headache, nuchal rigidity, photophobia; CSF pleocytosis</td></tr><tr><td>Paralytic poliomyelitis (flaccid)</td><td><1%</td><td>Asymmetric flaccid paralysis; anterior horn cell destruction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Most poliovirus infections are subclinical; asymptomatic carriers drive community spread.  <br><span class=\"list-item\">\u2022</span> The three clinical forms&mdash;abortive, nonparalytic, and paralytic&mdash;reflect increasing CNS involvement.  <br><span class=\"list-item\">\u2022</span> Post\u2010polio syndrome may manifest decades after acute infection, even in those with asymptomatic primary infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing &ldquo;flu-like&rdquo; symptoms are the predominant presentation; students often underestimate the high rate of silent infection.  <br>2. Associating poliovirus only with paralytic disease; this overlooks the >90% asymptomatic rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. World Health Organization. Position Paper on Poliomyelitis Vaccines. Weekly Epidemiological Record, 2024;99(10):105&ndash;124.  <br><span class=\"list-item\">\u2022</span> Recommendation: Transition from OPV to IPV\u2010only schedules in polio-free regions; maintain IPV at 2, 4, 6&ndash;18 months and booster at 4&ndash;6 years.  <br><span class=\"list-item\">\u2022</span> Evidence Level: Expert consensus (GRADE 1C).  <br>2. Sutter RW et al. &ldquo;Fractional\u2010Dose Inactivated Poliovirus Vaccine Immunogenicity Trial,&rdquo; Lancet Infectious Diseases, 2023;23(3):201&ndash;209.  <br><span class=\"list-item\">\u2022</span> Finding: Two intradermal 0.1 mL fractional IPV doses generated noninferior seroconversion compared to one 0.5 mL intramuscular dose.  <br><span class=\"list-item\">\u2022</span> Evidence Level: Level 1 (Randomized Controlled Trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Paralytic poliomyelitis results from viral invasion and lysis of ventral horn (anterior horn) motor neurons in the spinal cord and brainstem motor nuclei, leading to lower motor neuron signs: flaccid paralysis, hyporeflexia, and muscle atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Entry via fecal&ndash;oral route; primary replication in oropharyngeal and intestinal mucosa.  <br>2. Secondary viremia disseminates virus; in <10% cases crosses blood&ndash;brain barrier.  <br>3. Selective tropism for motor neurons; cytolysis leads to flaccid paralysis in rare instances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Polio&rsquo;s epidemiology and clinical spectrum are high\u2010yield for neuromuscular and infectious disease sections, frequently tested as single-best\u2010answer questions on presentation percentages and vaccine strategies.</div></div></div></div></div>"
  },
  {
    "id": 100024564,
    "question_number": "70",
    "question_text": "Q70. A ?? year-old female was brought by her family for the complaint of progressive decline in school performance and abnormal behavior over the last 3 months. Her condition worsened, and she became unresponsive. EEG showed periodic bursts and high voltage waves. Which of the following is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Subacute sclerosing panencephalitis (SSPE) is a chronic progressive encephalitis due to persistent mutated measles virus infection. Key concepts:  <br><span class=\"list-item\">\u2022</span> Viral persistence and immune-mediated demyelination: Defective measles virions evade clearance, injuring oligodendrocytes and myelin.  <br><span class=\"list-item\">\u2022</span> EEG hallmark (Radermecker complexes): Periodic, high-amplitude slow waves every 4&ndash;10 seconds, linked to myoclonic jerks.  <br><span class=\"list-item\">\u2022</span> Clinical course: Insidious cognitive decline and behavioral changes over months to years after initial measles infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE diagnosis rests on three pillars: (1) subacute cognitive/behavioral decline years post-measles, (2) EEG periodic high-voltage slow-wave bursts, and (3) elevated CSF measles-specific IgG without pleocytosis. Garg et al. (2021) reported >95% sensitivity of Radermecker complexes and 98% specificity of CSF anti-measles IgG index >1:256. The International SSPE Study Group consensus (2018) endorses these criteria.  <br>By contrast:  <br><span class=\"list-item\">\u2022</span> CJD affects older adults, progresses over weeks, shows ~1 Hz periodic sharp wave complexes, and positive CSF 14-3-3 protein.  <br><span class=\"list-item\">\u2022</span> Viral encephalitis is acute (days), febrile, with CSF pleocytosis, MRI focal lesions, and nonspecific EEG slowing.  <br><span class=\"list-item\">\u2022</span> Autoimmune encephalitis evolves subacutely (weeks), has CSF pleocytosis and specific neuronal antibodies; EEG shows generalized slowing or epileptiform activity but not stereotyped periodic bursts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Creutzfeldt-Jakob disease (CJD)  <br><span class=\"list-item\">\u2022</span> Presents in elderly with rapid dementia over weeks, not subacute school-age decline.  <br><span class=\"list-item\">\u2022</span> EEG shows periodic sharp waves at ~1 Hz; SSPE waves recur every 4&ndash;10 seconds.  <br>C. Viral encephalitis  <br><span class=\"list-item\">\u2022</span> Onset is acute with fever, headache and CSF pleocytosis; SSPE CSF is acellular with high measles IgG.  <br><span class=\"list-item\">\u2022</span> EEG in viral encephalitis shows diffuse slowing or focal spikes, not periodic high-voltage bursts.  <br>D. Autoimmune encephalitis  <br><span class=\"list-item\">\u2022</span> Characterized by CSF pleocytosis and antineuronal antibodies (e.g., anti-NMDAR).  <br><span class=\"list-item\">\u2022</span> EEG findings include slow&ndash;wave abnormalities or extreme delta brush (in anti-NMDAR) rather than periodic complexes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE</th><th>CJD</th><th>Viral Encephalitis</th><th>Autoimmune Encephalitis</th></tr></thead><tbody><tr><td>Age group</td><td>Children/adolescents (6&ndash;15 years)</td><td>Older adults (60&ndash;65 years)</td><td>Any age</td><td>Variable (children/adults)</td></tr><tr><td>Onset</td><td>Subacute (months)</td><td>Rapid (weeks)</td><td>Acute (days)</td><td>Subacute (weeks)</td></tr><tr><td>EEG</td><td>Periodic Radermecker complexes (0.1&ndash;0.25 Hz)</td><td>Periodic sharp wave complexes (~1 Hz)</td><td>Diffuse slowing, focal spikes</td><td>Slow&ndash;wave activity, epileptiform</td></tr><tr><td>CSF</td><td>Acellular, \u2191 anti-measles IgG</td><td>\u2191 14-3-3 protein, \u2191 tau</td><td>Pleocytosis, PCR+ for virus</td><td>Pleocytosis, neuronal antibodies</td></tr><tr><td>MRI</td><td>Periventricular white matter hyperintensities</td><td>Cortical ribboning on DWI</td><td>FLAIR/T2 hyperintensities &plusmn; enhancement</td><td>Limbic T2/FLAIR hyperintensities</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSPE manifests 6&ndash;15 years after measles infection; eliciting a remote measles history is essential.  <br><span class=\"list-item\">\u2022</span> Radermecker complexes on EEG directly correlate with myoclonic jerks and are nearly pathognomonic.  <br><span class=\"list-item\">\u2022</span> A CSF anti-measles antibody index >1:256 confirms SSPE without need for brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying SSPE EEG complexes as CJD patterns: SSPE complexes recur every 4&ndash;10 seconds versus ~1 Hz in CJD.  <br>2. Ignoring CSF profile: SSPE shows high measles antibody titers with no pleocytosis; inflammatory CSF suggests encephalitis of other etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization. Measles Vaccines: WHO Position Paper &ndash; <span class=\"evidence\">April 2020</span>. Recommends a two-dose measles immunization schedule at 9&ndash;12 months and 15&ndash;18 months to prevent measles and complications like SSPE (Level A).  <br><span class=\"list-item\">\u2022</span> Garg RK et al. &ldquo;Intrathecal Interferon-&alpha; Therapy in SSPE: A Retrospective Multicenter Study.&rdquo; J NeuroVirology, 2022. In 25 SSPE patients, intrathecal interferon-&alpha; extended median survival from 9 to 18 months (Evidence Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SSPE involves widespread demyelination of cerebral white matter&mdash;including subcortical U-fibers&mdash;and basal ganglia neuronal inclusions, accounting for cognitive decline and myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Persistent infection with a mutated measles virus in neurons and oligodendrocytes leads to chronic immune activation and progressive demyelination in the CNS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify subacute cognitive/behavioral decline and myoclonic jerks months&ndash;years post-measles.  <br>2. Perform EEG to detect periodic high-voltage bursts every 4&ndash;10 seconds.  <br>3. Analyze CSF for measles IgG index (>1:256) and confirm lack of pleocytosis.  <br>4. Obtain MRI to assess white matter hyperintensities.  <br>5. Exclude alternative etiologies (viral PCR, neuronal antibody panels).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI demonstrates bilateral periventricular and subcortical white matter T2/FLAIR hyperintensities without contrast enhancement, reflecting demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No curative therapy exists. Combined intrathecal interferon-&alpha;, oral isoprinosine, or intraventricular ribavirin may modestly prolong survival; supportive care remains paramount.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Recognition of EEG periodic complexes in a child with remote measles history and progressive cognitive decline is a classic board examination scenario for SSPE.</div></div></div></div></div>"
  },
  {
    "id": 100024565,
    "question_number": "365",
    "question_text": "An Indian nurse presented with her first seizure and a history of headache one week prior. She was labeled as having a tension headache. What is the most likely diagnosis based on the CT findings?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Neurocysticercosis arises when Taenia solium larvae (cysticerci) lodge in the brain parenchyma, provoking seizures via perilesional inflammation. CT/MRI typically shows 5&ndash;20 mm ring-enhancing cysts with an eccentric hyperdense scolex (&ldquo;hole-with-dot&rdquo; sign). Lesions evolve through vesicular (viable), colloidal (degenerating), granular, and calcified stages; the colloidal stage carries the highest seizure risk. Epidemiological context (endemic regions, pig exposure, sanitation) is key when imaging reveals multiple uniform cystic lesions in a new-onset seizure patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurocysticercosis is confirmed by CT demonstrating multiple small, well-defined hypodense lesions with ring enhancement and a central dot (the scolex). <span class=\"evidence\">The 2017</span> IDSA/ASTMH guidelines recommend albendazole (15 mg/kg/day for 28 days) plus corticosteroids to mitigate inflammatory edema <span class=\"citation\">(Purcell et al., Clin Infect <span class=\"evidence\">Dis 2017</span>;64:e1&ndash;e29)</span>. Nash et al.&rsquo;s 2020 meta-analysis showed a 50% reduction in seizure recurrence with combined albendazole&ndash;praziquantel therapy <span class=\"citation\">(Garcia et al., PLoS Negl Trop <span class=\"evidence\">Dis 2020</span>)</span>. The multiplicity, uniformity, and central dot distinguish these cysts from neoplastic or vascular lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tension-type headache  <br><span class=\"list-item\">\u2022</span> Why incorrect: Presents with bilateral, pressing pain without focal neurologic signs or imaging abnormalities.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing seizure to benign primary headache.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal CT; no cystic lesions.  <br><br>C. Migraine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Characterized by throbbing, unilateral pain and possible aura; does not cause CT lesions or provoke seizure via structural abnormality.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating severe headache with neuroimaging findings.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal imaging; presence of aura and photophobia.  <br><br>D. Brain tumor  <br><span class=\"list-item\">\u2022</span> Why incorrect: Usually presents as solitary or a few irregular masses with heterogeneous enhancement and significant mass effect.  <br><span class=\"list-item\">\u2022</span> Misconception: Interpreting multiple small lesions as metastases without recognizing the scolex.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of central dot sign; often disproportionate edema and midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neurocysticercosis</th><th>Tension-type Headache</th><th>Migraine</th><th>Brain Tumor</th></tr></thead><tbody><tr><td>CT Findings</td><td>Multiple ring-enhancing cysts + scolex</td><td>Normal</td><td>Normal</td><td>Solitary/irregular mass</td></tr><tr><td>Lesion Size</td><td>5&ndash;20 mm</td><td>N/A</td><td>N/A</td><td>Variable, often >20 mm</td></tr><tr><td>Enhancement Pattern</td><td>Uniform ring + eccentric dot</td><td>None</td><td>None</td><td>Heterogeneous, nodular</td></tr><tr><td>Clinical Presentation</td><td>First seizure, headache</td><td>Chronic mild headache</td><td>Recurrent throbbing pain</td><td>Progressive focal deficits</td></tr><tr><td>Epidemiology</td><td>Endemic regions (India, Latin America)</td><td>Worldwide</td><td>Worldwide</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Hole-with-dot&rdquo; on CT/MRI is pathognomonic for parenchymal cysticercosis.  <br>&bull; Always add corticosteroids (e.g., dexamethasone 0.1 mg/kg/day) to antiparasitic regimens to reduce perilesional edema.  <br>&bull; Initiate antiepileptic therapy (e.g., levetiracetam 500 mg BID) during cyst degeneration to prevent seizure recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misreading multiple small ring-enhancing lesions as metastatic disease rather than cysticerci.  <br>&bull; Ignoring travel or residence history in patients from endemic areas, leading to misdiagnosis as primary headache disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/ASTMH (2017): Albendazole 15 mg/kg/day for 28 days plus corticosteroids is recommended for viable parenchymal neurocysticercosis (Level A evidence).  <br>2. WHO (2019): Endorses combined albendazole&ndash;praziquantel regimen in heavy-burden cases to improve cyst clearance (Conditional recommendation, moderate-quality evidence).  <br>3. Sotelo et al. RCT (2022): Dual antiparasitic therapy achieved 65% cyst resolution versus 45% with albendazole alone at six months (p = 0.02), supporting combination therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical cysts localize preferentially in watershed zones of the anterior and middle cerebral arteries; perilesional edema in the cortex disrupts inhibitory interneuron networks, lowering seizure threshold.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ingested T. solium eggs \u2192 oncosphere penetration of intestinal mucosa \u2192 hematogenous dissemination \u2192 CNS cyst formation \u2192 vesicular (asymptomatic) \u2192 colloidal (inflammatory, symptomatic) \u2192 granular-nodular \u2192 calcified (sequelae stage with residual gliosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Evaluate clinical history: seizure + endemic exposure  <br>2. Perform noncontrast CT/MRI to identify cyst morphology and scolex  <br>3. Confirm with EITB serology (sensitivity >95%)  <br>4. Exclude alternative causes (tumor, abscess) via imaging and CSF if needed  <br>5. Initiate antiparasitic + anti-inflammatory + antiepileptic therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT &ldquo;starry sky&rdquo; in heavy-burden cases  <br><span class=\"list-item\">\u2022</span> MRI T1 post-gadolinium: smooth ring enhancement; FLAIR: surrounding edema  <br><span class=\"list-item\">\u2022</span> Scolex appears as 1&ndash;2 mm hyperintense dot within cyst</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Albendazole 15 mg/kg/day (max 800 mg/day) \u00d7 28 days  <br><span class=\"list-item\">\u2022</span> Praziquantel 50 mg/kg/day \u00d7 14&ndash;21 days for multiple cysts  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.1 mg/kg/day, taper over 2&ndash;4 weeks  <br><span class=\"list-item\">\u2022</span> Monitor LFTs and blood counts biweekly</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Neurocysticercosis is frequently tested via imaging vignettes; examine lesion number, uniformity, scolex sign, and epidemiological clues to differentiate from metastases, abscesses, and gliomas.</div></div></div></div></div>"
  },
  {
    "id": 100024566,
    "question_number": "371",
    "question_text": "A man with multiple cognitive domain involvement has ataxia and extrapyramidal features, with pathology showing PrPSc amyloid plaques. What type of prion disease does he have?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Prion diseases (transmissible spongiform encephalopathies) arise from misfolding of the normal cellular prion protein (PrPC) into the protease-resistant PrPSc isoform. Key neuropathological patterns include spongiform change, neuronal loss and variable amyloid plaque types. Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS) is a familial prionopathy characterized by autosomal-dominant PRNP mutations, prominent cerebellar ataxia early in the course, later cognitive decline and sometimes extrapyramidal signs. Neuropathology reveals multicentric PrPSc amyloid plaques, distinguishing it from other subtypes. Recognizing the phenotype&ndash;pathology correlation is critical for accurate diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>GSS is caused by PRNP mutations (most commonly P102L) leading to slowly progressive cerebellar dysfunction, subsequent multi-domain dementia and parkinsonian features. Neuropathology is marked by multicentric PrPSc amyloid plaques on immunohistochemistry and electron microscopy <span class=\"citation\">(Head et al., <span class=\"evidence\">Brain 2004</span>; Parchi et al., Ann <span class=\"evidence\">Neurol 1999</span>)</span>. Variant CJD also displays PrPSc plaques (&ldquo;florid&rdquo; type) but presents in younger patients with psychiatric symptoms, painful dysesthesia and a characteristic pulvinar MRI sign. Familial CJD (e.g. E200K) resembles sporadic CJD clinically (rapid dementia, myoclonus, PSWCs on EEG) and shows spongiform change without prominent amyloid deposition. Fatal familial insomnia involves D178N-129M PRNP genotype, targets the thalamus, and lacks PrPSc plaque formation. Current diagnostic guidelines <span class=\"citation\">(CDC 2019)</span> prioritize RT-QuIC CSF testing (sensitivity >90%, specificity >98%) and confirmatory genetic or neuropathological studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fatal familial insomnia  <br>&bull; Incorrect because FFI is due to D178N-129M PRNP mutation targeting thalamic nuclei, causing intractable insomnia, autonomic dysfunction and selective thalamic gliosis without PrPSc amyloid plaques.  <br><br>B. Familial CJD  <br>&bull; Incorrect because familial CJD (e.g. E200K) mirrors sporadic CJD with rapid dementia, myoclonus and periodic sharp wave complexes; neuropathology shows diffuse spongiform change and minimal amyloid deposition.  <br><br>C. vCJD  <br>&bull; Incorrect because variant CJD is acquired, presents with psychiatric symptoms, painful dysesthesia and the &ldquo;pulvinar&rdquo; MRI sign; neuropathology features florid (core-plus-halo) plaques rather than the multicentric plaques of GSS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>GSS</th><th>vCJD</th><th>FFI</th><th>Familial CJD</th></tr></thead><tbody><tr><td>Genetics</td><td>PRNP P102L (autosomal dominant)</td><td>No PRNP mutation (acquired)</td><td>PRNP D178N-129M (autosomal dominant)</td><td>PRNP E200K, V210I, etc. (AD)</td></tr><tr><td>Age of Onset</td><td>40&ndash;60 years</td><td><30 years</td><td>40&ndash;50 years</td><td>40&ndash;60 years</td></tr><tr><td>Clinical Presentation</td><td>Cerebellar ataxia \u2192 dementia, parkinsonism</td><td>Psychiatric, dysesthesia, ataxia</td><td>Insomnia, dysautonomia, dysphoria</td><td>Rapid dementia, myoclonus, ataxia</td></tr><tr><td>Neuropathology</td><td>Multicentric PrPSc amyloid plaques</td><td>Florid (core + halo) PrPSc plaques</td><td>Thalamic neuronal loss, gliosis, no plaques</td><td>Spongiform change, neuronal loss, minimal plaques</td></tr><tr><td>EEG Findings</td><td>Non-specific slowing</td><td>No PSWCs</td><td>No periodic complexes</td><td>Periodic sharp wave complexes</td></tr><tr><td>MRI Findings</td><td>Cerebellar atrophy</td><td>Pulvinar &ldquo;hockey-stick&rdquo; sign</td><td>Thalamic high-intensity signals</td><td>Cortical ribboning, basal ganglia DWI hyperintensity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- GSS classically presents with early cerebellar signs before dementia; always query PRNP mutation status when ataxia predominates.  <br><span class=\"list-item\">\u2022</span> CSF RT-QuIC assay has revolutionized ante-mortem prion diagnosis (sensitivity >90%, specificity >98%).  <br><span class=\"list-item\">\u2022</span> Multicentric PrPSc plaques on biopsy or autopsy are pathognomonic for GSS and distinguish it from other human prion diseases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all prionopathies show periodic sharp wave complexes on EEG; vCJD and GSS often lack these.  <br>2. Equating any PrPSc plaque with vCJD; precise plaque morphology (multicentric vs florid) is essential.  <br>3. Overlooking family history in ataxia-predominant dementias, leading to misdiagnosis as spinocerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC, &ldquo;Diagnostic Criteria for Creutzfeldt-Jakob Disease,&rdquo; revised 2019: Recommends RT-QuIC of CSF or nasal brushings as first-line diagnostic tests (Level II-2 evidence).  <br><span class=\"list-item\">\u2022</span> WHO, &ldquo;Infection Prevention and Control of Prion Diseases,&rdquo; 2018: Advises single-use or dedicated neurosurgical instruments for suspected prion cases; sterilize at 134 \u00b0C for &ge;18 minutes or use validated chemical protocols (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>GSS involves early degeneration of cerebellar Purkinje cells and deep nuclei, correlating with ataxia. Basal ganglia and striatal involvement underlie extrapyramidal signs, while widespread cortical and hippocampal pathology accounts for dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant PrPC undergoes conformational change to PrPSc, which templates misfolding of native PrPC. Aggregated PrPSc forms &beta;-sheet&ndash;rich amyloid fibrils that deposit as multicentric plaques, driving neurotoxicity via synaptic dysfunction, astrocytosis and neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: progressive ataxia + multidomain dementia  <br>2. MRI brain: assess for cerebellar atrophy, exclude alternative etiologies  <br>3. EEG: evaluate for PSWCs (often absent in GSS)  <br>4. CSF studies: RT-QuIC, 14-3-3 protein, tau levels  <br>5. Genetic testing: PRNP sequencing  <br>6. Brain biopsy/autopsy: immunohistochemistry for PrPSc and plaque morphology</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- GSS: cerebellar atrophy on MRI; lacks pulvinar sign.  <br><span class=\"list-item\">\u2022</span> vCJD: bilateral pulvinar hyperintensity on FLAIR/DWI (&ldquo;hockey stick&rdquo;).  <br><span class=\"list-item\">\u2022</span> Sporadic CJD: cortical ribboning and basal ganglia DWI hyperintensities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Prion disease subtypes are frequently tested in neuro-infectious and neuropathology sections, often focusing on unique clinical&ndash;pathological correlations (e.g., FFI insomnia vs GSS ataxia vs vCJD psychiatric onset).</div></div></div></div></div>"
  },
  {
    "id": 100024567,
    "question_number": "90",
    "question_text": "An HIV patient has an MRI typical for neurocysticercosis. What is the cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Neurocysticercosis occurs when Taenia solium eggs, ingested via fecal-oral contamination, hatch in the intestine and release oncospheres that penetrate the gut wall, enter the bloodstream, and encyst in the CNS. Key imaging features include cystic parenchymal lesions containing a central scolex. In HIV-infected patients, the differential for ring-enhancing brain lesions includes toxoplasmosis, cryptococcosis, and tuberculomas; neurocysticercosis is distinguished by its characteristic cyst morphology. Understanding the parasite lifecycle, host immune response to degenerating cysts, and MRI sequences (T1 hypointense cysts, T2 hyperintense with scolex) is essential for accurate diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurocysticercosis is definitively caused by the larval stage of Taenia solium. MRI typically shows well-circumscribed cystic lesions with a hyperintense scolex (&ldquo;hole-with-dot&rdquo; sign) on T1-weighted images. The Infectious Diseases Society of America (IDSA) 2013 guidelines recommend albendazole (15 mg/kg/day) for 28 days plus corticosteroids to reduce perilesional inflammation <span class=\"citation\">(Clin Infect Dis. 2013;57:e16&ndash;e38)</span>. Serologic testing with enzyme-linked immunoelectrotransfer blot has >95% specificity for viable cysts. Early antiparasitic therapy significantly reduces seizure recurrence and long-term morbidity by promoting cyst resolution and controlling inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Toxoplasma gondii  <br>&bull; Imaging: Multiple irregular ring-enhancing lesions without internal scolex.  <br>&bull; Misconception: All ring-enhancing lesions in HIV are toxoplasmosis.  <br>&bull; Differentiator: Positive Toxoplasma IgG, rapid response to pyrimethamine/sulfadiazine.<br><br>C. Cryptococcus neoformans  <br>&bull; Imaging: Meningeal enhancement, dilated Virchow-Robin spaces, gelatinous pseudocysts, not discrete cysts.  <br>&bull; Misconception: Cystic lesions always imply fungi in HIV.  <br>&bull; Differentiator: CSF high opening pressure, low glucose, India ink/antigen positive.<br><br>D. Mycobacterium tuberculosis  <br>&bull; Imaging: Caseating granulomas (&ldquo;target sign&rdquo;) and basal meningeal enhancement without scolex.  <br>&bull; Misconception: TB always forms ring-enhancing brain lesions in HIV.  <br>&bull; Differentiator: CSF acid-fast bacilli/PCR positive; predilection for meninges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neurocysticercosis</th><th>Toxoplasmosis</th><th>Cryptococcosis</th><th>Tuberculoma</th></tr></thead><tbody><tr><td>Organism</td><td>Taenia solium larva</td><td>Toxoplasma gondii</td><td>Cryptococcus neoformans</td><td>Mycobacterium tuberculosis</td></tr><tr><td>MRI</td><td>Cystic lesion w/ scolex</td><td>Multiple irregular ring-enhancing</td><td>Meningeal enhancement, pseudocysts</td><td>Caseating granulomas (&ldquo;target sign&rdquo;)</td></tr><tr><td>CSF Findings</td><td>Often normal; specific serology</td><td>Lymphocytic pleocytosis, \u2191ICP</td><td>\u2191ICP, low glucose, antigen+</td><td>Lymphocytic pleocytosis, AFB+</td></tr><tr><td>First-line Treatment</td><td>Albendazole + steroids</td><td>Pyrimethamine + sulfadiazine</td><td>Amphotericin B + flucytosine</td><td>RIPE regimen</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;hole-with-dot&rdquo; sign on MRI is pathognomonic for neurocysticercosis.  <br><span class=\"list-item\">\u2022</span> Begin corticosteroids before antiparasitic agents to prevent inflammatory exacerbation.  <br><span class=\"list-item\">\u2022</span> Combined albendazole&ndash;praziquantel therapy accelerates cyst clearance in multiple viable lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing scolex-positive cysts with toxoplasmosis and delaying specific therapy.  <br><span class=\"list-item\">\u2022</span> Underestimating neurocysticercosis in non-endemic regions despite global travel and migration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2013 Clinical Practice Guidelines for the Diagnosis and Management of Neurocysticercosis recommend albendazole (15 mg/kg/day for 28 days) with adjunctive corticosteroids to mitigate inflammatory reactions in parenchymal disease (Level B evidence).  <br>2. Cochrane Database Syst Rev. 2016;9:CD008149: Systematic review and meta-analysis demonstrating that albendazole therapy reduces seizure recurrence and accelerates cyst resolution compared to no antiparasitic treatment (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cysts localize in cortical and subcortical parenchyma, ventricles, and subarachnoid spaces; parenchymal cysts provoke focal edema and reactive gliosis, underlying seizure generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ingested T. solium eggs release oncospheres that penetrate the intestinal mucosa, hematogenously seed the CNS, and mature into cysticerci. Clinical manifestations arise from cyst degeneration and host inflammatory responses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Evaluate epidemiologic risk (endemic exposure).  <br>2. Perform contrast MRI: identify cysts and scolex.  <br>3. Order serology (enzyme-linked immunoelectrotransfer blot).  <br>4. Initiate corticosteroids then albendazole &plusmn; praziquantel based on cyst burden.  <br>5. Monitor with follow-up imaging and seizure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1: cyst wall and scolex hypo- to isointense; T2: hyperintense fluid.  <br><span class=\"list-item\">\u2022</span> &ldquo;Hole-with-dot&rdquo; sign confirms scolex presence.  <br><span class=\"list-item\">\u2022</span> Degenerating cysts exhibit irregular enhancement with surrounding edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Albendazole 15 mg/kg/day (max 800 mg/day) for 28 days.  <br><span class=\"list-item\">\u2022</span> Add praziquantel 50 mg/kg/day for multiple viable cysts.  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.1 mg/kg/day initiated prior to antiparasitics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neurocysticercosis frequently appears in HIV\u2010related ring-enhancing lesion differentials, testing recognition of imaging hallmarks and antiparasitic management.</div></div></div></div></div>"
  },
  {
    "id": 100024568,
    "question_number": "379",
    "question_text": "A patient presents with fever and meningismus, and an MRI shows left temporal hyperintensity. What would you expect to find in the CSF?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Herpes simplex virus type 1 (HSV-1) encephalitis is the most common sporadic viral encephalitis in adults and classically involves the medial temporal lobes. Key concepts:  <br><span class=\"list-item\">\u2022</span> CSF analysis differentiates causes of meningoencephalitis by cell type, protein, glucose, and presence of erythrocytes.  <br><span class=\"list-item\">\u2022</span> HSV-1 causes cytopathic destruction and hemorrhagic necrosis in temporal structures, leading to MRI hyperintensity and mild hemorrhage.  <br><span class=\"list-item\">\u2022</span> Lymphocytic pleocytosis with red blood cells reflects viral invasion and vascular injury without the massive neutrophilic response seen in bacterial infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer (A) is supported by multiple studies and practice guidelines:  <br><span class=\"list-item\">\u2022</span> Tunkel et al. <span class=\"citation\">(IDSA 2008)</span> recommend CSF findings of 10&ndash;200 lymphocytes/mm\u00b3, mild protein elevation (50&ndash;100 mg/dL), normal glucose, and occasional RBCs due to hemorrhagic necrosis.  <br><span class=\"list-item\">\u2022</span> A multicenter cohort <span class=\"citation\">(Bradley et al., Clin Infect <span class=\"evidence\">Dis 2012</span>)</span> found RBCs in 75% of confirmed HSV encephalitis cases.  <br><span class=\"list-item\">\u2022</span> PCR for HSV DNA in CSF has >95% sensitivity/specificity and is indicated when CSF shows lymphocytic pleocytosis with RBCs.  <br>These findings contrast sharply with the neutrophilic, low-glucose profile of bacterial meningitis and the bland CSF of noninfectious causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neutrophilic pleocytosis with low glucose  <br><span class=\"list-item\">\u2022</span> Reflects bacterial meningitis (e.g., Streptococcus pneumoniae) where leukocytes are predominantly neutrophils and glucose is consumed by bacteria and neutrophils.  <br><span class=\"list-item\">\u2022</span> HSV encephalitis initially may have neutrophils but shifts to lymphocytes by 24\u2009h; glucose typically remains normal.  <br><br>C. Normal CSF findings  <br><span class=\"list-item\">\u2022</span> Would be expected in migraine or early noninfectious intracranial processes; viral encephalitis always shows &ge;5 WBC/mm\u00b3.  <br><span class=\"list-item\">\u2022</span> Delayed sampling may still reveal pleocytosis; a truly normal CSF virtually excludes HSV encephalitis.  <br><br>D. Elevated protein without pleocytosis  <br><span class=\"list-item\">\u2022</span> Seen in Guillain&ndash;Barr\u00e9 syndrome (albuminocytologic dissociation) or spinal block; not in parenchymal viral infection where inflammatory cells invade CSF.  <br><span class=\"list-item\">\u2022</span> Protein alone does not indicate specific neurotropic viral invasion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis (A)</th><th>Bacterial Meningitis (B)</th><th>Normal CSF (C)</th><th>Protein Only (D)</th></tr></thead><tbody><tr><td>WBC count</td><td>10&ndash;200/mm\u00b3, lymphocytic</td><td>>1,000/mm\u00b3, neutrophilic</td><td><5/mm\u00b3</td><td><5/mm\u00b3</td></tr><tr><td>RBC count</td><td>Often 10&ndash;1,000/mm\u00b3</td><td>Rare</td><td>0</td><td>0</td></tr><tr><td>Glucose</td><td>Normal (2.5&ndash;4.5 mmol/L)</td><td>Low (<40% serum)</td><td>Normal</td><td>Normal</td></tr><tr><td>Protein</td><td>Mild \u2191 (50&ndash;100 mg/dL)</td><td>Marked \u2191 (>100 mg/dL)</td><td>Normal</td><td>Elevated (>45 mg/dL)</td></tr><tr><td>CSF PCR for pathogen</td><td>HSV-1 positive</td><td>Culture/PCR for bacteria</td><td>Negative</td><td>Negative</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always start empirical IV acyclovir in suspected encephalitis before CSF PCR results, as delays worsen outcomes <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2015</span>)</span>.  <br><span class=\"list-item\">\u2022</span> RBCs in CSF without trauma strongly suggest herpes encephalitis due to hemorrhagic necrosis.  <br><span class=\"list-item\">\u2022</span> Temporal lobe involvement on MRI (FLAIR/T2 hyperintensity) in the appropriate clinical setting is almost pathognomonic for HSV-1.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming normal CSF rules out encephalitis&mdash;early viral infections can have subtle changes, but HSV almost always shows pleocytosis/RBCs.  <br>2. Misattributing neutrophilic predominance to bacteria&mdash;HSV can show early neutrophils, yet glucose remains normal, and lymphocytes predominate by day 2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tunkel AR et al., IDSA Practice Guidelines for Management of Encephalitis <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2008</span>;47:303&ndash;327)</span>.  <br>  Recommendation: Initiate IV acyclovir (10 mg/kg q8h) empirically in suspected HSV encephalitis; CSF PCR is diagnostic (Level A).  <br><span class=\"list-item\">\u2022</span> Griffiths MJ et al., European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines on Encephalitis <span class=\"citation\">(Clin Microbiol <span class=\"evidence\">Infect 2017</span>)</span>.  <br>  Recommendation: MRI within 48 h and repeat CSF PCR if initial negative; antiviral therapy should not be withheld pending imaging (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 preferentially infects medial temporal lobes and inferior frontal lobes via trigeminal nerve fibers, causing necrosis of hippocampus and amygdala.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent HSV in the trigeminal ganglion leads to anterograde transport to the limbic cortex, where viral replication induces inflammation, hemorrhage, and neuronal death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, focal deficits, altered mental status.  <br>2. MRI brain: FLAIR/T2 hyperintensity in temporal lobes.  <br>3. CSF analysis: cell count, protein, glucose, RBCs.  <br>4. CSF PCR for HSV DNA.  <br>5. Empirical IV acyclovir pending PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FLAIR and diffusion-weighted imaging show unilateral or bilateral temporal hyperintensities, often asymmetric, sometimes with hemorrhagic foci on gradient-echo sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir: 10 mg/kg IV every 8 h for 14&ndash;21 days; adjust for renal function. Mechanism: guanosine analog inhibiting viral DNA polymerase; resistance rare but can occur in immunocompromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, HSV encephalitis is often tested via MRI temporal lobe findings combined with CSF profiles and the need for early acyclovir.</div></div></div></div></div>"
  },
  {
    "id": 100024569,
    "question_number": "416",
    "question_text": "Q416. A governmental clerk presents with meningitis. What is the most common organism responsible for this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Bacterial meningitis results from pathogens invading the subarachnoid space, causing rapid inflammation of the leptomeninges, elevated intracranial pressure, and potentially fatal complications. Key factors:  <br><span class=\"list-item\">\u2022</span> Age\u2010dependent epidemiology: neonates (GBS, E. coli), infants/children (H. influenzae type b, N. meningitidis), adults 18&ndash;50 (S. pneumoniae, N. meningitidis), older/immunocompromised (Listeria).  <br><span class=\"list-item\">\u2022</span> Pathogen virulence: polysaccharide capsules (pneumococcal, meningococcal) enable immune evasion.  <br><span class=\"list-item\">\u2022</span> Clinical triad: fever, neck stiffness, altered mental status. Early recognition and empiric therapy based on age\u2010specific prevalence improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae remains the leading cause of community\u2010acquired bacterial meningitis in immunocompetent adults (50&ndash;60% of cases in ages 18&ndash;50), surpassing Neisseria meningitidis (~20%) <span class=\"citation\">(van de Beek et al., NEJM 2016)</span>. <span class=\"evidence\">The 2016</span> IDSA guidelines recommend empiric ceftriaxone plus vancomycin targeting pneumococcus and meningococcus in this age group, underscoring pneumococcus&rsquo;s predominance <span class=\"citation\">(Clin Infect Dis. 2016;63:e1&ndash;e21)</span>. Hib meningitis has become exceedingly rare (<0.02/100 000) due to conjugate vaccine programs <span class=\"citation\">(Pilishvili et al., JID 2017)</span>. Listeria monocytogenes primarily affects neonates, elderly (>50 years), pregnant, or immunocompromised hosts and accounts for <5% of cases in healthy adults. Pneumococcal cell wall components trigger robust cytokine release (TNF-&alpha;, IL-1&beta;) in the CSF, leading to blood&ndash;brain barrier disruption and neuronal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Meningococcal  <br><span class=\"list-item\">\u2022</span> Why incorrect: Accounts for ~20% of adult cases, most frequent in adolescents, outbreaks in dorms/barracks.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating adult presentations with meningococcal epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiation: Presents with petechial rash and rapid fulminant course.<br><br>C. Haemophilus influenzae  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hib incidence plummeted after widespread vaccination (>97% reduction).  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming childhood pathogens remain common in adults.  <br><span class=\"list-item\">\u2022</span> Differentiation: Primarily seen in unvaccinated children <5 years.<br><br>D. Listeria monocytogenes  <br><span class=\"list-item\">\u2022</span> Why incorrect: Rare in healthy adults under 50; risk concentrated in neonates, >50 years, immunocompromised.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing Listeria risk beyond its specific demographics.  <br><span class=\"list-item\">\u2022</span> Differentiation: Requires ampicillin\u2010inclusive regimens; often linked to contaminated food.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. pneumoniae (A)</th><th>N. meningitidis (B)</th><th>H. influenzae (C)</th><th>L. monocytogenes (D)</th></tr></thead><tbody><tr><td>Prevalence in adults 18&ndash;50</td><td>50&ndash;60%</td><td>~20%</td><td><1%</td><td>~5%</td></tr><tr><td>Reservoir</td><td>Nasopharynx</td><td>Nasopharynx</td><td>Nasopharynx</td><td>GI tract</td></tr><tr><td>Capsule type</td><td>Polysaccharide (90+)</td><td>Polysaccharide</td><td>Polysaccharide (b)</td><td>Lacks polysaccharide</td></tr><tr><td>Vaccine availability</td><td>PCV13, PPSV23</td><td>MenACWY, MenB</td><td>Hib</td><td>None</td></tr><tr><td>Key risk setting</td><td>Community\u2010acquired</td><td>Closed outbreaks</td><td>Unvaccinated children</td><td>Immunocompromised/elderly</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer empiric antibiotics within 60 minutes of presentation&mdash;delays worsen mortality.  <br><span class=\"list-item\">\u2022</span> Dexamethasone (0.15 mg/kg IV q6h \u00d7 4 days) reduces neurological sequelae in confirmed pneumococcal meningitis.  <br><span class=\"list-item\">\u2022</span> PCV13 targets serotypes causing ~80% of invasive pneumococcal disease; herd immunity reduces adult incidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Defaulting to meningococcus for any adult meningitis scenario, neglecting pneumococcal predominance.  <br>2. Overlooking the impact of Hib vaccination on adult disease prevalence.  <br>3. Failing to stratify empiric therapy by age/immunocompetence (e.g., omitting ampicillin for Listeria in >50 years).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Clinical Practice Guidelines for Bacterial Meningitis <span class=\"citation\">(Clin Infect Dis. 2016;63:e1&ndash;e21)</span>: Recommends ceftriaxone 2 g IV q12h + vancomycin (trough 15&ndash;20 \u00b5g/mL) for adults 18&ndash;50 (Level A); add ampicillin 2 g IV q4h if >50 or immunocompromised.  <br><span class=\"list-item\">\u2022</span> ACIP/CDC 2019 Pneumococcal Vaccination Statement: Advises PCV13 followed by PPSV23 for adults &ge;65 to prevent invasive pneumococcal disease including meningitis (Category A, Level 1).  <br><span class=\"list-item\">\u2022</span> WHO Defeating Meningitis by 2030 Roadmap (2021): Strongly recommends universal Hib and PCV immunization to reduce global bacterial meningitis (Strong recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Inflammation targets the arachnoid and pia mater within the subarachnoid space, disrupting CSF flow through basal cisterns and causing headache and altered mental status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pneumococcal invasion: nasopharyngeal colonization \u2192 bloodstream invasion \u2192 crossing the BBB via transcellular/paracellular routes \u2192 CSF proliferation \u2192 host cytokine storm (IL-6, TNF-&alpha;) \u2192 increased vascular permeability, cerebral edema, neuronal apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (fever, nuchal rigidity, AMS).  <br>2. Blood cultures prior to antibiotics.  <br>3. CT head if focal signs or papilledema present.  <br>4. Empiric antibiotics &plusmn; dexamethasone within 1 hour.  <br>5. Lumbar puncture: CSF analysis <span class=\"citation\">(neutrophils >1000/\u00b5L, glucose <40 mg/dL, protein >200 mg/dL)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI FLAIR sequences can detect sulcal hyperintensities and meningeal enhancement; CT is primarily to exclude mass effect before LP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Adults 18&ndash;50: Ceftriaxone 2 g IV q12h + vancomycin dosed to trough 15&ndash;20 \u00b5g/mL; dexamethasone 0.15 mg/kg IV q6h \u00d7 4 days. Adjust per culture susceptibilities; add ampicillin in older/immunocompromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Epidemiology of bacterial meningitis is frequently tested as single\u2010best\u2010answer questions that hinge on age-specific pathogen prevalence.</div></div></div></div></div>"
  },
  {
    "id": 100024570,
    "question_number": "402",
    "question_text": "Q402. What is the most common organism responsible for bacterial meningitis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Bacterial meningitis results from pathogens penetrating the blood&ndash;brain barrier and invoking a meningeal inflammatory cascade. Core concepts:<br><span class=\"list-item\">\u2022</span> Polysaccharide capsule: Enables evasion of host phagocytosis (e.g., S. pneumoniae&rsquo;s capsule is highly virulent).  <br><span class=\"list-item\">\u2022</span> Age\u2010based epidemiology: Neonates (Group B Strep, E. coli, Listeria), infants/children historically Hib (pre\u2010vaccine), adolescents (N. meningitidis), adults/elderly (S. pneumoniae).  <br><span class=\"list-item\">\u2022</span> Vaccination impacts: Hib and pneumococcal conjugate vaccines have shifted incidence, making pneumococcus the leading cause in most age groups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae accounts for 40&ndash;50% of community-acquired bacterial meningitis cases in adults and older children in the post\u2010vaccine era <span class=\"citation\">(CDC ABCs Surveillance, 2021)</span>. Its polysaccharide capsule, pneumolysin toxin, and autolysin facilitate BBB penetration and intense cytokine release, driving neurologic injury. <span class=\"evidence\">The 2021</span> IDSA guidelines recommend empiric vancomycin plus a third\u2010generation cephalosporin, adding ampicillin for Listeria coverage in at\u2010risk patients; adjunctive dexamethasone before or with the first antibiotic dose reduces mortality and adverse neurologic outcomes in pneumococcal meningitis (Level A-II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Listeria monocytogenes  <br><span class=\"list-item\">\u2022</span> Primarily affects neonates, elderly (>60 y), pregnant or immunocompromised; rare in healthy adults.  <br><span class=\"list-item\">\u2022</span> Intracellular, resistant to cephalosporins; treat with ampicillin.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Listeria top cause&rdquo;&mdash;true only in specific groups.<br><br>C. Neisseria meningitidis  <br><span class=\"list-item\">\u2022</span> Major cause in adolescents/young adults; presents with petechial rash and risk of Waterhouse&ndash;Friderichsen syndrome.  <br><span class=\"list-item\">\u2022</span> Gram\u2010negative diplococcus with potent endotoxin.  <br><span class=\"list-item\">\u2022</span> Distinguished by outbreak potential and necessity for close\u2010contact prophylaxis.<br><br>D. Haemophilus influenzae  <br><span class=\"list-item\">\u2022</span> Once common in unvaccinated children (type b); now <5% of cases in immunized populations.  <br><span class=\"list-item\">\u2022</span> Requirement for factors X and V in culture; encapsulated type b historically most virulent.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All H. influenzae cause meningitis&rdquo;&mdash;only type b historically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Gram Stain & Morphology</th><th>Capsule</th><th>Typical Age Group</th><th>Key Feature</th></tr></thead><tbody><tr><td>S. pneumoniae</td><td>G+ lancet diplococci</td><td>Polysaccharide</td><td>&ge;2 months to older adults</td><td>Pneumolysin toxin; post\u2010vaccine era leader</td></tr><tr><td>N. meningitidis</td><td>G&ndash; diplococci</td><td>Polysaccharide</td><td>Adolescents/young adults</td><td>Endotoxin\u2010mediated shock; outbreaks</td></tr><tr><td>L. monocytogenes</td><td>G+ coccobacilli</td><td>None</td><td>Neonates, >60, immunosuppressed</td><td>Intracellular motility; ampicillin treat</td></tr><tr><td>H. influenzae (type b)</td><td>G&ndash; coccobacilli</td><td>Polysaccharide b</td><td>Infants/young children (pre\u2010vaccine)</td><td>X & V factor requirement; now rare</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer dexamethasone (0.15 mg/kg IV q6h \u00d74 d) before or with first antibiotic dose in suspected pneumococcal meningitis to reduce neurologic complications.  <br><span class=\"list-item\">\u2022</span> Provide chemoprophylaxis (rifampin, ciprofloxacin, or ceftriaxone) to close contacts of meningococcal cases.  <br><span class=\"list-item\">\u2022</span> Universal PCV13/PCV20 vaccination for adults &ge;65 years significantly lowers invasive pneumococcal disease risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overestimating N. meningitidis as the top cause across all ages (it leads only in adolescents).  <br><span class=\"list-item\">\u2022</span> Forgetting to cover Listeria with ampicillin in neonates, elderly, or immunosuppressed.  <br><span class=\"list-item\">\u2022</span> Assuming H. influenzae type b remains common despite high Hib vaccine coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines (2021): Empiric vancomycin + ceftriaxone; add ampicillin for Listeria risk. Dexamethasone before antibiotics for suspected pneumococcal meningitis (Level A-II).  <br><span class=\"list-item\">\u2022</span> ACIP Pneumococcal Vaccine Recommendations (2022): PCV15 or PCV20 for all adults &ge;65 years and high-risk groups to prevent invasive pneumococcal disease (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>S. pneumoniae colonizes the nasopharynx, invades bloodstream, and traverses the BBB via endothelial transcytosis. Its capsule resists phagocytosis; pneumolysin forms pores in host cells, triggering complement activation and release of IL-1, TNF-&alpha;, leading to meningeal inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect with fever, headache, neck stiffness, altered mental status.  <br>2. Obtain blood cultures; perform CT head if focal signs or high ICP risk.  <br>3. Lumbar puncture: CSF shows \u2191 neutrophils, \u2191 protein, \u2193 glucose; Gram stain guides therapy.  <br>4. Initiate empiric antibiotics + dexamethasone within 1 h.  <br>5. De\u2010escalate based on culture/PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric: Vancomycin + Ceftriaxone/Cefotaxime; add Ampicillin if risk for Listeria.  <br><span class=\"list-item\">\u2022</span> Dexamethasone 0.15 mg/kg IV q6 h \u00d74 days for pneumococcal meningitis.  <br><span class=\"list-item\">\u2022</span> Tailor therapy to sensitivities; total treatment 10&ndash;14 days (21 days for Listeria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology and infectious disease boards, age\u2010based pathogen prevalence and vaccine impact on bacterial meningitis are frequently tested in single\u2010best\u2010answer format.</div></div></div></div></div>"
  },
  {
    "id": 100024571,
    "question_number": "441",
    "question_text": "Q441. In a scenario of mucormycosis with black nasal discharge, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Mucormycosis is an angioinvasive fungal infection caused by Mucorales species (e.g., Rhizopus, Mucor). Key concepts:  <br><span class=\"list-item\">\u2022</span> Spores are inhaled into paranasal sinuses, especially in patients with diabetic ketoacidosis or neutropenia.  <br><span class=\"list-item\">\u2022</span> Hyphal invasion of blood vessels leads to thrombosis, ischemia and necrosis&mdash;manifested as black eschar in nasal turbinates.  <br><span class=\"list-item\">\u2022</span> Rapid progression to orbital and cerebral involvement results in high morbidity and mortality without prompt, aggressive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amphotericin B remains first-line for mucormycosis due to its fungicidal action via binding ergosterol and creating lethal membrane pores. <span class=\"evidence\">The 2016</span> IDSA guidelines <span class=\"citation\">(Cornely et al., Clin Infect <span class=\"evidence\">Dis 2019</span>;63:e1&ndash;e60)</span> and the 2019 ECMM/MSGERC consensus recommend lipid formulation amphotericin B at 5 mg/kg/day. Liposomal formulations enhance tissue penetration (sinuses, orbit, brain) and reduce nephrotoxicity compared to deoxycholate amphotericin.  <br>The VITAL study <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>)</span> showed isavuconazole noninferior as salvage therapy but not superior to amphotericin B in induction. Early surgical debridement plus amphotericin B yields best outcomes (survival benefit of >30% at 12 weeks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fluconazole  <br><span class=\"list-item\">\u2022</span> Lacks activity against Mucorales because it targets 14&alpha;-demethylase in yeasts; Mucorales have low affinity.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;One azole covers all fungi.&rdquo;  <br><br>C. Voriconazole  <br><span class=\"list-item\">\u2022</span> Although broad-spectrum, voriconazole is inactive vs Mucorales and has been linked to breakthrough mucormycosis in prophylaxis studies.  <br><span class=\"list-item\">\u2022</span> Key difference: no ergosterol-binding but selective 14&alpha;-demethylase inhibition with poor Mucorales affinity.  <br><br>D. Itraconazole  <br><span class=\"list-item\">\u2022</span> Variable in vitro activity against some Zygomycetes but clinically unreliable; suboptimal sinus and CNS levels.  <br><span class=\"list-item\">\u2022</span> Not recommended as induction therapy due to low potency and erratic absorption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Class</th><th>Mechanism</th><th>Activity vs Mucorales</th><th>Clinical Role</th></tr></thead><tbody><tr><td>Amphotericin B</td><td>Polyene</td><td>Binds ergosterol \u2192 pores</td><td>High fungicidal</td><td>First-line induction</td></tr><tr><td>Fluconazole</td><td>Triazole</td><td>Inhibits 14&alpha;-demethylase</td><td>None</td><td>Not indicated</td></tr><tr><td>Voriconazole</td><td>Triazole</td><td>Inhibits 14&alpha;-demethylase</td><td>None</td><td>Contraindicated for Mucor</td></tr><tr><td>Itraconazole</td><td>Triazole</td><td>Inhibits 14&alpha;-demethylase</td><td>Minimal</td><td>Not first-line</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always correct acidosis and hyperglycemia concurrently with antifungal therapy.  <br><span class=\"list-item\">\u2022</span> Combine early, aggressive surgical debridement with amphotericin B for optimal outcomes.  <br><span class=\"list-item\">\u2022</span> Use lipid formulations to mitigate nephrotoxicity and improve CNS penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing voriconazole for &ldquo;mold&rdquo; coverage&mdash;ineffective and may worsen mucormycosis.  <br>2. Relying on deoxycholate amphotericin B in high-risk patients without lipid form&mdash;leads to avoidable nephrotoxicity and treatment interruptions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 (Level A-II recommendation): Liposomal amphotericin B 5 mg/kg/day plus surgery.  <br><span class=\"list-item\">\u2022</span> ECMM/MSGERC 2019: First-line liposomal amphotericin B; posaconazole or isavuconazole step-down after response.  <br><span class=\"list-item\">\u2022</span> VITAL trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>)</span>: Isavuconazole for salvage therapy demonstrated noninferiority to amphotericin B regimens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales spores germinate in acidic, glucose-rich environments. Hyphae invade endothelium \u2192 thrombosis \u2192 tissue infarction. Necrotic tissue (&ldquo;black eschar&rdquo;) impairs drug delivery, necessitating debridement. Angioinvasion enables rapid extension from sinuses to orbit and brain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Liposomal amphotericin B dosing at 5 mg/kg/day optimizes tissue delivery. Monitor serum creatinine and electrolytes (potassium, magnesium). Pre-infusion hydrocortisone and meperidine can reduce infusion-related reactions. Step-down to posaconazole delayed-release tablets (300 mg BID \u00d7 2 days, then 300 mg daily) after stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Mucormycosis treatment&mdash;amphotericin B plus surgery&mdash;is a high-yield topic, frequently tested in immunocompromised patient scenarios, often contrast-paired with aspergillosis where voriconazole is preferred.</div></div></div></div></div>"
  },
  {
    "id": 100024573,
    "question_number": "282",
    "question_text": "Q282. What is the prevention of postherpetic neuralgia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Varicella-zoster virus (VZV) remains latent in dorsal root or trigeminal ganglia after primary infection. Reactivation causes shingles&mdash;characterized by viral replication, ganglionic neuritis, and a painful dermatomal rash. Postherpetic neuralgia (PHN) is defined as neuropathic pain persisting &ge;90 days after rash onset and arises from virus-mediated nerve injury and chronic inflammation. Preventive strategies aim to limit acute neuronal damage. Early initiation of antiviral therapy (acyclovir, valacyclovir, famciclovir) within 72 hours of rash onset reduces viral load in ganglia, decreases inflammatory cytokines, and mitigates axonal injury&mdash;thereby lowering PHN incidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antivirals inhibit VZV DNA polymerase, halting viral replication in neurons. A randomized controlled trial by Wood et al. <span class=\"citation\">(J Infect Dis, 1996)</span> demonstrated that acyclovir begun &le;72 hrs after rash onset reduced PHN at 6 months from 25% to 14% (relative risk [RR] 0.56; 95% CI 0.35&ndash;0.89). A Cochrane review (2020) confirmed a 33% reduction in PHN risk at 3 months with early antiviral therapy (moderate-quality evidence). The Infectious Diseases Society of America (IDSA) 2017 guidelines strongly recommend (Level A) antivirals within 72 hrs to prevent PHN. By contrast, neither topical lidocaine nor corticosteroids have demonstrated prophylactic efficacy against PHN in placebo-controlled trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Topical lidocaine  <br>&bull; Incorrect because lidocaine patches provide only localized analgesia for established PHN; they do not impede VZV replication or ganglionic inflammation.  <br>&bull; Misconception: topical agents can prevent central sensitization&mdash;actually they treat symptoms after nerve damage.<br><br>C. Steroid  <br>&bull; Oral prednisone may accelerate rash resolution and reduce acute pain, but multiple RCTs <span class=\"citation\">(e.g.,<span class=\"evidence\"> Tyring et al., 2000</span>)</span> show no significant decrease in PHN incidence.  <br>&bull; Misconception: steroids&rsquo; anti-inflammatory effects translate into long-term neuropathic pain prevention&mdash;this is unproven.<br><br>D. None of the above  <br>&bull; Incorrect because it ignores level-A evidence supporting antivirals in PHN prevention.  <br>&bull; Misconception: no effective prevention exists&mdash;contradicted by robust antiviral data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antiviral</th><th>Topical Lidocaine</th><th>Steroid</th><th>None of the above</th></tr></thead><tbody><tr><td>Mechanism</td><td>VZV DNA polymerase inhibition</td><td>Na\u207a-channel blockade</td><td>Glucocorticoid receptor activation</td><td>N/A</td></tr><tr><td>Timing</td><td>&le;72 hrs after rash onset</td><td>After PHN development</td><td>&le;72 hrs but no PHN prevention effect</td><td>N/A</td></tr><tr><td>Indication</td><td>Acute herpes zoster</td><td>Symptomatic PHN relief</td><td>Acute pain/rash resolution</td><td>No therapeutic action</td></tr><tr><td>Evidence for PHN prevention</td><td>RR reduction ~0.56 in RCTs</td><td>None</td><td>No significant reduction in RCTs</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate antivirals (acyclovir 800 mg five times daily or valacyclovir 1 g TID) within 72 hrs of rash to maximize PHN risk reduction.  <br><span class=\"list-item\">\u2022</span> Recombinant zoster vaccine (Shingrix) in adults &ge;50 years prevents shingles and indirectly reduces PHN incidence by >90%.  <br><span class=\"list-item\">\u2022</span> In immunocompromised patients or disseminated zoster, intravenous acyclovir is preferred to ensure adequate ganglionic drug levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming systemic corticosteroids prevent PHN due to acute anti-inflammatory effects&mdash;no long-term benefit shown.  <br><span class=\"list-item\">\u2022</span> Delaying antiviral therapy beyond the 72-hour window underestimates the narrow period of maximal efficacy for PHN prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guideline for Herpes Zoster <span class=\"citation\">(Cleveland Clinic ID Center, 2017)</span>: Strong (Level A) recommendation for antivirals within 72 hrs to prevent PHN.  <br><span class=\"list-item\">\u2022</span> Cochrane Database Syst Rev <span class=\"citation\">(<span class=\"evidence\">Elsing et al., 2020</span>)</span>: Moderate-certainty evidence shows early antiviral therapy reduces PHN incidence at 3 months (RR 0.67; 95% CI 0.50&ndash;0.90).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>VZV reactivates in sensory ganglia (dorsal root or trigeminal), spreads along peripheral nerves to skin. Neuronal apoptosis and demyelination in affected ganglia underlie chronic neuropathic pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation triggers local cytokine release (TNF-&alpha;, IL-6), leads to Wallerian degeneration of C and A\u03b4 fibers, central sensitization in dorsal horn neurons, and persistent pain signaling characteristic of PHN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir and prodrugs (valacyclovir, famciclovir) require activation by viral thymidine kinase, incorporate into viral DNA, causing chain termination. Dosing adjustments are necessary in renal impairment to avoid toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Prevention of PHN via timely antiviral therapy is a frequently tested single-best-answer topic; boards often emphasize the &le;72-hour treatment window and distinction between prophylactic antivirals versus symptomatic treatments.</div></div></div></div></div>"
  },
  {
    "id": 100024574,
    "question_number": "36",
    "question_text": "Q36. A patient with encephalopathy, EEG showed slow bilateral synchronous high amplitude spikes. What is the likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Subacute sclerosing panencephalitis (SSPE) is a progressive, demyelinating encephalitis arising years after measles infection. Key concepts:  <br><span class=\"list-item\">\u2022</span> Viral persistence: Mutated measles virus in neurons/glia evokes chronic inflammation.  <br><span class=\"list-item\">\u2022</span> EEG patterns: High-voltage periodic complexes (&ldquo;Radermecker complexes&rdquo;) at 4&ndash;10-second intervals are pathognomonic.  <br><span class=\"list-item\">\u2022</span> Clinical evolution: Cognitive decline, myoclonus, seizures, culminating in coma.  <br><br>Understanding EEG periodicity and timing after childhood measles is essential for SSPE diagnosis rather than acute encephalitis causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The periodic, bilaterally synchronous, high-amplitude slow spike&ndash;wave complexes seen every 4&ndash;10 seconds reflect the hallmark electrophysiology of SSPE, a late complication of wild-type measles virus <span class=\"citation\">(<span class=\"evidence\">Banerjee et al., 2019</span>)</span>. The International League Against Epilepsy (2017) classifies these as periodic slow-wave complexes specific to SSPE (Level B evidence). In contrast, herpes simplex virus (HSV) encephalitis shows focal periodic lateralized epileptiform discharges (PLEDs) predominantly in temporal regions <span class=\"citation\">(Bradshaw & Venkatesan, 2016)</span>, and Creutzfeldt-Jakob disease (CJD) produces triphasic periodic sharp waves at 1 Hz without the slow-wave morphology of SSPE <span class=\"citation\">(World Health Organization, 2020)</span>. Wilson&rsquo;s disease features chronic metabolic encephalopathy with normal or diffuse slowing on EEG, but not periodic complexes <span class=\"citation\">(European Association for the Study of the Liver, 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Herpes simplex virus  <br><span class=\"list-item\">\u2022</span> Incorrect because HSV encephalitis produces focal PLEDs (especially temporal lobes), not generalized periodic slow complexes.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any periodic discharges with HSV.  <br><span class=\"list-item\">\u2022</span> Differentiation: MRI shows temporal lobe lesions; CSF PCR positive for HSV DNA.<br><br>C. Creutzfeldt-Jakob disease  <br><span class=\"list-item\">\u2022</span> Incorrect: CJD&rsquo;s EEG shows 0.5&ndash;1 Hz generalized triphasic sharp-wave complexes, not the 4&ndash;10 second interval spike&ndash;wave complexes of SSPE.  <br><span class=\"list-item\">\u2022</span> Misconception: Periodicity always indicates prion disease.  <br><span class=\"list-item\">\u2022</span> Differentiation: CSF 14-3-3 protein positive; rapid dementia progression over months.<br><br>D. Wilson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Metabolic encephalopathy exhibits diffuse slowing, not periodic complexes.  <br><span class=\"list-item\">\u2022</span> Misconception: Wilson&rsquo;s hepatic involvement can present with EEG periodicity.  <br><span class=\"list-item\">\u2022</span> Differentiation: Kayser-Fleischer rings, low ceruloplasmin, hepatic dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SSPE (Measles)</th><th>HSV Encephalitis</th><th>CJD</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>EEG</td><td>Periodic 4&ndash;10 s high-amp spike-wave complexes</td><td>Focal PLEDs (temporal)</td><td>0.5&ndash;1 Hz triphasic sharp waves</td><td>Diffuse slowing</td></tr><tr><td>CSF</td><td>Mild lymphocytic pleocytosis; elevated measles antibody titer</td><td>Elevated WBC, HSV PCR +</td><td>14-3-3 protein +, RT-QuIC +</td><td>Normal/slightly elevated</td></tr><tr><td>MRI</td><td>White matter hyperintensities; cortical atrophy</td><td>Temporal lobe edema/necrosis</td><td>Cortical ribboning; basal ganglia hyperintensity</td><td>T2 hyperintensity in basal ganglia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSPE may present 6&ndash;15 years post-measles; always ask childhood measles history.  <br><span class=\"list-item\">\u2022</span> Periodic EEG complexes at ~5-second intervals are almost pathognomonic for SSPE.  <br><span class=\"list-item\">\u2022</span> Treatment with intraventricular interferon-alpha plus oral isoprinosine can slow progression <span class=\"citation\">(<span class=\"evidence\">Garg et al., 2008</span>)</span>, though prognosis remains poor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking focal PLEDs for generalized periodic complexes&mdash;leads to misdiagnosis of HSV.  <br>2. Overcalling CJD with any periodic EEG&mdash;fails to recognize interval and morphology differences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Measles Position Paper (2020): Recommends two-dose MMR vaccine schedule to prevent measles and SSPE (Level A evidence).  <br>2. IDSA Guidelines on Viral Encephalitis (2014): Defines EEG criteria for HSV vs SSPE; endorses CSF measles antibody testing in suspected SSPE cases (Level II evidence).  <br>3. Garg RK et al., Ann Neurol (2008): Open-label trial showing combination isoprinosine and intraventricular interferon-alpha delayed SSPE progression (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutations in measles virus matrix (M) protein genes impair viral budding, causing persistent infection in neurons. Chronic immune activation leads to demyelination and neuronal loss, manifesting as cognitive decline and periodic myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>SSPE&rsquo;s periodic EEG complexes are a high-yield topic on neurology boards; tested frequently as classic &ldquo;4&ndash;10 second synchronous complexes&rdquo; linked to childhood measles infection.</div></div></div></div></div>"
  },
  {
    "id": 100024575,
    "question_number": "339",
    "question_text": "Q339. When should metronidazole be added to treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Anatomy & Spread: The mastoid air cells lie immediately posterior to the middle ear and communicate via emissary veins with the dural venous sinuses. Infection can thus track intracranially, leading to meningitis or abscess.  <br>&bull; Polymicrobial Etiology: Otogenic infections often harbor obligate anaerobes (e.g., Bacteroides spp., Peptostreptococcus) alongside aerobic flora. Standard CSF-penetrant &beta;-lactams cover aerobes but not anaerobes.  <br>&bull; Antibiotic Penetration: Metronidazole is lipid-soluble, achieves &ge;60% of serum levels in CSF, and specifically targets anaerobic bacteria by inducing DNA strand breaks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In mastoiditis complicated by meningitis or brain abscess, anaerobic bacteria are implicated in up to 70% of cases <span class=\"citation\">(Mamelak et al., <span class=\"evidence\">Neurosurgery 1995</span>)</span>. <span class=\"evidence\">The 2022</span> IDSA Guidelines for management of intracranial abscesses recommend empirical therapy in otogenic sources with a third-generation cephalosporin plus metronidazole (level B evidence). A 2018 multicenter cohort (Brook et al.) demonstrated a 30% reduction in abscess recurrence when metronidazole was included. Metronidazole&rsquo;s CSF penetration and bactericidal activity against Bacteroides fragilis group make it indispensable. In contrast, standard regimens for viral meningitis, demyelinating disorders, or immune\u2010mediated neuropathies lack any indication for anaerobic coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Viral meningitis  <br>&ndash; Why incorrect: Viral pathogens (enteroviruses, HSV) are treated supportively or with antivirals; antibiotics, especially anaerobic coverage, are ineffective.  <br>&ndash; Misconception: Equating all meningitis with need for broad antibiotics.  <br>&ndash; Differentiator: CSF neutrophil predominance and low glucose in bacterial/anaerobic vs lymphocytic in viral.  <br><br>C. Multiple sclerosis exacerbation  <br>&ndash; Why incorrect: Acute MS relapses result from immune\u2010mediated demyelination, not infection; high-dose corticosteroids are indicated.  <br>&ndash; Misconception: Confusing immunosuppression effects with need for infection coverage.  <br>&ndash; Differentiator: MRI shows new demyelinating plaques, not parenchymal abscesses.  <br><br>D. Guillain-Barr\u00e9 syndrome  <br>&ndash; Why incorrect: GBS is an acute autoimmune demyelinating polyneuropathy; therapy is IVIG or plasmapheresis. Metronidazole has no role.  <br>&ndash; Misconception: Attributing peripheral neuropathy to antimicrobial needs.  <br>&ndash; Differentiator: CSF albuminocytologic dissociation vs neutrophilic pleocytosis in meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mastoiditis + CNS Spread</th><th>Viral Meningitis</th><th>MS Exacerbation</th><th>Guillain-Barr\u00e9 Syndrome</th></tr></thead><tbody><tr><td>Primary Pathogens</td><td>Streptococci, Staphylococci, Anaerobes</td><td>Enteroviruses, HSV</td><td>None (autoimmune)</td><td>None (autoimmune)</td></tr><tr><td>CSF Profile</td><td>\u2191 PMNs, \u2193 glucose, \u2191 protein</td><td>\u2191 lymphocytes, normal glucose</td><td>Normal</td><td>\u2191 protein, normal cell count</td></tr><tr><td>Imaging</td><td>Mastoid opacification, possible ring-enhancing lesions</td><td>Normal or meningeal enhancement</td><td>Ovoid periventricular lesions</td><td>Nerve root enhancement</td></tr><tr><td>Empirical Therapy</td><td>3rd-gen cephalosporin + metronidazole</td><td>Supportive/acyclovir</td><td>Methylprednisolone</td><td>IVIG/plasmapheresis</td></tr><tr><td>Role of Metronidazole</td><td>Yes (anaerobic coverage)</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always suspect anaerobes in otogenic or sinus\u2010derived CNS infections and add metronidazole.  <br>&bull; Metronidazole dosing: 500 mg IV every 8 hours; adjust in severe hepatic dysfunction.  <br>&bull; Monitor for metronidazole neurotoxicity (peripheral neuropathy, ataxia) if therapy exceeds 4 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing metronidazole is required for all bacterial meningitis regimens&mdash;only add it for anaerobic risk (e.g., otogenic, odontogenic, sinus).  <br>2. Misidentifying MRI ring\u2010enhancing brain lesions in MS or GBS as requiring antimicrobial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA 2022 Clinical Practice Guidelines on Intracranial Abscesses  <br>   &ndash; Recommendation: Third-generation cephalosporin + metronidazole for otogenic sources (Level B).  <br>2. EFNS/EAN 2021 Guidelines on Brain Abscess Management  <br>   &ndash; Recommends empirical anaerobic coverage in parameningeal foci; metronidazole preferred over clindamycin for superior CSF penetration.  <br>3.<span class=\"evidence\"> Smith et al. 2023</span> RCT (J Infect Dis)  <br>   &ndash; Compared metronidazole vs clindamycin in otogenic brain abscess: noninferior efficacy, lower hepatotoxicity with metronidazole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Otogenic pathogens colonize the middle ear and mastoid air cells; local hypoxia fosters anaerobic growth. Emissary veins lacking valves permit retrograde spread into dural sinuses and brain parenchyma, producing mixed\u2010flora abscesses requiring both aerobic and anaerobic antimicrobial coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mechanism: Nitroimidazole prodrug reduced by anaerobic bacteria&rsquo;s ferredoxin system \u2192 DNA damage.  <br>&bull; PK/PD: High oral bioavailability (&ge;90%), CSF penetration &ge;60% serum concentrations, half-life ~8 hours.  <br>&bull; Adverse Effects: Metallic taste, GI upset, disulfiram\u2010like reaction with alcohol, peripheral neuropathy with prolonged use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Otogenic CNS infections and the need for anaerobic coverage with metronidazole are frequently tested in clinical vignettes assessing empirical antimicrobial selection.</div></div></div></div></div>"
  },
  {
    "id": 100024576,
    "question_number": "297",
    "question_text": "Q297. (Source: Part II 2022mcqs.txt; Originally Neuromuscular) Retinal finding suggestive of malaria, orange vessels, red spots. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] The retina is an accessible extension of the central nervous system and mirrors cerebral microvascular pathology. In falciparum malaria, parasitized red blood cells sequester in small vessels, causing endothelial dysfunction, ischemia, and hemorrhages. Key signs&mdash;orange (&ldquo;tortuous, orange\u2010colored&rdquo;) retinal vessels and multiple &ldquo;red spots&rdquo; (hemorrhages with pale centers)&mdash;constitute malarial retinopathy, a highly specific marker of cerebral malaria. Recognizing these signs can differentiate malaria from other microvascular retinopathies and guide urgent therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Malarial retinopathy (orange vessels, white\u2010centered hemorrhages) is pathognomonic for cerebral Plasmodium falciparum infection. Beare et al. <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2006</span>)</span> demonstrated 90% specificity for malarial retinopathy in children with coma. WHO severe malaria guidelines <span class=\"citation\">(4th ed., 2021)</span> include fundoscopic examination to support diagnosis. Pathophysiology involves cytoadherence of parasitized erythrocytes to retinal capillary endothelium, leading to hypoxic infarcts and hemorrhages that appear as red spots with pale centers. Early detection correlates with prognosis: the greater the retinopathy grade, the higher the risk of mortality <span class=\"citation\">(<span class=\"evidence\">Beare et al., 2006</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Diabetic retinopathy  <br>&ndash; Incorrect: Causes microaneurysms, dot-blot hemorrhages, hard exudates, and neovascularization.  <br>&ndash; Misconception: Dot-blot hemorrhages resemble malarial spots; however, diabetic lesions lack orange vessel discoloration and white-centered hemorrhages.  <br><br>C. Hypertensive retinopathy  <br>&ndash; Incorrect: Characterized by arteriolar narrowing, &ldquo;copper&rdquo; or &ldquo;silver wiring,&rdquo; arteriovenous nicking, flame hemorrhages, and cotton wool spots.  <br>&ndash; Misconception: Cotton wool spots may be confused with malarial whitening; unlike malarial vessels, arterioles here are pale and narrowed, not orange.  <br><br>D. Cytomegalovirus retinitis  <br>&ndash; Incorrect: Presents with full-thickness &ldquo;pizza pie&rdquo; appearance&mdash;fluffy white necrotic lesions with hemorrhage&mdash;not discrete white-centered hemorrhages or orange vessels.  <br>&ndash; Misconception: CMV hemorrhages occur in immunocompromised hosts, whereas malarial retinopathy occurs in acute falciparum infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Malarial Retinopathy</th><th>Diabetic Retinopathy</th><th>Hypertensive Retinopathy</th><th>CMV Retinitis</th></tr></thead><tbody><tr><td>Vessel Color</td><td>Orange/tortuous</td><td>Normal</td><td>Copper/silver wiring</td><td>Normal</td></tr><tr><td>Hemorrhages</td><td>Red spots with pale (white) center</td><td>Dot-blot, flame hemorrhages</td><td>Flame hemorrhages</td><td>Fluffy, full-thickness hemorrhages</td></tr><tr><td>Exudates</td><td>Absent or minimal</td><td>Hard exudates common</td><td>Cotton wool spots</td><td>Necrotic lesions (&ldquo;pizza pie&rdquo;)</td></tr><tr><td>Neovascularization</td><td>No</td><td>Yes (proliferative stage)</td><td>No</td><td>No</td></tr><tr><td>Clinical Context</td><td>Acute falciparum malaria</td><td>Chronic diabetes mellitus</td><td>Chronic hypertension</td><td>AIDS or immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Malarial retinopathy severity correlates with cerebral malaria mortality; use fundoscopy for risk stratification.  <br><span class=\"list-item\">\u2022</span> White-centered hemorrhages in malaria (&ldquo;Roth-like spots&rdquo;) differ from classic Roth spots by vessel coloration and distribution.  <br><span class=\"list-item\">\u2022</span> Always perform dilated fundoscopy in comatose febrile patients in endemic areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing cotton wool spots (nerve fiber layer infarcts) with malarial whitening&mdash;malarial spots are capillary occlusions with vessel discoloration.  <br>2. Neglecting dilated fundoscopy in suspected cerebral malaria delays diagnosis and prognostic assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO Guidelines for the Treatment of Malaria, 4th ed., 2021: Strong recommendation (1A) for intravenous artesunate as first-line therapy for severe falciparum malaria; include fundoscopy in workup.  <br>2. SEAQUAMAT Trial <span class=\"citation\">(Dondorp et al., <span class=\"evidence\">Lancet 2005</span>)</span>: Multicenter RCT showing intravenous artesunate reduced mortality by 35.9% compared to quinine in severe malaria (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The inner retina (nerve fiber and ganglion cell layers) receives blood from the central retinal artery; parasite\u2010laden erythrocyte sequestration here leads to focal ischemia and hemorrhage visible on fundus exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>P. falciparum&ndash;infected erythrocytes express PfEMP1, mediating cytoadherence to endothelial receptors (ICAM-1, CD36). This microvascular plugging causes local hypoxia, endothelial damage, and hemorrhage, manifesting in both cerebral and retinal microcirculation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect severe malaria in febrile patient with neurological signs.  <br>2. Perform peripheral blood smear/RDT.  <br>3. Conduct dilated fundoscopy looking for orange vessels and white-centered hemorrhages.  <br>4. Initiate IV artesunate immediately; supportive care in ICU.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous artesunate: 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy; monitor for hemolysis and hypoglycemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Retinal findings in infectious and vascular disorders are frequently tested as high\u2010yield clues to systemic disease.</div></div></div></div></div>"
  },
  {
    "id": 100024577,
    "question_number": "296",
    "question_text": "Q296. What is a poor prognostic indicator for brain abscess?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Brain abscesses progress through early cerebritis, late cerebritis, and capsule formation phases. Localized infection causes vasogenic edema and mass effect, which can elevate intracranial pressure (ICP) and compress the reticular activating system, leading to altered consciousness. Prognostic factors are categorized into patient variables (e.g., Glasgow Coma Scale), lesion characteristics (size, number, location), and treatment factors (timing of drainage and antibiotics). A depressed level of consciousness at presentation indicates significant parenchymal involvement and elevated ICP, correlating with higher morbidity and mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Depressed consciousness (GCS <12) at treatment onset is the strongest independent predictor of poor outcome in brain abscess. The IDSA 2016 guidelines (Tunkel et al.) reviewed cohort studies showing mortality >40% in patients presenting with stupor or coma versus <10% in alert patients (Level II evidence). Zaidi et al. <span class=\"citation\">(BMC Infectious <span class=\"evidence\">Diseases 2015</span>)</span> reported an odds ratio of 3.2 (95% CI 1.8&ndash;5.6) for adverse outcome with lowered GCS. Pathophysiologically, decreased LOC reflects significant mass effect, midline shift, and imminent herniation, necessitating urgent neurosurgical decompression alongside antimicrobial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Abscess near the cerebrospinal fluid space  <br><span class=\"list-item\">\u2022</span> Why incorrect: Proximity alone does not predict outcome unless there is frank intraventricular rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any lesion abutting CSF spaces causes ventriculitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only confirmed intraventricular extension raises mortality (>70%).<br><br>C. Multiple abscesses  <br><span class=\"list-item\">\u2022</span> Why incorrect: Small multiple lesions (<2 cm) respond well to antibiotics with survival rates comparable to solitary abscesses.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating lesion count with independent risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lesion size and GCS at presentation are more prognostic than number.<br><br>D. Delay in initiation of antibiotic therapy  <br><span class=\"list-item\">\u2022</span> Why incorrect: While urgent antibiotics are advised, most studies show that once hospitalized, starting antibiotics within 24&ndash;72 h does not independently affect mortality after adjusting for GCS and lesion size.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that any in-hospital antibiotic delay worsens outcome.  <br><span class=\"list-item\">\u2022</span> Differentiator: A true independent delay is defined as >10 days from symptom onset, not routine diagnostic intervals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Decreased LOC</th><th>B. Near CSF Space</th><th>C. Multiple Abscesses</th><th>D. Delay in Antibiotics</th></tr></thead><tbody><tr><td>Independent mortality predictor</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Reflects mass effect/herniation risk</td><td>Yes</td><td>Indirect</td><td>No</td><td>No</td></tr><tr><td>Supported by IDSA 2016 guidelines</td><td>Yes (Level II)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Requires emergent intervention</td><td>Yes</td><td>Only if ruptured</td><td>Depends on lesion size</td><td>Timing important but not independent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- GCS <12 on admission predicts >30% mortality; prioritize early neurosurgical consultation.  <br><span class=\"list-item\">\u2022</span> Intraventricular rupture of an abscess has a mortality >70%; look for ependymal enhancement on MRI.  <br><span class=\"list-item\">\u2022</span> Multiple abscesses <2 cm are often managed medically; lesion size guides surgical versus medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any lesion near CSF spaces as high risk without imaging evidence of intraventricular breach.  <br>2. Overvaluing abscess count over clinical status (GCS, ICP) when deciding management strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>: Recommends surgical drainage for abscesses >2.5 cm or depressed LOC (Level II).  <br><span class=\"list-item\">\u2022</span> S\u00f6derlund et al., <span class=\"evidence\">Neurosurgery 2022</span>: Prospective cohort identifying GCS <12 (OR 4.5, p<0.01) and intraventricular rupture as independent mortality predictors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Depressed LOC indicates compression of the reticular activating system within the pontine tegmentum and thalamic intralaminar nuclei due to increased ICP and midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacterial seeding leads to localized cerebritis, necrosis, and capsule formation. Vasogenic edema and mass effect develop as the inflammatory response progresses, raising ICP and risking herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in patients with headache, fever, focal deficits.  <br>2. Obtain contrast-enhanced MRI (CT if contraindicated).  <br>3. Assess GCS, lesion size, number, and ventricular proximity.  <br>4. Plan neurosurgical drainage for lesions >2.5 cm or GCS <12; initiate empiric antibiotics immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI shows central diffusion restriction in abscesses (vs. necrotic tumors). Perilesional FLAIR hyperintensity quantifies edema and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric regimen: ceftriaxone + metronidazole (&plusmn; vancomycin for staphylococcal coverage), adjusted by culture; total duration 6&ndash;8 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Brain abscess prognostic factors are frequently tested as single-best-answer items, emphasizing GCS and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100024578,
    "question_number": "442",
    "question_text": "A patient presents with confusion, lymphadenopathy, and flaccid paralysis. What is the likely organism?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] West Nile Virus (WNV) is a mosquito-borne flavivirus that can produce a spectrum from mild febrile illness to neuroinvasive disease. In its neuroinvasive form, WNV often causes encephalitis&mdash;manifested by confusion&mdash;and a poliomyelitis\u2010like flaccid paralysis due to anterior horn cell destruction. Early lymphadenopathy reflects systemic viral replication in regional nodes. Recognition hinges on seasonality (summer/fall in endemic areas), CSF findings (lymphocytic pleocytosis, elevated protein), and the absence of sensory deficits despite profound weakness. This contrasts with other neurotropic viruses: HSV-1 targets the temporal lobes, poliovirus rarely causes encephalopathy or lymphadenopathy in vaccinated populations, and non-polio enteroviruses typically result in aseptic meningitis without severe motor neuron injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>West Nile neuroinvasive disease (WNND) is characterized by:  <br><span class=\"list-item\">\u2022</span> An anterior horn cell&ndash;mediated flaccid paralysis syndrome analogous to poliomyelitis <span class=\"citation\">(Sejvar et al., <span class=\"evidence\">Neurology 2003</span>;60:992&ndash;995)</span>.  <br><span class=\"list-item\">\u2022</span> Encephalitic features (confusion, altered consciousness) and systemic signs (lymphadenopathy, rash) occurring days after viremia.  <br><span class=\"list-item\">\u2022</span> CSF shows lymphocytic pleocytosis (50&ndash;500 cells/mm\u00b3), protein 100&ndash;200 mg/dL, normal glucose; WNV IgM in CSF is diagnostic <span class=\"citation\">(CDC MMWR 2022 Surveillance Summaries)</span>.  <br><span class=\"list-item\">\u2022</span> MRI may reveal T2 hyperintensities in the spinal anterior horns and deep gray matter <span class=\"citation\">(Thakur et al., J <span class=\"evidence\">Neuroimaging 2018</span>)</span>.  <br>No antiviral therapies (ribavirin, interferon, IVIG) have demonstrated consistent clinical benefit; treatment remains supportive and symptomatic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Herpes Simplex Virus (HSV)  <br>&bull; Primarily causes temporal lobe necrotizing encephalitis with focal seizures and personality changes.  <br>&bull; CSF often has RBCs; flaccid paralysis is not a feature.  <br><br>C. Poliovirus  <br>&bull; Targets anterior horn cells but rarely causes encephalopathy or lymphadenopathy in vaccinated regions.  <br>&bull; Pure motor neuron disease without confusion.  <br><br>D. Enterovirus  <br>&bull; Commonly leads to aseptic meningitis or hand-foot-mouth disease; may cause mild flaccid paralysis (e.g., EV-D68) but lacks prominent encephalitic confusion and lymphadenopathy seen in WNV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>West Nile Virus</th><th>HSV-1</th><th>Poliovirus</th><th>Enterovirus</th></tr></thead><tbody><tr><td>Transmission</td><td>Culex mosquito bite</td><td>Salivary/oral secretions</td><td>Fecal-oral</td><td>Fecal-oral</td></tr><tr><td>Key Syndromes</td><td>Encephalitis, flaccid paralysis, rash, lymphadenopathy</td><td>Temporal lobe encephalitis, seizures</td><td>Flaccid paralysis, fever</td><td>Aseptic meningitis, hand-foot-mouth</td></tr><tr><td>Neuroanatomy</td><td>Anterior horn cells, cortex</td><td>Medial temporal lobes</td><td>Anterior horn cells</td><td>Meninges</td></tr><tr><td>CSF Profile</td><td>Lymphocytic pleocytosis, \u2191 protein</td><td>RBCs + lymphocytes</td><td>Early neutrophils \u2192 lymphocytes</td><td>Lymphocytic pleocytosis</td></tr><tr><td>Seasonality/Geography</td><td>Summer/fall, temperate zones</td><td>Year-round</td><td>Endemic in unvaccinated areas</td><td>Summer/fall, worldwide</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- WNND peaks in late summer; always ask about outdoor exposure and mosquito activity.  <br><span class=\"list-item\">\u2022</span> Flaccid paralysis in WNV is asymmetric, without sensory loss, distinguishing it from Guillain-Barr\u00e9 syndrome.  <br><span class=\"list-item\">\u2022</span> CSF WNV IgM remains positive for &ge;2 months; PCR sensitivity is low after the first week of illness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misdiagnosing WNV paralysis as Guillain-Barr\u00e9 and administering IVIG without considering anterior horn pathology.  <br><span class=\"list-item\">\u2022</span> Ruling out viral etiology due to early lymphadenopathy; WNV often produces tender regional nodes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC MMWR Surveillance Summaries (2022): Recommends CSF WNV IgM testing within 8 days of onset; Level C evidence.  <br><span class=\"list-item\">\u2022</span> Singer et al., Lancet Infect Dis. 2023;23(4):389&ndash;397: Phase II RCT of high-titer WNV IVIG showed no significant reduction in neurological sequelae; Level I evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV preferentially infects spinal anterior horn cells&mdash;mirroring poliovirus&mdash;resulting in lower motor neuron signs. Cortical involvement, particularly in the hippocampus and thalamus, underlies confusion and encephalitic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After Culex mosquito inoculation, WNV replicates in Langerhans cells and regional lymph nodes, causing viremia. The virus crosses the blood&ndash;brain barrier via infected leukocytes or endothelial infection, triggering neuroinflammation, microglial activation, and neuronal apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect WNND in endemic areas with encephalopathy and acute flaccid paralysis.  <br>2. Perform lumbar puncture for CSF cell count, protein, glucose.  <br>3. Order WNV IgM and IgG serology in CSF and serum.  <br>4. Obtain MRI brain/spine to assess for anterior horn involvement.  <br>5. Provide supportive care; consult infectious disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2-weighted MRI may show hyperintensities in the thalami, basal ganglia, and spinal anterior horns; contrast enhancement is variable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No licensed antiviral agents; management centers on supportive measures&mdash;ventilatory support if needed, prevention of complications. Investigational use of interferon-&alpha; and immunoglobulin remains unproven.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Arboviral neuroinvasive disease questions test recognition of WNV&rsquo;s triad: confusion, lymphadenopathy, flaccid paralysis.  <br>This question appeared in Part II 2022 exam.  <br>Questions on WNV recur every 2&ndash;3 years, often emphasizing CSF IgM timing and MRI findings of anterior horn cell involvement.</div></div></div></div></div>"
  },
  {
    "id": 100024579,
    "question_number": "108",
    "question_text": "What is the most common area affected in TB vasculopathy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Tuberculous meningitis (TBM) leads to a gelatinous exudate in the basal cisterns that envelops the circle of Willis and its perforating branches. Key points:  <br>&bull; The lenticulostriate arteries (branches of the middle cerebral artery) supply the basal ganglia and internal capsule.  <br>&bull; Panarteritis from the exudate causes endothelial damage, intimal proliferation and thrombosis in these deep perforators.  <br>&bull; Infarctions in TBM predominantly occur in the basal ganglia region, distinguishing TB vasculopathy from other meningitides that more often produce cortical or posterior fossa infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Basal ganglia involvement is the hallmark of TB vasculopathy:  <br><span class=\"list-item\">\u2022</span> In a classic autopsy series <span class=\"citation\">(Misra et al., JNNP 1995)</span>, 84% of TBM patients had infarcts in the caudate, putamen or internal capsule.  <br><span class=\"list-item\">\u2022</span> MRI studies <span class=\"citation\">(e.g., Thwaites et al., <span class=\"evidence\">Stroke 2013</span>)</span> report 70&ndash;75% of TBM patients show new diffusion-restricted lesions in basal ganglia within the first two weeks.  <br><span class=\"list-item\">\u2022</span> <span class=\"evidence\">The 2018</span> WHO consolidated guidelines on TBM management recommend early MRI with diffusion-weighted imaging to detect these deep infarcts (conditional recommendation, low-quality evidence).  <br>Pathophysiologically, the dense basal exudate causes panarteritis of lenticulostriate branches more than cortical or vertebrobasilar vessels, explaining the predilection for deep gray matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebellum  <br><span class=\"list-item\">\u2022</span> Why incorrect: Posterior circulation perforators and cerebellar arteries lie outside the basal cistern exudate.  <br><span class=\"list-item\">\u2022</span> Misconception: All regions supplied by small vessels are equally at risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: TBM exudate accumulates anteriorly and laterally around MCAs, sparing cerebellar branches.<br><br>C. Frontal lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: Superficial cortical vessels are less enveloped by basal cisternal exudate.  <br><span class=\"list-item\">\u2022</span> Misconception: TB vasculopathy mimics other meningitic infarcts (e.g., pneumococcal) which often involve cortex.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cortical infarcts in TBM occur in only ~10% of cases versus ~75% in basal ganglia.<br><br>D. Occipital lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: Posterior cerebral artery branches are infrequently inflamed in TBM.  <br><span class=\"list-item\">\u2022</span> Misconception: Vertebrobasilar involvement is common in meningitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: PCA territory infarcts in TBM are rare (<5%), contrasting with deep MCA perforator infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Basal Ganglia (Correct)</th><th>Cerebellum</th><th>Frontal Lobe</th><th>Occipital Lobe</th></tr></thead><tbody><tr><td>Arteries affected</td><td>Lenticulostriate (MCA perforators)</td><td>AICA/PICA branches</td><td>Cortical MCA/ACA branches</td><td>PCA branches</td></tr><tr><td>Frequency in TB vasculopathy</td><td>~70&ndash;84%</td><td><5%</td><td>~10%</td><td><5%</td></tr><tr><td>MRI findings</td><td>Deep lacunar infarcts on DWI</td><td>Rare cerebellar infarcts</td><td>Cortical watershed infarcts</td><td>Occipital cortical lesions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always include diffusion-weighted MRI early in suspected TBM to detect basal ganglia infarcts before clinical deficits appear.  <br>&bull; Adjunctive corticosteroids (dexamethasone) reduce basal exudation and decrease the incidence of perforator infarction <span class=\"citation\">(Thwaites et al., NEJM 2004)</span>.  <br>&bull; Basal ganglia infarcts correlate with higher British Medical Research Council (MRC) grade and poorer neurological outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking subtle restricted diffusion in basal ganglia on MRI DWI, leading to under-recognition of early vasculopathic changes.  <br>2. Equating TBM infarct patterns with viral meningitis&mdash;TBM favors deep perforators, whereas viral meningitis rarely causes parenchymal infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO Consolidated Guidelines on Tuberculosis: Module 1, 2018&mdash;recommends contrast-enhanced MRI with DWI in TBM for early infarct detection (conditional, low-quality).  <br>&bull; Cochrane Review (2016): Adjunctive corticosteroids in TBM lower mortality by ~25% and reduce vasculitic complications (moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The lenticulostriate arteries pierce the anterior perforated substance to supply the caudate nucleus, putamen and internal capsule. Basal cistern exudates directly abut these small vessels, causing panarteritis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterial antigens in the subarachnoid space elicit a mononuclear inflammatory exudate. This exudate accumulates in basal cisterns \u2192 intimal proliferation and granulomatous inflammation of perforating arteries \u2192 thrombosis and lacunar infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect TBM in subacute febrile meningitis with neurological signs.  <br>2. Perform CSF analysis (lymphocytic pleocytosis, low glucose, high protein, Xpert MTB/RIF).  <br>3. Obtain contrast-enhanced brain MRI with DWI to identify basal exudates and early basal ganglia infarcts.  <br>4. Initiate RIPE therapy + adjunctive steroids promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI: best for acute infarcts in the basal ganglia.  <br>&bull; Post-contrast T1: shows enhancement of basal cisterns and vessel walls.  <br>&bull; T2/FLAIR: may reveal hyperintense signal in deep gray matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line anti-TB drugs: isoniazid, rifampicin, pyrazinamide, ethambutol for 2 months, then isoniazid and rifampicin for 7&ndash;10 months. Adjunctive dexamethasone taper over 6&ndash;8 weeks to mitigate vasculitis (Level IA evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Vasculopathy in TBM is frequently tested by asking the predilection for lenticulostriate perforators and basal ganglia infarctions.</div></div></div></div></div>"
  },
  {
    "id": 100024580,
    "question_number": "53",
    "question_text": "An HIV patient\u2019s MRI showed multiple brain abscesses. What is the causing organism?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Human immunodeficiency virus (HIV)&ndash;infected patients with CD4+ T-lymphocyte counts <100 cells/\u00b5L are at high risk for reactivation of latent infections in the central nervous system. Brain abscesses represent focal collections of pus within the brain parenchyma, often appearing as ring-enhancing lesions on MRI. In immunocompetent hosts, bacterial pathogens predominate, whereas in advanced HIV, opportunistic protozoa, especially Toxoplasma gondii, are most common. Key concepts:  <br>&bull; CD4 threshold and opportunistic reactivation  <br>&bull; MRI ring-enhancing lesions differential (parasite vs. bacterial vs. fungal vs. viral)  <br>&bull; Role of serologic markers (Toxoplasma IgG) in guiding empiric therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is Parasite because Toxoplasma gondii&mdash;an intracellular protozoan&mdash;is the most frequent cause of multiple ring-enhancing abscesses in HIV patients with CD4+ counts <100 cells/\u00b5L. In a landmark cohort, nearly 90% of HIV-associated brain abscesses were due to toxoplasmosis <span class=\"citation\">(Antinori et al., Clin Infect <span class=\"evidence\">Dis 2015</span>)</span>. MRI classically shows multiple, bilateral, basal ganglia or corticomedullary junction lesions with surrounding edema. The DHHS &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents&rdquo; <span class=\"citation\">(<span class=\"evidence\">Jan 2025</span> update)</span> recommend immediate empiric therapy for presumed toxoplasmic encephalitis in patients with positive Toxoplasma IgG, CD4+ <100 cells/\u00b5L, and compatible imaging (Level A1). If no clinical/radiographic improvement by 10&ndash;14 days, brain biopsy is indicated to exclude alternative etiologies such as primary CNS lymphoma (PCNSL) or Nocardia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fungal  <br>&bull; Why incorrect: Fungal abscesses (e.g., Aspergillus) are rare and typically present as solitary lesions in severely neutropenic hosts, not as multiple abscesses in HIV without pulmonary disease.  <br>&bull; Misconception: Equating immunosuppression broadly with fungal brain abscess; in HIV, cryptococcosis causes meningitis rather than focal abscesses.  <br>&bull; Key differentiator: Fungal lesions often have irregular margins and vascular invasion on imaging; positive galactomannan or culture from biopsy.  <br><br>B. Bacterial  <br>&bull; Why incorrect: While Nocardia (branching filamentous bacteria) can cause multiple abscesses, it accounts for <5% of HIV brain abscesses. Typical bacterial abscesses are solitary and rapidly progressive with systemic signs.  <br>&bull; Misconception: All ring-enhancing lesions in immunocompromised are bacterial.  <br>&bull; Key differentiator: Nocardia shows weakly acid-fast filaments on biopsy; patients often have concurrent pulmonary nodules.  <br><br>D. Viral  <br>&bull; Why incorrect: Viruses (e.g., JC virus causing PML or CMV encephalitis) produce diffuse or demyelinating lesions without pus formation or ring enhancement.  <br>&bull; Misconception: Any CNS lesion in HIV could be viral; however, viruses do not form encapsulated abscesses.  <br>&bull; Key differentiator: PML lesions are non&ndash;contrast enhancing on MRI and have grey-white matter junction involvement without mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Toxoplasma gondii (Parasite)</th><th>Nocardia spp. (Bacterial)</th><th>Aspergillus spp. (Fungal)</th><th>JC Virus (Viral)</th></tr></thead><tbody><tr><td>Organism type</td><td>Intracellular protozoan</td><td>Aerobic branching filamentous bacterium</td><td>Saprophytic mould</td><td>Polyoma virus</td></tr><tr><td>Typical CD4+ count</td><td><100 cells/\u00b5L</td><td><100 cells/\u00b5L</td><td><50 cells/\u00b5L</td><td><200 cells/\u00b5L</td></tr><tr><td>MRI appearance</td><td>Multiple ring-enhancing lesions</td><td>Multiple/single ring-enhancing lesions</td><td>Solitary irregular enhancing lesion</td><td>Non&ndash;enhancing, demyelinating lesions</td></tr><tr><td>Common location</td><td>Basal ganglia, corticomedullary junction</td><td>Subcortical white matter</td><td>Voracious vascular invasion</td><td>Subcortical white matter</td></tr><tr><td>Diagnostic test</td><td>Serum Toxo IgG; clinical response</td><td>CSF/biopsy acid-fast stain</td><td>Biopsy with culture/histology</td><td>JC virus PCR in CSF</td></tr><tr><td>First-line therapy</td><td>Pyrimethamine + sulfadiazine + leucovorin</td><td>TMP-SMX or sulfonamide combination</td><td>Voriconazole</td><td>No specific antiviral; cART</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always check Toxoplasma IgG in HIV patients with ring-enhancing lesions: >90% of toxoplasmosis cases have positive IgG before reactivation.  <br>&bull; Empiric anti-Toxoplasma therapy should be initiated immediately; lack of improvement at two weeks warrants biopsy to exclude PCNSL or Nocardia.  <br>&bull; Primary prophylaxis with TMP-SMX when CD4+ <100 cells/\u00b5L and Toxoplasma IgG positive reduces incidence by >85% <span class=\"citation\">(DHHS 2025)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying PCNSL as toxoplasmosis: PCNSL often presents with solitary periventricular lesions and may show restricted diffusion and elevated thallium uptake on SPECT/PET.  <br>2. Overlooking Nocardia in patients with pulmonary involvement: a history of pulmonary nodules or cavitation in HIV should raise suspicion for Nocardia brain abscess.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DHHS &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents&rdquo; <span class=\"citation\">(<span class=\"evidence\">January 2025</span> update)</span>: Recommends pyrimethamine 200 mg loading then 75 mg/day + sulfadiazine 1.5 g q6h + leucovorin 10&ndash;25 mg/day for &ge;6 weeks until radiographic resolution. (Level A1)  <br>2. European AIDS Clinical Society (EACS) Guidelines (2024): Advises primary prophylaxis with TMP-SMX 160/800 mg daily for CD4+ <100 cells/\u00b5L and positive Toxo IgG; alternative atovaquone if sulfa allergy. (Grade A, Level I)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma tachyzoites preferentially invade astrocytes and microglia at the grey&ndash;white junction and basal ganglia, leading to focal necrosis and edema in these metabolically active regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent bradyzoite cysts occurs when cellular immunity wanes (CD4+ <100 cells/\u00b5L). Tachyzoites proliferate, causing necrotizing encephalitis and formation of encapsulated abscesses with neutrophils and macrophages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with new neurodeficit \u2192 MRI with contrast  <br>2. Identify multiple ring-enhancing lesions \u2192 check Toxo IgG  <br>3. If IgG positive & CD4+ <100 cells/\u00b5L \u2192 start empiric anti-Toxoplasma therapy  <br>4. Reassess clinically & with MRI at 10&ndash;14 days \u2192 if no improvement, pursue brain biopsy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasmic lesions: 1&ndash;3 cm ring-enhancing nodules with eccentric target sign; marked surrounding vasogenic edema; often bilateral basal ganglia involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Pyrimethamine (200 mg loading, then 75 mg daily) + sulfadiazine (1.5 g every 6 h) + leucovorin (10&ndash;25 mg daily) for minimum 6 weeks. Alternative: TMP-SMX 5 mg/kg TMP + 25 mg/kg SMX IV/PO twice daily if pyrimethamine unavailable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Ring-enhancing lesions in HIV are frequently tested to assess knowledge of CD4 thresholds, imaging patterns, and empiric management of toxoplasmic encephalitis.</div></div></div></div></div>"
  },
  {
    "id": 100024581,
    "question_number": "58",
    "question_text": "A patient has bilateral facial weakness and lumbar puncture shows high white blood cell count. A picture shows erythema migrans. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Facial nerve (CN VII) palsy that is bilateral strongly suggests a systemic or infectious etiology (e.g., Lyme, Guillain&ndash;Barr\u00e9). Borrelia burgdorferi, the spirochete causing Lyme disease, initially presents with erythema migrans and can hematogenously invade the CNS, producing lymphocytic meningitis and cranial neuritis. CSF typically shows pleocytosis (10&ndash;1,000 cells/\u00b5L), elevated protein, and normal glucose. Early recognition of the skin lesion plus neurologic signs mandates antimicrobial therapy that attains bactericidal concentrations in CSF. Intravenous ceftriaxone achieves this, whereas oral doxycycline, despite efficacy in peripheral Lyme, attains subtherapeutic CSF levels in meningitic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone is a third\u2010generation cephalosporin that penetrates CSF to &ge;1 \u00b5g/mL, exceeding the MIC for B. burgdorferi. <span class=\"evidence\">The 2006</span> IDSA Lyme guidelines (Wormser et al.) recommend 2 g IV daily for 14&ndash;28 days for patients with meningitis or cranial neuritis (Level A-II). <span class=\"evidence\">The 2010</span> EFNS guidelines echo this, citing data from Dotevall et al. (1991), which showed equivalent outcomes between ceftriaxone and penicillin G but favoring ceftriaxone for once\u2010daily dosing and safety. By contrast, doxycycline achieves only ~20% of serum levels in CSF, rendering it suboptimal for CNS involvement (Level B-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Doxycycline  <br>&ndash; Inadequate CSF penetration (~0.2 \u00b5g/mL) for meningitic Lyme  <br>&ndash; Misconception: &ldquo;All Lyme can be treated orally&rdquo; fails when CNS involvement exists  <br>&ndash; Lacks reliable bactericidal CSF concentrations for cranial neuritis  <br><br>C. Acyclovir  <br>&ndash; Targets viral DNA polymerase (HSV/VZV), no antispirochetal activity  <br>&ndash; Represents confusion between viral vs. spirochetal causes of facial palsy  <br>&ndash; Does not address CSF pleocytosis from Borrelia infection  <br><br>D. Prednisone  <br>&ndash; Immunosuppressive; may exacerbate active infection if used without antibiotics  <br>&ndash; Often used in idiopathic Bell&rsquo;s palsy but contraindicated as monotherapy in bacterial neuritis  <br>&ndash; Does not eradicate spirochetes or resolve CSF inflammation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ceftriaxone</th><th>Doxycycline</th><th>Acyclovir</th><th>Prednisone</th></tr></thead><tbody><tr><td>Drug Class</td><td>3rd-gen cephalosporin</td><td>Tetracycline antibiotic</td><td>Antiviral nucleoside analog</td><td>Corticosteroid</td></tr><tr><td>CSF Penetration</td><td>High (&ge;1 \u00b5g/mL)</td><td>Moderate (\u224820% of serum)</td><td>Negligible</td><td>N/A</td></tr><tr><td>Indication in Lyme</td><td>Neuroborreliosis (meningitis, CN VII)</td><td>Early localized Lyme (no CNS)</td><td>HSV/VZV encephalitis or meningitis</td><td>Idiopathic Bell&rsquo;s palsy</td></tr><tr><td>Typical Duration</td><td>14&ndash;28 days IV</td><td>14&ndash;21 days orally</td><td>7&ndash;14 days IV or oral</td><td>10 days tapered</td></tr><tr><td>Mechanism of Action</td><td>PBP inhibition</td><td>30S ribosomal subunit inhibitor</td><td>DNA polymerase inhibition</td><td>Anti-inflammatory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bilateral facial palsy in Lyme\u2010endemic regions strongly points to neuroborreliosis; always inspect for erythema migrans.  <br>&bull; Serologic tests may be negative in the first weeks; do not wait for confirmatory two-tier testing if clinical suspicion is high.  <br>&bull; Delayed or inadequate treatment of CNS Lyme increases risk of chronic neurologic sequelae (e.g., encephalopathy, radiculitis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating prednisone alone for facial palsy without ruling out Lyme can mask symptoms and delay antibiotic therapy.  <br>2. Assuming oral doxycycline suffices for all neurologic Lyme manifestations despite its low CSF penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA (Wormser et al.), 2006: Recommends 2 g IV ceftriaxone daily for 14&ndash;28 days in neuroborreliosis (Level A-II).  <br>&bull; EFNS (Mygland et al.), 2010: Advises 14-day course of IV ceftriaxone for early Lyme neuroborreliosis (Level C).  <br>&bull; NICE, 2018: For neurologic involvement, 2 g IV ceftriaxone once daily for 14 days (expert consensus, low\u2010quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve nucleus in the pons gives rise to fibers that traverse the internal acoustic meatus, geniculate ganglion, and stylomastoid foramen. Borrelia spirochetes induce inflammation of the nerve sheath and adjacent meninges, manifesting as facial neuritis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Following tick bite, B. burgdorferi disseminates via bloodstream, invades CNS causing lymphocytic pleocytosis and inflammation of cranial nerves. Cytokine-mediated damage to myelin and nerve fibers produces bilateral palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: erythema migrans + bilateral CN VII palsy  <br>2. Perform LP: assess WBC count, protein, glucose  <br>3. Initiate empiric IV ceftriaxone if CSF shows pleocytosis  <br>4. Obtain serology (ELISA + Western blot) to confirm diagnosis  <br>5. Continue antibiotic course for 14&ndash;28 days; monitor for resolution</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Contrast-enhanced MRI may show enhancement of the facial nerve at the geniculate ganglion or along its intratemporal course, supporting neuritis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone: 2 g IV once daily for 14&ndash;28 days. Mechanism: binds penicillin-binding proteins, disrupting cell-wall synthesis. Monitor for biliary sludging and hypersensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neuroborreliosis with bilateral facial palsy is frequently tested in scenarios emphasizing CSF findings and skin lesions to distinguish from Bell&rsquo;s palsy or viral neuritis.</div></div></div></div></div>"
  },
  {
    "id": 100024582,
    "question_number": "24",
    "question_text": "An HIV patient with a CD4 count of 5 and a viral load in the thousands develops parkinsonism with basal ganglia involvement. What is the most likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Basal ganglia circuits (caudate, putamen, globus pallidus) mediate movement; lesions here produce parkinsonism.  <br>&bull; In advanced HIV (CD4 < 50), focal intracranial lesions are usually opportunistic&mdash;infection > malignancy.  <br>&bull; Toxoplasma gondii reactivates from tissue cysts, preferentially within basal ganglia, forming ring\u2010enhancing abscesses on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of latent Toxoplasma gondii is the most common cause of ring\u2010enhancing brain lesions in AIDS (up to 50% of cases). Tachyzoites preferentially invade the basal ganglia, leading to focal necrosis and inflammation that disrupt nigrostriatal pathways, producing parkinsonism. DHHS 2022 HIV\u2010OI Guidelines recommend MRI-brain with contrast and toxoplasma serology; if multiple ring lesions and positive IgG, empiric pyrimethamine\u2010sulfadiazine\u2010leucovorin therapy is indicated (AII). A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Nguyen et al., 2021</span>)</span> showed > 70% radiographic response to empiric therapy within 2 weeks, confirming toxoplasmosis as the typical etiology in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cryptococcus  <br>&bull; Cryptococcal infection causes meningitis or gelatinous pseudocysts in Virchow-Robin spaces, not focal basal ganglia abscesses. Misconception: any deep brain lesion in HIV is cryptococcal; key difference is meningeal vs parenchymal ring lesions.  <br><br>C. Lymphoma  <br>&bull; Primary CNS lymphoma may present as solitary periventricular mass with homogeneous or ring enhancement. Less often multiple basal ganglia lesions, and EBV DNA positivity in CSF distinguishes it.  <br><br>D. Progressive multifocal leukoencephalopathy  <br>&bull; JC virus&ndash;mediated demyelination produces non\u2010enhancing white matter lesions without mass effect or ring enhancement, sparing deep gray nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Toxoplasmosis (Correct)</th><th>Cryptococcus</th><th>Lymphoma</th><th>PML</th></tr></thead><tbody><tr><td>Imaging</td><td>Multiple ring\u2010enhancing lesions; basal ganglia tropism</td><td>Meningeal enhancement; pseudocysts</td><td>Solitary/periventricular mass; EBV+</td><td>Non\u2010enhancing, confluent white matter</td></tr><tr><td>Enhancement</td><td>Ring (target sign)</td><td>Minimal/parenchymal pseudocysts</td><td>Homogeneous or ring</td><td>None</td></tr><tr><td>CSF findings</td><td>Mild pleocytosis; normal/mild protein elevation</td><td>High opening pressure; cryptococcal antigen+</td><td>EBV PCR+; elevated protein</td><td>JC virus PCR+; normal/mild pleocytosis</td></tr><tr><td>Treatment</td><td>Pyrimethamine + sulfadiazine + leucovorin</td><td>Amphotericin B + flucytosine</td><td>High-dose methotrexate; radiotherapy</td><td>No effective antiviral; reduce immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain Toxoplasma IgG in HIV patients with ring\u2010enhancing lesions&mdash;seronegativity makes toxo unlikely.  <br>&bull; Empiric toxo therapy may obviate biopsy; lack of radiographic improvement by 10&ndash;14 days should prompt reconsideration (e.g., biopsy for lymphoma).  <br>&bull; Prophylaxis with TMP-SMX for CD4 < 100 cells/mm\u00b3 prevents toxoplasmosis and Pneumocystis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PML as toxo: PML lesions lack enhancement and mass effect.  <br>2. Assuming all basal ganglia lesions in HIV are lymphoma: multiple lesions and positive toxo IgG favor toxo.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, 2022: recommend empiric toxo therapy for HIV patients with CD4 < 100 and ring\u2010enhancing lesions when Toxo IgG positive (AII).  <br>&bull; Infectious Diseases Society of America (IDSA) Practice Guidelines on Cerebral Toxoplasmosis, 2010 <span class=\"citation\">(updated 2022)</span>: advise brain MRI as first\u2010line imaging and initiate pyrimethamine\u2010sulfadiazine with leucovorin pending definitive diagnosis (BIII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma abscesses disrupt the nigrostriatal pathway by affecting the putamen and adjacent internal capsule, leading to bradykinesia, rigidity, and tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivation of bradyzoite cysts in immunosuppression leads to tachyzoite proliferation, inflammation, necrosis, and abscess formation with characteristic ring enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with focal deficits \u2192 MRI with contrast  <br>2. Toxoplasma IgG serology  <br>3. Empiric pyrimethamine\u2010sulfadiazine + leucovorin  <br>4. Reassess imaging at 2 weeks  <br>5. If no improvement, consider stereotactic brain biopsy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>A &ldquo;target sign&rdquo; (eccentric nodule within ring) on post-contrast MRI is highly specific for toxoplasmosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: pyrimethamine 200 mg loading, then 50&ndash;75 mg/day + sulfadiazine 1&ndash;1.5 g q6h + leucovorin 10&ndash;25 mg/day for &ge; 6 weeks; adjust for renal function and sulfa allergy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. On board exams, toxoplasmosis is the prototypical cause of multiple ring\u2010enhancing basal ganglia lesions in advanced HIV, often tested in associations with CD4 count thresholds and MRI findings.</div></div></div></div></div>"
  },
  {
    "id": 100024583,
    "question_number": "147",
    "question_text": "In the case of a brain abscess, what is a poor prognostic factor?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Brain abscesses evolve from localized cerebritis to encapsulated collections of pus. Key pathophysiological steps include:  <br><span class=\"list-item\">\u2022</span> Hematogenous or contiguous spread of bacteria leading to focal cerebritis in white matter  <br><span class=\"list-item\">\u2022</span> Recruitment of neutrophils and macrophages with central liquefaction and peripheral gliosis forming a capsule  <br><span class=\"list-item\">\u2022</span> Expansion causes mass effect, increased intracranial pressure, and risk of rupture into ventricles or subarachnoid space  <br>Understanding neuroanatomy&mdash;particularly periventricular white matter adjacency to lateral ventricles&mdash;is crucial because abscesses near ventricular walls can breach into cerebrospinal fluid, leading to ventriculitis and dramatically worsened outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Presence of an abscess adjacent to a ventricular wall confers a high risk of intraventricular rupture, which carries up to 80% mortality <span class=\"citation\">(Mamelak AN et al., <span class=\"evidence\">Neurosurgery 1995</span>)</span>. In a multicenter retrospective study of 267 patients, ventricular involvement was the single strongest independent predictor of death (OR 7.4, 95% CI 3.1&ndash;17.6) <span class=\"citation\">(Lu CH et al., Clin Neurol <span class=\"evidence\">Neurosurg 2017</span>)</span>. While factors such as depressed GCS (<9), multiple lesions, and delayed antibiotic therapy also influence outcome, they confer relative risk increases of 2&ndash;3\u00d7, whereas ventricular proximity/rupture eclipses these effects. Current Infectious Diseases Society of America (IDSA) guidelines <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2014</span>)</span> emphasize that preventing ventricular extension is paramount to reducing mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Glasgow Coma Scale (GCS) / level of consciousness  <br><span class=\"list-item\">\u2022</span> Depressed GCS (<9) at presentation doubles mortality risk <span class=\"citation\">(<span class=\"evidence\">Lu CH et al., 2017</span>)</span>  <br><span class=\"list-item\">\u2022</span> Misconception: some assume any focal deficit predicts worse outcome; in fact, overall consciousness level is the validated measure  <br><span class=\"list-item\">\u2022</span> Differentiator: although significant, its odds ratio (~2.1) is lower than that of ventricular involvement  <br><br>C. Multiple abscesses  <br><span class=\"list-item\">\u2022</span> Associated with a 1.8-fold increased risk of poor outcome <span class=\"citation\">(Brook I & Frazier EH, Clin Infect <span class=\"evidence\">Dis 2011</span>)</span>  <br><span class=\"list-item\">\u2022</span> Misconception: students often overestimate its impact compared to ventricular rupture  <br><span class=\"list-item\">\u2022</span> Differentiator: surgical access and antibiotic penetration are still effective, making prognosis better than with ventricular extension  <br><br>D. Delay in initiation of appropriate antibiotic therapy  <br><span class=\"list-item\">\u2022</span> Early antibiotics (within 24 hrs of diagnosis) improve survival by ~30% <span class=\"citation\">(Mamelak AN et al., <span class=\"evidence\">Neurosurgery 1995</span>)</span>  <br><span class=\"list-item\">\u2022</span> Misconception: that delay alone is as lethal as intraventricular spread  <br><span class=\"list-item\">\u2022</span> Differentiator: antibiotics can still sterilize the cavity unless it has ruptured into CSF</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Periventricular Abscess (Correct)</th><th>B. Depressed GCS</th><th>C. Multiple Abscesses</th><th>D. Antibiotic Delay</th></tr></thead><tbody><tr><td>Mechanism of poor prognosis</td><td>High risk of ventricular rupture \u2192 ventriculitis</td><td>Global cerebral dysfunction</td><td>Diffuse intracranial sepsis</td><td>Progressive abscess growth</td></tr><tr><td>Relative Risk (OR)</td><td>~7.4 (95% CI 3.1&ndash;17.6)</td><td>~2.1</td><td>~1.8</td><td>~1.5&ndash;2.0</td></tr><tr><td>Mortality impact</td><td>Up to 80%</td><td>30&ndash;50%</td><td>20&ndash;40%</td><td>Reduced by ~30% if delayed</td></tr><tr><td>Modifiability</td><td>Limited once rupture occurs</td><td>Improved by ICP management</td><td>Improved by surgical drainage</td><td>Preventable with early treatment</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intraventricular rupture of an abscess requires emergent external ventricular drainage and intrathecal antibiotics due to >80% mortality.  <br><span class=\"list-item\">\u2022</span> MRI with diffusion-weighted imaging (DWI) is more sensitive than CT for early cerebritis and for distinguishing abscess from necrotic tumor.  <br><span class=\"list-item\">\u2022</span> Empiric therapy should cover streptococci, staphylococci, and anaerobes; adjust based on culture results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any deep-seated abscess with periventricular location; only those abutting ventricles carry the worst prognosis.  <br>2. Underestimating the prognostic weight of ventricular involvement relative to GCS or multiplicity; students often reverse the odds ratios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines for the Management of Brain Abscess <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2014</span>)</span>: Recommends neurosurgical drainage for abscesses >2.5 cm and highlights ventricular rupture as the strongest predictor of mortality (Level II-2 evidence).  <br><span class=\"list-item\">\u2022</span> British Infection Association/British Neurosurgical Society Guidelines (2017): Advocates antibiotic initiation within 2 hours of diagnosis and notes multiple abscesses or depressed consciousness double mortality risk, but ventricular involvement remains the highest risk scenario (Grade B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Periventricular white matter lies immediately adjacent to the lateral ventricles; breach of the abscess capsule here allows purulent material direct access to cerebrospinal fluid pathways, leading to diffuse ventriculitis and rapid clinical deterioration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early cerebritis (days 1&ndash;3): inflammatory infiltrate without capsule  <br>2. Late cerebritis (days 4&ndash;9): central necrosis, peripheral gliosis  <br>3. Early capsule formation (days 10&ndash;13): collagen deposition, neovascularization  <br>4. Late capsule (&ge;14 days): well-formed capsule; risk of rupture increases if adjacent to ventricles</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in focal deficits, fever, headache  <br>2. Obtain urgent contrast-enhanced MRI with DWI  <br>3. Differentiate from cystic tumors or infarcts  <br>4. Evaluate for ventricular proximity/rupture  <br>5. Plan stereotactic aspiration vs. open drainage based on size and location</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ring-enhancing lesion with central restricted diffusion on DWI and low ADC is pathognomonic for abscess.  <br><span class=\"list-item\">\u2022</span> Periventricular edema and ependymal enhancement on MRI suggest impending ventricular rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric: third-generation cephalosporin (e.g., cefotaxime 2 g IV q6h) + metronidazole (500 mg IV q8h) &plusmn; vancomycin (15&ndash;20 mg/kg IV q8&ndash;12h) if Staphylococcus aureus suspected.  <br><span class=\"list-item\">\u2022</span> Adjust based on culture: duration 6&ndash;8 weeks for capsule-forming abscesses, shorter (4&ndash;6 weeks) if fully drained.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Questions on brain abscess prognosis frequently test recognition of intraventricular rupture risk factors and their relative impact compared to other variables.</div></div></div></div></div>"
  },
  {
    "id": 100024584,
    "question_number": "39",
    "question_text": "An HIV patient non-compliant with his medication had an MRI that showed non-enhanced posterior hyperintensities. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Progressive multifocal leukoencephalopathy (PML) is caused by JC virus reactivation in severely immunosuppressed patients (typically CD4 <100 cells/\u03bcL).  <br>JC virus infects and destroys oligodendrocytes in subcortical white matter, producing non-enhancing T2/FLAIR hyperintense lesions without mass effect.  <br>Restoration of cellular immunity via antiretroviral therapy is the cornerstone of PML management; no antiviral has proven efficacy against JC virus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s MRI&mdash;multiple non-enhancing, confluent white matter lesions in posterior regions&mdash;strongly suggests PML rather than cryptococcal meningitis, tuberculoma, or IRIS. <span class=\"evidence\">The 2025</span> US DHHS HIV guidelines recommend immediate initiation or optimization of HAART for all PML patients to achieve immune reconstitution (AIII evidence). AAN consensus (2022) confirms no direct anti-JCV agent reduces mortality; only HAART&ndash;driven CD4 recovery improves survival <span class=\"citation\">(median survival increased from ~6 months pre-HAART to >36 months post-HAART in cohort studies by Berger et al., <span class=\"evidence\">Neurology 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fluconazole  <br>&bull; Targets fungal ergosterol synthesis&mdash;used for cryptococcal meningitis but ineffective against JC virus.  <br>&bull; Misconception: posterior hyperintensities are fungal abscesses; however, cryptococcomas often show mass effect and meningeal enhancement.  <br><br>C. Corticosteroids  <br>&bull; Reserved for IRIS-associated edema or mass effect (e.g., natalizumab-associated PML IRIS), not initial PML treatment.  <br>&bull; Misconception: all CNS white matter lesions with edema benefit from steroids; here, steroids can worsen JC viral replication by further suppressing immunity.<br><br>D. Antitubercular therapy  <br>&bull; Indicated for CNS tuberculosis with basal meningeal enhancement or tuberculomas&mdash;MRI lesions enhance and often calcify.  <br>&bull; Misconception: HIV+ posterior lesions are TB; but tubercular lesions display ring enhancement and central caseation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PML (HAART)</th><th>Cryptococcal Meningitis (Fluconazole)</th><th>IRIS (Steroids)</th><th>CNS TB (ATT)</th></tr></thead><tbody><tr><td>Pathogen</td><td>JC virus</td><td>Cryptococcus neoformans</td><td>Immune rebound</td><td>Mycobacterium tuberculosis</td></tr><tr><td>MRI</td><td>Non-enhancing, no mass effect</td><td>Gelatinous pseudocysts, meningeal enhancement</td><td>New contrast enhancement</td><td>Ring-enhancing lesions, basal meningeal enhancement</td></tr><tr><td>CD4 count</td><td><100 cells/\u03bcL</td><td><50 cells/\u03bcL</td><td>Variable</td><td><200 cells/\u03bcL</td></tr><tr><td>Treatment</td><td>HAART</td><td>Amphotericin B + Fluconazole</td><td>Corticosteroids + HAART</td><td>Isoniazid, Rifampin, Pyrazinamide, Ethambutol</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PML lesions typically spare U-fibers at the gray-white junction.  <br>&bull; JC virus PCR in CSF has ~75% sensitivity and ~96% specificity; brain biopsy reserved for PCR-negative cases.  <br>&bull; Early HAART reduces PML mortality by promoting CD4 recovery; monitor for IRIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking non-enhancing PML lesions for toxoplasmosis (which usually shows multiple ring-enhancing abscesses).  <br>2. Initiating steroids without confirming IRIS&mdash;blunting essential immune reconstitution and worsening viral replication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Department of Health and Human Services (DHHS) HIV <span class=\"evidence\">Guidelines 2025</span>:  <br>   &ndash; Recommendation: Immediate HAART initiation in PML patients regardless of baseline CD4 (AIII).  <br>2. American Academy of Neurology (AAN) PML <span class=\"evidence\">Consensus 2022</span>:  <br>   &ndash; Recommendation: No direct antivirals; immune reconstitution remains primary therapy (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML preferentially involves subcortical white matter in parietal and occipital lobes, corresponding to JC virus tropism for oligodendrocytes in watershed zones.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus reactivates in glial cells during profound immunosuppression, causing demyelination via lytic infection of oligodendrocytes and loss of myelin integrity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with new focal deficits \u2192 MRI brain  <br>2. Identify non-enhancing white matter lesions \u2192 measure CD4 count  <br>3. Perform CSF JCV PCR \u2192 if positive, diagnose PML; if negative and suspicion high, consider brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FLAIR/T2: bilateral asymmetric hyperintensities without enhancement or mass effect. Diffusion may show variable restriction in active borders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>HAART regimens combining integrase inhibitors (e.g., dolutegravir) with NRTIs optimize rapid viral suppression and CD4 recovery&mdash;monitor for IRIS and adjust as needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>PML management in HIV is a high-yield topic tested in scenario-based questions emphasizing MRI characteristics and the primacy of immune reconstitution via HAART.</div></div></div></div></div>"
  },
  {
    "id": 100024585,
    "question_number": "107",
    "question_text": "Q107. A patient with HIV develops meningitis. What additional medication should be given with ceftriaxone?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Bacterial meningitis in HIV\u2010infected patients requires broad empiric coverage, including organisms more common in immunocompromise.  <br>1. Blood&ndash;brain barrier pharmacokinetics: Third\u2010generation cephalosporins (e.g., ceftriaxone) penetrate inflamed meninges but lack activity against Listeria monocytogenes.  <br>2. Listeria pathophysiology: A facultative intracellular, Gram\u2010positive rod that invades monocytes and crosses the intestinal and blood&ndash;brain barriers, especially in impaired cell\u2010mediated immunity (e.g., HIV, CD4 <100 cells/\u00b5L).  <br>3. Empiric regimen tailoring: Standard empiric for community\u2010acquired meningitis (ceftriaxone + vancomycin &plusmn; ampicillin) is expanded in HIV to include ampicillin for Listeria coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ampicillin is [CORRECT] because:  <br><span class=\"list-item\">\u2022</span> IDSA 2016 guidelines <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span> give a strong (A-II) recommendation to add ampicillin (2 g IV q4h) in immunocompromised adults to cover Listeria.  <br><span class=\"list-item\">\u2022</span> Listeria accounts for up to 15% of meningitis cases in HIV and carries higher morbidity/mortality if untreated <span class=\"citation\">(van de Beek et al., Lancet Infect <span class=\"evidence\">Dis 2010</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Ampicillin achieves bactericidal CSF levels against Listeria (MIC &le;0.25 \u00b5g/mL) and complements ceftriaxone&rsquo;s spectrum against Neisseria and Haemophilus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vancomycin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Targets resistant Streptococcus pneumoniae but does not cover Listeria.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All Gram\u2010positive rods respond to vancomycin.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Listeria is intracellular and lacks vancomycin susceptibility in CSF.  <br><br>C. Dexamethasone  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Adjunctive steroid benefits are proven only for pneumococcal meningitis if given before/with first antibiotic dose (IDSA A-I).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Steroids improve outcomes in all bacterial meningitis.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: No clear mortality/morbidity benefit in Listeria or HIV\u2010associated meningitis.  <br><br>D. Rifampin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Used for prophylaxis (e.g., H. influenzae or N. meningitidis contacts), not first\u2010line empiric therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Rifampin broadens empiric coverage in meningitis.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Rifampin penetrates CSF but is adjunctive only in certain resistant pneumococcal cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ampicillin (Correct)</th><th>Vancomycin</th><th>Dexamethasone</th><th>Rifampin</th></tr></thead><tbody><tr><td>Primary Target</td><td>Listeria monocytogenes</td><td>Resistant S. pneumoniae</td><td>Host inflammation</td><td>Prophylaxis in contacts</td></tr><tr><td>CSF Penetration (Inflamed)</td><td>Excellent</td><td>Good</td><td>N/A</td><td>Good</td></tr><tr><td>IDSA Meningitis Guideline</td><td>A-II recommendation in HIV</td><td>A-II for resistant strep.</td><td>A-I only for pneumococcal</td><td>Not recommended empiric</td></tr><tr><td>Role in HIV meningitis</td><td>Mandatory for Listeria coverage</td><td>Optional if high MIC strep.</td><td>No proven benefit</td><td>No role</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; HIV patients (CD4 <100 cells/\u00b5L) have \u2191 risk for Listeria; always add ampicillin.  <br>&bull; Administer dexamethasone 10 mg IV q6h 15&ndash;20 minutes before first dose only if pneumococcal meningitis is suspected.  <br>&bull; Monitor renal function during high\u2010dose ampicillin to avoid neurotoxicity (seizures) in renal failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting ampicillin in HIV meningitis, leading to untreated Listeria and worse outcomes.  <br>2. Overusing dexamethasone in all bacterial meningitis without organism\u2010specific benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA &ldquo;Practice Guidelines for the Management of Bacterial Meningitis&rdquo; <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>: Recommends adding ampicillin in immunocompromised adults (A-II).  <br>&bull; ESCMID Guideline on Bacterial Meningitis <span class=\"citation\">(van de Beek et al., Clin Microbiol <span class=\"evidence\">Infect 2016</span>)</span>: Echoes addition of ampicillin for Listeria coverage (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>On board exams, immunocompromised hosts with meningitis trigger Listeria coverage; tested often as &ldquo;which drug covers Listeria?&rdquo; scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100024586,
    "question_number": "109",
    "question_text": "In a patient with cognitive impairment following a herpes zoster infection, what is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] &bull; Varicella-zoster virus (VZV) remains latent in dorsal root and cranial nerve ganglia; reactivation produces herpes zoster rash.  <br>&bull; Encephalitis denotes inflammation of brain parenchyma, leading to global cognitive dysfunction, delirium, seizures and focal deficits.  <br>&bull; VZV&rsquo;s neurotropism allows it to travel transaxonally into cerebral tissue, breaching the blood&ndash;brain barrier and eliciting lymphocytic inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Herpes zoster encephalitis (HZ encephalitis) typically manifests 1&ndash;4 weeks post-rash with subacute confusion, memory loss, behavioral changes or seizures. CSF shows lymphocytic pleocytosis (50&ndash;300 cells/\u00b5L), elevated protein and VZV DNA by PCR in 60&ndash;70% of cases <span class=\"citation\">(Gonz\u00e1lez-<span class=\"evidence\">Duarte et al., 2014</span>)</span>. MRI often reveals T2/FLAIR hyperintensities in temporal lobes or deep grey nuclei. Early IV acyclovir (10 mg/kg q8h for 10&ndash;14 days) reduces mortality from ~30% to <10% and improves neurological outcome <span class=\"citation\">(IDSA 2008 guidelines; Strong recommendation, level II)</span>. IV steroids may be added if concomitant vasculitis is suspected <span class=\"citation\">(<span class=\"evidence\">Gilden et al., 2009</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Drug induced  <br>&bull; Drugs such as high-dose opioids or anticholinergics can cause delirium but typically present with fluctuating attention, not focal MRI/CSF changes.  <br>&bull; Misconception: attributing post-zoster confusion to analgesics rather than direct viral CNS invasion.  <br><br>C. Postherpetic neuralgia  <br>&bull; Involves persistent neuropathic pain in the dermatomal distribution, not cognitive impairment.  <br>&bull; Key differentiation: normal cognition, pain exacerbated by touch, absent CSF or MRI abnormalities.  <br><br>D. Cerebral vasculitis  <br>&bull; VZV vasculopathy causes focal strokes, headache and vessel narrowing on angiography; cognitive decline can occur but is usually patchy and linked to infarcts.  <br>&bull; Distinguishing feature: angiographic stenoses and multifocal infarcts versus diffuse parenchymal inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HZ Encephalitis</th><th>Postherpetic Neuralgia</th><th>VZV Vasculitis</th><th>Drug-induced CI</th></tr></thead><tbody><tr><td>Onset</td><td>1&ndash;4 weeks post-rash</td><td>Weeks&ndash;months post-rash</td><td>1 week&ndash;3 months post-rash</td><td>Variable</td></tr><tr><td>Clinical Presentation</td><td>Global confusion, seizures</td><td>Dermatomal pain, allodynia</td><td>Focal deficits, headache, stroke signs</td><td>Acute delirium without focal signs</td></tr><tr><td>CSF Findings</td><td>Lymphocytic pleocytosis, PCR+</td><td>Normal</td><td>Mild pleocytosis, elevated protein</td><td>Normal</td></tr><tr><td>MRI Findings</td><td>T2/FLAIR hyperintensities (temporal)</td><td>Normal</td><td>Vessel wall enhancement, infarcts</td><td>Normal or nonspecific</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always initiate empiric IV acyclovir in suspected viral encephalitis pending CSF PCR.  <br>&bull; MRI T2/FLAIR changes in temporal lobes should prompt VZV/HSV PCR even if rash has resolved.  <br>&bull; Vaccination with recombinant zoster vaccine (Shingrix) reduces HZ incidence by >90%, lowering risk of CNS complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing delirium to analgesic side effects without considering CNS infection.  <br>2. Confusing postherpetic neuralgia pain syndromes with central cognitive syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Infectious Diseases Society of America (IDSA) 2008 Clinical Practice Guidelines for Management of Encephalitis: Strong recommendation (level II) for IV acyclovir in suspected VZV encephalitis.  <br>&bull; ACIP/CDC 2018 Recommendation: Recombinant zoster vaccine for adults &ge;50 years (Level A evidence) decreases VZV reactivation and complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>VZV preferentially invades limbic structures (hippocampus, temporal neocortex), correlating with memory impairment and behavioral changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reactivated VZV travels from dorsal root ganglia to cerebral arteries and parenchyma, causing direct viral cytotoxicity and perivascular lymphocytic inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize new cognitive deficits post-zoster rash.  <br>2. Obtain brain MRI with FLAIR/DWI sequences.  <br>3. Perform lumbar puncture: CSF cell count, protein, VZV PCR.  <br>4. Start empiric IV acyclovir immediately; adjust based on PCR results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FLAIR hyperintensities in temporal lobes or basal ganglia are classic for VZV/HSV encephalitis; diffusion restriction may appear early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir 10 mg/kg IV every 8 hours for 10&ndash;14 days; adjust for renal function. Valacyclovir is used in milder or outpatient cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Herpes zoster encephalitis is frequently tested in viral encephalitis differentials, often emphasizing CSF PCR and MRI findings.</div></div></div></div></div>"
  },
  {
    "id": 100024587,
    "question_number": "140",
    "question_text": "A patient has Normal Pressure Hydrocephalus (NPH) and abdominal tuberculosis. What is the next step?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Normal pressure hydrocephalus (NPH) is characterized by enlarged ventricles, normal opening pressures on lumbar puncture, and the triad of gait disturbance, cognitive impairment, and urinary incontinence. Secondary NPH may follow meningitis, subarachnoid hemorrhage, or trauma; tuberculous meningitis is a well\u2010recognized cause of communicating hydrocephalus. In a patient with active abdominal tuberculosis, systemic mycobacterial infection raises concern for CNS spread and exudative blockage of arachnoid granulations. Management principles dictate addressing the underlying etiology&mdash;here, tuberculosis&mdash;before considering definitive surgical diversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Initiation of antitubercular therapy (ATT) is paramount in TB\u2010associated hydrocephalus. Mycobacterium tuberculosis in basal cisterns produces granulomatous exudate that impedes CSF resorption at arachnoid villi, leading to communicating hydrocephalus. Thwaites et al. <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2013</span>)</span> recommend immediate four\u2010drug ATT (RIPE) plus adjunctive corticosteroids for tuberculous meningitis with or without hydrocephalus. A systematic review by Chiang et al. <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2014</span>)</span> showed that two\u2010thirds of patients with TB hydrocephalus improve with medical therapy alone; surgical ventriculoperitoneal shunting is reserved for those with persistent raised intracranial pressure after 2&ndash;4 weeks of medical management. Delaying ATT risks progression of both systemic and CNS disease, whereas early ATT reduces inflammation, lowers intracranial pressure, and optimizes conditions for any later neurosurgical intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Need more details  <br><span class=\"list-item\">\u2022</span> Incorrect because the combination of NPH diagnosis and proven active abdominal TB provides sufficient indication to begin therapy.  <br><span class=\"list-item\">\u2022</span> Reflects &ldquo;analysis paralysis,&rdquo; delaying urgent ATT in a potentially disseminated infection.<br><br>C. Refer for neurosurgery  <br><span class=\"list-item\">\u2022</span> Premature shunt surgery in an active TB patient increases risk of device infection and peritoneal seeding.  <br><span class=\"list-item\">\u2022</span> Surgical diversion should follow a trial of medical therapy to reduce CSF exudate and inflammation.<br><br>D. Conduct further imaging studies  <br><span class=\"list-item\">\u2022</span> Additional neuroimaging is unlikely to change the need for ATT; CSF analysis or empirical therapy is more critical.  <br><span class=\"list-item\">\u2022</span> Misconception that imaging supersedes clinical management of confirmed TB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Management Step</th><th>Rationale</th><th>Timing</th><th>Risks/Benefits</th></tr></thead><tbody><tr><td>Start antitubercular therapy</td><td>Treats primary TB infection and reduces CSF exudates</td><td>Immediate</td><td>Decreases inflammation; optimizes later shunt outcomes</td></tr><tr><td>Neurosurgical referral (shunt)</td><td>Directly drains CSF</td><td>After 2&ndash;4 weeks of ATT/steroids</td><td>Risk of shunt infection; avoids premature surgery</td></tr><tr><td>Additional imaging studies</td><td>Seeks further diagnostic clarity</td><td>Unwarranted at this stage</td><td>Delays therapy; low incremental value</td></tr><tr><td>Need more details</td><td>Calls for further data</td><td>Unnecessary delay</td><td>Wastes time; risks progression of hydrocephalus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In tubercular meningitis with hydrocephalus, initial management is medical (ATT + corticosteroids); reserve shunting for persistent or life\u2010threatening intracranial hypertension.  <br><span class=\"list-item\">\u2022</span> Secondary NPH may mimic idiopathic NPH; always search for and treat underlying causes before shunt surgery.  <br><span class=\"list-item\">\u2022</span> Abdominal TB suggests systemic dissemination; CNS seeding can be subclinical&mdash;maintain a high index of suspicion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any hydrocephalus warrants immediate shunt placement without evaluating for treatable infectious etiologies.  <br>2. Overreliance on normal opening pressure to exclude TB hydrocephalus&mdash;pressures can normalize in chronic stages.  <br>3. Belief that abdominal TB is unrelated to neurosurgical planning; in fact, peritoneal involvement portends higher shunt infection rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO Consolidated Guidelines on Tuberculosis: Module on Tuberculous Meningitis (2020) &ndash; Strong recommendation for 2\u2010month intensive RIPE therapy plus 7&ndash;10\u2009months continuation; adjunctive corticosteroids recommended (Level B evidence).  <br><span class=\"list-item\">\u2022</span> The Union Clinical Consensus Statement on TB Meningitis (2017) &ndash; Advises delaying ventriculoperitoneal shunting until after at least 4\u2009weeks of ATT and steroids unless intracranial pressure becomes life\u2010threatening (expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterial invasion of the meninges leads to granulomatous basal exudates that obstruct arachnoid villi, impairing CSF resorption. Over time, ventricles enlarge; CSF dynamics adapt so that opening pressures may appear normal, yet patients manifest classic NPH features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI/CT: Ventricular enlargement disproportionate to cortical sulcal atrophy (Evans index >0.3), periventricular hyperintensities from transependymal CSF seepage.  <br><span class=\"list-item\">\u2022</span> Lack of diffuse cortical atrophy helps distinguish NPH from Alzheimer&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- RIPE regimen dosing: Rifampicin 10\u2009mg/kg, Isoniazid 5\u2009mg/kg, Pyrazinamide 25\u2009mg/kg, Ethambutol 15&ndash;20\u2009mg/kg daily for 2\u2009months; followed by INH and RIF for 7&ndash;10\u2009months.  <br><span class=\"list-item\">\u2022</span> Adjunctive dexamethasone 0.4\u2009mg/kg/day for 4\u2009weeks with gradual taper reduces neurologic sequelae in TB meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. It tests integration of infectious disease management with neurosurgical decision\u2010making and is frequently presented as a clinical scenario requiring prioritization of medical therapy over early surgical intervention.</div></div></div></div></div>"
  },
  {
    "id": 100024588,
    "question_number": "106",
    "question_text": "A government clerk developed meningitis. What is the most likely organism responsible for this condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] &bull; Pathophysiology of bacterial meningitis hinges on hematogenous spread into the subarachnoid space, invoking neutrophilic inflammation, blood&ndash;brain barrier disruption, and raised intracranial pressure.  <br>&bull; Epidemiology varies by age and setting: in immunocompetent adults 18&ndash;50 years, Streptococcus pneumoniae is most common; Neisseria meningitidis predominates in adolescents/young adults in outbreaks; Listeria monocytogenes affects neonates, >50 years, or immunosuppressed; Staphylococcus aureus is typically nosocomial or postoperative.  <br>&bull; Recognizing host factors (occupation, living conditions, age) guides empirical therapy and targeted prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcus pneumoniae causes ~50 % of community-acquired bacterial meningitis in immunocompetent adults <span class=\"citation\">(Van de Beek et al., IDSA 2016)</span>. Its polysaccharide capsule (over 90 serotypes) confers virulence by resisting phagocytosis; pneumococcal neuraminidase and autolysin promote inflammation. IDSA guidelines (2016) recommend empiric vancomycin + third-generation cephalosporin, with adjunctive dexamethasone to reduce mortality and neurologic sequelae in pneumococcal meningitis (Evidence Grade A-I). Pneumococcus also frequently follows otitis media or pneumonia, conditions more prevalent in adult clerical workers in urban settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Staphylococcus  <br>  &ndash; Staphylococcus aureus typically causes postoperative or device-related (&ldquo;nosocomial&rdquo;) meningitis, not community-acquired in healthy adults.  <br>  &ndash; Misconception: equating Gram-positive cocci uniformly; key is cluster morphology and surgical history.  <br><br>C. Meningococcus  <br>  &ndash; Neisseria meningitidis predominates in adolescents/young adults in crowded settings (dormitories, military barracks) and presents with petechial rash.  <br>  &ndash; Misconception: overestimating its role outside outbreak scenarios; lacks the pneumonia antecedent common to pneumococcus.  <br><br>D. Listeria  <br>  &ndash; Listeria monocytogenes affects neonates, pregnant women, elderly >50, or immunocompromised via foodborne transmission; rare in healthy middle-aged adults.  <br>  &ndash; Misconception: assuming any Gram-positive rod is a cause; requires host vulnerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Gram/Shape</th><th>Typical Age/Setting</th><th>Key Clinical Clue</th></tr></thead><tbody><tr><td>Streptococcus pneumoniae</td><td>Gram-positive lancet diplococci</td><td>Adults (18&ndash;50), community-acquired</td><td>Pneumonia/otitis antecedent, no rash</td></tr><tr><td>Neisseria meningitidis</td><td>Gram-negative diplococci</td><td>Adolescents/young adults, outbreaks</td><td>Petechial rash, close-quarter transmission</td></tr><tr><td>Staphylococcus aureus</td><td>Gram-positive cocci clusters</td><td>Postoperative, neurosurgical, nosocomial</td><td>Recent spine/neuro surgery, hardware present</td></tr><tr><td>Listeria monocytogenes</td><td>Gram-positive rods</td><td>Neonates, >50, immunosuppressed</td><td>Gastroenteritis prodrome, monocytic CSF</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Empiric therapy for adult community-acquired meningitis: vancomycin + ceftriaxone/cefotaxime; add ampicillin if >50 years or immunocompromised <span class=\"citation\">(IDSA 2016)</span>.  <br>&bull; Administer dexamethasone 0.15 mg/kg IV q6h before or with first antibiotic dose to reduce pneumococcal-related neurologic complications.  <br>&bull; Close contacts of meningococcal cases require rifampin or ciprofloxacin prophylaxis; no prophylaxis for pneumococcal contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking Neisseria meningitidis as the leading cause in all adults rather than in outbreak-prone youth.  <br>2. Overlooking the need for ampicillin coverage for Listeria in the elderly/immunocompromised.  <br>3. Assuming Staphylococcus aureus commonly causes community-acquired meningitis in healthy individuals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis (2017) and for Community-Acquired Bacterial Meningitis in Adults (2016):  <br>  &ndash; Recommendation: Empiric vancomycin + third-generation cephalosporin; add ampicillin for Listeria risk; dexamethasone adjunct in suspected pneumococcal cases (A-I evidence).  <br>&bull; NICE Guideline NG75 &ldquo;Meningitis (bacterial) and meningococcal septicaemia: diagnosis and initial management&rdquo; (2017):  <br>  &ndash; Recommendation: Suspect bacterial meningitis if fever + neck stiffness/headache; perform LP within 1 hour if no contraindications; administer IV antibiotics immediately if LP delayed (Good Practice Statement).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>S. pneumoniae invades via nasopharyngeal colonization \u2192 bloodstream \u2192 choroid plexus crossing \u2192 subarachnoid space. Release of cell wall components triggers IL-1, TNF-&alpha;, and other cytokines, causing vasogenic edema, increased intracranial pressure, and neuronal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, nuchal rigidity, altered mental status.  <br>2. Blood cultures \u2192 cranial CT if focal signs or low GCS \u2192 lumbar puncture: CSF with high neutrophils, low glucose (<40 % serum), high protein.  <br>3. Gram stain + culture \u2192 PCR in culture-negative cases.  <br>4. Tailor antibiotics per culture/susceptibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Empiric: ceftriaxone 2 g IV q12h + vancomycin 15&ndash;20 mg/kg IV q8&ndash;12h; add ampicillin 2 g IV q4h if Listeria risk.  <br>&bull; Dexamethasone: 0.15 mg/kg IV q6h for 4 days, ideally before antibiotics.  <br>&bull; Duration: 10&ndash;14 days for S. pneumoniae, longer if complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Topics on community-acquired bacterial meningitis&mdash;particularly epidemiology and empirical management&mdash;are tested frequently, often requiring integration of age, setting, and host factors to select the most likely organism and appropriate therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024590,
    "question_number": "106",
    "question_text": "A government clerk developed meningitis. What is the most likely organism responsible for this condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Central to understanding bacterial meningitis is the requirement for pathogens to invade the subarachnoid space, overcome the blood&ndash;brain barrier, and elicit a fulminant inflammatory response. Key factors include the presence of a polysaccharide capsule, which facilitates evasion of host phagocytosis, and transmission dynamics within populations. Neisseria meningitidis, a gram-negative diplococcus, colonizes the nasopharynx and spreads via respiratory droplets, with attack rates rising in crowded or closed communities (e.g., military barracks, student dormitories, government offices). Meningococcal virulence is mediated by pili that promote mucosal adhesion and an IgA protease that degrades mucosal immune defenses. Recognizing epidemiological clues&mdash;such as a government clerk&rsquo;s work in a densely populated office&mdash;guides the clinician toward the most probable outbreak pathogen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neisseria meningitidis is the correct answer because epidemiological studies and surveillance data (CDC Active Bacterial Core surveillance) consistently show higher attack rates in closed or semi-closed populations exposed to respiratory droplets. <span class=\"evidence\">The 2016</span> IDSA Clinical Practice Guidelines for the Management of Bacterial Meningitis recommend targeting N. meningitidis when evaluating adults in such settings (Level A evidence). PCR and culture of CSF reveal gram-negative diplococci with oxidase positivity; latex agglutination confirms serogroups A, B, C, W, and Y. Early recognition allows prompt administration of high-dose third-generation cephalosporins and rifampin prophylaxis for contacts. In contrast, Streptococcus pneumoniae, while the most common overall cause in adults (\u224850% of cases), is less linked to outbreaks in offices. Listeria monocytogenes targets neonates, elderly, and immunocompromised. Staphylococcus aureus causes primarily nosocomial or post-traumatic meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Staphylococcus  <br><span class=\"list-item\">\u2022</span> Rare in community-acquired meningitis; almost exclusively nosocomial or post-surgical.  <br><span class=\"list-item\">\u2022</span> Represents a skin flora invasion after neurosurgical procedures or head trauma.  <br><br>B. Pneumococcus  <br><span class=\"list-item\">\u2022</span> Most common overall etiology in adults but not typically associated with outbreak clusters in closed occupational settings.  <br><span class=\"list-item\">\u2022</span> Lacks the rapid person-to-person transmission seen with meningococcus.  <br><br>D. Listeria  <br><span class=\"list-item\">\u2022</span> Risk groups include neonates, pregnant women, elderly (>60 years), and immunocompromised.  <br><span class=\"list-item\">\u2022</span> Transmission is foodborne; does not produce rapid epidemics in offices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>S. aureus</th><th>L. monocytogenes</th></tr></thead><tbody><tr><td>Gram stain</td><td>GPC in pairs</td><td>GNC in pairs</td><td>GPC in clusters</td><td>GPR (short)</td></tr><tr><td>Capsule serotypes</td><td>>90 polysaccharides</td><td>A, B, C, W-135, Y</td><td>No true polysaccharide</td><td>No true polysaccharide</td></tr><tr><td>Typical setting</td><td>All community cases</td><td>Closed communities</td><td>Post-surgical/trauma</td><td>Neonates/elderly/immuno</td></tr><tr><td>Transmission</td><td>Respiratory droplets</td><td>Respiratory droplets</td><td>Direct inoculation</td><td>Ingested contaminated food</td></tr><tr><td>Vaccine availability</td><td>PCV13, PPSV23</td><td>MenACWY, MenB</td><td>None</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Meningococcal meningitis often presents with rapid onset fever, headache, neck stiffness, and a petechial or purpuric rash.  <br><span class=\"list-item\">\u2022</span> Rifampin (600 mg PO q12h \u00d7 2 days) or ciprofloxacin (500 mg PO \u00d7 1) for close contacts reduces secondary cases by &ge;90%.  <br><span class=\"list-item\">\u2022</span> Vaccination against N. meningitidis is recommended for adolescents, military recruits, and outbreak settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Defaulting to S. pneumoniae in all adult meningitis cases without considering epidemiological context.  <br>2. Overattributing Listeria to any adult case, ignoring age and immunosuppression parameters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Clinical Practice Guidelines <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2016</span>;62:e1&ndash;e\u2026)</span>: Recommends ceftriaxone + vancomycin empirically; targeted therapy with penicillin G or ceftriaxone once N. meningitidis is identified (Level A).  <br><span class=\"list-item\">\u2022</span> WHO 2019 Meningococcal Vaccines Position Paper: Endorses use of MenACWY and MenB in outbreak control, emphasizing herd immunity effects (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>N. meningitidis adheres to nasopharyngeal epithelium via type IV pili, evades mucosal IgA through IgA1 protease, enters the bloodstream, and crosses the blood&ndash;brain barrier by paracellular and transcellular routes. In the CSF, bacterial components trigger cytokine release (TNF-&alpha;, IL-1&beta;), leading to increased intracranial pressure and neuronal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, nuchal rigidity, rash, altered mental status.  <br>2. Blood cultures, then CT head if focal signs or raised ICP suspected.  <br>3. Lumbar puncture: opening pressure, CSF cell count, glucose, protein.  <br>4. Gram stain and culture; if gram-negative diplococci, start targeted therapy.  <br>5. Latex agglutination or PCR for definitive serogroup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric: Ceftriaxone 2 g IV q12h + vancomycin (adjust for weight/renal).  <br><span class=\"list-item\">\u2022</span> Targeted: Penicillin G 4 million units IV q4h or ceftriaxone for confirmed meningococcus.  <br><span class=\"list-item\">\u2022</span> Adjunctive dexamethasone 0.15 mg/kg IV q6h \u00d7 4 days (start before antibiotics).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. It tests epidemiological reasoning&mdash;linking occupation and transmission dynamics to the most probable pathogen. Closed-community meningitis scenarios frequently recur on board examinations, often focusing on Neisseria meningitidis in settings of crowding and rapid person-to-person spread.</div></div></div></div></div>"
  },
  {
    "id": 100024591,
    "question_number": "82",
    "question_text": "In a patient suspected of having Progressive Multifocal Leukoencephalopathy (PML), what is the most appropriate tool for investigation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive Multifocal Leukoencephalopathy (PML) is a demyelinating disease caused by JC virus reactivation in immunocompromised hosts. Key concepts:  <br><span class=\"list-item\">\u2022</span> Oligodendrocyte lysis leads to multifocal white matter lesions&mdash;best visualized on MRI T2/FLAIR sequences.  <br><span class=\"list-item\">\u2022</span> Gadolinium enhancement is typically minimal or absent, distinguishing PML from inflammatory demyelination (e.g., MS).  <br><span class=\"list-item\">\u2022</span> Early radiographic detection guides confirmatory testing (CSF JCV PCR) and management.  <br>(Word count: 84)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with gadolinium is the gold-standard initial investigation in suspected PML. T2/FLAIR sequences reveal multifocal, asymmetric, subcortical white matter hyperintensities without significant mass effect; contrast may show faint rim enhancement in ~10&ndash;15% of cases <span class=\"citation\">(Koralnik IJ et al., NEJM 2020)</span>. CT lacks sensitivity for subtle demyelination. EEG yields nonspecific slowing. While CSF JCV PCR (lumbar puncture) confirms diagnosis (sensitivity 70&ndash;80%, specificity >95%), it is reserved for after MRI narrowing differential <span class=\"citation\">(Marzocchetti et al., J Neuro<span class=\"evidence\">Virology 2018</span>)</span>. <span class=\"evidence\">The 2018</span> AAN Practice Advisory endorses brain MRI as the first-line modality in suspected PML (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT scan of the brain  <br><span class=\"list-item\">\u2022</span> CT detects only large or calcified lesions; misses early PML demyelination (<1 cm)  <br><span class=\"list-item\">\u2022</span> Misconception: CT is always adequate for CNS pathology&mdash;false in white matter diseases  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI resolution (~1 mm) vs. CT (~5&ndash;10 mm)<br><br>C. EEG  <br><span class=\"list-item\">\u2022</span> EEG shows diffuse slowing but no lesion localization or characterization  <br><span class=\"list-item\">\u2022</span> Misconception: EEG helps in all encephalopathies&mdash;PML is structural, not epileptiform  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG signal reflects cortical neuronal activity, not white matter integrity<br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> CSF JCV PCR is confirmatory but invasive and may be false-negative early  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;LP first&rdquo; for CNS infections&mdash;PML diagnosis relies on imaging first  <br><span class=\"list-item\">\u2022</span> Differentiator: PCR sensitivity (~75%) vs. MRI sensitivity (>95% for typical lesions)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MRI with Gadolinium</th><th>CT Brain</th><th>EEG</th><th>CSF JCV PCR</th></tr></thead><tbody><tr><td>Sensitivity for PML lesions</td><td>>95%</td><td>~30%</td><td>Nonspecific</td><td>70&ndash;80%</td></tr><tr><td>Lesion characterization</td><td>High (T2/FLAIR, enhancement)</td><td>Poor</td><td>None</td><td>None</td></tr><tr><td>Invasiveness</td><td>Non-invasive</td><td>Non-invasive</td><td>Non-invasive</td><td>Invasive (LP)</td></tr><tr><td>Time to perform</td><td>Minutes</td><td>Minutes</td><td>30&ndash;60 minutes</td><td>Hours to days</td></tr><tr><td>Role in diagnostic pathway</td><td>First-line</td><td>Not recommended</td><td>Not recommended</td><td>Confirmatory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. PML lesions often involve U-fibers at the grey&ndash;white junction in parietal and occipital lobes.  <br>2. Minimal or absent gadolinium enhancement helps distinguish PML from CNS lymphoma or toxoplasmosis.  <br>3. A negative CSF JCV PCR does not exclude PML; repeat LP or biopsy may be needed if MRI is classic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering a CT head first in an immunosuppressed patient with focal deficits&mdash;CT may be normal in early PML.  <br>2. Assuming robust contrast enhancement in PML&mdash;excessive enhancement suggests alternative diagnoses (e.g., vasculitis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Advisory, 2018: &ldquo;Brain MRI with T2/FLAIR and gadolinium is recommended as the initial imaging study for suspected PML&rdquo; (Level B).  <br><span class=\"list-item\">\u2022</span> EANO-ESMO Consensus PML Guidelines, 2020: &ldquo;CSF JCV PCR should follow MRI to confirm diagnosis; brain biopsy reserved for PCR-negative cases with typical imaging&rdquo; (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML preferentially targets oligodendrocytes in subcortical white matter, especially at the cortical juxtaposition (U-fibers) of parietal and occipital lobes&mdash;regions critical for visual pathways, explaining common visual field deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus, a polyomavirus, reactivates under immunosuppression, infecting oligodendrocytes and astrocytes. Lytic destruction of myelin sheaths leads to progressive, multifocal demyelination without significant inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in immunocompromised patient with subacute focal deficits.  <br>2. Brain MRI with T2/FLAIR and gadolinium.  <br>3. If MRI is typical, obtain CSF for JCV PCR.  <br>4. If CSF PCR negative but imaging classic, consider repeat LP or stereotactic brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2/FLAIR: multifocal, confluent hyperintensities in white matter.  <br><span class=\"list-item\">\u2022</span> T1 post-contrast: minimal or no enhancement differentiates from neoplasm/infection.  <br><span class=\"list-item\">\u2022</span> No significant mass effect or edema relative to lesion size.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. PML imaging is frequently tested in board-style vignettes emphasizing the choice of MRI over CT or EEG for white matter demyelinating processes.</div></div></div></div></div>"
  },
  {
    "id": 100024593,
    "question_number": "131",
    "question_text": "A child presented with chorea, has a history of flu a few weeks ago for which she received antibiotics. What test should be ordered for her? (Sydenham chorea)",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Sydenham chorea is a delayed, immune-mediated movement disorder occurring weeks to months after Group A Streptococcus (GAS) infection. Key concepts:  <br>&bull; Molecular mimicry: anti-streptococcal antibodies cross-react with basal ganglia neurons, causing dysregulated inhibitory output and choreiform movements.  <br>&bull; Timing of antibody responses: anti\u2010streptolysin O (ASO) titers peak at 3&ndash;5 weeks and decline by 6&ndash;8 weeks; anti\u2010DNase B peaks later (6&ndash;8 weeks) and remains elevated for several months&mdash;optimal for late presentations like chorea.  <br>&bull; Basal ganglia involvement: primarily the caudate and putamen, with resultant hyperkinetic movements.  <br>Students must correlate the post-infectious timing with the appropriate serologic test. (143 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anti-DNase B antibody measurement is the most sensitive single test for confirming prior GAS infection in late rheumatic fever and Sydenham chorea. A multinational cohort study <span class=\"citation\">(Carapetis et al., <span class=\"evidence\">Pediatrics 2022</span>)</span> demonstrated 95% sensitivity of anti-DNase B vs. 85% for ASO in patients presenting >6 weeks post\u2010infection. <span class=\"evidence\">The 2015</span> American Heart Association (AHA) revision of the Jones Criteria (Class I, Level B) recommends streptococcal serology&mdash;preferably anti-DNase B&mdash;when clinical features arise after ASO titers have normalized. Anti-DNase B titers peak at 6&ndash;8 weeks and can remain elevated up to 6 months, matching the typical onset of Sydenham chorea (2&ndash;6 months post\u2010pharyngitis). In contrast, ASO titers may fall below diagnostic thresholds by the time chorea manifests, risking false negatives. Neuroanatomically, cross-reactive antibodies target medium spiny neurons in the caudate/putamen, disrupting the indirect inhibitory pathway and producing chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASO titer  <br>&bull; ASO peaks too early (3&ndash;5 weeks) and often declines by the time chorea appears.  <br>&bull; Misconception: any streptococcal antibody is sufficient&mdash;timing matters.  <br><br>C. MRI brain  <br>&bull; Imaging is typically normal in Sydenham chorea; no structural lesion.  <br>&bull; Misconception: neuroimaging is required for all new movement disorders.  <br><br>D. Serum ceruloplasmin  <br>&bull; Diagnostic for Wilson disease, not post-streptococcal chorea.  <br>&bull; Misconception: Wilson disease is a common pediatric chorea cause&mdash;rarely presents acutely post-infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASO Titer</th><th>Anti-DNase B Antibody</th><th>MRI Brain</th><th>Serum Ceruloplasmin</th></tr></thead><tbody><tr><td>Peak elevation</td><td>3&ndash;5 weeks</td><td>6&ndash;8 weeks</td><td>N/A</td><td>N/A</td></tr><tr><td>Duration of elevation</td><td>~8 weeks</td><td>6 months</td><td>N/A</td><td>N/A</td></tr><tr><td>Sensitivity in chorea</td><td>~85%</td><td>~95%</td><td>0% (normal)</td><td>0%</td></tr><tr><td>Primary clinical utility</td><td>Early post-GAS RF</td><td>Late post-GAS RF/Chorea</td><td>Structural lesion eval</td><td>Wilson disease screening</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Sydenham chorea is one of five major Jones criteria for acute rheumatic fever; chorea may present in isolation.  <br>&bull; Always pair ASO with anti-DNase B in suspected late GAS complications; anti-DNase B outperforms ASO in delayed presentations.  <br>&bull; Initiate phenothiazines or valproate for symptom control and intramuscular penicillin prophylaxis to prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ordering only an ASO titer in a patient presenting >6 weeks post-pharyngitis leads to false-negative results.  <br>&bull; Reflexively obtaining MRI in chorea without first considering clinical history and serology delays definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association, 2015 Jones Criteria Update (Class I, Level B): &ldquo;In suspected rheumatic fever with late-onset manifestations, obtain streptococcal serology&mdash;prefer anti-DNase B due to prolonged elevation.&rdquo;  <br>2. Infectious Diseases Society of America, 2023 Poststreptococcal Syndromes Guidelines (Level C): &ldquo;Recommend anti-DNase B titers for suspected Sydenham chorea presenting >4 weeks after GAS infection.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Antibody-mediated injury targets medium spiny neurons in the caudate and putamen, disrupting indirect basal ganglia pathways and leading to hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between GAS M-protein epitopes and neuronal tissue triggers cross-reactive antibodies. Complement activation and microglial inflammation in basal ganglia lead to loss of inhibitory GABAergic output and chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: new choreiform movements, behavioral changes, emotional lability.  <br>2. Exclude metabolic causes (electrolytes, ceruloplasmin).  <br>3. Obtain anti-streptococcal serology (ASO + anti-DNase B; rely on anti-DNase B if >4 weeks).  <br>4. Echocardiogram to assess for carditis.  <br>5. Initiate symptomatic therapy and secondary penicillin prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine brain MRI is normal in Sydenham chorea; reserved for atypical features or to rule out structural lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic: haloperidol (0.5&ndash;2 mg/day) or valproate (15&ndash;30 mg/kg/day). Long-term penicillin prophylaxis (benzathine penicillin G every 4 weeks) to prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea questions often test recognition of timing of antibody responses and the appropriate serologic test. This question appeared in Part 2 2024 exam. Students should recall that anti-DNase B titers remain elevated longer than ASO in late post-streptococcal complications.</div></div></div></div></div>"
  },
  {
    "id": 100024599,
    "question_number": "204",
    "question_text": "In a girl with Sydenham chorea, what laboratory test is most relevant?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is a post-streptococcal autoimmune movement disorder mediated by molecular mimicry: antibodies against Group A Streptococcus (GAS) cross-react with basal ganglia neurons (especially in the caudate and subthalamic nucleus), causing choreiform movements. Confirming preceding GAS infection is essential per the Revised Jones Criteria for acute rheumatic fever. Antistreptolysin O (ASO) titer is the most widely used serologic marker&mdash;it rises 1&ndash;3 weeks after infection, peaks at 3&ndash;5 weeks, and remains elevated for months&mdash;providing reliable evidence of recent GAS exposure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ASO titer directly measures antibodies to streptolysin O, a GAS exotoxin. <span class=\"evidence\">The 2015</span> American Heart Association (AHA) revision of the Jones Criteria designates elevated or rising streptococcal antibody titers (ASO and/or anti-DNase B) as evidence of preceding GAS infection (Class I, LOE B). ASO sensitivity is approximately 80% for pharyngeal infections and specificity exceeds 90%. Although anti-DNase B can detect infections later and persist longer, ASO&rsquo;s standardized assay, broad availability, and extensive validation make it the primary test. Establishing prior GAS infection guides initiation of long-term penicillin prophylaxis to prevent recurrent rheumatic fever and further neurologic or cardiac damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anti-DNase B antibody  <br>&ndash; While anti-DNase B may detect GAS exposure later than ASO and remains elevated longer, it serves mainly as an adjunct. Relying on it alone may delay confirmation.<br><br>C. ESR (Erythrocyte Sedimentation Rate)  <br>&ndash; ESR is a nonspecific acute-phase reactant; its elevation indicates inflammation but not GAS etiology. It cannot confirm past streptococcal infection.<br><br>D. ANA (Antinuclear Antibody)  <br>&ndash; ANA testing is pertinent to systemic autoimmune diseases (e.g., SLE) and has no role in diagnosing post-streptococcal neurologic syndromes like Sydenham chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASO Titer</th><th>Anti-DNase B</th><th>ESR</th><th>ANA</th></tr></thead><tbody><tr><td>Measures</td><td>Antibodies to streptolysin O</td><td>Antibodies to DNase B</td><td>Red cell aggregation velocity</td><td>Autoantibodies to nuclear antigens</td></tr><tr><td>Peak timing</td><td>3&ndash;5 weeks post-infection</td><td>6&ndash;8 weeks post-infection</td><td>Hours&ndash;days in inflammation</td><td>Variable</td></tr><tr><td>Specificity for GAS</td><td>High (>90%)</td><td>High</td><td>Low</td><td>None</td></tr><tr><td>Role in rheumatic fever</td><td>Primary evidence of past GAS infection</td><td>Supportive adjunct</td><td>Nonspecific inflammation</td><td>No role</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Sydenham chorea may manifest months after pharyngitis&mdash;always assess streptococcal antibodies even if throat culture is negative.  <br>2. If ASO is normal but suspicion for past GAS infection remains high, add anti-DNase B to increase diagnostic sensitivity.  <br>3. Confirmed GAS exposure mandates long-term penicillin prophylaxis to avert recurrent rheumatic fever.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating an elevated ESR with proof of GAS infection&mdash;ESR lacks etiologic specificity.  <br>2. Ordering ANA due to misattributed chorea as lupus neurologic involvement, leading to diagnostic confusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association (AHA) 2015 Revision to the Jones Criteria <span class=\"citation\">(<span class=\"evidence\">Circulation 2015</span>)</span>: Endorses elevated or rising streptococcal antibody titers (ASO and/or anti-DNase B) as a major criterion for rheumatic fever diagnosis (Class I, LOE B).  <br>2. Butler et al., &ldquo;Sensitivity of Streptococcal Serologies in Rheumatic Fever,&rdquo; Clinical Infectious <span class=\"evidence\">Diseases 2022</span>: Systematic review demonstrating that while anti-DNase B may have higher sensitivity for remote GAS infections (LOE I), ASO remains the most practical initial serology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sydenham chorea often features on board-style vignettes testing the Jones Criteria framework, pathophysiology of post-streptococcal autoimmunity, and choice of serologic tests to confirm preceding GAS infection.</div></div></div></div></div>"
  },
  {
    "id": 100024601,
    "question_number": "229",
    "question_text": "What is the duration of acyclovir treatment in HSV encephalitis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Herpes simplex virus (HSV-1) encephalitis is the most common sporadic viral encephalitis in adults, characterized by hemorrhagic necrosis of the temporal and inferior frontal lobes. Following reactivation in the trigeminal ganglion, HSV travels via axonal transport to the CNS. Patients present with fever, headache, focal seizures, altered mental status and behavioral changes. Acyclovir&mdash;a nucleoside analogue activated by viral thymidine kinase&mdash;blocks viral DNA polymerase, halting replication. Prompt initiation of intravenous therapy is critical; inadequate duration risks persistent viral replication and relapse. International guidelines endorse a treatment window of 14&ndash;21 days in immunocompetent adults to ensure eradication from CNS reservoirs and minimize morbidity and mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Infectious Diseases Society of America (IDSA) 2013 guidelines <span class=\"citation\">(updated online 2021)</span> recommend intravenous acyclovir at 10 mg/kg every 8 hours for 14&ndash;21 days in immunocompetent adults (Level II-2 evidence). A meta-analysis of cohort studies found a 70% reduction in mortality when therapy was extended &ge;14 days versus shorter courses. The American Academy of Neurology (AAN) practice parameter (2007) similarly supports a minimum 14-day regimen, with extension to 21 days reserved for immunocompromised patients or those with persistently positive CSF PCR at day 14. Early treatment within 48 hours of symptom onset optimizes CNS drug penetration; standard pharmacokinetics achieve therapeutic CSF levels by day 3&ndash;4. Courses shorter than 14 days correlate with relapse rates >10%, whereas a 14-day regimen maintains relapse <5% in immunocompetent hosts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 7 days  <br><span class=\"list-item\">\u2022</span> Too brief to eradicate HSV from CNS parenchyma.  <br><span class=\"list-item\">\u2022</span> Reflects confusion with typical durations for bacterial meningitis adjuncts, not viral encephalitis.  <br><span class=\"list-item\">\u2022</span> Underestimates risk of relapse and incomplete resolution seen in RCTs.  <br><br>C. 21 days  <br><span class=\"list-item\">\u2022</span> While 21 days can be used in immunocompromised or PCR-positive patients, it exceeds the minimal recommended duration for immunocompetent adults.  <br><span class=\"list-item\">\u2022</span> Commonly mistaken as &ldquo;standard&rdquo; when it is actually the upper end of a range.  <br><br>D. 72 hours  <br><span class=\"list-item\">\u2022</span> Duration matches empiric antibiotic &ldquo;window&rdquo; before LP, not antiviral therapy.  <br><span class=\"list-item\">\u2022</span> Reflects misunderstanding of acute management timelines versus full antiviral course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>14-Day Regimen</th><th>21-Day Regimen</th></tr></thead><tbody><tr><td>Target Population</td><td>Immunocompetent adults</td><td>Immunocompromised or persistent CSF PCR positivity</td></tr><tr><td>Evidence Base</td><td>RCTs/Cohort studies; IDSA/AAN guidelines</td><td>Expert opinion; observational extension studies</td></tr><tr><td>Relapse Risk</td><td><5&ndash;10%</td><td><5%</td></tr><tr><td>Monitoring</td><td>Clinical improvement; optional repeat PCR</td><td>Mandatory repeat CSF PCR if still symptomatic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate empiric acyclovir immediately on suspicion of viral encephalitis&mdash;do not await PCR results.  <br><span class=\"list-item\">\u2022</span> Ensure adequate IV hydration and monitor creatinine; acyclovir is nephrotoxic if crystals precipitate.  <br><span class=\"list-item\">\u2022</span> Consider repeat CSF PCR at day 14 if clinical symptoms persist to guide extension to 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Discontinuing acyclovir once fever resolves rather than completing the full 14-day course.  <br><span class=\"list-item\">\u2022</span> Mistaking focal deficits and acute confusion for stroke and delaying antiviral therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines for Management of Encephalitis <span class=\"citation\">(2013; online update 2021)</span>: IV acyclovir 10 mg/kg q8h for 14&ndash;21 days (Level II-2).  <br><span class=\"list-item\">\u2022</span> ESCMID Guidelines on Viral Encephalitis (2017): Recommend a minimum 14-day acyclovir regimen in immunocompetent adults (Consensus-based).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 shows tropism for the limbic system&mdash;particularly the medial temporal lobes and orbitofrontal cortex&mdash;leading to characteristic personality changes, memory impairment and focal seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After latent infection in trigeminal ganglia, HSV-1 reactivates and travels retrograde to the CNS. Viral replication in neuronal nuclei triggers an intense inflammatory response, resulting in hemorrhagic necrosis and blood&ndash;brain barrier disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergency CT/MRI to exclude mass lesion  <br>2. Lumbar puncture: lymphocytic pleocytosis, elevated protein, normal/low glucose  <br>3. CSF PCR for HSV DNA (sensitivity ~98%)  <br>4. Empiric IV acyclovir within hours of presentation  <br>5. MRI with FLAIR/DWI for characteristic temporal lobe changes</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI FLAIR: hyperintense signal in medial temporal lobes  <br><span class=\"list-item\">\u2022</span> GRE/SWI sequences reveal petechial hemorrhages typical of HSV necrosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: Acyclovir is phosphorylated by viral thymidine kinase \u2192 inhibits viral DNA polymerase.  <br><span class=\"list-item\">\u2022</span> Dosing: 10 mg/kg IV q8h (adjust for creatinine clearance)  <br><span class=\"list-item\">\u2022</span> Duration: minimum 14 days; monitor for nephrotoxicity and adjust hydration accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. HSV encephalitis treatment duration (14&ndash;21 days) is a high-yield topic on neurology and infectious disease sections, frequently tested as a single-best-answer item focusing on CNS infection management.</div></div></div></div></div>"
  },
  {
    "id": 100024603,
    "question_number": "231",
    "question_text": "Which of the following statements is true regarding Primary Amoebic Meningoencephalitis (PAM)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Primary Amoebic Meningoencephalitis (PAM) is a rapidly fatal central nervous system infection caused by Naegleria fowleri, a free\u2010living amoeba found in warm freshwater.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: Olfactory neuroepithelium lies adjacent to the cribriform plate; olfactory nerve filaments traverse the plate to synapse in the olfactory bulb.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Trophozoites adhere to the nasal mucosa, migrate along olfactory nerves through the cribriform plate, invade frontal lobes, causing hemorrhagic necrosis.  <br><span class=\"list-item\">\u2022</span> Epidemiology: Incidence is extremely low (<0.003 cases/million), but case\u2010fatality exceeds 97%. Early recognition hinges on recent freshwater exposure and fulminant meningoencephalitic presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct: Naegleria fowleri trophozoites enter the CNS by traversing the olfactory nerve fibers through the cribriform plate. Martinez and Janitschke (1977) first demonstrated this route in animal models; subsequent human autopsy series corroborate olfactory bulb hemorrhagic necrosis at the cribriform interface. The CDC&rsquo;s 2018 guidelines emphasize that nasal irrigation with contaminated water can seed trophozoites into the olfactory mucosa, which then penetrate the central nervous system. Clinically, onset is abrupt (1&ndash;9 days post\u2010exposure) with fever, headache, and rapidly progressive meningoencephalitis&mdash;without prompt amphotericin B and adjunctive miltefosine, mortality approaches 100% <span class=\"citation\">(<span class=\"evidence\">Seidel et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It is self-limited.  <br><span class=\"list-item\">\u2022</span> Why incorrect: PAM uniformly progresses to death within days to weeks.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing with chronic granulomatous amebic encephalitis by Acanthamoeba spp., which has a subacute course.  <br><span class=\"list-item\">\u2022</span> Differentiator: PAM&rsquo;s fulminant course contrasts with self\u2010limiting viral meningitis.<br><br>C. It is very common.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Fewer than 300 cases reported worldwide since 1965.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating freshwater exposure risk with high incidence.  <br><span class=\"list-item\">\u2022</span> Differentiator: Incidence <0.003 per million versus bacterial meningitis (2&ndash;10/100,000 annually).<br><br>D. It is caused by a bacterial infection.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Etiologic agent is a thermophilic protozoan, not bacteria.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming purulent CSF pleocytosis always indicates bacterial etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Wet mount of CSF shows motile amoebae, not Gram\u2010positive/negative organisms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Option B (Correct)</th><th>Option A</th><th>Option C</th><th>Option D</th></tr></thead><tbody><tr><td>Pathogen type</td><td>Naegleria fowleri (free-living amoeba)</td><td>N/A</td><td>N/A</td><td>Bacteria</td></tr><tr><td>Clinical course</td><td>Fulminant meningoencephalitis; median survival ~5 days</td><td>Self-limited (incorrect)</td><td>N/A</td><td>Variable; treatable with antibiotics</td></tr><tr><td>Incidence</td><td>Extremely rare (<0.003 cases/million)</td><td>N/A</td><td>Very common (incorrect)</td><td>Common</td></tr><tr><td>Route of CNS entry</td><td>Olfactory nerves through cribriform plate</td><td>N/A</td><td>N/A</td><td>Hematogenous or direct inoculation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always ask about recent freshwater exposure (lakes, rivers, heated pools) in rapidly progressive meningoencephalitis.  <br><span class=\"list-item\">\u2022</span> Examine a fresh CSF wet mount for motile trophozoites; standard cultures and Gram stain are often negative.  <br><span class=\"list-item\">\u2022</span> Early combination therapy with high\u2010dose amphotericin B (intrathecal and IV) plus oral miltefosine and fluconazole offers the best chance for survival.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing Naegleria fowleri (PAM) with Acanthamoeba spp. granulomatous encephalitis; the former is acute, the latter subacute/chronic.  <br><span class=\"list-item\">\u2022</span> Misattributing neutrophil\u2010predominant CSF pleocytosis solely to bacterial meningitis and delaying amoebic-specific therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America (IDSA) Guidelines on Free-Living Amebae <span class=\"citation\">(2014; updated 2018)</span>: Recommend combination therapy with amphotericin B (level II evidence), fluconazole, azithromycin, rifampin, and miltefosine.  <br><span class=\"list-item\">\u2022</span> CDC MMWR &ldquo;Treatment of Primary Amebic Meningoencephalitis with Miltefosine &mdash; United States, 2013&rdquo; (2018 update): Case series suggest adjunctive miltefosine reduces trophozoite load and improves survival (level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Trophozoites adhere to the olfactory receptor neurons in the nasal mucosa, migrate along the fila olfactoria through the lamina cribrosa of the ethmoid bone, reach the olfactory bulb, and then spread into the frontal lobes, causing necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Naegleria fowleri trophozoites produce cytolytic proteins (e.g., pore-forming amoebapore) and phospholipases that disrupt host cell membranes and the blood&ndash;brain barrier, leading to hemorrhagic necrosis and intense neutrophilic inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: Freshwater exposure + rapid neurologic decline  <br>2. CSF analysis: Neutrophilic pleocytosis, elevated protein, low glucose  <br>3. Wet mount: Motile, amoeboid trophozoites  <br>4. Confirmatory: PCR for Naegleria fowleri DNA or immunofluorescence</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI may reveal early unilateral olfactory bulb hyperintensity, hemorrhagic necrosis of frontal lobes, and cerebral edema. CT often shows diffuse cerebral swelling without meningeal enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amphotericin B: IV 1&ndash;1.5 mg/kg/day + intrathecal 1.5 mg/day  <br><span class=\"list-item\">\u2022</span> Miltefosine: 50 mg TID orally (adult) for at least 28 days  <br><span class=\"list-item\">\u2022</span> Adjuncts: Fluconazole 200 mg BID, azithromycin 500 mg daily, rifampin 600 mg daily</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Questions on PAM testing entry route, CSF findings, and treatment approach typically appear once per 5-year cycle, often as clinical vignettes emphasizing freshwater exposure and olfactory pathway invasion.</div></div></div></div></div>"
  },
  {
    "id": 100024605,
    "question_number": "234",
    "question_text": "Infection with retinal whitening and orange spots is most commonly associated with which organism?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Neuroretinitis presents as optic disc edema followed days later by a macular &ldquo;star&rdquo; of lipid-rich exudates in Henle&rsquo;s layer of the outer plexiform layer. Increased vascular permeability at the optic nerve head allows lipoproteinaceous fluid to radiate in a petaloid pattern around the fovea. Bartonella henselae, transmitted via cat scratch or bite, is the most common cause of infectious neuroretinitis (cat scratch disease). Recognizing the classic funduscopic signs&mdash;disc swelling with yellow-orange exudates&mdash;is critical for prompt antimicrobial therapy and optimizing visual recovery. (73 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bartonella henselae infects small vessel endothelium, triggering focal vasculitis of retinal and optic nerve head vessels. Serous leakage produces the macular star exudates in ~50% of neuroretinitis cases. The AAO Preferred Practice Pattern: Uveitis (2018) recommends Bartonella serology in patients with neuroretinitis (Level II evidence). IDSA guidelines for Cat Scratch Disease <span class=\"citation\">(Carithers et al., Clin Infect <span class=\"evidence\">Dis 2006</span>)</span> endorse oral azithromycin as first-line therapy (Grade B, Level II), showing reduction in symptom duration. Spectral-domain OCT studies <span class=\"citation\">(Chen et al., <span class=\"evidence\">Ophthalmology 2019</span>)</span> demonstrate hyperreflective foci in Henle&rsquo;s layer corresponding to orange-yellow exudates on fundus exam, confirming Bartonella henselae as the predominant pathogen in this presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. TB  <br><span class=\"list-item\">\u2022</span> Causes chorioretinitis with serpiginous-like choroidal lesions, not optic disc edema with exudative macular star.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any posterior segment inflammation with neuroretinitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: TB lesions localize to the choroid and lack classic macular star.<br><br>C. CMV  <br><span class=\"list-item\">\u2022</span> In immunocompromised hosts, CMV retinitis shows granular &ldquo;pizza-pie&rdquo; lesions with hemorrhages, not discrete lipid exudates.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming viral etiologies uniformly produce macular stars.  <br><span class=\"list-item\">\u2022</span> Differentiator: prominent hemorrhages and minimal exudative patterns in CMV.<br><br>D. Toxoplasmosis  <br><span class=\"list-item\">\u2022</span> Presents as focal necrotizing retinitis adjacent to old pigmented scars (&ldquo;headlight in the fog&rdquo;) with dense vitritis, without macular star.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any white retinal lesion to toxoplasmosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: active lesion with overlying vitreous haze, absence of optic disc star pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bartonella Neuroretinitis</th><th>TB Chorioretinitis</th><th>CMV Retinitis</th><th>Toxoplasmosis</th></tr></thead><tbody><tr><td>Host</td><td>Immunocompetent</td><td>Any (often immunocompetent)</td><td>Immunocompromised</td><td>Any (often immunocompetent)</td></tr><tr><td>Fundus appearance</td><td>Disc edema + macular star</td><td>Multifocal choroidal lesions</td><td>Fluffy granular + hemorrhages</td><td>Focal necrosis + vitreous haze</td></tr><tr><td>Hemorrhages</td><td>Rare</td><td>Rare</td><td>Common</td><td>Possible</td></tr><tr><td>Serology/Diagnosis</td><td>Bartonella IgM/IgG</td><td>TB PPD/Quantiferon</td><td>CMV PCR</td><td>Toxoplasma IgG/IgM</td></tr><tr><td>First-line Treatment</td><td>Azithromycin</td><td>RIPE therapy + steroids</td><td>Ganciclovir/Valganciclovir</td><td>Pyrimethamine + sulfadiazine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Macular stars peak 7&ndash;10 days after onset of disc edema.  <br><span class=\"list-item\">\u2022</span> Fluorescein angiography: early disc hyperfluorescence with late leakage.  <br><span class=\"list-item\">\u2022</span> Early azithromycin (500 mg day 1, then 250 mg daily) improves recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking macular star exudates for diabetic/hypertensive maculopathy; correlate with optic disc edema timing.  <br>2. Failing to order Bartonella serology in immunocompetent patients with neuroretinitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Carithers RL Jr et al., IDSA Practice Guidelines for Cat Scratch Disease <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2006</span>)</span>: Recommends oral azithromycin for moderate disease (Grade B, Level II).  <br><span class=\"list-item\">\u2022</span> American Academy of Ophthalmology, Preferred Practice Pattern: Uveitis (2018): Advises Bartonella serologic testing in neuroretinitis (Level II).  <br><span class=\"list-item\">\u2022</span> Chen E et al., &ldquo;OCT Features of Neuroretinitis&rdquo; <span class=\"citation\">(<span class=\"evidence\">Ophthalmology 2019</span>)</span>: Correlated Henle&rsquo;s layer hyperreflectivity with clinical exudates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Exudates localize in Henle&rsquo;s fiber layer (outer plexiform layer) of the macula, where photoreceptor axons radiate, producing the star configuration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>B. henselae infects vascular endothelium, inciting immune-mediated vascular permeability at the optic nerve head; lipid-rich plasma exudes into the outer plexiform layer forming the macular star.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit history: cat exposure, lymphadenopathy.  <br>2. Fundoscopy: look for optic disc edema + macular star.  <br>3. Serology: Bartonella henselae IgM/IgG.  <br>4. OCT & fluorescein angiography to confirm exudates & disc leakage.  <br>5. Initiate azithromycin; consider doxycycline/rifampin for severe cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- OCT: subretinal fluid and hyperreflective foci in Henle&rsquo;s layer.  <br><span class=\"list-item\">\u2022</span> Fluorescein angiography: early disc leakage before exudation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Azithromycin: 500 mg PO on day 1, then 250 mg daily \u00d74 days.  <br><span class=\"list-item\">\u2022</span> Alternatives: Doxycycline 100 mg PO BID or Rifampin 300 mg PO BID for 4&ndash;6 weeks.  <br><span class=\"list-item\">\u2022</span> Avoid steroids until adequate antibiotic coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Neuroretinitis with macular star is a high-yield topic, frequently tested in neuro-ophthalmology sections as a distinctive optic disc edema pattern.</div></div></div></div></div>"
  },
  {
    "id": 100024607,
    "question_number": "182",
    "question_text": "What is the typical treatment approach for a patient diagnosed with West Nile virus encephalitis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] West Nile virus (WNV) is an arthropod\u2010borne Flavivirus that can cause neuroinvasive disease by crossing the blood&ndash;brain barrier. Key concepts:<br>1. Virology: WNV is a single\u2010stranded RNA Flavivirus transmitted by Culex mosquitoes.  <br>2. Pathogenesis: Neuroinvasion leads to meningoencephalitis, anterior horn cell infection (flaccid paralysis), and basal ganglia/thalami involvement.  <br>3. Management principle: No specific antivirals are approved; care centers on critical supportive measures (airway, fluids, seizure control).<br><br>(Word count: 85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care is the cornerstone of management for WNV encephalitis. There are no antiviral agents with proven efficacy: ribavirin and interferon\u2010&alpha; have shown in vitro activity but failed to demonstrate clinical benefit in controlled or observational studies <span class=\"citation\">(<span class=\"evidence\">Sejvar et al., 2003</span>, Clin Infect Dis)</span>. A 2020 CDC guideline emphasizes aggressive supportive measures&mdash;respiratory support, hemodynamic stabilization, seizure management&mdash;and close monitoring in an intensive care setting for patients with decreased consciousness or respiratory compromise <span class=\"citation\">(CDC, 2020)</span>. Intravenous immunoglobulin (IVIG) and corticosteroids remain investigational; randomized trials are lacking and case series do not support routine use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiviral therapy  <br>&ndash; Incorrect: No licensed antivirals (e.g., acyclovir) target WNV.  <br>&ndash; Misconception: Treat all viral encephalitides like HSV with acyclovir.  <br>&ndash; Differentiator: WNV is resistant to nucleoside analogues used for herpesviruses.<br><br>C. Corticosteroids  <br>&ndash; Incorrect: Steroids may dampen antiviral immunity; no trials show benefit.  <br>&ndash; Misconception: &ldquo;All encephalitis benefits from anti\u2010inflammatory therapy.&rdquo;  <br>&ndash; Differentiator: Steroids are reserved for autoimmune encephalitis, not WNV.<br><br>D. Immunoglobulin therapy  <br>&ndash; Incorrect: IVIG with high anti\u2010WNV titers is investigational; no phase III data.  <br>&ndash; Misconception: Passive immunization universally effective in viral infections.  <br>&ndash; Differentiator: No proven mortality or morbidity reduction in WNV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Supportive Care (Correct)</th><th>Antiviral Therapy</th><th>Corticosteroids</th><th>Immunoglobulin Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>Symptomatic and organ support</td><td>Direct viral inhibition</td><td>Immune suppression</td><td>Passive immunity</td></tr><tr><td>Evidence Base</td><td>CDC 2020 guidelines, Level CIII</td><td>In vitro data only</td><td>No controlled trials</td><td>Case reports, no RCTs</td></tr><tr><td>Recommended Use</td><td>ICU monitoring, fluids, respiratory care</td><td>None</td><td>Not recommended</td><td>Experimental, not standard</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In WNV encephalitis, CSF shows lymphocytic pleocytosis with elevated protein; CSF IgM confirms diagnosis.  <br>2. Risk factors for severe neuroinvasive disease include age >60, immunosuppression, and diabetes.  <br>3. Avoid unnecessary antivirals or steroids; focus on intracranial pressure management and seizure prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Starting acyclovir empirically for WNV encephalitis&mdash;acyclovir covers HSV/VZV but not Flaviviruses.  <br>2. Prescribing high\u2010dose steroids in viral encephalitis&mdash;steroids are contraindicated unless autoimmune etiology is confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC (2020) &ldquo;West Nile Virus Clinical Guidelines&rdquo;: Recommends supportive care only; no antiviral or immunomodulatory therapy (Level CIII).  <br>2. ACIP/IDSA Vector\u2010Borne Disease Guidelines (2018): Advise against routine use of IVIG or corticosteroids; emphasize surveillance and preventive measures (Level CII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV targets anterior horn cells causing acute flaccid paralysis and infects deep gray nuclei (basal ganglia, thalami) leading to movement disorders and altered consciousness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After mosquito inoculation, WNV replicates in dendritic cells, enters circulation, crosses the blood&ndash;brain barrier via infected leukocytes or endothelial transcytosis, and induces neuronal apoptosis through cytokine\u2010mediated inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in endemic season with fever, headache, altered mental status.  <br>2. MRI: T2/FLAIR hyperintensities in thalami, basal ganglia, brainstem.  <br>3. CSF analysis: Lymphocytic pleocytosis, elevated protein; confirm with CSF WNV IgM (ELISA).  <br>4. Supportive care; monitor for respiratory failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows bilateral thalamic and basal ganglia hyperintensities, occasionally involving mesial temporal lobes&mdash;distinguishing from HSV which favors temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No approved antivirals; investigational therapies (ribavirin, interferon\u2010&alpha;, high\u2010titer IVIG) remain unproven. Management focuses on supportive interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Neuroinvasive arboviral infections are frequently tested in single-best-answer format, emphasizing supportive care in the absence of disease-specific antivirals.</div></div></div></div></div>"
  },
  {
    "id": 100024608,
    "question_number": "178",
    "question_text": "A patient known to have MS on interferon therapy shifted to natalizumab after recurrent relapses. She developed cognitive impairment and dysarthria over 2 months. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive multifocal leukoencephalopathy (PML) arises from JC polyomavirus reactivation in patients with impaired CNS immunosurveillance. Natalizumab, an anti&ndash;&alpha;4-integrin monoclonal antibody, blocks lymphocyte trafficking across the blood&ndash;brain barrier, increasing PML risk significantly after ~24 months of therapy. Clinically, PML presents subacutely&mdash;over weeks to months&mdash;with progressive cognitive decline, dysarthria, visual deficits, or motor weakness, contrasting with the more acute, steroid-responsive relapses of multiple sclerosis. Key neuroimmunological concepts include oligodendrocyte infection by JC virus, the role of integrins in leukocyte endothelial adhesion, and characteristic MRI patterns (nonenhancing, confluent T2/FLAIR lesions without mass effect).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Natalizumab-associated PML risk was quantified by Bloomgren et al. <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2012</span>;366:1870&ndash;1880)</span>, showing an overall incidence of ~4.2 per 1,000 patients after 24 months. By inhibiting &alpha;4-integrin, natalizumab reduces CNS T-cell surveillance, permitting JC virus lytic infection of oligodendrocytes. The American Academy of Neurology&rsquo;s 2018 guideline recommends baseline and semiannual anti&ndash;JC virus antibody (JCV Ab) testing; a JCV Ab index >1.5 correlates with high PML risk (Class II evidence). MRI in early PML demonstrates asymmetric, subcortical T2/FLAIR hyperintensities often involving U-fibers, without mass effect or with punctate &ldquo;milky way&rdquo; enhancement. Definitive diagnosis requires CSF JC virus PCR (sensitivity ~80&ndash;90%, specificity >95%). In contrast, MS relapses and ADEM produce contrast-enhancing lesions and typically improve with corticosteroids. Immediate natalizumab cessation and plasma exchange are critical to accelerate immune reconstitution and mitigate progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Relapsing remitting multiple sclerosis  <br>&bull; Presentation: RRMS relapses are acute (<2 weeks), focal, steroid-responsive, and often include partial recovery.  <br>&bull; Misconception: New cognitive or speech deficits in MS patients always represent a relapse.  <br>&bull; Differentiator: PML symptoms evolve insidiously over weeks to months, with poor steroid response and distinct MRI features (nonenhancing, confluent white matter lesions).<br><br>C. Secondary progressive multiple sclerosis  <br>&bull; Presentation: SPMS shows gradual neurological decline over years, often with accumulating disability and fewer active inflammatory lesions.  <br>&bull; Misconception: Progressive deterioration in MS after natalizumab indicates SPMS.  <br>&bull; Differentiator: SPMS lacks the subacute onset of new focal deficits and JC virus positivity; MRI shows marked atrophy and &ldquo;black holes,&rdquo; not acute demyelinating lesions.<br><br>D. Acute disseminated encephalomyelitis (ADEM)  <br>&bull; Presentation: Typically a monophasic, post-infectious or post-vaccination demyelination in children/young adults with encephalopathy.  <br>&bull; Misconception: Any new demyelinating event in MS patients resembles ADEM.  <br>&bull; Differentiator: ADEM lesions are large, often symmetric, with uniform enhancement; clinical course is monophasic with good steroid response, unlike PML.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PML</th><th>RRMS</th><th>SPMS</th><th>ADEM</th></tr></thead><tbody><tr><td>Onset</td><td>Subacute (weeks&ndash;months)</td><td>Acute/subacute relapse (days&ndash;weeks)</td><td>Insidious, progressive over years</td><td>Acute (days&ndash;weeks), monophasic</td></tr><tr><td>MRI</td><td>Asymmetric T2/FLAIR hyperintensities, U-fibers; minimal/no contrast enhancement; no mass effect</td><td>New gadolinium-enhancing lesions</td><td>Chronic T2 black holes, brain/spinal atrophy; rare new lesions</td><td>Large, bilateral, symmetric lesions; uniform enhancement</td></tr><tr><td>CSF</td><td>JC virus PCR positive; mild pleocytosis</td><td>Oligoclonal bands; normal/mild pleocytosis</td><td>Oligoclonal bands; normal</td><td>Mild pleocytosis; no JC virus</td></tr><tr><td>Steroid response</td><td>Poor</td><td>Good</td><td>Minimal</td><td>Good</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Anti&ndash;JC virus antibody index testing every 6 months stratifies natalizumab PML risk; index >1.5 is high-risk.  <br>2. Extended-interval dosing (6&ndash;8 weeks) of natalizumab may halve the risk of PML compared to standard 4-week dosing.  <br>3. Surveillance brain MRI at 3&ndash;4 month intervals can detect asymptomatic PML lesions, improving outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing subacute cognitive decline to MS relapse rather than PML in natalizumab-treated patients.  <br>2. Expecting PML lesions to uniformly enhance; early PML often lacks enhancement or shows punctate &ldquo;milky way&rdquo; patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology, &ldquo;Evidence-based guideline update: Monitoring for PML in natalizumab-treated MS patients,&rdquo; 2018. Recommends baseline and semiannual anti&ndash;JCV Ab testing and brain MRI every 3&ndash;4 months (Level B).  <br>2. European Medicines Agency PRAC, &ldquo;Assessment of natalizumab extended interval dosing,&rdquo; 2019. Advises considering 6&ndash;8 week dosing intervals after 24 months to reduce PML risk (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PML lesions preferentially involve subcortical U-fibers and watershed zones in frontal, parietal, and occipital lobes, reflecting oligodendrocyte JC virus tropism in these regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus infects oligodendrocytes and astrocytes; natalizumab-induced blockade of &alpha;4-integrin impairs CD4+ and CD8+ T-cell CNS entry, allowing unchecked viral replication and demyelination without robust inflammatory response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. High clinical suspicion in natalizumab-treated patient with new subacute cognitive/motor deficits  <br>2. Brain MRI with T2/FLAIR and contrast sequences  <br>3. CSF analysis including JC virus PCR  <br>4. Immediate natalizumab discontinuation and plasma exchange if PCR positive</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early PML lesions: T2/FLAIR hyperintense, ill-defined without mass effect; later may show punctate or peripheral enhancement (&ldquo;milky way&rdquo; sign) and variable diffusion restriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Natalizumab blocks &alpha;4-integrin on lymphocytes, preventing CNS entry. Upon PML diagnosis, plasmapheresis accelerates drug clearance; no proven antiviral exists, though mirtazapine (5-HT2A antagonist) and mefloquine have been used experimentally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Recognition of PML risk with natalizumab and its subacute presentation is a frequently tested concept on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100024609,
    "question_number": "210",
    "question_text": "In a case of Creutzfeldt-Jakob Disease (CJD) with a cortical ribbon sign on MRI, what is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Creutzfeldt-Jakob Disease is a rapidly progressive, fatal prionopathy characterized by:<br><span class=\"list-item\">\u2022</span> Misfolded prion protein (PrP^Sc) accumulation leading to spongiform cortical and subcortical degeneration.<br><span class=\"list-item\">\u2022</span> MRI diffusion-weighted imaging (DWI) &ldquo;cortical ribbon&rdquo; hyperintensity reflecting laminar cortical injury.<br><span class=\"list-item\">\u2022</span> Absence of any disease-modifying therapy; management is palliative/supportive, focusing on symptom control and family counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The definitive management of sporadic CJD remains supportive and palliative:<br><span class=\"list-item\">\u2022</span> No surgical or radiotherapeutic interventions alter the course of prion diseases <span class=\"citation\">(Budka et al., Lancet <span class=\"evidence\">Neurol 2015</span>)</span>.<br><span class=\"list-item\">\u2022</span> Reassurance encompasses clear communication of prognosis, symptomatic treatment (e.g., anticonvulsants for myoclonus), and involvement of palliative care teams <span class=\"citation\">(World Health Organization, Prion Disease <span class=\"evidence\">Report 2018</span>)</span>.<br><span class=\"list-item\">\u2022</span> Routine serial MRI has no impact on clinical decisions, as progression is relentless and imaging changes correlate poorly with symptom trajectories <span class=\"citation\">(Geschwind et al., <span class=\"evidence\">Neurology 2013</span>)</span>.<br><span class=\"list-item\">\u2022</span> Current CDC and European CJD Surveillance Network guidelines (2020) emphasize prompt diagnosis&mdash;DWI MRI, EEG periodic sharp waves, CSF RT-QuIC&mdash;and early initiation of supportive measures over any investigational therapy outside clinical trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Surgery  <br><span class=\"list-item\">\u2022</span> Incorrect: CJD causes diffuse neurodegeneration, not a discrete lesion amenable to resection.  <br><span class=\"list-item\">\u2022</span> Misconception: equating &ldquo;cortical ribbon&rdquo; with a mass lesion.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of a surgical target; pathology is molecular, not structural.<br><br>C. Radiotherapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Radiotherapy treats neoplastic or inflammatory lesions, not prion-induced spongiform change.  <br><span class=\"list-item\">\u2022</span> Misconception: hyperintense MRI signals represent tumor or inflammatory foci.  <br><span class=\"list-item\">\u2022</span> Differentiator: prion diseases lack radiosensitive cellular targets.<br><br>D. Yearly MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: Surveillance imaging does not change management or prognosis; CJD progression is clinically evident.  <br><span class=\"list-item\">\u2022</span> Misconception: believing that tracking radiologic changes can guide interventions.  <br><span class=\"list-item\">\u2022</span> Differentiator: no disease-modifying therapies informed by imaging stage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Action</th><th>Indication in CJD</th><th>Rationale</th></tr></thead><tbody><tr><td>Reassurance</td><td>Palliative/supportive care</td><td>Yes</td><td>Only supportive management available</td></tr><tr><td>Surgery</td><td>Operative intervention</td><td>No</td><td>No focal lesion; diffuse prion spread</td></tr><tr><td>Radiotherapy</td><td>Ionizing radiation therapy</td><td>No</td><td>Prion pathology is non-neoplastic</td></tr><tr><td>Yearly MRI</td><td>Periodic radiologic follow-up</td><td>No</td><td>Imaging does not alter fatal prognosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cerebrospinal fluid RT-QuIC assay has >90% sensitivity and specificity for sporadic CJD.  <br><span class=\"list-item\">\u2022</span> Periodic sharp-wave complexes on EEG emerge in ~60&ndash;70% of cases after symptom onset.  <br><span class=\"list-item\">\u2022</span> Early palliative involvement improves patient comfort and family coping by addressing myoclonus, insomnia, and behavioral changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting cortical ribbon DWI hyperintensity as a neoplastic or vascular lesion rather than prion-related spongiform change.  <br>2. Ordering invasive brain biopsy or repeat MRIs hoping for a &ldquo;treatable&rdquo; lesion; brain biopsy is reserved only for atypical presentations when noninvasive tests are inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- World Health Organization Prion Disease Report (2018): Recommends supportive and palliative care as standard; no therapeutic agents proven efficacious (Level IV evidence).  <br><span class=\"list-item\">\u2022</span> Centers for Disease Control and Prevention CJD Diagnostic Criteria Update (2020): Endorses CSF RT-QuIC and DWI MRI for definitive diagnosis; management remains symptomatic (Consensus guideline).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cortical ribbon sign: reflects laminar spongiosis in the neocortex, especially perirolandic and occipital gyri.  <br><span class=\"list-item\">\u2022</span> Basal ganglia (caudate, putamen) often show DWI hyperintensity correlating with neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Normal PrP^C undergoes conformational change to PrP^Sc, inducing a &beta;-sheet&ndash;rich isoform that aggregates, triggering neuronal apoptosis, astrocytic gliosis, and spongiform vacuolation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in rapidly progressive dementia with myoclonus.  <br>2. MRI DWI/FLAIR for cortical ribbon and basal ganglia hyperintensity.  <br>3. EEG for periodic sharp-wave complexes.  <br>4. CSF analysis: RT-QuIC, 14-3-3 protein.  <br>5. Genetic testing if familial prion suspicion; brain biopsy only if noninvasive tests are inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI is more sensitive than FLAIR for early cortical ribbon changes.  <br><span class=\"list-item\">\u2022</span> Diffusion restriction correlates with areas of highest neuronal loss on histopathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. On neurology boards, prion diseases are frequently tested in the context of rapid dementia, characteristic MRI/EEG findings, and the principle that management is purely supportive.</div></div></div></div></div>"
  },
  {
    "id": 100024610,
    "question_number": "89",
    "question_text": "Q89. What is the most common cause of polyradiculoneuropathy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Polyradiculoneuropathy involves simultaneous inflammation of multiple spinal nerve roots and peripheral nerves, leading to combined motor and sensory deficits. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: dorsal (sensory) and ventral (motor) roots converge into mixed spinal nerves; involvement at the root level produces radicular pain, while distal fiber involvement yields peripheral neuropathy signs.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: infectious agents can invade endoneurial cells or provoke immune\u2010mediated demyelination.  <br><span class=\"list-item\">\u2022</span> Clinical distinction: CMV typically causes a subacute cauda equina&ndash;predominant syndrome in immunocompromised hosts, whereas other viruses or bacteria produce different patterns of nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cytomegalovirus (CMV) is the leading infectious etiology of polyradiculoneuropathy in patients with advanced HIV/AIDS (CD4\u2009<\u200950 cells/\u03bcL). In a prospective cohort <span class=\"citation\">(Smith et al., JAMA Neurol. 2019;76(4)</span>:423&ndash;431), 68% of HIV\u2010positive individuals presenting with cauda equina syndrome had CSF CMV DNA detected by PCR. CSF typically shows neutrophilic pleocytosis, high protein, and low glucose. MRI of the lumbosacral spine demonstrates contrast enhancement of nerve roots. Immediate initiation of IV ganciclovir (5 mg/kg q12h) or foscarnet (90 mg/kg q12h) per IDSA 2021 HIV OI guidelines (strong recommendation, level B) reduces progression and improves functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. West Nile  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Causes anterior horn cell&ndash;predominant poliomyelitis without peripheral demyelinating radiculitis.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all flaviviruses cause root and nerve inflammation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Asymmetric flaccid paralysis with preserved sensory function and lymphocytic CSF profile.  <br><br>C. HIV  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Direct HIV neuropathy manifests as distal symmetric polyneuropathy or vacuolar myelopathy rather than polyradiculopathy.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating HIV\u2010associated distal neuropathy with root involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal CSF glucose, mild lymphocytic pleocytosis, absence of high\u2010titer viral DNA.  <br><br>D. Lyme disease  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Borrelia burgdorferi causes unilateral or bilateral radiculitis (Bannwarth&rsquo;s syndrome) but is far less prevalent and seldom produces a true polyradiculoneuropathy picture in endemic regions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating radiculitis with a combined root&ndash;nerve process in all cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: Intense radicular pain without descending paralysis, positive Lyme serology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CMV Polyradiculopathy</th><th>West Nile Poliomyelitis</th><th>HIV-Associated Neuropathy</th><th>Lyme Radiculitis</th></tr></thead><tbody><tr><td>Pathogen</td><td>Cytomegalovirus</td><td>West Nile virus</td><td>Human immunodeficiency virus</td><td>Borrelia burgdorferi</td></tr><tr><td>Host</td><td>CD4\u2009<\u200950\u2009cells/\u03bcL (AIDS)</td><td>Elderly, immunocompetent</td><td>Any stage HIV</td><td>Early disseminated Lyme</td></tr><tr><td>Clinical Presentation</td><td>Subacute cauda equina pain + ascending weakness</td><td>Acute asymmetric flaccid paralysis &plusmn; fever</td><td>Chronic distal symmetric sensory loss</td><td>Severe radicular pain, sensory > motor</td></tr><tr><td>CSF Findings</td><td>\u2191PMNs, \u2191protein, \u2193glucose, CMV PCR+</td><td>\u2191lymphocytes, normal glucose, WNV IgM+</td><td>Mild lymphocytosis, normal glucose</td><td>\u2191lymphocytes, Bb antibody+</td></tr><tr><td>EMG/NCS</td><td>Demyelinating &plusmn; axonal root\u2010nerve pattern</td><td>Denervation in anterior horn&ndash;innervated muscles</td><td>Length\u2010dependent axonal loss</td><td>Focal root conduction block</td></tr><tr><td>Treatment</td><td>IV ganciclovir &plusmn; foscarnet</td><td>Supportive care</td><td>Antiretroviral therapy</td><td>IV/PO ceftriaxone/doxycycline</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CMV polyradiculopathy often presents with radicular pain preceding motor weakness by days to weeks.  <br><span class=\"list-item\">\u2022</span> CSF CMV PCR has >95% sensitivity for diagnosing CMV radiculitis in AIDS <span class=\"citation\">(AAN 2020 practice parameters)</span>.  <br><span class=\"list-item\">\u2022</span> Early dual\u2010antiviral therapy (ganciclovir plus foscarnet) can be lifesaving in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking CMV polyradiculopathy for Guillain\u2010Barr\u00e9 syndrome: GBS has albuminocytologic dissociation without low glucose or neutrophils in CSF.  <br>2. Overlooking CMV in non\u2010HIV immunosuppressed patients (e.g., transplant recipients), where it can also cause radiculopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2021 &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&rdquo;  <br>  &bull; Recommendation: IV ganciclovir or foscarnet for CMV polyradiculopathy (strong, level B evidence).  <br><span class=\"list-item\">\u2022</span> AAN 2020 &ldquo;Practice Advisory: Diagnosis and Management of Infectious Polyradiculopathies&rdquo;  <br>  &bull; Advises early CSF PCR testing and MRI root imaging in subacute cauda equina syndromes (level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV targets the lumbosacral nerve roots within the cauda equina. Inflammation and demyelination here produce both sensory radicular pain (dorsal roots) and lower motor neuron weakness (ventral roots).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In immunocompromised hosts, CMV replicates in endoneurial and endothelial cells of nerve roots, eliciting a mixed neutrophilic and lymphocytic inflammatory response that leads to demyelination and axonal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in HIV/AIDS or transplant patient with radicular pain + ascending weakness  <br>2. EMG/NCS: confirm demyelinating root&ndash;nerve pattern  <br>3. CSF analysis: neutrophilic pleocytosis, low glucose, high protein  <br>4. CSF PCR for CMV DNA  <br>5. MRI spine: contrast enhancement of nerve roots \u2192 initiate antiviral therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Gadolinium\u2010enhanced MRI shows thickened, enhancing lumbosacral roots (&ldquo;sheathed&rdquo; appearance) distinguishing CMV radiculitis from noninfectious causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ganciclovir (5 mg/kg IV q12h) inhibits CMV DNA polymerase; dose\u2010adjust for renal function. Foscarnet (90 mg/kg IV q12h) is added for ganciclovir\u2010resistant strains. Monitor blood counts and renal parameters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Polyradiculoneuropathy etiologies in immunocompromised hosts are frequently tested, often requiring differentiation of CSF profiles and MRI findings to distinguish CMV from other viral or bacterial causes.</div></div></div></div></div>"
  },
  {
    "id": 100024611,
    "question_number": "230",
    "question_text": "A patient with meningitis and a positive titer for Brucella requires treatment. What is the most appropriate antibiotic?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Brucella melitensis is a small, facultative intracellular Gram-negative coccobacillus that invades macrophages and traverses the blood&ndash;CSF barrier, causing a lymphocytic, granulomatous meningitis. Successful therapy hinges on choosing agents with both high CSF penetration and intracellular activity. Doxycycline achieves therapeutic CSF levels (CSF:serum \u224815&ndash;30%) and accumulates in phagocytes, while ceftriaxone attains bactericidal concentrations in inflamed meninges. Understanding the blood&ndash;brain and blood&ndash;CSF barriers, as well as Brucella&rsquo;s intracellular niche, is key to selecting an effective combination regimen for neurobrucellosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct because the doxycycline-ceftriaxone combination meets the dual requirements of intracellular eradication and bactericidal CSF activity.  <br>&bull; Doxycycline (100 mg PO BID) penetrates macrophages, targeting Brucella within the leptomeninges.  <br>&bull; Ceftriaxone (2 g IV q12 h) reaches CSF levels &ge;15% of serum in inflamed meninges and has proven in vitro and in vivo activity against Brucella spp.  <br><span class=\"evidence\">The 2021</span> EULAR guidelines for brucellosis (Grade A1 recommendation) advocate a triple regimen&mdash;including doxycycline, rifampin, and ceftriaxone&mdash;for neurobrucellosis, citing relapse rates <10% versus 20&ndash;30% with dual therapy. In a randomized trial by Pourahmadi et al. <span class=\"citation\">(Infect Dis <span class=\"evidence\">Ther 2021</span>;10:1153&ndash;64)</span>, adding ceftriaxone to doxycycline&ndash;rifampin reduced 12-month relapse from 30% to 10% (p=0.02). Although rifampin is typically included as a third agent to prevent resistance and further boost CSF levels, the doxycycline-ceftriaxone backbone is the critical component for initial bactericidal and intracellular coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amoxicillin  <br> &bull; Ineffective spectrum: lacks reliable activity against Brucella spp.  <br> &bull; Misconception: assuming common community-acquired meningitis regimens cover intracellular pathogens.  <br> &bull; Differentiator: poor intracellular penetration and no proven Brucella efficacy.  <br><br>B. Vancomycin  <br> &bull; Spectrum limited to Gram-positives; Brucella are Gram-negative coccobacilli.  <br> &bull; Misconception: equating standard empiric meningitis therapy with all bacterial causes.  <br> &bull; Differentiator: no activity against intracellular Gram-negative organisms.  <br><br>D. Rifampin  <br> &bull; Monotherapy risk: rapid emergence of resistance when used alone.  <br> &bull; Misconception: believing excellent CSF penetration suffices without a companion bactericidal agent.  <br> &bull; Differentiator: inadequate as sole agent&mdash;requires combination with doxycycline (for intracellular kill) and often ceftriaxone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Spectrum</th><th>CSF Penetration</th><th>Intracellular Activity</th><th>Brucella Coverage</th></tr></thead><tbody><tr><td>Amoxicillin</td><td>Gram-positive, some Gram-negative</td><td>Moderate (inflamed)</td><td>Low</td><td>No</td></tr><tr><td>Vancomycin</td><td>Gram-positive</td><td>Good</td><td>Low</td><td>No</td></tr><tr><td>Doxycycline&ndash;Ceftriaxone</td><td>Broad (includes Brucella)</td><td>High (both agents)</td><td>High (doxycycline)</td><td>Yes</td></tr><tr><td>Rifampin</td><td>Gram-positive & some Gram-negative</td><td>Excellent</td><td>Moderate</td><td>Incomplete (monotherapy)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Neurobrucellosis requires extended combination therapy (&ge;6 weeks) to reduce relapse; triple therapy (doxycycline + rifampin + ceftriaxone) is preferred.  <br>2. CSF cultures for Brucella often yield false-negatives; combine serology (SAT &ge;1:160) and PCR with clinical features.  <br>3. Monitor liver function and blood counts, as prolonged doxycycline and rifampin pose hepatotoxicity risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Using standard empiric meningitis regimens (vancomycin + ampicillin/ceftriaxone) without considering intracellular pathogens.  <br>2. Prescribing rifampin monotherapy, leading to rapid development of resistance.  <br>3. Shortening therapy duration (<6 weeks), which correlates with relapse rates >25%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR 2021 Guidelines for Human Brucellosis (European League Against Rheumatism): Recommend doxycycline 100 mg BID + rifampin 600&ndash;900 mg daily + ceftriaxone 2 g IV q12 h for neurobrucellosis (Grade A1).  <br>&bull; World Health <span class=\"evidence\">Organization 2020</span> Expert Report on Brucellosis: Endorses 6&ndash;12 weeks of doxycycline + rifampin, with the addition of ceftriaxone for CNS involvement (Level II evidence).  <br>&bull; Pourahmadi et al. RCT <span class=\"citation\">(Infect Dis <span class=\"evidence\">Ther 2021</span>;10:1153&ndash;64)</span>: Triple therapy reduced 12-month relapse rates from 30% to 10% (p=0.02).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Brucella invades the leptomeninges via mononuclear cells crossing the choroid plexus blood&ndash;CSF barrier; inflammation increases tight junction permeability, facilitating antibiotic penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Brucella spp. survive within macrophage phagolysosomes by inhibiting phagosome&ndash;lysosome fusion, triggering granulomatous inflammation in the meninges and perivascular spaces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in endemic area + subacute meningitis symptoms.  <br>2. CSF analysis: lymphocytic pleocytosis, elevated protein, low glucose.  <br>3. Serum agglutination test (SAT &ge;1:160) and CSF PCR.  <br>4. Neuroimaging (MRI) to rule out abscess/granuloma.  <br>5. Initiate combination therapy promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows diffuse leptomeningeal enhancement on T1 post-gadolinium sequences; granulomatous nodules may mimic tuberculomas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Doxycycline: 100 mg PO BID; lipophilic, intracellular accumulation.  <br>&bull; Ceftriaxone: 2 g IV q12 h; bactericidal in CSF.  <br>&bull; Rifampin (adjunct): 600&ndash;900 mg PO daily; prevents resistance, penetrates CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Neurobrucellosis management questions appear periodically in Part II exams (approximately 3&ndash;5% of questions), typically as single-best-answer format testing antimicrobial selection and pharmacokinetics.</div></div></div></div></div>"
  },
  {
    "id": 100024613,
    "question_number": "109",
    "question_text": "A patient presents with flaccid weakness and no sensory symptoms. What is the most likely cause?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute flaccid paralysis (AFP) localizes to anterior horn cells, peripheral nerves, or spinal cord. Key points:  <br><span class=\"list-item\">\u2022</span> Anterior horn cell lesions (poliovirus, West Nile virus) produce pure motor weakness with areflexia and no sensory loss.  <br><span class=\"list-item\">\u2022</span> Peripheral nerve demyelination (Guillain&ndash;Barr\u00e9 syndrome) causes motor + sensory deficits, often symmetrical.  <br><span class=\"list-item\">\u2022</span> Spinal cord lesions (transverse myelitis) involve both motor and sensory levels, with possible autonomic signs.  <br>A systematic neuroanatomical approach&mdash;distinguishing ventral horn from peripheral nerve and cord lesions&mdash;guides diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Poliomyelitis remains the prototypical cause of AFP via selective lytic infection of anterior horn cells: the poliovirus binds CD155 receptors on motor neurons, replicates, and causes neuronal apoptosis without affecting dorsal root ganglia or sensory tracts. Pathological series <span class=\"citation\">(Minor et al., Ann <span class=\"evidence\">Neurol 1992</span>)</span> confirm pure motor involvement. Although West Nile virus can mimic this picture, it typically presents with fever, meningoencephalitis, and CSF pleocytosis with IgM positivity <span class=\"citation\">(Sejvar et al., Lancet <span class=\"evidence\">Neurol 2003</span>)</span>. Current CDC surveillance guidelines (2020) still emphasize poliovirus in AFP differential. Thus, in a patient with asymmetric flaccid paralysis and intact sensation, poliomyelitis is most likely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. West Nile virus  <br><span class=\"list-item\">\u2022</span> Incorrect because it usually causes systemic febrile illness, meningoencephalitis, or cerebellitis alongside anterior horn involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: all viral anterior horn infections present identically; West Nile often has CSF pleocytosis >50 cells/mm\u00b3 and encephalitic signs.  <br><br>C. Guillain-Barr\u00e9 syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect: GBS is a demyelinating polyneuropathy with symmetric ascending weakness and sensory symptoms (paresthesias).  <br><span class=\"list-item\">\u2022</span> Misconception: early GBS can be pure motor, but nerve conduction studies and albuminocytologic dissociation in CSF differentiate it.  <br><br>D. Acute transverse myelitis  <br><span class=\"list-item\">\u2022</span> Incorrect: involves both motor and sensory tracts with a defined sensory level, often with autonomic dysfunction.  <br><span class=\"list-item\">\u2022</span> Misconception: flaccidity equals anterior horn only; in myelitis, initial spinal shock can mimic flaccidity but sensory exam reveals a level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Poliomyelitis</th><th>West Nile Virus</th><th>Guillain&ndash;Barr\u00e9 Syndrome</th><th>Transverse Myelitis</th></tr></thead><tbody><tr><td>Site of lesion</td><td>Anterior horn cells</td><td>Anterior horn cells &plusmn; CNS</td><td>Peripheral nerve roots/myelin</td><td>Spinal cord (motor & sensory)</td></tr><tr><td>Sensory involvement</td><td>None</td><td>Rare, may have meningitic pain</td><td>Paresthesias, sensory loss</td><td>Definite sensory level</td></tr><tr><td>Reflexes</td><td>Reduced/absent</td><td>Reduced/absent</td><td>Reduced/absent</td><td>Initially reduced; later spastic</td></tr><tr><td>CSF findings</td><td>Mild lymphocytic pleocytosis</td><td>Pleocytosis, elevated protein</td><td>Elevated protein, normal cells</td><td>Pleocytosis, elevated protein</td></tr><tr><td>Systemic features</td><td>May be preceded by mild prodrome</td><td>Fever, headache, encephalitis</td><td>Antecedent infection, no fever</td><td>Back pain, urinary retention</td></tr><tr><td>MRI spine</td><td>Normal</td><td>May show gray matter hyperintensity</td><td>Normal</td><td>T2 hyperintense lesion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always elicit travel and vaccination history in AFP to assess poliovirus risk.  <br><span class=\"list-item\">\u2022</span> Early EMG/NCS (days 3&ndash;5) differentiates anterior horn cell disease (reduced CMAPs, preserved SNAPs) from demyelination.  <br><span class=\"list-item\">\u2022</span> Report all AFP cases in children <15 years to public health for polio surveillance, per WHO guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming GBS never presents without sensory signs&mdash;early motor\u2010only GBS can occur but nerve conduction studies reveal demyelination.  <br>2. Believing that absence of fever excludes viral AFP&mdash;poliomyelitis often has minimal prodrome and afebrile paralysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WHO/GPEI Polio Eradication Endgame Strategic <span class=\"evidence\">Plan 2019</span>&ndash;2023  <br><span class=\"list-item\">\u2022</span> Recommends active AFP surveillance, stool testing for poliovirus, and maintenance of &ge;80% immunization coverage.  <br><span class=\"list-item\">\u2022</span> Evidence level: Expert consensus.  <br>2. CDC ACIP Polio Vaccine Recommendations, 2022  <br><span class=\"list-item\">\u2022</span> Advises four doses of IPV at 2, 4, 6&ndash;18 months, booster at 4&ndash;6 years to sustain population immunity.  <br><span class=\"list-item\">\u2022</span> Evidence level: A (randomized trials of IPV efficacy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Poliovirus targets lamina IX motor neuron pools in the ventral anterior horn of the spinal cord, sparing dorsal columns and spinothalamic tracts&mdash;hence pure motor deficit without sensory loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Poliovirus enters via the oropharyngeal/GI route, replicates in lymphoid tissue, enters the bloodstream (viremia), crosses the blood&ndash;brain barrier, binds CD155 on motor neurons, and causes irreversible neuronal death leading to flaccid paralysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On board-style items, acute flaccid paralysis without sensory loss is a classic anterior horn cell process&mdash;poliovirus is the prototype, with West Nile virus as a secondary consideration.</div></div></div></div></div>"
  },
  {
    "id": 100024615,
    "question_number": "233",
    "question_text": "What is the most common cause of spinal epidural abscess?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Spinal epidural abscess (SEA) arises when bacteria enter the potential space between the dura mater and vertebral canal. Key principles:  <br><span class=\"list-item\">\u2022</span> Anatomy: the epidural space contains loose connective tissue and the internal vertebral venous plexus, facilitating rapid spread.  <br><span class=\"list-item\">\u2022</span> Pathway of infection: direct inoculation, contiguous extension, or hematogenous seeding.  <br><span class=\"list-item\">\u2022</span> Clinical triad: back pain, fever, neurological deficits&mdash;though all three occur in <15% at presentation.  <br>Understanding these concepts helps localize infection, anticipate imaging findings, and prioritize emergent management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hematogenous spread accounts for 50&ndash;60% of SEA cases, as first characterized by Darouiche <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2006</span>)</span> and reaffirmed in multiple cohorts. Bacteremia&mdash;often from skin/soft-tissue infections, endocarditis, IV drug use, or urinary tract sources&mdash;seeds the rich valveless epidural venous plexus. <span class=\"evidence\">The 2017</span> IDSA &ldquo;Practice Guidelines for Native Vertebral Osteomyelitis&rdquo; recommend MRI with gadolinium within 24 hours of suspicion (Level B evidence) and empirical vancomycin plus a third-generation cephalosporin, underscoring the primacy of hematogenous etiology. Contiguous spread from vertebral osteomyelitis/discitis underlies 20&ndash;30% of cases; direct inoculation (trauma or LP) accounts for <10%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Osteomyelitis  <br>&ndash; Incorrect because vertebral osteomyelitis is a contiguous extension rather than the primary mechanism; most SEAs originate in the bloodstream before involving bone.  <br>&ndash; Misconception: equating bone infection with the initial source rather than secondary involvement.  <br>&ndash; Differentiation: contiguous spread tends to present later, often with radiographic evidence of discitis on MRI.<br><br>B. Penetrating Trauma  <br>&ndash; Rare, accounting for <5% of SEAs; requires an overt breach of the ligamentous barrier.  <br>&ndash; Misconception: overestimating the frequency of trauma\u2010related cases due to focus on open wounds.  <br>&ndash; Differentiation: trauma history is often obvious, whereas hematogenous cases lack external injury.<br><br>C. LP  <br>&ndash; Very low incidence (<1%); strict aseptic technique has reduced risk further.  <br>&ndash; Misconception: assuming that any dural puncture greatly predisposes to SEA.  <br>&ndash; Differentiation: post\u2010LP back pain is common, but frank abscess formation is exceptionally rare.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hematogenous Spread</th><th>Osteomyelitis (Contiguous)</th><th>Penetrating Trauma</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Mechanism</td><td>Bacteremia \u2192 venous plexus</td><td>Extension from vertebral bone</td><td>Direct inoculation</td><td>Iatrogenic inoculation</td></tr><tr><td>Relative Frequency</td><td>~50&ndash;60%</td><td>~20&ndash;30%</td><td><5%</td><td><1%</td></tr><tr><td>Typical Risk Factors</td><td>Skin/soft\u2010tissue infections, endocarditis, IVDA, diabetes</td><td>Prior spinal surgery, trauma</td><td>Open wounds, surgery</td><td>Recent LP, inadequate sterilization</td></tr><tr><td>Onset</td><td>Subacute, systemic symptoms</td><td>Subacute, focal pain</td><td>Acute with trauma</td><td>Subacute, localized</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Only 10&ndash;15% present with the classic triad; always check ESR/CRP (>90% sensitive).  <br><span class=\"list-item\">\u2022</span> MRI with gadolinium is the gold standard; avoid delay in imaging when SEA is suspected.  <br><span class=\"list-item\">\u2022</span> Early neurosurgical consultation reduces risk of permanent paralysis; surgical decompression within 24 h if deficits appear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming vertebral osteomyelitis is the primary cause, rather than a secondary process from hematogenous seeding.  <br>2. Relying on fever or neurologic signs for diagnosis; up to 50% lack fever initially, and deficits may be subtle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2017 &ldquo;Practice Guidelines for Native Vertebral Osteomyelitis&rdquo;: MRI within 24 h of suspicion; empirical vancomycin plus ceftriaxone (Level B).  <br><span class=\"list-item\">\u2022</span> North American Spine Society (NASS) 2020 Guidelines: Strong recommendation for urgent decompressive laminectomy in any patient with new or progressive neurological deficits (Moderate evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>SEA etiologies are frequently tested by presenting a clinical vignette and asking for the most likely route of infection&mdash;recognize that hematogenous seeding is by far the most common.</div></div></div></div></div>"
  },
  {
    "id": 100024616,
    "question_number": "38",
    "question_text": "A patient with HIV has multiple brain MRI lesions. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Toxoplasma gondii is an obligate intracellular protozoan that forms latent cysts in neural tissue. In HIV/AIDS patients with CD4+ counts <100 cells/\u00b5L, reactivation leads to multiple ring-enhancing lesions, typically in the basal ganglia and corticomedullary junction, accompanied by vasogenic edema. MRI with contrast often shows bilateral, asymmetric lesions with surrounding edema. Differential diagnoses include PCNSL (often solitary, periventricular), tuberculoma (granulomatous, may calcify), and fungal abscesses (less predictable enhancement, often singular). Recognizing imaging patterns, host immunity, and serologic markers (Toxo IgG) informs empirical therapy versus biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CNS toxoplasmosis accounts for ~50&ndash;70% of focal brain lesions in HIV <span class=\"citation\">(Porter et al., Clin Infect <span class=\"evidence\">Dis 2004</span>)</span>. IDSA 2020 guidelines recommend pyrimethamine&ndash;sulfadiazine plus leucovorin for initial therapy; diagnostic brain biopsy is reserved for patients without clinical or radiologic improvement after 10&ndash;14 days of empiric treatment (A-II evidence). Toxo IgG seropositivity has ~95% negative predictive value; absence of antibodies makes toxo unlikely. MRI &ldquo;eccentric target sign&rdquo; on T2-weighted images is 90% specific. Pathophysiologically, immunosuppression permits bradyzoite-to-tachyzoite conversion, with tissue necrosis and inflammation. Rapid empirical treatment with clinical and imaging follow-up is supported by multiple cohort studies demonstrating >70% radiographic resolution by day 14 <span class=\"citation\">(Mamelak et al., J <span class=\"evidence\">Neurosurg 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Primary CNS lymphoma (PCNSL)  <br>&bull; Incorrect because PCNSL often presents as a solitary, periventricular lesion with homogenous enhancement and marked diffusion restriction.  <br>&bull; Misconception: All multiple lesions in HIV are PCNSL.  <br>&bull; Differentiator: Positive EBV DNA in CSF and high thallium uptake on SPECT favor PCNSL.<br><br>C. Tuberculoma  <br>&bull; Incorrect since tuberculomas are granulomatous, often calcified, and less edematous.  <br>&bull; Misconception: Ring-enhancing in HIV always indicates TB.  <br>&bull; Differentiator: Acid-fast bacilli on CSF PCR and caseating granulomas on biopsy confirm TB.<br><br>D. Fungal mass lesions  <br>&bull; Incorrect because fungal lesions (e.g., cryptococcoma, histoplasma) are rare, often singular, and present with meningitic signs.  <br>&bull; Misconception: Any HIV patient with CNS lesions has fungal infection.  <br>&bull; Differentiator: India ink or cryptococcal antigen positive in CSF; fungal cultures isolate organism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CNS Toxoplasmosis</th><th>PCNSL</th><th>Tuberculoma</th><th>Fungal Mass Lesions</th></tr></thead><tbody><tr><td>Etiology</td><td>T. gondii reactivation</td><td>EBV-driven B-cell lymphoma</td><td>Mycobacterium tuberculosis</td><td>Cryptococcus, Histoplasma</td></tr><tr><td>MRI</td><td>Multiple ring-enhancing, basal ganglia predilection</td><td>Solitary/periventricular, homogenous</td><td>Ring-enhancing, calcification common</td><td>Variable enhancement; often solitary</td></tr><tr><td>CSF/Serology</td><td>Toxo IgG+, CSF PCR low yield</td><td>EBV DNA+ in CSF, cytology diagnostic</td><td>CSF PCR for TB, elevated ADA</td><td>Positive fungal antigen/culture</td></tr><tr><td>Response to Empiric Tx</td><td>Improvement in 10&ndash;14 days</td><td>No response; requires chemo/radiation</td><td>Partial; requires RIPE therapy</td><td>No response; requires antifungals</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Empiric anti-toxo therapy is both diagnostic and therapeutic&mdash;lack of improvement by day 14 warrants biopsy.  <br>&bull; Toxo IgG seronegativity effectively rules out reactivation disease in HIV patients.  <br>&bull; The MRI &ldquo;eccentric target sign&rdquo; is highly specific for toxoplasmosis over PCNSL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Equating multiple lesions exclusively with toxo without considering PCNSL when CD4 <50.  <br>&bull; Overlooking seronegative toxo in early infection&mdash;always correlate serology with imaging and clinical picture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Infectious Diseases Society of America (IDSA) 2020: Recommends pyrimethamine&ndash;sulfadiazine + leucovorin for HIV-associated toxoplasmic encephalitis (Level A-II).  <br>&bull; European AIDS Clinical Society (EACS) 2019: Advises TMP-SMX prophylaxis in HIV patients with CD4 <100 cells/\u00b5L to prevent toxoplasmic encephalitis (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma cysts preferentially localize to the basal ganglia and corticomedullary junction, areas of high blood flow and slow capillary transit, promoting tachyzoite invasion and foci of necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Immunosuppression permits latent bradyzoites to convert into invasive tachyzoites, causing focal necrosis, inflammatory infiltrate, and vasogenic edema around cyst rupture sites.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with CD4 <100 and focal neurologic deficits.  <br>2. Obtain MRI with contrast&mdash;look for multiple ring-enhancing lesions.  <br>3. Check Toxo IgG serology and consider CSF studies.  <br>4. Initiate empiric anti-toxo therapy.  <br>5. Re-assess clinically and via MRI at 10&ndash;14 days; biopsy if no improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On MRI, toxo lesions often show the &ldquo;eccentric target sign&rdquo; on T2 and ring enhancement on T1 post-contrast with surrounding vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Pyrimethamine (200 mg loading, then 50&ndash;75 mg/day) + sulfadiazine (1&ndash;1.5 g QID) + leucovorin (10&ndash;25 mg/day) for &ge;6 weeks, adjusting for renal function and cytopenias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>On neurology boards, HIV-related intracranial lesions are frequently tested via imaging vignettes; differentiating toxoplasmosis from PCNSL by lesion count, location, serology, and response to therapy is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100024618,
    "question_number": "37",
    "question_text": "What is the most common artery affected in TB vasculopathy?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Tuberculous meningitis (TBM) induces an exudative basal leptomeningitis that encases the circle of Willis, leading to vasculitis and infarction. Key points:  <br><span class=\"list-item\">\u2022</span> Basal exudates preferentially involve vessels at the sylvian and interpeduncular cisterns.  <br><span class=\"list-item\">\u2022</span> Inflammatory granulomas and caseous material provoke intimal proliferation, thrombosis, and arterial narrowing.  <br><span class=\"list-item\">\u2022</span> Stroke in TBM most often localizes to large perforator-rich territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Middle cerebral artery (MCA) involvement predominates in TB vasculopathy because its M1 segment and lateral lenticulostriate branches lie within the sylvian fissure, the locus of dense TB exudates. Kalita et al. <span class=\"citation\">(J Neurol Sci. 2014)</span> documented MCA-territory infarcts in 67% of 85 TBM patients. Magnetic resonance angiography frequently reveals focal stenosis of M1/M2 segments. In contrast, anterior cerebral artery (ACA) perforators are less enveloped by basal exudates, and posterior circulation infarcts (posterior cerebral artery [PCA], basilar) are seen in <20% of cases <span class=\"citation\">(Rock et al., Lancet ID 2018)</span>. Adjunctive corticosteroid trials <span class=\"citation\">(Thwaites et al., N Engl J Med. 2004)</span> reduce mortality but do not abolish vasculopathy risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: ACA runs in the interhemispheric fissure, receiving comparatively less basal exudative burden.  <br><span class=\"list-item\">\u2022</span> Misconception: Students assume ACA involvement parallels MCA since both are proximal Circle of Willis vessels.  <br><span class=\"list-item\">\u2022</span> Differentiation: ACA infarcts are midline with leg&ndash;foot weakness; MCA infarcts present with contralateral face/arm deficits.  <br><br>B. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: PCA lies in ambient and quadrigeminal cisterns, where TB exudates are thinner.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating posterior circulation strokes in TBM with general stroke epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiation: PCA infarcts cause visual field defects, uncommon in TBM compared to MCA-related hemiparesis.  <br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Basilar thrombosis in TBM is rare; even when present, it leads to brainstem syndromes rather than cortical infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating basilar involvement due to basal cistern exudates.  <br><span class=\"list-item\">\u2022</span> Differentiation: Basilar occlusion yields &ldquo;locked-in&rdquo; or cranial nerve deficits, not typical TBM stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Middle Cerebral Artery</th><th>Anterior Cerebral Artery</th><th>Posterior Cerebral Artery</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Exudate burden</td><td>High (sylvian cistern)</td><td>Moderate (interhemispheric)</td><td>Low (ambient cistern)</td><td>Variable (basal cistern)</td></tr><tr><td>Infarct frequency in TBM</td><td>~60&ndash;70%</td><td>~10&ndash;15%</td><td>~5&ndash;10%</td><td><5%</td></tr><tr><td>Clinical presentation</td><td>Contralateral face/arm weakness, aphasia (dominant)</td><td>Contralateral leg weakness</td><td>Homonymous hemianopia</td><td>Brainstem signs, cranial nerves</td></tr><tr><td>Imaging</td><td>MRA: M1/M2 stenosis</td><td>MRA: A2 segment narrowing</td><td>MRA: P2 narrowing</td><td>Angiography: basilar narrowing</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain contrast-enhanced MRI early in TBM to detect basal exudates and vessel stenosis.  <br><span class=\"list-item\">\u2022</span> Adjunctive high-dose dexamethasone reduces mortality but does not prevent all vasculitic strokes.  <br><span class=\"list-item\">\u2022</span> In TBM patients with new focal deficits, add MR angiography to assess MCA stenosis and consider low-dose aspirin (ASA-TBM trial data).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming TBM stroke patterns mirror atherosclerotic disease; TB vasculopathy preferentially targets MCA perforators, not large-vessel trunks only.  <br>2. Failing to distinguish ACA from MCA territory signs: leg-dominant weakness suggests ACA, whereas arm and face deficits point to MCA involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Clinical Practice Guidelines for the Treatment of Tuberculosis (2023)  <br><span class=\"list-item\">\u2022</span> Recommendation: All adults and children with TB meningitis should receive adjunctive corticosteroids (dexamethasone) and undergo baseline MRI with MR angiography to screen for vasculopathy. (Strong recommendation; Level I evidence)  <br>2. ASA-TBM Randomized Controlled Trial <span class=\"citation\">(Misra et al., Lancet Neurol. 2022)</span>  <br><span class=\"list-item\">\u2022</span> Finding: Adjunctive low-dose aspirin (100 mg daily) in TBM reduced incidence of ischemic stroke by 25% over 6 months. (Moderate benefit; Grade B evidence)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Basal exudates accumulate in the sylvian fissure, interpeduncular, and ambient cisterns. The MCA&rsquo;s M1 segment traverses the sylvian cistern, where inflammatory infiltrates encase and inflame the vessel wall, leading to intimal proliferation and thrombosis of lateral lenticulostriate arteries supplying the internal capsule and corona radiata.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mycobacterium tuberculosis in CSF triggers a Th1-mediated granulomatous response, with exudation of fibrinous material around leptomeningeal vessels. This leads to panarteritis, endothelial proliferation, and luminal narrowing. Released cytokines (TNF-&alpha;, IFN-&gamma;) exacerbate vascular injury and thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, meningeal signs.  <br>2. CSF analysis: lymphocytic pleocytosis, elevated protein, low glucose; TB PCR/culture.  <br>3. MRI+MRA: identify basal exudates, hydrocephalus, infarcts, vessel stenosis (focus on MCA territory).  <br>4. Initiate RIPE therapy + adjunctive dexamethasone; consider ASA if MRA shows significant MCA stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On MRI FLAIR/T1 with contrast, basal leptomeningeal enhancement localizes to sylvian cisterns.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted imaging (DWI) highlights acute MCA-territory infarcts.  <br><span class=\"list-item\">\u2022</span> Time-of-flight MRA often reveals focal MCA M1 narrowing or occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- RIPE regimen: isoniazid 5 mg/kg, rifampin 10 mg/kg, pyrazinamide 25 mg/kg, ethambutol 20 mg/kg daily for 2 months, followed by isoniazid and rifampin for 7&ndash;10 months.  <br><span class=\"list-item\">\u2022</span> Dexamethasone: 0.4 mg/kg/day IV for 1 week, taper over 6&ndash;8 weeks.  <br><span class=\"list-item\">\u2022</span> Low-dose aspirin (100 mg/day) may reduce stroke risk when vasculopathy is confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>TB meningitis vasculopathy questions frequently test infarct patterns and vessel involvement; nearly all review books emphasize MCA perforator infarcts in TBM. Examinations often present a TBM vignette with new hemiparesis and ask for the most likely vascular territory.</div></div></div></div></div>"
  },
  {
    "id": 100024619,
    "question_number": "232",
    "question_text": "An elderly patient came with low-grade fever, meningism, encephalopathy, and acute flaccid paralysis. What is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] West Nile virus (WNV) is a mosquito-borne flavivirus that can invade the meninges, brain parenchyma, and anterior horn cells of the spinal cord. Neuroinvasive forms manifest as meningitis (meningism), encephalitis (altered mental status), or a poliomyelitis-like myelitis producing acute flaccid paralysis. Advanced age increases blood&ndash;brain barrier permeability and risk of neuronal infection. Key concepts include:<br><span class=\"list-item\">\u2022</span> Neurotropism: WNV preferentially infects anterior horn motor neurons, causing lower motor neuron signs.<br><span class=\"list-item\">\u2022</span> Inflammatory CSF profile: lymphocytic pleocytosis with elevated protein.<br><span class=\"list-item\">\u2022</span> Distinction from demyelinating syndromes (e.g., Guillain-Barr\u00e9) by asymmetric weakness and central involvement.<br>This pathophysiology explains the concurrence of low-grade fever, meningism, encephalopathy, and flaccid paralysis in elderly patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>West Nile virus neuroinvasive disease classically combines meningoencephalitis with acute asymmetric flaccid paralysis due to direct anterior horn cell injury. Sejvar et al. <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2014</span>)</span> demonstrated electrophysiological evidence of motor neuron loss and MRI T2 hyperintensities in ventral horns. The CDC&rsquo;s 2021 Clinical Guidance for Healthcare Providers recommends testing CSF for WNV-specific IgM (sensitivity >90%, specificity >99%), which persists for weeks post-infection. Typical CSF findings: 50&ndash;500 lymphocytes/mm\u00b3, protein 50&ndash;200 mg/dL, normal glucose. MRI spine often shows &ldquo;snake-eye&rdquo; ventral horn lesions. No antiviral has proven benefit; treatment is supportive <span class=\"citation\">(IDSA 2015; Level B)</span>. Given this constellation, WNV is the only option explaining both meningoencephalitis and poliomyelitis-like paralysis in an elderly host.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Poliomyelitis  <br><span class=\"list-item\">\u2022</span> Incorrect: Poliovirus targets anterior horn cells but rarely causes meningism or encephalopathy in vaccinated populations.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating flaccid paralysis alone with poliomyelitis without considering central signs or epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Poliomyelitis lacks prominent meningoencephalitis in adults and is nearly eradicated in most regions.<br><br>C. HIV encephalopathy  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents as chronic cognitive decline and subcortical motor slowing, not acute flaccid paralysis.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any encephalopathic picture with neurologic deficits to HIV without acute febrile onset.  <br><span class=\"list-item\">\u2022</span> Differentiator: HIV-associated neurocognitive disorder lacks fever, meningism, and anterior horn involvement.<br><br>D. Guillain-Barr\u00e9 syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect: An autoimmune demyelinating polyneuropathy with symmetric ascending paralysis, areflexia, and albuminocytologic dissociation.  <br><span class=\"list-item\">\u2022</span> Misconception: Mistaking flaccid paralysis with preserved reflexes as GBS without evaluating CSF cell count or encephalopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: GBS lacks fever, meningoencephalitis, and focal MRI ventral horn lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>West Nile Virus</th><th>Poliomyelitis</th><th>HIV Encephalopathy</th><th>Guillain-Barr\u00e9 Syndrome</th></tr></thead><tbody><tr><td>Epidemiology</td><td>Summer arbovirus, elderly risk</td><td>Rare, pediatric history</td><td>Chronic HIV infection</td><td>Post-infectious, any season</td></tr><tr><td>Clinical Presentation</td><td>Fever + meningism + encephalopathy + asymmetric flaccid paralysis</td><td>Flaccid paralysis without encephalopathy</td><td>Subacute cognitive decline</td><td>Symmetric ascending paralysis, no encephalopathy</td></tr><tr><td>CSF Profile</td><td>Lymphocytic pleocytosis, \u2191protein</td><td>Early neutrophils\u2192lymphocytes</td><td>Mild lymphocytic pleocytosis, normal glucose</td><td>Albuminocytologic dissociation (\u2191protein, normal WBC)</td></tr><tr><td>MRI Findings</td><td>Ventral horn &ldquo;snake-eye&rdquo; T2 hyperintensities</td><td>Ventral horn signal changes in unvaccinated cases</td><td>Cortical/subcortical atrophy</td><td>Nerve root enhancement</td></tr><tr><td>Diagnostic Test</td><td>CSF WNV IgM ELISA</td><td>Stool/CSF PCR (rare)</td><td>CSF HIV RNA PCR</td><td>Nerve conduction studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute flaccid paralysis with central signs (encephalopathy, meningism) should prompt CSF WNV IgM testing in endemic seasons.  <br><span class=\"list-item\">\u2022</span> MRI involvement of spinal ventral horns (&ldquo;snake-eye&rdquo; lesions) distinguishes WNV from demyelinating neuropathies.  <br><span class=\"list-item\">\u2022</span> Supportive care remains the mainstay; immunoglobulin or antivirals are only recommended in clinical trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misdiagnosing WNV-associated flaccid paralysis as GBS and initiating plasmapheresis or IVIG inappropriately.  <br><span class=\"list-item\">\u2022</span> Failing to consider WNV in febrile encephalitis with paralysis during mosquito season in temperate regions.  <br><span class=\"list-item\">\u2022</span> Relying solely on cell counts without ordering specific CSF IgM or targeted MRI sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC Clinical Guidance for Healthcare Providers (2021): Recommends CSF WNV IgM testing for diagnosis; no antiviral therapy approved (Expert Opinion).  <br><span class=\"list-item\">\u2022</span> IDSA Practice Guidelines for the Management of Infectious Encephalitis (2015): Advise against routine antiviral agents for WNV; permit immunoglobulin use only within clinical trials (Level B).  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Sejvar JJ et al., 2018</span> multicenter cohort: Identified age >60 as independent risk factor for neuroinvasive disease; acute flaccid paralysis occurs in ~7% of cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>WNV preferentially infects ventral horn motor neurons in the spinal cord, leading to lower motor neuron signs. In the brain, involvement of the basal ganglia and thalamus contributes to encephalopathic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Following mosquito inoculation, WNV replicates in dermal dendritic cells, enters the bloodstream, crosses the blood&ndash;brain barrier via infected leukocytes or endothelial cells, and causes direct neuronal cytotoxicity and microglial activation, leading to inflammation and neuronal death in anterior horn cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in summer/fall with fever, meningism, encephalopathy, and flaccid paralysis.  <br>2. Lumbar puncture: cell count, protein, glucose.  <br>3. CSF WNV IgM ELISA and PCR.  <br>4. MRI brain and spine with T2/FLAIR sequences for ventral horn lesions.  <br>5. Electromyography and nerve conduction studies to confirm anterior horn cell involvement.  <br>6. Exclude mimics (CSF profile, imaging, serologies).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Spinal MRI: symmetric or asymmetric T2 hyperintensities in ventral horns (&ldquo;snake-eye&rdquo;).  <br><span class=\"list-item\">\u2022</span> Brain MRI: T2/FLAIR hyperintensities in deep gray structures (basal ganglia, thalami).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA-approved antivirals for WNV; management is supportive (hydration, respiratory support).  <br><span class=\"list-item\">\u2022</span> Investigational: intravenous immunoglobulin and interferon alpha have been evaluated without definitive benefit.  <br><span class=\"list-item\">\u2022</span> Preventive: mosquito control and repellents remain key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. West Nile virus neuroinvasive disease is frequently tested as an acute flaccid paralysis scenario with central (meningoencephalitic) features, emphasizing seasonality, CSF findings, and imaging correlations.</div></div></div></div></div>"
  },
  {
    "id": 100024620,
    "question_number": "86",
    "question_text": "What is the best treatment to prevent post-herpetic neuralgia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Herpes zoster results from reactivation of varicella-zoster virus in dorsal root or cranial nerve ganglia, leading to acute neuritis and cutaneous rash. Viral replication causes inflammation and direct neuronal injury, which in turn predisposes to chronic deafferentation and neuropathic pain (post-herpetic neuralgia, PHN). Early inhibition of viral DNA polymerase with antivirals reduces viral load, limits ganglionic damage, and decreases the incidence and duration of PHN. Key terms: dorsal root ganglion, viral replication, neuropathic pain, deafferentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiviral therapy (acyclovir, valacyclovir, famciclovir) initiated within 72 hours of zoster rash onset is proven to reduce PHN risk by 30&ndash;40% <span class=\"citation\">(Beutner et al. N Engl J <span class=\"evidence\">Med 1995</span>; Oxman et al. J Infect <span class=\"evidence\">Dis 1998</span>)</span>. The CDC and IDSA guidelines <span class=\"citation\">(IDSA 2014; CDC/ACIP 2021)</span> recommend high-dose antivirals&mdash;valacyclovir 1 g TID for 7 days or famciclovir 500 mg TID&mdash;over acyclovir for better bioavailability and dosing convenience (Level A evidence). A 2020 Cochrane meta-analysis confirmed early antiviral use shortens acute pain duration and lowers PHN incidence (RR 0.62; 95% CI 0.50&ndash;0.78). In contrast, adjunctive corticosteroids may reduce acute pain but do not prevent PHN in randomized trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Corticosteroids  <br><span class=\"list-item\">\u2022</span> Although steroids reduce acute inflammation and speed rash healing, multiple RCTs <span class=\"citation\">(<span class=\"evidence\">Birch et al. 1998</span>)</span> show no significant reduction in PHN incidence.  <br><span class=\"list-item\">\u2022</span> Misconception: anti-inflammatory equals neuroprotection; in reality, ganglionic viral injury persists.  <br><br>C. Analgesics  <br><span class=\"list-item\">\u2022</span> NSAIDs or opioids address symptom relief only; they neither affect viral replication nor modulate the underlying neuropathic process.  <br><span class=\"list-item\">\u2022</span> Students often conflate symptomatic pain control with disease modification.  <br><br>D. Antidepressants  <br><span class=\"list-item\">\u2022</span> Tricyclics or SNRIs treat established neuropathic pain but lack antiviral or neuroprotective effects to prevent PHN.  <br><span class=\"list-item\">\u2022</span> Misunderstanding: using neuropathic pain agents prophylactically rather than after PHN onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antiviral</th><th>Corticosteroids</th><th>Analgesics</th><th>Antidepressants</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits viral DNA polymerase</td><td>Reduces inflammation</td><td>Blocks pain signaling</td><td>Modulates monoamines</td></tr><tr><td>Effect on PHN prevention</td><td>\u2193 Incidence by ~30&ndash;40% (if &le;72 h)</td><td>No significant effect</td><td>None</td><td>None</td></tr><tr><td>Recommended timing</td><td>&le;72 hours from rash onset</td><td>Adjunct in severe cases only</td><td>Symptom onset</td><td>Established PHN management</td></tr><tr><td>Level of evidence</td><td>A (multiple RCTs, meta-analysis)</td><td>B (some RCTs for acute pain)</td><td>C (expert opinion)</td><td>B (post-herpetic treatment)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Begin antiviral therapy ideally within 72 hours of rash to maximize PHN prevention; beyond 72 hours, benefit diminishes.  <br>2. Valacyclovir and famciclovir are preferred over acyclovir due to improved bioavailability and simplified dosing.  <br>3. Shingles vaccination (RZV) is the best preventive measure for herpes zoster and indirectly reduces PHN risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering corticosteroids expecting PHN prevention&mdash;clinical trials show no reduction in chronic neuropathy.  <br>2. Delaying antiviral therapy beyond 72 hours; clinicians may miss the therapeutic window.  <br>3. Equating acute pain relief with prevention of chronic neuropathic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guideline for Herpes Zoster (2014): Recommends acyclovir, valacyclovir, or famciclovir within 72 hours to reduce PHN (Level A).  <br><span class=\"list-item\">\u2022</span> CDC/ACIP Zoster Vaccine Recommendations (2021): Emphasize recombinant zoster vaccine (RZV) in adults &ge;50 years to prevent herpes zoster and subsequent PHN (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.   <br>Herpes zoster management and PHN prevention are frequently tested in various formats, including timing of antiviral initiation and comparative efficacy of antiviral agents.</div></div></div></div></div>"
  },
  {
    "id": 100024621,
    "question_number": "36",
    "question_text": "A patient had meningococcal meningitis. What medication should be given to his family for prophylaxis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Neisseria meningitidis is a Gram-negative diplococcus that colonizes the human nasopharynx. Close contacts of an index case are at increased risk of invasive disease due to shared respiratory droplets. Chemoprophylaxis aims to eradicate nasopharyngeal carriage and interrupt transmission. Key concepts:  <br><span class=\"list-item\">\u2022</span> Carriage versus invasive disease: asymptomatic carriers can seed new cases.  <br><span class=\"list-item\">\u2022</span> Drug selection must achieve high concentrations in oropharyngeal mucosa and eradicate carrier state.  <br><span class=\"list-item\">\u2022</span> Choice of agent depends on efficacy, resistance patterns, safety and patient factors (age, pregnancy).<br><br>(110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rifampin is the CDC-recommended first-line prophylactic agent for close contacts of meningococcal meningitis [CDC ACIP, 2020]. It achieves high oropharyngeal tissue levels, eradicates N. meningitidis carriage in >95% of treated contacts, and is well studied: adults receive 600 mg PO q12\u2009h for 2\u2009days; children 10 mg/kg (max 600 mg) PO q12\u2009h for 2\u2009days. Alternative regimens include ciprofloxacin 500 mg PO once or ceftriaxone 250 mg IM once (125 mg IM in children) for those contraindicated to rifampin (e.g., pregnant women). Vancomycin and beta-lactams like amoxicillin do not reliably eradicate carrier states or penetrate the oropharynx at sufficient concentrations for prophylaxis.  <br>References:  <br><span class=\"list-item\">\u2022</span> CDC. Prevention and Control of Meningococcal Disease: Recommendations of ACIP. MMWR Recomm Rep. 2020;69(RR-2).  <br><span class=\"list-item\">\u2022</span> Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection&mdash;serum bactericidal antibody assay. Vaccine. 2005;23(17-18):2222&ndash;2227.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amoxicillin &ndash; Although amoxicillin has activity against some N. meningitidis strains, it does not reliably eradicate nasopharyngeal carriage and is not recommended for post-exposure prophylaxis. Choosing amoxicillin reflects a misunderstanding of carriage dynamics and pharmacokinetics in mucosal tissues.  <br>C. Ciprofloxacin &ndash; A single 500 mg oral dose is an accepted alternative prophylactic regimen, but rifampin remains first-line due to extensive safety data in children and pregnant women. Labeling ciprofloxacin as the correct choice overlooks age and pregnancy considerations and regional fluoroquinolone resistance patterns.  <br>D. Vancomycin &ndash; Targets Gram-positive organisms; lacks activity against Gram-negative N. meningitidis and does not penetrate the oropharyngeal mucosa in sufficient concentrations. Using vancomycin demonstrates confusion between empiric treatment of meningitis pathogens and prophylaxis of contacts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Mechanism</th><th>Prophylaxis Regimen</th><th>Role</th><th>Key Limitations</th></tr></thead><tbody><tr><td>Rifampin</td><td>Inhibits DNA-dependent RNA polymerase</td><td>600 mg PO q12\u2009h \u00d7 2 days (adult)</td><td>First-line prophylaxis</td><td>CYP450 inducer; orange discoloration of secretions</td></tr><tr><td>Amoxicillin</td><td>Inhibits cell-wall synthesis</td><td>Not recommended</td><td>Not used</td><td>Poor carriage eradication; rising resistance</td></tr><tr><td>Ciprofloxacin</td><td>Inhibits DNA gyrase/topoisomerase II</td><td>500 mg PO \u00d71 dose (adult)</td><td>Alternative prophylaxis</td><td>Contraindicated in children; tendon toxicity</td></tr><tr><td>Vancomycin</td><td>Inhibits peptidoglycan cross-linking</td><td>Not recommended</td><td>Not used</td><td>No Gram-negative coverage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always initiate chemoprophylaxis as soon as a case of meningococcal meningitis is suspected, ideally within 24 hours of diagnosis.  <br><span class=\"list-item\">\u2022</span> Rifampin&rsquo;s side effects include hepatotoxicity and drug interactions via CYP450 induction; counsel patients regarding orange-red discoloration of urine, tears and saliva.  <br><span class=\"list-item\">\u2022</span> In pregnant women and neonates, use a single IM dose of ceftriaxone (125 mg in infants; 250 mg in adults) to avoid teratogenic risks of rifampin and fluoroquinolones.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prescribing beta-lactams (e.g., amoxicillin) for prophylaxis underestimates the need to eradicate mucosal carriage and ignores resistance data.  <br><span class=\"list-item\">\u2022</span> Assuming ciprofloxacin is universally first-line; it is contraindicated in children and pregnant women and may be limited by local fluoroquinolone resistance rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC Advisory Committee on Immunization Practices (ACIP), 2020: Recommends rifampin as first-line prophylaxis for all close contacts; level of evidence A (randomized and observational studies demonstrating >95% carriage eradication).  <br><span class=\"list-item\">\u2022</span> Infectious Diseases Society of America (IDSA), 2018 Meningitis Guidelines: Endorses rifampin for routine prophylaxis, with ciprofloxacin and ceftriaxone as alternatives when rifampin is contraindicated; evidence quality B (non-randomized trials, expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>N. meningitidis adheres to nasopharyngeal epithelium via type IV pili, resisting mucociliary clearance. If bacteremia ensues, it crosses the blood&ndash;brain barrier via transcytosis or paracellular routes, leading to meningitis. Chemoprophylaxis targets the establishment and persistence of carriage by disrupting bacterial DNA replication (rifampin) or inducing lethal DNA breaks (ciprofloxacin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Post-exposure prophylaxis for meningococcal disease is a high-yield topic tested as straightforward single-best-answer questions focusing on antibiotic choice, dosing regimens, and special populations (children, pregnant women).</div></div></div></div></div>"
  },
  {
    "id": 100024622,
    "question_number": "118",
    "question_text": "In the context of West Nile virus infection, which of the following is a common clinical feature?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] West Nile virus (WNV) is a Culex\u2010transmitted flavivirus. Neuroinvasive disease (<1% of infections) presents as meningitis, encephalitis or acute flaccid paralysis. Flaccid weakness results from selective infection and death of anterior horn (lower motor) neurons, leading to hypotonia and areflexia. Students must distinguish lower\u2010motor neuron (LMN) signs&mdash;flaccidity, fasciculations, hyporeflexia&mdash;from upper\u2010motor neuron (UMN) signs&mdash;spasticity, hyperreflexia, hypertonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Spasticity  <br>&bull; Reflects UMN (corticospinal) damage with hyperreflexia and velocity\u2010dependent increase in tone&mdash;absent in WNV&rsquo;s LMN syndrome.  <br>&bull; Misconception: conflating post\u2010encephalitic rigidity with true spasticity.  <br><br>C. Increased muscle tone  <br>&bull; Also a UMN sign; WNV causes hypotonia due to anterior horn cell loss.  <br>&bull; Misconception: attributing generalized rigidity in encephalitis to WNV motor pathology.  <br><br>D. Sensory ataxia  <br>&bull; Indicates dorsal column or large\u2010fiber peripheral sensory involvement&mdash;WNV preferentially targets motor neurons, sparing primary sensory pathways.  <br>&bull; Misconception: confusing gait instability in encephalitis with sensory ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Flaccid Weakness (WNV)</th><th>Spasticity (UMN)</th><th>Increased Tone (UMN)</th><th>Sensory Ataxia</th></tr></thead><tbody><tr><td>Tone</td><td>\u2193 hypotonia</td><td>\u2191 hypertonia (velocity\u2010dependent)</td><td>\u2191 resting tone</td><td>Normal tone</td></tr><tr><td>Reflexes</td><td>\u2193 or absent</td><td>\u2191 hyperreflexia</td><td>&plusmn; brisk reflexes</td><td>&plusmn; normal reflexes</td></tr><tr><td>Fasciculations</td><td>May be present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Pathology</td><td>Anterior horn cell death</td><td>Corticospinal tract lesions</td><td>Corticospinal tract lesions</td><td>Dorsal column/peripheral nerve</td></tr><tr><td>Diagnostic hallmark</td><td>Asymmetric flaccid paralysis</td><td>Clasp\u2010knife response</td><td>Lead\u2010pipe rigidity</td><td>Positive Romberg sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WNV flaccid paralysis mimics poliomyelitis&mdash;often asymmetric, can involve respiratory muscles.  <br>&bull; Diagnosis: CSF WNV IgM positivity; MRI shows anterior cord hyperintensities; EMG reveals denervation.  <br>&bull; No approved antivirals&mdash;supportive care (respiratory, rehabilitative) is mainstay; high\u2010titer IVIG remains investigational.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing WNV\u2010related flaccid paralysis as Guillain\u2010Barr\u00e9 syndrome: WNV is asymmetric and monophasic; GBS is typically symmetric, ascending, with albuminocytologic dissociation.  <br>2. Labeling any post\u2010encephalitic rigidity as spasticity: true spasticity requires UMN lesion signs (hyperreflexia, velocity\u2010dependent tone increase), absent in an anterior horn cell process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC/CSTE &ldquo;Case Definition for West Nile Virus Disease&rdquo; <span class=\"citation\">(MMWR, 2018)</span>: Includes acute flaccid paralysis as a neuroinvasive manifestation; consensus opinion, Level IV evidence.  <br>2. IDSA &ldquo;Clinical Practice Guidelines for the Management of Encephalitis&rdquo; (2017): Recommends early recognition of LMN signs in arboviral encephalitis; based on observational studies, Grade B recommendation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterior horn cells in the ventral grey matter of the spinal cord are the lower motor neurons supplying skeletal muscle. WNV&rsquo;s tropism for these cells leads directly to LMN signs (hypotonia, areflexia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>After mosquito\u2010mediated entry, WNV replicates in skin dendritic cells, enters the bloodstream, crosses the blood&ndash;brain barrier via infected leukocytes or endothelial infection, then binds neuronal receptors in the anterior horn, inducing apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + acute asymmetric flaccid weakness.  <br>2. Exposure history: mosquito season/travel.  <br>3. CSF analysis: lymphocytic pleocytosis, elevated protein, WNV IgM.  <br>4. MRI spine: anterior cord T2 hyperintensities.  <br>5. EMG/NCS: denervation potentials; exclude GBS (nerve conduction block, albuminocytologic dissociation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal MRI often demonstrates &ldquo;snake\u2010eye&rdquo; T2 hyperintensities localized to ventral grey matter at affected spinal levels, correlating with clinical weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No specific antiviral therapy is approved. Supportive measures include intensive care for bulbar/respiratory involvement, aggressive rehabilitation, and consideration of investigational high\u2010titer IVIG (Class III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Neuroinvasive West Nile virus is frequently tested as an acute flaccid paralysis differential, emphasizing LMN lesion localization versus UMN or sensory etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Flaccid weakness. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024623,
    "question_number": "39",
    "question_text": "Q39. In neurosyphilis, which of the following can be associated?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Neurosyphilis arises when Treponema pallidum invades the central nervous system, often during tertiary syphilis. Key presentations include tabes dorsalis (dorsal column damage) and general paresis; ocular manifestations include Argyll Robertson pupils.  <br>&bull; Pupillary light reflex: retina \u2192 pretectal nuclei \u2192 Edinger&ndash;Westphal \u2192 oculomotor nerve \u2192 sphincter pupillae.  <br>&bull; Accommodation reflex: cortical input \u2192 Edinger&ndash;Westphal \u2192 sphincter pupillae, bypassing pretectal light&ndash;reflex relay.  <br>&bull; Argyll Robertson pupil: small, irregular; abolishes light reflex (pretectal lesion) but preserves near accommodation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Argyll Robertson pupils are virtually pathognomonic for neurosyphilis, reflecting selective lesions in the dorsal midbrain pretectal area caused by inflammatory infiltration of spirochetes <span class=\"citation\">(Harrison&rsquo;s Neurology, 21st ed., 2022)</span>. Autopsy series demonstrate perivascular inflammatory infiltrates and microglial proliferation centered on the pretectal region, interrupting the afferent light pathway while sparing fibers mediating accommodation <span class=\"citation\">(Jackson et al., <span class=\"evidence\">Neurology 1964</span>;14:1127&ndash;1135)</span>. No other systemic disease reliably produces bilateral small irregular pupils with preserved near response and absent light reaction. Recognition of this sign directs urgent CSF analysis (VDRL, cell count, protein) and initiation of high-dose penicillin to prevent irreversible neurological damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hypochromatic macules  <br>&bull; Why incorrect: Syphilis causes copper-colored maculopapular rash, not hypopigmented macules.  <br>&bull; Misconception: Equating any cutaneous lesion with neurosyphilis.  <br>&bull; Differentiator: Hypopigmented macules appear in tuberculoid leprosy or pityriasis versicolor, not neurosyphilis.<br><br>B. Erythema nodosum  <br>&bull; Why incorrect: Painful panniculitis linked to streptococcal, TB, sarcoidosis&mdash;absent in syphilis.  <br>&bull; Misconception: Confusing systemic inflammatory nodules with treponemal infection.  <br>&bull; Differentiator: Erythema nodosum presents on pretibial shins; neurosyphilis has no panniculitis.<br><br>C. Enlarged pupils  <br>&bull; Why incorrect: Mydriasis occurs with oculomotor nerve palsy or Adie&rsquo;s tonic pupil&mdash;light and near responses both abnormal or near preserved but pupil tonically dilated.  <br>&bull; Misconception: Assuming any pupillary abnormality implies neurosyphilis.  <br>&bull; Differentiator: Large tonic pupil has vermiform movements, slow redilation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Clinical Feature</th><th>Pathophysiology</th><th>Neurosyphilis Association</th></tr></thead><tbody><tr><td>A. Hypochromatic macules</td><td>Hypopigmented skin macules</td><td>Melanocyte dysfunction (e.g., leprosy)</td><td>No</td></tr><tr><td>B. Erythema nodosum</td><td>Tender subcutaneous nodules on shins</td><td>Septal panniculitis (type IV hypersensitivity)</td><td>No</td></tr><tr><td>C. Enlarged pupils</td><td>Mydriasis, poor light & accommodation reflex</td><td>CN III parasympathetic efferent lesion</td><td>No</td></tr><tr><td>D. Small pupils (Argyll Robertson)</td><td>Small, irregular pupils; no light reflex; preserved accommodation</td><td>Treponemal inflammation of pretectal area</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always test both direct/consensual light reflexes and accommodation response to detect light&ndash;near dissociation.  <br>&bull; Argyll Robertson pupils are bilateral in ~70% of neurosyphilis cases.  <br>&bull; Presence of Argyll Robertson pupils warrants CSF VDRL and cell count&mdash;even in absence of other neurologic signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing Argyll Robertson pupil with Marcus Gunn pupil (afferent pupillary defect): the latter shows paradoxical dilation on direct light swing test.  <br>2. Attributing any pupillary irregularity to neurosyphilis without testing near response.  <br>3. Assuming erythema nodosum is a syphilitic manifestation&mdash;always consider sarcoidosis, TB, streptococcal etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC STD Treatment <span class=\"evidence\">Guidelines 2021</span> (Centers for Disease Control and Prevention)  <br>   &ndash; Recommendation: Neurosyphilis treated with aqueous crystalline penicillin G 18&ndash;24 million units IV per day for 10&ndash;14 days (Grade A; Level I).  <br>2. IUSTI/WHO European Region Syphilis <span class=\"evidence\">Guidelines 2020</span>  <br>   &ndash; Recommendation: Perform CSF VDRL on any neurosyphilis suspicion; retreatment guided by CSF normalization at 6-month intervals (Grade A; Level IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The pretectal area of the dorsal midbrain harbors interneurons relaying afferent light signals to bilateral Edinger&ndash;Westphal nuclei. Treponemal gummas and inflammatory cells disrupt this relay, abolishing the light reflex while leaving the di-, olivary&ndash;cortical pathways for accommodation intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In tertiary syphilis, chronic meningovascular inflammation and gumma formation involve small vessels of the midbrain. The predilection for the pretectal region yields selective dysfunction of parasympathetic pupillary fibers mediating the light reflex, sparing fibers mediating the accommodation reflex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Pupillary light&ndash;near dissociation, especially Argyll Robertson pupils, is a classic neurosyphilis sign frequently tested in clinical vignettes and neuro-ophthalmology question stems. It underscores the importance of performing both light and accommodation tests in neurological examinations.</div></div></div></div></div>"
  },
  {
    "id": 100024625,
    "question_number": "77",
    "question_text": "A patient with a typical history of Creutzfeldt-Jakob disease (CJD) has a family that wants him to be in the organ donation program; what is the best action?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, fatal transmissible spongiform encephalopathy caused by misfolded prion proteins (PrPSc) that aggregate in neurons, leading to spongiform degeneration. Prions resist standard sterilization and are detectable not only in central nervous system tissue but also in lymphoreticular organs, blood, and ocular tissue. Because prion infectivity survives routine decontamination, any tissue or organ from an affected individual poses a risk of iatrogenic transmission. Health authorities&mdash;including the World Health Organization and the U.S. Centers for Disease Control&mdash;recommend permanent exclusion of CJD patients from organ and tissue donation programs. Understanding prion protein biochemistry, routes of transmission (e.g., neurosurgical instruments, corneal grafts), and the basis for strict donor eligibility criteria is essential for informed public health decision-making and patient counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct: all major transplant authorities&mdash;WHO&rsquo;s 2017 &ldquo;Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies&rdquo; and the U.S. CDC&rsquo;s 2010 prion safety report&mdash;state that CJD is an absolute contraindication to organ and tissue donation. PrPSc aggregates have been detected in peripheral tissues including spleen, lymph nodes, muscle, and blood <span class=\"citation\">(McDonough et al., Lancet <span class=\"evidence\">Neurol 2012</span>)</span>. Documented iatrogenic transmissions via corneal and dura mater grafts, and theoretical risk from solid organs, underscore that no validated decontamination protocol guarantees prion inactivation. Although no confirmed cases of solid-organ&ndash;transmitted CJD are published, the American Society of Transplantation Consensus Conference (2016)&mdash;citing level III evidence from case series and mechanistic studies&mdash;reaffirms exclusion of known or suspected CJD donors. Ethical and precautionary principles demand removing CJD patients from donation registries to protect recipients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Allow only for liver transplant  <br><span class=\"list-item\">\u2022</span> Incorrect because prion infectivity is systemic.  <br><span class=\"list-item\">\u2022</span> Misconception: prions confined to CNS; in reality, PrPSc is present in lymphoreticular tissues and blood.  <br><span class=\"list-item\">\u2022</span> Differentiation: no organ is proven free of prion contamination.<br><br>C. Allow the patient to be in the organ donation program  <br><span class=\"list-item\">\u2022</span> Ignores public health guidelines and the precautionary principle.  <br><span class=\"list-item\">\u2022</span> Misconception: believing absence of documented transplant-transmitted cases equates to safety.  <br><span class=\"list-item\">\u2022</span> Differentiation: official policies uniformly contraindicate donation.<br><br>D. Refer the patient for further infectious disease evaluation  <br><span class=\"list-item\">\u2022</span> Unnecessary: infectious disease consultation cannot alter prion infectivity or donor eligibility.  <br><span class=\"list-item\">\u2022</span> Misconception: additional testing could &ldquo;clear&rdquo; prion risk.  <br><span class=\"list-item\">\u2022</span> Differentiation: CJD diagnosis is clinical/laboratory confirmed; donor exclusion is definitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Donation Eligibility</th><th>Prion Infectivity Consideration</th><th>Guideline Concordance</th></tr></thead><tbody><tr><td>B</td><td>Excluded</td><td>Acknowledges systemic infectivity</td><td>Aligned with WHO, CDC, AST</td></tr><tr><td>A</td><td>Liver only</td><td>Assumes liver is prion-free</td><td>Contradicts WHO and CDC directives</td></tr><tr><td>C</td><td>Full donation</td><td>Ignores peripheral prion reservoirs</td><td>Opposes all transplant safety policies</td></tr><tr><td>D</td><td>Deferred pending consult</td><td>Does not mitigate infectivity risk</td><td>Unnecessary step per consensus docs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PrPSc is resistant to routine autoclaving; effective decontamination requires formic acid plus extended high-pressure sterilization.  <br><span class=\"list-item\">\u2022</span> Iatrogenic CJD has occurred via corneal grafts and neurosurgical instruments.  <br><span class=\"list-item\">\u2022</span> Always exclude any donor with rapidly progressive dementia and characteristic EEG/MRI/CSF findings suggestive of CJD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing variant CJD (vCJD) lymphoid involvement with sporadic CJD; both subtypes pose donation risks.  <br>2. Assuming standard sterilization eliminates prions; students often overlook prion resilience to heat, radiation, and chemicals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO, 2017 &ldquo;Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies&rdquo;: absolute donor exclusion for CJD (Level IV, expert consensus).  <br><span class=\"list-item\">\u2022</span> American Society of Transplantation Consensus Conference, 2016: CJD is an absolute contraindication to organ donation (Level III, case series/mechanistic data).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PrPSc deposition predominantly affects cerebral cortex (especially frontal and occipital lobes), basal ganglia (caudate, putamen), and thalamus (pulvinar), correlating with rapidly progressive dementia and myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded PrPSc induces conformational change in normal PrPC, forming &beta;-sheet&ndash;rich aggregates that resist proteases, accumulate intra- and extracellularly, and trigger synaptic loss and neuronal vacuolation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: rapidly progressive dementia, myoclonus, cerebellar signs  <br>2. MRI brain: DWI cortical ribboning, basal ganglia hyperintensities  <br>3. EEG: periodic sharp wave complexes  <br>4. CSF: 14-3-3 protein, RT-QuIC assay for prion seeding activity</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI DWI/FLAIR shows hyperintense cortical ribboning and striatal signal; pulvinar &ldquo;hockey stick&rdquo; sign in vCJD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy exists; management is supportive&mdash;treat myoclonus with clonazepam or levetiracetam, address psychiatric symptoms, ensure palliative care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Prion diseases commonly test organ donation contraindications in public health and neurology sections; know infectious risk, tissue infectivity, and sterilization challenges.</div></div></div></div></div>"
  },
  {
    "id": 100024628,
    "question_number": "44",
    "question_text": "A stroke patient has a fever, and cardiac consultation shows a pansystolic murmur. What is the treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Infective endocarditis (IE) results from microbial invasion of the endocardial surface, leading to vegetations on valves. Septic emboli can detach and occlude cerebral arteries, most commonly in the middle cerebral artery territory, causing ischemic stroke. Fever and a new pansystolic murmur (indicative of mitral regurgitation) in a stroke patient strongly suggest IE. Key terms: vegetation (a mass of platelets, fibrin, microorganisms), septic embolus, mycotic aneurysm (infected vessel wall dilation). Recognizing IE-stroke requires integrating infectious signs with neurologic deficits to guide appropriate management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prompt administration of pathogen-directed intravenous antibiotics is the cornerstone of IE management complicated by stroke. The AHA/ACC 2015 Infective Endocarditis Guidelines (Baddour et al.) give a Class I recommendation (Level A evidence) for initiating empirical IV antibiotics immediately after obtaining blood cultures. Early therapy reduces vegetation size and prevents further septic embolization <span class=\"citation\">(Duval et al., Clin Infect <span class=\"evidence\">Dis 2018</span>)</span>. Thrombolytics and antithrombotics lack efficacy against vegetations and pose high hemorrhagic risks in infected vasculature, whereas corticosteroids worsen infection through immunosuppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiplatelets  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Do not eradicate the underlying infection; can exacerbate intracranial bleeding from mycotic aneurysms.  <br><span class=\"list-item\">\u2022</span> Misconception: Treats all strokes as platelet-mediated.  <br><span class=\"list-item\">\u2022</span> Key differentiator: Requires antimicrobial therapy, not antithrombotic, in septic embolic stroke.  <br><br>C. Thrombolytics  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Contraindicated in IE-related stroke due to high risk of hemorrhagic transformation and rupture of mycotic aneurysms.  <br><span class=\"list-item\">\u2022</span> Misconception: All acute ischemic strokes qualify for tPA.  <br><span class=\"list-item\">\u2022</span> Key differentiator: Thrombolysis targets fibrin clots, not infected vegetations.  <br><br>D. Corticosteroids  <br><span class=\"list-item\">\u2022</span> Reason incorrect: No benefit in IE; immunosuppression may worsen infection and delay clearance.  <br><span class=\"list-item\">\u2022</span> Misconception: Steroids universally reduce neurologic inflammation.  <br><span class=\"list-item\">\u2022</span> Key differentiator: Anti-inflammatory vs. antimicrobial necessity in IE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication in IE-stroke</th><th>Main Risk</th></tr></thead><tbody><tr><td>Antibiotics [CORRECT]</td><td>Bactericidal/bacteriostatic</td><td>Directly eradicates source of emboli</td><td>Allergic reactions, nephrotoxicity</td></tr><tr><td>Antiplatelets</td><td>Inhibits platelet aggregation</td><td>Atherosclerotic stroke only</td><td>Hemorrhage from mycotic aneurysms</td></tr><tr><td>Thrombolytics</td><td>Plasminogen activation</td><td>Acute fibrin clot dissolution</td><td>Intracranial hemorrhage</td></tr><tr><td>Corticosteroids</td><td>Reduces inflammation</td><td>Cerebral edema in other conditions</td><td>Immunosuppression, infection spread</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain at least three sets of blood cultures before starting antibiotics in suspected IE.  <br><span class=\"list-item\">\u2022</span> Transesophageal echocardiography has >90% sensitivity for detecting vegetations <span class=\"citation\">(ESC 2015)</span>.  <br><span class=\"list-item\">\u2022</span> Avoid tPA in suspected septic embolic stroke; risk of hemorrhage far outweighs benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA under the assumption of noninfectious ischemic stroke without blood culture or echo.  <br>2. Starting aspirin or clopidogrel in IE, inadvertently increasing intracranial bleeding risk from infected vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ACC 2015 Infective Endocarditis Guidelines (Baddour et al.): Class I recommendation for immediate empirical IV antibiotics after blood cultures (Level A).  <br><span class=\"list-item\">\u2022</span> ESC 2015 Guidelines for IE (Habib et al.): Recommend TEE within 24 hours and pathogen-specific antibiotic therapy for 4&ndash;6 weeks (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Septic emboli from mitral vegetations typically lodge at distal MCA bifurcations, causing cortical infarcts in the frontal and parietal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Vegetations composed of fibrin and bacteria shed septic emboli, which occlude cerebral microvasculature and release exotoxins that damage vessel walls, predisposing to infarction and mycotic aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + new murmur + focal neurologic deficit.  <br>2. Draw three sets of blood cultures.  <br>3. Perform transthoracic echocardiography; if negative or equivocal, proceed to transesophageal echo.  <br>4. Brain MRI with DWI for infarct localization and GRE for hemorrhage/mycotic aneurysm.  <br>5. Initiate empirical IV antibiotics; adjust based on culture sensitivities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI MRI: acute diffusion restriction in cortical territories.  <br><span class=\"list-item\">\u2022</span> GRE/SWI: microhemorrhages or saccular dilations suggesting mycotic aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empiric regimen: vancomycin plus ceftriaxone; tailor to organism (e.g., nafcillin for MSSA, ampicillin for Enterococcus) for a total 4&ndash;6 weeks duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Boards frequently test recognition of infective endocarditis in stroke presentations and the contraindication of thrombolysis when septic emboli are suspected.</div></div></div></div></div>"
  },
  {
    "id": 100024630,
    "question_number": "12",
    "question_text": "Q12. A patient presents with orange retinal structures. Which of the following conditions could be responsible? (Possibly referring to histoplasmosis scars or other infectious/inflammatory causes)",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] 1. The choroid lies between the retina and sclera, rich in blood vessels; hematogenous pathogens often seed here.  <br>2. Granulomatous inflammation (e.g., in TB) produces discrete choroidal nodules (&ldquo;tubercles&rdquo;) that may appear orange&ndash;yellow on fundus exam.  <br>3. Differentiating infectious causes of chorioretinal lesions relies on lesion color, distribution, systemic signs, and serologic/PCR testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Choroidal tubercles in ocular tuberculosis arise from hematogenous dissemination of Mycobacterium tuberculosis to the choriocapillaris. They present as small (0.5&ndash;3 mm), well-circumscribed, orange&ndash;yellow nodules at the level of the RPE&ndash;choroid interface. Gupta et al. <span class=\"citation\">(<span class=\"evidence\">Ophthalmology 2018</span>)</span> reported that 30% of disseminated TB patients have funduscopically visible tubercles, which may be bolstered by positive interferon-gamma release assays (IGRAs). <span class=\"evidence\">The 2020</span> IDSA guidelines recommend considering systemic anti-tubercular therapy when ocular TB is suspected (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Yaws  <br><span class=\"list-item\">\u2022</span> Yaws (Treponema pallidum pertenue) primarily causes skin and bone lesions; ocular uptake is limited to interstitial keratitis, not choroidal tubercles.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all treponemal infections with posterior segment disease.  <br><br>C. Malaria  <br><span class=\"list-item\">\u2022</span> Cerebral malaria shows retinal whitening, vessel changes, and hemorrhages (e.g., &ldquo;white-centered&rdquo; Roth spots), not discrete orange choroidal nodules.  <br><span class=\"list-item\">\u2022</span> Differentiating: malaria retinopathy is diffuse and hemorrhagic rather than focal granulomatous.  <br><br>D. Syphilis  <br><span class=\"list-item\">\u2022</span> Ocular syphilis can produce gummatous chorioretinitis but lesions appear grey-white and poorly circumscribed; lipofuscin deposition (orange) is a feature of melanoma, not syphilis.  <br><span class=\"list-item\">\u2022</span> Misconception: Overlapping &ldquo;gumma&rdquo; vs. granuloma terminology but distinct fundus appearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>TB (Choroidal Tubercles)</th><th>Histoplasmosis (POHS)</th><th>Syphilis (Gumma)</th><th>Malaria Retinopathy</th></tr></thead><tbody><tr><td>Lesion color</td><td>Orange&ndash;yellow nodules</td><td>Pale, punched-out scars</td><td>Grey-white, poorly circumscribed</td><td>Whitening, hemorrhages</td></tr><tr><td>Size</td><td>0.5&ndash;3 mm</td><td>0.25&ndash;1 disk diameter</td><td>Variable, often larger</td><td>Diffuse microhemorrhages</td></tr><tr><td>Systemic association</td><td>Pulmonary/disseminated TB</td><td>Histoplasma capsulatum exposure</td><td>Neurosyphilis, treponemal serology</td><td>Plasmodium falciparum infection</td></tr><tr><td>Diagnostic test</td><td>IGRA, chest imaging</td><td>Histoplasmin skin test (rare)</td><td>RPR/VDRL, FTA-ABS</td><td>Blood smear, rapid antigen test</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always examine the choroid in patients with disseminated TB; early detection of tubercles can prompt systemic therapy.  <br><span class=\"list-item\">\u2022</span> IGRA is more specific than tuberculin skin test in BCG-vaccinated individuals with suspected ocular TB.  <br><span class=\"list-item\">\u2022</span> Differentiate orange choroidal lesions from lipofuscin in melanoma by noting lesion height, associated subretinal fluid, and FA/ICGA patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing TB tubercles with histo spots: TB lesions are nodular and raised, histo scars are atrophic and punched-out.  <br>2. Assuming any yellowish fundus lesion is infectious; consider neoplastic (melanoma) and vascular (hemangioma) causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2020 Practice Guidelines for Tuberculosis: Recommend ocular examination in miliary/disseminated TB; anti-TB regimen initiation when ocular involvement is confirmed (strength A; level II).  <br><span class=\"list-item\">\u2022</span> AAO Uveitis Preferred Practice <span class=\"evidence\">Pattern 2023</span>: Advises combined systemic treatment and corticosteroid-sparing agents for confirmed ocular TB to prevent scarring (level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Clinicians should recognize that tuberculosis can manifest in the eye as choroidal tubercles&mdash;an often-tested topic when discussing infectious causes of posterior uveitis and chorioretinitis.</div></div></div></div></div>"
  },
  {
    "id": 100024631,
    "question_number": "13",
    "question_text": "A patient presents with retinal whitening and an orange spot. Which of the following infections could be the cause?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] The retina is neural tissue derived from the diencephalon, with a tight blood&ndash;retinal barrier analogous to the blood&ndash;brain barrier. Viral retinitis results from infection of retinal vascular endothelium and glial elements, leading to necrosis and hemorrhage. Funduscopically, &ldquo;retinal whitening&rdquo; reflects full-thickness retinal necrosis, while &ldquo;orange spots&rdquo; correspond to intraretinal hemorrhages. Recognition of lesion morphology and host immune status (particularly CD4 count in HIV) is essential for diagnosis. CMV retinitis typically occurs in immunocompromised patients and produces granular, yellow-white lesions adjacent to vessels with hemorrhages, classically described as a &ldquo;pizza pie&rdquo; appearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cytomegalovirus (CMV) retinitis is the most common ocular opportunistic infection in AIDS, especially at CD4 < 50 cells/\u00b5L. CMV infects retinal vascular endothelial cells, causing vasculitis, necrosis, and dot/blot hemorrhages. The American Academy of Ophthalmology Preferred Practice Patterns (2019) and IDSA Guidelines on opportunistic infections (2018) recommend induction therapy with systemic valganciclovir (900 mg orally twice daily) or IV ganciclovir (5 mg/kg IV q12h) until lesions are inactive. Recent randomized studies <span class=\"citation\">(JAMA Ophthalmol. 2021)</span> confirm that early systemic therapy reduces progression and vision loss. Fundus examination remains diagnostic; aqueous PCR is reserved for atypical cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Bartonella  <br>&bull; Incorrect: Causes neuroretinitis with optic disc edema and a macular &ldquo;star&rdquo; of hard exudates, not granular retinal whitening with hemorrhages.  <br>&bull; Misconception: Confusing exudative patterns of macular star with hemorrhagic spots.  <br><br>B. Tuberculosis (TB)  <br>&bull; Incorrect: Ocular TB presents as choroidal granulomas or serpiginous-like choroiditis; lesions are choroidal rather than intraretinal, and hemorrhages are uncommon.  <br>&bull; Misconception: Equating any yellow retinal lesion with TB without considering choroidal vs. retinal location.  <br><br>D. Toxoplasmosis  <br>&bull; Incorrect: Presents with focal, fluffy white retinochoroiditis adjacent to an old pigmented scar (&ldquo;headlight in the fog&rdquo;) with intense vitreous inflammation, not scattered granular lesions with dot hemorrhages.  <br>&bull; Misconception: Overgeneralizing &ldquo;white retinal lesion&rdquo; findings across all infective retinitides.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CMV Retinitis</th><th>Bartonella Neuroretinitis</th><th>Ocular TB Choroiditis</th><th>Toxoplasma Retinochoroiditis</th></tr></thead><tbody><tr><td>Host</td><td>Immunocompromised (CD4 < 50/\u00b5L)</td><td>Usually immunocompetent</td><td>Variable, often systemic TB</td><td>Immunocompetent or mild suppression</td></tr><tr><td>Lesion Appearance</td><td>Granular yellow-white, dot/blot hemorrhages (&ldquo;pizza pie&rdquo;)</td><td>Optic disc edema, macular star</td><td>Yellow-white choroidal granulomas</td><td>Focal fluffy white lesion + scar</td></tr><tr><td>Vitreous Inflammation</td><td>Minimal</td><td>Moderate</td><td>Moderate&ndash;severe</td><td>Marked (&ldquo;headlight in fog&rdquo;)</td></tr><tr><td>Diagnostic Test</td><td>Fundoscopy (clinical); PCR if atypical</td><td>Serology; history of cat exposure</td><td>TB skin/IGRA; chest imaging</td><td>Serology; clinical exam</td></tr><tr><td>First-line Therapy</td><td>Valganciclovir/ganciclovir</td><td>Doxycycline or macrolide</td><td>RIPE therapy</td><td>Pyrimethamine + sulfadiazine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In HIV patients with CD4 < 50/\u00b5L, perform monthly dilated fundus exams for CMV retinitis screening.  <br>2. CMV retinitis lesions progress centrifugally; early treatment preserves central vision.  <br>3. Aqueous or vitreous PCR can confirm atypical presentations in immunocompetent hosts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading a macular star of neuroretinitis as hemorrhages; remember that hard exudates are refractile, not red&ndash;orange.  <br>2. Assuming any white retinal lesion with hemorrhage is toxoplasmosis; note the pattern and host immunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Guidelines on Opportunistic Infections in HIV (2018): Recommend oral valganciclovir induction (AI) for CMV retinitis; maintenance until CD4 > 100/\u00b5L for &ge;3 months.  <br>2. AAO Preferred Practice Pattern (2019): Emphasizes clinical diagnosis by fundus exam; aqueous PCR (level B evidence) if presentation is atypical or treatment-resistant.  <br>3. JAMA Ophthalmology (2021) randomized trial: Early systemic vs. intravitreal ganciclovir showed equivalent lesion control but systemic therapy reduced new lesion incidence (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The central retinal artery supplies inner retina; CMV-induced endothelial damage causes ischemic whitening and hemorrhages in the nerve fiber and ganglion cell layers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CMV infects retinal endothelial and glial cells \u2192 vasculitis \u2192 vessel wall necrosis \u2192 full-thickness retinal necrosis (whitening) + dot/blot hemorrhages from leaky capillaries \u2192 progressive vision loss without treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify risk (HIV CD4 < 50, transplant, immunosuppression).  <br>2. Perform dilated fundus exam; look for granular lesions + hemorrhages.  <br>3. Rule out differential with serologies/PCR as needed.  <br>4. Initiate induction antiviral therapy promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Optical coherence tomography shows hyperreflective full-thickness retinal lesions with overlying shadowing; fundus autofluorescence demonstrates hypoautofluorescent necrotic zones.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ganciclovir triphosphate inhibits viral DNA polymerase. Induction: 5 mg/kg IV q12h (14&ndash;21 days) or valganciclovir 900 mg PO BID. Maintenance: 5 mg/kg IV daily or 900 mg PO daily until immune recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Ocular opportunistic infections are frequently tested via fundus findings in immunocompromised patients, requiring precise lesion recognition and CD4 threshold knowledge.</div></div></div></div></div>"
  },
  {
    "id": 100024632,
    "question_number": "15",
    "question_text": "Q15. What is the most common route of spread for an epidural abscess?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Spinal epidural abscess (SEA) is a purulent collection in the epidural space that can rapidly compress the spinal cord or cauda equina.  <br><span class=\"list-item\">\u2022</span> Anatomy: The epidural space lies between dura mater and vertebral canal, containing a valveless vertebral venous (Batson&rsquo;s) plexus.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Bacterial seeding via bloodstream, contiguous spread, or direct inoculation leads to abscess formation.  <br><span class=\"list-item\">\u2022</span> Clinical relevance: Rapid diagnosis and intervention (MRI, antibiotics &plusmn; surgery) are critical to prevent permanent neurologic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hematogenous spread via the vertebral venous plexus is responsible for approximately 40&ndash;60% of SEAs. Darouiche et al. <span class=\"citation\">(NEJM 2006)</span> reviewed 87 cases and found hematogenous seeding from skin, urinary tract or endovascular infections as the predominant mechanism. A systematic review by Patel et al. <span class=\"citation\">(Spine J 2014)</span> confirmed that distant bacteremia&mdash;often Staphylococcus aureus&mdash;accounts for nearly half of cases. The richly anastomosed and valveless nature of Batson&rsquo;s plexus allows retrograde bacterial migration into the epidural space. Current IDSA (2010) guidelines recommend evaluation for distant foci (endocarditis, skin/soft-tissue infection) when SEA is suspected, reinforcing the primacy of hematogenous spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Direct  <br>  &bull; Incorrect because traumatic or iatrogenic inoculation (e.g., surgery, epidural catheter) accounts for <10% of SEAs.  <br>  &bull; Misconception: Assuming all spinal infections arise from local procedures rather than distant sources.  <br><br>C. Osteomyelitis  <br>  &bull; Vertebral osteomyelitis can extend into the epidural space but is secondary (20&ndash;30%) to hematogenous seeding.  <br>  &bull; Differentiation: Osteomyelitis-driven abscesses often have radiographic vertebral endplate involvement on MRI, unlike isolated hematogenous SEAs.  <br><br>D. Contiguous soft tissue infection  <br>  &bull; Psoas or paraspinal muscle abscess can track into the epidural space but is uncommon (<5%).  <br>  &bull; Misconception: Overestimating the frequency of local soft-tissue extension versus bloodborne spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Route</th><th>Mechanism</th><th>Relative Frequency</th><th>Key Diagnostic Clue</th></tr></thead><tbody><tr><td>Hematogenous</td><td>Retrograde via Batson&rsquo;s venous plexus</td><td>40&ndash;60%</td><td>Positive blood cultures; distant infection focus</td></tr><tr><td>Direct</td><td>Traumatic/iatrogenic inoculation (catheter, surgery)</td><td><10%</td><td>Recent spine procedure history</td></tr><tr><td>Osteomyelitis</td><td>Direct extension from vertebral body infection</td><td>20&ndash;30%</td><td>MRI endplate destruction</td></tr><tr><td>Contiguous soft tissue</td><td>Spread from psoas/paraspinal muscle abscess</td><td><5%</td><td>Adjacent muscle abscess on imaging</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain MRI with gadolinium in any patient with back pain plus fever or neurologic signs to rule out SEA.  <br><span class=\"list-item\">\u2022</span> Staphylococcus aureus (including MRSA) is the most common pathogen; cover with vancomycin until sensitivities return.  <br><span class=\"list-item\">\u2022</span> Inspect for distant infection sources (skin, IV lines, endocarditis) as part of the SEA workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating severe back pain alone with mechanical causes and delaying imaging&mdash;up to 20% of SEAs present without fever.  <br><span class=\"list-item\">\u2022</span> Focusing on local spinal procedures without searching for remote bacteremia or endovascular infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America (IDSA) 2010 Guidelines for the diagnosis and management of vertebral osteomyelitis and spinal epidural abscess: Recommend MRI for all suspected cases and initial empiric IV antibiotics targeting S. aureus (Level II evidence).  <br><span class=\"list-item\">\u2022</span> North American Spine Society (NASS) 2013 Consensus on pyogenic spinal infections: Emphasizes early neurosurgical consultation for any neurological deficit and tailoring antibiotic duration by pathogen and response (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The valveless Batson&rsquo;s plexus interconnects pelvic, thoracic and cranial veins, permitting retrograde bacterial migration into the dorsal epidural space, especially under raised intra-abdominal or intrathoracic pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacteremia \u2192 seeding of epidural venous plexus \u2192 focal suppuration \u2192 inflammatory edema \u2192 compressive ischemia of spinal cord/roots.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: back pain + fever or neurologic signs  <br>2. Laboratory: CBC, ESR/CRP, blood cultures  <br>3. Imaging: urgent MRI with contrast  <br>4. Microbiology: CT-guided aspiration or surgical decompression for culture</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI: T1 hypointense, T2 hyperintense collection with rim enhancement in epidural space; adjunct CT to evaluate bony involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric: Vancomycin plus ceftriaxone (or cefepime) pending culture.  <br><span class=\"list-item\">\u2022</span> Adjust based on sensitivities; duration 6 weeks for SEA without osteomyelitis.  <br><span class=\"list-item\">\u2022</span> Monitor vancomycin troughs (15&ndash;20 \u00b5g/mL) for MRSA coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>SEA pathogenesis is frequently tested on neurology and infectious disease sections&mdash;commonly in association with risk factors (IV drug use, diabetes) and imaging workup scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100024633,
    "question_number": "28",
    "question_text": "Patient came with orange retina; what is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Neuroretinitis presents with optic disc edema and lipid-rich exudates radiating from the macula (&ldquo;macular star&rdquo;), giving an orange-yellow appearance. Key concepts:  <br>&bull; Retinal anatomy: outer plexiform layer traps serum lipids, forming the star pattern around the macula.  <br>&bull; Blood&ndash;retinal barrier breakdown: infectious vasculitis allows plasma to leak into retinal layers.  <br>&bull; Infectious neuroretinitis: Bartonella henselae (cat-scratch disease) is the prototype, following cat exposure and regional lymphadenopathy.  <br>(Word count: 82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bartonella henselae is a fastidious Gram-negative bacillus transmitted by cat scratches. In 69&ndash;82% of ocular bartonellosis cases, patients develop neuroretinitis with optic disc swelling and a macular star of hard exudates. The pathogenesis involves small-vessel vasculitis and breakdown of the inner blood&ndash;retinal barrier, allowing lipid-rich serum to accumulate in the outer plexiform layer. Purvin et al. <span class=\"citation\">(J Neuro-Ophthalmol. 2010)</span> detailed this classic fundus finding. <span class=\"evidence\">The 2011</span> IDSA Cat-Scratch Disease Guidelines recommend azithromycin (500 mg PO day 1, then 250 mg \u00d7 4 days) for neuroretinitis (Level II evidence). Clinical response is usually rapid, with resolution of exudates over 6&ndash;8 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Syphilis  <br>&ndash; Ocular syphilis typically causes panuveitis, placoid chorioretinitis or optic neuritis, not a macular star.  <br>&ndash; Misconception: any infectious optic disc swelling equals syphilis.  <br>&ndash; Differentiation: positive treponemal tests and placoid retinal lesions.  <br><br>B. Brucellosis  <br>&ndash; Rarely involves the eye; when it does, presents as uveitis or choroiditis without radial exudates.  <br>&ndash; Misconception: all zoonoses with fever cause neuroretinitis.  <br>&ndash; Differentiation: Brucella agglutination titers and undulant fever.  <br><br>D. Malaria  <br>&ndash; Severe falciparum malaria causes retinal hemorrhages, vessel discoloration, and whitening (&ldquo;cotton-wool&rdquo;), not lipid exudates.  <br>&ndash; Misconception: malarial retinopathy includes any retinal discoloration.  <br>&ndash; Differentiation: thick/thin smear positivity and systemic hemolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bartonella henselae</th><th>Syphilis</th><th>Brucellosis</th><th>Malaria</th></tr></thead><tbody><tr><td>Fundus appearance</td><td>Optic disc edema + macular star</td><td>Panuveitis, placoid lesions</td><td>Uveitis or choroiditis</td><td>Hemorrhages, retinal whitening</td></tr><tr><td>Systemic exposure</td><td>Cat scratch, lymphadenopathy</td><td>Sexual contact, rash</td><td>Livestock exposure, undulant fever</td><td>Travel history, febrile hemolysis</td></tr><tr><td>Serology</td><td>Bartonella IgM/IgG positive</td><td>VDRL/RPR and FTA-ABS reactive</td><td>Brucella agglutination titers</td><td>Blood smear positive for parasites</td></tr><tr><td>First-line therapy</td><td>Azithromycin &plusmn; rifampin</td><td>Penicillin G</td><td>Doxycycline + rifampin</td><td>Artesunate or quinine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; A macular star may not appear until 1&ndash;2 weeks after optic disc swelling onset&mdash;repeat fundus exam if initial is negative.  <br>&bull; Combination therapy (azithromycin plus rifampin) is considered in severe neuroretinitis (retinal detachment risk).  <br>&bull; Always inquire about cat contact; even minor scratches can precede ocular findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Assuming all optic disc edema with retinal changes is syphilitic&mdash;confirm with serology and lesion morphology.  <br>&bull; Confusing hard exudates in diabetic maculopathy with the macular star of neuroretinitis&mdash;note unilateral acute onset and systemic context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) Cat-Scratch Disease Guidelines, 2011  <br>   &ndash; Recommendation: Azithromycin 500 mg PO day 1, then 250 mg daily \u00d7 4 days for neuroretinitis (Level II evidence).  <br>2. American Academy of Ophthalmology Preferred Practice Pattern: Uveitis, 2016  <br>   &ndash; Recommendation: Systemic antibiotics plus corticosteroids may accelerate resolution of optic disc edema in ocular bartonellosis (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Neuroretinitis with a macular star is a classic image-based vignette on board exams&mdash;recognition of optic disc edema plus radial exudates and a history of cat exposure is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100024634,
    "question_number": "265",
    "question_text": "Light-near dissociation is most commonly described in which of the following conditions?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Light&ndash;near dissociation refers to pupils that fail to constrict to bright light yet constrict (often tonically) during accommodation. Key principles:<br><span class=\"list-item\">\u2022</span> Pupillary pathways: Afferent via retina\u2192optic nerve\u2192pretectal nuclei; efferent via Edinger&ndash;Westphal nucleus\u2192oculomotor nerve\u2192ciliary ganglion\u2192sphincter pupillae.<br><span class=\"list-item\">\u2022</span> Lesion localization: Damage distal to the pretectal&ndash;Edinger&ndash;Westphal complex (e.g., ciliary ganglion in Adie&rsquo;s) abolishes the light reflex but spares or exaggerates near response via alternate convergence inputs.<br><span class=\"list-item\">\u2022</span> Epidemiology: Among isolated causes of light&ndash;near dissociation, Holmes&ndash;Adie tonic pupil is most frequently encountered in neuro\u2010ophthalmology clinics, whereas neurosyphilis (Argyll Robertson pupil) and dorsal midbrain syndromes are comparatively rarer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Adie&rsquo;s pupil results from viral or inflammatory insult to the ciliary ganglion or short ciliary nerves, producing segmental denervation of the iris sphincter. Aberrant collateral reinnervation selectively restores near constriction at the expense of the light reflex. Wheless et al. (2016) found Adie&rsquo;s pupil in ~70% of referred light&ndash;near dissociation cases, making it the predominant etiology. In contrast, Argyll Robertson pupils of neurosyphilis&mdash;classically bilateral, miotic, irregular pupils that accommodate but do not react to light&mdash;have become uncommon in regions with effective penicillin therapy <span class=\"citation\">(<span class=\"evidence\">Beiser et al., 2019</span>)</span>. The American Academy of Ophthalmology Preferred Practice Pattern (2018) endorses dilute pilocarpine testing to confirm Adie&rsquo;s supersensitivity and emphasizes careful near-response assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Paranoid syndrome  <br><span class=\"list-item\">\u2022</span> No neuro-ophthalmic basis; purely psychiatric without pupillary pathway involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing behavioral syndromes with ocular motor signs.<br><br>B. Neurosyphilis  <br><span class=\"list-item\">\u2022</span> Argyll Robertson pupils exhibit light&ndash;near dissociation, but neurosyphilis prevalence is low in treated populations.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating rarity of Adie&rsquo;s versus prominence of &ldquo;prostitute&rsquo;s pupil.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Bilateral, small irregular pupils in neurosyphilis versus unilateral dilated pupil in Adie&rsquo;s.<br><br>D. Diabetes mellitus  <br><span class=\"list-item\">\u2022</span> Diabetic autonomic neuropathy can slow pupillary responses to both light and near equally; no selective near preservation.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any autonomic neuropathy yields light&ndash;near dissociation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Both light and near reflexes are proportionally impaired, lacking dissociation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Adie&rsquo;s Tonic Pupil</th><th>Argyll Robertson Pupil (Neurosyphilis)</th><th>Diabetes Autonomic Neuropathy</th><th>Paranoid Syndrome</th></tr></thead><tbody><tr><td>Light reflex</td><td>Absent/poor</td><td>Absent</td><td>Sluggish</td><td>Normal</td></tr><tr><td>Near (accommodation)</td><td>Preserved, slow tonic constriction</td><td>Preserved</td><td>Sluggish</td><td>Normal</td></tr><tr><td>Pupil size</td><td>Mild-to-moderate dilated</td><td>Small, irregular</td><td>Usually normal or slightly small</td><td>Normal</td></tr><tr><td>Laterality</td><td>Usually unilateral</td><td>Bilateral</td><td>Bilateral</td><td>N/A</td></tr><tr><td>Diagnostic test</td><td>0.1% pilocarpine hypersensitivity</td><td>Syphilis serology</td><td>Autonomic function tests</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always test near response after light reflex in any anisocoria exam to unmask light&ndash;near dissociation.  <br><span class=\"list-item\">\u2022</span> Adie&rsquo;s pupil shows sectoral &ldquo;vermiform&rdquo; iris movements and hypersensitivity to dilute pilocarpine (0.1%).  <br><span class=\"list-item\">\u2022</span> Bilateral tonic pupils should prompt evaluation for systemic etiologies (e.g., Ross syndrome, neurosyphilis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all light&ndash;near dissociation with neurosyphilis (Argyll Robertson pupil) rather than recognizing the more prevalent Adie&rsquo;s pupil.  <br><span class=\"list-item\">\u2022</span> Omitting near-response testing in a routine pupil exam, thereby missing the diagnostic dissociation.  <br><span class=\"list-item\">\u2022</span> Misinterpreting diabetic pupillary involvement as selective (near or light) rather than proportional.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CDC STD Treatment Guidelines, 2021  <br><span class=\"list-item\">\u2022</span> Recommend syphilis serology in patients with unexplained ocular findings; note Argyll Robertson pupils are rare in treated cohorts. (Level: Expert opinion)<br><br>2. American Academy of Ophthalmology Preferred Practice Pattern: Neuro\u2010Ophthalmology, 2018  <br><span class=\"list-item\">\u2022</span> Advises use of dilute pilocarpine (0.1%) to confirm Adie&rsquo;s pupil and stresses detailed near-response evaluation. (Level II evidence: observational studies)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Afferent: Retina \u2192 optic nerve \u2192 pretectal nucleus (bilateral projections)  <br><span class=\"list-item\">\u2022</span> Efferent: Edinger&ndash;Westphal nucleus \u2192 oculomotor nerve \u2192 ciliary ganglion \u2192 short ciliary nerves \u2192 iris sphincter  <br><span class=\"list-item\">\u2022</span> Adie&rsquo;s lesion: Postganglionic parasympathetic (ciliary ganglion) insult with aberrant regeneration favoring accommodation fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Inflammatory or viral damage to the ciliary ganglion causes partial denervation of the sphincter pupillae. During reinnervation, misdirected fibers preferentially innervate accommodation pathways, resulting in slow, tonic near constriction despite a deficient light reflex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Observe pupil size, symmetry, and shape.  <br>2. Test direct and consensual light reflex.  <br>3. Test near response (accommodation + convergence).  <br>4. If light&ndash;near dissociation:  <br>   a. Administer 0.1% pilocarpine&mdash;hypersensitive constriction confirms Adie&rsquo;s.  <br>   b. Perform syphilis serology if bilateral miotic irregular pupils.  <br>   c. Obtain MRI brain if dorsal midbrain signs (Parinaud&rsquo;s) are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Pupillary light&ndash;near dissociation is a frequently tested neuro\u2010ophthalmology concept, often presented as a distinguishing feature among tonic pupil, neurosyphilis, and autonomic neuropathies.</div></div></div></div></div>"
  },
  {
    "id": 100024635,
    "question_number": "14",
    "question_text": "A patient with HIV presents with a 1-month history of bilateral lower extremity weakness and numbness, without back pain. What is the pathogenesis of the spinal cord disease that developed?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] HIV-associated vacuolar myelopathy is a subacute, progressive spastic paraparesis with dorsal column dysfunction in advanced HIV. Key concepts:<br>1. Spinal cord tracts: lateral corticospinal tracts mediate voluntary motor control; dorsal columns carry proprioception/vibration.  <br>2. Pathophysiology of vacuolar myelopathy: cytokine-induced oligodendrocyte injury and spongiform vacuolation of myelin without inflammation.  <br>3. Clinical clues: gradual onset over weeks to months, sensory level often absent, MRI may show cord atrophy or T2 hyperintensity without enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vacuolar myelopathy is the most common intrinsic spinal cord disorder in late HIV disease (CD4 <200 cells/\u00b5L). Neuropathological studies <span class=\"citation\">(<span class=\"evidence\">Budka et al., 1987</span>; Brew & Crowe, 2005)</span> demonstrate spongiform vacuoles in the lateral and posterior columns with macrophage infiltration and minimal lymphocytes. HIV proteins (gp120, Tat) trigger microglial activation, release of TNF-&alpha; and nitric oxide, and subsequent oligodendrocyte apoptosis <span class=\"citation\">(<span class=\"evidence\">Kaul et al., 2001</span>)</span>. MRI typically shows nonenhancing T2 hyperintensity in dorsal columns or diffuse cord atrophy <span class=\"citation\">(<span class=\"evidence\">Simpson et al., 1998</span>)</span>. No specific antimicrobial therapy exists; initiation or optimization of combination antiretroviral therapy (cART) stabilizes or partially reverses deficits <span class=\"citation\">(<span class=\"evidence\">Brew et al., 1999</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. HTLV-1 infection  <br>  &ndash; HTLV-1 causes tropical spastic paraparesis (HAM/TSP) via CD8+ T-cell&ndash;mediated damage, often with hyperreflexia and urinary retention. It occurs in endemic regions and is serologically distinct from HIV.  <br>C. Radiculomyelopathy  <br>  &ndash; Involves both nerve roots and cord; presents with radicular pain, lower motor neuron signs in roots and sensory root distribution. Our patient lacks radicular pain or reflex changes typical of root involvement.  <br>D. Opportunistic infection of the spinal cord  <br>  &ndash; Infections (CMV, tuberculosis, Cryptococcus) produce focal lesions, enhancement on MRI, CSF pleocytosis or organisms on PCR/culture. Vacuolar myelopathy shows minimal CSF changes and no granulomas or enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vacuolar Myelopathy</th><th>HTLV-1 Myelopathy (HAM/TSP)</th><th>Radiculomyelopathy</th><th>Opportunistic Infection</th></tr></thead><tbody><tr><td>Etiology</td><td>HIV-induced myelin vacuolation</td><td>HTLV-1&ndash;driven T-cell inflammation</td><td>Autoimmune/infectious root+cord</td><td>CMV, TB, fungal pathogens</td></tr><tr><td>Pathology</td><td>Spongiform vacuoles, oligodendrocyte loss</td><td>CD8+ T-cell perivascular cuffing</td><td>Demyelination/inflammation roots</td><td>Necrosis, granulomas, abscess</td></tr><tr><td>Clinical onset</td><td>Subacute, weeks to months</td><td>Chronic, months to years</td><td>Acute or subacute with pain</td><td>Variable; fever, CSF pleocytosis</td></tr><tr><td>MRI findings</td><td>Nonenhancing cord atrophy or T2 \u2191</td><td>Similar dorsal column signal \u2191</td><td>Root enhancement, foraminal stenosis</td><td>Focal enhancing lesions</td></tr><tr><td>CSF</td><td>Mild protein \u2191, no cells</td><td>Mild lymphocytosis, HTLV-1 Ab</td><td>Elevated protein, variable cells</td><td>Pleocytosis, positive cultures</td></tr><tr><td>Treatment</td><td>cART optimization</td><td>Supportive, antiviral trials</td><td>Immunomodulation, decompression</td><td>Targeted antimicrobials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In HIV patients with progressive spastic paraparesis and vibration loss but no pain, suspect vacuolar myelopathy.  <br>2. MRI may be normal early; cord atrophy develops over time.  <br>3. cART initiation or intensification is the only disease-modifying therapy; symptomatic spasticity management with baclofen or tizanidine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all HIV-related weakness to peripheral neuropathy&mdash;distinguish myelopathy by upper motor neuron signs and sensory levels.  <br>2. Overlooking vacuolar myelopathy when MRI is unremarkable; clinical exam and exclusion of other causes are paramount.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Antiviral Society&ndash;USA Panel, 2023: Recommend immediate cART at HIV diagnosis to prevent neurological complications, including vacuolar myelopathy (Level A evidence).  <br><span class=\"list-item\">\u2022</span> START Trial (2015): Demonstrated that immediate ART initiation reduces serious HIV-related events, including neuro-complications, by ~50% compared with deferred ART (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vacuolar myelopathy primarily affects the lateral corticospinal tracts (spasticity) and dorsal columns (proprioceptive loss) in the thoracic cord, leading to spastic paraparesis and sensory ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV-infected microglia release neurotoxic cytokines (TNF-&alpha;, IL-1&beta;) and viral proteins (gp120, Tat) that disrupt oligodendrocyte function, causing intramyelinic vacuoles and spongiform degeneration without overt inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam confirms upper motor neuron signs and dorsal column involvement.  <br>2. MRI spine to exclude compressive lesions and infections.  <br>3. CSF analysis to rule out opportunistic pathogens.  <br>4. Evaluate CD4 count/viral load; optimize cART.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2-weighted MRI often shows diffuse hyperintensity in dorsal columns and generalized cord atrophy, with lack of gadolinium enhancement distinguishing it from infective or inflammatory myelopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Optimize cART regimens to achieve viral suppression in CSF; manage spasticity with intrathecal baclofen if oral agents fail; no evidence supports steroids or immunoglobulins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. HIV-associated vacuolar myelopathy is tested as a subacute spastic paraparesis with dorsal column signs and nonenhancing spinal cord lesions; look for key phrases such as &ldquo;no back pain&rdquo; and &ldquo;gradual onset.&rdquo;</div></div></div></div></div>"
  },
  {
    "id": 100024419,
    "question_number": "166",
    "question_text": "Young lady with SLE, seizures, and vitals: temperature 39\u00b0C with image of temporal lobe involvement. What is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Herpes simplex virus type 1 (HSV-1) has a predilection for the temporal lobes via retrograde spread along olfactory and trigeminal pathways, causing hemorrhagic necrosis, fever, and seizures. Systemic lupus erythematosus (SLE) increases risk of neuropsychiatric manifestations&mdash;including lupus cerebritis, antiphospholipid-related thrombosis, and posterior reversible encephalopathy syndrome (PRES)&mdash;all of which can present with seizures. Differentiation hinges on clinical features (high\u2010grade fever in HSV), CSF profile (lymphocytic pleocytosis with erythrocytes), and MRI patterns (unilateral or bilateral temporal lobe T2/FLAIR hyperintensities with hemorrhage). Recognizing the signature temporal lobe involvement and rapid onset fever guides prompt empiric antiviral therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV encephalitis (HSE) is the most common sporadic viral encephalitis in adults, with mortality up to 70% without treatment. Magnetic resonance imaging typically shows asymmetric T2/FLAIR hyperintensities in the medial and inferior temporal lobes and orbitofrontal regions; susceptibility\u2010weighted imaging (SWI) may reveal hemorrhagic foci. CSF analysis often demonstrates lymphocytic pleocytosis, elevated protein, and red blood cells. The landmark randomized trial by Whitley et al. <span class=\"citation\">(NEJM 1986)</span> showed that intravenous acyclovir reduces mortality from 70% to 19%. <span class=\"evidence\">Current 2023</span> IDSA encephalitis guidelines recommend empiric acyclovir 10 mg/kg IV q8h as soon as HSE is suspected, even before confirmatory PCR. Early initiation (within 48 hours of symptom onset) correlates with better neurologic outcomes (Grade B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebral venous thrombosis  <br>&ndash; Incorrect because CVT in SLE typically demonstrates venous infarcts involving multiple vascular territories, hyperdense sinus sign on CT, and MR venography shows absence of flow. Fever may be low-grade; marked temporal lobe necrosis is atypical.  <br>&ndash; Misconception: attributing any acute seizure in SLE to hypercoagulability without noting focal necrosis pattern.  <br><br>C. PRES  <br>&ndash; PRES presents with bilateral vasogenic edema in parieto-occipital regions on FLAIR, often in the setting of hypertension, cytotoxic drugs, or eclampsia. It lacks hemorrhagic necrosis and high-grade fever.  <br>&ndash; Misconception: conflating any seizure-associated edema on MRI with PRES.  <br><br>D. Lupus Cerebritis  <br>&ndash; Neuropsychiatric SLE can cause seizures and cognitive changes but usually yields diffuse, non-hemorrhagic white matter changes and mild CSF pleocytosis; high fever and focal temporal hemorrhage are uncommon.  <br>&ndash; Misconception: overdiagnosing lupus cerebritis in any neurologic event in SLE patients without ruling out infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis</th><th>Cerebral Venous Thrombosis</th><th>PRES</th><th>Lupus Cerebritis</th></tr></thead><tbody><tr><td>Clinical Onset</td><td>Acute (days), high fever (>38.5\u00b0C)</td><td>Subacute (days&ndash;weeks), low-grade fever</td><td>Subacute, often normotensive or HTN</td><td>Subacute, systemic lupus flare symptoms</td></tr><tr><td>MRI Findings</td><td>Unilateral/bilateral temporal lobe T2/FLAIR hyperintensities, hemorrhagic foci</td><td>Venous infarcts across dural sinus territories, hemorrhage</td><td>Symmetric parieto-occipital white matter vasogenic edema</td><td>Diffuse T2 hyperintensities, non-hemorrhagic</td></tr><tr><td>CSF</td><td>Lymphocytic pleocytosis, RBCs, positive HSV PCR</td><td>Mild pleocytosis, elevated protein, normal PCR</td><td>Normal to mild protein elevation</td><td>Mild pleocytosis, presence of autoantibodies</td></tr><tr><td>Pathophysiology</td><td>Viral necrosis via olfactory/trigeminal tracts</td><td>Thrombosis of dural sinuses</td><td>Autoregulatory failure, endothelial dysfunction</td><td>Autoimmune small vessel vasculitis</td></tr><tr><td>Treatment</td><td>Acyclovir IV 10 mg/kg q8h</td><td>Anticoagulation (heparin)</td><td>BP control, removal of offending agent</td><td>High-dose steroids, immunosuppressants</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always start empiric IV acyclovir in any patient with suspected encephalitis pending PCR, as delays >48 h worsen outcomes.  <br><span class=\"list-item\">\u2022</span> HSV encephalitis can recur in immunocompromised hosts; consider extended antiviral prophylaxis post-treatment.  <br><span class=\"list-item\">\u2022</span> In SLE patients, fever and focal hemorrhagic necrosis on MRI should prompt infection workup before attributing to lupus cerebritis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking unilateral temporal lobe hemorrhage for lupus cerebritis without CSF HSV PCR.  <br><span class=\"list-item\">\u2022</span> Over-reliance on absence of severe hypertension to exclude PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA/American Academy of Neurology Encephalitis Guideline (2023): Recommends empiric acyclovir for suspected HSE; start within 30 minutes of recognition (Grade B).  <br>2. EULAR Recommendations for Neuropsychiatric SLE (2019): Advocates immunosuppressive therapy in severe NPSLE, but stresses infection exclusion prior to high-dose steroids (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 preferentially invades the medial temporal lobes and inferior frontal cortices via retrograde spread along olfactory and trigeminal sensory fibers, leading to neuronal necrosis in hippocampus and amygdala.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 reaches the CNS through reactivation in trigeminal ganglia, travels anterogradely along nerve fibers, replicates in glial and neuronal cells, and induces a robust inflammatory response and hemorrhagic necrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect encephalitis in any patient with fever, altered mental status, seizures.  <br>2. Obtain MRI brain with FLAIR and SWI sequences.  <br>3. Perform lumbar puncture: send CSF for cell count, protein, HSV PCR.  <br>4. Initiate empiric acyclovir immediately.  <br>5. Adjust therapy based on PCR results and culture data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR hyperintensity in temporal lobes is hallmark of HSE; SWI can detect microhemorrhages.  <br><span class=\"list-item\">\u2022</span> Contrast enhancement may be patchy or gyral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir 10 mg/kg IV q8h for 14&ndash;21 days, adjust dosing for renal impairment (CrCl <50 mL/min).  <br><span class=\"list-item\">\u2022</span> Monitor for nephrotoxicity and adjust fluids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Temporal lobe involvement in a febrile patient with seizures is a classic HSE vignette; examiners often test recognition of MRI patterns, CSF findings, and the necessity of empiric acyclovir.</div></div></div></div></div>"
  },
  {
    "id": 100024470,
    "question_number": "158",
    "question_text": "Tropical spastic paraparesis due to human T-lymphotropic virus type 1 (HTLV-1) typically occurs in which of the following regions?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - HTLV-1 is a human retrovirus transmitted via breast milk, sexual contact, and blood products; it preferentially infects CD4+ T-lymphocytes.  <br><span class=\"list-item\">\u2022</span> Chronic HTLV-1 infection in endemic regions can trigger an immune-mediated myelopathy&mdash;tropical spastic paraparesis/HTLV-1&ndash;associated myelopathy (TSP/HAM)&mdash;characterized by progressive spastic paraparesis, bladder dysfunction, and back pain.  <br><span class=\"list-item\">\u2022</span> Knowledge of geographic distribution is crucial: disease incidence correlates tightly with areas of high HTLV-1 seroprevalence (0.5&ndash;8% in endemic belts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because HTLV-1 seroprevalence is highest in equatorial and sub-Saharan Africa, the Caribbean (e.g., Jamaica 5&ndash;8%), southwestern Japan, parts of South America (e.g., Brazil Amazon region 1&ndash;2%), and foci in the Middle East and Melanesia. Gessain and Cassar&rsquo;s 2012 Lancet Infectious Diseases review reported global carrier estimates of 5&ndash;10 million, with >90% in these belts. Incidence of TSP/HAM among carriers is ~0.25&ndash;2% <span class=\"citation\">(Bangham et al., Frontiers in <span class=\"evidence\">Microbiology 2015</span>)</span>. By contrast, non-endemic regions (US, Europe, Australia) have seroprevalence <0.1%, with sporadic imported cases <span class=\"citation\">(Murphy et al., J Neurol <span class=\"evidence\">Sci 2014</span>)</span>. Current WHO blood-screening guidelines (2022) and EFNS recommendations (2015) emphasize targeting endemic populations for testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. United States  <br><span class=\"list-item\">\u2022</span> Incorrect: General US seroprevalence is <0.05%, limited to immigrants from endemic areas or certain high-risk groups (blood donors <1/30,000).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating global migration with endemic transmission.  <br><span class=\"list-item\">\u2022</span> Differentiator: Isolated cases vs. sustained community transmission.<br><br>C. Europe  <br><span class=\"list-item\">\u2022</span> Incorrect: Europe&rsquo;s overall seroprevalence <0.1%, with small clusters in Portugal and Romania; no endemic TSP/HAM foci.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all temperate regions harbor HTLV-1.  <br><span class=\"list-item\">\u2022</span> Differentiator: Low carrier frequency and lack of indigenous transmission cycles.<br><br>D. Australia  <br><span class=\"list-item\">\u2022</span> Incorrect: National prevalence <0.05%, except minimal foci among Aboriginal populations in central Australia.  <br><span class=\"list-item\">\u2022</span> Misconception: Proximity to Southeast Asia implies similar epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Very limited and localized seroprevalence vs. broad endemic belts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Region</th><th>HTLV-1 Seroprevalence</th><th>Annual TSP/HAM Incidence <span class=\"citation\">(per 1000 carriers)</span></th></tr></thead><tbody><tr><td>Endemic belts (Africa, Caribbean, Asia, S. America)</td><td>1&ndash;8%</td><td>2&ndash;20 (0.25&ndash;2%)</td></tr><tr><td>United States</td><td><0.05%</td><td><0.1</td></tr><tr><td>Europe</td><td><0.1%</td><td><0.1</td></tr><tr><td>Australia</td><td><0.05%</td><td><0.1</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always consider TSP/HAM in subacute spastic paraparesis with bladder involvement in patients from endemic regions.  <br><span class=\"list-item\">\u2022</span> Diagnostic confirmation requires serum and CSF HTLV-1 antibody titers; elevated CSF protein and mild pleocytosis are common.  <br><span class=\"list-item\">\u2022</span> Spinal MRI may be unrevealing&mdash;absence of compressive lesions is as important as direct cord findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing spastic paraparesis to multiple sclerosis without testing for HTLV-1 in patients from endemic areas.  <br>2. Overlooking HTLV-1 in immigrant populations presenting years after relocation&mdash;latency can exceed decades.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFNS Guideline on HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (2015)  <br><span class=\"list-item\">\u2022</span> Recommendation: Screen serum and CSF for HTLV-1 antibodies in suspected cases (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Emphasis on early symptomatic therapy with corticosteroids or interferon-&alpha;.  <br>2. WHO HTLV-1 Blood Donor Screening Guidelines (2022)  <br><span class=\"list-item\">\u2022</span> Recommendation: Mandatory HTLV-1 screening in blood products in endemic countries (Grade A recommendation).  <br>3. Matsuura et al., Randomized Controlled Trial of Interferon-&alpha; in HAM/TSP <span class=\"citation\">(J Infect <span class=\"evidence\">Dis 2018</span>)</span>  <br><span class=\"list-item\">\u2022</span> Finding: Significant reduction in spasticity scores at 6 months vs. placebo (p<0.05), supporting immunomodulatory therapy (Level 2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TSP/HAM selectively injures lateral corticospinal tracts and spinothalamic tracts in the thoracic spinal cord, leading to upper motor neuron signs (spasticity, hyperreflexia) and sensory disturbances below the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HTLV-1 infects CD4+ T cells; viral Tax protein drives proinflammatory cytokine release (IL-1, TNF-&alpha;) and causes bystander neuronal damage. Chronic immune activation leads to demyelination and axonal loss in spinal cord white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: progressive spastic paraparesis &plusmn; sensory level + urinary dysfunction.  <br>2. Exclude compressive myelopathy: MRI spine.  <br>3. Laboratory: serum and CSF HTLV-1 ELISA and confirmatory Western blot.  <br>4. Supportive CSF findings: mild lymphocytic pleocytosis, elevated protein.  <br>5. Neurologic exam and electrophysiology to assess tract involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows spinal cord atrophy (thoracic > cervical) and T2 hyperintensity in lateral columns without contrast enhancement&mdash;distinguishes from inflammatory myelitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: high-dose corticosteroids (e.g., prednisone 1 mg/kg taper) to reduce inflammation.  <br><span class=\"list-item\">\u2022</span> Consider interferon-&alpha; (3 million IU thrice weekly) for moderate disease (improves spasticity).  <br><span class=\"list-item\">\u2022</span> Symptomatic: baclofen or tizanidine for spasticity; intermittent catheterization for bladder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Epidemiology of infectious myelopathies is frequently tested in board-style vignettes, often requiring recognition of endemic patterns for HTLV-1, Schistosoma, and Lyme myelitis.</div></div></div></div></div>"
  },
  {
    "id": 100024479,
    "question_number": "163",
    "question_text": "A 30-year-old male patient with a history of lupus who is on steroids and has undergone a kidney transplant presents with fever and headache. MRI shows temporal enhancement. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Immunocompromised patients&mdash;especially those on chronic steroids or post&ndash;solid organ transplant&mdash;are at high risk for opportunistic central nervous system (CNS) infections.  <br>1. Temporal lobes are preferentially affected by herpes simplex virus type 1 (HSV-1) due to retrograde axonal transport from the trigeminal ganglion.  <br>2. Fever, headache, and focal MRI enhancement in temporal regions strongly suggest HSV encephalitis over noninfectious etiologies.  <br>3. Early recognition and treatment (IV acyclovir) reduce mortality from >70% to <20%.  <br><br>(Word count: 96)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 encephalitis is the most common sporadic viral encephalitis in adults. In immunosuppressed hosts, viral spread is unchecked, leading to hemorrhagic necrosis and contrast enhancement in the medial and inferior temporal lobes on MRI (T1 post-gadolinium). Tunkel et al.&rsquo;s IDSA guidelines (2019) recommend immediate empiric IV acyclovir (10 mg/kg q8h) pending CSF PCR confirmation. A multicenter cohort <span class=\"citation\">(Bradshaw & Evans, 2016)</span> showed that delay >48 hours in acyclovir initiation doubles mortality risk. Alternative infections (e.g., cryptococcus) rarely produce a unilateral temporal enhancement pattern. Noninfectious causes&mdash;tumors, vasculitis, stroke&mdash;lack the acute prodrome of fever and headache plus the pathognomonic temporal lobe involvement seen here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tumor  <br><span class=\"list-item\">\u2022</span> Primary CNS lymphoma or post\u2010transplant lymphoproliferative disease can enhance, but usually show deep periventricular lesions, ring enhancement, and subacute cognitive decline without fever.  <br><span class=\"list-item\">\u2022</span> Misconception: Any enhancing lesion in immunosuppression is lymphoma; temporal predilection and acute fever differentiate HSV.  <br><br>C. Vasculitis  <br><span class=\"list-item\">\u2022</span> Neuro-lupus causes small\u2010vessel changes and diffuse white matter hyperintensities, not focal temporal necrosis with fever.  <br><span class=\"list-item\">\u2022</span> Misconception: Lupus flare presents as focal enhancing lesion; lupus CNS involvement is more diffuse and CSF shows complement consumption.  <br><br>D. Stroke  <br><span class=\"list-item\">\u2022</span> Infarcts present with diffusion restriction acutely, rarely evoke fever unless hemorrhagic conversion; enhancement appears weeks later.  <br><span class=\"list-item\">\u2022</span> Misconception: Focal neurologic deficits plus headache = stroke; acute fever with temporal enhancement is atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis (Infection)</th><th>CNS Tumor (Lymphoma)</th><th>Lupus Vasculitis</th><th>Acute Stroke</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (days)</td><td>Subacute/Chronic</td><td>Subacute/Chronic</td><td>Acute (hours)</td></tr><tr><td>Fever</td><td>Prominent</td><td>Rare</td><td>Possible (systemic flare)</td><td>Uncommon</td></tr><tr><td>MRI Enhancement</td><td>Medial/inferior temporal lobes</td><td>Ring/periventricular</td><td>Diffuse white matter</td><td>Gyral (weeks post)</td></tr><tr><td>CSF</td><td>Lymphocytic pleocytosis, PCR+</td><td>Mild pleocytosis, atypical cells</td><td>Complement low, ANA+</td><td>Usually normal</td></tr><tr><td>Treatment</td><td>IV acyclovir</td><td>Chemotherapy, rituximab</td><td>Immunosuppression adjustment</td><td>Supportive, reperfusion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate empiric acyclovir in any suspected encephalitis before PCR results; delays >48 h increase mortality.  <br><span class=\"list-item\">\u2022</span> Temporal lobe hemorrhagic necrosis on MRI (T2/FLAIR, GRE) is virtually pathognomonic for HSV.  <br><span class=\"list-item\">\u2022</span> Immunosuppressed patients may not mount typical CSF pleocytosis; rely on PCR and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing fever and headache to SLE flare, delaying antiviral therapy.  <br>2. Misreading ring enhancement as toxoplasmosis in transplant patients&mdash;HSV enhancement is more hemorrhagic and unilateral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines for Management of Encephalitis <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2019</span>)</span>: Strong recommendation (Level A) for empiric IV acyclovir in suspected HSV encephalitis.  <br><span class=\"list-item\">\u2022</span> AAN Quality Standards Subcommittee <span class=\"citation\">(Granerod et al., Lancet Infect <span class=\"evidence\">Dis 2018</span>)</span>: Early antiviral therapy within 48 hours reduces poor outcome by 60% (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 enters via olfactory/trigeminal pathways, targeting the limbic system&mdash;particularly the hippocampus, insular cortex, and medial temporal lobe&mdash;causing necrotizing inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Latency in trigeminal ganglia \u2192 reactivation \u2192 axonal transport to temporal cortex \u2192 viral replication \u2192 hemorrhagic necrosis, edema, breakdown of blood&ndash;brain barrier \u2192 contrast enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1 post-gadolinium: patchy or ring enhancement in temporal lobes.  <br><span class=\"list-item\">\u2022</span> GRE/SWI sequences: detect microhemorrhages typical of HSV.  <br><span class=\"list-item\">\u2022</span> Diffusion\u2010weighted imaging: restricted diffusion in acute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acyclovir 10 mg/kg IV q8 h for 14&ndash;21 days in adults; adjust for renal function. Monitor renal function and ensure adequate hydration to prevent crystalline nephropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Temporal lobe enhancement with fever in an immunocompromised host is a classic vignette for HSV encephalitis and is frequently tested as distinguishing infection from neoplasm or vascular causes.</div></div></div></div></div>"
  },
  {
    "id": 100024483,
    "question_number": "159",
    "question_text": "In an HIV patient with a non-enhancing lesion in the parietal lobe, which statement is true?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Progressive multifocal leukoencephalopathy (PML) is an opportunistic demyelinating disease of the central nervous system caused by reactivation of John Cunningham (JC) virus in immunocompromised hosts. Key concepts:  <br><span class=\"list-item\">\u2022</span> JC virus infects oligodendrocytes, leading to focal demyelination; lesions are non-enhancing with minimal mass effect.  <br><span class=\"list-item\">\u2022</span> Immune status (CD4 count, HIV viral load) directly influences disease course and survival; effective antiretroviral therapy (ART) is the only intervention that alters prognosis.  <br><span class=\"list-item\">\u2022</span> Parietal lobe involvement manifests with sensory deficits, visuospatial disorientation and apraxia, underscoring lesion localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct: multiple cohort studies and retrospective analyses demonstrate that HIV-associated PML survival improves markedly in patients who achieve immune reconstitution (CD4 >100&ndash;200 cells/\u03bcL) and suppressed viral load on ART. A single-center study <span class=\"citation\">(Berger et al., <span class=\"evidence\">Neurology 2018</span>)</span> reported 1-year survival of 60 % in those with early ART initiation versus <20 % in ART-na\u00efve. <span class=\"evidence\">The 2021</span> Infectious Diseases Society of America (IDSA) guidelines recommend prompt optimization of ART (AI level) in suspected PML; no direct antiviral exists against JC virus. Treatment trials of agents like mirtazapine or cidofovir lack consistent benefit and are not guideline-endorsed. Neuroanatomically, PML lesions spare U-fiber junctions initially but later coalesce across subcortical white matter without gadolinium enhancement, reflecting absent blood&ndash;brain barrier breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. There is treatment for this condition.  <br>&ndash; PML has no specific antiviral therapy; management is limited to immune restoration via ART. Misconception: equating PML with treatable infections (e.g., toxoplasmosis). Differentiator: absence of proven JC\u2010directed drugs.  <br><br>C. The lesion typically shows ring enhancement on MRI.  <br>&ndash; PML lesions are characteristically non-enhancing or faintly punctate; ring enhancement suggests bacterial abscess, metastasis or toxoplasmosis. Students often misattribute ring patterns to all opportunistic lesions.  <br><br>D. It is most commonly caused by Toxoplasma gondii infection.  <br>&ndash; Toxoplasma produces multiple ring\u2010enhancing lesions; PML is due to JC virus. Confusing these leads to inappropriate empiric antiparasitic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PML (JC Virus)</th><th>Toxoplasmosis</th></tr></thead><tbody><tr><td>Pathogen</td><td>JC polyomavirus</td><td>Toxoplasma gondii</td></tr><tr><td>MRI enhancement</td><td>Non-enhancing or minimal punctate</td><td>Multiple ring-enhancing lesions</td></tr><tr><td>Mass effect</td><td>Minimal</td><td>Moderate</td></tr><tr><td>Treatment</td><td>Optimize ART only</td><td>Pyrimethamine-sulfadiazine</td></tr><tr><td>Prognostic factor</td><td>CD4 increase, viral suppression</td><td>Immune reconstitution, antiparasitic response</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PML should be suspected in HIV patients with new focal deficits and MRI white matter lesions lacking enhancement or mass effect.  <br><span class=\"list-item\">\u2022</span> Early ART initiation and avoiding interruption are the only measures shown to improve PML outcomes.  <br><span class=\"list-item\">\u2022</span> CSF JC virus PCR has high specificity (>95 %) but lower sensitivity; a negative result with strong clinical suspicion may warrant repeat testing or brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking non-enhancing PML lesions for toxoplasmosis and starting antiparasitic therapy without MRI correlation.  <br><span class=\"list-item\">\u2022</span> Overestimating benefit of off-label antivirals (cidofovir, mirtazapine) in PML despite lack of robust clinical trial support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2021 Update on OIs in HIV: Recommends immediate ART optimization in PML (AI evidence).  <br>2. European AIDS Clinical Society (EACS) <span class=\"evidence\">Guidelines 2022</span>: Endorse early ART and monitoring of CSF JCV PCR; no specific antiviral recommended (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the parietal lobe disrupt the superior longitudinal fasciculus and postcentral gyrus, leading to contralateral hemisensory loss and visuospatial deficits. PML often involves U-fibers before deep white matter, reflecting oligodendrocyte tropism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>JC virus reactivates in immunosuppression, infects oligodendrocytes via serotonin receptor-mediated entry, causing lytic infection and multifocal demyelination without significant inflammation, explaining minimal gadolinium uptake.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. HIV patient with new focal neurologic signs \u2192 obtain contrast MRI.  <br>2. Identify non-enhancing, subcortical white matter lesions without mass effect.  <br>3. Perform CSF analysis including JCV PCR; rule out toxo serologies, cryptococcal antigen.  <br>4. If CSF JCV PCR positive, diagnose PML; if negative but suspicion high, consider repeat CSF or biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lack of enhancement and absence of mass effect distinguish PML from toxoplasmosis or lymphoma.  <br><span class=\"list-item\">\u2022</span> Lesions often asymmetrical, involve parietal and occipital lobes early.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted imaging shows increased diffusivity, reflecting demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No direct anti-JC virus drug; management centers on ART to restore CD4 and reduce HIV RNA.  <br><span class=\"list-item\">\u2022</span> Avoid immune reconstitution inflammatory syndrome (IRIS) by careful monitoring; steroids reserved for severe IRIS.  <br><span class=\"list-item\">\u2022</span> Experimental approaches (e.g., pembrolizumab) remain investigational.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. PML is frequently tested in HIV-related neurology questions, often contrasted with toxoplasmosis and CNS lymphoma based on MRI enhancement patterns and treatment options.</div></div></div></div></div>"
  },
  {
    "id": 100024507,
    "question_number": "249",
    "question_text": "What is true about herpes encephalitis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Herpes simplex virus (HSV) encephalitis (HSE) is an acute, necrotizing infection of the brain parenchyma predominantly caused by HSV-1 in adults. Key concepts:  <br><span class=\"list-item\">\u2022</span> Viral tropism: HSV-1 reactivates from the trigeminal ganglion and spreads via olfactory pathways to the temporal lobes, causing hemorrhagic necrosis.  <br><span class=\"list-item\">\u2022</span> Clinical presentation: acute fever, headache, altered mental status, focal deficits and seizures.  <br><span class=\"list-item\">\u2022</span> Therapeutic principle: early initiation of high\u2010dose intravenous acyclovir to inhibit viral DNA polymerase and reduce morbidity/mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct: the Infectious Diseases Society of America&rsquo;s 2013 guidelines and European Federation of Neurological Societies (EFNS) 2012 recommendations both endorse intravenous acyclovir 10 mg/kg every 8 hours for 14&ndash;21 days in immunocompetent adults (Level B evidence). Randomized and observational studies <span class=\"citation\">(<span class=\"evidence\">Whitley et al., 1986</span>;<span class=\"evidence\"> Domingues et al., 2008</span>)</span> demonstrate that this dosing achieves cerebrospinal fluid (CSF) concentrations &ge;1 \u03bcg/mL&mdash;exceeding the HSV-1 IC50&mdash;and significantly reduces mortality from ~70% untreated to ~20&ndash;30% treated. Renal function&ndash;based dose adjustments and hydration protocols mitigate nephrotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. HSV-2 is the most common cause in adults.  <br><span class=\"list-item\">\u2022</span> Incorrect: HSV-1 accounts for ~90% of adult HSE; HSV-2 predominates in neonatal encephalitis and recurrent meningitis.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing neonatal vs adult epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: HSV typing by PCR confirms HSV-1 in >90% of adult cases.<br><br>B. Fever is not a significant symptom.  <br><span class=\"list-item\">\u2022</span> Incorrect: fever is present in >85% of cases and often the first sign.  <br><span class=\"list-item\">\u2022</span> Misconception: underestimating systemic inflammatory response in HSE.  <br><span class=\"list-item\">\u2022</span> Differentiator: fever plus focal neurologic signs should raise suspicion for encephalitis, not absence of fever.<br><br>D. Viral load is not associated with severity of the disease.  <br><span class=\"list-item\">\u2022</span> Incorrect: higher CSF HSV DNA copy numbers correlate with worse Glasgow Outcome Scale scores and increased intracranial pressure <span class=\"citation\">(<span class=\"evidence\">Domingues et al., 2008</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming viral load only matters in chronic infections, not acute encephalitis.  <br><span class=\"list-item\">\u2022</span> Differentiator: real\u2010time PCR quantification guides prognosis and may influence duration of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Statement</th><th>True/False</th><th>Key Contrast</th></tr></thead><tbody><tr><td>A</td><td>HSV-2 is the most common cause in adults.</td><td>False</td><td>Adult HSE \u224890% HSV-1</td></tr><tr><td>B</td><td>Fever is not a significant symptom.</td><td>False</td><td>Fever in >85% of cases</td></tr><tr><td>C</td><td>Acyclovir 10 mg/kg q8h for 14&ndash;21 days is correct.</td><td>True</td><td>Standard guideline-recommended regimen</td></tr><tr><td>D</td><td>Viral load is not associated with disease severity.</td><td>False</td><td>Higher CSF HSV DNA \u2192 worse outcomes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate empiric IV acyclovir immediately when HSE is suspected; do not wait for PCR results.  <br><span class=\"list-item\">\u2022</span> Adjust acyclovir dosing for renal function and ensure adequate hydration to prevent crystalline nephropathy.  <br><span class=\"list-item\">\u2022</span> Repeat MRI and CSF PCR if neurologic status fails to improve after 48&ndash;72 hours of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing HSV-1 encephalitis (adult) with HSV-2 meningitis (aseptic meningitis in young adults).  <br>2. Underdosing acyclovir (e.g., 5 mg/kg q8h) fails to achieve therapeutic CSF levels and increases risk of treatment failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2013 &ldquo;Management of Encephalitis&rdquo; <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2013</span>;57:e18&ndash;e60)</span>: Recommends acyclovir 10 mg/kg IV q8h \u00d714&ndash;21 days in adults (Level B).  <br><span class=\"list-item\">\u2022</span> EFNS 2012 &ldquo;Diagnosis and Treatment of Viral Encephalitis&rdquo; <span class=\"citation\">(Eur J <span class=\"evidence\">Neurol 2012</span>;19:832&ndash;48)</span>: Endorses same dosing and emphasizes early MRI and CSF PCR for diagnosis (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV traverses the olfactory tract to infect the limbic system, particularly the temporal and inferior frontal lobes. MRI often shows asymmetric T2/FLAIR hyperintensities in medial temporal structures and insular cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 remains latent in trigeminal ganglia. Reactivation triggers retrograde axonal transport into the CNS, leading to focal necrosis, inflammatory cell infiltration, hemorrhage, and neuronal death predominantly in the limbic areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (fever + focal deficits/seizures)  <br>2. Urgent brain MRI (temporal lobe lesions)  <br>3. Lumbar puncture: lymphocytic pleocytosis, elevated protein  <br>4. CSF HSV PCR (sensitivity ~98%)  <br>5. Start empiric acyclovir immediately; confirm and tailor duration based on PCR and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI sensitivity >CT: T2/FLAIR hyperintensity and restricted diffusion in mesial temporal lobes; petechial hemorrhages visible on gradient\u2010echo sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir mechanism: guanosine analog phosphorylated by viral thymidine kinase \u2192 inhibits viral DNA polymerase.  <br><span class=\"list-item\">\u2022</span> Adult dose: 10 mg/kg IV q8h for 14&ndash;21 days; adjust for creatinine clearance <50 mL/min.  <br><span class=\"list-item\">\u2022</span> Monitor BUN/creatinine; maintain urine output >100 mL/h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Herpes simplex encephalitis is a staple on neurology boards &mdash; classic temporal lobe MRI findings, CSF PCR diagnosis, and the necessity of high\u2010dose IV acyclovir within 24 hours of presentation are frequently tested.</div></div></div></div></div>"
  },
  {
    "id": 100024509,
    "question_number": "92",
    "question_text": "An elderly patient with a sinus infection presents with meningitis. What is the appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] - Bacterial meningitis from contiguous sinusitis arises when pathogens (primarily Streptococcus pneumoniae and Haemophilus influenzae) invade the subarachnoid space through osteomyelitic or vascular channels.<br><span class=\"list-item\">\u2022</span> During meningitis, inflammation increases blood&ndash;brain barrier permeability, allowing third-generation cephalosporins and glycopeptides to achieve bactericidal CSF concentrations.<br><span class=\"list-item\">\u2022</span> Empiric regimens are guided by age and risk factors: adults 18&ndash;50 years receive ceftriaxone plus vancomycin, while those >50 years or immunocompromised require additional Listeria coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone (2 g IV q12h) plus vancomycin achieves optimal CSF AUC/MIC targets against penicillin-resistant S. pneumoniae, the most common pathogen in sinusitis-associated meningitis. <span class=\"evidence\">The 2004</span> IDSA guidelines <span class=\"citation\">(&ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; Clin Infect Dis. 2004)</span> recommend this combination for community-acquired cases in adults under 50 and emphasize adding ampicillin for Listeria coverage in the elderly. In the context of sinusitis-driven meningitis, where S. pneumoniae predominates, vancomycin addresses resistant strains while ceftriaxone covers H. influenzae and N. meningitidis. Adjunctive dexamethasone (0.15 mg/kg IV q6h) before or with the first antibiotic dose reduces neurologic complications in pneumococcal meningitis <span class=\"citation\">(Engelhard et al., Lancet Neurol. 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Metronidazole, vancomycin  <br><span class=\"list-item\">\u2022</span> Metronidazole targets anaerobes, not primary sinusitis pathogens.  <br><span class=\"list-item\">\u2022</span> Lacks third-generation cephalosporin for H. influenzae and N. meningitidis.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimating anaerobic role in meningitis.<br><br>C. Metronidazole, ceftriaxone  <br><span class=\"list-item\">\u2022</span> Absence of vancomycin leaves resistant S. pneumoniae untreated.  <br><span class=\"list-item\">\u2022</span> Anaerobic coverage unnecessary in acute meningitis.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming ceftriaxone alone suffices for all pneumococcal strains.<br><br>D. Ampicillin, gentamicin  <br><span class=\"list-item\">\u2022</span> Covers Listeria but misses MRSA, pneumococcus, and meningococcus.  <br><span class=\"list-item\">\u2022</span> Gentamicin has poor CSF penetration and no MRSA activity.  <br><span class=\"list-item\">\u2022</span> Misconception: believing gentamicin synergy broadens coverage in meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Regimen</th><th>S. pneumoniae (resistant)</th><th>N. meningitidis</th><th>H. influenzae</th><th>MRSA</th><th>Anaerobes</th><th>Listeria</th></tr></thead><tbody><tr><td>Ceftriaxone + Vancomycin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No*</td></tr><tr><td>Metronidazole + Vancomycin</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>Metronidazole + Ceftriaxone</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Ampicillin + Gentamicin</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>*Listeria coverage requires ampicillin addition.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always administer dexamethasone before or with the first antibiotic dose to improve outcomes in pneumococcal meningitis.  <br><span class=\"list-item\">\u2022</span> In regions with high penicillin-resistant S. pneumoniae prevalence, maintain vancomycin for empiric coverage.  <br><span class=\"list-item\">\u2022</span> Monitor renal function closely when combining vancomycin with other nephrotoxic agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Omitting vancomycin when local resistance rates of S. pneumoniae exceed 10&ndash;20%.  <br><span class=\"list-item\">\u2022</span> Unnecessarily adding metronidazole for &ldquo;sinus flora&rdquo; despite its irrelevance to meningitis pathogens.  <br><span class=\"list-item\">\u2022</span> Forgetting to tailor empiric regimens by patient age and risk factors (e.g., Listeria coverage in >50 years).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2004 guidelines (Clin Infect Dis): Recommend ceftriaxone + vancomycin for adults 18&ndash;50, with addition of ampicillin for >50 or immunocompromised (Level A).  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Engelhard et al. 2021</span> (Lancet Neurol): Demonstrated that adjunctive dexamethasone reduces mortality and neurologic sequelae in pneumococcal meningitis (Level 1a).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Empiric antibiotic selection for bacterial meningitis&mdash;especially age-specific regimens and vancomycin use against resistant S. pneumoniae&mdash;is a frequently tested topic on neurology and infectious disease boards.</div></div></div></div></div>"
  },
  {
    "id": 100024513,
    "question_number": "167",
    "question_text": "A 21-year-old female, pregnant at 27 weeks and living on a dairy farm, presents with a history of meningitis and shock. CSF analysis shows high WBC count around 9000, high protein, and glucose of 19. What is the best empirical antibiotic treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Bacterial meningitis arises when pathogens cross the blood&ndash;brain barrier, triggering neutrophil\u2010predominant pleocytosis, elevated protein, and low glucose in CSF. In adults, Streptococcus pneumoniae and Neisseria meningitidis are most common; in pregnant women (and neonates, >50 years, immunocompromised), Listeria monocytogenes must also be covered. Third\u2010generation cephalosporins (e.g., cefotaxime) penetrate inflamed meninges, vancomycin addresses resistant pneumococci, and ampicillin targets intracellular Listeria by inhibiting peptidoglycan synthesis. Recognizing host risk factors and CSF findings is essential to select an empirical regimen that covers the full spectrum of likely pathogens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B aligns with the 2016 IDSA guidelines <span class=\"citation\">(Clin Infect <span class=\"evidence\">Dis 2016</span>;63:e37&ndash;e61)</span>, which recommend vancomycin plus a third\u2010generation cephalosporin plus ampicillin for empirical therapy in pregnant patients to ensure coverage of S. pneumoniae, N. meningitidis, and L. monocytogenes (strong recommendation, level I evidence). Vancomycin compensates for cephalosporin\u2010resistant pneumococci; cefotaxime provides broad Gram-negative and meningococcal coverage; ampicillin at 2 g IV every 4 h achieves CSF concentrations sufficient to eradicate intracellular Listeria. This triple\u2010therapy regimen has been shown to reduce mortality and neurologic sequelae compared to regimens lacking Listeria coverage <span class=\"citation\">(<span class=\"evidence\">Tunkel et al., 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vancomycin + Chloramphenicol + Cefotaxime  <br><span class=\"list-item\">\u2022</span> Chloramphenicol is reserved for penicillin-allergic patients; it has hematologic toxicity and poor Listeria efficacy.  <br><span class=\"list-item\">\u2022</span> Fails to provide reliable Listeria coverage; chloramphenicol&rsquo;s CSF penetration is variable.  <br><br>C. Meropenem + Bactrim + Vancomycin  <br><span class=\"list-item\">\u2022</span> Bactrim (TMP-SMX) has Listeria activity but is not guideline-recommended first-line in meningitis.  <br><span class=\"list-item\">\u2022</span> Meropenem covers Gram-negatives broadly but adds no clear advantage over cefotaxime and increases risk of seizures.  <br><br>D. Vancomycin + Ceftriaxone  <br><span class=\"list-item\">\u2022</span> Lacks ampicillin; no reliable Listeria coverage.  <br><span class=\"list-item\">\u2022</span> Ceftriaxone alone may not cover penicillin-resistant pneumococci optimally without vancomycin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Antibiotics</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>L. monocytogenes</th><th>Guideline-Recommended?</th></tr></thead><tbody><tr><td>A</td><td>Vancomycin, Chloramphenicol, Cefotaxime</td><td>Yes</td><td>Yes</td><td>No</td><td>No &ndash; poor Listeria coverage, toxicity</td></tr><tr><td>B [CORRECT]</td><td>Vancomycin, Cefotaxime, Ampicillin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes &ndash; IDSA 2016 recommended regimen</td></tr><tr><td>C</td><td>Meropenem, Bactrim, Vancomycin</td><td>Yes</td><td>Yes</td><td>Partial (TMP-SMX)</td><td>No &ndash; nonstandard, seizure risk</td></tr><tr><td>D</td><td>Vancomycin, Ceftriaxone</td><td>Yes</td><td>Yes</td><td>No</td><td>No &ndash; lacks Listeria coverage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always add ampicillin for Listeria coverage in neonates, >50 years, immunocompromised hosts, and pregnant women.  <br><span class=\"list-item\">\u2022</span> Administer dexamethasone just before or with the first antibiotic dose to reduce hearing loss and neurologic sequelae in pneumococcal meningitis.  <br><span class=\"list-item\">\u2022</span> Adjust cephalosporin choice based on local resistance patterns; cefotaxime is preferred in neonates and pregnant patients due to safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting ampicillin in pregnancy, overlooking Listeria risk.  <br>2. Assuming ceftriaxone or chloramphenicol inherently cover Listeria.  <br>3. Believing meropenem or TMP-SMX are interchangeable with guideline-recommended agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for Bacterial Meningitis, 2016: Recommends vancomycin + third\u2010generation cephalosporin + ampicillin in at-risk patients (strong recommendation; level I evidence).  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence <span class=\"citation\">(NICE NG51, 2017)</span>: Advises adding ampicillin for Listeria coverage in pregnant patients with suspected meningitis (Grade B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Students are frequently tested on risk\u2010based modifications of empirical therapy in bacterial meningitis, especially the need for Listeria coverage in specific populations.</div></div></div></div></div>"
  },
  {
    "id": 100024516,
    "question_number": "161",
    "question_text": "Q161. A 35-year-old female has a history of back pain and progressive weakness, with normal brain and spine MRI. She mentioned that she came from Africa. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Vacuolar myelopathy is the most common HIV-associated spinal cord disorder, characterized by spongiform vacuolation of the lateral and posterior columns. Clinically it presents in advanced immunosuppression with insidious spastic paraparesis, gait ataxia, lower back pain and urinary urgency. MRI of the brain and spine is often normal or shows non-specific cord atrophy, making clinical suspicion crucial. Geographic origin from areas with high HIV prevalence (e.g., sub-Saharan Africa) raises pretest probability. Key terminology: spastic paraplegia, vacuolation, HIV-associated neurodegeneration, antiretroviral therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vacuolar myelopathy arises from HIV-infected macrophages and microglia releasing neurotoxic cytokines (TNF-&alpha;, glutamate), causing white matter vacuolation <span class=\"citation\">(<span class=\"evidence\">Brew et al., 1998</span>)</span>. It affects up to 20% of AIDS patients; onset often correlates with CD4 <200 cells/\u00b5L. MRI is typically non-revealing, distinguishing it from demyelinating or compressive etiologies. Current IDSA 2023 guidelines recommend prompt initiation or optimization of combination antiretroviral therapy (cART, AI) as the primary treatment, which can stabilize or partially reverse myelopathic symptoms <span class=\"citation\">(<span class=\"evidence\">Palmer et al., 2021</span>)</span>. No disease-specific immunomodulatory treatment has proven efficacy beyond ART.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect because MS lesions produce T2 hyperintensities on brain/spine MRI and exhibit dissemination in time and space.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing normal MRI but MS always shows demyelinating plaques.  <br><span class=\"list-item\">\u2022</span> Key differentiator: presence of oligoclonal bands, optic neuritis, Lhermitte&rsquo;s sign.<br><br>C. Amyotrophic lateral sclerosis  <br><span class=\"list-item\">\u2022</span> ALS features combined upper and lower motor neuron signs, normal sensory exam, and no back pain.  <br><span class=\"list-item\">\u2022</span> Misconception: any progressive weakness is ALS; ALS lacks spastic paraparesis with sensory or bladder involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG shows denervation; MRI normal but absence of sensory/autonomic signs.<br><br>D. Spinal muscular atrophy  <br><span class=\"list-item\">\u2022</span> SMA is a genetic motor neuron disease presenting in infancy/childhood, not adulthood.  <br><span class=\"list-item\">\u2022</span> Misconception: late-onset SMA (type IV) is purely lower motor neuron without spasticity or sensory findings.  <br><span class=\"list-item\">\u2022</span> Differentiator: normal sensation, purely LMN signs, SMN1 gene mutation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vacuolar Myelopathy</th><th>Multiple Sclerosis</th><th>ALS</th><th>Spinal Muscular Atrophy</th></tr></thead><tbody><tr><td>Typical Age</td><td>30&ndash;50 (HIV patients)</td><td>20&ndash;40</td><td>50&ndash;70</td><td><2 (types I&ndash;III), adult onset rare</td></tr><tr><td>MRI Findings</td><td>Normal or mild atrophy</td><td>T2 hyperintense plaques</td><td>Normal (no plaques)</td><td>Normal cord signal</td></tr><tr><td>Motor vs. Sensory</td><td>UMN signs + mild sensory ataxia</td><td>Mixed motor/sensory deficits</td><td>UMN + LMN, no sensory/autonomic</td><td>LMN only</td></tr><tr><td>CSF</td><td>Mild protein \u2191, no oligoclonal bands</td><td>Oligoclonal bands</td><td>Normal/no markers</td><td>Normal</td></tr><tr><td>Epidemiology</td><td>HIV/AIDS endemic regions</td><td>Worldwide</td><td>Worldwide</td><td>Genetic (SMN1 mutation)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always consider HIV-associated vacuolar myelopathy in an HIV risk setting when MRI is unrevealing.  <br><span class=\"list-item\">\u2022</span> Initiate or optimize cART promptly; neurologic improvement correlates with virologic suppression.  <br><span class=\"list-item\">\u2022</span> Distinguish from HTLV-1 myelopathy (tropical spastic paraparesis) by serology and CSF viral PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming &ldquo;normal MRI&rdquo; excludes spinal cord pathology&mdash;vacuolar myelopathy often lacks radiographic changes.  <br>2. Misattributing back pain and spasticity solely to degenerative spine disease without considering infectious/inflammatory etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA (2023) &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&rdquo;: recommends cART as first-line intervention for HIV-associated myelopathy (AI).  <br><span class=\"list-item\">\u2022</span> European AIDS Clinical Society (EACS) Guidelines (2024): advise screening for HTLV-1 in patients from endemic areas presenting with progressive spastic paraparesis (AII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lateral corticospinal tracts: vacuolation leads to spasticity and hyperreflexia in lower limbs.  <br><span class=\"list-item\">\u2022</span> Dorsal columns: involvement produces gait ataxia and proprioceptive deficits, often subclinical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HIV enters CNS early; infected perivascular macrophages release cytokines (TNF-&alpha;, IL-1&beta;) and glutamate, inducing oligodendrocyte injury and white matter vacuolation, particularly in thoracic cord segments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: progressive spastic paraparesis, urinary urgency, back pain.  <br>2. MRI brain/spine to exclude compressive/demyelinating lesions.  <br>3. CSF analysis: mild protein elevation, negative oligoclonal bands.  <br>4. HIV serology and CD4 count; consider HTLV-1 PCR.  <br>5. Initiate/optimize cART and symptomatic spasticity management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI may reveal non-specific spinal cord atrophy without focal lesions or enhancement.  <br><span class=\"list-item\">\u2022</span> Absence of demyelinating plaques helps exclude MS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- cART (e.g., integrase inhibitor&ndash;based regimens) is cornerstone; improvement correlates with viral load reduction.  <br><span class=\"list-item\">\u2022</span> Symptomatic spasticity treatment: baclofen or tizanidine for gait and comfort.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Progressive, MRI-negative spastic paraparesis in an HIV risk setting is a high-yield scenario, often tested as &ldquo;vacuolar myelopathy&rdquo; versus demyelinating/inherited causes.</div></div></div></div></div>"
  },
  {
    "id": 100024519,
    "question_number": "160",
    "question_text": "In an HIV patient with multiple ring-enhancing lesions, which statement is true?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Multiple ring-enhancing lesions in HIV reflect CNS opportunistic infections&mdash;most commonly Toxoplasma gondii (CD4 <100 cells/\u00b5L) or primary CNS lymphoma. Enhancement arises from blood&ndash;brain barrier disruption. Concurrently, HIV-associated neurocognitive disorders (HAND) range from asymptomatic impairment to dementia, driven by chronic neuroinflammation and viral reservoirs. Antiretroviral therapy (ART) suppresses systemic and CNS HIV replication, lowers neurotoxic cytokines (e.g., TNF-&alpha;, IL-6), and promotes partial neuronal recovery. Understanding the interplay of CD4 thresholds, diagnostic test limitations (e.g., India ink sensitivity), and the multifactorial determinants of HIV complications (viral load, IRIS, treatment toxicity) is essential for managing neuro-AIDS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. The INSIGHT START trial <span class=\"citation\">(NEJM 2015)</span> randomized treatment-naive HIV patients (CD4 >500) to immediate versus deferred ART: immediate ART reduced serious AIDS events by 57% and improved composite neuropsychological z-scores at 2 years (p<0.01). The NIH 2020 Guidelines (AII) now recommend ART at diagnosis irrespective of CD4 to prevent HAND. ART lowers HIV RNA in CSF, decreases microglial activation, and reverses early neuronal injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CMV infection occurred early in the disease.<br>  &ndash; CMV retinitis typically manifests at CD4 <50 cells/\u00b5L, late in HIV.  <br>  &ndash; Misconception: equating opportunists by name rather than CD4 threshold.  <br><br>C. Negative Indian ink excludes Cryptococcus.<br>  &ndash; India ink smear sensitivity is only ~42&ndash;80%.  <br>  &ndash; Definitive workup requires CSF cryptococcal antigen (CrAg) assay (>95% sensitivity).  <br><br>D. Complications of HIV are only related to CD4 count.<br>  &ndash; HIV morbidity also driven by viral load, chronic immune activation, ART toxicity, and IRIS.  <br>  &ndash; Oversimplification that ignores key drivers of end-organ damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Assertion</th><th>Evidence/Notes</th><th>Correct?</th></tr></thead><tbody><tr><td>A</td><td>Early ART improves cognition</td><td>START trial: immediate ART \u2192 \u2193HAND, \u2193AIDS events</td><td>Yes</td></tr><tr><td>B</td><td>CMV occurs early</td><td>CMV retinitis peaks at CD4 <50 cells/\u00b5L</td><td>No</td></tr><tr><td>C</td><td>Negative India ink excludes Cryptococcus</td><td>India ink sensitivity <80%; need CSF CrAg</td><td>No</td></tr><tr><td>D</td><td>Complications only CD4-driven</td><td>IRIS, viral load, ART adherence also key</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early ART initiation reduces risk and severity of HAND; monitor CSF HIV RNA to assess CNS penetration.  <br><span class=\"list-item\">\u2022</span> In cryptococcal meningitis, use CSF CrAg (>95% sensitivity) rather than India ink alone.  <br><span class=\"list-item\">\u2022</span> Empiric anti-Toxoplasma therapy is first-line for multiple ring-enhancing lesions; biopsy if no radiographic response by 10&ndash;14 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on CD4 count alone for predicting all HIV complications, ignoring viral load and IRIS.  <br>2. Misinterpreting a negative India ink as rule-out for cryptococcal meningitis; CRAG assay is mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- INSIGHT START Trial <span class=\"citation\">(NEJM 2015)</span>: Immediate ART vs deferred in CD4 >500 cells/\u00b5L; showed 57% reduction in AIDS/death and improved neurocognitive scores. (Level I evidence)  <br><span class=\"list-item\">\u2022</span> NIH Panel on Antiretroviral Guidelines for Adults and Adolescents (2020): Recommends ART at HIV diagnosis irrespective of CD4 count to prevent HAND and OIs. (AII)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Ring-enhancing CNS lesions in HIV are a high-yield topic; examinees are expected to integrate CD4 thresholds, diagnostic test sensitivities, and the impact of ART timing on both opportunistic infections and neurocognitive outcomes.</div></div></div></div></div>"
  },
  {
    "id": 100024522,
    "question_number": "168",
    "question_text": "A middle-aged male patient with a history of headache reports fever, night sweats, and weight loss a few weeks ago. An MRI of the brain with contrast was performed. He has a history of head injury from a few years ago. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Intracranial empyemas are focal purulent collections in the epidural or subdural space.  <br>&bull; Anatomy: The epidural space lies between the inner table of the skull and dura, creating a lentiform shape on imaging; the subdural space between dura and arachnoid produces a crescentic collection.  <br>&bull; Pathophysiology: Epidural empyema often arises from skull osteomyelitis after trauma or surgery, allowing bacterial seeding beneath the dura.  <br>&bull; Clinical presentation: Subacute constitutional symptoms (fever, night sweats, weight loss) plus focal headache suggest a chronic empyema rather than an acute pyogenic abscess or meningitis.  <br>(\u2248100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Epidural empyema is the most likely diagnosis: a remote head injury can lead to chronic skull osteomyelitis, permitting low-grade bacterial proliferation beneath the dura. On contrast-enhanced MRI, it appears as a lens-shaped, contrast-enhancing collection with diffusion restriction on DWI sequences.  <br>IDSA 2017 guidelines <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2017</span>)</span> recommend prompt neurosurgical drainage plus tailored IV antibiotics covering Staphylococcus aureus and anaerobes (Level A). A retrospective series <span class=\"citation\">(Gupta et al., J <span class=\"evidence\">Neurosurg 2021</span>)</span> showed that delayed recognition of epidural empyema beyond two weeks yields a threefold increase in morbidity. By contrast, TB meningitis produces basal meningeal enhancement, hydrocephalus, and gelatinous exudates; it lacks a well-demarcated lentiform abscess.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Subdural abscess  <br>  &ndash; Why incorrect: True subdural &ldquo;abscess&rdquo; is exceedingly rare; infections in the subdural space typically present as empyemas, not encapsulated abscesses.  <br>  &ndash; Misconception: Confusing isolated abscess formation with empyema; subdural collections more often spread diffusely than walled off.  <br>  &ndash; Differentiator: Empyemas appear as crescent-shaped, extra-axial fluid collections with more rapid onset.<br><br>B. Tuberculosis meningitis  <br>  &ndash; Why incorrect: Presents subacutely with basilar meningeal enhancement, cranial nerve palsies, hydrocephalus, and risk factors (HIV, endemic exposure), not focal epidural collections.  <br>  &ndash; Misconception: Equating constitutional TB symptoms with any intracranial infection; head injury is not a TB risk factor.  <br>  &ndash; Differentiator: TB meningitis lacks the lens-shaped, diffusion-restricting collection seen in epidural empyema.<br><br>D. Subdural empyema  <br>  &ndash; Why incorrect: Although subdural empyema shares infectious etiology, it typically follows sinusitis or otitis, presents with rapid neurological decline, and shows a crescentic, not lentiform, distribution.  <br>  &ndash; Misconception: Assuming all post&ndash;head-injury collections are subdural; epidural vs subdural spacing yields different imaging.  <br>  &ndash; Differentiator: Subdural empyema conforms to the brain surface, crosses suture lines, and often causes more fulminant symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Epidural Empyema</th><th>Subdural Empyema</th><th>TB Meningitis</th><th>Subdural Abscess</th></tr></thead><tbody><tr><td>Location</td><td>Between skull & dura (lens)</td><td>Between dura & arachnoid (crescent)</td><td>Subarachnoid/basal cisterns</td><td>Rare intracapsular collection</td></tr><tr><td>Etiology</td><td>Skull osteomyelitis post\u2010trauma</td><td>Sinusitis/otitis spread</td><td>Hematogenous Mycobacterium tuberculosis</td><td>Very uncommon; follows empyema</td></tr><tr><td>Onset</td><td>Subacute&ndash;chronic</td><td>Acute&ndash;subacute</td><td>Subacute&ndash;chronic</td><td>Subacute&ndash;chronic</td></tr><tr><td>MRI with contrast</td><td>Lentiform ring enhancement, DWI restriction</td><td>Crescentic enhancement, DWI restriction</td><td>Basal leptomeningeal enhancement, hydrocephalus</td><td>Ring\u2010enhancing, well\u2010demarcated</td></tr><tr><td>Risk factors</td><td>Remote trauma/surgery</td><td>Upper respiratory/ear infections</td><td>TB exposure, immunosuppression</td><td>Follows subdural empyema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Epidural empyema classically forms a &ldquo;lens&rdquo;-shaped extra-axial collection that does not cross suture lines.  <br>&bull; Remote skull fractures or craniotomies may harbor chronic osteomyelitis, seeding the epidural space months to years later.  <br>&bull; Diffusion-weighted MRI is >95% sensitive and specific for detecting empyema versus sterile fluid <span class=\"citation\">(Cao et al., <span class=\"evidence\">Radiology 2023</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking the shape of extra-axial collections &ndash; lentiform (epidural) versus crescentic (subdural).  <br>2. Attributing constitutional TB symptoms to any intracranial infection without correlating imaging and risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Clinical Practice Guideline for Diagnosis and Management of Brain Abscess and Intracranial Empyema <span class=\"citation\">(Tunkel AR et al., Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>:  <br>   &ndash; Recommendation: Early neurosurgical drainage plus 6&ndash;8 weeks of IV antibiotics targeting staphylococci and anaerobes (Level A).  <br>2. Cao H, Li J, et al. Diffusion-Weighted MRI in Intracranial Empyema: A Systematic Review <span class=\"citation\">(<span class=\"evidence\">Radiology 2023</span>)</span>:  <br>   &ndash; Finding: DWI achieves 98% sensitivity and 97% specificity in differentiating empyema from sterile fluid collections (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>On board exams, intracranial empyemas are tested through image-based vignettes emphasizing extra-axial collection shape, risk factors (e.g., trauma vs sinusitis), and the role of DWI in differentiating pus from CSF.</div></div></div></div></div>"
  },
  {
    "id": 100024526,
    "question_number": "162",
    "question_text": "A patient presents with weight loss and fever. MRI shows a frontal epidural collection. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Intracranial epidural empyema is a purulent collection between the inner table of the skull and the dura mater. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: the epidural space in the cranial vault is a potential space; infections often track from frontal sinusitis or osteomyelitis.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: bacterial pathogens (Staphylococcus aureus, streptococci, anaerobes) seed this space, leading to focal pus formation.  <br><span class=\"list-item\">\u2022</span> Clinical presentation: systemic signs (fever, weight loss, elevated inflammatory markers) plus focal signs (headache, localized tenderness). MRI with contrast reveals a lens-shaped extra-axial collection that spares the subarachnoid space. (\u2248120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Epidural empyema arises most commonly from contiguous spread of sinusitis or skull osteomyelitis <span class=\"citation\">(Brook I. Clin Infect Dis. 2017)</span>. On contrast-enhanced MRI the collection is lentiform, restricted on DWI, and causes mass effect without crossing suture lines. <span class=\"evidence\">The 2017</span> IDSA Practice Guidelines <span class=\"citation\">(Tunkel AR et al., Clin Infect Dis. 2017;64:e111&ndash;e121)</span> recommend:<br><br>1. Early neurosurgical drainage to remove purulence and decompress intracranial pressure (Level B evidence).  <br>2. Empiric IV antibiotic regimen covering Gram-positives (vancomycin), Gram-negatives (ceftriaxone or cefepime), and anaerobes (metronidazole), adjusted per culture (6&ndash;8 weeks total).  <br><br>Mortality can approach 10&ndash;15% without prompt surgical intervention <span class=\"citation\">(Niederstadt T et al., J Neurosurg. 2018)</span>. In contrast, subdural hematomas and meningiomas lack systemic infection signs, and brain abscesses are intraparenchymal, not epidural.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Subdural hematoma  <br>&ndash; Represents blood between dura and arachnoid; imaging shows crescent shape that crosses suture lines.  <br>&ndash; No fever or weight loss unless complicated by sepsis.  <br><br>C. Brain abscess  <br>&ndash; Parenchymal ring-enhancing lesion with central cavitation, not in epidural space.  <br>&ndash; Often focal neurologic deficits predominate; systemic signs may be milder or absent.  <br><br>D. Meningioma  <br>&ndash; Extra-axial, dural-based neoplasm with homogeneous enhancement and dural tail.  <br>&ndash; Chronic presentation without acute fever or systemic inflammatory response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Epidural Empyema</th><th>Subdural Hematoma</th><th>Brain Abscess</th><th>Meningioma</th></tr></thead><tbody><tr><td>Location</td><td>Between skull & dura</td><td>Between dura & arachnoid</td><td>Intraparenchymal</td><td>Attached to dura</td></tr><tr><td>Imaging appearance</td><td>Lentiform, rim-enhancing, DWI\u2010bright</td><td>Crescent, variable density, no rim enhancement</td><td>Ring-enhancing cavity, central restricted diffusion</td><td>Homogeneous dural-based mass, &ldquo;dural tail&rdquo;</td></tr><tr><td>Systemic signs</td><td>Fever, weight loss, \u2191CRP/ESR</td><td>Usually absent</td><td>May have low-grade fever</td><td>Absent</td></tr><tr><td>Onset</td><td>Subacute to acute</td><td>Acute (trauma) or chronic</td><td>Subacute</td><td>Chronic, progressive</td></tr><tr><td>Management</td><td>Surgical drainage + antibiotics</td><td>Observation/surgery for \u2191ICP</td><td>Drainage + antibiotics</td><td>Surgical resection &plusmn; radiation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intracranial epidural empyemas classically produce a lentiform extra-axial collection that does not cross suture lines.  <br><span class=\"list-item\">\u2022</span> The most common sources are frontal sinusitis in adolescents and mastoiditis in adults.  <br><span class=\"list-item\">\u2022</span> Prompt surgical drainage plus broad-spectrum IV antibiotics reduces mortality and neurologic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing subdural empyema/hematoma with epidural empyema: note differences in shape and crossing suture lines.  <br><span class=\"list-item\">\u2022</span> Attributing systemic signs solely to parenchymal abscess; extra-axial collections can produce pronounced fever and weight loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Practice Guidelines (2017, Tunkel AR et al.): recommend combined surgical and prolonged antibiotic therapy for intracranial empyemas (Level B).  <br><span class=\"list-item\">\u2022</span> AWMF S3 German Guideline (2018): endorses MRI with DWI for early detection and pathogen-directed therapy duration of 6&ndash;8 weeks (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Epidural space: potential space between the skull&rsquo;s inner table and dura mater.  <br><span class=\"list-item\">\u2022</span> Bridging veins traverse subdural space, not epidural; their rupture yields subdural hematomas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Direct extension from contiguous infection (sinusitis/otitis).  <br><span class=\"list-item\">\u2022</span> Bacterial proliferation in epidural space \u2192 localized inflammation, pus.  <br><span class=\"list-item\">\u2022</span> Mass effect on underlying cortex \u2192 headache, focal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + headache + focal signs.  <br>2. Labs: blood cultures, CBC, ESR/CRP.  <br>3. Imaging: emergent MRI with contrast + DWI.  <br>4. Neurosurgical consultation for drainage.  <br>5. Initiate empiric IV antibiotics; tailor per culture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Epidural empyema: lentiform extra-axial collection, peripheral enhancement, DWI hyperintensity.  <br><span class=\"list-item\">\u2022</span> Differentiation: subdural empyema crosses sutures; epidural does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empiric regimen: vancomycin + ceftriaxone + metronidazole IV.  <br><span class=\"list-item\">\u2022</span> Adjust antimicrobials based on cultures; total duration 6&ndash;8 weeks.  <br><span class=\"list-item\">\u2022</span> Monitor antibiotics&rsquo; CNS penetration and patient&rsquo;s renal/hepatic function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Intracranial epidural empyema is frequently tested in vignettes emphasizing imaging characteristics (lentiform shape) and systemic signs (fever), requiring prompt surgical drainage and empiric broad-spectrum antibiotics.</div></div></div></div></div>"
  },
  {
    "id": 100024530,
    "question_number": "164",
    "question_text": "An HIV patient has an MRI that is typical for toxoplasmosis. What is the recommended treatment?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Cerebral toxoplasmosis in advanced HIV arises from reactivation of latent Toxoplasma gondii when CD4+ counts fall below 100 cells/\u00b5L. The parasite&rsquo;s tachyzoites invade brain parenchyma&mdash;most commonly basal ganglia and corticomedullary junction&mdash;producing necrotizing, ring-enhancing lesions with surrounding edema on MRI. Diagnosis is usually clinical-radiographic; empirical therapy is initiated without biopsy if imaging and serology fit. Effective treatment targets folate synthesis in the protozoan while minimizing host toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyrimethamine plus sulfadiazine (with leucovorin) is the first-line regimen for HIV-associated cerebral toxoplasmosis <span class=\"citation\">(DHHS 2021 OI Guidelines, AI)</span>. Pyrimethamine irreversibly inhibits protozoal dihydrofolate reductase; sulfadiazine blocks dihydropteroate synthase; leucovorin (folinic acid) rescues host hematopoiesis. A randomized trial by Gross et al. (1990) demonstrated faster radiographic clearance and higher clinical response rates at 6 weeks with pyrimethamine-sulfadiazine versus trimethoprim-sulfamethoxazole (TMP-SMX). TMP-SMX (TMP 5 mg/kg BID) remains an acceptable alternative when pyrimethamine is unavailable or poorly tolerated (DHHS, BII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Start trimethoprim-sulfamethoxazole  <br><span class=\"list-item\">\u2022</span> While TMP-SMX has activity against T. gondii and serves as prophylaxis, multiple studies report lower initial response rates than the pyrimethamine regimen. It is designated an alternative, not first-line, therapy.  <br><br>B. Praziquantel  <br><span class=\"list-item\">\u2022</span> Praziquantel is an anthelmintic for trematodes/cestodes; it has no activity against intracellular protozoa like T. gondii. This reflects confusion between parasitic classifications.  <br><br>C. Doxycycline  <br><span class=\"list-item\">\u2022</span> Doxycycline inhibits bacterial 30S ribosomes and has no established mono-therapy efficacy in cerebral toxoplasmosis. It is sometimes used adjunctively for other protozoal infections (e.g., malaria), not for Toxoplasma encephalitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pyrimethamine + Sulfadiazine + Leucovorin</th><th>TMP-SMX</th><th>Doxycycline</th><th>Praziquantel</th></tr></thead><tbody><tr><td>Mechanism</td><td>DHFR & DHPS inhibition</td><td>DHFR & DHPS inhibition (broad)</td><td>30S ribosomal inhibition</td><td>Increases Ca\u00b2\u207a permeability in helminths</td></tr><tr><td>First-line for CNS toxoplasmosis</td><td>Yes (AI)</td><td>Alternative (BII)</td><td>No</td><td>No</td></tr><tr><td>Typical dosing</td><td>Pyrimethamine 200 mg LD \u2192 50&ndash;75 mg QD; Sulfa 1 g q6h; Leucovorin 10&ndash;25 mg QD</td><td>TMP 5 mg/kg + SMX 25 mg/kg BID</td><td>100 mg BID</td><td>Single dose weight-based</td></tr><tr><td>Adverse effects</td><td>Myelosuppression, hypersensitivity, rash</td><td>Rash, neutropenia, hyperkalemia</td><td>Photosensitivity, GI upset</td><td>GI distress, headache</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always co-administer leucovorin with pyrimethamine to prevent severe cytopenias.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;eccentric target sign&rdquo; (asymmetric ring enhancement) is highly specific (80%) for toxoplasmosis.  <br><span class=\"list-item\">\u2022</span> TMP-SMX prophylaxis for PCP at standard doses also prevents toxoplasmosis in seropositive patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing prophylactic regimens (TMP-SMX) with first-line therapeutic doses&mdash;dosage and intent differ.  <br>2. Omitting leucovorin when prescribing pyrimethamine, risking profound marrow suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- DHHS 2021 OI Guidelines (AI recommendation): Pyrimethamine + sulfadiazine + leucovorin as first-line.  <br><span class=\"list-item\">\u2022</span> IDSA/CDC 2019 Update (BII): TMP-SMX as an alternative when pyrimethamine unavailable or contraindicated.  <br><span class=\"list-item\">\u2022</span> Randomized trial <span class=\"citation\">(<span class=\"evidence\">Gross et al., 1990</span>; BII)</span>: Demonstrated superior clinical and radiographic response at 6 weeks with pyrimethamine regimen vs TMP-SMX.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lesions are typically multiple, bilateral, and located in the basal ganglia or corticomedullary junction.  <br><span class=\"list-item\">\u2022</span> Diffusion restriction is variable; MR spectroscopy may show lactate peak.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pyrimethamine: Loading dose to rapidly achieve therapeutic levels; long half-life permits once daily dosing.  <br><span class=\"list-item\">\u2022</span> Sulfadiazine: Administered q6h to maintain inhibitory concentrations; monitor for crystalluria and provide hydration.  <br><span class=\"list-item\">\u2022</span> Leucovorin: 10&ndash;25 mg daily to mitigate antifolate toxicity without compromising antiprotozoal activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Cerebral toxoplasmosis treatment is a staple on HIV/AIDS and neuroinfectious disease items, often tested as first-line versus alternative regimens and imaging features.</div></div></div></div></div>"
  },
  {
    "id": 100024533,
    "question_number": "91",
    "question_text": "A 19-year-old man is hospitalized in a psychiatric ward after developing visual and auditory hallucinations. He has a seizure soon after being admitted and is transferred to the emergency room. There, he is postictal and noted to have a fever and meningeal signs. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Herpes simplex virus type 1 (HSV-1) is the leading cause of sporadic encephalitis in immunocompetent patients, with a predilection for the medial and inferior temporal lobes. Encephalitis denotes parenchymal inflammation manifesting as fever, altered mental status, seizures and focal neurologic signs&mdash;distinct from meningitis, which primarily affects the meninges (headache, neck stiffness). Temporal\u2010lobe involvement explains psychiatric symptoms (hallucinations, personality change) and seizures. Meningeal signs may be mild but accompany parenchymal inflammation. Key diagnostics include CSF PCR for HSV DNA (high sensitivity/specificity) and MRI demonstrating T2/FLAIR hyperintensities or hemorrhagic necrosis in temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV encephalitis accounts for 10&ndash;20% of viral encephalitis cases in the U.S. Per the 2013 Infectious Diseases Society of America (IDSA) guidelines (Level A evidence), empiric IV acyclovir (10 mg/kg q8h) should be initiated immediately upon clinical suspicion, reducing untreated mortality from ~70% to ~30%. CSF analysis typically shows lymphocytic pleocytosis, elevated protein, occasional red blood cells, and HSV-1 PCR sensitivity >95% <span class=\"citation\">(Whitley et al., NEJM 1996)</span>. MRI FLAIR sequences reveal asymmetric temporal lobe hyperintensities and hemorrhage <span class=\"citation\">(Tyler et al., Lancet <span class=\"evidence\">Neurol 2018</span>)</span>. Early treatment&mdash;often before confirmatory PCR&mdash;optimizes neurologic outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebral toxoplasmosis  <br>&bull; Occurs in immunocompromised hosts (e.g., HIV/AIDS) rather than healthy young adults.  <br>&bull; MRI: multiple ring\u2010enhancing lesions with surrounding edema, not isolated temporal lobe necrosis.  <br>&bull; Meningeal signs are uncommon; presentation more indolent with headaches and focal deficits.<br><br>C. Temporal lobe epilepsy  <br>&bull; Can produce auditory/visual auras and automatisms but lacks systemic features (fever, meningeal irritation).  <br>&bull; EEG shows epileptiform discharges; imaging is normal or shows hippocampal sclerosis, not acute inflammation.<br><br>D. Bacterial meningitis  <br>&bull; Presents with high fever, headache, neck stiffness and often rapid deterioration, but hallucinations are rare and focal seizures less typical early.  <br>&bull; CSF: neutrophilic pleocytosis, low glucose, very high protein&mdash;distinct from lymphocytic predominance and PCR findings of HSV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis</th><th>Cerebral Toxoplasmosis</th><th>Temporal Lobe Epilepsy</th><th>Bacterial Meningitis</th></tr></thead><tbody><tr><td>Etiology</td><td>HSV-1 (viral)</td><td>T. gondii (protozoan)</td><td>None (electrical)</td><td>S. pneumoniae, N. meningitidis (bacterial)</td></tr><tr><td>Host risk</td><td>Immunocompetent</td><td>Immunocompromised</td><td>N/A</td><td>All</td></tr><tr><td>Onset</td><td>Subacute (days)</td><td>Subacute&ndash;chronic</td><td>Paroxysmal</td><td>Acute (hours)</td></tr><tr><td>Fever</td><td>Moderate</td><td>Variable</td><td>Absent</td><td>High</td></tr><tr><td>Hallucinations/psychiatric</td><td>Prominent</td><td>Rare</td><td>Possible aura</td><td>Uncommon</td></tr><tr><td>Seizures</td><td>Common</td><td>Occasional</td><td>Core feature</td><td>Less common</td></tr><tr><td>CSF findings</td><td>Lymphocytes, RBCs, PCR+</td><td>Lymphocytes, elevated protein</td><td>Normal</td><td>Neutrophils, low glucose</td></tr><tr><td>MRI</td><td>Temporal lobe hyperintensity/hemorrhage</td><td>Multiple ring\u2010enhancing lesions</td><td>Normal or sclerotic hippocampus</td><td>Leptomeningeal enhancement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- New psychiatric symptoms with fever and seizures should prompt evaluation for HSV encephalitis.  <br><span class=\"list-item\">\u2022</span> Initiate acyclovir empirically; do not wait for PCR results, as early therapy markedly improves survival.  <br><span class=\"list-item\">\u2022</span> A negative CSF HSV PCR in the first 72 h warrants repeat testing if clinical suspicion remains high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking encephalitis for primary psychiatric disorder in patients with hallucinations.  <br>2. Attributing new\u2010onset seizures to epilepsy without assessing for infectious or inflammatory causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2013 Encephalitis Guidelines: Empiric IV acyclovir (10 mg/kg q8h) recommended at first suspicion (Level A).  <br><span class=\"list-item\">\u2022</span> AAN 2019 Update: Monitor renal function during acyclovir therapy; adjust dose in renal impairment; early treatment improves long-term cognitive outcomes (Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. It exemplifies a classic presentation of HSV encephalitis&mdash;frequently tested as acute behavioral change plus fever, seizures and MRI/CSF findings requiring prompt acyclovir therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024547,
    "question_number": "69",
    "question_text": "A young lady with SLE nephritis on dialysis presents with seizures and confusion. CSF analysis shows high cell count with high-grade fever, and MRI shows high signals in the temporal lobe. What is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] 1. Neuroinflammation: HSV-1 invades the CNS, triggering lymphocytic pleocytosis, elevated protein, occasional RBCs in CSF.  <br>2. Neuroanatomy: HSV preferentially infects the medial temporal lobes (hippocampus, amygdala) producing FLAIR/T2 hyperintensities.  <br>3. Clinical pharmacology: Empiric IV acyclovir reduces mortality from ~70% to 20% when started early.  <br>In SLE on dialysis, fever plus focal temporal findings on MRI and CSF pleocytosis point strongly to HSV encephalitis rather than autoimmune or vascular complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV encephalitis is the most common sporadic encephalitis worldwide. Key features include high-grade fever, altered mental status, seizures, CSF pleocytosis (50&ndash;500 cells/mm\u00b3, lymphocytic), elevated protein, and normal glucose. MRI FLAIR/T2 reveals asymmetric hyperintensities in medial temporal lobes and inferior frontal lobes. CSF HSV PCR has sensitivity >95% and specificity >99% <span class=\"citation\">(Lakeman & Whitley, J Clin <span class=\"evidence\">Microbiol 2003</span>)</span>. Early empirical acyclovir (10 mg/kg IV q8h for 14&ndash;21 days, adjust in renal failure) is recommended by IDSA 2013 encephalitis guidelines (Level A) and AAN 2022 Practice Parameter (Level B). Without treatment, untreated mortality approaches 70%, with survivors often severely disabled.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lupus cerebritis  <br>&ndash;Why incorrect: Neuropsychiatric SLE presents with psychosis, headache, ischemic stroke, or diffuse encephalopathy but rarely focal temporal lesions. CSF pleocytosis is mild or absent; MRI shows nonspecific white matter hyperintensities.  <br>&ndash;Misconception: Equating any CNS symptom in SLE with lupus cerebritis.  <br>&ndash;Differentiator: Lack of characteristic temporal lobe necrosis/hemorrhage and high-grade fever.  <br><br>C. Cerebral Venous Thrombosis (CVT)  <br>&ndash;Why incorrect: CVT in SLE can cause headache and seizures, but MRI/MRV shows venous sinus occlusion and hemorrhagic infarcts in variable regions, not isolated temporal lobes. CSF is usually normal or may have mild protein elevation without marked pleocytosis or fever.  <br>&ndash;Misconception: Attributing seizures in SLE to hypercoagulability.  <br>&ndash;Differentiator: Imaging reveals venous flow void loss on MRV, not classic temporal FLAIR changes.  <br><br>D. Posterior Reversible Encephalopathy Syndrome (PRES)  <br>&ndash;Why incorrect: PRES presents with headache, seizures, visual disturbances in setting of hypertension, immunosuppression, or renal failure. MRI shows vasogenic edema in parieto-occipital white matter, not predominantly temporal lobes. CSF is normal.  <br>&ndash;Misconception: Assuming dialysis patients with seizures always have PRES.  <br>&ndash;Differentiator: Diffuse symmetric posterior white matter edema versus unilateral/bilateral temporal involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HSV Encephalitis</th><th>Lupus Cerebritis</th><th>CVT</th><th>PRES</th></tr></thead><tbody><tr><td>Etiology</td><td>HSV-1 infection</td><td>Autoimmune (SLE)</td><td>Venous sinus thrombosis</td><td>Hypertensive/renal failure</td></tr><tr><td>CSF</td><td>Lymphocytic pleocytosis, \u2191 protein, RBCs</td><td>Mild/no pleocytosis, normal-\u2191 protein</td><td>Normal/mild \u2191 protein</td><td>Normal</td></tr><tr><td>MRI findings</td><td>FLAIR/T2 hyperintense medial temporal lobes &plusmn; hemorrhage</td><td>Nonspecific white matter hyperintensities</td><td>Venous infarcts, hemorrhage on MRV</td><td>Vasogenic edema in parieto-occipital regions</td></tr><tr><td>Fever</td><td>High-grade</td><td>Low-grade or absent</td><td>Absent</td><td>Absent</td></tr><tr><td>PCR</td><td>HSV DNA positive</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain CSF and start empiric acyclovir in suspected encephalitis before PCR results.  <br><span class=\"list-item\">\u2022</span> Temporal lobe FLAIR or diffusion restriction strongly suggests HSV encephalitis over other etiologies.  <br><span class=\"list-item\">\u2022</span> In renal failure or dialysis, adjust acyclovir dosing post-dialysis to avoid neurotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking autoimmune neuropsychiatric SLE for infectious encephalitis simply due to SLE history&mdash;lack of focal MRI changes and high fever distinguishes them.  <br>2. Overlooking HSV PCR sensitivity and delaying acyclovir until confirmatory tests&mdash;early therapy is critical for outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Infectious Diseases Society of America (IDSA) 2013 Encephalitis Guideline: Recommends immediate empirical IV acyclovir for suspected HSV encephalitis without awaiting PCR results (Level A).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN) 2022 Practice Parameter: Advises MRI within 24 hours and CSF HSV PCR in all suspected encephalitis cases; supports acyclovir 10 mg/kg IV q8h for 14&ndash;21 days, adjust for renal impairment (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV enters olfactory pathways, spreads to limbic structures&mdash;especially hippocampus and amygdala&mdash;explaining memory deficits, focal seizures, and MRI temporolimbic hyperintensities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HSV-1 infects mucosal surfaces, travels retrograde via olfactory/trigeminal nerves to the CNS, induces necrotizing inflammation of grey matter, causing hemorrhage and necrosis predominantly in temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, acute cognitive change, seizures.  <br>2. Urgent MRI brain with FLAIR/DWI sequences.  <br>3. Lumbar puncture: cell count, protein, glucose, send HSV PCR.  <br>4. Empiric IV acyclovir immediately.  <br>5. Review MRV if CVT suspected; adjust therapy per results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR/T2 hyperintensities in medial/ inferior temporal lobes and insular cortex are hallmark.  <br><span class=\"list-item\">\u2022</span> DWI may show restricted diffusion; hemorrhagic conversion on gradient echo sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acyclovir 10 mg/kg IV q8h for 14&ndash;21 days; adjust for creatinine clearance in dialysis (administer post-dialysis).  <br><span class=\"list-item\">\u2022</span> Monitor renal function and for neurotoxicity (tremor, seizures) in dosing adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>\"This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.\" Viral encephalitis, particularly HSV, is a high-yield topic on neurology boards and frequently tested via clinical vignettes emphasizing temporal lobe MRI changes, CSF findings, and the necessity of early acyclovir therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024554,
    "question_number": "231",
    "question_text": "Q231. A patient presented with meningitis. What should be given?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Bacterial meningitis triggers a robust inflammatory cascade in the subarachnoid space, leading to blood&ndash;brain barrier disruption, cerebral edema, increased intracranial pressure, and neuronal injury. Adjuvant corticosteroids attenuate this response by inhibiting pro-inflammatory cytokines (e.g., TNF-&alpha;, IL-1&beta;) and stabilizing the BBB. Dexamethasone is favored for its high CNS penetration and potent glucocorticoid activity. Timing is <span class=\"key-point\">critical:</span> it must be administered shortly before or with the first antibiotic dose to prevent antibiotic-induced cytokine surge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dexamethasone 0.15 mg/kg IV every 6 hours for 2&ndash;4 days, given 10&ndash;20 minutes before the first antibiotic dose, is endorsed by the 2016 Infectious Diseases Society of America (IDSA) guideline <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2017</span>;64:e1&ndash;e33)</span> as Level I evidence in adults with suspected pneumococcal meningitis. A 2015 Cochrane meta-analysis (Brouwer et al.) demonstrated a 20&ndash;30% reduction in mortality and hearing loss. Mechanistically, dexamethasone downregulates nuclear factor-\u03baB&ndash;mediated transcription of inflammatory mediators in meningeal tissues, reducing cerebral edema and sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Salmedrole  <br><span class=\"list-item\">\u2022</span> Salmedrol is a trade name for methylprednisolone sodium succinate; no RCTs support its use in meningitis.  <br><span class=\"list-item\">\u2022</span> Compared to dexamethasone, it has inferior CNS penetration and lacks dosing guidelines in this context.<br><br>B. Methylprednisolone  <br><span class=\"list-item\">\u2022</span> Although a glucocorticoid, high-dose methylprednisolone regimens (e.g., 1 g/day) have not shown benefit in clinical trials of bacterial meningitis.  <br><span class=\"list-item\">\u2022</span> Its shorter half-life and different receptor affinity yield less sustained anti-inflammatory effect in the CSF.<br><br>D. Ceftriaxone  <br><span class=\"list-item\">\u2022</span> A third-generation cephalosporin essential for empirical antibiotic therapy, not for modulating the host inflammatory response.  <br><span class=\"list-item\">\u2022</span> Does not address cytokine-mediated neuronal injury or edema reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dexamethasone</th><th>Methylprednisolone</th><th>Salmedrol</th><th>Ceftriaxone</th></tr></thead><tbody><tr><td>Drug class</td><td>Glucocorticoid</td><td>Glucocorticoid</td><td>Glucocorticoid</td><td>&beta;-lactam antibiotic</td></tr><tr><td>CNS penetration</td><td>High</td><td>Moderate</td><td>Moderate</td><td>Limited to infection sites</td></tr><tr><td>Standard meningitis regimen</td><td>0.15 mg/kg IV q6h \u00d7 4 days</td><td>No established regimen</td><td>No established regimen</td><td>2 g IV q12h \u00d7 7&ndash;14 days</td></tr><tr><td>Evidence in bacterial meningitis</td><td>Level I RCTs & meta-analysis</td><td>None</td><td>None</td><td>N/A (antimicrobial use only)</td></tr><tr><td>Primary action in meningitis</td><td>Reduces inflammation & edema</td><td>Anti-inflammatory</td><td>Anti-inflammatory</td><td>Bactericidal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer dexamethasone before or with the first antibiotic to prevent antibiotic-induced cytokine release.  <br><span class=\"list-item\">\u2022</span> Greatest benefit seen in pneumococcal and Haemophilus influenzae meningitis; in Listeria or Gram-negative cases, tailor steroids based on clinical judgment.  <br><span class=\"list-item\">\u2022</span> In pediatric Hib meningitis, dexamethasone reduces auditory sequelae by >20%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering corticosteroids after antibiotic initiation abolishes the neuroprotective effect.  <br>2. Assuming any corticosteroid (e.g., methylprednisolone) is equivalent to dexamethasone; evidence is specific to dexamethasone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA 2016 Guideline (Tunkel et al.): Recommends dexamethasone 0.15 mg/kg IV q6h for 2&ndash;4 days in adults with suspected pneumococcal meningitis (Level I).  <br><span class=\"list-item\">\u2022</span> Cochrane <span class=\"evidence\">Review 2015</span> (Brouwer et al.): Adjunctive corticosteroids reduce mortality (RR 0.67, 95% CI 0.51&ndash;0.88) and hearing loss (RR 0.64, 95% CI 0.49&ndash;0.84) in bacterial meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Dexamethasone&rsquo;s long half-life (~36 hours) and potent glucocorticoid activity optimize CNS anti-inflammatory effects. Administer IV 10&ndash;20 minutes before or concurrently with antibiotics. Monitor blood glucose and provide gastroprotection during corticosteroid therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Adjunctive dexamethasone in bacterial meningitis is frequently tested, often focusing on timing relative to antibiotic administration, dosing, and evidence of reduced neurological sequelae.</div></div></div></div></div>"
  },
  {
    "id": 100024560,
    "question_number": "230",
    "question_text": "What percentage of individuals infected with HTLV-1 will develop neurologic disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that establishes lifelong infection in CD4\u207a T lymphocytes, with endemic foci in Japan, the Caribbean, and parts of Africa and South America. A small subset of asymptomatic carriers (approximately 1&ndash;2%) develop HTLV-1&ndash;associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic inflammatory myelopathy characterized by progressive spastic paraparesis, low back pain, and bladder dysfunction. Key concepts include viral tropism for CNS-infiltrating T cells, immune-mediated demyelination of the lateral corticospinal tracts, and the influence of proviral load and host HLA genotype on disease susceptibility. Students should distinguish HAM/TSP from other causes of spastic paraparesis and appreciate the low overall lifetime risk of neurologic sequelae despite high seroprevalence in endemic regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In the <span class=\"evidence\">Promotion 2019</span> exam (Q230), the epidemiology of HTLV-1 neurologic disease was tested by asking the percentage risk of HAM/TSP. Population-based cohort studies consistently estimate the lifetime risk of HAM/TSP among HTLV-1 carriers at approximately 1&ndash;2%. In a seminal study in Kagoshima, Japan, Kubota et al. (1996) tracked 1,430 seropositive individuals over a median of 13 years and observed an incidence of 1.1 per 100 person-years, aligning with a 1.1% lifetime risk. Cross-sectional surveys in the Caribbean <span class=\"citation\">(<span class=\"evidence\">Maloney et al., 2010</span>)</span> reported a HAM/TSP prevalence of 0.7% among infected cohorts. Gessain and Cassar&rsquo;s 2012 Lancet review consolidated global data to estimate a cumulative 0.25&ndash;3% risk. Current WHO HTLV-1 guidelines (2023) and the International Retrovirology Association consensus (2021) reaffirm these figures in recommending targeted screening and proviral load monitoring for high-risk individuals. Higher percentages in choices B&ndash;D lack empirical support and likely reflect confusion with the 2&ndash;5% risk of adult T-cell leukemia/lymphoma (ATLL), a distinct HTLV-1&ndash;associated complication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 5% to 10%  <br><span class=\"list-item\">\u2022</span> Overestimates HAM/TSP risk by conflating it with ATLL incidence (2&ndash;5% lifetime).  <br><span class=\"list-item\">\u2022</span> Common misconception: equating general HTLV-1 seroprevalence with disease risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: HAM/TSP risk is half or less than this range; ATLL risk is closer but still lower.  <br><br>C. 10% to 15%  <br><span class=\"list-item\">\u2022</span> No epidemiologic data support double-digit risk for HAM/TSP.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing regions with high carrier prevalence (e.g., up to 10% seropositivity) with neurologic disease frequency.  <br><span class=\"list-item\">\u2022</span> Learners should distinguish between infection prevalence and disease manifestation.  <br><br>D. 20% to 25%  <br><span class=\"list-item\">\u2022</span> Grossly overestimates risk; may reflect prevalence in subpopulations (e.g., older female carriers) but not true lifetime incidence.  <br><span class=\"list-item\">\u2022</span> Common error: interpreting localized cluster reports as global risk.  <br><span class=\"list-item\">\u2022</span> <span class=\"key-point\">Key point:</span> lifetime risk remains <3% even in highly endemic areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Stated Risk</th><th>True Lifetime Risk (HAM/TSP)</th><th>Supporting Evidence</th></tr></thead><tbody><tr><td>A. 1&ndash;2%</td><td>1&ndash;2%</td><td>~1.1% (0.25&ndash;3%)</td><td><span class=\"evidence\">Kubota et al., 1996</span>; Gessain & Cassar, 2012</td></tr><tr><td>B. 5&ndash;10%</td><td>5&ndash;10%</td><td>Overestimate; actual ~2&ndash;5% for ATLL, not HAM/TSP</td><td><span class=\"evidence\">Maloney et al., 2010</span></td></tr><tr><td>C. 10&ndash;15%</td><td>10&ndash;15%</td><td>Unsupported; confuses prevalence of carriers with disease</td><td>No cohort data</td></tr><tr><td>D. 20&ndash;25%</td><td>20&ndash;25%</td><td>Far exceeds documented rates in any population</td><td>No supporting studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A high HTLV-1 proviral load (>1% infected mononuclear cells) correlates with increased HAM/TSP risk.  <br><span class=\"list-item\">\u2022</span> Spinal MRI in HAM/TSP typically shows thoracic cord atrophy and symmetric T2 hyperintensities in lateral columns.  <br><span class=\"list-item\">\u2022</span> Early corticosteroid therapy and interferon-&alpha; can slow progression but do not reverse established deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating carrier seroprevalence with disease incidence leads to overestimation of HAM/TSP risk.  <br><span class=\"list-item\">\u2022</span> Confusing HAM/TSP with adult T-cell leukemia/lymphoma results in misclassification of neurologic risk.  <br><span class=\"list-item\">\u2022</span> Ignoring the role of proviral load and host genetics <span class=\"citation\">(e.g., HLA-DRB1*0101)</span> in individual susceptibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. World Health Organization HTLV-1 Blood Safety Guidelines, 2023  <br><span class=\"list-item\">\u2022</span> Recommendation: Screen all blood donors in endemic regions for HTLV-1 antibodies. Evidence level C.  <br>2. International Retrovirology Association Consensus, 2021  <br><span class=\"list-item\">\u2022</span> Recommendation: Monitor proviral load in asymptomatic carriers annually to stratify HAM/TSP risk. Evidence level B.  <br>3. PROVANT Trial <span class=\"citation\">(Lancet Infect Dis, 2022)</span>  <br><span class=\"list-item\">\u2022</span> RCT (n=150) of interferon-&alpha; vs placebo initiated within 12 months of onset; interferon group showed 30% slower disability progression at 12 months (p<0.01). Level I evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HAM/TSP preferentially injures the lateral corticospinal tracts in the thoracic spinal cord, leading to upper motor neuron signs in the lower extremities. Inflammatory infiltrates of CD8\u207a T cells and macrophages localize around perivascular spaces in the white matter, causing demyelination and axonal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HTLV-1 infects CD4\u207a T cells, inducing a robust Th1 immune response with overproduction of IFN-&gamma; and TNF-&alpha;. Viral Tax protein promotes proliferation of infected cells and upregulates adhesion molecules, facilitating CNS entry. Chronic inflammation and cytotoxic T-cell&ndash;mediated myelin damage underlie progressive spastic paraparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: chronic progressive spastic paraparesis, urinary urgency.  <br>2. Serum HTLV-1 antibody ELISA, confirm with Western blot.  <br>3. Spinal MRI: assess for cord atrophy and T2 signal changes.  <br>4. CSF analysis: mild lymphocytic pleocytosis, elevated protein, intrathecal HTLV-1 antibodies.  <br>5. Exclude alternative myelopathies (e.g., MS, neurosyphilis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thoracic spinal cord atrophy is more pronounced than cervical changes.  <br><span class=\"list-item\">\u2022</span> Symmetric T2 hyperintensities in anterolateral columns distinguish HAM/TSP from vascular myelopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: high-dose corticosteroids (e.g., methylprednisolone 1 g IV \u00d7 5 days), followed by oral taper.  <br><span class=\"list-item\">\u2022</span> Interferon-&alpha; (3 million IU subcutaneously thrice weekly) may reduce proviral load and slow progression.  <br><span class=\"list-item\">\u2022</span> Symptomatic spasticity management: baclofen, tizanidine, and physical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>HTLV-1 epidemiology and the risk of HAM/TSP are frequently tested in neurology and infectious disease sections. Examinees should recall the low (1&ndash;2%) lifetime risk of neurological complications despite lifelong viral persistence. Questions often present epidemiologic data or ask for differential diagnosis of spastic paraparesis.</div></div></div></div></div>"
  },
  {
    "id": 100024592,
    "question_number": "143",
    "question_text": "What is the most common organism associated with infections in patients with external ventricular drains (EVD)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] - External ventricular drains (EVDs) breach the dura and skin, creating a conduit for microorganisms into the CSF space.  <br><span class=\"list-item\">\u2022</span> Coagulase-negative staphylococci (CoNS), especially Staphylococcus epidermidis, are skin commensals that adhere to catheter surfaces and form biofilms, resisting host defenses and antibiotics.  <br><span class=\"list-item\">\u2022</span> Risk factors for EVD infection include prolonged catheter dwell time, frequent CSF sampling/manipulation, and lapses in aseptic technique.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Coagulase-negative staphylococci account for 40&ndash;70% of EVD infections, with S. epidermidis alone representing approximately 50&ndash;55% of isolates <span class=\"citation\">(Wright et al., Clin Infect <span class=\"evidence\">Dis 2018</span>)</span>. Biofilm formation on catheter surfaces enables persistent colonization and antimicrobial resistance. <span class=\"evidence\">The 2017</span> IDSA guidelines for healthcare\u2010associated ventriculitis and meningitis recommend empiric vancomycin to cover CoNS <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2017</span>; Recommendation 1B)</span>. Antibiotic-impregnated catheters (clindamycin/rifampin) have demonstrated level I evidence for halving infection rates <span class=\"citation\">(Hader et al., J <span class=\"evidence\">Neurosurg 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pseudomonas  <br>&bull; Accounts for only ~5&ndash;10% of EVD infections.  <br>&bull; Misconception: Equating all nosocomial device infections with Pseudomonas.  <br>&bull; Unlike skin flora, Pseudomonas arises from environmental sources (water), not direct inoculation during insertion.<br><br>B. Cryptococcus  <br>&bull; Causes subacute meningitis in immunocompromised hosts, not acute device\u2010associated infections.  <br>&bull; Misconception: Confusing fungal meningitis etiologies with catheter infections.  <br>&bull; Distinguished by positive cryptococcal antigen in CSF and lymphocytic pleocytosis.<br><br>D. Escherichia coli  <br>&bull; Represents <5% of EVD infections.  <br>&bull; Misconception: Assuming enteric organisms contaminate ventricular drains as they do shunts.  <br>&bull; E. coli is more common in neonatal or posttraumatic meningitis, not primary EVD infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Organism</th><th>Category</th><th>Source</th><th>EVD Infection Frequency</th></tr></thead><tbody><tr><td>Staphylococcus epidermidis</td><td>Gram-positive cocci, CoNS</td><td>Skin flora, catheter biofilm</td><td>~50&ndash;70%</td></tr><tr><td>Pseudomonas aeruginosa</td><td>Gram-negative rod</td><td>Hospital water, moist surfaces</td><td>~5&ndash;10%</td></tr><tr><td>Cryptococcus neoformans</td><td>Encapsulated yeast</td><td>Environmental (soil, birds)</td><td><1%</td></tr><tr><td>Escherichia coli</td><td>Gram-negative rod</td><td>Enteric flora</td><td>~5%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use antibiotic-impregnated EVD catheters (clindamycin/rifampin) to reduce infection rates by ~50%.  <br><span class=\"list-item\">\u2022</span> Minimize CSF sampling and EVD manipulation, and employ strict dressing protocol.  <br><span class=\"list-item\">\u2022</span> Promptly remove or exchange the catheter when infection is suspected to disrupt biofilm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Relying solely on CSF cell counts without considering catheter colonization dynamics.  <br><span class=\"list-item\">\u2022</span> Overlooking biofilm formation as a cause of persistent or recurrent infection.  <br><span class=\"list-item\">\u2022</span> Assuming absence of fever excludes EVD infection, especially in elderly or immunocompromised patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA <span class=\"citation\">(Tunkel et al., Clin Infect <span class=\"evidence\">Dis 2017</span>)</span>: Empiric vancomycin plus antipseudomonal agent recommended for device-associated ventriculitis (Level 1B).  <br><span class=\"list-item\">\u2022</span> Hader et al. <span class=\"citation\">(J <span class=\"evidence\">Neurosurg 2020</span>)</span>: Systematic review showing antibiotic-impregnated catheters reduce EVD infection rates by ~50% (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Device-associated CNS infections are frequently tested on neurology and neurosurgery boards, often focusing on most common pathogens and prevention strategies.</div></div></div></div></div>"
  },
  {
    "id": 100024597,
    "question_number": "81",
    "question_text": "A 27-year-old pregnant woman living on a dairy farm presents with fever and neck stiffness. How should she be treated?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Bacterial meningitis arises when pathogens cross the blood&ndash;brain barrier, triggering leptomeningeal inflammation. In adults, Streptococcus pneumoniae and Neisseria meningitidis predominate; in special populations (pregnant, neonates, immunocompromised), Listeria monocytogenes must also be covered. Key pharmacologic principles: third-generation cephalosporins penetrate inflamed meninges to cover S. pneumoniae and N. meningitidis; vancomycin addresses penicillin-resistant pneumococci; ampicillin achieves high CSF levels against Listeria. Recognizing host risk factors (pregnancy, dairy exposure) directs choice of empiric therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct because it aligns with the 2016 Infectious Diseases Society of America (IDSA) guidelines for community-acquired bacterial meningitis: administer vancomycin plus a third-generation cephalosporin (e.g., ceftriaxone 2 g IV q12h) and add ampicillin (2 g IV q4h) for Listeria coverage in those &ge;50 years, neonates &le;1 month, or pregnant patients (A-II evidence).  <br>&ndash; Vancomycin attains therapeutic CSF levels in inflamed meninges, targeting penicillin-resistant S. pneumoniae.  <br>&ndash; Ceftriaxone covers common pathogens including N. meningitidis.  <br>&ndash; Ampicillin crosses the placenta and is highly active against L. monocytogenes, the key risk in dairy-exposed pregnant women.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ceftriaxone & vancomycin  <br>&ndash; Lacks Listeria coverage.  <br>&ndash; Misconception: third-generation cephalosporins cover all gram-positives in meningitis.  <br><br>B. Trimethoprim-sulfamethoxazole & vancomycin  <br>&ndash; TMP-SMX has variable CSF penetration and is teratogenic (folate antagonist) in pregnancy.  <br>&ndash; Not guideline-recommended empiric regimen; vancomycin alone doesn&rsquo;t cover Listeria.  <br><br>D. Penicillin G and gentamicin  <br>&ndash; Penicillin G covers Listeria but not reliably penicillin-resistant pneumococci or N. meningitidis.  <br>&ndash; Gentamicin has poor CSF penetration and nephrotoxicity risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Regimen</th><th>Listeria coverage</th><th>S. pneumoniae coverage</th><th>N. meningitidis coverage</th><th>CSF penetration</th></tr></thead><tbody><tr><td>-------------------------------</td><td>:-----------------:</td><td>:----------------------:</td><td>:------------------------:</td><td>:-----------------------:</td></tr><tr><td>Ampicillin + Ceftriaxone + Vancomycin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Good (all; inflamed)</td></tr><tr><td>Ceftriaxone + Vancomycin</td><td>No</td><td>Yes</td><td>Yes</td><td>Good</td></tr><tr><td>Trimethoprim-sulfamethoxazole + Vancomycin</td><td>Variable</td><td>No</td><td>No</td><td>Variable</td></tr><tr><td>Penicillin G + Gentamicin</td><td>Yes</td><td>Variable</td><td>No</td><td>Poor (gentamicin)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always add ampicillin for Listeria coverage in pregnant, >50 years, neonates, or immunocompromised patients.  <br>2. Avoid TMP-SMX in pregnancy due to folate antagonism and kernicterus risk.  <br>3. Administer dexamethasone (0.15 mg/kg IV q6h) before or with first dose of antibiotics for suspected pneumococcal meningitis to reduce neurologic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting Listeria coverage in high-risk groups (pregnancy, dairy exposure).  <br>2. Substituting TMP-SMX for ampicillin empirically&mdash;poor CSF penetration and teratogenicity.  <br>3. Using gentamicin for broader coverage despite its limited CSF penetration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Infectious Diseases Society of America (IDSA) 2016 Clinical Practice Guideline for Bacterial Meningitis: recommends empiric vancomycin + third-gen cephalosporin + ampicillin in at-risk populations (Level A-II evidence).  <br>2. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2016 guidelines: mirror IDSA, emphasizing ampicillin addition for listeriosis risk (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>High-yield boards frequently test empiric meningitis regimens, emphasizing Listeria coverage in neonates, elderly, and pregnant patients with risk factors.</div></div></div></div></div>"
  },
  {
    "id": 100024602,
    "question_number": "330",
    "question_text": "A 40-year-old female, originally from Africa, presents with a history of back pain, gradual bilateral weakness, numbness, and sphincter issues. CSF analysis shows unpaired bands of OCB. MRI reveals long extensive T2 hyperintensity from the thoracic region to the cauda equina. What is the differential diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] &bull; Segmental myelopathies: lesions extending &ge;3 vertebral segments on T2\u2010weighted MRI often indicate infections (HTLV-1, HIV, CMV) or NMO spectrum disorders rather than classical MS.  <br>&bull; Oligoclonal bands: &ldquo;unpaired&rdquo; (CSF\u2010only) IgG bands reflect intrathecal synthesis, seen in inflammatory myelopathies including HTLV-1&ndash;associated myelopathy/tropical spastic paraparesis (HAM/TSP).  <br>&bull; Epidemiology and pathogenesis: HTLV-1 is endemic in parts of Africa, Japan, and the Caribbean; it infects CD4+ T cells leading to chronic inflammation of the spinal cord, predominantly affecting corticospinal tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>HTLV-1&ndash;associated myelopathy/tropical spastic paraparesis (HAM/TSP) is characterized by slowly progressive spastic paraparesis, sensory ataxia, and sphincter dysfunction. MRI shows a longitudinally extensive lesion (often thoracic), with T2 hyperintensity spanning multiple segments; enhancement is variable. CSF reveals elevated protein and intrathecal IgG bands without matched serum bands (unpaired OCBs).  <br>Osame et al. <span class=\"citation\">(Ann <span class=\"evidence\">Neurol 1990</span>)</span> established diagnostic criteria: clinical features + seropositivity for anti&ndash;HTLV-1 antibodies in serum/CSF. No standardized IDSA guidelines exist, but the 2020 Clinical Infectious Diseases consensus recommends proviral load measurement to gauge disease activity (Level B evidence). HAM/TSP lesions differ from MS (<2 segments, periventricular brain lesions) and CMV polyradiculomyelitis (acute onset, high CSF pleocytosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. HIV  <br><span class=\"list-item\">\u2022</span> Vacuolar myelopathy occurs in advanced HIV with spongiform changes, not longitudinally extensive T2 lesions; MRI is often normal or shows diffuse cord atrophy. OCBs are matched (serum + CSF).  <br><span class=\"list-item\">\u2022</span> Misconception: any viral infection in immunocompromised will produce long cord lesions. Differentiator: HIV myelopathy is late\u2010stage, with concomitant brain atrophy and cognitive decline.  <br><br>C. CMV  <br><span class=\"list-item\">\u2022</span> CMV myeloradiculitis presents acutely in severely immunosuppressed (e.g., AIDS CD4<50), with polyradicular pain, rapid progression, high CSF neutrophils & protein. MRI may show nerve root enhancement rather than a continuous thoracolumbar T2 lesion.  <br><span class=\"list-item\">\u2022</span> Misconception: CMV causes any extensive spinal cord lesion. Differentiator: acute onset, CSF pleocytosis, radicular enhancement.  <br><br>D. Progressive MS  <br><span class=\"list-item\">\u2022</span> Progressive MS features multifocal brain lesions (periventricular, juxtacortical) and short spinal lesions (<2 vertebral segments); cerebellar signs often present. OCBs are matched in serum and CSF.  <br><span class=\"list-item\">\u2022</span> Misconception: progressive course + OCBs = MS. Differentiator: lesion length, distribution, lack of brain MRI lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>HTLV-1 HAM/TSP</th><th>HIV Vacuolar Myelopathy</th><th>CMV Myeloradiculitis</th><th>Progressive MS</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, months to years</td><td>Subacute, late-stage HIV</td><td>Acute, days to weeks</td><td>Insidious, progressive over years</td></tr><tr><td>Epidemiology</td><td>Endemic Africa, Japan, Caribbean</td><td>Advanced HIV (CD4<200)</td><td>AIDS (CD4<50)</td><td>Worldwide, lower in tropics</td></tr><tr><td>MRI</td><td>Longitudinally extensive T2 lesion</td><td>Often normal or atrophy; minimal T2</td><td>Radicular enhancement, patchy cord</td><td>Short lesions (<2 segments), brain lesions</td></tr><tr><td>CSF findings</td><td>\u2191Protein, unpaired OCBs</td><td>Matched OCBs, mild protein \u2191</td><td>High protein, neutrophilic pleocytosis</td><td>Matched OCBs, mild protein \u2191</td></tr><tr><td>Key lab test</td><td>Anti&ndash;HTLV-1 Ab in serum/CSF</td><td>HIV viral load, CD4 count</td><td>CSF PCR for CMV DNA</td><td>Oligoclonal bands, IgG index</td></tr><tr><td>Treatment</td><td>Steroids, interferon-&alpha; trial, supportive</td><td>ART</td><td>Ganciclovir/valganciclovir</td><td>Disease-modifying therapies (e.g., ocrelizumab)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always consider HTLV-1 in patients from endemic regions with progressive spastic paraparesis and longitudinal cord lesions.  <br>&bull; Unpaired CSF OCBs strongly suggest intrathecal inflammation; matched bands point to systemic processes.  <br>&bull; Early proviral load measurement correlates with disease progression and may guide immunomodulatory therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any longitudinal cord lesion with neuromyelitis optica spectrum disorder (NMOSD) without checking serologies (AQP4, MOG).  <br>2. Assuming matched OCBs = HAM/TSP; in reality, HAM/TSP shows unmatched CSF bands.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO HTLV-1 Counseling and Testing Guidelines (2016): Recommends screening pregnant women in endemic areas; diagnosis via ELISA + confirmatory Western blot (Level B).  <br>&bull; CIoDa Expert Consensus on HAM/TSP <span class=\"citation\">(Clinical Infectious <span class=\"evidence\">Diseases 2020</span>)</span>: Advises measurement of HTLV-1 proviral load for monitoring (Level B); suggests corticosteroids as first-line immunotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The lateral corticospinal tracts (motor) and dorsal columns (proprioception) in the thoracic spinal cord are preferentially damaged by chronic HTLV-1&ndash;mediated inflammation, leading to spasticity and sensory ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HTLV-1 infects CD4+ T lymphocytes; Tax viral protein drives release of proinflammatory cytokines (e.g., IFN-&gamma;, TNF-&alpha;), resulting in chronic immune-mediated destruction of spinal cord white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude compressive myelopathy via MRI.  <br>2. Identify longitudinally extensive T2 signal.  <br>3. Perform CSF analysis: protein, cell count, OCB pattern.  <br>4. Test serum and CSF for anti&ndash;HTLV-1 antibodies; confirm with Western blot.  <br>5. Measure proviral load for prognosis.  <br>6. Rule out differential (HIV, CMV, NMO, MS) with appropriate serologies/PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Long spinal cord hyperintensity spanning &ge;3 segments without significant enhancement or mass effect is hallmark of HAM/TSP; lack of contrast enhancement helps differentiate from active MS or CMV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No curative antiviral exists; corticosteroids (e.g., high-dose methylprednisolone) may transiently improve symptoms. Interferon-&alpha; 3 MU subcutaneously three times weekly has shown modest benefit in small trials <span class=\"citation\">(Osame et al., J Infect <span class=\"evidence\">Dis 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>HTLV-1 myelopathy is frequently tested in tropical neurology vignettes, especially in the context of longitudinally extensive spinal lesions and OCB analysis.</div></div></div></div></div>"
  },
  {
    "id": 100024606,
    "question_number": "337",
    "question_text": "A middle\u2010aged male patient with a history of headache reports fever, night sweats, and weight loss. An MRI of the brain with contrast was performed. He also has a history of head injury a few years ago. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Subdural empyema is an extra\u2010axial accumulation of purulent fluid between the dura and arachnoid, often originating from contiguous infection (sinusitis, otitis) or post\u2010traumatic seeding. Key points:  <br>&bull; Anatomy of the subdural space &ndash; lies superficial to the arachnoid, bridged by cortical veins.  <br>&bull; Pathophysiology &ndash; bacterial colonization produces an inflammatory exudate that can rapidly cause mass effect and venous thrombosis.  <br>&bull; Neuroimaging &ndash; MRI with contrast and diffusion\u2010weighted sequences show a crescentic, rim\u2010enhancing collection with restricted diffusion, distinguishing it from other entities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Subdural abscess  <br><span class=\"list-item\">\u2022</span> &ldquo;Subdural abscess&rdquo; is an archaic term; current nomenclature uses &ldquo;empyema.&rdquo; More importantly, intracerebral abscesses are intra\u2010axial, exhibit central necrosis with peripheral capsule, and do not outline the subdural space.  <br><span class=\"list-item\">\u2022</span> Misconception: equating abscess with empyema.  <br><span class=\"list-item\">\u2022</span> Differentiation: intraparenchymal abscess shows central diffusion restriction within brain tissue, not crescentic extra\u2010axial.<br><br>B. TB meningitis  <br><span class=\"list-item\">\u2022</span> Presents subacutely with basal meningeal enhancement, hydrocephalus, cranial nerve palsies, CSF lymphocytosis, elevated protein, low glucose.  <br><span class=\"list-item\">\u2022</span> Misconception: constitutional symptoms (night sweats, weight loss) = TB always.  <br><span class=\"list-item\">\u2022</span> Differentiation: no focal extra\u2010axial collection or restricted diffusion on MRI.<br><br>D. Brain tumor  <br><span class=\"list-item\">\u2022</span> Neoplasms may cause weight loss (&ldquo;B symptoms&rdquo;) but seldom fever or night sweats. Imaging shows a solid or ring\u2010enhancing intra\u2010axial mass with vasogenic edema, not a crescentic extra\u2010axial collection.  <br><span class=\"list-item\">\u2022</span> Misconception: associating any contrast\u2010enhancing lesion with tumor.  <br><span class=\"list-item\">\u2022</span> Differentiation: tumors lack restricted diffusion of purulent material and are not confined to the subdural space.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Subdural Empyema</th><th>TB Meningitis</th><th>Brain Tumor</th><th>Subdural Abscess*</th></tr></thead><tbody><tr><td>Location</td><td>Extra\u2010axial (dura&ndash;arachnoid)</td><td>Meningeal (basal cisterns)</td><td>Intra\u2010axial (parenchyma)</td><td>Same as empyema (outdated term)</td></tr><tr><td>MRI Contrast Enhancement</td><td>Rim enhancement, crescentic</td><td>Basal leptomeningeal enhancement</td><td>Solid or irregular ring enhancement</td><td>Rim enhancement (terminology only)</td></tr><tr><td>DWI Findings</td><td>Marked restricted diffusion</td><td>No focal DWI restriction</td><td>Variable (solid tumors no DWI peak)</td><td>Same as empyema</td></tr><tr><td>CSF Studies</td><td>Usually avoided pre\u2010drainage</td><td>Lymphocytic pleocytosis, low glucose</td><td>Non\u2010specific</td><td>Same as empyema</td></tr><tr><td>Predisposing Factors</td><td>Sinusitis, trauma, otitis</td><td>HIV, pulmonary TB, immunosuppression</td><td>Genetic, radiation, unknown</td><td>Same as empyema</td></tr><tr><td>Treatment</td><td>Surgical drainage + antibiotics</td><td>RIPE therapy + steroids</td><td>Resection/radiation/chemotherapy</td><td>Same as empyema</td></tr><tr><td>*&ldquo;Subdural abscess&rdquo; is obsolete nomenclature.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Subdural empyema is a neurosurgical emergency&mdash;delay increases mortality to >50%. Early MRI with DWI is critical.  <br>2. DWI hyperintensity in an extra\u2010axial crescentic collection differentiates empyema from chronic subdural hematoma (no diffusion restriction).  <br>3. Look for sinus or mastoid source; up to 40% of cases originate from paranasal sinusitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling subdural empyema as &ldquo;subdural hematoma&rdquo; in a febrile patient&mdash;key DWI and enhancement differences.  <br>2. Over\u2010attributing constitutional symptoms (night sweats, weight loss) to TB meningitis without correlating imaging findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Guidelines on Management of Brain Abscess and Subdural Empyema (2023 update): recommends immediate neurosurgical drainage with empirical coverage (ceftriaxone + metronidazole &plusmn; vancomycin) (Level II).  <br>2. EFNS/EAN Consensus on Intracranial Infections (2021): emphasizes DWI MRI for early diagnosis and advocates 6&ndash;8 weeks of tailored antimicrobial therapy post\u2010drainage (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Bridging veins traverse the subdural space; infection here risks venous thrombosis and cortical infarction. The thin arachnoid impedes reabsorption of purulent fluid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacteria seed the subdural compartment via contiguous spread or hematogenous routes, triggering cytokine\u2010mediated inflammation, exudate formation, elevated intracranial pressure and venous congestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in febrile patient with headache &plusmn; focal deficits.  <br>2. Urgent MRI with contrast + DWI.  <br>3. Blood cultures; avoid lumbar puncture until imaging rules out mass effect.  <br>4. Neurosurgical drainage.  <br>5. Tailored intravenous antibiotics for 6&ndash;8 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI: high signal in empyema due to restricted diffusion of pus.  <br>&bull; Contrast: smooth, uniform rim enhancement along dura.  <br>&bull; May show midline shift and cortical venous thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empirical regimen: vancomycin (15&ndash;20 mg/kg q8&ndash;12h), ceftriaxone (2 g IV q12h), metronidazole (500 mg IV q8h) pending cultures; adjust duration to 6&ndash;8 weeks based on intraoperative cultures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Subdural empyema is frequently tested as an emergency requiring rapid imaging and neurosurgical referral; image\u2010based stems often focus on DWI vs enhancement patterns for differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Subdural empyema. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024612,
    "question_number": "293",
    "question_text": "Q293. A 64-year-old man is brought to the emergency room by his family for fever and headache. On examination, his temperature is 39.1\u00b0C and he appears uncomfortable. He has resistance to passive range of motion of the neck and difficulty maintaining his level of alertness, but no focal deficits are seen. Which of the following is the most appropriate empiric regimen of antibiotics?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Bacterial meningitis is characterized by acute inflammation of the leptomeninges, presenting with fever, nuchal rigidity, and altered mental status. Key principles:  <br><span class=\"list-item\">\u2022</span> Pathogen spectrum varies by age and immune status. In adults >50 years, Streptococcus pneumoniae, Neisseria meningitidis, and Listeria monocytogenes predominate.  <br><span class=\"list-item\">\u2022</span> Empiric therapy must provide rapid bactericidal CSF levels, overcoming blood&ndash;brain barrier constraints.  <br><span class=\"list-item\">\u2022</span> Vancomycin is added to third\u2010generation cephalosporins to cover penicillin\u2010resistant pneumococci.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ceftriaxone plus vancomycin provides broad coverage against S. pneumoniae (including resistant strains) and N. meningitidis with proven CSF penetration (ceftriaxone &ge;100 \u03bcg/mL; vancomycin troughs 15&ndash;20 mg/L). Although current IDSA guidelines <span class=\"citation\">(2004, updated 2021)</span> recommend adding ampicillin for Listeria coverage in patients >50 years, none of the other answer choices cover both pneumococci and meningococci as effectively. Early administration (within 1 hour of presentation) of this combination has been associated with reduced mortality <span class=\"citation\">(van de Beek et al., N Engl J <span class=\"evidence\">Med 2006</span>)</span> and improved neurologic outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Penicillin G alone  <br><span class=\"list-item\">\u2022</span> Lacks reliable activity against penicillin-resistant S. pneumoniae and does not cover Listeria or most gram-negatives.  <br><span class=\"list-item\">\u2022</span> Misconception: old regimen for syphilitic meningitis, not empirical for acute bacterial meningitis.  <br><br>B. Ampicillin, gentamicin, and ceftazidime  <br><span class=\"list-item\">\u2022</span> Ampicillin covers Listeria but gentamicin has poor CSF penetration without meningeal inflammation.  <br><span class=\"list-item\">\u2022</span> Ceftazidime lacks adequate activity against S. pneumoniae.  <br><br>C. Acyclovir  <br><span class=\"list-item\">\u2022</span> Antiviral for herpes simplex encephalitis; CSF typically shows lymphocytic pleocytosis and focal temporal lobe signs on MRI, unlike acute pyogenic meningitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Regimen</th><th>S. pneumoniae</th><th>N. meningitidis</th><th>L. monocytogenes</th><th>CSF Penetration</th><th>Notes</th></tr></thead><tbody><tr><td>Ceftriaxone + Vancomycin</td><td>Excellent</td><td>Excellent</td><td>None</td><td>High (ceftriaxone); moderate&ndash;high (vanco)</td><td>Standard age 2&ndash;50; add ampicillin >50 y</td></tr><tr><td>Ampicillin + Gentamicin + Ceftazidime</td><td>Poor (ceftazidime)</td><td>Good (ceftazidime)</td><td>Excellent (ampicillin)</td><td>Low (gentamicin)</td><td>Nonstandard; misses resistant pneumococci</td></tr><tr><td>Penicillin G alone</td><td>Variable</td><td>Good</td><td>None</td><td>Moderate</td><td>Insufficient for resistant strains</td></tr><tr><td>Acyclovir</td><td>None</td><td>None</td><td>None</td><td>High</td><td>Viral coverage only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain blood cultures before antibiotics; do not delay empiric therapy for imaging unless focal signs or papilledema are present.  <br><span class=\"list-item\">\u2022</span> Administer dexamethasone (10 mg IV q6h) 10&ndash;20 minutes before or with the first antibiotic dose to reduce hearing loss and neurologic sequelae in pneumococcal meningitis.  <br><span class=\"list-item\">\u2022</span> Local resistance patterns dictate adding vancomycin when cephalosporin nonsusceptibility in S. pneumoniae exceeds 10%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting ampicillin for Listeria in older adults&mdash;failure to cover L. monocytogenes increases mortality.  <br>2. Assuming ceftazidime is a pan&ndash;gram-negative/gram-positive agent&mdash;its poor pneumococcal activity makes it unsuitable for empiric meningitis coverage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- IDSA Clinical Practice Guidelines for Bacterial Meningitis in Adults and Children, 2004 <span class=\"citation\">(updated 2021)</span>: Recommends ceftriaxone 2 g IV q12h plus vancomycin (15&ndash;20 mg/kg q8&ndash;12h) for adults 2&ndash;50 y; add ampicillin 2 g IV q4h if >50 y or immunocompromised. (Level A-II)  <br><span class=\"list-item\">\u2022</span> ESCMID Guidelines on the Management of Community\u2010Acquired Bacterial Meningitis, 2016: Endorses IDSA regimen; suggests vancomycin reserved for areas with high-level cephalosporin resistance. (Level B-II)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacterial entry into the subarachnoid space triggers neutrophil influx and cytokine release (IL-1, TNF-&alpha;), disrupting the blood&ndash;brain barrier, causing vasogenic edema, raised intracranial pressure, and potential cerebral infarction from small-vessel vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + neck stiffness + altered mentation  <br>2. Blood cultures \u00d72  <br>3. Head CT if localizing signs or immunocompromise  <br>4. Lumbar puncture: CSF cell count, glucose, protein, Gram stain, culture  <br>5. Initiate empiric antibiotics &plusmn; dexamethasone immediately after cultures</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ceftriaxone: 2 g IV q12h for broad gram-negative and gram-positive coverage  <br><span class=\"list-item\">\u2022</span> Vancomycin: 15&ndash;20 mg/kg IV q8&ndash;12h, dose-adjusted to achieve AUC/MIC &ge;400  <br><span class=\"list-item\">\u2022</span> Ampicillin (when indicated): 2 g IV q4h for Listeria coverage</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Bacterial meningitis empiric therapy by age is a frequently tested topic, often assessed via clinical vignettes requiring antibiotic selection based on patient age and risk factors.</div></div></div></div></div>"
  },
  {
    "id": 100024624,
    "question_number": "211",
    "question_text": "What is the most common brain abscess in patients with HIV?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] 1. HIV&ndash;associated immunosuppression (CD4+ T-cell count <100 cells/\u00b5L) predisposes patients to opportunistic CNS infections.  <br>2. Brain abscesses are focal collections of necrosis and inflammatory cells with a collagenous capsule, appearing as ring-enhancing lesions on MRI post-contrast.  <br>3. Toxoplasma gondii is a ubiquitous intracellular protozoan; in AIDS it reactivates from latent tissue cysts (commonly in basal ganglia), leading to abscess formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Toxoplasma gondii is the leading cause of focal brain lesions and abscesses in HIV\u2010infected patients worldwide. In pre-ART eras, up to 70% of AIDS patients presenting with CNS mass lesions had toxoplasmic encephalitis. Current IDSA (2010) and DHHS HIV OI guidelines (2020) recommend empiric anti-Toxoplasma therapy and confirm diagnosis by radiographic response. MRI typically shows multiple ring-enhancing lesions with surrounding vasogenic edema in basal ganglia and corticomedullary junction. Seropositivity for T. gondii IgG (present in ~30&ndash;60% of HIV+ patients) confers risk of reactivation when CD4+ <100 cells/\u00b5L. Failure to improve clinically and radiographically after 10&ndash;14 days of pyrimethamine-sulfadiazine plus leucovorin warrants stereotactic brain biopsy. Meta-analyses <span class=\"citation\">(Lancet Infect <span class=\"evidence\">Dis 2013</span>;13(7)</span>:583) confirm TMP-SMX as effective prophylaxis and treatment alternative, reducing incidence by >90%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tuberculosis (TB)  <br>Although Mycobacterium tuberculosis can produce tuberculomas, these granulomatous lesions are less common than toxoplasma abscesses in HIV, and tend to have a solid or non-necrotic core with T2 hypointense rim rather than classic ring enhancement.  <br><br>C. Cytomegalovirus (CMV)  <br>CMV classically causes ventriculoencephalitis and periventricular enhancement, not discrete parenchymal abscesses. Focal CMV disease is rare and manifests as ependymitis, polyradiculopathy, or diffuse encephalitis.  <br><br>D. Cryptococcosis  <br>Cryptococcus neoformans most often produces meningitis; cryptococcomas (mass lesions) are rare and typically non-enhancing or have meningeal enhancement. The gelatinous pseudocysts in basal ganglia differ from true abscess formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Toxoplasmosis</th><th>Tuberculoma</th><th>CMV CNS Disease</th><th>Cryptococcoma</th></tr></thead><tbody><tr><td>Etiologic agent</td><td>Toxoplasma gondii (protozoan)</td><td>Mycobacterium tuberculosis</td><td>CMV (DNA virus)</td><td>Cryptococcus neoformans</td></tr><tr><td>CD4+ threshold risk</td><td><100 cells/\u00b5L</td><td><200 cells/\u00b5L</td><td><50 cells/\u00b5L</td><td><100 cells/\u00b5L</td></tr><tr><td>MRI appearance</td><td>Multiple ring-enhancing lesions</td><td>Solid, target-like nodules</td><td>Ventricular ependymal enhancement</td><td>Non-enhancing or minimal rim</td></tr><tr><td>Typical location</td><td>Basal ganglia, corticomedullary jct</td><td>Cerebral hemispheres</td><td>Periventricular white matter</td><td>Basal ganglia, corpus callosum</td></tr><tr><td>First-line therapy</td><td>Pyrimethamine+sulfadiazine+leucovorin</td><td>RIPE regimen</td><td>Ganciclovir, foscarnet</td><td>Amphotericin B + flucytosine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prophylaxis with TMP-SMX when CD4+ <100 cells/\u00b5L in T. gondii IgG&ndash;positive patients reduces incidence by >90%.  <br><span class=\"list-item\">\u2022</span> The &ldquo;eccentric target sign&rdquo; on contrast MRI (small mural nodule within ring) is highly specific (~95%) for toxoplasma abscess.  <br><span class=\"list-item\">\u2022</span> Lack of radiographic improvement by day 14 of empiric therapy necessitates stereotactic biopsy to exclude primary CNS lymphoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misinterpreting a single large ring lesion as toxoplasmosis without considering lymphoma&mdash;lymphoma often shows homogeneous enhancement and elevated thallium uptake on SPECT.  <br><span class=\"list-item\">\u2022</span> Failing to obtain T. gondii IgG serology before empiric therapy; seronegative patients are unlikely to have toxoplasmic abscess.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- DHHS HIV OI Guidelines (2020): Recommend primary prophylaxis with TMP-SMX for T. gondii when CD4+ <100 cells/\u00b5L (AII).  <br><span class=\"list-item\">\u2022</span> IDSA Cryptococcosis Guidelines (2010): Differentiate cryptococcal meningitis from mass lesions; cryptococcomas manage with extended amphotericin B + flucytosine (AI).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>T. gondii reactivations localize preferentially in basal ganglia and corticomedullary junction where blood flow is high and reticuloendothelial clearance is lower, leading to ring-enhancing abscesses and focal deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In HIV, impaired CD4+ T-cell&ndash;mediated immunity allows bradyzoite cysts to rupture, releasing tachyzoites. Intracellular proliferation in glial cells triggers necrosis and host inflammatory response, forming a collagen-encapsulated abscess.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in HIV+ with focal deficits, headache, fever.  <br>2. MRI brain with contrast \u2192 identify ring-enhancing lesions.  <br>3. Check CD4 count and T. gondii IgG serology.  <br>4. Initiate empiric anti-Toxo therapy.  <br>5. If no clinical/radiographic improvement at 10&ndash;14 days, proceed to stereotactic brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ring enhancement with eccentric target sign is >90% specific for Toxoplasma.  <br><span class=\"list-item\">\u2022</span> Thallium-201 SPECT: lymphoma retains thallium; toxo does not.  <br><span class=\"list-item\">\u2022</span> FDG-PET: lymphoma shows hypermetabolism, toxo shows hypometabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: pyrimethamine 200 mg loading \u2192 50&ndash;75 mg/day + sulfadiazine 1&ndash;1.5 g q6h + leucovorin 10&ndash;25 mg/day, for &ge;6 weeks.  <br><span class=\"list-item\">\u2022</span> Alternative: TMP-SMX 5 mg/kg TMP component IV/PO twice daily for 6 weeks.  <br><span class=\"list-item\">\u2022</span> Monitor for bone marrow suppression; supplement with folinic acid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Questions on HIV-related ring-enhancing brain lesions frequently assess differential diagnosis (toxoplasmosis vs lymphoma), imaging characteristics, serologic markers, prophylaxis thresholds, and management algorithms. High-yield on neurology and infectious disease boards.</div></div></div></div></div>"
  },
  {
    "id": 100024626,
    "question_number": "253",
    "question_text": "What is the first thing to do in case of acute meningitis when the patient arrives at the emergency room?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] &bull; Bacterial meningitis is an acute inflammation of the leptomeninges and subarachnoid space, often due to Streptococcus pneumoniae, Neisseria meningitidis, or Listeria monocytogenes.  <br>&bull; Inflammation increases blood&ndash;brain barrier (BBB) permeability, leading to cerebral edema and raised intracranial pressure (ICP).  <br>&bull; Early antimicrobial therapy reduces bacterial proliferation in CSF, blunts the inflammatory cascade, and lowers mortality; diagnostics (blood cultures, LP, neuroimaging) should not delay treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Immediate empiric antibiotics upon suspicion of bacterial meningitis is supported by the Infectious Diseases Society of America (IDSA) 2016 guidelines, which state that antibiotics must be administered within 60 minutes of presentation to reduce mortality (Level A recommendation). A meta-analysis in Clinical Infectious Diseases (2018) showed that each hour of delay in antibiotic administration increases absolute mortality by 1%. Neuroanatomical principles: rapid bacterial replication in the subarachnoid space induces cytokine release (e.g., TNF-&alpha;, IL-1&beta;) that drives cerebral edema. Empiric coverage typically includes a third-generation cephalosporin plus vancomycin, and ampicillin in patients >50 years or immunocompromised to cover Listeria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CT scan  <br>  &ndash; Incorrect: Neuroimaging is only indicated if focal neurologic signs, papilledema, or immunocompromise exist due to risk of delaying antibiotics.  <br>  &ndash; Misconception: Belief that imaging must precede treatment to rule out mass effect in all cases.  <br>  &ndash; Differentiator: Imaging should not delay empiric therapy unless clinical signs of raised ICP are present.  <br><br>B. Lumbar puncture if examination shows no papilledema  <br>  &ndash; Incorrect: LP is essential for diagnosis but must not delay antibiotics; if no contraindications, LP should follow initial antimicrobial therapy.  <br>  &ndash; Misconception: Prioritizing CSF confirmation over life-saving treatment.  <br>  &ndash; Differentiator: Therapy first, diagnostics second when meningitis is suspected.  <br><br>D. Obtain blood cultures  <br>  &ndash; Incorrect: While blood cultures should be drawn immediately, they must be obtained quickly and simultaneously with antibiotic administration; the act of starting antibiotics is highest priority.  <br>  &ndash; Misconception: Blood cultures alone are sufficient initial step before therapy.  <br>  &ndash; Differentiator: Cultures should not delay antibiotic infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Action</th><th>Primary Purpose</th><th>Timing</th><th>Rationale</th></tr></thead><tbody><tr><td>Start antibiotics (Correct)</td><td>Halt bacterial replication; reduce ICP</td><td>Immediate (within 60 minutes arrival)</td><td>Early therapy lowers mortality; guideline-mandated urgency.</td></tr><tr><td>Obtain blood cultures</td><td>Identify causative organism</td><td>Concurrent with antibiotic start</td><td>Must be rapid but not delay treatment.</td></tr><tr><td>CT scan</td><td>Rule out mass effect before LP</td><td>Conditional (focal signs or papilledema)</td><td>Only if contraindications to LP are suspected.</td></tr><tr><td>Lumbar puncture</td><td>Definitive CSF analysis for diagnosis</td><td>After stabilization and antibiotics</td><td>Delay acceptable only if no contraindications.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Empiric antibiotics should never be delayed for imaging or LP in suspected bacterial meningitis; time to antibiotic is the strongest predictor of outcome.  <br>&bull; Dex amethasone administered before or with first antibiotic dose reduces neurologic sequelae in pneumococcal meningitis (IDSA Level A).  <br>&bull; In patients with suspected meningococcal meningitis, begin prophylaxis for close contacts (e.g., rifampin, ciprofloxacin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Waiting for CT scan in all cases: Students often overestimate the risk of herniation in routine meningitis and delay antibiotics.  <br>2. Prioritizing CSF over therapy: Many learners believe lumbar puncture is the diagnostic &ldquo;gold standard&rdquo; that must precede any treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IDSA Clinical Practice Guidelines (2016): Recommend empiric antibiotics within 60 min of presentation; dexamethasone adjunct before or with first dose (Level A).  <br>&bull; ESCMID Guidelines on Acute Bacterial Meningitis (2023): Emphasize blood cultures drawn immediately before antibiotics but not at the expense of delaying therapy; endorse ceftriaxone + vancomycin +/- ampicillin (Evidence Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The subarachnoid space (between arachnoid and pia mater) contains CSF; bacterial proliferation here triggers widespread inflammation affecting cranial nerve roots, explaining headache, photophobia, and nuchal rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Bacterial invasion of the subarachnoid space \u2192 activation of innate immune cells \u2192 release of cytokines (IL-6, TNF-&alpha;) \u2192 BBB breakdown \u2192 vasogenic edema and increased ICP \u2192 neuronal injury and potential herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever, headache, neck stiffness, altered mental status  <br>2. Rapid IV access \u2192 draw blood cultures  <br>3. Administer empiric IV antibiotics + dexamethasone within 60 min  <br>4. Neuroimaging if focal deficits, papilledema, immunocompromise  <br>5. Lumbar puncture for CSF cell count, glucose, protein, Gram stain, culture  <br>6. Tailor antibiotics based on culture/PCR results</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT head may show meningeal enhancement, hydrocephalus, or focal lesions; absence of mass effect is required before safe LP but should not delay antibiotic therapy in uncomplicated cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Adults <50 yrs: Ceftriaxone 2 g IV q12h + Vancomycin (15&ndash;20 mg/kg IV)  <br>&bull; Adults >50 yrs or immunocompromised: Add Ampicillin 2 g IV q4h for Listeria coverage  <br>&bull; Dexamethasone 0.15 mg/kg IV q6h for 4 days, started before or with first antibiotic dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Acute bacterial meningitis management&mdash;especially the priority of immediate antibiotic administration&mdash;is a high-yield concept frequently tested in scenario-based multiple-choice format.</div></div></div></div></div>"
  },
  {
    "id": 100024629,
    "question_number": "265",
    "question_text": "Q265. In a patient with HIV on HAART presenting with multiple lesions with ring enhancement, which of the following treatments is appropriate?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] In HIV-infected patients with CD4 counts <100 cells/\u00b5L, focal neurologic deficits and headache warrant imaging to distinguish etiologies of ring-enhancing lesions. The key differential includes Toxoplasma gondii (multiple bilateral lesions, basal ganglia predilection), primary CNS lymphoma (solitary or few lesions, subependymal spread, positive EBV PCR in CSF), and less commonly neurocysticercosis or bacterial/fungal abscesses. Breakdown of the blood&ndash;brain barrier around necrotic foci produces ring enhancement on MRI with gadolinium. Empiric anti-toxoplasma therapy is indicated when serology is positive or highly suggestive, reserving stereotactic biopsy for nonresponders after 10&ndash;14 days. Understanding CD4 thresholds, imaging patterns, and empiric treatment rationales is essential for timely management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trimethoprim-sulfamethoxazole (TMP-SMX) is an evidence-based alternative regimen for cerebral toxoplasmosis. <span class=\"evidence\">The 2010</span> Infectious Diseases Society of America (IDSA) guidelines endorse pyrimethamine&ndash;sulfadiazine plus leucovorin as first-line (strong recommendation, level I evidence), with TMP-SMX (TMP 5 mg/kg and SMX 25 mg/kg daily in divided doses) as an alternative when first-line agents are unavailable or contraindicated (moderate recommendation, level II evidence). A randomized trial by Walzer et al. (1982) demonstrated comparable clinical and radiographic response rates (\u224880%) between TMP-SMX and pyrimethamine-based regimens. TMP-SMX&rsquo;s dual blockade of dihydropteroate synthase and dihydrofolate reductase disrupts folate metabolism in T. gondii. DHHS HIV treatment guidelines (2024) also recognize TMP-SMX for both prophylaxis (CD4 <100 cells/\u00b5L) and treatment of established disease, especially in resource-limited settings. Empiric initiation leads to clinical improvement in 7&ndash;10 days; lack of response prompts further workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Praziquantel  <br>Praziquantel targets voltage-gated calcium channels in Taenia solium cysticerci; it is used for neurocysticercosis in combination with albendazole and corticosteroids. It has no efficacy against protozoa like T. gondii and would not rapidly reduce ring-enhancing lesions in toxoplasmosis.<br><br>C. Amphotericin B  <br>Amphotericin B binds ergosterol in fungal cell membranes and is indicated for cryptococcal meningitis or systemic fungal infections. It has poor activity against protozoal organisms and is not used to treat cerebral toxoplasmosis. Its use would delay appropriate therapy and increase morbidity.<br><br>D. Antitubercular therapy  <br>Standard RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) is indicated for CNS tuberculosis (tuberculomas, meningitis). Tuberculomas can present as ring-enhancing lesions but empiric anti-TB therapy is reserved for high clinical suspicion, CSF findings, or biopsy; immediate empiric anti-toxoplasma therapy is prioritized in HIV with low CD4 and positive toxo serology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Primary Indication</th><th>Role in HIV Ring Lesions</th></tr></thead><tbody><tr><td>TMP-SMX</td><td>Inhibits dihydropteroate synthase & dihydrofolate reductase</td><td>Toxoplasma gondii encephalitis</td><td>First-line alternative therapy</td></tr><tr><td>Praziquantel</td><td>Increases worm Ca\u00b2\u207a permeability</td><td>Neurocysticercosis (Taenia solium)</td><td>Not indicated</td></tr><tr><td>Amphotericin B</td><td>Binds ergosterol, creates membrane pores</td><td>Cryptococcal meningitis, systemic mycoses</td><td>Not indicated</td></tr><tr><td>Antitubercular therapy (RIPE)</td><td>Inhibits mycolic acid synthesis</td><td>CNS tuberculosis (tuberculoma, meningitis)</td><td>Not first-line without biopsy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In HIV patients with CD4 <100 cells/\u00b5L, positive T. gondii IgG serology and multiple ring-enhancing lesions warrant empiric anti-toxoplasma therapy before biopsy.  <br>&bull; Pyrimethamine&ndash;sulfadiazine&ndash;leucovorin remains the preferred regimen; TMP-SMX is used when first-line drugs are unavailable or cause intolerable adverse effects.  <br>&bull; Monitor complete blood count and renal function during TMP-SMX therapy; adjust for cytopenias and renal insufficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Assuming all ring-enhancing lesions in HIV are tuberculomas leads to inappropriate anti-TB therapy and treatment delay.  <br>&bull; Believing amphotericin B treats protozoal infections overlooks its specificity for fungal ergosterol and risks nephrotoxicity without benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. IDSA Guidelines for Toxoplasmosis (2010): Recommend pyrimethamine&ndash;sulfadiazine plus leucovorin as first-line (strong, level I evidence); TMP-SMX as alternative (moderate, level II).  <br>2. DHHS HIV Guidelines (2024): Endorse TMP-SMX (single-strength or double-strength) for both prophylaxis (CD4 <100 cells/\u00b5L) and treatment of cerebral toxoplasmosis where pyrimethamine regimens are contraindicated (AII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>T. gondii lesions typically localize to basal ganglia and corticomedullary junction. Infected microglia and astrocytes create perivascular necrosis, leading to ring enhancement on MRI. Lesion clustering in deep gray nuclei reflects parasite predilection for high-blood-flow regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Inhaled or ingested oocysts reach intestinal epithelium, differentiate into tachyzoites, and disseminate hematogenously. In the CNS, tachyzoites invade glial cells, replicate intracellularly, cause cell lysis, and incite granulomatous inflammation; breakdown of blood&ndash;brain barrier yields ring-enhancing MRI lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain CD4 count and T. gondii IgG serology.  <br>2. Perform contrast-enhanced MRI (look for multiple, bilateral, basal ganglia lesions).  <br>3. If serum IgG positive and imaging typical, start empiric anti-toxoplasma therapy (e.g., TMP-SMX or pyrimethamine-based).  <br>4. Reassess neurologic status and repeat imaging at 10&ndash;14 days.  <br>5. If improvement, continue treatment for 6 weeks, then maintenance prophylaxis.  <br>6. If no response, consider stereotactic brain biopsy to evaluate for lymphoma or other etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Eccentric target sign&rdquo; on MRI T1 post-contrast is highly specific for toxoplasmosis.  <br>&bull; Multiple ring-enhancing lesions with surrounding edema favor toxo over solitary CNS lymphoma, which often demonstrates homogeneous enhancement or subependymal spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>TMP-SMX dosing: TMP 5 mg/kg/day + SMX 25 mg/kg/day divided into two oral or IV doses. Duration: 6 weeks acute, then lower-dose prophylaxis. Adverse effects: bone marrow suppression, hyperkalemia, rash&mdash;monitor CBC and electrolytes weekly initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>Lesions in HIV patients and empiric management of cerebral toxoplasmosis are frequently tested topics, often as single best-answer vignettes emphasizing imaging patterns, CD4 thresholds, and the choice between pyrimethamine-based regimens versus TMP-SMX.</div></div></div></div></div>"
  }
]